,CID,name,smiles,7.1-Drug Indication,8.1-Pharmacodynamics,8.2-MeSH Pharmacological Classification,"8.5-Absorption, Distribution and Excretion",8.6-Metabolism/Metabolites,8.7-Biological Half-Life
0,440001,N-Glycolyl-Neuraminic acid,C1[C@@H]([C@H]([C@@H](OC1(C(=O)O)O)[C@@H]([C@@H](CO)O)O)NC(=O)CO)O,,,,,,
1,440002,N-Glycosyl-L-asparagine,C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)NC(=O)C[C@@H](C(=O)O)N)O)O)O)O,,,,,,
2,440003,N(2)-malonyl-D-tryptophan,C1=CC=C2C(=C1)C(=CN2)C[C@H](C(=O)O)NC(=O)CC(=O)O,,,,,,
3,440004,"N6,N6-Dimethyladenosine",CN(C)C1=NC=NC2=C1N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O,,,,,,
4,440005,Nitroarginine,C(C[C@@H](C(=O)O)N)CN=C(N)N[N+](=O)[O-],,,['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],,,
5,440006,"[(2R,3S,4S,5S,6S)-6-[(2R,3S,4R,5R,6S)-5-acetamido-6-[(2R,3S,4R,5R)-5-acetamido-6-[[(3S)-3-acetamido-4-amino-4-oxobutanoyl]amino]-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl hexadecanoate",CCCCCCCCCCCCCCCC(=O)OC[C@@H]1[C@H]([C@@H]([C@@H]([C@@H](O1)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2O)NC(=O)C)O[C@@H]3[C@H](OC([C@@H]([C@H]3O)NC(=O)C)NC(=O)C[C@@H](C(=O)N)NC(=O)C)CO)CO)O)O)O,,,,,,
6,440007,CID 440007,CC(=CCNC1=NC=NC2=C1NC=N2)CO[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
7,440008,CID 440008,CC(=CCCC(=CCCC(=CCCC(=C[C@H]1[C@@H]([C@@]1(C)CCC=C(C)CCC=C(C)CCC=C(C)C)COP(=O)(O)OP(=O)(O)O)C)C)C)C,,,,,,
8,440009,"[(1S,2S,3S)-2-(4,8-dimethylnona-3,7-dienyl)-2-methyl-3-(2,6,10-trimethylundeca-1,5,9-trienyl)cyclopropyl]methyl phosphono hydrogen phosphate",CC(=CCCC(=CCCC(=C[C@H]1[C@@H]([C@@]1(C)CCC=C(C)CCC=C(C)C)COP(=O)(O)OP(=O)(O)O)C)C)C,,,,,,
9,440010,"2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3-dihydrochromen-4-one",C1=CC(=C(C=C1C2C(C(=O)C3=C(C=C(C=C3O2)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O)O)O,,,,,,
10,440011,CID 440011,C1=NC(=O)C2=C(N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CSCC[C@@H](C(=O)O)N)O)O,,,,,,
11,440012,"4,8,12,16,20,24,28,32,36-Nonamethylheptatriaconta-3,7,11,15,19,23,27,31,35-nonaenyl phosphono hydrogen phosphate",CC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCOP(=O)(O)OP(=O)(O)O)C)C)C)C)C)C)C)C)C,,,,,,
12,440013,Streptamine 4-phosphate,[C@H]1([C@H]([C@@H]([C@H]([C@@H]([C@H]1O)O)OP(=O)(O)O)N)O)N,,,,,,
13,440014,cis-4-Hydroxy-D-proline,C1[C@H](CN[C@H]1C(=O)O)O,,,,,,
14,440015,cis-4-Hydroxy-L-proline,C1[C@@H](CN[C@@H]1C(=O)O)O,,,,,,
15,440016,"[(2S,3R,4S,5S)-3,4-dihydroxy-4-(hydroxymethyl)-5-methyloxolan-2-yl] [hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl] hydrogen phosphate",C[C@H]1[C@@]([C@H]([C@@H](O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)O)(CO)O,,,,,,
16,440017,5-Hydroxycamphor,CC1(C2CC(=O)C1(CC2O)C)C,,,,,,
17,440018,(R)-S-lactoylglutathione,C[C@H](C(=O)SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)O,,,['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)'],,,
18,440019,5-Oxo-2-hexenedioic acid,C(C=CC(=O)O)C(=O)C(=O)O,,,,,,
19,440020,"2,3,6-Trihydroxypyridine",C1=CC(=O)NC(=C1O)O,,,,,,
20,440021,methacrylyl-CoA; (Acyl-CoA); [M+H]+,CC(=C)C(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
21,440022,3''-Adenylylstreptomycin,C[C@H]1[C@@]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)O)N=C(N)N)O)N=C(N)N)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)NC)(C=O)O,,,,,,
22,440023,3-Methyl-3-butenoyl-CoA,CC(=C)CC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
23,440024,4-Methyl-3-oxopentanoic acid,CC(C)C(=O)CC(=O)O,,,,,,
24,440025,"11-(3-amino-3-carboxypropanoyl)-1,5-dioxo-12,12a-dihydro-4H-pyrido[3,2-a]phenoxazine-3-carboxylic acid",C1=CC(=C2C(=C1)OC3=CC(=O)C4=C(C3N2)C(=O)C=C(N4)C(=O)O)C(=O)CC(C(=O)O)N,,,,,,
25,440026,CDP-N-methylethanolamine,CNCCOP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=CC(=NC2=O)N)O)O,,,,,,
26,440027,CID 440027,CC(CCC(=O)NCCS(=O)(=O)O)C1CCC2C1(CCC3C2[C@@H](C[C@H]4C3(CC[C@H](C4)O)C)O)C,,,,,,
27,440028,"Phosphoric acid (2R,3R)-2,3,4-trihydroxybutyl ester",C([C@H]([C@@H](COP(=O)(O)O)O)O)O,,,,,,
28,440029,2-deoxy-beta-D-ribose 1-phosphate,C1[C@@H]([C@H](O[C@H]1OP(=O)(O)O)CO)O,,,,,,
29,440030,Ethyl (R)-3-hydroxybutyrate,CCOC(=O)C[C@@H](C)O,,,,,,
30,440031,fustin 3-O-beta-D-galactoside,C1=CC(=C(C=C1[C@@H]2[C@@H](C(=O)C3=C(O2)C=C(C=C3)O)O[C@H]4[C@@H]([C@H]([C@H]([C@H](O4)CO)O)O)O)O)O,,,,,,
31,440032,Glucosyloxyanthraquinone,C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=CC=C3)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O,,,,,,
32,440033,L-2-Amino-3-oxobutanoic acid,CC(=O)[C@@H](C(=O)O)N,,,,,,
33,440034,CID 440034,C1=CC(=C(C=C1C2=CC(=C3C(=CC(=CC3=O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)O2)O)O)O,,,,,,
34,440035,Magnesium protoporphyrin IX,CC1=C(C2=CC3=NC(=CC4=C(C(=C([N-]4)C=C5C(=C(C(=N5)C=C1[N-]2)C=C)C)C=C)C)C(=C3CCC(=O)O)C)CCC(=O)O.[Mg+2],,,,,,
35,440036,Glycolyl-D-mannosamine,C([C@@H]1[C@H]([C@@H]([C@@H]([C@H](O1)O)NC(=O)CO)O)O)O,,,,,,
36,440037,"N-[[(2S,5R,6R)-5-amino-6-[(1R,2S,3S,4R,6S)-4,6-diamino-3-[(2R,3R,4R,5R)-3,5-dihydroxy-5-methyl-4-(methylamino)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxan-2-yl]methyl]acetamide",CC(=O)NC[C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@](CO3)(C)O)NC)O)N)N)N,,,,,,
37,440038,9-O-acetylneuraminic acid,CC(=O)OC[C@H]([C@H]([C@H]1[C@@H]([C@H](CC(O1)(C(=O)O)O)O)N)O)O,,,,,,
38,440039,CID 440039,COC1=CC(=CC(=C1O)OC)C=CC(=O)OC[C@@H]2[C@H]([C@@H]([C@H](C(=O)O2)O)O)O,,,,,,
39,440040,"[(2R,3S,4R,5R)-3,4-dihydroxy-5-(2H-pyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate",C1N=CC=CN1[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O,,,,,,
40,440041,S-Ribosylhomocysteine,C(CSC[C@@H]1[C@H]([C@H]([C@@H](O1)O)O)O)[C@@H](C(=O)O)N,,,,,,
41,440042,CID 440042,C1C(NC2=C(N1)NC(=NC2=O)N)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)O,,,,,,
42,440043,1D-myo-inositol 4-phosphate,[C@H]1([C@H](C([C@H]([C@H](C1O)O)O)OP(=O)(O)O)O)O,,,,,,
43,440044,"(2R,3R)-oxirane-2,3-dicarboxylic acid",[C@@H]1([C@@H](O1)C(=O)O)C(=O)O,,,,,,
44,440045,"{[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-2-({[hydroxy({hydroxy[3-hydroxy-3-({2-[(2-{[(3R)-3-hydroxybutanoyl]sulfanyl}ethyl)carbamoyl]ethyl}carbamoyl)-2,2-dimethylpropoxy]phosphoryl}oxy)phosphoryl]oxy}methyl)oxolan-3-yl]oxy}phosphonic acid",C[C@H](CC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O)O,,,,,,
45,440046,"3,4-Dihydro-2H-pyrrole-5-carboxylic acid",C1CC(=NC1)C(=O)O,,,,,,
46,440047,2'-Hydroxydihydrodaidzein,C1C(C(=O)C2=C(O1)C=C(C=C2)O)C3=C(C=C(C=C3)O)O,,,,,,
47,440048,2'-Phospho-5'-adenylyl sulfate,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OS(=O)(=O)O)O)OP(=O)(O)O)N,,,,,,
48,440049,D-Mannosamine,C([C@@H]1[C@H]([C@@H]([C@@H](C(O1)O)N)O)O)O,,,,,,
49,440050,CID 440050,C(CCC=CCC=CC=CC=C[C@H]([C@H](CCCC(=O)O)O)SC[C@@H](C(=O)O)N)CCO,,,,,,
50,440051,2beta-Hydroxygibberellin 1,CC12[C@H]3[C@@H]([C@@]45CC(=C)[C@@](C4)(CC[C@H]5[C@@]3(C[C@@H]([C@@H]1O)O)OC2=O)O)C(=O)O,,,,,,
51,440052,3''-Adenylylspectinomycin,C[C@@H]1CC(=O)[C@]2([C@@H](O1)O[C@H]3[C@H](O2)[C@H]([C@H]([C@H]([C@@H]3OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)NC)O)NC)O,,,,,,
52,440053,Willardiine,C1=CN(C(=O)NC1=O)C[C@@H](C(=O)O)N,,,,,,
53,440054,"4,5alpha-Dihydrocortisone",C[C@]12CCC(=O)C[C@@H]1CC[C@@H]3[C@@H]2C(=O)C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C,,,,,,
54,440055,5-Methyl-2'-deoxycytidine,CC1=CN(C(=O)N=C1N)[C@H]2C[C@@H]([C@H](O2)CO)O,,,,,,
55,440056,CID 440056,COC1=CC=C(C=C1)C2=COC3=CC(=CC(=C3C2O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)COC(=O)CC(=O)O)O)O)O,,,,,,
56,440057,CID 440057,CCCCCC=CCC=CCC=CCCCCCCC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
57,440058,"CDP-3,6-dideoxy-D-glucose",C[C@@H]1[C@H](C[C@H](C(O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=NC3=O)N)O)O)O)O,,,,,,
58,440059,"CDP-3,6-dideoxy-D-mannose",C[C@@H]1[C@H](C[C@@H](C(O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=NC3=O)N)O)O)O)O,,,,,,
59,440060,Acetic acid 2-[(dichloroacetyl)amino]-3-hydroxy-3-(4-nitrophenyl)propyl ester,CC(=O)OCC(C(C1=CC=C(C=C1)[N+](=O)[O-])O)NC(=O)C(Cl)Cl,,,,,,
60,440061,"(2,4-Dihydroxy-3-oxobutyl) dihydrogen phosphate",C(C(C(=O)CO)O)OP(=O)(O)O,,,,,,
61,440062,"[(3R,4R,5R)-2,4,5-trihydroxy-3-(hydroxymethyl)oxan-3-yl] dihydrogen phosphate",C1[C@H]([C@H]([C@@](C(O1)O)(CO)OP(=O)(O)O)O)O,,,,,,
62,440063,CID 440063,C1=NC(=O)C2=C(N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O,,,,,,
63,440064,threo-3-methyl-L-aspartic acid,C[C@@H]([C@@H](C(=O)O)N)C(=O)O,,,,,,
64,440065,N-methyl-2-oxoglutaramic acid,CNC(=O)CCC(=O)C(=O)O,,,,,,
65,440066,[Amino-(phosphonoamino)methylidene]-(2-sulfoethyl)azanium,C(CS(=O)(=O)O)[NH+]=C(N)NP(=O)(O)O,,,,,,
66,440067,O-phosphonohydroxylamine,NOP(=O)(O)O,,,,,,
67,440068,(2-Oxo-3-phosphonooxypropyl) octadec-9-enoate,CCCCCCCCC=CCCCCCCCC(=O)OCC(=O)COP(=O)(O)O,,,,,,
68,440069,"2-[[(2S,3R)-2-amino-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium",CCCCCCCCCCCCCC=C[C@H]([C@H](COP(=O)(O)OCC[N+](C)(C)C)N)O,,,,,,
69,440070,Sterol 3-beta-D-glucoside,C1CC2CCC3C4CC[C@@H](CC4CCC3C2C1)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O,,,,,,
70,440071,Taurolithocholic acid 3-sulfate,C[C@H](CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)OS(=O)(=O)O)C)C,,,,,,
71,440072,Bis-gamma-glutamylcystine,C(CC(=O)NC(CSSCC(C(=O)O)NC(=O)CCC(C(=O)O)N)C(=O)O)C(C(=O)O)N,,,,,,
72,440073,"cis-3,4-Leucopelargonidin",C1=CC(=CC=C1[C@@H]2[C@H]([C@H](C3=C(C=C(C=C3O2)O)O)O)O)O,,,,,,
73,440074,trans-4-Hydroxy-D-proline,C1[C@@H](CN[C@H]1C(=O)O)O,,,,,,
74,440075,"(3S)-2-hydroxy-2,3-dimethylbutanedioic acid",C[C@H](C(=O)O)C(C)(C(=O)O)O,,,,,,
75,440076,"(3S,4R)-Ketose 1-phosphate",C(C([C@H]([C@@H](C(=O)COP(=O)(O)O)O)O)O)O,,,,,,
76,440077,(S)-5-amino-3-oxohexanoate,C[C@@H](CC(=O)CC(=O)O)N,,,,,,
77,440078,1D-1-O-Methyl-myo-inositol,COC1[C@@H]([C@H](C([C@H]([C@H]1O)O)O)O)O,,,,,,
78,440079,1D-3-O-Methyl-myo-inositol,COC1[C@H]([C@H](C([C@H]([C@@H]1O)O)O)O)O,,,,,,
79,440080,1-Kestose,C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)CO)O)O)CO[C@]3([C@H]([C@@H]([C@H](O3)CO)O)O)CO)O)O)O)O,,,,,,
80,440081,CID 440081,C1=CC2=C(C=C(OC2=CC1=O)C3=CC(=C(C(=C3O)O)O)O)O,,,,,,
81,440082,"2,4'-Dihydroxyacetophenone",C1=CC(=CC=C1C(=O)CO)O,,,,,,
82,440083,3-ADP-2-phosphoglyceric acid,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OCC(C(=O)O)OP(=O)(O)O)O)O)N,,,,,,
83,440084,CID 440084,C(=CC(=O)O)C(=O)C=C(O)O,,,,,,
84,440085,CID 440085,CC=C1C=[N+]2CCC3=C([C@@H]2C[C@@H]1C(=CO)C(=O)OC)NC4=CC=CC=C34,,,,,,
85,440086,6-Acetamido-3-oxohexanoic acid,CC(=O)NCCCC(=O)CC(=O)O,,,,,,
86,440087,CID 440087,C1=CC(=C2C(=C1)OC3=C4[C@@H]5C=CO[C@@H]5OC4=CC(=O)C3=C2O)O,,,,,,
87,440088,7-Methyl-3-oxooctanoyl-CoA; (Acyl-CoA); [M+H]+,CC(C)CCCC(=O)CC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
88,440089,CID 440089,C1[C@@H]([C@H]([C@@H](O[C@@]1(C(=O)O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=NC3=O)N)O)O)C(C(CO)O)O)NC(=O)CO)O,,,,,,
89,440090,"[(2S,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(phosphonooxymethyl)oxan-2-yl] dihydrogen phosphate",C([C@@H]1[C@H]([C@@H]([C@@H]([C@@H](O1)OP(=O)(O)O)O)O)O)OP(=O)(O)O,,,,,,
90,440091,"(2S,3R)-1-[[(2R,3S)-2,3-dihydroxy-4-sulfanylbutyl]disulfanyl]-4-sulfanylbutane-2,3-diol",C([C@H]([C@H](CSSC[C@H]([C@H](CS)O)O)O)O)S,,,,,,
91,440092,L-5-Carboxymethylhydantoin,C([C@H]1C(=O)NC(=O)N1)C(=O)O,,,,,,
92,440093,N-Adenylyl-L-phenylalanine,C1=CC=C(C=C1)C[C@@H](C(=O)O)NP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=CN=C43)N)O)O,,,,,,
93,440094,CID 440094,C1=CC=C(C=C1)CC(=NO)S,,,,,,
94,440095,"S-[2-[3-[[4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] 5-hydroxyfuran-2-carbothioate",CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)C4=CC=C(O4)O)O,,,,,,
95,440096,S-Acetylphosphopantetheine,CC(=O)SCCNC(=O)CCNC(=O)[C@@H](C(C)(C)COP(=O)(O)O)O,,,,,,
96,440097,Streptomycin 3''-phosphate,C[C@H]1[C@@]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)O)N=C(N)N)O)N=C(N)N)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)OP(=O)(O)O)NC)(C=O)O,,,,,,
97,440098,UDP-alpha-D-galactofuranose,C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)O[C@@H]3[C@@H]([C@H]([C@@H](O3)[C@@H](CO)O)O)O)O)O,,,,,,
98,440099,D-alpha-glutamyl phosphate,C(CC(=O)O)[C@H](C(=O)OP(=O)(O)O)N,,,,,,
99,440100,alpha-D-Hexose 6-phosphate,C(C1C(C(C([C@H](O1)O)O)O)O)OP(=O)(O)O,,,,,,
100,440101,5-O-phosphono-alpha-D-ribofuranose,C([C@@H]1[C@H]([C@H]([C@H](O1)O)O)O)OP(=O)(O)O,,,,,,
101,440102,alpha-D-Xylose 1-phosphate,C1[C@H]([C@@H]([C@H]([C@H](O1)OP(=O)(O)O)O)O)O,,,,,,
102,440103,gamma-Glutamylalanine,C[C@@H](C(=O)O)NC(=O)CC[C@@H](C(=O)O)N,,,,,,
103,440104,(S)-4-Hydroxymandelonitrile,C1=CC(=CC=C1[C@@H](C#N)O)O,,,,,,
104,440105,11a-Hydroxyprogesterone,CC(=O)C1CC[C@@H]2[C@@]1(C[C@H]([C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)O)C,,,,,,
105,440106,"(8S,9S,10R,13S,14S,16R)-17-acetyl-16-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one",CC(=O)C1[C@@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O,,,,,,
106,440107,"2,6-Dioxo-6-phenylhexanoic acid",C1=CC=C(C=C1)C(=O)CCCC(=O)C(=O)O,,,,,,
107,440108,"5-Amino-2,3,4,6-tetrahydroxyhexanoic acid",C(C(C(C(C(C(=O)O)O)O)O)N)O,,,,,,
108,440109,2-Methylpropanoyl phosphate,CC(C)C(=O)OP(=O)(O)O,,,,,,
109,440110,CID 440110,C[C@H]1[C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)O)N=C(N)N)O)N=C(N)N)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)O)NC)C=O,,,,,,
110,440111,"3,4-Dihydroxymandelonitrile",C1=CC(=C(C=C1C(C#N)O)O)O,,,,,,
111,440112,3-Imidazol-1-yl-2-oxopropanoic acid,C1=CN(C=N1)CC(=O)C(=O)O,,,,,,
112,440113,4-Hydroxyphenylacetaldehyde,C1=CC(=CC=C1CC=O)O,,,,,['2-(4-hydroxyphenyl)acetaldehyde is a known human metabolite of astemizole.'],
113,440114,Etiocholanedione,C[C@]12CCC(=O)C[C@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C,,,,,,
114,440115,N-Acetyl-D-mannosaminolactone,CC(=O)N[C@H]1[C@H]([C@@H]([C@H](OC1=O)CO)O)O,,,,,,
115,440116,"[(2S,3R,4R,5R,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl] dihydrogen phosphate",C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)OP(=O)(O)O)N)O)O)O,,,,,,
116,440117,"D-tagatofuranose 1,6-bisphosphate",C([C@@H]1[C@@H]([C@@H](C(O1)(COP(=O)(O)O)O)O)O)OP(=O)(O)O,,,,,,
117,440118,"N,6-O-Disulfo-D-glucosamine",C([C@@H]1[C@H]([C@@H]([C@H](C(O1)O)NS(=O)(=O)O)O)O)OS(=O)(=O)O,,,,,,
118,440119,(S)-2-((Carboxymethyl)amino)propanoic acid,C[C@@H](C(=O)O)NCC(=O)O,,,,,,
119,440120,"N6,N6,N6-Trimethyl-L-lysine",C[N+](C)(C)CCCC[C@@H](C(=O)[O-])N,,,"['Substances that stimulate mitosis and lymphocyte transformation. They include not only substances associated with LECTINS, but also substances from streptococci (associated with streptolysin S) and from strains of alpha-toxin-producing staphylococci. (Stedman, 25th ed) (See all compounds classified as Mitogens.)']",,,
120,440121,N-Trimethyllysine,C[N+](C)(C)CCCC[C@@H](C(=O)O)N,,,"['Substances that stimulate mitosis and lymphocyte transformation. They include not only substances associated with LECTINS, but also substances from streptococci (associated with streptolysin S) and from strains of alpha-toxin-producing staphylococci. (Stedman, 25th ed) (See all compounds classified as Mitogens.)']",,,
121,440122,Aspartyl adenylate,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)NC(CC(=O)O)C(=O)O,,,,,,
122,440123,Oleandomycin 2'-O-phosphate,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)O)OC)C)C)C)O)C)C)OP(=O)(O)O)N(C)C,,,,,,
123,440124,CID 440124,CC(=CCCC(=CCOP(=O)(O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)C)C,,,,,,
124,440125,CID 440125,C1=CC(=CC=C1C(=O)N[C@@H](CCC(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)N=C(N3)N,,,,,,
125,440126,S-methyl D-thioglycerate,CSC(=O)[C@@H](CO)O,,,,,,
126,440127,Stearoylglycerone phosphate,CCCCCCCCCCCCCCCCCC(=O)OCC(=O)COP(=O)(O)O,,,,,,
127,440128,alpha-D-Glucose 3-phosphate,C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O)O)OP(=O)(O)O)O)O,,,,,,
128,440129,(S)-2-hydroxy-3-(1H-imidazol-4-yl)propanoic acid,C1=C(NC=N1)C[C@@H](C(=O)O)O,,,,,,
129,440130,CID 440130,C[C@@H]([C@H](C(=O)C=C(O)O)O)O,,,,,,
130,440131,CID 440131,C([C@H](C=C(C(=O)O)O)O)O,,,,,,
131,440132,"2,4,5-Trihydroxyhex-2-enoic acid",CC(C(C=C(C(=O)O)O)O)O,,,,,,
132,440133,2-Deoxystreptamine phospahte,C1[C@H]([C@@H](C([C@@H]([C@H]1N)O)OP(=O)(O)O)O)N,,,,,,
133,440134,CID 440134,CC1=CC2=CC(=O)C=C(C2=C(O1)O)O,,,,,,
134,440135,"3,5,3'-Triiodothyropyruvic acid",C1=CC(=C(C=C1OC2=C(C=C(C=C2I)CC(=O)C(=O)O)I)I)O,,,,,,
135,440136,3beta-Hydroxy-delta5-steroid,CC12CCCC1C3CC=C4C[C@H](CCC4(C3CC2)C)O,,,,,,
136,440137,"[(2R,5R)-5-[(2-aminoacetyl)amino]-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate",C([C@@H]1C(C([C@@H](O1)NC(=O)CN)O)O)OP(=O)(O)O,,,,,,
137,440138,"5-exo-Hydroxy-1,2-campholide",CC1(C2CC(=O)OC1(C[C@H]2O)C)C,,,,,,
138,440139,6-Acetamido-3-aminohexanoic acid,CC(=O)NCCCC(CC(=O)O)N,,,,,,
139,440140,Planteose,C([C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)OC[C@@H]2[C@H]([C@@H]([C@](O2)(CO)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O)O)O)O)O,,,,,,
140,440141,Adenosine-2'-5'-diphosphate,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)OP(=O)(O)O)N,,,,,,
141,440142,Adenosine 5'-phosphoramidate,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(N)O)O)O)N,,,,,,
142,440143,"Androstan-3alpha,17beta-diol",CC12CCC3C(C1CC[C@@H]2O)CCC4C3(CC[C@H](C4)O)C,,,,,,
143,440144,Bis(glycerophospho)glycerol,C(C(COP(=O)(O)OCC(COP(=O)(O)OCC(CO)O)O)O)O,,,,,,
144,440145,Cholesteryl glucoside,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)C)C,,,,,,
145,440146,D-Fructosyl-D-fructofuranose,C([C@@H]1[C@H]([C@@H]([C@](O1)(COC[C@@H]2[C@H]([C@@H]([C@](O2)(CO)O)O)O)O)O)O)O,,,,,,
146,440147,D-Glucosyldihydrosphingosine,CCCCCCCCCCCCCCCC(C(CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)N)O,,,,,,
147,440148,deaminohydroxyblasticidin S,CN(CCC(CC(=O)N[C@H]1C=C[C@@H](O[C@@H]1C(=O)O)N2C=CC(=O)NC2=O)N)C(=N)N,,,,,,
148,440149,CID 440149,CC(CCC=C(C)CCC=C(C)C)CCOP(=O)(O)O[C@H]1[C@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
149,440150,Ethyl (R)-3-hydroxyhexanoate,CCC[C@H](CC(=O)OCC)O,,,,,,
150,440151,Ethyl (S)-3-hydroxyhexanoate,CCC[C@@H](CC(=O)OCC)O,,,,,,
151,440152,1D-1-O-(indol-3-yl)acetyl-myo-inositol,C1=CC=C2C(=C1)C(=CN2)CC(=O)OC3[C@@H]([C@H](C([C@H]([C@H]3O)O)O)O)O,,,,,,
152,440153,CID 440153,C[C@H]1[C@@H]([C@H]([C@H](C(O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C(C4=C(C=C(OC4=CC3=O)C5=CC(=C(C=C5)O)O)O)O)CO)O)O)O)O)O,,,,,,
153,440154,"[(2R,3S,4R,5R)-5-[6-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]purin-1-ium-9-yl]-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate",C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)N=C[N+](=C2N)[C@H]4[C@@H]([C@@H]([C@H](O4)COP(=O)(O)O)O)O,,,,,,
154,440155,"3,7,11,15,19,23,27,31,35-Nonamethylhexatriaconta-2,6,10,14,18,22,26,30,34-nonaenyl 4-hydroxybenzoate",CC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCOC(=O)C1=CC=C(C=C1)O)C)C)C)C)C)C)C)C)C,,,,,,
155,440156,"1,2-Propanediol, 1-phosphate",CC(COP(=O)(O)O)O,,,,,,
156,440157,CID 440157,C1=CC(=C(C=C1C2=C(C(=C3C(=CC(=CC3=O)OS(=O)(=O)O)O2)O)OS(=O)(=O)O)OS(=O)(=O)O)O,,,,,,
157,440158,CID 440158,C1=CC(=C(C=C1C2=C(C(=C3C(=CC(=CC3=O)OS(=O)(=O)O)O2)O)OS(=O)(=O)O)O)OS(=O)(=O)O,,,,,,
158,440159,Thiomorpholine-3-carboxylic acid,C1CSCC(N1)C(=O)O,,,,,,
159,440160,beta-L-Arabinose 1-phosphate,C1[C@@H]([C@@H]([C@H]([C@H](O1)OP(=O)(O)O)O)O)O,,,,,,
160,440161,"(3beta,24R,24'R)-fucosterol epoxide",C[C@@H]1[C@@](O1)(CC[C@@H](C)[C@H]2CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC=C5[C@@]4(CC[C@@H](C5)O)C)C)C(C)C,,,,,,
161,440162,(S)-1-pyrroline-5-carboxylate,C1C[C@H](N=C1)C(=O)O,,,,,,
162,440163,(S)-3-(indol-3-yl)-2-oxobutyric acid,C[C@@H](C1=CNC2=CC=CC=C21)C(=O)C(=O)O,,,,,,
163,440164,"4,7-Dihydroxy-N,N,N-trimethyl-4,10-dioxo-3,5,9-trioxa-4lambda~5~-phosphaheptacos-18-en-1-aminium",CCCCCCCCC=CCCCCCCCC(=O)OCC(COP(=O)(O)OCC[N+](C)(C)C)O,,,,,,
164,440165,2-dehydro-3-deoxy-D-glucaric acid,C([C@@H]([C@@H](C(=O)O)O)O)C(=O)C(=O)O,,,,,,
165,440166,3-Phosphoglycerol-glutathione,C(CC(=O)N[C@@H](CS)C(=O)NCC(=O)O)[C@@H](C(=O)OCC(COP(=O)(O)O)O)N,,,,,,
166,440167,3alpha-Hydroxyglycyrrhetinic acid,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O)C)(C)C(=O)O,,,,,,
167,440168,6beta-Hydroxyestradiol-17beta,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)C[C@H](C4=C3C=CC(=C4)O)O,,,,,,
168,440169,"(2R,4S)-2,4-diaminopentanoic acid",C[C@@H](C[C@H](C(=O)O)N)N,,,,,,
169,440170,CID 440170,COC1=C(C2=C([C@@H]3CCO[C@@H]3O2)C4=C1C(=C5C(=O)C=CC=C5O4)O)O,,,,,,
170,440171,"Glycerol 1,2-cyclic phosphate",C1C(OP(=O)(O1)O)CO,,,,,,
171,440172,N-glycoloyl-D-mannosaminolactone,C([C@@H]1[C@H]([C@@H]([C@@H](C(=O)O1)NC(=O)CO)O)O)O,,,,,,
172,440173,N-Acetylglucosamine 4-sulfate,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O)CO)OS(=O)(=O)O)O,,,,,,
173,440174,H-DL-Pyr-His-Pro-NH2,C1C[C@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)C3CCC(=O)N3)C(=O)N,,,,,,
174,440175,beta-Hydroxyaspartic acid,[C@H](C(C(=O)O)O)(C(=O)O)N,,,,,,
175,440176,Menthyl glucopyranoside,CC1CCC(C(C1)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)C(C)C,,,,,,
176,440177,(2R)-2-hydroxy-3-(4-hydroxyphenyl)propanoic acid,C1=CC(=CC=C1C[C@H](C(=O)O)O)O,,,,,,
177,440178,alpha-D-galactopyranosyl-(1->6)-beta-D-fructofuranosyl alpha-D-galactopyranosyl-(1->6)-alpha-D-glucopyranoside,C([C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@H](O2)O[C@]3([C@H]([C@@H]([C@H](O3)CO[C@@H]4[C@@H]([C@H]([C@H]([C@H](O4)CO)O)O)O)O)O)CO)O)O)O)O)O)O)O,,,,,,
178,440179,"(S)-2,3,4,5-tetrahydrodipicolinic acid",C1C[C@H](N=C(C1)C(=O)O)C(=O)O,,,,,,
179,440180,CID 440180,C([C@@H](C=C(C(=O)O)O)O)O,,,,,,
180,440181,"2-Oxo-4,5-dihydroxyhexanoic acid",CC(C(CC(=O)C(=O)O)O)O,,,,,,
181,440182,2-Deoxystreptamine 4-phosphate,C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)OP(=O)(O)O)O)O)N,,,,,,
182,440183,CID 440183,C(=C(O)O)C(=O)C(=O)O,,,,,,
183,440184,4-Hydroxy-3-iodophenylpyruvic acid,C1=CC(=C(C=C1CC(=O)C(=O)O)I)O,,,,,,
184,440185,3F-alpha-D-Galactosylraffinose,C([C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@H](O2)O[C@]3([C@H]([C@@H]([C@H](O3)CO)O)O[C@@H]4[C@@H]([C@H]([C@H]([C@H](O4)CO)O)O)O)CO)O)O)O)O)O)O)O,,,,,,
185,440186,4-(beta-D-glucosyloxy)benzoic acid,C1=CC(=CC=C1C(=O)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O,,,,,,
186,440187,4-Nitrophenyl-3-ketovalidamine,C1[C@@H]([C@H](C(=O)[C@H]([C@H]1NC2=CC=C(C=C2)[N+](=O)[O-])O)O)CO,,,,,,
187,440188,5'-O-beta-D-Glucosylpyridoxine,CC1=NC=C(C(=C1O)CO)CO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O,,,,,,
188,440189,5-Hydroxymethyldeoxycytidylic acid,C1[C@@H]([C@H](O[C@H]1N2C=C(C(=NC2=O)N)CO)COP(=O)(O)O)O,,,,,,
189,440190,CID 440190,CN1C=[N+](C2=C1C(=O)N=C(N2)N)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O,,,,,,
190,440191,"[[3-[2,3-Dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl] 2-aminopropanoate",CC(C(=O)OP(=O)(O)OCC(COP(=O)(O)OCC(CO)O)O)N,,,,,,
191,440192,Benzyl 2-methyl-3-oxobutanoate,CC(C(=O)C)C(=O)OCC1=CC=CC=C1,,,,,,
192,440193,CID 440193,C(CC(=O)O)C(=CC(=O)O)C(=O)O,,,,,,
193,440194,1D-myo-inositol 3-phosphate,[C@H]1([C@@H](C([C@H]([C@@H](C1O)O)O)OP(=O)(O)O)O)O,,,,,,
194,440195,Flavanone 7-O-glucoside,C1C(OC2=C(C1=O)C=CC(=C2)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)C4=CC=CC=C4,,,,,,
195,440196,"[(2R,3S,4S,5S,6S)-6-[(2R,3S,4R,5S,6S)-6-[(2R,3S,4R,5R,6S)-5-acetamido-6-[(2R,3S,4R,5R)-5-acetamido-6-[[(3S)-3-acetamido-4-amino-4-oxobutanoyl]amino]-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl dihydrogen phosphate",CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O[C@@H]2[C@H](OC([C@@H]([C@H]2O)NC(=O)C)NC(=O)C[C@@H](C(=O)N)NC(=O)C)CO)CO)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)CO)O[C@H]4[C@H]([C@H]([C@@H]([C@H](O4)COP(=O)(O)O)O)O)O)O)O)O,,,,,,
196,440197,N-acetyl-4-O-acetylneuraminic acid,CC(=O)N[C@@H]1[C@H](C[C@](O[C@H]1C(C(CO)O)O)(C(=O)O)O)OC(=O)C,,,,,,
197,440198,CID 440198,CC(=O)N[C@@H]1[C@H](C[C@](O[C@H]1C(C(CO)O)OC(=O)C)(C(=O)O)O)O,,,,,,
198,440199,"(2S,4S,5R,6R)-5-acetamido-6-(3-acetoxy-1,2-dihydroxy-propyl)-2,4-dihydroxy-tetrahydropyran-2-carboxylic acid",CC(=O)N[C@@H]1[C@H](C[C@](O[C@H]1C(C(COC(=O)C)O)O)(C(=O)O)O)O,,,,,,
199,440200,CID 440200,C1=CC(=CC=C1C2=CC(=C3C(=O)C=C(C(=C3O2)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O)O)O,,,,,,
200,440201,"2,3-Dihydroxybenzoyl 5'-adenylate",C1=CC(=C(C(=C1)O)O)C(=O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=CN=C43)N)O)O,,,,,,
201,440202,"1,3,6,8-Tetrahydroxynaphthalene",C1=C2C=C(C=C(C2=C(C=C1O)O)O)O,,,,,,
202,440203,1-phospho-alpha-D-galacturonic acid,[C@@H]1([C@H]([C@H](O[C@@H]([C@@H]1O)OP(=O)(O)O)C(=O)O)O)O,,,,,,
203,440204,"(10R,13S)-17-[(1S)-1-hydroxyethyl]-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one",C[C@@H](C1CCC2[C@@]1(CCC3C2CCC4=CC(=O)CC[C@]34C)C)O,,,,,,
204,440205,"S-[2-[3-[[4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] 3-hydroxy-2-methylpropanethioate",CC(CO)C(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
205,440206,4-Hydroxy-4-methyl-2-oxohexanedioic acid,CC(CC(=O)C(=O)O)(CC(=O)O)O,,,,,,
206,440207,"Hexuronic acid, 4-deoxy-5-keto-",C(C(C(C=O)O)O)C(=O)C(=O)O,,,,,,
207,440208,CID 440208,C/C/1=C/2\C(C(C([N-]2)/C=C/3\C(C(C([N-]3)/C(=C\4/C(C(C([N-]4)CC5C(C(C1[N-]5)(C)CCC(=O)NCC(C)OP(=O)([O-])O[C@H]6[C@@H](O[C@H]([C@@H]6O)N7C[N-]C8=C7C=C(C=C8)O)CO)CC(=O)N)(C)CC(=O)N)CCC(=O)N)/C)(C)CC(=O)N)CC(=O)N)(C)C)CCC(=O)N.[Co],,,,,,
208,440209,CID 440209,CC1=C2C(C(C(N2)C=C3C(C(C(N3)C(=C4C(C(C(N4)CC5C(C(C1N5)(C)CCC(=O)NCC(C)OP(=O)(O)O[C@@H]6[C@H](O[C@@H]([C@@H]6O)N7CNC8=C7C=C(C=C8)O)CO)CC(=O)N)(C)CC(=O)N)CCC(=O)N)C)(C)CC(=O)N)CC(=O)N)(C)C)CCC(=O)N,,,,,,
209,440210,Bis(adenosine)-5'-pentaphosphate,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)N,,,['Drugs used to cause constriction of the blood vessels. (See all compounds classified as Vasoconstrictor Agents.)'],,,
210,440211,"1D-myo-Inositol 3,4-bisphosphate",[C@@H]1([C@@H]([C@@H]([C@@H]([C@H]([C@@H]1O)OP(=O)(O)O)OP(=O)(O)O)O)O)O,,,,,,
211,440212,"(2R,3S)-2-(3,4-dihydroxyphenyl)-7-hydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxan-2-yl]oxy-2,3-dihydrochromen-4-one",C1[C@H]([C@@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H](OC4=C(C3=O)C=CC(=C4)O)C5=CC(=C(C=C5)O)O)O)O)O)O)O)O,,,,,,
212,440213,"(1R,2R,5S,8S,9S,10R,12S)-5-hydroxy-11-methyl-6-methylidene-16-oxo-12-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-15-oxapentacyclo[9.3.2.15,8.01,10.02,8]heptadecane-9-carboxylic acid",CC12[C@H](CC[C@@]3([C@@H]1[C@@H]([C@]45[C@H]3CC[C@](C4)(C(=C)C5)O)C(=O)O)OC2=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O,,,,,,
213,440214,Guanidinoethyl methyl phosphate,COP(=O)(O)OCCN=C(N)N,,,,,,
214,440215,Isoflavone 7-O-beta-D-glucoside,C1=CC=C(C=C1)C2=COC3=C(C2=O)C=CC(=C3)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O,,,,,,
215,440216,(2S)-2-amino-4-chloropent-4-enoic acid,C=C(C[C@@H](C(=O)O)N)Cl,,,,,,
216,440217,D-Pantothenoyl-L-cysteine,CC(C)(CO)[C@H](C(=O)NCCC(=O)N[C@@H](CS)C(=O)O)O,,,,,,
217,440218,"(10S,13S)-17-acetyl-10,13-dimethyl-1,2,6,7,8,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one",CC(=O)C1CCC2[C@@]1(CC=C3C2CCC4=CC(=O)CC[C@@]43C)C,,,,,,
218,440219,"[(2S,3R,4R,6R)-3,4-dihydroxy-6-methyl-5-oxooxan-2-yl] [[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] hydrogen phosphate",C[C@@H]1C(=O)[C@@H]([C@H]([C@@H](O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=O)NC3=O)O)O)O)O,,,,,,
219,440220,"2-[Hydroxy-(2-hydroxy-3-octadeca-9,12-dienoyloxypropoxy)phosphoryl]oxyethyl-trimethylazanium",CCCCCC=CCC=CCCCCCCCC(=O)OCC(COP(=O)(O)OCC[N+](C)(C)C)O,,,,,,
220,440221,"1,6-bis-O-galloyl-beta-D-glucose",C1=C(C=C(C(=C1O)O)O)C(=O)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC(=O)C3=CC(=C(C(=C3)O)O)O)O)O)O,,,,,,
221,440222,13-(beta-D-glucosyloxy)docosanoic acid,CCCCCCCCCC(CCCCCCCCCCCC(=O)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
222,440223,2-(Hydroxymethyl)-4-oxobutanoic acid,C(C=O)C(CO)C(=O)O,,,,,,
223,440224,20-Hydroxy-3-oxopregn-4-en-21-al,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(C=O)O)CCC4=CC(=O)CC[C@]34C,,,,,,
224,440225,CID 440225,C1=CC(=C(C=C1C2=C(C(=C3C(=CC(=O)C(=C3O2)O)O)O)O)O)O,,,,,,
225,440226,"2,8-Dihydroxy-1,4-naphthoquinone",C1=CC2=C(C(=C1)O)C(=O)C(=O)C=C2O,,,,,,
226,440227,3-(phosphoacetamido)-L-alanine,C([C@@H](C(=O)O)N)NC(=O)COP(=O)(O)O,,,,,,
227,440228,"3-Methylhexa-2,4-dienedioic acid",CC(=CC(=O)O)C=CC(=O)O,,,,,,
228,440229,(S)-Tetrahydrocolumbamine,COC1=C(C2=C(C[C@H]3C4=CC(=C(C=C4CCN3C2)OC)O)C=C1)OC,,,,,,
229,440230,"8-[[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-4,5,6,7-tetrahydroxy-2-oxooctanoic acid",C1=CN(C(=O)N=C1N)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OCC(C(C(C(CC(=O)C(=O)O)O)O)O)O)O)O,,,,,,
230,440231,(S)-1-Aminopropan-2-yl phosphate,C[C@@H](CN)OP(=O)(O)O,,,,,,
231,440232,"1-[1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyindol-3-yl]ethanone",CC(=O)C1=CN(C2=CC=CC=C21)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
232,440233,(R)-1-Aminopropan-2-yl phosphate,C[C@H](CN)OP(=O)(O)O,,,,,,
233,440234,Methyl 2-diazoacetamidohexanoate,CCCCC(C(=O)OC)(NC(=O)C)[N+]#N,,,,,,
234,440235,2-(Acetylamino)-2-Deoxy-6-O-Sulfo-Beta-D-Glucopyranose,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O)COS(=O)(=O)O)O)O,,,,,,
235,440236,N-Acetyl-L-glutamyl 5-phosphate,CC(=O)N[C@@H](CCC(=O)OP(=O)(O)O)C(=O)O,,,,,,
236,440237,N2-(1-Carboxyethyl)-L-arginine,CC(C(=O)O)N[C@@H](CCCN=C(N)N)C(=O)O,,,,,,
237,440238,N(alpha)-gamma-L-Glutamylhistamine,C1=C(NC=N1)CCNC(=O)CC[C@@H](C(=O)O)N,,,,,,
238,440239,"(4S)-4-amino-5-[[2-amino-6-[1,2-bis[[(2S)-2-amino-4-carboxybutanoyl]oxy]propyl]-5,8-dihydropteridin-4-yl]oxy]-5-oxopentanoic acid",CC(C(C1=CNC2=C(N1)C(=NC(=N2)N)OC(=O)[C@H](CCC(=O)O)N)OC(=O)[C@H](CCC(=O)O)N)OC(=O)[C@H](CCC(=O)O)N,,,,,,
239,440240,alpha-D-glucosyl-(1->3)-beta-D-mannose,C([C@@H]1[C@H]([C@@H]([C@@H]([C@@H](O1)O)O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O,,,,,,
240,440241,CID 440241,CC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCOP(=O)(O)O[C@H]1[C@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)C)C)C)C)C)C)C)C)C)C,,,,,,
241,440242,"[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] 3-phenylprop-2-enoate",C1=CC=C(C=C1)C=CC(=O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O,,,,,,
242,440243,(+)-neomenthyl beta-D-glucoside,C[C@@H]1CC[C@H]([C@H](C1)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)C(C)C,,,,,,
243,440244,Corchoionol C,CC1=CC(=O)CC(C1(C=CC(C)O)O)(C)C,,,,,,
244,440245,"trans-Acenaphthen-1,2-diol",C1=CC2=C3C(=C1)[C@@H]([C@H](C3=CC=C2)O)O,,,,,,
245,440246,CID 440246,CC=C(C)C(=O)O[C@H]1CCN2C[C@@H]3C[C@@H]([C@@H]2C1)CN4[C@@H]3CCCC4=O,,,,,,
246,440247,"[(2S,4S,5R)-4-hydroxy-5-(phosphonooxymethyl)oxolan-2-yl] dihydrogen phosphate",C1[C@@H]([C@H](O[C@H]1OP(=O)(O)O)COP(=O)(O)O)O,,,,,,
247,440248,3-Hydroxy-3-methyl-2-oxobutanoic acid,CC(C)(C(=O)C(=O)O)O,,,,,,
248,440249,4-Hydroxy-4-methyl-2-oxoglutaric acid,CC(CC(=O)C(=O)O)(C(=O)O)O,,,,,,
249,440250,5-Methyldeoxycytidine 5'-(trihydrogen diphosphate),CC1=CN(C(=O)N=C1N)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)O)O,,,,,,
250,440251,Methylthioribose 1-phosphate,CSC[C@@H]1[C@H]([C@H]([C@@H](O1)OP(=O)(O)O)O)O,,,,,,
251,440252,Dihydrostreptomycin 3''-phosphate,C[C@H]1[C@@]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)O)N=C(N)N)O)N=C(N)N)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)OP(=O)(O)O)NC)(CO)O,,,,,,
252,440253,"(2R,3S)-2-(3,4-dihydroxyphenyl)-7-hydroxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxan-2-yl]oxy-2,3-dihydrochromen-4-one",C1[C@H]([C@@H]([C@H]([C@@H](O1)OC[C@@H]2[C@@H]([C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H](OC4=C(C3=O)C=CC(=C4)O)C5=CC(=C(C=C5)O)O)O)O)O)O)O)O,,,,,,
253,440254,Flavonol-3-O-L-rhamnosylglucoside,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@@H]([C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H](OC4=C(C3=O)C=CC(=C4)O)C5=CC(=C(C=C5)O)O)O)O)O)O)O)O,,,,,,
254,440255,1-O-Indol-3-ylacetyl-beta-D-glucose,C1=CC=C2C(=C1)C(=CN2)CC(=O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
255,440256,L-Tyrosine methyl ester 4-sulfate,COC(=O)[C@H](CC1=CC=C(C=C1)OS(=O)(=O)O)N,,,,,,
256,440257,CID 440257,CC(=O)N[C@@H]1[C@H](C[C@](O[C@H]1C(C(CO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O)(C(=O)O)O)O,,,,,,
257,440258,2-Benzamido-4-methoxybenzoic acid,COC1=CC(=C(C=C1)C(=O)O)NC(=O)C2=CC=CC=C2,,,,,,
258,440259,Dencichin,C([C@@H](C(=O)O)N)NC(=O)C(=O)O,,,,,,
259,440260,CID 440260,C[C@@H](C(=O)O)N[C@H](CCCN)C(=O)O,,,,,,
260,440261,"3,7,11,15,19-Pentamethylicosa-2,6,10,14,18-pentaenyl phosphono hydrogen phosphate",CC(=CCCC(=CCCC(=CCCC(=CCCC(=CCOP(=O)(O)OP(=O)(O)O)C)C)C)C)C,,,,,,
261,440262,CID 440262,CCCCCCCCCCCCCCC(C(CCCCCCCC=CCCCCCC)O)C(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@H]2[C@H]([C@@H]([C@H]([C@@H](O2)CO)O)O)O)O)O)O,,,,,,
262,440263,"2-[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5,6-tetrahydroxyhexanal",C([C@@H]1[C@H]([C@@H]([C@](O1)(CO)OC(C=O)C(C(C(CO)O)O)O)O)O)O,,,,,,
263,440264,CID 440264,C1[C@H]([C@@H]([C@@H](C[C@]1(C(=O)O)O)OC2=CC=C(C=C2)C=CC(=O)O)O)O,,,,,,
264,440265,"4-Hydroxy-3,5,5-trimethyl-4-(3-oxo-1-butenyl)-2-cyclohexen-1-one",CC1=CC(=O)CC(C1(C=CC(=O)C)O)(C)C,,,,,,
265,440266,p-Hydroxyphenylethanolamine,C1=CC(=CC=C1[C@H](CN)O)O,,,"['Drugs that selectively bind to and activate alpha adrenergic receptors. (See all compounds classified as Adrenergic alpha-Agonists.)', 'Drugs used to cause constriction of the blood vessels. (See all compounds classified as Vasoconstrictor Agents.)']",,,
266,440267,"2,3,4,5-Tetrahydroxy-2-(phosphonooxymethyl)pentanoic acid",C(C(C(C(COP(=O)(O)O)(C(=O)O)O)O)O)O,,,,,,
267,440268,3-Carboxy-4-methyl-2-oxopentanoic acid,CC(C)C(C(=O)C(=O)O)C(=O)O,,,,,,
268,440269,3-Hydroxy-3-methyl-2-oxopentanoic acid,CCC(C)(C(=O)C(=O)O)O,,,,,,
269,440270,"Amino acid(Tyr-, Trp-, Phe-, Leu-)",CC(C)CC(C(=O)O)N.C1=CC=C(C=C1)CC(C(=O)O)N.C1=CC=C2C(=C1)C(=CN2)CC(C(=O)O)N.C1=CC(=CC=C1CC(C(=O)O)N)O,,,,,,
270,440271,N-Acetyl-D-galactosamine 6-sulfate,CC(=O)N[C@@H]1[C@H]([C@H]([C@H](O[C@H]1O)COS(=O)(=O)O)O)O,,,,,,
271,440272,N-Acetylglucosamine-1-phosphate,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](OC1OP(=O)(O)O)CO)O)O,,,,,,
272,440273,2-(acetylamino)-2-deoxy-6-O-phosphono-alpha-D-mannopyranose,CC(=O)N[C@H]1[C@H]([C@@H]([C@H](O[C@@H]1O)COP(=O)(O)O)O)O,,,,,,
273,440274,"N,N-Dimethyl-L-histidine",CN(C)[C@@H](CC1=CN=CN1)C(=O)O,,,,,,
274,440275,(4-Bromophenylsulfanyl)pyruvic acid,C1=CC(=CC=C1SCC(=O)C(=O)O)Br,,,,,,
275,440276,palmitoyl(-6)Glc(a1-1a)L-Glc,CCCCCCCCCCCCCCCC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@H]2[C@H]([C@@H]([C@H]([C@@H](O2)CO)O)O)O)O)O)O,,,,,,
276,440277,"[(2S,3R,4S,6R)-5-amino-3,4-dihydroxy-6-methyloxan-2-yl] [hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl] hydrogen phosphate",C[C@@H]1C([C@@H]([C@H]([C@@H](O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)O)O)N,,,,,,
277,440278,"[(2S,3R,4R,6R)-3,4-dihydroxy-6-methyl-5-oxooxan-2-yl] [hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl] hydrogen phosphate",C[C@@H]1C(=O)[C@@H]([C@H]([C@@H](O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)O)O,,,,,,
278,440279,"(R)-2,3-Dihydroxy-isovalerate",CC(C)([C@H](C(=O)O)O)O,,,,,,
279,440280,"[(2S,3R,4S,5S,6R)-4,5-dihydroxy-2-[3-(4-hydroxy-3,5-dimethoxyphenyl)prop-2-enoyloxy]-6-(hydroxymethyl)oxan-3-yl] 3-(4-hydroxy-3,5-dimethoxyphenyl)prop-2-enoate",COC1=CC(=CC(=C1O)OC)C=CC(=O)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC(=O)C=CC3=CC(=C(C(=C3)OC)O)OC)CO)O)O,,,,,,
280,440281,1-Guanidino-1-deoxy-scyllo-inositol,[C@H]1([C@H](C([C@H]([C@@H](C1N=C(N)N)O)O)O)O)O,,,,,,
281,440282,1-Pyrroline-4-hydroxy-2-carboxylate,C1C(CN=C1C(=O)O)O,,,,,,
282,440283,"3,5-Dibromo-4-hydroxyphenylpyruvic acid",C1=C(C=C(C(=C1Br)O)Br)CC(=O)C(=O)O,,,,,,
283,440284,"3,5-Dinitro-4-hydroxyphenylpyruvic acid",C1=C(C=C(C(=C1[N+](=O)[O-])O)[N+](=O)[O-])CC(=O)C(=O)O,,,,,,
284,440285,"2,3-Dioxo-2,3,4-trideoxy-epi-inositol",C1[C@@H]([C@H]([C@@H](C(=O)C1=O)O)O)O,,,,,,
285,440286,4-(3-Methylbut-2-enyl)-L-tryptophan,CC(=CCC1=C2C(=CC=C1)NC=C2C[C@@H](C(=O)O)N)C,,,,,,
286,440287,"[[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2S,3R,6R)-3-hydroxy-6-methyl-5-oxooxan-2-yl] hydrogen phosphate",C[C@@H]1C(=O)C[C@H]([C@@H](O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=NC3=O)N)O)O)O,,,,,,
287,440288,"(2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[[(17R)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl]oxy]oxane-2-carboxylic acid",CC12CCC3C(C1CC[C@H]2O)CCC4=C3C=CC(=C4)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)C(=O)O)O)O)O,,,,,,
288,440289,N-(5-phospho-beta-D-ribosyl)anthranilic acid,C1=CC=C(C(=C1)C(=O)O)N[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O,,,,,,
289,440290,N-Benzoyl-D-arginine-4-nitroanilide,C1=CC=C(C=C1)C(=O)N[C@H](CCCN=C(N)N)C(=O)NC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
290,440291,CID 440291,C1[C@@H]([C@H]([C@@H](O[C@@]1(C(=O)O)O)C(C(CO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O)NC(=O)CO)O,,,,,,
291,440292,"P(1),P(2)-bis(5'-adenosyl) triphosphate",C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)OP(=O)(O)O)O)O)N,,,,,,
292,440293,2-Hydroxy-3-phosphonooxybut-3-enoic acid,C=C(C(C(=O)O)O)OP(=O)(O)O,,,,,,
293,440294,"(1R,2S)-1,2-Dihydronaphthalene-1,2-diol",C1=CC=C2[C@H]([C@H](C=CC2=C1)O)O,,,,,,
294,440295,(1-Hydroxycyclohexan-1-yl)acetyl-CoA; (Acyl-CoA); [M+H]+,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)CC4(CCCCC4)O)O,,,,,,
295,440296,"Methyl 3beta,4beta,16-trihydroxy-1-methyl-6,7-didehydro-2beta,5alpha,12beta,19alpha-aspidospermidine-3alpha-carboxylate",CC[C@@]12C=CCN3[C@@H]1[C@]4(CC3)[C@H]([C@]([C@@H]2O)(C(=O)OC)O)N(C5=C4C=CC(=C5)O)C,,,,,,
296,440297,"3,5-Dichloro-4-hydroxyphenylpyruvate",C1=C(C=C(C(=C1Cl)O)Cl)CC(=O)C(=O)O,,,,,,
297,440298,CID 440298,C[C@H]1[C@@H]2[C@H](N(C=[N+]2C3=C(N1)NC(=NC3=O)N)C4=CC=C(C=C4)C[C@@H]([C@@H]([C@@H](CO[C@@H]5[C@@H]([C@@H]([C@H](O5)COP(=O)(O)O[C@@H](CCC(=O)O)C(=O)O)O)O)O)O)O)C,,,,,,
298,440299,"bis-D-fructos 2',1:2,1'-dianhydride",C1[C@@]2([C@H]([C@@H]([C@H](O2)CO)O)O)OC[C@]3(O1)[C@H]([C@@H]([C@H](O3)CO)O)O,,,,,,
299,440300,N-Glycolyl-D-mannosamine 6-phosphate,C([C@@H]1[C@H]([C@@H]([C@@H]([C@@H](O1)O)NC(=O)CO)O)O)OP(=O)(O)O,,,,,,
300,440301,"[(2S,3R,4S,5R,6R)-5-amino-3,4-dihydroxy-6-methyloxan-2-yl] [hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl] hydrogen phosphate",C[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)O)O)N,,,,,,
301,440302,malyl-CoA,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)C[C@@H](C(=O)O)O)O,,,,,,
302,440303,"3-deoxy-D-glycero-hexo-2,5-diulosonic acid",C([C@@H](C(=O)CO)O)C(=O)C(=O)O,,,,,,
303,440304,N-[(R)-4-phosphopantothenoyl]-L-cysteine,CC(C)(COP(=O)(O)O)[C@H](C(=O)NCCC(=O)N[C@@H](CS)C(=O)O)O,,,,,,
304,440305,2-(beta-D-glucopyranosyluronic acid)-D-glucuronic acid,[C@@H]1([C@@H]([C@H](O[C@H]([C@@H]1O)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2O)C(=O)O)O)O)C(=O)O)O)O,,,,,,
305,440306,"1-(3,4-Dimethylphenyl)ethane-1,2-diol",CC1=C(C=C(C=C1)C(CO)O)C,,,,,,
306,440307,"(2,3,4,5-Tetrahydroxy-6-oxoheptyl) dihydrogen phosphate",CC(=O)C(C(C(C(COP(=O)(O)O)O)O)O)O,,,,,,
307,440308,"1,2,6-Trigalloylglucose",C1=C(C=C(C(=C1O)O)O)C(=O)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC(=O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O)O)O,,,,,,
308,440309,"4-(Carboxymethylidene)hepta-2,5-dienedioic acid",C(=CC(=O)O)C(=CC(=O)O)C=CC(=O)O,,,,,,
309,440310,"3-(4-Hydroxy-3,5-diiodophenyl)lactic acid",C1=C(C=C(C(=C1I)O)I)CC(C(=O)O)O,,,,,,
310,440311,3-Amino-3-(4-hydroxyphenyl)propanoic acid,C1=CC(=CC=C1C(CC(=O)O)N)O,,,,,,
311,440312,3-Sulfanyl-2-(sulfanylmethyl)propanoic acid,C(C(CS)C(=O)O)S,,,,,,
312,440313,"[(2R,5R)-5-[(2-formamidoacetyl)amino]-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate",C([C@@H]1C(C([C@@H](O1)NC(=O)CNC=O)O)O)OP(=O)(O)O,,,,,,
313,440314,CID 440314,C[C@H]1[C@@H]2[C@H](N(CN2C3=C(N1)NC(=NC3=O)N)C4=CC=C(C=C4)C[C@@H]([C@@H]([C@@H](CO[C@@H]5[C@@H]([C@@H]([C@H](O5)COP(=O)(O)O[C@@H](CCC(=O)O)C(=O)O)O)O)O)O)O)C,,,,,,
314,440315,7-(5-phospho-alpha-D-ribosyl)adenine,C1=NC(=C2C(=N1)N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)N,,,,,,
315,440316,"9,11alpha-Epoxypregn-4-ene-3,20-dione",CC(=O)[C@H]1CC[C@@H]2[C@@]1(C[C@@H]3[C@]4([C@H]2CCC5=CC(=O)CC[C@@]54C)O3)C,,,,,,
316,440317,Phosphothiophosphoric acid-adenylate ester,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=S)(O)O)O)O)N,,,"['Analogs of those substrates or compounds which bind naturally at the active sites of proteins, enzymes, antibodies, steroids, or physiological receptors. These analogs form a stable covalent bond at the binding site, thereby acting as inhibitors of the proteins or steroids. (See all compounds classified as Affinity Labels.)']",,,
317,440318,CID 440318,C[C@H]1[C@@]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)O)N=C(N)N)O)N=C(N)N)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)O)NC)(CO)OP(=O)(O)O,,,,,,
318,440319,CID 440319,C1=CC(=C(C=C1[C@@H]2[C@@H](C(=O)C3=C(O2)C=C(C=C3)OC(=O)CC(=O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O,,,,,,
319,440320,"n2-(1,3-Dicarboxypropyl)-l-arginine",C(C[C@@H](C(=O)O)NC(CCC(=O)O)C(=O)O)CN=C(N)N,,,,,,
320,440321,"(2S,6S)-2-acetamido-6-aminoheptanedioic acid",CC(=O)N[C@@H](CCC[C@@H](C(=O)O)N)C(=O)O,,,,,,
321,440322,"P1,P4-Bis(5'-xanthosyl) tetraphosphate",C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C5NC(=O)NC6=O)O)O)O)O)NC(=O)NC2=O,,,,,,
322,440323,CID 440323,C[C@H](C(=O)N[C@H](CON)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C)C(=O)O)NC(=O)[C@@H](C)O[C@@H]1[C@H]([C@@H](O[C@@H]([C@H]1O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)NC(=O)C)CO)O)NC(=O)C,,,,,,
323,440324,S-methyl 3-phospho-1-thio-D-glycerate,CSC(=O)[C@@H](COP(=O)(O)O)O,,,,,,
324,440325,CID 440325,CC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCOP(=O)(O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)C)C)C)C)C)C)C)C)C)C)C,,,,,,
325,440326,2-methyl-3-hydroxybutyryl-CoA,C[C@@H]([C@H](C)O)C(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
326,440327,"[2-decanoyloxy-3-[hydroxy-[(2R,3S,5R,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxypropyl] decanoate",CCCCCCCCCC(=O)OCC(COP(=O)(O)OC1[C@@H]([C@H](C([C@H]([C@H]1O)O)O)O)O)OC(=O)CCCCCCCCC,,,,,,
327,440328,"3-[4-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyphenyl]prop-2-enoic acid",C1=CC(=CC=C1C=CC(=O)O)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2O)O)O)CO,,,,,,
328,440329,"(3S,5R,9S,10R,13R,14R,17R)-17-[(2R,5R)-5,6-dimethylhept-3-en-2-yl]-10,13-dimethyl-1,2,3,4,6,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthrene-3,5-diol",C[C@H](C=C[C@H](C)C(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3C2=CC[C@@]4([C@@]3(CC[C@@H](C4)O)C)O)C,,,,,,
329,440330,Glc(?1-4)Glc(?1-6)a-Glc,C([C@@H]1[C@H]([C@@H]([C@H](C(O1)O[C@@H]2[C@H](OC([C@@H]([C@H]2O)O)OC[C@@H]3[C@H]([C@@H]([C@H]([C@H](O3)O)O)O)O)CO)O)O)O)O,,,,,,
330,440331,"N-Acetyl-L-phenylalanyl-3,5-diiodo-L-tyrosine",CC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC(=C(C(=C2)I)O)I)C(=O)O,,,,,,
331,440332,"bis-beta-D-fructofuranose 1,2':2,3'-dianhydride",C1[C@@]2([C@H]([C@@H]([C@H](O2)CO)O)O)O[C@H]3[C@@H]([C@H](O[C@]3(O1)CO)CO)O,,,,,,
332,440333,"N-succinyl-LL-2,6-diaminopimelic acid",C(C[C@@H](C(=O)O)N)C[C@@H](C(=O)O)NC(=O)CCC(=O)O,,,,,,
333,440334,CID 440334,C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C4NC=NC5=O)O)O)O)O)C(=O)N,,,,,,
334,440335,S-(8-amino-8-oxo-1-sulfanyloctan-3-yl) 2-methylpropanethioate,CC(C)C(=O)SC(CCCCC(=O)N)CCS,,,,,,
335,440336,S-adenosyl-4-methylthio-2-oxobutanoate,C[S+](CCC(=O)C(=O)O)C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O,,,,,,
336,440337,Uridine 5'-diphosphoric acid beta-[4-O-sulfo-2-(acetylamino)-2-deoxy-beta-D-galactopyranosyl] ester,CC(=O)N[C@@H]1[C@H]([C@H]([C@H](O[C@H]1OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=O)NC3=O)O)O)CO)OS(=O)(=O)O)O,,,,,,
337,440338,CID 440338,CC(=O)N[C@@H]1[C@H]([C@H]([C@H](O[C@H]1OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=O)NC3=O)O)O)C(=O)O)O)O,,,,,,
338,440339,alpha-D-Galactosyl-N-acetyllactosamine,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O)CO[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO[C@@H]3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)O)O)O)O)O)O)O,,,,,,
339,440340,"2-Methyl-5-isopropylhexa-2,5-dienal",CC(C)C(=C)CC=C(C)C=O,,,,,,
340,440341,1-(5-Phosphoribosyl)imidazole-4-acetate,C1=C(N=CN1[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O)CC(=O)O,,,,,,
341,440342,2-(3-Carboxy-3-aminopropyl)-L-histidine,C1=C(NC(=N1)CCC(C(=O)O)N)C[C@@H](C(=O)O)N,,,,,,
342,440343,"3-(3,4-dihydroxypyridinium-1-yl)-L-alanine",C1=C[N+](=CC(=C1O)O)C[C@@H](C(=O)O)N,,,,,,
343,440344,"4-Methoxy-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid",CN1C=CC(=C(C1=O)C(=O)O)OC,,,,,,
344,440345,4alpha-Methyl-5alpha-cholest-7-en-3-one,C[C@H]1[C@@H]2CC=C3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@]2(CCC1=O)C)C)[C@H](C)CCCC(C)C,,,,,,
345,440346,CID 440346,C[C@H](C(=O)N[C@@H](C)C(=O)OP(=O)(O)OCC(COP(=O)(O)OCC(CO)O)O)N,,,,,,
346,440347,"Dihydrostreptomycin 3'',6-bisphosphate",C[C@H]1[C@@]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)OP(=O)(O)O)N=C(N)N)O)N=C(N)N)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)OP(=O)(O)O)NC)(CO)O,,,,,,
347,440348,"[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(phosphonooxymethyl)oxan-2-yl] dihydrogen phosphate",CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OP(=O)(O)O)COP(=O)(O)O)O)O,,,,,,
348,440349,(2S)-2-(3-carboxypropanamido)-6-oxoheptanedioic acid,C(C[C@@H](C(=O)O)NC(=O)CCC(=O)O)CC(=O)C(=O)O,,,,,,
349,440350,CID 440350,CCCCCCCCCCCCCCC(C(CCCCCCCC=CCCCCCC)O)C(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@H]2[C@H]([C@@H]([C@H]([C@@H](O2)COC(=O)C(CCCCCCCCCCCCCC)C(CCCCCCCC=CCCCCCC)O)O)O)O)O)O)O,,,,,,
350,440351,"(3S,4R)-3,4-dihydrophenanthrene-3,4-diol",C1=CC=C2C(=C1)C=CC3=C2[C@H]([C@H](C=C3)O)O,,,,,,
351,440352,"(4S,5S)-4,5-dihydroxy-2,6-dioxohexanoic acid",C([C@@H]([C@@H](C=O)O)O)C(=O)C(=O)O,,,,,,
352,440353,CID 440353,C1[C@H]([C@H]([C@H](OC1(C(=O)O)O)[C@H](COP(=O)(O)O)O)O)O,,,,,,
353,440354,CID 440354,C(=CO)C=C(C(=O)C(=O)O)C(=O)O,,,,,,
354,440355,"(4R)-4-[(3R,5R,8R,9S,10S,12S,14S,17R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid",C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2C1([C@H](C[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C,,,,,,
355,440356,"5-(4-Acetoxybut-1-ynyl)-2,2'-bithiophene",CC(=O)OCCC#CC1=CC=C(S1)C2=CC=CS2,,,,,,
356,440357,"5-(4-Hydroxybut-1-ynyl)-2,2'-bithiophene",C1=CSC(=C1)C2=CC=C(S2)C#CCCO,,,,,,
357,440358,CID 440358,C[C@H]1[C@@H](N(C2=C(N1)NC(=NC2=O)N)C)[C@H](C)NC3=CC=C(C=C3)C[C@@H]([C@@H]([C@@H](CO[C@@H]4[C@@H]([C@@H]([C@H](O4)COP(=O)(O)O[C@@H](CCC(=O)O)C(=O)O)O)O)O)O)O,,,,,,
358,440359,"(4S)-4-amino-5-[[2-amino-6-[1,2-bis[[(2S)-2-amino-4-carboxybutanoyl]oxy]propyl]-5-methyl-8H-pteridin-4-yl]oxy]-5-oxopentanoic acid",CC(C(C1=CNC2=C(N1C)C(=NC(=N2)N)OC(=O)[C@H](CCC(=O)O)N)OC(=O)[C@H](CCC(=O)O)N)OC(=O)[C@H](CCC(=O)O)N,,,,,,
359,440360,CID 440360,C[C@@H]1[C@H]([C@@H]([C@@H]([C@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3C=C4C(=CC(=CC4=[O+]C3C5=CC(=C(C=C5)O)O)O)O)O)O)O)O)O)O.[Cl-],,,,,,
360,440361,CID 440361,C[C@@H]1[C@H]([C@@H]([C@@H]([C@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3C=C4C(=CC(=CC4=[O+]C3C5=CC(=C(C=C5)O)O)O)O)O)O)O)O)O)O,,,,,,
361,440362,p-Cumaroylagmatin,C1=CC(=CC=C1C=CC(=O)NCCCCN=C(N)N)O,,,,,,
362,440363,"[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl] [hydroxy(3,7,11-trimethyldodeca-6,10-dienoxy)phosphoryl] hydrogen phosphate",CC(CCC=C(C)CCC=C(C)C)CCOP(=O)(O)OP(=O)(O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)NC(=O)C,,,,,,
363,440364,N-acetyl-alpha-D-glucosamine 1-phosphate,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1OP(=O)(O)O)CO)O)O,,,,,,
364,440365,N'-phosphoguanidinoethyl methyl hydrogen phosphate,COP(=O)(O)OCCN=C(N)NP(=O)(O)O,,,,,,
365,440366,CID 440366,CC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCOP(=O)(O)OP(=O)(O)O[C@@H]1[C@@H]([C@H]([C@H]([C@H](O1)CO)O)O)O)C)C)C)C)C)C)C)C)C)C)C,,,,,,
366,440367,"[3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] [(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hydrogen phosphate",C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)OP(=O)(O)OCC(COP(=O)(O)OCC(CO)O)O)O)O)O)O,,,,,,
367,440368,"(20S)-17,20-dihydroxypregn-4-en-3-one",C[C@@H]([C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O)O,,,,,,
368,440369,"(1R,2R,3S,5R)-2-acetamido-7-(1,2-dihydroxyethyl)-3-hydroxy-6,8-dioxabicyclo[3.2.1]octane-5-carboxylic acid",CC(=O)N[C@@H]1[C@H](C[C@]2(O[C@H]1C(O2)C(CO)O)C(=O)O)O,,,,,,
369,440370,"2-(3,4-Dihydroxybenzoyloxy)-4,6-dihydroxybenzoic acid",C1=CC(=C(C=C1C(=O)OC2=CC(=CC(=C2C(=O)O)O)O)O)O,,,,,,
370,440371,Fecosterol,C[C@H](CCC(=C)C(C)C)[C@H]1CC[C@@H]2[C@@]1(CCC3=C2CC[C@@H]4[C@@]3(CC[C@@H](C4)O)C)C,,,,,,
371,440372,CID 440372,C[C@H]1[C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)O)N=C(N)N)O)N=C(N)N)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)OP(=O)(O)O)NC)C=O,,,,,,
372,440373,CID 440373,COC1=C2C(=C(C(=C(O2)C3=CC(=C(C=C3)O)O)O)O)C(=CC1=O)O,,,,,,
373,440374,"(3S,4R)-3-hydroxytetradecane-1,3,4-tricarboxylic acid",CCCCCCCCCC[C@@H](C(=O)O)[C@@](CCC(=O)O)(C(=O)O)O,,,,,,
374,440375,"4,4-Dimethylcholest-7-ene-3-ol",C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CCC3C2=CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)C,,,,,,
375,440376,6-phospho-beta-D-glucosyl-(1->4)-beta-D-glucose,C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)O)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O)O)O,,,,,,
376,440377,Mg-Protoporphyrin IX 13-monomethyl ester,CC1=C(C2=CC3=NC(=CC4=C(C(=C([N-]4)C=C5C(=C(C(=N5)C=C1[N-]2)C=C)C)C=C)C)C(=C3CCC(=O)O)C)CCC(=O)OC.[Mg+2],,,,,,
377,440378,CID 440378,CC(CCC=C(C)CCC=C(C)C)CCOP(=O)(O)OP(=O)(O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)NC(=O)C)O)NC(=O)C,,,,,,
378,440379,N5-Dinitrophenyl-L-ornithine methyl ester,COC(=O)[C@H](CCCN(C1=CC=C(C=C1)[N+](=O)[O-])C2=CC=C(C=C2)[N+](=O)[O-])N,,,,,,
379,440380,Homoglutathione,C(CC(=O)N[C@@H](CS)C(=O)NCCC(=O)O)[C@@H](C(=O)O)N,,,,,,
380,440381,CID 440381,C[C@H](CC(=O)O[C@@H](C)CC(=O)O)O,,,,,,
381,440382,"4,4'-Dihydroxy-3,3'-dimethoxy-stilbene",COC1=C(C=CC(=C1)C=CC2=CC(=C(C=C2)O)OC)O,,,,,,
382,440383,"2-(Carboxymethyl)-5-oxo-2,5-dihydro-3-furoic acid",C1=C(C(OC1=O)CC(=O)O)C(=O)O,,,,,,
383,440384,"3,7-Dihydroxycoprostanic acid",C[C@H](CCCC(C)C(=O)O)C1CCC2[C@@]1(CCC3C2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C,,,,,,
384,440385,"4-Carboxymethyl-4-methylbut-2-en-1,4-olide",CC1(C=CC(=O)O1)CC(=O)O,,,,,,
385,440386,"benzyl (2R,3S)-3-hydroxy-2-methylbutanoate",C[C@H]([C@H](C)O)C(=O)OCC1=CC=CC=C1,,,,,,
386,440387,"Benzyl (2S,3S)-2-methyl-3-hydroxybutanoate",C[C@@H]([C@H](C)O)C(=O)OCC1=CC=CC=C1,,,,,,
387,440388,"1D-myo-inositol 1,2,4,5,6-pentakisphosphate",[C@@H]1([C@H](C([C@H]([C@@H](C1O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O,,,,,,
388,440389,UDP-N-Acetyl-2-amino-2-deoxy-D-glucronate,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=O)NC3=O)O)O)C(=O)O)O)O,,,,,,
389,440390,"2,3-Diketogulonic acid",C([C@@H]([C@H](C(=O)C(=O)C(=O)O)O)O)O,,,,,,
390,440391,"3-Hydroxy-16-methoxy-2,3-dihydrotabersonine",CC[C@]12C[C@@]([C@H]3[C@@]4([C@H]1N(CC4)CC=C2)C5=C(N3)C=C(C=C5)OC)(C(=O)OC)O,,,,,,
391,440392,"(4S)-5beta-(Acetylamino)-4alpha-hydroxy-6alpha-(1,2,3-trihydroxypropyl)-5,6-dihydro-4H-pyran-2-carboxylic acid",CC(=O)N[C@@H]1[C@H](C=C(O[C@H]1C(C(CO)O)O)C(=O)O)O,,,,,,
392,440393,"(2R,3R,4S,5R)-2-(6-hydroxy-3,6-dihydropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol",C1=NC(C2=C(N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
393,440394,"6-Imino-5-oxocyclohexa-1,3-dienecarboxylic acid",C1=CC(=O)C(=N)C(=C1)C(=O)O,,,,,,
394,440395,"Diethyl (2R,3R)-2-methyl-3-hydroxysuccinate",CCOC(=O)[C@H](C)[C@H](C(=O)OCC)O,,,,,,
395,440396,"Diethyl (2S,3R)-2-methyl-3-hydroxysuccinate",CCOC(=O)[C@@H](C)[C@H](C(=O)OCC)O,,,,,,
396,440397,"[(2S,3R,4R,5R,6R)-3-acetamido-4-hydroxy-5-sulfooxy-6-(sulfooxymethyl)oxan-2-yl] [[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] hydrogen phosphate",CC(=O)N[C@@H]1[C@H]([C@H]([C@H](O[C@H]1OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=O)NC3=O)O)O)COS(=O)(=O)O)OS(=O)(=O)O)O,,,,,,
397,440398,"[2-Hydroxy-3-(3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenoxy)propyl] dihydrogen phosphate",CC(=CCCC(=CCCC(=CCCC(=CCOCC(COP(=O)(O)O)O)C)C)C)C,,,,,,
398,440399,"(1S,2R)-3-Methylcyclohexa-3,5-diene-1,2-diol",CC1=CC=C[C@@H]([C@@H]1O)O,,,,,,
399,440400,"(2R,3R)-3-hydroxybutane-1,2,3-tricarboxylic acid",C[C@@]([C@@H](CC(=O)O)C(=O)O)(C(=O)O)O,,,,,,
400,440401,CID 440401,CCCCC[C@@H]1C(=CC=CCCCCCCCC(=O)O)O1,,,,,,
401,440402,"1,2-Bis(3,4-dimethoxyphenyl)propane-1,3-diol",COC1=C(C=C(C=C1)C(CO)C(C2=CC(=C(C=C2)OC)OC)O)OC,,,,,,
402,440403,"5-Hydroxy-6-methylpyridine-3,4-dicarboxylic acid",CC1=NC=C(C(=C1O)C(=O)O)C(=O)O,,,,,,
403,440404,"5-(3,4-Diacetoxybut-1-ynyl)-2,2'-bithiophene",CC(=O)OCC(C#CC1=CC=C(S1)C2=CC=CS2)OC(=O)C,,,,,,
404,440405,beta-D-Galp-(1->3)-beta-D-GalpNAc,CC(=O)N[C@@H]1[C@H]([C@H]([C@H](O[C@H]1O)CO)O)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O)O,,,,,,
405,440406,(indol-3-ylacetyl)-myo-inositol 3-L-arabinoside,C1[C@@H]([C@@H]([C@H]([C@H](O1)OC2[C@@H]([C@@H](C([C@H]([C@@H]2O)O)OC(=O)CC3=CNC4=CC=CC=C43)O)O)O)O)O,,,,,,
406,440407,"UDP-2-acetamido-4-dehydro-2,6-dideoxy-beta-D-glucose",C[C@@H]1C(=O)[C@@H]([C@H]([C@@H](O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=O)NC3=O)O)O)NC(=O)C)O,,,,,,
407,440408,CID 440408,CC(CCC=C(C)CCC=C(C)C)CCOP(=O)(O)OP(=O)(O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O[C@@H]3[C@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)NC(=O)C)O)NC(=O)C,,,,,,
408,440409,L-threo-isocitric acid,C([C@H]([C@@H](C(=O)O)O)C(=O)O)C(=O)O,,,,,,
409,440410,"2,4-Dichloro-5-oxo-2,5-dihydro-2-furylacetic acid",C1=C(C(=O)OC1(CC(=O)O)Cl)Cl,,,,,,
410,440411,CID 440411,C[C@@H]([C@@H](C(=O)O)NC(=O)CCCCCCS)OP(=O)(O)O,,,,,,
411,440412,"[(2S,3R,4S,5S,6R)-3-acetamido-5-amino-4-hydroxy-6-methyloxan-2-yl] [[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] hydrogen phosphate",C[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=O)NC3=O)O)O)NC(=O)C)O)N,,,,,,
412,440413,Uridine 5'-diphosphoric acid beta-[2-acetylamino-2-deoxy-3-O-(1-carboxyethenyl)-beta-D-glucopyranosyl] ester,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=O)NC3=O)O)O)CO)O)OC(=C)C(=O)O,,,,,,
413,440414,"1,2-Dihydroxycyclohexa-3,5-diene-1-carboxylate",C1=CC(C(C=C1)(C(=O)O)O)O,,,,,,
414,440415,"2,3-Bis(3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenoxy)propyl dihydrogen phosphate",CC(=CCCC(=CCCC(=CCCC(=CCOCC(COP(=O)(O)O)OCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C)C)C)C,,,,,,
415,440416,"5,6-Dihydrouridine 5'-monophosphate",C1CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O,,,,,,
416,440417,2-(Formamido)-N1-(5'-phosphoribosyl)acetamidine,C([C@@H]1[C@H]([C@H]([C@@H](O1)N=C(CNC=O)N)O)O)OP(=O)(O)O,,,,,,
417,440418,Poly(galactosylglycerol phosphate),C([C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)OC(CO)COP(=O)(O)O)O)O)O)O,,,,,,
418,440419,"(4S)-4-[(3R,5S,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-7-oxo-1,2,3,4,5,6,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]pentanoic acid",C[C@@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2C(=O)C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C,,,,,,
419,440420,"3alpha,7alpha-Dihydroxy-5beta-cholestanoyl-CoA",CC(CCCC(C)C(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O)C4CCC5[C@@]4(CCC6C5[C@@H](C[C@H]7[C@@]6(CC[C@H](C7)O)C)O)C,,,,,,
420,440421,"[(2R,3S,4S,5S,6R)-6-[[(2R,3S,4S,5S,6S)-6-[(2R,3S,4R,5R,6S)-5-acetamido-6-[(2R,3S,4R,5R)-5-acetamido-6-[[(3S)-3-acetamido-4-amino-4-oxobutanoyl]amino]-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methoxy]-3,4,5-trihydroxyoxan-2-yl]methyl [(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hydrogen phosphate",CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O[C@@H]2[C@H](OC([C@@H]([C@H]2O)NC(=O)C)NC(=O)C[C@@H](C(=O)N)NC(=O)C)CO)CO)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)CO[C@H]4[C@H]([C@H]([C@@H]([C@H](O4)COP(=O)(O)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O)O)O)O)O)O)O,,,,,,
421,440422,CID 440422,C(CP(=O)CO)[C@@H](C(=O)O)N,,,,,,
422,440423,"[(2S,3R,4R,5S,6R)-2-[[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-5-hydroxy-6-(hydroxymethyl)-3-(3-hydroxytetradecanoylamino)oxan-4-yl] 3-hydroxytetradecanoate",CCCCCCCCCCCC(CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=O)NC3=O)O)O)CO)O)OC(=O)CC(CCCCCCCCCCC)O)O,,,,,,
423,440424,"7-[(1R,2R,3R)-3-hydroxy-5-oxo-2-(3-oxooct-1-enyl)cyclopentyl]heptanoic acid",CCCCCC(=O)C=C[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O,,,,,,
424,440425,"(2S,3R)-2-hydroxytridecane-1,2,3-tricarboxylic acid",CCCCCCCCCC[C@@H](C(=O)O)[C@@](CC(=O)O)(C(=O)O)O,,,,,,
425,440426,CID 440426,C[C@H]1[C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)OP(=O)(O)O)N=C(N)N)O)N=C(N)N)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)OP(=O)(O)O)NC)C=O,,,,,,
426,440427,"(4S)-4-[(3R,5S,7R,8R,9S,10S,12R,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid",C[C@@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,,,,,,
427,440428,CID 440428,C1=C(O[C@@H]([C@@H]([C@H]1O)O)O)C(CO)O,,,,,,
428,440429,5-Amino-1-ribofuranosylimidazole-4-carboxyamide,C1=NC(=C(N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N)NC(=O)O,,,,,,
429,440430,CID 440430,[CH3-].C/C/1=C/2\C(C(C([N-]2)/C=C/3\C(C(C([N-]3)/C(=C\4/C(C(C([N-]4)CC5C(C(C1[N-]5)(C)CCC(=O)NCC(C)OP(=O)([O-])O[C@H]6[C@@H](O[C@H]([C@@H]6O)N7C[N-]C8=C7C=C(C=C8)O)CO)CC(=O)N)(C)CC(=O)N)CCC(=O)N)/C)(C)CC(=O)N)CC(=O)N)(C)C)CCC(=O)N.[Co],,,,,,
430,440431,D-erythro-1-(Imidazol-4-yl)glycerol 3-phosphate,C1=C(NC=N1)[C@@H]([C@@H](COP(=O)(O)O)O)O,,,,,,
431,440432,"(1S,4S)-4-hydroxy-3-oxocyclohexane-1-carboxylic acid",C1C[C@@H](C(=O)C[C@H]1C(=O)O)O,,,,,,
432,440433,11-[(3S)-3-pent-2-enyloxiran-2-ylidene]undec-9-enoic acid,CCC=CC[C@H]1C(=CC=CCCCCCCCC(=O)O)O1,,,,,,
433,440434,"2-[(1R,2R,3S,4R,6S)-2,3,4,6-tetrahydroxy-5-oxocyclohexyl]guanidine",[C@H]1([C@H]([C@@H]([C@H](C(=O)[C@H]1O)O)O)O)N=C(N)N,,,,,,
434,440435,"3-D-glucuronosyl-N(2),6-disulfo-beta-D-glucosamine",C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)NS(=O)(=O)O)OC2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O)O)O)O)OS(=O)(=O)O,,,,,,
435,440436,CID 440436,CC(=CCCC(CC=O)(CC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O)O)C,,,,,,
436,440437,CID 440437,CC(CCC=C(C)CCC=C(C)C)CCOP(=O)(O)O[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)NC(=O)C,,,,,,
437,440438,3-[(3-Amino-3-oxo-2-phenylpropoxy)-hydroxyphosphoryl]oxybenzoic acid,C1=CC=C(C=C1)C(COP(=O)(O)OC2=CC=CC(=C2)C(=O)O)C(=O)N,,,,,,
438,440439,CID 440439,CCCCC[C@@H](C=C[C@H]1C=CC(=O)C1CCCCCCC(=O)O)O,,,,,,
439,440440,7-[(1R)-2-[(3S)-3-hydroxyoct-1-enyl]-5-oxocyclopent-2-en-1-yl]heptanoic acid,CCCCC[C@@H](C=CC1=CCC(=O)[C@@H]1CCCCCCC(=O)O)O,,,,,,
440,440441,"(1S,3S,4S)-3,4-dihydroxycyclohexane-1-carboxylic acid",C1C[C@@H]([C@H](C[C@H]1C(=O)O)O)O,,,,,,
441,440442,"Butanedioic acid, [(acetylamino)methylene](hydroxymethyl)-",CC(=O)NC=C(C(CO)C(=O)O)C(=O)O,,,,,,
442,440443,2-[3-Carboxy-3-(methylammonio)propyl]-L-histidine,C[NH2+]C(CCC1=NC=C(N1)C[C@@H](C(=O)O)N)C(=O)O,,,,,,
443,440444,4-[5-(2-amino-2-carboxyethyl)-1H-imidazol-2-yl]-2-(methylamino)butanoic acid,CNC(CCC1=NC=C(N1)CC(C(=O)O)N)C(=O)O,,,,,,
444,440445,"[(1S,2S,3S,4S,5R,6S)-2,3,4,6-tetrahydroxy-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycyclohexyl] 2-(1H-indol-3-yl)acetate",C1=CC=C2C(=C1)C(=CN2)CC(=O)O[C@H]3[C@H]([C@H]([C@@H]([C@H]([C@@H]3O)O[C@H]4[C@@H]([C@H]([C@H]([C@H](O4)CO)O)O)O)O)O)O,,,,,,
445,440446,Methyl-2-alpha-L-fucopyranosyl-beta-D-galactoside,C[C@H]1[C@H]([C@H]([C@@H]([C@@H](O1)O[C@@H]2[C@H]([C@H]([C@H](O[C@H]2OC)CO)O)O)O)O)O,,,,,,
446,440447,"(2S)-2-[[(2R)-2-[[(2S)-2-[2-[(2R,3R,4R,5S,6R)-3-acetamido-2-[[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]oxy-5-hydroxy-6-(hydroxymethyl)tetrahydropyran-4-yl]oxypropanoylamino]propanoyl]amino]-4-carboxy-butanoyl]amino]-6-amino-hexanoic acid",C[C@@H](C(=O)N[C@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)C(C)O[C@@H]1[C@H]([C@H](O[C@@H]([C@H]1O)CO)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=O)NC3=O)O)O)NC(=O)C,,,,,,
447,440448,"uridine 5'-(3-{2-acetamido-3-O-[(2R,5R,8S,16S)-8-(4-aminobutyl)-2,13-dicarboxy-5,16-dimethyl-4,7,10,15,18-pentaoxo-3,6,9,14,17-pentaazaicosan-19-yl]-2-deoxy-alpha-D-glucopyranosyl} dihydrogen diphosphate)",C[C@H](C(=O)N[C@H](C)C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)CC[C@H](C(=O)O)NC(=O)[C@H](C)NC(=O)C(C)O[C@@H]1[C@H]([C@H](O[C@@H]([C@H]1O)CO)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=O)NC3=O)O)O)NC(=O)C,,,,,,
448,440449,"[2-hydroxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] dihydrogen phosphate",C([C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)OCC(COP(=O)(O)O)O)O)O)O)O,,,,,,
449,440450,CID 440450,C[C@H]1[C@@]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)OP(=O)(O)O)N=C(N)N)O)N=C(N)N)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)O)NC)(C=O)OP(=O)(O)O,,,,,,
450,440451,"5-(3-Hydroxy-4-acetoxybut-1-ynyl)-2,2'-bithiophene",CC(=O)OCC(C#CC1=CC=C(S1)C2=CC=CS2)O,,,,,,
451,440452,(7R)-7-(5-Carboxy-5-oxopentanoyl)aminocephalosporinate,CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CCCC(=O)C(=O)O)SC1)C(=O)O,,,,,,
452,440453,Nuatigenin,C[C@H]1[C@H]2[C@H](C[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC=C5[C@@]4(CC[C@@H](C5)O)C)C)O[C@]16CC[C@@](O6)(C)CO,,,,,,
453,440454,(25S)-5beta-spirostan-3beta-yl beta-D-glucoside,C[C@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC[C@H]6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)C)C)C)OC1,,,,,,
454,440455,"13(s)-Hydroperoxy-9,11-octadecadienoic acid",CCCCC[C@@H](C=CC=CCCCCCCCC(=O)O)OO,,,,,,
455,440456,"1,6,6-Trimethyl-2,7-dioxabicyclo[3.2.2]nonan-3-one",CC1(C2CCC(O1)(OC(=O)C2)C)C,,,,,,
456,440457,"1-hydroxy-2-[(2R,3R,4S,5R,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]oxyanthracene-9,10-dione",C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=C(C=C3)O[C@@H]4[C@H]([C@H]([C@H](O[C@H]4O)CO)O)O)O,,,,,,
457,440458,"2,4-Dihydroxy-7-methoxy-4a,7,8,8a-tetrahydro-1,4-benzoxazin-3-one",COC1CC2C(C=C1)N(C(=O)C(O2)O)O,,,,,,
458,440459,"2-[[(4S)-4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]acetic acid",C[C@@H](CCC(=O)NCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C,,,,,,
459,440460,"3alpha,7alpha,12alpha-Trihydroxy-5beta-cholestanate",C[C@H](CCCC(C)C(=O)O)C1CCC2[C@@]1([C@H](CC3C2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,,,,,,
460,440461,"[1-[(2R,3R,4S,5R,6R)-6-[[(2R,3R,4S,5R,6S)-3,4-dihydroxy-6-methyl-5-[(2S,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-3-phosphonooxypropan-2-yl] dihydrogen phosphate",C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@@H]([C@@H]([C@H]([C@@H](O2)OCC(COP(=O)(O)O)OP(=O)(O)O)O)O)O)O)O)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
461,440462,4-(4-Deoxy-beta-D-gluc-4-enuronosyl)-D-galacturonate,C1=C(O[C@H]([C@@H]([C@H]1O)O)O[C@@H]2[C@@H]([C@H]([C@@H](O[C@@H]2C(=O)O)O)O)O)C(=O)O,,,,,,
462,440463,UDP-3-O-(3-hydroxytetradecanoyl)-N-acetyl-beta-glucosamine,CCCCCCCCCCCC(CC(=O)O[C@@H]1[C@H]([C@@H](O[C@@H]([C@H]1O)CO)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=O)NC3=O)O)O)NC(=O)C)O,,,,,,
463,440464,"[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-[[hydroxy-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphosphoryl]oxymethyl]oxan-2-yl] [[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] hydrogen phosphate",CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=O)NC3=O)O)O)COP(=O)(O)O[C@H]4[C@@H]([C@H]([C@H]([C@H](O4)CO)O)O)O)O)O,,,,,,
464,440465,"(15S)-15-hydroxyicosa-5,8,11,13-tetraenoic acid",CCCCC[C@@H](C=CC=CCC=CCC=CCCCC(=O)O)O,,,,,,
465,440466,3beta-Hydroxy-5alpha-cholest-7-ene-4alpha-carboxylate,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3C2=CC[C@@H]4[C@@]3(CC[C@@H]([C@H]4C(=O)O)O)C)C,,,,,,
466,440467,"[(2R,3S,4S,5S,6S)-6-[(2R,3S,4R,5S,6S)-6-[(2R,3S,4R,5R,6S)-5-acetamido-6-[(2R,3S,4R,5R)-5-acetamido-6-[[(3S)-3-acetamido-4-amino-4-oxobutanoyl]amino]-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl [(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl] hydrogen phosphate",CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OP(=O)(O)OC[C@@H]2[C@H]([C@@H]([C@@H]([C@@H](O2)O[C@@H]3[C@H](O[C@H]([C@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@H]([C@@H]([C@H]4O)NC(=O)C)O[C@@H]5[C@H](OC([C@@H]([C@H]5O)NC(=O)C)NC(=O)C[C@@H](C(=O)N)NC(=O)C)CO)CO)CO)O)O)O)CO)O)O,,,,,,
467,440468,CID 440468,CCCCCC(=O)C=C[C@@H]1[C@H]([C@H](CC1=O)O)CC=CCCCC(=O)O,,,,,,
468,440469,"S-[2-[3-[[4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] (6R)-2-methyl-6-[(3R,5S,7R,10S,12S,13R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]heptanethioate",C[C@H](CCCC(C)C(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O)C4CCC5[C@@]4([C@H](CC6C5[C@@H](C[C@H]7[C@@]6(CC[C@H](C7)O)C)O)O)C,,,,,,
469,440470,Unsaturated digalacturonate,C1=C(O[C@@H]([C@@H]([C@H]1O)O)O[C@@H]2[C@@H]([C@H]([C@@H](O[C@@H]2C(=O)O)O)O)O)C(=O)O,,,,,,
470,440471,"diaminomethylidene-[(1R,2S,3S,4R,5S,6S)-3-(diaminomethylideneazaniumyl)-4-[(2R,3R,4S,5S)-3,4-dihydroxy-4-(hydroxymethyl)-5-methyloxolan-2-yl]oxy-2,5-dihydroxy-6-phosphonooxycyclohexyl]azanium",C[C@H]1[C@@]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)OP(=O)(O)O)[NH+]=C(N)N)O)[NH+]=C(N)N)O)(CO)O,,,,,,
471,440472,CID 440472,C[C@H]1[C@@]([C@H]([C@@H](O1)OC2[C@H]([C@@H]([C@H](C([C@H]2O)OP(=O)(O)O)N=C(N)N)O)N=C(N)N)O)(CO)O,,,,,,
472,440473,L-mimosine,C1=CN(C=C(C1=O)O)C[C@@H](C(=O)O)N,,['Mimosine inhibits DNA synthesis at the level of elongation of nascent chains by altering deoxyribonucleotide metabolism. It arrests the cell cycle in the late G(1) phase.'],,,"['EXPERIMENTAL POISONING OF SHEEP HAS SHOWN THAT MIMOSINE IS LARGELY BROKEN DOWN IN THE RUMEN TO 3,4-DIHYDROXYPYRIDINE, AND EXCRETED AS SUCH. /MIMOSINE/']",
473,440474,5-Pyridoxic acid,CC1=NC=C(C(=C1O)CO)C(=O)O,,,,,,
474,440475,O-[2-(Acetylamino)-2-deoxy-3-O-beta-D-galactopyranosyl-beta-D-galactopyranosyl]-L-serine,CC(=O)N[C@@H]1[C@H]([C@H]([C@H](O[C@H]1OC[C@@H](C(=O)O)N)CO)O)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O)O,,,,,,
475,440476,"1-(5-O-Phosphono-beta-D-ribofuranosyl)-5,6-dimethyl-1H-benzimidazole",CC1=CC2=C(C=C1C)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O,,,,,,
476,440477,Oxo-(pentenyl)cyclopentaneoctanoic acid,CCC=CC[C@H]1[C@H](CCC1=O)CCCCCCCC(=O)O,,,,,,
477,440478,"cis-4,5-Dihydroxycyclohexa-2,6-diene-1,2-dicarboxylic acid",C1=C(C(=C[C@@H]([C@@H]1O)O)C(=O)O)C(=O)O,,,,,,
478,440479,CID 440479,CCCC=C[C@@H](C=CC=CCCCCCCCC(=O)O)OO,,,,,,
479,440480,CID 440480,C[C@@H]1[C@H]([C@@H]([C@@H]([C@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3C=C4C(=CC(=CC4=[O+]C3C5=CC(=C(C=C5)O)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)O)O)O)O)O)O.[Cl-],,,,,,
480,440481,CID 440481,C[C@@H]1[C@H]([C@@H]([C@@H]([C@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3C=C4C(=CC(=CC4=[O+]C3C5=CC(=C(C=C5)O)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)O)O)O)O)O)O,,,,,,
481,440482,"[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl] [(2R,3S,4S,5S,6R)-3,4,5,6-tetrahydroxyoxan-2-yl]methyl hydrogen phosphate",CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OP(=O)(O)OC[C@@H]2[C@H]([C@@H]([C@@H]([C@@H](O2)O)O)O)O)CO)O)O,,,,,,
482,440483,"3,4-Dihydroxy-9,10-secoandrosta-1,3,5(10)-triene-9,17-dione",CC1=C(C(=C(C=C1)O)O)CC[C@H]2[C@@H]3CCC(=O)[C@]3(CCC2=O)C,,,,,,
483,440484,3-(4-deoxy-alpha-L-threo-hex-4-enopyranosyluronic acid)-2-acetamido-2-deoxy-D-glucose,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O)CO)O)O[C@H]2[C@@H]([C@H](C=C(O2)C(=O)O)O)O,,,,,,
484,440485,(6S)-6-amino-4-(2-hydroxyethenyl)-2-oxohept-3-enedioic acid,C([C@@H](C(=O)O)N)C(=CC(=O)C(=O)O)C=CO,,,,,,
485,440486,(7S)-7-amino-5-(hydroxymethylidene)-2-oxooct-3-enedioic acid,C([C@@H](C(=O)O)N)C(=CO)C=CC(=O)C(=O)O,,,,,,
486,440487,"5-amino-4-chloro-2-(2,3-dihydroxyphenyl)pyridazin-3(2H)-one",C1=CC(=C(C(=C1)O)O)N2C(=O)C(=C(C=N2)N)Cl,,,,,,
487,440488,"(6S)-6-[[(4R)-4-[[(2S)-2-[2-[(3R,4R,5S,6S)-3-acetamido-2-[[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-5,6-dihydroxyoxan-4-yl]oxypropanoylamino]propanoyl]amino]-4-carboxybutanoyl]amino]-2-amino-7-[[(1R)-1-carboxyethyl]amino]-7-oxoheptanoic acid",C[C@@H](C(=O)N[C@H](CCC(=O)N[C@@H](CCCC(C(=O)O)N)C(=O)N[C@H](C)C(=O)O)C(=O)O)NC(=O)C(C)O[C@H]1[C@@H]([C@H](OC([C@@H]1NC(=O)C)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=O)NC3=O)O)O)O)O,,,,,,
488,440489,17alpha-(N-Acetyl-D-glucosaminyl)-estradiol 3-D-glucuronide,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O[C@@H]2CCC3C2(CCC4C3CCC5=C4C=CC(=C5)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O)O)O)C)CO)O)O,,,,,,
489,440490,"[(2R,3S,4R,5R)-5-[5-amino-4-[(4-amino-4-oxo-butanoyl)amino]imidazol-1-yl]-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl dihydrogen phosphate",C1=NC(=C(N1[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O)N)NC(=O)CCC(=O)N,,,,,,
490,440491,"[(1S,3R,5R,6S)-2-amino-4-(diaminomethylideneamino)-3,5,6-trihydroxycyclohexyl] dihydrogen phosphate",[C@@H]1([C@@H](C([C@@H](C([C@@H]1OP(=O)(O)O)N)O)N=C(N)N)O)O,,,,,,
491,440492,"[(1R,3R,5S,6R)-4-amino-2-(diaminomethylideneamino)-3,5,6-trihydroxycyclohexyl] dihydrogen phosphate",[C@H]1([C@H](C([C@H](C([C@H]1OP(=O)(O)O)N=C(N)N)O)N)O)O,,,,,,
492,440493,"(3S,4S,5R,10R,13R,14R,17R)-17-[(1R)-1,5-dimethylhexyl]-4-(hydroxymethyl)-4,10,13-trimethyl-1,2,3,5,6,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-ol",C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CCC3C2=CC[C@@H]4[C@@]3(CC[C@@H]([C@]4(C)CO)O)C)C,,,,,,
493,440494,"(5R,6R)-2,6-dihydroxy-5-(hydroxymethyl)cyclohex-2-en-1-one",C1C=C(C(=O)[C@@H]([C@H]1CO)O)O,,,,,,
494,440495,CID 440495,CCN[C@@H]1[C@H]([C@H]([C@@H](OC1O)CO)O[C@@H]2[C@@H]([C@H]([C@H]([C@@H](O2)CO)O[C@@H]3[C@@H]([C@@H]([C@H]([C@@H](O3)CO)O)O)O)O)NC(=O)C)OC(C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)O)C(=O)N,,,,,,
495,440496,CID 440496,CCCCCC=CC[C@@H](C=CC=CCC=CCCCC(=O)OO)O,,,,,,
496,440497,CID 440497,CCCCCC=CCC=CC=C[C@H](CC=CCCCC(=O)OO)O,,,,,,
497,440498,(2S)-2-[5-amino-1-(5-phospho-beta-D-ribosyl)imidazole-4-carboxamido]succinic acid,C1=NC(=C(N1[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O)N)C(=O)NC(CC(=O)O)C(=O)O,,,,,,
498,440499,"N,3-O-Bis(3-hydroxytetradecanoyl)-beta-D-glucosamine 1-phosphoric acid",CCCCCCCCCCCC(CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OP(=O)(O)O)CO)O)OC(=O)CC(CCCCCCCCCCC)O)O,,,,,,
499,440500,CID 440500,C1=C(NC(=C(C1=O)C=CC(=O)C(=O)O)C(=O)O)O,,,,,,
500,440501,"(6S)-6-[[(4R)-4-[[(2S)-2-[2-[(3R,4R,5S,6S)-3-acetamido-2-[[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-5,6-dihydroxyoxan-4-yl]oxypropanoylamino]propanoyl]amino]-4-carboxybutanoyl]amino]-2-amino-7-[[(2R)-1-[[(1R)-1-carboxyethyl]amino]-1-oxopropan-2-yl]amino]-7-oxoheptanoic acid",C[C@H](C(=O)N[C@H](C)C(=O)O)NC(=O)[C@H](CCCC(C(=O)O)N)NC(=O)CC[C@H](C(=O)O)NC(=O)[C@H](C)NC(=O)C(C)O[C@H]1[C@@H]([C@H](OC([C@@H]1NC(=O)C)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=O)NC3=O)O)O)O)O,,,,,,
501,440502,CID 440502,CC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCOP(=O)(O)OP(=O)(O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)NC(=O)C)C)C)C)C)C)C)C)C)C)C)C,,,,,,
502,440503,CID 440503,COC1CC2C(C=C1)N(C(=O)C(O2)OC3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O,,,,,,
503,440504,CID 440504,C[C@@H]([C@@H](C(=O)O)NC(=O)CCCCCCSSCCS(=O)(=O)O)OP(=O)(O)O,,,,,,
504,440505,CID 440505,CC[C@@]1([C@H](O1)CCC(=CCCC(=CC(=O)O)C)C)C,,,,,,
505,440506,"3-O-(3,6-Anhydro-alpha-D-galactopyranosyl)-D-galactose 4-O-sulfate",C1[C@@H]2[C@@H]([C@H](O1)[C@H]([C@H](O2)O[C@@H]3[C@H]([C@H](O[C@@H]([C@@H]3OS(=O)(=O)O)CO)O)O)O)O,,,,,,
506,440507,3beta-Hydroxy-4beta-methyl-5alpha-cholest-7-ene-4alpha-carboxylic acid,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3C2=CC[C@@H]4[C@@]3(CC[C@@H]([C@@]4(C)C(=O)O)O)C)C,,,,,,
507,440508,CID 440508,CCCCCC=CC[C@@H](C(C=CC(CC=CCCCC(=O)O)O)O)O,,,,,,
508,440509,"8-[(3aS,4S,7aS)-7a-methyl-1,5-dioxo-2,3,3a,4,6,7-hexahydroinden-4-yl]-2-hydroxy-5-methyl-6-oxoocta-2,4-dienoic acid",CC(=CC=C(C(=O)O)O)C(=O)CC[C@H]1[C@@H]2CCC(=O)[C@]2(CCC1=O)C,,,,,,
509,440510,CID 440510,C[C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)C(C)O[C@@H]1[C@H]([C@H](O[C@H]([C@@H]1O)CO)OP(=O)(O)OP(=O)(O)OC[C@H]2[C@@H]([C@H]([C@@H](O2)N3C=CC(=O)NC3=O)O)O)NC(=O)C,,,,,,
510,440511,Galalpha1-3Galbeta1-4GlcNAcbeta,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O)CO)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O[C@@H]3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)O)O)O)O,,,,,,
511,440512,CID 440512,CCCCCC=CCC1[C@@H](O1)C=CC(CC=CCCCC(=O)O)O,,,,,,
512,440513,CID 440513,C[C@H](C(=O)N[C@H](C)C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)CC[C@H](C(=O)O)NC(=O)[C@H](C)NC(=O)C(C)O[C@H]1[C@@H]([C@H](OC([C@@H]1NC(=O)C)OP(=O)(O)OP(=O)(O)OCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)CO)O,,,,,,
513,440514,"(5S,12R)-5,12,20-trihydroxyicosa-6,8,10,14-tetraenoic acid",C(CCC=CC[C@H](C=CC=CC=C[C@H](CCCC(=O)O)O)O)CCO,,,,,,
514,440515,(S)-Nadhx(1+),C1CC(=C[NH+]([C@H]1O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O)C(=O)N,,,,,,
515,440516,(S)-Nadhx,C1CC(=CN([C@H]1O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O)C(=O)N,,,,,,
516,440517,nuatigenin 3-beta-D-glucopyranoside,C[C@H]1[C@H]2[C@H](C[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC=C5[C@@]4(CC[C@@H](C5)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)C)O[C@]17CC[C@@](O7)(C)CO,,,,,,
517,440518,"(2R,3S,4S,5S,6R)-3-[(2R,3S,4S,5S,6R)-3-[(2R,3S,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,4,5-triol",C([C@@H]1[C@H]([C@@H]([C@@H]([C@@H](O1)O)O[C@@H]2[C@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O[C@@H]3[C@H]([C@H]([C@@H]([C@H](O3)CO)O)O[C@@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O)O)O,,,,,,
518,440519,2-[[2-[Hexadecyl(hydroxy)phosphoryl]oxy-2-hexadecylsulfanylethoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium,CCCCCCCCCCCCCCCCP(=O)(O)OC(COP(=O)(O)OCC[N+](C)(C)C)SCCCCCCCCCCCCCCCC,,,,,,
519,440520,"(2R,3R,4S)-2-[(2R,3R,4R,5S,6R)-3-acetamido-2-hydroxy-6-(hydroxymethyl)-5-sulfooxyoxan-4-yl]oxy-3,4-dihydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid",CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O)CO)OS(=O)(=O)O)O[C@H]2[C@@H]([C@H](C=C(O2)C(=O)O)O)O,,,,,,
520,440521,"(2R,3R,4S)-2-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(sulfooxymethyl)oxan-4-yl]oxy-3,4-dihydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid",CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O)COS(=O)(=O)O)O)O[C@H]2[C@@H]([C@H](C=C(O2)C(=O)O)O)O,,,,,,
521,440522,"methyl 9-[(2S,3R)-3-ethyl-3-methyloxiran-2-yl]-3,7-dimethylnona-2,6-dienoate",CC[C@@]1([C@@H](O1)CCC(=CCCC(=CC(=O)OC)C)C)C,,,,,,
522,440523,2-[[2-(15-Carboxypentadecylamino)-2-hexadecylsulfanylethoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium,CCCCCCCCCCCCCCCCSC(COP(=O)(O)OCC[N+](C)(C)C)NCCCCCCCCCCCCCCCC(=O)O,,,,,,
523,440524,"5-[[1-(3-Hydroxypropoxy)-2-methylpropan-2-yl]amino]-1,2,3,4-tetrahydronaphthalen-1-ol",CC(C)(COCCCO)NC1=CC=CC2=C1CCCC2O,,,,,,
524,440525,CID 440525,C[C@H](C(=O)N[C@H](CCC(=O)N[C@@H](CCCC(C(=O)O)N)C(=O)O)C(=O)O)NC(=O)C(C)O[C@H]1[C@@H]([C@H](OC([C@@H]1NC(=O)C)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)NC(=O)C)O,,,,,,
525,440526,CID 440526,C[C@H](C(=O)N[C@H](CCC(=O)NC(CCCC(C(=O)O)N)C(=O)O)C(=O)O)NC(=O)C(C)O[C@H]1[C@@H]([C@H](OC([C@@H]1NC(=O)C)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=O)NC3=O)O)O)CO)O,,,,,,
526,440527,"(2R)-2-[[(2S)-2-[[(4R)-4-[[(2S)-2-[2-[(3R,4R,5S,6R)-5-[(2S,3R,4R,5S,6R)-3-acetamido-5-[(2S,3R,4S,5S,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(ethylamino)-2-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoylamino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-6-aminohexanoyl]amino]propanoic acid",CCN[C@@H]1[C@H]([C@@H]([C@H](OC1O)CO)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O[C@H]3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)O[C@@H]4[C@@H]([C@H]([C@H]([C@H](O4)CO)O)O)O)O)O)NC(=O)C)OC(C)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C)C(=O)O)C(=O)N,,,,,,
527,440528,CID 440528,CC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCOP(=O)(O)OP(=O)(O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O[C@H]2[C@H]([C@H]([C@@H]([C@H](O2)CO)O)O)NC(=O)C)O)NC(=O)C)C)C)C)C)C)C)C)C)C)C)C,,,,,,
528,440529,"(6S)-6-[[(4R)-4-[[(2S)-2-[2-[(3R,4R,5S,6R)-3-acetamido-2-[[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoylamino]propanoyl]amino]-4-carboxybutanoyl]amino]-2-amino-7-[[(2R)-1-(1-carboxyethylamino)-1-oxopropan-2-yl]amino]-7-oxoheptanoic acid",C[C@H](C(=O)NC(C)C(=O)O)NC(=O)[C@H](CCCC(C(=O)O)N)NC(=O)CC[C@H](C(=O)O)NC(=O)[C@H](C)NC(=O)C(C)O[C@H]1[C@@H]([C@H](OC([C@@H]1NC(=O)C)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=O)NC3=O)O)O)CO)O,,,,,,
529,440530,"5-[[1-(3-hydroxypropoxy)-2-methylpropan-2-yl]amino]-3,4-dihydro-2H-naphthalen-1-one",CC(C)(COCCCO)NC1=CC=CC2=C1CCCC2=O,,,,,,
530,440531,CID 440531,CC(=O)N[C@@H]1[C@@H](C[C@@](O[C@H]1C(C(CO)O)O)(C(=O)O)OC[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)O[C@H]3[C@@H](O[C@@H]([C@@H]([C@H]3O)NC(=O)C)O)CO)O)O)O)O,,,,,,
531,440532,"6-Benzyl-4a-(4-hydroxyphenyl)-3-[(4-hydroxyphenyl)methyl]-1,5-dihydroimidazo[1,2-b][1,2,4]triazin-2-one",C1=CC=C(C=C1)CC2=CN3C(N2)(N=C(C(=O)N3)CC4=CC=C(C=C4)O)C5=CC=C(C=C5)O,,,,,,
532,440533,CID 440533,C[C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](C)NC(=O)C(C)O[C@@H]1[C@H]([C@H](O[C@H]([C@@H]1O)CO)OP(=O)(O)OP(=O)(O)OC[C@H]2[C@@H]([C@H]([C@@H](O2)N3C=CC(=O)NC3=O)O)O)NC(=O)C,,,,,,
533,440534,1-(5-phospho-beta-D-ribosyl)-5-[(5-phospho-beta-D-ribosylamino)methylideneamino]imidazole-4-carboxamide,C1=NC(=C(N1[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O)NC=N[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)C(=O)N,,,,,,
534,440535,"[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-[(2S)-5-carbamoyl-2-hydroxy-1,2,3,4-tetrahydropyridin-1-ium-1-yl]-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate",C1CC(=C[NH+]([C@H]1O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)OP(=O)(O)O)O)O)O)C(=O)N,,,,,,
535,440536,(S)-Nadphx,C1CC(=CN([C@H]1O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)OP(=O)(O)O)O)O)O)C(=O)N,,,,,,
536,440537,CID 440537,C1=CC(=C(C=C1C2=CC(=C3C(=CC(=CC3=O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)C(=O)O)O)O)O)O2)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O)O)O,,,,,,
537,440538,CID 440538,C[C@H](C(=O)N[C@H](CCC(=O)N[C@@H](CCCC(C(=O)O)N)C(=O)N[C@@H](C)C(=O)O)C(=O)O)NC(=O)C(C)O[C@@H]1[C@H]([C@H](O[C@@H]([C@H]1O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)NC(=O)C)CO)O)NC(=O)C,,,,,,
538,440539,CID 440539,CC(=O)N[C@@H]1[C@@H](C[C@@](O[C@H]1C(C(CO)O)O)(C(=O)O)O[C@@H]2[C@H]([C@@H](O[C@@H]([C@@H]2O)O[C@H]3[C@@H](O[C@@H]([C@@H]([C@H]3O)NC(=O)C)O[C@H]4[C@@H](OC([C@@H]([C@H]4O)NC(=O)C)NC(=O)C[C@@H](C(=O)N)NC(=O)C)CO)CO)CO)O)O,,,,,,
539,440540,"[(2R,3S,4R,5R,6S)-3-hydroxy-2-[[(2R,3R,4R,5S,6R)-5-hydroxy-3-(3-hydroxytetradecanoylamino)-4-(3-hydroxytetradecanoyloxy)-6-(phosphonooxymethyl)oxan-2-yl]oxymethyl]-5-(3-hydroxytetradecanoylamino)-6-phosphonooxyoxan-4-yl] 3-hydroxytetradecanoate",CCCCCCCCCCCC(CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OP(=O)(O)O)CO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)OC(=O)CC(CCCCCCCCCCC)O)NC(=O)CC(CCCCCCCCCCC)O)O)OC(=O)CC(CCCCCCCCCCC)O)O,,,,,,
540,440541,GlcNAc(a1-2)[Man(a1-3)]Man(a1-2)Man(a1-2)a-Man,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1O[C@H]2[C@H]([C@@H]([C@H](O[C@@H]2O[C@H]3[C@H]([C@@H]([C@H](O[C@@H]3O[C@H]4[C@H]([C@@H]([C@H](O[C@@H]4O)CO)O)O)CO)O)O)CO)O)O[C@@H]5[C@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)CO)O)O,,,,,,
541,440542,"(2R,4R)-1-[5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid",C[C@@H]1CCN([C@H](C1)C(=O)O)C(=O)C(CCCN=C(N)N)NS(=O)(=O)C2=CC=CC3=C2NCC(C3)C,,,,,,
542,440543,"[(2R,3R,4R,5S,6R)-5-hydroxy-2-[[(2R,3S,4R,5R,6S)-3-hydroxy-5-(3-hydroxytetradecanoylamino)-4-(3-hydroxytetradecanoyloxy)-6-phosphonooxyoxan-2-yl]methoxy]-6-(hydroxymethyl)-3-(3-hydroxytetradecanoylamino)oxan-4-yl] 3-hydroxytetradecanoate",CCCCCCCCCCCC(CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OP(=O)(O)O)NC(=O)CC(CCCCCCCCCCC)O)OC(=O)CC(CCCCCCCCCCC)O)O)CO)O)OC(=O)CC(CCCCCCCCCCC)O)O,,,,,,
543,440544,D-fructopyranose 1-phosphate,C1[C@H]([C@H]([C@@H](C(O1)(COP(=O)(O)O)O)O)O)O,,,,,,
544,440545,alpha-D-fructopyranose,C1[C@H]([C@H]([C@@H]([C@@](O1)(CO)O)O)O)O,,,,,,
545,440546,CID 440546,CC1=C(C=NC1=CC2=C(C(=C([N-]2)C=C3C(=C(C(=N3)C=C4C5=C(CCC(=O)O5)C(=O)[N-]4)C)C=C)C)C=C)CCC(=O)C.CC(=O)C[C@H](C[S-])C(=O)C.[Fe+3],,,,,,
546,440547,"7-[[4-ethenyl-5-[[4-ethenyl-3-methyl-5-[[3-methyl-4-(3-oxobutyl)pyrrol-2-ylidene]methyl]-1H-pyrrol-2-yl]methylidene]-3-methylpyrrol-2-ylidene]methyl]-3,4-dihydropyrano[2,3-c]pyrrole-2,5-dione",CC1=C(C=NC1=CC2=C(C(=C(N2)C=C3C(=C(C(=CC4=NC(=O)C5=C4OC(=O)CC5)N3)C)C=C)C)C=C)CCC(=O)C,,,,,,
547,440548,"(3S)-3-(sulfanylmethyl)hexane-2,5-dione",CC(=O)C[C@H](CS)C(=O)C,,,,,,
548,440549,Histidinyl-Leucine,CC(C)CC(C(=O)O)NC(=O)C(CC1=CN=CN1)N,,,,,,
549,440550,H-Glu-OMe,COC(=O)[C@H](CCC(=O)O)N,,,,,,
550,440551,2-Amino-5-[[amino-(phosphonoamino)methylidene]amino]pentanoic acid,C(CC(C(=O)O)N)CN=C(N)NP(=O)(O)O,,,,,,
551,440552,N-Acetyl-beta-D-galactosamine,CC(=O)N[C@@H]1[C@H]([C@H]([C@H](O[C@H]1O)CO)O)O,,,,,,
552,440553,N3-Metyladenine,CN1C=NC(C2=C1N=CN2)N,,,,,,
553,440554,Hydroxy cyclohexadienone,C1=CC(C(=O)C=C1)O,,,,,,
554,440555,"[(3S,4R,5S,6S)-5-hydroxy-6-[2-hydroxy-3-[[5-[[2-hydroxy-7-[(2S,3S,4R,5S)-3-hydroxy-5-methoxy-6,6-dimethyl-4-(5-methyl-1H-pyrrole-2-carbonyl)oxyoxan-2-yl]oxy-8-methyl-4-oxochromen-3-yl]carbamoyl]-4-methyl-1H-pyrrole-3-carbonyl]amino]-8-methyl-4-oxochromen-7-yl]oxy-3-methoxy-2,2-dimethyloxan-4-yl] 5-methyl-1H-pyrrole-2-carboxylate",CC1=CC=C(N1)C(=O)O[C@@H]2[C@@H]([C@H](OC([C@H]2OC)(C)C)OC3=C(C4=C(C=C3)C(=O)C(=C(O4)O)NC(=O)C5=CNC(=C5C)C(=O)NC6=C(OC7=C(C6=O)C=CC(=C7C)O[C@@H]8[C@H]([C@H]([C@@H](C(O8)(C)C)OC)OC(=O)C9=CC=C(N9)C)O)O)C)O,,,,,,
555,440556,CID 440556,C[C@H]1[C@@H]2CCC3=C(C2(CCC1O)C)CCC4(C3CCC4C(C)CCC=C(C)C)C,,,,,,
556,440557,"delta7,24-Cholestadien-3beta-ol",C[C@H](CCC=C(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3C2=CCC4[C@@]3(CC[C@@H](C4)O)C)C,,,,,,
557,440558,7-Dehydrodesmosterol,C[C@H](CCC=C(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3C2=CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,,,,,
558,440559,"4,4-Dimethyl-8,24-cholestadienol",C[C@H](CCC=C(C)C)[C@H]1CCC2[C@@]1(CCC3=C2CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)C,,,,,,
559,440560,"24,25-Dihydrolanosterol",C[C@H](CCCC(C)C)[C@H]1CC[C@@]2([C@@]1(CCC3=C2CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)C)C,,,,,,
560,440561,4alpha-Methylcholest-8-en-3beta-ol,C[C@@H]1[C@H](CC[C@]2(C1CCC3=C2CC[C@]4([C@H]3CC[C@@H]4[C@H](C)CCCC(C)C)C)C)O,,,,,,
561,440562,Methostenol,C[C@@H]1[C@H](CC[C@]2(C1CC=C3C2CC[C@]4(C3CCC4C(C)CCCC(C)C)C)C)O,,,,,,
562,440563,"S-[2-[3-[[4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] 3-hydroxybutanethioate",CC(CC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O)O,,,,,,
563,440564,3-Aminobutanoyl-CoA; (Acyl-CoA); [M+H]+,CC(CC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O)N,,,,,,
564,440565,S-(2-Methylbutanoyl)-dihydrolipoamide,CCC(C)C(=O)SCCC(CCCCC(=O)N)S,,,,,,
565,440566,S-(3-Methylbutanoyl)-dihydrolipoamide-E,CC(C)CC(=O)SCCC(CCCCC(=O)N)S,,,,,,
566,440567,"2-[4-[(3R,5S,7R,12S)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoylamino]ethanesulfonic acid",CC(CCC(=O)NCCS(=O)(=O)O)C1CCC2C1([C@H](CC3C2[C@@H](C[C@H]4C3(CC[C@H](C4)O)C)O)O)C,,,,,,
567,440568,2-(alpha-Hydroxyethyl)thiamine diphosphate,CC1=C(SC(=[N+]1CC2=CN=C(N=C2N)C)C(C)O)CCOP(=O)(O)OP(=O)(O)O,,,,,,
568,440569,Imidazoleacetic acid riboside,C1=C(N=CN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)CC(=O)O,,,,,,
569,440570,"4-Oxo-4,5-dihydroimidazole-5-acetic acid",C1=NC(C(=O)N1)CC(=O)O,,,,,,
570,440571,5-Hydroxyimidazole-4-acetic acid,C1=NC(=C(N1)CC(=O)O)O,,,,,,
571,440572,CID 440572,C[C@@H]1[C@@H](C[C@H]([C@@H](O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C3NC(=NC4=O)N)O)O)O)O,,,,,,
572,440573,CID 440573,CC(=O)[C@]1(CCC2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C)O,,,,,,
573,440574,16alpha-Hydroxyandrostenedione,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3C[C@H](C4=O)O)C,,,,,,
574,440575,trans-3-hydroxy-L-proline,C1CN[C@@H]([C@H]1O)C(=O)O,,,,,,
575,440576,CID 440576,C[C@H]1CC([C@]23CC([C@H](C(O2)C(C)CCC(C4=CC(=CC=C4)O)OC)C)OC(=O)CC(OC(=O)C[C@]1(O3)O)C(C)O)(C)C,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)']",,,
576,440577,"[(1S,3S,7R,11S,12S,15S,17R,21R,23R,25S)-25-acetyloxy-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl] octa-2,4-dienoate",CCCC=CC=CC(=O)O[C@H]1C(=CC(=O)OC)C[C@H]2C[C@@H](OC(=O)C[C@@H](C[C@@H]3C[C@@H](C([C@@](O3)(C[C@@H]4CC(=CC(=O)OC)C[C@@H](O4)C=CC([C@@]1(O2)O)(C)C)O)(C)C)OC(=O)C)O)[C@@H](C)O,,,,,,
577,440578,CID 440578,C1=NN(C(=O)C(=C1N)Cl)C(=O)C(=O)C=CC=C(O)O,,,,,,
578,440579,"2,5-Diaminohexanoic acid",CC(CCC(C(=O)O)N)N,,,,,,
579,440580,"(3S,4R,5R)-5-(1,2-dihydroxyethyl)-3,4-dihydroxyoxolan-2-one",C(C([C@@H]1[C@@H]([C@@H](C(=O)O1)O)O)O)O,,,,,,
580,440581,2-Amino-5-oxo-cyclohex-1-enecarboxy-CoA,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)C4=C(CCC(=O)C4)N)O,,,,,,
581,440582,(S)-Cheilanthifoline,COC1=C(C=C2[C@@H]3CC4=C(CN3CCC2=C1)C5=C(C=C4)OCO5)O,,,,,,
582,440583,(S)-Stylopine,C1CN2CC3=C(C[C@H]2C4=CC5=C(C=C41)OCO5)C=CC6=C3OCO6,,,,,,
583,440584,(S)-N-Methylcoclaurine,CN1CCC2=CC(=C(C=C2[C@@H]1CC3=CC=C(C=C3)O)O)OC,,,,,,
584,440585,Berbamunine,CN1CCC2=CC(=C(C=C2[C@@H]1CC3=CC=C(C=C3)OC4=C(C=CC(=C4)C[C@@H]5C6=CC(=C(C=C6CCN5C)OC)O)O)O)OC,,,,,,
585,440586,(R)-Reticuline,CN1CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C=C3)OC)O)O)OC,,,,,,
586,440587,6-Hydroxyprotopine,CN1CC2=C(CC(=O)C3=CC4=C(C=C3CC1O)OCO4)C=CC5=C2OCO5,,,,,,
587,440588,12-Hydroxydihydrochelirubine,CN1CC2=C3C(=CC(=C2C4=C1C5=CC6=C(C=C5C(=C4)O)OCO6)OC)OCO3,,,,,,
588,440589,Dihydrochelirubine,CN1CC2=C3C(=CC(=C2C4=C1C5=CC6=C(C=C5C=C4)OCO6)OC)OCO3,,,,,,
589,440590,3-Hydroxybenzoyl-CoA; (Acyl-CoA); [M+H]+,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)C4=CC(=CC=C4)O)O,,,,,,
590,440591,(S)-3'-Hydroxy-N-methylcoclaurine,CN1CCC2=CC(=C(C=C2[C@@H]1CC3=CC(=C(C=C3)O)O)O)OC,,,,,,
591,440592,"(1S,9S,12S)-4,13-Dimethoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5,10,13-pentaene-3,12-diol",CN1CC[C@]23C=C([C@H](C=C2[C@@H]1CC4=C3C(=C(C=C4)OC)O)O)OC,,,,,,
592,440593,Phaseollidin hydrate,CC(C)(CCC1=C(C=CC2=C1O[C@@H]3[C@H]2COC4=C3C=CC(=C4)O)O)O,,,,,,
593,440594,"S-[2-[3-[[4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] (3S)-3-aminobutanethioate",C[C@@H](CC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O)N,,,,,,
594,440595,(R)-N-Methylcoclaurine,CN1CCC2=CC(=C(C=C2[C@H]1CC3=CC=C(C=C3)O)O)OC,,,,,,
595,440596,10-Hydroxydihydrosanguinarine,CN1CC2=C(C3=C1C4=CC5=C(C=C4C=C3)OCO5)C(=CC6=C2OCO6)O,,,,,,
596,440597,CID 440597,C(C(C(C1(C(N(C2=C(N1O)C(=O)N=C(N2)N)O)O)O)O)O)O,,,,,,
597,440598,CID 440598,CC(=O)C(=O)C1=NC2=C(NC(=NC2=O)N)N(C1O)O,,,,,,
598,440599,(s)-3-Aminoazepan-2-one,C1CCNC(=O)[C@H](C1)N,,,,,,
599,440600,beta-Hydroxypalmitoyl-coa,CCCCCCCCCCCCC[C@@H](CC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O)O,,,,,,
600,440601,3-ketopalmitoleoyl-CoA,CCCCCCCCCCCCCC(=O)CC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
601,440602,(S)-3-Hydroxytetradecanoyl-CoA.,CCCCCCCCCCC[C@@H](CC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O)O,,,,,,
602,440603,(S)-3-Hydroxydodecanoyl-CoA,CCCCCCCCC[C@@H](CC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O)O,,,,,,
603,440604,3-Oxododecanoyl-CoA,CCCCCCCCCC(=O)CC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
604,440605,3-Hydroxydecanoyl-coenzyme A,CCCCCCC[C@@H](CC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O)O,,,,,,
605,440606,3-ketodecanoyl-CoA,CCCCCCCC(=O)CC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
606,440607,"S-[2-[3-[[4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] (3S)-3-hydroxyoctanethioate",CCCCC[C@@H](CC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O)O,,,,,,
607,440608,3-Oxooctanoyl coenzyme A,CCCCCC(=O)CC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
608,440609,"S-[2-[3-[[4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] (3S)-3-hydroxyhexanethioate",CCC[C@@H](CC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O)O,,,,,,
609,440610,ketohexanoyl-CoA,CCCC(=O)CC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
610,440611,"S-[2-[3-[[4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] hexanethioate",CCCCCC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
611,440612,"S-[2-[3-[[4-[[[(2R,3S,4R,5R)-5-(6-Aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] hex-2-enethioate",CCCC=CC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
612,440613,"S-[2-[3-[[4-[[[(2R,3S,4R,5R)-5-(6-Aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] hexadec-2-enethioate",CCCCCCCCCCCCCC=CC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
613,440614,"S-[2-[3-[[4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] tetradec-2-enethioate",CCCCCCCCCCCC=CC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
614,440615,decanoyl CoA,CCCCCCCCCC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
615,440616,"S-[2-[3-[[4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] dec-2-enethioate",CCCCCCCC=CC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
616,440617,"S-[2-[3-[[4-[[[(2R,3S,4R,5R)-5-(6-Aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] oct-2-enethioate",CCCCCC=CC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
617,440618,CID 440618,CCCCCC=CCCC=CC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
618,440619,"S-[2-[3-[[4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] dodeca-3,6-dienethioate",CCCCCC=CCC=CCC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
619,440620,2-Methyl-5-oxohexanoic acid,CC(CCC(=O)C)C(=O)O,,,,,,
620,440621,CID 440621,CC12CCC3C(C1CCC2O)[C@@H](CC4=CC(=O)CCC34C)O,,,,,,
621,440622,"13-methyl-3,17-dioxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-10-carbaldehyde",CC12CCC3C(C1CCC2=O)CCC4=CC(=O)CCC34C=O,,,,,,
622,440623,2-Hydroxyestrone,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=CC(=C(C=C34)O)O,,,['Agents that reduce the frequency or rate of spontaneous or induced tumors independently of the mechanism involved. (See all compounds classified as Anticarcinogenic Agents.)'],,"['2-hydroxyestrone has known human metabolites that include 2-Methoxyestrone, 3-O-methoxyestrone, and Estrone 2-O-glucuronide.']",
623,440624,2-Methoxyestrone,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=CC(=C(C=C34)OC)O,,,,,"['2-Methoxyestrone has known human metabolites that include (8R,9S,13S,14S)-2-Methoxy-13-methyl-3-[(2R,3R,4S,5S,6S)-3,4,5,6-tetrahydroxyoxan-2-yl]oxy-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-one.']",
624,440625,"(8S,9R,13S,14R,16R)-3,16-dihydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-one",C[C@]12CC[C@@H]3[C@@H]([C@H]1C[C@H](C2=O)O)CCC4=C3C=CC(=C4)O,,,,,,
625,440626,CID 440626,CCC1=C(C2=NC1=CC3=C(C4=C([N-]3)C(=C5[C@H]([C@@H](C(=N5)C=C6C(=C(C(=C2)[N-]6)C=C)C)C)CCC(=O)OCC=C(C)CCCC(C)CCCC(C)CCCC(C)C)C(C4=O)C(=O)OC)C)C.[Mg+2],,,,,,
626,440627,CID 440627,CCC1=C(C2=NC1=CC3=C(C4=C(C(C(=C5[C@@H]([C@@H](C(=CC6=NC(=C2)C(=C6C)C=C)N5)C)CCC(=O)OCC=C(C)CCCC(C)CCCC(C)CCCC(C)C)C4=N3)C(=O)OC)O)C)C,,,,,,
627,440628,CID 440628,CCC1=C(C2=NC1=CC3=C(C4=C([N-]3)C(=C5[C@H]([C@@H](C(=N5)C=C6C(=C(C(=C2)[N-]6)C=C)C)C)CCC(=O)OCC=C(C)CCCC(C)CCCC(C)CCCC(C)C)C(C4=O)C(=O)OC)C)C=O.[Mg+2],,,,,,
628,440629,CID 440629,CCC1=C2C=C3C(=C4C(=O)C(C(=C5[C@@H]([C@@H](C(=CC6=NC(=CC(=N2)C1=CO)C(=C6C)C=C)N5)C)CCC(=O)OCC=C(C)CCCC(C)CCCC(C)CCCC(C)C)C4=N3)C(=O)OC)C,,,,,,
629,440630,"1-Benzyl-2-methyl-1,2,3,4-tetrahydroisoquinoline",CN1CCC2=CC=CC=C2C1CC3=CC=CC=C3,,,,,,
630,440631,Dihydromacarpine,CN1CC2=C3C(=CC(=C2C4=C1C5=CC6=C(C=C5C(=C4)OC)OCO6)OC)OCO3,,,,,,
631,440632,Nororientaline,COC1=C(C=C2C(NCCC2=C1)CC3=CC(=C(C=C3)O)OC)O,,,,,,
632,440633,"[(1S,9S,12S)-3-hydroxy-4,13-dimethoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5,10,13-pentaen-12-yl] acetate",CC(=O)O[C@H]1C=C2[C@@H]3CC4=C([C@@]2(CCN3C)C=C1OC)C(=C(C=C4)OC)O,,,,,,
633,440634,1-[(3S)-3-[[(3S)-3-amino-3-carboxypropyl]amino]-3-carboxypropyl]azetidine-2-carboxylic acid,C1CN(C1C(=O)O)CC[C@@H](C(=O)O)NCC[C@@H](C(=O)O)N,,,,,,
634,440635,CID 440635,CC(CCC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O)C4CC[C@@H]5C4(CC[C@H]6C5[C@@H](CC7C6(CC[C@H](C7)O)C)O)C,,,,,,
635,440636,"S-[2-[3-[[4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] 2-(4-hydroxyphenyl)ethanethioate",CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)CC4=CC=C(C=C4)O)O,,,,,,
636,440637,beta-Alanyl-L-arginine,C(C[C@@H](C(=O)O)NC(=O)CCN)CN=C(N)N,,,,,,
637,440638,beta-Alanyl-L-lysine,C(CCN)C[C@@H](C(=O)O)NC(=O)CCN,,,,,,
638,440639,(R)-4-hydroxymandelic acid,C1=CC(=CC=C1[C@H](C(=O)O)O)O,,,,,,
639,440640,CID 440640,C[C@H]1C(=O)[C@H]([C@H]([C@@H](O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C3NC(=NC4=O)N)O)O)O)O,,,,,,
640,440641,beta-D-Fructose 6-phosphate,C([C@@H]1[C@H]([C@@H]([C@](O1)(CO)O)O)O)OP(=O)(O)O,,,,,,
641,440642,2-Hydroxy-3-(4-hydroxy-phenyl)-propenoic acid,C1=CC(=CC=C1C=C(C(=O)O)O)O,,,,,,
642,440643,"5(s)-Hydroperoxy-6,8,11,14-eicosatetraenoic acid",CCCCCC=CCC=CCC=CC=C[C@H](CCCC(=O)O)OO,,,,,,
643,440644,CID 440644,C[C@@H]1[C@H](C[C@]2(C([C@H]([C@H](O2)[C@H](C[C@@H]([C@@H](C)[C@@H]([C@H](C)C=C(C)C(=CC=CC(=CC#N)C)C)O)O)OC)OP(=O)(O)O)(C)C)O[C@@H]1CC=CC3=COC(=N3)[C@@H](C)CCNC(=O)[C@H]([C@H]([C@H](COC)N(C)C)O)O)O,,,,,,
644,440645,"(5R,8S,11R,12S,15S,18S,19S,22R)-15-[3-(diaminomethylideneamino)propyl]-18-[(5S,6S)-6-methoxy-3,5-dimethyl-7-phenylhepta-1,3-dienyl]-1,5,12,19-tetramethyl-2-methylidene-8-(2-methylpropyl)-3,6,9,13,16,20,25-heptaoxo-1,4,7,10,14,17,21-heptazacyclopentacosane-11,22-dicarboxylic acid",C[C@H]1[C@@H](NC(=O)[C@@H](NC(=O)[C@H]([C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)C(=C)N(C(=O)CC[C@@H](NC1=O)C(=O)O)C)C)CC(C)C)C(=O)O)C)CCCN=C(N)N)C=CC(=C[C@H](C)[C@H](CC2=CC=CC=C2)OC)C,,,,,,
645,440646,Tautomycin,C[C@@H]1CC[C@@]2(CC[C@@H]([C@@H](O2)[C@H](C)CC[C@@H]([C@H](C)C(=O)C[C@H]([C@H]([C@@H](C(C)C)OC(=O)C[C@H](C3=C(C(=O)OC3=O)C)O)OC)O)O)C)O[C@H]1CC[C@H](C)C(=O)C,,,"['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)']",,,
646,440647,"2-hydroxy-2H-pyran-4,6-dicarboxylic acid",C1=C(C=C(OC1O)C(=O)O)C(=O)O,,,,,,
647,440648,CID 440648,COC1=CC=C(C=C1)C2=COC3=CC(=CC(=O)C3=C2O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O,,,,,,
648,440649,3-Carboxy-1-hydroxypropylthiamine diphosphate,CC1=C(SC(=[N+]1CC2=CN=C(N=C2N)C)C(CCC(=O)O)O)CCOP(=O)(O)OP(=O)(O)O,,,,,,
649,440650,D-glucuronic acid 1-phosphate,[C@@H]1([C@@H]([C@H](OC([C@@H]1O)OP(=O)(O)O)C(=O)O)O)O,,,,,,
650,440651,CID 440651,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C3NC(=NC4=O)N)O)O)O)O)O,,,,,,
651,440652,CID 440652,C[C@H]1C(=O)[C@H]([C@@H](C(O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C3NC(=NC4=O)N)O)O)O)O,,,,,,
652,440653,3-keto-beta-D-galactose,C([C@@H]1[C@@H](C(=O)[C@H]([C@@H](O1)O)O)O)O,,,,,,
653,440654,Lactose 6-phosphate,C([C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)O)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)COP(=O)(O)O)O)O)O)O,,,,,,
654,440655,Melibiitol,C([C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)O)O)O)O)OC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O,,,,,,
655,440656,Epimelibiose,C([C@@H]1[C@H]([C@@H]([C@@H]([C@H](O1)OC[C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)O)O)O)O)O)O)O)O,,,,,,
656,440657,CID 440657,C([C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)O)O)O)O)OCC(CO)O,,,,,,
657,440658,6-O-(alpha-D-Galactopyranosyl)-D-glucopyranose,C([C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H](C(O2)O)O)O)O)O)O)O)O,,,,,,
658,440659,3-Ketolactose,C([C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)O)O[C@H]2[C@@H](C(=O)[C@H]([C@H](O2)CO)O)O)O,,,,,,
659,440660,D-Gal alpha 1->6D-Gal alpha 1->6D-Glucose,C([C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)OC[C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)OC[C@@H]3[C@H]([C@@H]([C@H](C(O3)O)O)O)O)O)O)O)O)O)O)O,,,,,,
660,440661,"L-Arabino-1,5-lactone",C1[C@@H]([C@@H]([C@H](C(=O)O1)O)O)O,,,,,,
661,440662,"2,6,10,14,19,23,27,31-Octamethyldotriaconta-2,12,14,16,18,20,30-heptaene",CC(CCCC(C)CC=CC(=CC=CC=C(C)C=CCC(C)CCCC(C)CCC=C(C)C)C)CCC=C(C)C,,,,,,
662,440663,Cholest-5-ene,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CCCC4)C)C,,,,,,
663,440664,"5,6beta-Epoxy-5beta-cholestane",C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C[C@@H]4[C@]5([C@@]3(CCCC5)C)O4)C,,,,,,
664,440665,"5,6beta-Epoxy-5alpha-cholestan-3beta-ol",C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C[C@@H]4[C@@]5([C@@]3(CC[C@@H](C5)O)C)O4)C,,,,,,
665,440666,"2,6,10,14,19,23,27,31-Octamethyldotriaconta-2,6,10,14,16,18,22,26-octaene",CC(C)CCCC(=CCCC(=CCCC(=CC=CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C)C)C,,,,,,
666,440667,Dehydroascorbic acid,C([C@@H]([C@@H]1C(=O)C(=O)C(=O)O1)O)O,"['There is no approved indication for dehydroascorbic acid, but it has potential therapeutic use in patients with certain viruses and ischemic stroke.']","['Dehydroascorbic acid has similar biological activity as ascorbic acid. Both compounds have been shown to have antiviral effects against herpes simplex virus type 1, influenza virus type A and poliovirus type 1 with dehydroascorbic acid having the stronger effect. In addition, unlike ascorbic acid, dehydroascorbic acid can cross the blood brain barrier and is then converted to ascorbic acid to enable retention in the brain. This is important because one study has found that after an ischemic stroke, dehydroascorbic acid has neuroprotective effects by reducing infarct volume, neurological deficits, and mortality.']","['Organic substances that are required in small amounts for maintenance and growth, but which cannot be manufactured by the human body. (See all compounds classified as Vitamins.)']",,,
667,440668,"Phosphono 3,7,11,15-tetramethylhexadec-2-enyl hydrogen phosphate",CC(C)CCCC(C)CCCC(C)CCCC(=CCOP(=O)(O)OP(=O)(O)O)C,,,,,,
668,440669,"6-(3,7,12,16,20,24-Hexamethylpentacosa-1,3,5,7,9,11,13,15,19,23-decaenyl)-1,5,5-trimethylcyclohexene",CC1=CCCC(C1C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)CCC=C(C)CCC=C(C)C)C)C)(C)C,,,,,,
669,440670,"(3S,5S,10S,13R,14R,17R)-10,13-dimethyl-17-[(2R)-6-methylhept-5-en-2-yl]-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol",C[C@H](CCC=C(C)C)[C@H]1CC[C@@H]2[C@@]1(CCC3C2=CC[C@@H]4[C@@]3(CC[C@@H](C4)O)C)C,,,,,,
670,440671,"10,13-dimethyl-17-(6-methyl-5-methylidenehept-3-en-2-yl)-2,3,4,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol",CC(C)C(=C)C=CC(C)C1CCC2C1(CCC3C2=CC=C4C3(CCC(C4)O)C)C,,,,,,
671,440672,"(3R,7R)-17-(7-hydroxy-6-methylheptan-2-yl)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol",CC(CCCC(C)C1CCC2C1(CCC3C2[C@@H](CC4C3(CC[C@H](C4)O)C)O)C)CO,,,,,,
672,440673,"6-[(3R,7R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methylheptanal",CC(CCCC(C)C1CCC2C1(CCC3C2[C@@H](CC4C3(CC[C@H](C4)O)C)O)C)C=O,,,,,,
673,440674,"S-[2-[3-[[4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] 6-[(3R,5S,7R,10S,13R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methylhept-2-enethioate",CC(CCC=C(C)C(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O)C4CCC5[C@@]4(CCC6C5[C@@H](C[C@H]7[C@@]6(CC[C@H](C7)O)C)O)C,,,,,,
674,440675,"3beta,7 alpha,24-Trihydroxy-5beta-cholestanoyl-CoA",CC(CCC(C(C)C(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O)O)C4CCC5[C@@]4(CCC6C5[C@@H](C[C@H]7[C@@]6(CC[C@H](C7)O)C)O)C,,,,,,
675,440676,"3alpha,7alpha-Dihydroxy-5beta-24-oxocholestanoyl-CoA",CC(CCC(=O)C(C)C(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O)C4CCC5[C@@]4(CCC6C5[C@@H](C[C@H]7[C@@]6(CC[C@H](C7)O)C)O)C,,,,,,
676,440677,"3a,7a,12a,24-Tetrahydroxy-5b-cholestanoyl-CoA",CC(CCC(C(C)C(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O)O)C4CCC5C4([C@H](CC6C5[C@@H](C[C@H]7C6(CC[C@H](C7)O)C)O)O)C,,,,,,
677,440678,"(7R)-7-hydroxy-10,13-dimethyl-17-(6-methylheptan-2-yl)-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one",CC(C)CCCC(C)C1CCC2C1(CCC3C2[C@@H](CC4C3(CCC(=O)C4)C)O)C,,,,,,
678,440679,"(3R,7R)-10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol",CC(C)CCCC(C)C1CCC2C1(CCC3C2[C@@H](CC4C3(CC[C@H](C4)O)C)O)C,,,,,,
679,440680,"(7R,12S)-7,12-dihydroxy-10,13-dimethyl-17-(6-methylheptan-2-yl)-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one",CC(C)CCCC(C)C1CCC2C1([C@H](CC3C2[C@@H](CC4C3(CCC(=O)C4)C)O)O)C,,,,,,
680,440681,"(7R)-7-hydroxy-10,13-dimethyl-17-(6-methylheptan-2-yl)-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one",CC(C)CCCC(C)C1CCC2C1(CCC3C2[C@@H](CC4=CC(=O)CCC34C)O)C,,,,,,
681,440682,"(7R,12S)-7,12-dihydroxy-10,13-dimethyl-17-(6-methylheptan-2-yl)-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one",CC(C)CCCC(C)C1CCC2C1([C@H](CC3C2[C@@H](CC4=CC(=O)CCC34C)O)O)C,,,,,,
682,440683,CID 440683,CC(C)CCCC(C)C1CCC2C1([C@H](CC3C2[C@@H](C[C@@H]4C3(CCC(=O)C4)C)O)O)C,,,,,,
683,440684,"S-[2-[3-[[4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] 2-methyl-6-[(3R,5S,7R,12S)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]hept-2-enethioate",CC(CCC=C(C)C(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O)C4CCC5C4([C@H](CC6C5[C@@H](C[C@H]7C6(CC[C@H](C7)O)C)O)O)C,,,,,,
684,440685,Chenodeoxyglycocholoyl-CoA,CC(CCC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O)C4CCC5[C@@]4(CCC6C5[C@@H](C[C@H]7[C@@]6(CC[C@H](C7)O)C)O)C,,,,,,
685,440686,"2-[4-[(3R,5S,7R,10S,13R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoylamino]acetic acid",CC(CCC(=O)NCC(=O)O)C1CCC2[C@@]1(CCC3C2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C,,,,,,
686,440687,"2-[4-[(3R,10S,12S,13R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoylamino]ethanesulfonic acid",CC(CCC(=O)NCCS(=O)(=O)O)C1CCC2[C@@]1([C@H](CC3C2CCC4[C@@]3(CC[C@H](C4)O)C)O)C,,,,,,
687,440688,"2-[4-[(3R,10S,12S,13R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoylamino]acetic acid",CC(CCC(=O)NCC(=O)O)C1CCC2[C@@]1([C@H](CC3C2CCC4[C@@]3(CC[C@H](C4)O)C)O)C,,,,,,
688,440689,CID 440689,CC(CCC(=O)NCCS(=O)(=O)O)C1CCC2[C@@]1(CCC3C2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C,,,,,,
689,440690,"3alpha,7alpha,12alpha-Trihydroxy-5beta-24-oxocholestanoyl-CoA",CC(CCC(=O)C(C)C(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O)C4CC[C@@H]5C4([C@H](C[C@H]6C5[C@@H](C[C@H]7C6(CC[C@H](C7)O)C)O)O)C,,,,,,
690,440691,5beta-Cyprinolsulfate,CC(CCCC(CO)COS(=O)(=O)O)C1CCC2C1([C@H](CC3C2[C@@H](CC4C3(CC[C@H](C4)O)C)O)O)C,,,,,,
691,440692,"(3alpha)-3,17,21-Trihydroxypregnane-11,20-dione",CC12CC[C@H](CC1CCC3C2C(=O)CC4(C3CC[C@@]4(C(=O)CO)O)C)O,,,,,,
692,440693,"2-hydroxy-1-[(3R,17R)-3,11,17-trihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone",CC12CC[C@H](CC1CCC3C2C(CC4(C3CC[C@@]4(C(=O)CO)O)C)O)O,,,,,,
693,440694,"11-Hydroxy-17-(2-hydroxyacetyl)-10-methyl-3-oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-13-carbaldehyde",CC12CCC(=O)CC1CCC3C2C(CC4(C3CCC4C(=O)CO)C=O)O,,,,,,
694,440695,"(3R)-3,11-dihydroxy-17-(2-hydroxyacetyl)-10-methyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-13-carbaldehyde",CC12CC[C@H](CC1CCC3C2C(CC4(C3CCC4C(=O)CO)C=O)O)O,,,,,,
695,440696,"5beta-Pregnane-11beta,21-diol-3,20-dione",CC12CCC(=O)CC1CCC3C2C(CC4(C3CCC4C(=O)CO)C)O,,,,,,
696,440697,"(8S,9S,10S,13S,14S)-17-(2-hydroxyacetyl)-10,13-dimethyl-2,4,5,6,7,8,9,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,11-dione",C[C@]12CCC(=O)CC1CC[C@@H]3[C@@H]2C(=O)C[C@]4([C@H]3CCC4C(=O)CO)C,,,,,,
697,440698,"5beta-Pregnane-3alpha,21-diol-11,20-dione",CC12CC[C@H](CC1CCC3C2C(=O)CC4(C3CCC4C(=O)CO)C)O,,,,,,
698,440699,"5-alpha-Pregnane-3,20-dione",CC(=O)C1CCC2C1(CCC3C2CCC4C3(CCC(=O)C4)C)C,,,,,,
699,440700,"1-[(3R)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone",CC(=O)C1CCC2C1(CCC3C2CCC4C3(CC[C@H](C4)O)C)C,,,,,,
700,440701,"(3alpha)-3,17,20,21-Tetrahydroxypregnan-11-one",CC12CC[C@H](CC1CCC3C2C(=O)CC4(C3CC[C@@]4(C(CO)O)O)C)O,,,,,,
701,440702,"(3R,17R)-17-(1,2-dihydroxyethyl)-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthrene-3,11,17-triol",CC12CC[C@H](CC1CCC3C2C(CC4(C3CC[C@@]4(C(CO)O)O)C)O)O,,,,,,
702,440703,"3alpha,20alpha,21-Trihydroxy-5beta-pregnane-11-one",CC12CC[C@H](CC1CCC3C2C(=O)CC4(C3CCC4C(CO)O)C)O,,,,,,
703,440704,"(3R)-17-(1-hydroxyethyl)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol",CC(C1CCC2C1(CCC3C2CCC4C3(CC[C@H](C4)O)C)C)O,,,,,,
704,440705,"3,21-Dihydroxypregn-5-en-20-one",CC12CCC3C(C1CCC2C(=O)CO)CC=C4C3(CCC(C4)O)C,,,,,"['2-Hydroxy-1-(3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethanone is a known human metabolite of pregnenolone.']",
705,440706,"1-[(17R)-3,17-dihydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl]-2-hydroxyethanone",CC12CCC(CC1=CCC3C2CCC4(C3CC[C@@]4(C(=O)CO)O)C)O,,,,,,
706,440707,Cortodoxone,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C,,,,,['17Beta-21-dihydroxyprogesterone is a known human metabolite of 17alpha-hydroxy-progesterone.'],
707,440708,"2-hydroxy-1-[(17R)-3,11,17-trihydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl]ethanone",CC12CCC(CC1=CCC3C2C(CC4(C3CC[C@@]4(C(=O)CO)O)C)O)O,,,,,,
708,440709,"(8S,9S,10R,13S,14S,17R)-17-acetyl-11,17-dihydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one",CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC([C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)O)C)O,,,,,,
709,440710,"(17R)-17-[(2R)-2-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-3,17-diol",CC(C)CCC[C@](C)([C@]1(CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C)O)O,,,,,,
710,440711,20alpha-Hydroxycholesterol,CC(C)CCC[C@](C)([C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C)O,,,,,,
711,440712,CID 440712,CC(C)CC[C@H]([C@](C)(C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C)O)O,,,,,,
712,440713,17beta-Estradiol 3-(beta-D-glucuronide),C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)C(=O)O)O)O)O,,,,,,
713,440714,2-Amino-3-oxohexanedioic acid,C(CC(=O)O)C(=O)C(C(=O)O)N,,,,,,
714,440715,"2(1H)-Pyrimidinone, 4-amino-5,6-dihydro-5-methyl-",CC1CNC(=O)N=C1N,,,,,,
715,440716,CID 440716,C(C(=O)C(=O)O)S(=O)=O,,,,,,
716,440717,Sulfopyruvate,C(C(=O)C(=O)O)S(=O)(=O)O,,,,,,
717,440718,Oxaloglutarate,C(CC(=O)O)C(C(=O)C(=O)O)C(=O)O,,,,,,
718,440719,(S)-2-acetamido-6-oxopimelic acid,CC(=O)N[C@@H](CCCC(=O)C(=O)O)C(=O)O,,,,,,
719,440720,"(2S,5S)-2,6-diamino-5-[(3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanoic acid",C(C[C@@H](C(=O)O)N)[C@@H](CN)OC1[C@@H]([C@H]([C@H]([C@H](O1)CO)O)O)O,,,,,,
720,440721,epsilon-N-Biotinyl-L-lysine,C1C2C([C@@H](S1)CCCCC(=O)NCCCC[C@@H](C(=O)O)N)NC(=O)N2,,,,,,
721,440722,delta-(L-2-Aminoadipyl)-L-cysteinyl-D-valine,CC(C)[C@H](C(=O)O)NC(=O)C(CS)NC(=O)CCC[C@@H](C(=O)O)N,,,,,,
722,440723,Isopenicillin N,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CCC[C@@H](C(=O)O)N)C(=O)O)C,,,,,,
723,440724,L-2-Aminoadipate adenylate,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OC(=O)CCC[C@@H](C(=O)O)N)O)O)N,,,,,,
724,440725,CID 440725,C1=C(NC(=N1)S)C=CC(=O)O,,,,,,
725,440726,4-Oxoglutaramic acid,C(CC(=O)O)C(=O)C(=O)N,,,,,,
726,440727,"N,N,N-Trimethyl-Histidine",C[N+](C)(C)[C@@H](CC1=CN=CN1)C(=O)O,,,,,,
727,440728,"Indole-5,6-quinone",C1=CNC2=CC(=O)C(=O)C=C21,,,,,,
728,440729,3-Methoxy-4-hydroxyphenylglycolaldehyde,COC1=C(C=CC(=C1)C(C=O)O)O,,,,,,
729,440730,CID 440730,C(C(=CC(=O)O)C=CC(=O)O)C(=O)O,,,,,,
730,440731,4-Hydroxyphenylacetylglutamate,C1=CC(=CC=C1CC(=O)NC(CCC(=O)O)C(=O)O)O,,,,,,
731,440732,4-Hydroxyphenylacetylglycine,C1=CC(=CC=C1CC(=O)NCC(=O)O)O,,,,,,
732,440733,3-(4-Hydroxyphenyl)prop-2-enal,C1=CC(=CC=C1C=CC=O)O,,,,,,
733,440734,CID 440734,C1[C@@]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=CC(=O)C4=C(C=C(OC4=C3)C5=CC=C(C=C5)O)O)COC(=O)CC(=O)O)O)O)O)(CO)O,,,,,,
734,440735,Eriodictyol,C1[C@H](OC2=CC(=CC(=C2C1=O)O)O)C3=CC(=C(C=C3)O)O,,,,,,
735,440736,3-Hydroxykynurenamine,C1=CC(=C(C(=C1)O)N)C(=O)CCN,,,,,,
736,440737,"Quinoline-4,8-diol",C1=CC2=C(C(=C1)O)NC=CC2=O,,,,,,
737,440738,"4,6-Dihydroxyquinoline",C1=CC2=C(C=C1O)C(=O)C=CN2,,,,,,
738,440739,"5-(3-carboxy-3-oxoprop-1-enyl)-4,6-dioxo-1H-pyridine-2-carboxylic acid",C1=C(NC(=O)C(C1=O)C=CC(=O)C(=O)O)C(=O)O,,,,,,
739,440740,3-(1H-indol-3-yl)-2-oxobutanoic acid,CC(C1=CNC2=CC=CC=C21)C(=O)C(=O)O,,,,,,
740,440741,"4-(2-Amino-3-hydroxyphenyl)-2,4-dioxobutanoic acid",C1=CC(=C(C(=C1)O)N)C(=O)CC(=O)C(=O)O,,,,,,
741,440742,5-Hydroxyindolepyruvate,C1=CC2=C(C=C1O)C(=CN2)CC(=O)C(=O)O,,,,,,
742,440743,Formyl-5-hydroxykynurenamine,C1=CC(=C(C=C1O)C(=O)CCN)NC=O,,,,,,
743,440744,5-Hydroxy-N-formylkynurenine,C1=CC(=C(C=C1O)C(=O)CC(C(=O)O)N)NC=O,,,,,,
744,440745,5-Hydroxykynurenine,C1=CC(=C(C=C1O)C(=O)CC(C(=O)O)N)N,,,,,,
745,440746,"4-(2-Amino-5-hydroxyphenyl)-2,4-dioxobutanoic acid",C1=CC(=C(C=C1O)C(=O)CC(=O)C(=O)O)N,,,,,,
746,440747,"4,6-dioxo-5-(3-oxopropyl)-1H-pyridine-2-carboxylic acid",C1=C(NC(=O)C(C1=O)CCC=O)C(=O)O,,,,,,
747,440748,"5-(2-carboxyethyl)-4,6-dioxo-1H-pyridine-2-carboxylic acid",C1=C(NC(=O)C(C1=O)CCC(=O)O)C(=O)O,,,,,,
748,440749,"5-(3-carboxy-3-oxopropyl)-4,6-dioxo-1H-pyridine-2-carboxylic acid",C1=C(NC(=O)C(C1=O)CCC(=O)C(=O)O)C(=O)O,,,,,,
749,440750,3-(6-Hydroxyindol-3-yl)lactic acid,C1=CC2=C(C=C1O)NC=C2CC(C(=O)O)O,,,,,,
750,440751,"(1R,2R)-1-hydroxybutane-1,2,4-tricarboxylic acid",C(CC(=O)O)[C@H]([C@H](C(=O)O)O)C(=O)O,,,,,,
751,440752,6-Hydroxykynurenic acid,C1=CC2=C(C=C1O)C(=O)C=C(N2)C(=O)O,,,,,,
752,440753,"S-[2-[3-[[4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] 3-hydroxypropanethioate",CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)CCO)O,,,,,,
753,440754,CMP-2-aminoethylphosphonate,C1=CN(C(=O)N=C1N)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(CCN)O)O)O,,,,,,
754,440755,CMP-2-trimethylaminoethylphosphonate,C[N+](C)(C)CCP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=CC(=NC2=O)N)O)O,,,,,,
755,440756,(2-Amino-1-hydroxyethyl)phosphonic acid,C(C(O)P(=O)(O)O)N,,,,,,
756,440757,"2-[[(4R)-4-[(3R,5S,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethylphosphonic acid",C[C@H](CCC(=O)NCCP(=O)(O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2C(C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,,,,,,
757,440758,Adenylylselenate,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O[Se](=O)(=O)O)O)O)N,,,,,,
758,440759,CID 440759,C[SeH](CCC(C(=O)O)N)C[C@@H]1[C@H]([C@H]([C@H](O1)N2C=NC3=C(N=CN=C32)N)O)O,,,,,,
759,440760,gamma-Glutamyl-Se-methylselenocysteine,C[Se]CC(C(=O)O)NC(=O)CCC(C(=O)O)N,,,,,,
760,440761,"[[(2R,3S,4R,5R)-5-(6-amino-7H-purin-3-ium-3-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] selenate",C1=NC2=[N+](C=NC(=C2N1)N)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O[Se](=O)(=O)[O-])OP(=O)(O)O)O,,,,,,
761,440762,"[(2R,3S,4R,5R)-5-(6-amino-7H-purin-3-ium-3-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methyl selenono hydrogen phosphate",C1=NC2=[N+](C=NC(=C2N1)N)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O[Se](=O)(=O)O)OP(=O)(O)O)O,,,,,,
762,440763,2-Amino-4-selanylbutanoic acid,C(C[SeH])C(C(=O)O)N,,,,,,
763,440764,Methylselenium(II),C[SeH],,,,,,
764,440765,2-Amino-3-seleninopropanoic acid,C(C(C(=O)O)N)[Se](=O)O,,,,,,
765,440766,2-Amino-3-prop-1-enylseleninylpropanoic acid,CC=C[Se](=O)CC(C(=O)O)N,,,,,,
766,440767,"Butanoic acid, 2-amino-4-(methylseleninyl)-",C[Se](=O)CCC(C(=O)O)N,,,,,,
767,440768,2-Amino-5-[(1-carboxy-2-cyanoethyl)amino]-5-oxopentanoic acid,C(CC(=O)NC(CC#N)C(=O)O)C(C(=O)O)N,,,,,,
768,440769,4-Amino-4-cyanobutanoic acid,C(CC(=O)O)C(C#N)N,,,,,,
769,440770,2-Amino-4-cyanobutanoic acid,C(CC(C(=O)O)N)C#N,,,,,,
770,440771,2-Amino-5-[[1-carboxy-4-[carboxy(2-carboxyethyl)amino]-4-oxobutyl]amino]-5-oxopentanoic acid,C(CC(=O)NC(CCC(=O)N(CCC(=O)O)C(=O)O)C(=O)O)C(C(=O)O)N,,,,,,
771,440772,Glutathionylspermidine,C(CCNCCCNC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@@H](C(=O)O)N)CN,,,,,,
772,440773,3-Ketosucrose,C([C@@H]1[C@H]([C@@H]([C@](O1)(CO)O[C@@H]2[C@@H](C(=O)[C@@H]([C@H](O2)CO)O)O)O)O)O,,,,,,
773,440774,alpha-L-glutamyl phosphate,C(CC(=O)O)[C@@H](C(=O)OP(=O)(O)O)N,,,,,,
774,440775,Uroporphyrinogen I,C1C2=C(C(=C(N2)CC3=C(C(=C(N3)CC4=C(C(=C(N4)CC5=C(C(=C1N5)CC(=O)O)CCC(=O)O)CC(=O)O)CCC(=O)O)CC(=O)O)CCC(=O)O)CC(=O)O)CCC(=O)O,,,,,['Uroporphyrinogen I has known human metabolites that include uroporphyrin.'],
775,440776,Coproporphyrinogen I,CC1=C2CC3=C(C(=C(N3)CC4=C(C(=C(N4)CC5=C(C(=C(N5)CC(=C1CCC(=O)O)N2)C)CCC(=O)O)C)CCC(=O)O)C)CCC(=O)O,,,,,,
776,440777,CID 440777,CC1=C2[C@@]([C@@H](C(=N2)C=C3[C@@]([C@@H](C(=CC4=C(C(=C(N4)CC5=C(C(=C1N5)CC(=O)O)CCC(=O)O)CCC(=O)O)CC(=O)O)N3)CCC(=O)O)(C)CC(=O)O)CCC(=O)O)(C)CC(=O)O,,,,,,
777,440778,CID 440778,CC1=C2[C@H]([C@]([C@@]([N-]2)([C@H]3[C@@H]([C@@](C(=N3)C(=C4[C@H](C(C(=N4)C=C5[C@H]([C@](C1=N5)(C)CC(=O)O)CCC(=O)O)(C)C)CCC(=O)O)C)(C)CCC(=O)O)CC(=O)O)C)(C)CC(=O)O)CCC(=O)O.[Co+2],,,,,,
778,440779,"3-[(1R,2S,3S,7S,8S,13S,17R,18R,19R)-3,13,17-tris(2-carboxyethyl)-2,7,18-tris(carboxymethyl)-1,2,5,7,12,12,15,17-octamethyl-3,8,13,18,19,22-hexahydrocorrin-8-yl]propanoic acid",CC1=C2[C@@]([C@@H](C(=CC3=NC(=C(C4=N[C@H]([C@@H]([C@@]4(C)CCC(=O)O)CC(=O)O)[C@]5([C@@]([C@@H](C1=N5)CCC(=O)O)(C)CC(=O)O)C)C)[C@H](C3(C)C)CCC(=O)O)N2)CCC(=O)O)(C)CC(=O)O,,,,,,
779,440780,"N1-(alpha-D-ribosyl)-5,6-dimethyl-benzimidazole",CC1=CC2=C(C=C1C)N(C=N2)[C@@H]3C(C([C@H](O3)CO)O)O,,,,,,
780,440781,CID 440781,C[C@@]12CC(=O)N[C@@]13CC4[C@H]([C@](C(=N4)CC5C([C@@H]6CCC(=O)C(C6=N5)C7[C@H]([C@@H](C(=CC(=N3)[C@H]2CCC(=O)O)[N-]7)CC(=O)O)CCC(=O)O)CC(=O)O)(C)C(=O)N)CCC(=O)O.[Ni+2],,,,,,
781,440782,"3-[(1S,4S,5S,11S,17S,18S,22S,23S)-5-carbamoyl-4,22-bis(2-carboxyethyl)-18,29-bis(carboxymethyl)-5,23-dimethyl-14,25-dioxo-9,26,27,28,30-pentazaheptacyclo[19.5.1.13,6.18,11.116,19.01,23.010,15]triaconta-6(30),9,19(28),20-tetraen-17-yl]propanoic acid",C[C@@]12CC(=O)N[C@@]13CC4[C@H]([C@](C(=N4)CC5C([C@@H]6CCC(=O)C(C6=N5)C7[C@H]([C@@H](C(=N7)C=C([C@H]2CCC(=O)O)N3)CC(=O)O)CCC(=O)O)CC(=O)O)(C)C(=O)N)CCC(=O)O,,,,,,
782,440783,L-Stercobilinogen,CCC1C(C(=O)NC1CC2=C(C(=C(N2)CC3=C(C(=C(N3)CC4C(C(C(=O)N4)CC)C)C)CCC(=O)O)CCC(=O)O)C)C,,,,,,
783,440784,D-Urobilinogen,CCC1=C(C(=O)NC1CC2=C(C(=C(N2)CC3=C(C(=C(N3)CC4C(=C(C(=O)N4)C=C)C)C)CCC(=O)O)CCC(=O)O)C)C,,,,,,
784,440785,"3,18-Diethyl-1,4,5,15,16,19,22,24-octahydro-2,7,13,17-tetramethyl-1,19-dioxo-21H-biline-8,12-dipropionic acid",CCC1=C(C(=O)NC1CC2=C(C(=C(N2)C=C3C(=C(C(=N3)CC4C(=C(C(=O)N4)CC)C)C)CCC(=O)O)CCC(=O)O)C)C,,,,,,
785,440786,"3-[2-[[3-(2-carboxyethyl)-5-[(3-ethyl-4-methyl-5-oxo-1,2-dihydropyrrol-2-yl)methyl]-4-methyl-1H-pyrrol-2-yl]methylidene]-5-[(4-ethenyl-3-methyl-5-oxo-1,2-dihydropyrrol-2-yl)methyl]-4-methylpyrrol-3-yl]propanoic acid",CCC1=C(C(=O)NC1CC2=C(C(=C(N2)C=C3C(=C(C(=N3)CC4C(=C(C(=O)N4)C=C)C)C)CCC(=O)O)CCC(=O)O)C)C,,,,,,
786,440787,CID 440787,CCC1=C(C2=NC1=CC3=C(C4=C([C@@H](C(=C5[C@H]([C@@H](C(=CC6=NC(=C2)C(=C6C)C(=O)C)N5)C)CCC(=O)OCCC=C(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C4=N3)C(=O)OC)O)C)C,,,,,,
787,440788,CID 440788,CC[C@@H]1[C@H](C2=CC3=C(C(=C(N3)C=C4[C@H]([C@@H](C(=N4)C5=C6C(=C(C(=CC1=N2)N6)C)C(=O)[C@@H]5C(=O)OC)CCC(=O)OCCC=C(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C)C)C(=O)C)C,,,,,,
788,440789,"2-(3,7,11,15,19,23-Hexamethyltetracosa-2,6,10,14,18,22-hexaenyl)phenol",CC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCC1=CC=CC=C1O)C)C)C)C)C)C,,,,,,
789,440790,"3-(3,7,11,15,19,23-Hexamethyltetracosa-2,6,10,14,18,22-hexaenyl)benzene-1,2-diol",CC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCC1=C(C(=CC=C1)O)O)C)C)C)C)C)C,,,,,,
790,440791,"2-(3,7,11,15,19,23-Hexamethyltetracosa-2,6,10,14,18,22-hexaenyl)-6-methoxyphenol",CC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCC1=C(C(=CC=C1)OC)O)C)C)C)C)C)C,,,,,,
791,440792,"2-(3,7,11,15,19,23-Hexamethyltetracosa-2,6,10,14,18,22-hexaenyl)-6-methoxycyclohexa-2,5-diene-1,4-dione",CC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCC1=CC(=O)C=C(C1=O)OC)C)C)C)C)C)C,,,,,,
792,440793,"3-(3,7,11,15,19,23-Hexamethyltetracosa-2,6,10,14,18,22-hexaenyl)-5-methoxy-2-methylcyclohexa-2,5-diene-1,4-dione",CC1=C(C(=O)C(=CC1=O)OC)CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C,,,,,,
793,440794,CID 440794,CC1=C(C(=C(C(=O)C1=O)OC)O)CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C,,,,,,
794,440795,"2-(3,7-Dimethylocta-2,6-dienyl)phenol",CC(=CCCC(=CCC1=CC=CC=C1O)C)C,,,,,,
795,440796,"4-(3,7-Dimethylocta-2,6-dienyl)benzene-1,3-diol",CC(=CCCC(=CCC1=C(C=C(C=C1)O)O)C)C,,,,,,
796,440797,"2-Methoxy-6-(3,7,11,15,19,23,27,31-octamethyldotriaconta-2,6,10,14,18,22,26,30-octaenyl)phenol",CC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCC1=C(C(=CC=C1)OC)O)C)C)C)C)C)C)C)C,,,,,,
797,440798,"4-[[2-[3-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-4-methyl-1,3-thiazol-3-ium-5-yl]ethoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-4-hydroxybutanoic acid",CC1=C(SC=[N+]1CC2=CN=C(N=C2N)C)CCOP(=O)(O)OP(=O)(O)O[C-](CCC(=O)O)O,,,,,,
798,440799,"(6R)-2-(3-carboxypropanoyl)-6-hydroxycyclohexa-2,4-diene-1-carboxylic acid",C1=C[C@H](C(C(=C1)C(=O)CCC(=O)O)C(=O)O)O,,,,,,
799,440800,"2-(3,7-Dimethylocta-2,6-dienyl)naphthalene-1,4-dione",CC(=CCCC(=CCC1=CC(=O)C2=CC=CC=C2C1=O)C)C,,,,,,
800,440801,"2-(3,7-Dimethylocta-2,6-dienyl)-3-methylnaphthalene-1,4-diol",CC1=C(C2=CC=CC=C2C(=C1CC=C(C)CCC=C(C)C)O)O,,,,,,
801,440802,"[(2R,3S,4R,5R)-5-(6-amino-7H-purin-9-ium-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methyl (2R)-2-amino-3-hydroxypropanoate",C1=[N+](C2=NC=NC(=C2N1)N)[C@H]3[C@@H]([C@@H]([C@H](O3)COC(=O)[C@@H](CO)N)OP(=O)(O)O)O,,,,,,
802,440803,2-Hydroxy-3-sulfanylpropanoate,C(C(C(=O)[O-])O)S,,,,,,
803,440804,S-Sulfo-D-cysteine,C([C@H](C(=O)O)N)SS(=O)(=O)O,,,,,,
804,440805,2-Amino-5-oxohexanoic acid,CC(=O)CCC(C(=O)O)N,,,,,,
805,440806,5-Hydroxyindoleacetylglycine,C1=CC2=C(C=C1O)C(=CN2)CC(=O)NCC(=O)O,,,,,,
806,440807,2-Formaminobenzoylacetate,C1=CC=C(C(=C1)C(=O)CC(=O)O)NC=O,,,,,,
807,440808,CID 440808,C1=CC=C2C(=C1)C(=CN2)CC(=NOS(=O)(=O)O)S[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
808,440809,beta-D-Glucosyl-2-hydroxycinnamate,C1=CC=C(C(=C1)C=CC(=O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O,,,,,,
809,440810,"1,4-Dihydro-1-methyl-4-oxo-3-pyridinecarboxamide",CN1C=CC(=O)C(=C1)C(=O)N,,,,,,
810,440811,CID 440811,CC(=CCCC(=CCC(=CCC(=CCC(=CCC(=CCC(=CCC(=CCC(=CCC(=CCC(=CCOP(=O)(O)OP(=O)(O)O[C@@H]1[C@@H]([C@H]([C@H]([C@H](O1)CO)O)O)NC(=O)C)C)C)C)C)C)C)C)C)C)C)C,,,,,,
811,440812,Agn-PC-0jram3,CC(=CCCC(=CCC1=C(C=CC(=C1)C(=O)O)O)C)C,,,,,,
812,440813,4-Methylene-2-oxoglutarate,C=C(CC(=O)C(=O)O)C(=O)O,,,,,,
813,440814,"(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[4-(3-hydroxyprop-1-enyl)phenoxy]oxane-3,4,5-triol",C1=CC(=CC=C1C=CCO)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O,,,,,,
814,440815,Thiamine(1+) aldehyde,CC1=C(SC=[N+]1CC2=CN=C(N=C2N)C)CC=O,,,,,,
815,440816,CID 440816,CC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCOP(=O)(O)OP(=O)(O)O[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O[C@H]2[C@H]([C@H]([C@@H]([C@H](O2)COCC(COP(=O)(O)OCC(COP(=O)(O)O)O)O)OCC(COP(=O)(O)OCC(COP(=O)(O)O)O)O)OCC(COP(=O)(O)OCC(COP(=O)(O)O)O)O)NC(=O)C)O)NC(=O)C)C)C)C)C)C)C)C)C)C)C)C,,,,,,
816,440817,CID 440817,CC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCCC(=CCOP(=O)(O)OP(=O)(O)O[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O[C@H]2[C@H]([C@H]([C@@H]([C@H](O2)COCC(COP(=O)(O)OCC(COP(=O)(O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)OCC(COP(=O)(O)OCC(COP(=O)(O)O)O[C@@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)OCC(COP(=O)(O)OCC(COP(=O)(O)O)O[C@@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O)NC(=O)C)O)NC(=O)C)C)C)C)C)C)C)C)C)C)C)C,,,,,,
817,440818,CID 440818,CC(CCC=C(C)CCC=C(C)C)CCOP(=O)(O)OP(=O)(O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)NC(=O)C)O)NC(=O)C,,,,,,
818,440819,CID 440819,CC(CCC=C(C)CCC=C(C)C)CCOP(=O)(O)OP(=O)(O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)CO)O)O[C@@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O)NC(=O)C)O)NC(=O)C,,,,,,
819,440820,CID 440820,CC(CCC=C(C)CCC=C(C)C)CCOP(=O)(O)OP(=O)(O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)CO[C@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O[C@H]5[C@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O[C@H]7[C@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)O)O)NC(=O)C)O)NC(=O)C,,,,,,
820,440821,CID 440821,CC(CCC=C(C)CCC=C(C)C)CCOP(=O)(O)OP(=O)(O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)CO[C@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO[C@H]5[C@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)O)O[C@H]7[C@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O[C@H]8[C@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O)O)O[C@H]9[C@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O[C@H]1[C@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O[C@H]1[C@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)O)O)NC(=O)C)O)NC(=O)C,,,,,,
821,440822,(R)-2-(Acetylamino)-3-O-(1-carboxyethyl)-2-deoxy-D-glucose,CC(C(=O)O)O[C@H]1[C@@H]([C@H](OC([C@@H]1NC(=O)C)O)CO)O,,,,,,
822,440823,CID 440823,C[C@H](C(=O)N[C@H](C)C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@H]1[C@@H]([C@H](OC([C@@H]1NC(=O)C)OP(=O)(O)OP(=O)(O)OCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)CO)O,,,,,,
823,440824,CID 440824,C[C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)C(C)O[C@H]1[C@H]([C@@H](OC([C@@H]1NC(=O)C)OP(=O)(O)OP(=O)(O)OCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)CO)O[C@@H]2[C@@H]([C@H]([C@H]([C@@H](O2)CO)O)O)NC(=O)C,,,,,,
824,440825,CID 440825,C[C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)NC(=O)C(C)O[C@H]1[C@H]([C@@H](OC([C@@H]1NC(=O)C)OP(=O)(O)OP(=O)(O)OCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)CO)O[C@@H]2[C@@H]([C@H]([C@H]([C@@H](O2)CO)O)O)NC(=O)C,,,,,,
825,440826,CID 440826,C[C@H](C(=O)NC(CCC(=O)N[C@@H](CCCCN)C(=O)O)C(=O)O)NC(=O)C(C)O[C@H]1[C@@H]([C@H](OC([C@@H]1NC(=O)C)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=O)NC3=O)O)O)CO)O,,,,,,
826,440827,CID 440827,C[C@H](C(=O)N[C@H](C)C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)CCC(C(=O)O)NC(=O)[C@H](C)NC(=O)C(C)O[C@H]1[C@@H]([C@H](OC([C@@H]1NC(=O)C)OP(=O)(O)OP(=O)(O)OCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)CO)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)NC(=O)C,,,,,,
827,440828,CID 440828,C[C@H](C(=O)N[C@H](C)C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)CCC(C(=O)N)NC(=O)[C@H](C)NC(=O)C(C)O[C@H]1[C@@H]([C@H](OC([C@@H]1NC(=O)C)OP(=O)(O)OP(=O)(O)OCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)CO)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)NC(=O)C,,,,,,
828,440829,CID 440829,C[C@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@@H](CCC[C@@H](C(=O)O)N)NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@H]1[C@@H]([C@H](OC([C@@H]1NC(=O)C)OP(=O)(O)OP(=O)(O)OCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)CO)O,,,,,,
829,440830,CID 440830,C[C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CCC[C@@H](C(=O)O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)C(C)O[C@H]1[C@H]([C@@H](OC([C@@H]1NC(=O)C)OP(=O)(O)OP(=O)(O)OCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)CO)O[C@@H]2[C@@H]([C@H]([C@H]([C@@H](O2)CO)O)O)NC(=O)C,,,,,,
830,440831,CID 440831,C[C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CCC[C@@H](C(=O)O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)NC(=O)C(C)O[C@H]1[C@H]([C@@H](OC([C@@H]1NC(=O)C)OP(=O)(O)OP(=O)(O)OCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)CO)O[C@@H]2[C@@H]([C@H]([C@H]([C@@H](O2)CO)O)O)NC(=O)C,,,,,,
831,440832,Pelargonidin,C1=CC(=CC=C1C2=[O+]C3=CC(=CC(=C3C=C2O)O)O)O,,,,,,
832,440833,Leucocianidol,C1=CC(=C(C=C1[C@@H]2[C@H]([C@H](C3=C(C=C(C=C3O2)O)O)O)O)O)O,,,,,,
833,440834,3-Deoxyleucocyanidin,C1[C@H](OC2=CC(=CC(=C2C1O)O)O)C3=CC(=C(C=C3)O)O,,,,,,
834,440835,Leucodelphidin,C1=C(C=C(C(=C1O)O)O)[C@@H]2[C@H]([C@H](C3=C(C=C(C=C3O2)O)O)O)O,,,,,,
835,440836,(2S)-dihydrotricetin,C1[C@H](OC2=CC(=CC(=C2C1=O)O)O)C3=CC(=C(C(=C3)O)O)O,,,,,,
836,440837,CID 440837,CC=C1[C@H](C(=O)N=C1C=C2C(=C(C(=CC3=C(C(=C(N3)C[C@@H]4C(=C(C(=O)N4)C=C)C)C)CCC(=O)O)N2)CCC(=O)O)C)C,,,,,,
837,440838,CID 440838,CC=C1[C@H](C(=O)NC1=CC2=C(C(=C(N2)C=C3C(=C(C(=CC4=NC(=O)C(=C4C)C=C)N3)C)CCC(=O)O)CCC(=O)O)C)C,,,,,,
838,440839,beta-AMP,C1C2C([C@@H](S1)CCCCC(=O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)NC(=O)N2,,,,,,
839,440840,CID 440840,C([C@@H]1[C@H]([C@H]([C@@H](O1)NC2=C(C(=O)N=C(N2)N)NC=O)O)O)OP(=O)(O)OP(=O)(O)OP(=O)(O)O,,,,,,
840,440841,CID 440841,C([C@@H]1[C@H]([C@H]([C@@H](O1)NC2=C(C(=O)N=C(N2)N)N)O)O)OP(=O)(O)OP(=O)(O)OP(=O)(O)O,,,,,,
841,440842,CID 440842,C1=C(N=C2C(=N1)NC(=NC2=O)N)[C@@H]([C@H](CO)O)O,,,,,,
842,440843,CID 440843,C[C@H]1C(=NC2=C(N1)NC(=NC2=O)N)[C@@H](C)NC3=CC=C(C=C3)C[C@@H]([C@@H]([C@@H](CO[C@@H]4[C@@H]([C@@H]([C@H](O4)COP(=O)(O)O[C@@H](CCC(=O)O)C(=O)O)O)O)O)O)O,,,,,,
843,440844,CID 440844,C1C(NC2=C(N1)NC(=NC2=O)N)CN(C=O)C3=CC=C(C=C3)C(=O)NC(CCC(=O)NC(CCC(=O)O)C(=O)O)C(=O)O,,,,,,
844,440845,CID 440845,C1C(NC2=C(N1)NC(=NC2=O)N)CN(C=O)C3=CC=C(C=C3)C(=O)NC(CCC(=O)NC(CCC(=O)NC(CCC(=O)O)C(=O)O)C(=O)O)C(=O)O,,,,,,
845,440846,H-gamma-Glu-gamma-Glu-Glu-OH,C(CC(=O)NC(CCC(=O)NC(CCC(=O)O)C(=O)O)C(=O)O)C(C(=O)O)N,,,,,,
846,440847,(2S)-2-(3-Carboxypropanoylamino)pentanedioic acid,C(CC(=O)O)[C@@H](C(=O)O)NC(=O)CCC(=O)O,,,,,,
847,440848,N2-Succinyl-L-glutamic acid 5-semialdehyde,C(C[C@@H](C(=O)O)NC(=O)CCC(=O)O)C=O,,,,,,
848,440849,Nomega-hydroxyarginine,C(CC(C(=O)O)N)CN=C(N)NO,,,,,,
849,440850,4-Acetamidobutanal,CC(=O)NCCCC=O,,,,,,
850,440851,L-4-Hydroxyglutamate semialdehyde,C([C@H](C=O)O)[C@@H](C(=O)O)N,,,,,,
851,440852,2-Oxo-4-hydroxy-5-aminovalerate,C([C@H](CN)O)C(=O)C(=O)O,,,,,,
852,440853,D-4-Hydroxy-2-oxoglutarate,C([C@H](C(=O)O)O)C(=O)C(=O)O,,,,,,
853,440854,"(2S,4R)-2-amino-4-hydroxypentanedioic acid",C([C@@H](C(=O)O)N)[C@H](C(=O)O)O,,,,,,
854,440855,"(5S)-5-Hydroxy-12-oxoicosa-6,8,10,14-tetraenoic acid",CCCCCC=CCC(=O)C=CC=CC=C[C@H](CCCC(=O)O)O,,,,,,
855,440856,"(5S,6R)-6-[(2R)-2-amino-3-(carboxymethylamino)-3-oxopropyl]sulfanyl-5-hydroxyicosa-7,9,11,14-tetraenoic acid",CCCCCC=CCC=CC=CC=C[C@H]([C@H](CCCC(=O)O)O)SC[C@@H](C(=O)NCC(=O)O)N,,,,,,
856,440857,"(5S,6R)-6-[(2R)-2-amino-2-carboxyethyl]sulfanyl-5-hydroxyicosa-7,9,11,14-tetraenoic acid",CCCCCC=CCC=CC=CC=C[C@H]([C@H](CCCC(=O)O)O)SC[C@@H](C(=O)O)N,,,,,,
857,440858,CID 440858,CCCCC[C@@H](C=CC1=CCC(=O)[C@@H]1CC=CCCCC(=O)O)O,,,,,,
858,440859,"7-[(1R,2R,3S,5S)-3,5-dihydroxy-2-[(3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid",CCCCC[C@@H](C=C[C@H]1[C@H](C[C@@H]([C@@H]1CC=CCCCC(=O)O)O)O)O,,,,,,
859,440860,"7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3S)-3-hydroxyoct-1-enyl]cyclopentyl]-6-oxoheptanoic acid",CCCCC[C@@H](C=C[C@H]1[C@@H](C[C@@H]([C@@H]1CC(=O)CCCCC(=O)O)O)O)O,,,,,,
860,440861,CID 440861,CCCCC[C@@H](C=C[C@@H]1[C@H]([C@H](C[C@H](O1)O)O)CC=CCCCC(=O)O)O,,,,,,
861,440862,"7-[(2R,3S,4S)-4-hydroxy-2-[(3S)-3-hydroxyoct-1-enyl]-6-oxooxan-3-yl]hept-5-enoic acid",CCCCC[C@@H](C=C[C@@H]1[C@H]([C@H](CC(=O)O1)O)CC=CCCCC(=O)O)O,,,,,,
862,440863,propanoyl-AMP,CCC(=O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O,,,,,,
863,440864,(S)-2-Hydroxybutyric acid,CC[C@@H](C(=O)O)O,,,,,,
864,440865,Malonyl-CoA semialdehyde,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)CC=O)O,,,,,,
865,440866,CID 440866,COC1=C(C=CC(=C1)C2=CC(=C3C(=CC(=O)C(=C3O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O2)O)O,,,,,,
866,440867,Acetyl adenylate,CC(=O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O,,,,,,
867,440868,2-Propylmalate,CCC[C@](CC(=O)O)(C(=O)O)O,,,,,,
868,440869,"1-deoxy-1-(7-hydroxy-6-methyl-2,4-dioxo-3,4-dihydropteridin-8(2H)-yl)-D-ribitol",CC1=NC2=C(NC(=O)NC2=O)N(C1=O)C[C@@H]([C@@H]([C@@H](CO)O)O)O,,,,,,
869,440870,CID440870; (Acyl-CoA); [M+H]+,CC(C)(CCSCCNC(CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O)O)O,,,,,,
870,440871,CID 440871,CC(C)(CC(=O)SCCNC(CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O)O)O,,,,,,
871,440872,CID 440872,C[C@@H](CO)C(=O)SCCNC(CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O)O,,,,,,
872,440873,(S)-3-hydroxyisobutyric acid,C[C@@H](CO)C(=O)O,,,,,,
873,440874,(r)-Methylmalonate semialdehyde,C[C@H](C=O)C(=O)O,,,,,,
874,440875,(2S)-2-ethyl-2-hydroxy-3-oxobutanoic acid,CC[C@](C(=O)C)(C(=O)O)O,,,,,,
875,440876,"(3R)-2,3-dihydroxy-3-methylpentanoic acid",CC[C@](C)(C(C(=O)O)O)O,,,,,,
876,440877,(R)-2-Oxo-3-methylpentanoate,CC[C@@H](C)C(=O)C(=O)O,,,,,,
877,440878,(2S)-2-hydroxy-2-methyl-3-oxobutanoic acid,CC(=O)[C@@](C)(C(=O)O)O,,,,,,
878,440879,Benzenamine sulfate,C1=CC=C(C=C1)NS(=O)(=O)[O-],,,,,,
879,440880,"(2S,3S,4S,5R,6R)-3,4,5-trihydroxy-6-[hydroxy-[hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl]oxyphosphoryl]oxyoxane-2-carboxylic acid",CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)C(=O)O)O)O)O)O,,,,,,
880,440881,"dTDP-4-acetamido-4,6-dideoxy-alpha-D-glucose",C[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)O)O)NC(=O)C,,,,,,
881,440882,"[(2S,3R,4R,5S,6R)-3-amino-2-[[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl] 3-hydroxytetradecanoate",CCCCCCCCCCCC(CC(=O)O[C@@H]1[C@H]([C@@H](O[C@@H]([C@H]1O)CO)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=O)NC3=O)O)O)N)O,,,,,,
882,440883,"(2R,3S,4R,5R,6S)-5-amino-6-[(2R,4R,5R)-5-amino-6-[(2R,3S,4R,5R,6R)-5-amino-4,6-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-2-(hydroxymethyl)oxane-3,4-diol",C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)OC2[C@H](OC([C@@H]([C@H]2O)N)O[C@@H]3[C@H](O[C@H]([C@@H]([C@H]3O)N)O)CO)CO)N)O)O)O,,,,,,
883,440884,"(2R,4R,5R,6R)-6-[(1R)-1,2-dihydroxyethyl]-4,5-dihydroxy-2-[[(2R,3S,4R,5R,6R)-6-[[(2R,3S,4R,5R,6R)-3-hydroxy-5-(3-hydroxytetradecanoylamino)-4-(3-hydroxytetradecanoyloxy)-6-phosphonooxyoxan-2-yl]methoxy]-5-(3-hydroxytetradecanoylamino)-4-(3-hydroxytetradecanoyloxy)-3-phosphonooxyoxan-2-yl]methoxy]oxane-2-carboxylic acid",CCCCCCCCCCCC(CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1OP(=O)(O)O)CO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO[C@@]3(C[C@H]([C@H]([C@H](O3)[C@@H](CO)O)O)O)C(=O)O)OP(=O)(O)O)OC(=O)CC(CCCCCCCCCCC)O)NC(=O)CC(CCCCCCCCCCC)O)O)OC(=O)CC(CCCCCCCCCCC)O)O,,,,,,
884,440885,"(2R,4R,5R,6R)-2-[(2R,4R,5R,6R)-2-carboxy-6-[(1R)-1,2-dihydroxyethyl]-5-hydroxy-2-[[(2R,3S,4R,5R,6R)-6-[[(2R,3S,4R,5R,6R)-3-hydroxy-5-(3-hydroxytetradecanoylamino)-4-(3-hydroxytetradecanoyloxy)-6-phosphonooxyoxan-2-yl]methoxy]-5-(3-hydroxytetradecanoylamino)-4-(3-hydroxytetradecanoyloxy)-3-phosphonooxyoxan-2-yl]methoxy]oxan-4-yl]oxy-6-[(1R)-1,2-dihydroxyethyl]-4,5-dihydroxyoxane-2-carboxylic acid",CCCCCCCCCCCC(CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1OP(=O)(O)O)CO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO[C@@]3(C[C@H]([C@H]([C@H](O3)[C@@H](CO)O)O)O[C@@]4(C[C@H]([C@H]([C@H](O4)[C@@H](CO)O)O)O)C(=O)O)C(=O)O)OP(=O)(O)O)OC(=O)CC(CCCCCCCCCCC)O)NC(=O)CC(CCCCCCCCCCC)O)O)OC(=O)CC(CCCCCCCCCCC)O)O,,,,,,
885,440886,"(2R,4R,5R,6R)-2-[(2R,4R,5R,6R)-2-carboxy-6-[(1R)-1,2-dihydroxyethyl]-2-[[(2R,3S,4R,5R,6R)-5-(3-dodecanoyloxytetradecanoylamino)-6-[[(2R,3S,4R,5R,6R)-3-hydroxy-5-(3-hydroxytetradecanoylamino)-4-(3-hydroxytetradecanoyloxy)-6-phosphonooxyoxan-2-yl]methoxy]-3-phosphonooxy-4-(3-tetradecanoyloxytetradecanoyloxy)oxan-2-yl]methoxy]-5-hydroxyoxan-4-yl]oxy-6-[(1R)-1,2-dihydroxyethyl]-4,5-dihydroxyoxane-2-carboxylic acid",CCCCCCCCCCCCCC(=O)OC(CCCCCCCCCCC)CC(=O)O[C@@H]1[C@H]([C@@H](O[C@@H]([C@H]1OP(=O)(O)O)CO[C@@]2(C[C@H]([C@H]([C@H](O2)[C@@H](CO)O)O)O[C@@]3(C[C@H]([C@H]([C@H](O3)[C@@H](CO)O)O)O)C(=O)O)C(=O)O)OC[C@@H]4[C@H]([C@@H]([C@H]([C@H](O4)OP(=O)(O)O)NC(=O)CC(CCCCCCCCCCC)O)OC(=O)CC(CCCCCCCCCCC)O)O)NC(=O)CC(CCCCCCCCCCC)OC(=O)CCCCCCCCCCC,,,,,,
886,440887,CID 440887,C[C@H]([C@@H](C(=O)O)O)C(=O)SCCNC(CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O)O,,,,,,
887,440888,CID 440888,CC(=CC(=O)O)C(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
888,440889,"(2S,3S)-2-hydroxy-3-methylbutanedioic acid",C[C@@H]([C@@H](C(=O)O)O)C(=O)O,,,,,,
889,440890,Methyloxaloacetate,C[C@@H](C(=O)C(=O)O)C(=O)O,,,,,,
890,440891,"(2R,3R)-2-hydroxy-3-methylbutanedioic acid",C[C@H]([C@H](C(=O)O)O)C(=O)O,,,,,,
891,440892,"(2R,3S)-2-hydroxy-3-methylbutanedioic acid",C[C@@H]([C@H](C(=O)O)O)C(=O)O,,,,,,
892,440893,(2S)-2-hydroxy-2-methyl-4-oxopentanedioic acid,C[C@](CC(=O)C(=O)O)(C(=O)O)O,,,,,,
893,440894,"(2S,4S)-4-amino-2-hydroxy-2-methylpentanedioic acid",C[C@](C[C@@H](C(=O)O)N)(C(=O)O)O,,,,,,
894,440895,"(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[2-(4-hydroxyphenyl)ethoxy]oxane-3,4,5-triol",C1=CC(=CC=C1CCO[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O,,,,,,
895,440896,Stizolobate,C1=C(C=C(OC1=O)C(=O)O)CC(C(=O)O)N,,,,,,
896,440897,Stizolobinate,C1=C(C(=O)OC(=C1)C(=O)O)CC(C(=O)O)N,,,,,,
897,440898,5-Formyl-3-hydroxy-2-methylpyridine-4-carboxylic acid,CC1=NC=C(C(=C1O)C(=O)O)C=O,,,,,,
898,440899,Isopyridoxal,CC1=NC=C(C(=C1O)CO)C=O,,,,,,
899,440900,(3S)-3-hydroxy-2-oxo-4-phosphonooxybutanoic acid,C([C@@H](C(=O)C(=O)O)O)OP(=O)(O)O,,,,,,
900,440901,4-(Phosphonooxy)-L-threonine,C([C@H]([C@@H](C(=O)O)N)O)OP(=O)(O)O,,,,,,
901,440902,"(S)-3-Amino-1,2-propanediol",C([C@@H](CO)O)N,,,,,,
902,440903,"Tryptophan, 4-(3-methyl-2-butenyl)-",CC(=CCC1=C2C(=CC=C1)NC=C2CC(C(=O)O)N)C,,,,,,
903,440904,Elymoclavine,CN1CC(=C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CO,,,,,,
904,440905,2-(2-Formyl-3-methylcyclopentyl)propanedial,CC1CCC(C1C=O)C(C=O)C=O,,,,,,
905,440906,Deoxyloganin,C[C@H]1CC[C@H]2[C@@H]1[C@@H](OC=C2C(=O)OC)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
906,440907,PR Toxin,C[C@H]1[C@H]([C@@H]2[C@@H](O2)C3=CC(=O)[C@@]4(C[C@]13C)[C@@](O4)(C)C=O)OC(=O)C,,,,,"['Rat liver microsome UDP-glucuronyltransferase and labeled UDP-glucuronic acid were incubated with /PR toxin/ P.R.T. or the compounds obtained by in vitro toxin metabolism. Under the same conditions, labeled P.R.T. or its labeled metabolites were incubated with UDP glucuronyltransferase. Radioactive metabolites were produced with Eremofortin C and Eremofortin C alcohol and in each case, were identified as the corresponding beta-glucuronide conjugate. No measurable glucuronidation of P.R.T. or P.R.T. alcohol was observed. A good correlation between biological effects and glucuronide conjugate formation was shown.']",
907,440908,CID 440908,CC1=C[C@@H]2[C@]([C@@H](C1=O)O)([C@]3([C@@H]([C@H]([C@H]([C@]34CO4)O2)O)O)C)CO,,,,"['Nivalenol is rapidly distributed to and eliminated from all examined tissues in mice with no apparent accumulation in any organ.', 'After long term oral administration of nivalenol to male rats, the dose was recovered as fecal nivalenol (7%), fecal de-epoxy nivalenol (80%), urinary nivalenol (1%) and urinary de-epoxy nivalenol (1%).', 'In order to investigate the comparative fates of nivalenol (NIV) and 4-acetyl derivative of NIV (fusarenon-X, FX) in mice, (3)H-FX or (3)H-NIV was given p.o. to mice. Radioactivity was excreted mainly via the urine in mice given (3)H-FX, but mainly via the feces in mice given (3)H-NIV. The plasma radioactivity reached a peak at 30 or 60 min after the administration of (3)H-FX or (3)H-NIV, respectively. The plasma peak level was 5 times higher, and the area under curve (AUC) was 10 times higher, in (3)H-FX-administered than (3)H-NIV-administered mice. These findings clearly demonstrate that FX is absorbed from the gastrointestinal tract more rapidly and efficiently than NIV. The HPLC profile of radioactivity of acetonitrile extracts of urine and feces indicated that FX is rapidly metabolized to NIV after being absorbed from the gastrointestinal tract. In vitro incubation of tissue homogenates with (3)H-FX demonstrated that the liver and kidney are the organs responsible for the FX-to-NIV conversion. Thus this study demonstrated that the higher oral toxicity of FX than NIV that has been observed in mice and rats is due to the efficient absorption of FX than NIV from the gastrointestinal tract, followed by its rapid conversion to NIV by the liver and kidney.']","['There is evidence of major species-dependent differences in the extent of de-epoxidation of nivalenol in non-ruminants, which may occur in the lower parts of the gastrointestinal tract in some species. The de-epoxy metabolite has been detected in feces of rats, pigs and laying hens, but not in mice or broiler chickens and, based on in vitro studies, it is unlikely to be formed in humans.', 'In ruminants, it is likely that, as for other trichothecenes, extensive de-epoxidation of nivalenol may occur in the rumen prior to absorption.', 'Nivalenol is metabolized to de-epoxy nivalenol.', ""The cytotoxicity of the de-epoxy metabolites of trichothecenes nivalenol (NIV) and deoxynivalenol (DON) was determined and compared with the cytotoxicity of the respective toxin with an intact epoxy group and their acetylated derivatives. The cytotoxic effects was determined by using the 5-bromo-2'-deoxyuridine (BrdU) incorporation assay assessing DNA-synthesis. The toxicity of NIV and DON expressed as the concentration inhibiting 50% of the DNA synthesis (IC(50)), was occurring at similar micromolar concentrations (1.19+/-0.06 and 1.50+/-0.34 uM). The toxicity of fusarenon X (4-acetyl NIV) in the assay was similar to the toxicity of NIV, and the toxicity of 15-AcDON was equal to the toxicity of DON. 3-AcDON was less toxic than DON and 15-AcDON. The IC(50) value for de-epoxy DON was 54 times higher in the assay than the IC(50) for DON, while the IC(50) of de-epoxy NIV was 55 times higher than the IC(50) for NIV. The results verify previous findings that the de-epoxidation is a detoxification reaction.""]",
908,440909,"Pimara-8(14),15-diene",C[C@]1(CC[C@H]2C(=C1)CC[C@@H]3[C@@]2(CCCC3(C)C)C)C=C,,,,,,
909,440910,CID 440910,C[C@]12CC[C@H]([C@@]([C@@H]1CC[C@@H]3[C@@]24CC[C@@]([C@@H](C3)C4)(CO)O)(C)CO)O,,,,,,
910,440911,"(4R,9R,10R,13R)-5,5,9-trimethyl-14-methylidenetetracyclo[11.2.1.01,10.04,9]hexadecane",C[C@@]12CCCC([C@H]1CCC34[C@H]2CC[C@H](C3)C(=C)C4)(C)C,,,,,,
911,440912,Veatchine,C[C@@]12CCC[C@@]3(C1CCC45C3CCC(C4)C(=C)[C@@H]5O)C6N(C2)CCO6,,,,,,
912,440913,"10-Formyl-1,4a-dimethyl-8-methylidenegibbane-1-carboxylic acid",C[C@@]12CCC[C@@](C1[C@@H]([C@]34[C@H]2CC[C@H](C3)C(=C)C4)C=O)(C)C(=O)O,,,,,,
913,440914,Gibberellin A53,C[C@@]12CCC[C@@]([C@H]1[C@@H]([C@]34[C@H]2CC[C@](C3)(C(=C)C4)O)C(=O)O)(C)C(=O)O,,,,,,
914,440915,Gibberellin A44 diacid,C[C@]1(CCC[C@@]2([C@@H]1[C@@H]([C@]34[C@H]2CC[C@](C3)(C(=C)C4)O)C(=O)O)CO)C(=O)O,,,,,,
915,440916,"(1R,2R,5S,9S,10R,11R,13R)-5,13-dihydroxy-11-methyl-6-methylidene-16-oxo-15-oxapentacyclo[9.3.2.15,8.01,10.02,8]heptadecane-9-carboxylic acid",C[C@@]12C[C@H](C[C@@]3([C@@H]1[C@@H](C45[C@H]3CC[C@](C4)(C(=C)C5)O)C(=O)O)OC2=O)O,,,,,,
916,440917,D-Limonene,CC1=CC[C@@H](CC1)C(=C)C,,,,"['The fate of dermally applied [(14)C]d-limonene was evaluated in humans and Long-Evans rats. In rats, 5 mg/kg body weight of [(14)C]d-limonene applied dermally to the shaved back under occlusion, resulted in the absorption of approximately 12% of the dose. The absorbed d-limonene was completely metabolized and excreted rapidly, primarily from the urine (80%) with a small fraction (20%) excreted in the feces. There was no long-term retention of the test material in body tissues. In humans, following dermal application of 12 mg of [(14)C]d-limonene in ethanol (1 mL) to the back under nonocclusive conditions (for 1 h after application to allow the material to dry, thereafter under occlusion), only 0.16% of the dose was absorbed and the radioactivity was recovered from the urine. Radioactivity in human feces was below the limit of detection. These results indicate that under conditions of simulated use of fragrances and cosmetics, d-limonene has a low potential for dermal absorption and tissue accumulation, and the d-limonene that is absorbed is rapidly excreted in the urine. Based upon these findings and the knowledge that d-limonene possesses a low-systemic toxicity profile, it is reasonable to conclude that dermal exposure to d-limonene from fragrance and cosmetic applications is highly unlikely to result in any clinically significant human toxicity.', 'After oral administration of (14)C-labeled d-limonene to animals and humans, 75-95 and <10% of the radioactivity was excreted in the urine and feces respectively within 2-3 days.', 'The toxicokinetics of d-limonene were studied in human volunteers exposed by inhalation (2 hr, work load 50 W) in an exposure chamber on three different occasions. The exposure concentrations were approximately 10, 225, and 450 mg/cu m d-limonene. The relative pulmonary uptake was high, approximately 70% of the amount supplied. The blood clearance of d-limonene observed in this study, 1.1 L/kg/hr, indicates that d-limonene is metabolized readily. About 1% of the total uptake was eliminated unchanged in the expired air after the end of exposure, while approximately 0.003% was eliminated in the urine. A long half-time in blood was observed in the slow elimination phase, which indicates accumulation in adipose tissues.', 'Orally administered d-limonene is rapidly and almost completely taken up from the gastrointestinal tract in humans as well as in animals. Infusion of labelled d-limonene into the common bile duct of volunteers revealed that the chemical was very poorly absorbed from the biliary system.', 'For more Absorption, Distribution and Excretion (Complete) data for (D)-LIMONENE (10 total), please visit the HSDB record page.']","['Incubation of d-limonene with rat liver microsomes produced d-limonene-1,2-diol and d-limonene-8,9-diol as metabolites and d-limonene-1,2-epoxide and d-limonene-8,9-epoxide were identified as intermediates.', 'After oral administration of (14)C-labeled d-limonene, 5 new metabolites were isolated from dog and rat urine: 2-hydroxy-p-menth-8-en-7-oic acid, perillylglycine, perillyl-beta-d-glucopyranosiduronic acid, p-mentha-1,8-dien-6-ol, and probably p-menth-1-ene-6,8,9-triol.', 'The major metabolite of d-limonene in urine was perillic acid 8,9-diol in rats and rabbits, perillyl-beta-d-glucopyranosiduronic acid in hamsters, p-menth-1-ene-8,9-diol in dogs, and 8-hydroxy-p-menth-1-ene-9-yl-beta-d-glucopyranosiduronic acid in guinea pigs and man.', 'Adult male and female Sprague Dawley rats were given single oral doses of 0, 0.1, 0.3, 1, or 3 mmol d-limonene/kg (0, 14, 41, 136, or 409 mg/kg) in corn oil. Gel filtration HPLC indicated that d-limonene in male rat kidney is associated with a protein fraction having a mol wt of approximately 20000. Using reverse phase HPLC, d-limonene was shown to be associated with alpha-2u-globulin which was identified by amino acid sequencing. The major metabolite associated with alpha-2u-globulin was d-limonene-1,2-oxide. Parent d-limonene was also identified as a minor component in the alpha-2u-globulin fraction.', 'For more Metabolism/Metabolites (Complete) data for (D)-LIMONENE (8 total), please visit the HSDB record page.', '(+)-limonene has known human metabolites that include Carveol and Limonen-10-ol.']","['75-95% excreted within 2-3 days; [AIHA]', 'Following the inhalation exposure of volunteers to d-limonene at 450 mg/cu m for 2 hours, three phases of elimination were observed in the blood, with half-lives of about 3, 33, and 750 minutes, respectively. ...']"
917,440918,6-Oxohexanoic acid,C(CCC(=O)O)CC=O,,,,,,
918,440919,Nerolidol diphosphate,CC(=CCCC(=CCCC(C)(C=C)OP(=O)(O)OP(=O)(O)O)C)C,,,,,,
919,440920,gamma-Glutamyl-beta-aminopropiononitrile,C(CNC(=O)CC[C@@H](C(=O)O)N)C#N,,,,,,
920,440921,l-Arabinofuranose,C([C@H]1[C@@H]([C@H](C(O1)O)O)O)O,,,,,,
921,440922,2-Amino-1-hydroxyoctadec-4-en-3-one,CCCCCCCCCCCCCC=CC(=O)C(CO)N,,,,,,
922,440923,CID 440923,C(C(C(C(=O)CNC1=C(C(=O)N=C(N1)N)N)O)O)OP(=O)(O)OP(=O)(O)OP(=O)(O)O,,,,,,
923,440924,CID 440924,CC1C(=NC2=C(N1)NC(=NC2=O)N)C(C)(C(COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O,,,,,,
924,440925,5-(8-Amino-8-oxo-1-sulfanyloctan-3-yl)sulfanyl-5-oxopentanoic acid,C(CCC(=O)N)CC(CCS)SC(=O)CCCC(=O)O,,,,,,
925,440926,"D-Fucono-1,4-lactone",C[C@H]([C@H]1[C@@H]([C@H](C(=O)O1)O)O)O,,,,,,
926,440927,(S)-Norcoclaurine,C1CN[C@H](C2=CC(=C(C=C21)O)O)CC3=CC=C(C=C3)O,,,,,,
927,440928,"(12bS)-6,7,12bbeta,13-Tetrahydro-5-methyl-4H-bis[1,3]benzodioxolo[5,6-a:4',5'-g]quinolizinium",C[N+]12CCC3=CC4=C(C=C3[C@@H]1CC5=C(C2)C6=C(C=C5)OCO6)OCO4,,,,,,
928,440929,Macarpine,C[N+]1=CC2=C3C(=CC(=C2C4=C1C5=CC6=C(C=C5C(=C4)OC)OCO6)OC)OCO3,,,,,,
929,440930,"1,2-Dehydroreticuline",C[N+]1=C(C2=CC(=C(C=C2CC1)OC)O)CC3=CC(=C(C=C3)OC)O,,,,,,
930,440931,CID 440931,CN1CC[C@]23C4C(=O)CC=C2[C@@H]1CC5=C3C(=C(C=C5)OC)O4,,,,,,
931,440932,1-Methylpyrrolinium,C[N+]1=CCCC1,,,,,,
932,440933,Hygrine,CC(=O)C[C@H]1CCCN1C,,,,,,
933,440934,Anapheline,C1CCN[C@@H](C1)CC(=O)C[C@@H]2CCCCN2,,,,,,
934,440935,"[(1S)-6-acetamido-1,2,3,5,6,7,8,8a-octahydroindolizin-1-yl] acetate",CC(=O)NC1CCC2[C@H](CCN2C1)OC(=O)C,,,,,,
935,440936,Arbutin,C1=CC(=CC=C1O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O,"['Indicated for over-the-counter use for epidermal hyperpigmentation in various skin conditions, such as melasma, freckles, and senile lentigines.']","['At non-toxic concentrations, arbutin inhibited the activity of tyrosinase in cultured human keratinocytes, while having minimal effect on the expression of tyrosinase mRNA or the synthesis of the enzyme. α-Arbutin produced a concentration-dependent inhibition of melanin synthesis of human melanoma cells, HMV-II. No inhibitory effect on HMV-II cell growth was seen at concentrations lower than 1.0 mM. At concentrations of 0.5 mM of arbutin, tyrosinase activity was reduced to 60% of that in non-treated cells. The addition of arbutin blocked and inhibited α-MSH-stimulated melanogenesis in B16 melanoma cells, brownish guinea pig, and human skin tissue. In a pilot study of healthy male adults exposed to UV B irradiation, topical administration of arbutin inhibited UV-induced nuclear factor-kappaB activation in human keratinocytes. In mouse skin, arbutin counteracted oxidative stress induced by 12-O-tetradecanoylphorbol-13-acetate.']",,"['Arbutin was found to be extensively absorbed from the gastrointestinal tract where it is primarily converted to hydroquinone.', 'During the first 4 hours following ingestion of a single dose of 210 mg arbutin in healthy volunteers, 224.5 μmol/L hydroquinone glucuronide and 182 μmol/L of hydroquinone sulfate were recovered in the urine.', 'No pharmacokinetic data available.', 'No pharmacokinetic data available.', 'The urinary excretion of arbutin metabolites was examined in a randomized crossover design in 16 healthy volunteers after the application of a single oral dose of bearberry leaves dry extract (BLDE). There were two groups of application using either film-coated tablets (FCT) or aqueous solution (AS). The urine sample analysis was performed by a validated HPLC coolarray method (hydroquinone) and a validated capillary electrophoresis method (hydroquinone-glucuronide, hydroquinone-sulfate). The total amounts of hydroquinone equivalents excreted in the urine from BLDE were similar in both groups. With FCT, 64.8% of the arbutin dose administered was excreted; with AS, 66.7% was excreted (p = 0.61). The maximum mean urinary concentration of hydroquinone equivalents was a little higher and peaked earlier in the AS group versus the FCT group, although this did not reach statistical significance (Cur max = 1.6893 umol/mL vs. 1.1250 umol/mL, p = 0.13; tmax (t midpoint) = 3.60 h vs. 4.40 hr, p = 0.38). The relative bioavailability of FCT compared to AS was 103.3% for total hydroquinone equivalents. There was substantial intersubject variability. No significant differences between the two groups were found in the metabolite patterns detected (hydroquinone, hydroquinone-glucuronide, and hydroquinone-sulfate).', 'To study the effects of aloesin and arbutin on normal cultured human melanocytes in synergetic method. Building up the system of cultured human melanocytes. The cultured melanocytes in vitro were treated with the mixture of aloesin and arbutin. The cell viability and tyrosinase activity was measured by MTT assay, utilization of L-Dopa as the substrate respectively; melanin content was measured by image analysis system. Furthermore, the effects of the mixture on melanocytes were compared with that of aloesin and arbutin. The mixture of aloesin and arbutin showed an inhibition on tyrosinase activity of human melanocytes and reduced significantly melanin content. Between the mixture and the single use of aloesin or arbutin, there is significant difference (P<0.05). On the other hand, the mixture has little influence on melanocytes viability and there is negative significance. The mixture of aloesin and arbutin can significantly inhibit the tyrosinase activity and melanogenesis of cultured human melanocytes. It showed the effects of aloesin and arbutin in a synergistic manner.']","['Arbutin is readily susceptible to hydrolysis in dilute acids to yield D-glucose and hydroquinone. It is expected that orally administered arbutin is easily hydrolyzed to free hydroquinone molecules by stomach acid. Hydroquinone is further metabolized into the main metabolites, hydroquinone glucuronide and hydroquinone sulfate.']",['No pharmacokinetic data available.']
936,440937,Arbutin 6-phosphate,C1=CC(=CC=C1O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O)O,,,,,,
937,440938,Salicin 6-phosphate,C1=CC=C(C(=C1)CO)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O)O,,,,,,
938,440939,"2,4-Dihydroxy-1,3,5,2,4-trioxadiphosphepane-7-carboxylic acid 2,4-dioxide",C1C(OP(=O)(OP(=O)(O1)O)O)C(=O)O,,,,,,
939,440940,ADP-mannose,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)O[C@@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O)N,,,,,,
940,440941,CID 440941,C1[C@@H]([C@H](O[C@H]1[N+]2=CNC3=C2NC=NC3=O)COP(=O)(O)O)O,,,,,,
941,440942,"4,7,7-Trihydroxy-2-oxoheptanoic acid",C(CC(O)O)C(CC(=O)C(=O)O)O,,,,,,
942,440943,"2,4-Dihydroxy-hept-2-ene-1,7-dioic acid",C(CC(=O)O)C(C=C(C(=O)O)O)O,,,,,,
943,440944,"(2,6-Dihydroxyphenyl)acetic acid",C1=CC(=C(C(=C1)O)CC(=O)O)O,,,,,,
944,440945,"1H-Indol-5-ol, 3-(2-aminoethyl)-1-methyl-",CN1C=C(C2=C1C=CC(=C2)O)CCN,,,,,,
945,440946,Polyfructose,C([C@@H]1[C@H]([C@@H]([C@](O1)(CO)OC[C@@H]2[C@H]([C@@H]([C@](O2)(CO)OC[C@@H]3[C@H]([C@@H]([C@](O3)(CO)O)O)O)O)O)O)O)O,,,['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)'],,,
946,440947,Glc(b1-4)Glc(b1-4)Glc(b1-4)Glc(b1-4)Glc(b1-4)Glc(b1-4)b-Glc,C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2O)O)O[C@@H]3[C@H](O[C@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](O[C@H]([C@@H]([C@H]5O)O)O[C@@H]6[C@H](O[C@H]([C@@H]([C@H]6O)O)O[C@@H]7[C@H](O[C@H]([C@@H]([C@H]7O)O)O)CO)CO)CO)CO)CO)CO)O)O)O)O,,,,,,
947,440948,beta-D-cellohexaose,C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2O)O)O[C@@H]3[C@H](O[C@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](O[C@H]([C@@H]([C@H]5O)O)O[C@@H]6[C@H](O[C@H]([C@@H]([C@H]6O)O)O)CO)CO)CO)CO)CO)O)O)O)O,,,,,,
948,440949,beta-Cellopentaose,C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2O)O)O[C@@H]3[C@H](O[C@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](O[C@H]([C@@H]([C@H]5O)O)O)CO)CO)CO)CO)O)O)O)O,,,,,,
949,440950,Cellulase,C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2O)O)O[C@@H]3[C@H](O[C@H]([C@@H]([C@H]3O)O)O)CO)CO)O)O)O)O,,,,,,
950,440951,"(3,4,5,6,7-Pentahydroxy-2-oxoheptyl) dihydrogen phosphate",C(C(C(C(C(C(=O)COP(=O)(O)O)O)O)O)O)O,,,,,,
951,440952,CID 440952,C[C@H](N(CCCC1C(=O)NC(C(=O)NC(C(=O)NCC(=O)NCC(=O)NCC(=O)N1)CCCN([C@H](C)O)O)CCCN([C@@H](C)O)O)O)O.[Fe],,,,,,
952,440953,"3,9-bis[3-[hydroxy-[(1S)-1-hydroxyethyl]amino]propyl]-6-[3-[hydroxy-[(1R)-1-hydroxyethyl]amino]propyl]-1,4,7,10,13,16-hexazacyclooctadecane-2,5,8,11,14,17-hexone",C[C@@H](N(CCCC1C(=O)NC(C(=O)NC(C(=O)NCC(=O)NCC(=O)NCC(=O)N1)CCCN([C@H](C)O)O)CCCN([C@@H](C)O)O)O)O,,,,,,
953,440954,"3-(Dihydroxymethyl)pentane-1,1,3,5,5-pentol;iron",C(C(O)O)C(CC(O)O)(C(O)O)O.C(C(O)O)C(CC(O)O)(C(O)O)O.[Fe],,,,,,
954,440955,"3-(Dihydroxymethyl)pentane-1,1,3,5,5-pentol",C(C(O)O)C(CC(O)O)(C(O)O)O,,,,,,
955,440956,"N-[7,11-bis[(2,3-dihydroxybenzoyl)amino]-2,6,10-trihydroxy-1,5,9-trioxacyclododec-3-yl]-2,3-dihydroxybenzamide;iron",C1C(C(OCC(C(OCC(C(O1)O)NC(=O)C2=C(C(=CC=C2)O)O)O)NC(=O)C3=C(C(=CC=C3)O)O)O)NC(=O)C4=C(C(=CC=C4)O)O.[Fe],,,,,,
956,440957,"N-[(2S,3S,6R,7S,10S,11R)-7,11-bis[(2,3-dihydroxybenzoyl)amino]-2,6,10-trihydroxy-1,5,9-trioxacyclododec-3-yl]-2,3-dihydroxybenzamide",C1[C@H]([C@H](OC[C@@H]([C@@H](OC[C@@H]([C@H](O1)O)NC(=O)C2=C(C(=CC=C2)O)O)O)NC(=O)C3=C(C(=CC=C3)O)O)O)NC(=O)C4=C(C(=CC=C4)O)O,,,,,,
957,440958,"2-Methyl-1,3-diazinane-4-carboxylic acid",CC1NCCC(N1)C(=O)O,,,,,,
958,440959,4-Methyl-L-glutamate,CC(C[C@@H](C(=O)O)N)C(=O)O,,,,,,
959,440960,L-Arabinose 1-phosphate,C1[C@@H]([C@@H]([C@H](C(O1)OP(=O)(O)O)O)O)O,,,,,,
960,440961,Udp-N-acetyl-D-mannosaminuronic acid,CC(=O)N[C@H]1[C@H]([C@@H]([C@H](O[C@@H]1OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=O)NC3=O)O)O)C(=O)O)O)O,,,,,,
961,440962,N-acetylneuraminic acid 9-phosphate,CC(=O)N[C@@H]1[C@H](CC(O[C@H]1[C@@H]([C@@H](COP(=O)(O)O)O)O)(C(=O)O)O)O,,,,,,
962,440963,"[(4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl] phosphono hydrogen phosphate",C1[C@@H]([C@H](OC1OP(=O)(O)OP(=O)(O)O)CO)O,,,,,,
963,440964,"(2R,4R,5R,6R)-2-[(2R,4R,5R,6R)-2-carboxy-6-[(1R)-1,2-dihydroxyethyl]-2-[[(2R,3S,4R,5R,6R)-5-(3-dodecanoyloxytetradecanoylamino)-6-[[(2R,3S,4R,5R,6R)-3-hydroxy-5-(3-hydroxytetradecanoylamino)-4-(3-hydroxytetradecanoyloxy)-6-phosphonooxyoxan-2-yl]methoxy]-4-(3-hydroxytetradecanoyloxy)-3-phosphonooxyoxan-2-yl]methoxy]-5-hydroxyoxan-4-yl]oxy-6-[(1R)-1,2-dihydroxyethyl]-4,5-dihydroxyoxane-2-carboxylic acid",CCCCCCCCCCCC(CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1OP(=O)(O)O)CO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO[C@@]3(C[C@H]([C@H]([C@H](O3)[C@@H](CO)O)O)O[C@@]4(C[C@H]([C@H]([C@H](O4)[C@@H](CO)O)O)O)C(=O)O)C(=O)O)OP(=O)(O)O)OC(=O)CC(CCCCCCCCCCC)O)NC(=O)CC(CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)O)OC(=O)CC(CCCCCCCCCCC)O)O,,,,,,
964,440965,"(3S)-2-Methyltetrahydrofuran-2,3beta,4alpha-triol",CC1([C@H]([C@@H](CO1)O)O)O,,,,,,
965,440966,(-)-Camphene,CC1([C@H]2CC[C@H](C2)C1=C)C,,,,,,
966,440967,(-)-beta-Pinene,CC1([C@H]2CCC(=C)[C@@H]1C2)C,,,,,,
967,440968,(-)-alpha-Pinene,CC1=CC[C@H]2C[C@@H]1C2(C)C,,,,,,
968,440969,Galactitol 1-phosphate,C([C@H]([C@@H]([C@@H]([C@H](COP(=O)(O)O)O)O)O)O)O,,,,,,
969,440970,L-tagatofuranose 6-phosphate,C([C@H]1[C@H]([C@H](C(O1)(CO)O)O)O)OP(=O)(O)O,,,,,,
970,440971,"(5S,6R,15S)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoic acid",CCCCC[C@@H](C=CC=CC=CC=C[C@H]([C@H](CCCC(=O)O)O)O)O,,,,,,
971,440972,"(5S,14R,15S)-5,14,15-trihydroxyicosa-6,8,10,12-tetraenoic acid",CCCCC[C@@H]([C@@H](C=CC=CC=CC=C[C@H](CCCC(=O)O)O)O)O,,,,,,
972,440973,CID 440973,C([C@@H]1C(=O)C(=C(O1)O)O)O,,,,,,
973,440974,"(3S,4R)-3,4-dihydroxycyclohexa-1,5-diene-1,4-dicarboxylic acid",C1=C[C@@]([C@H](C=C1C(=O)O)O)(C(=O)O)O,,,,,,
974,440975,CID 440975,C[C@@]12CC3=C([C@](C(=N3)C=C4[C@H]([C@]([C@@](N4)(C5[C@@H]([C@@](C(=N5)CC(=N1)C(=C2CC(=O)O)CCC(=O)O)(C)CCC(=O)O)CC(=O)O)C)(C)CC(=O)O)CCC(=O)O)(C)CC(=O)O)CCC(=O)O,,,,,,
975,440976,"3-[(1R,2S,3S,7S,11S,17R)-8,13,17-tris(2-carboxyethyl)-2,7,12,18-tetrakis(carboxymethyl)-1,2,7,11,17-pentamethyl-3,10,15,21-tetrahydrocorrin-3-yl]propanoic acid",C[C@@]12CC3=C([C@](C(=N3)C=C4[C@H]([C@]([C@@](N4)(C5=C([C@@](C(=N5)CC(=N1)C(=C2CC(=O)O)CCC(=O)O)(C)CCC(=O)O)CC(=O)O)C)(C)CC(=O)O)CCC(=O)O)(C)CC(=O)O)CCC(=O)O,,,,,,
976,440977,"(1R,6S)-1,6-dihydroxycyclohexa-2,4-dienecarboxylic acid",C1=C[C@@H]([C@](C=C1)(C(=O)O)O)O,,,,,,
977,440978,Cyclohexadiene-1-carboxylate coenzyme a,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)C4=CCCC=C4)O,,,,,,
978,440979,(2S)-2-[(R)-1-carboxyethylamino]pentanoic acid,CCC[C@@H](C(=O)O)N[C@H](C)C(=O)O,,,,,,
979,440980,"6-Chlorobenzene-1,2,4-triol",C1=C(C=C(C(=C1O)O)Cl)O,,,,,,
980,440981,"Quinoline-3,4-diol",C1=CC=C2C(=C1)C(=O)C(=CN2)O,,,,,,
981,440982,3-hydroxy-2-methylquinolin-4(1H)-one,CC1=C(C(=O)C2=CC=CC=C2N1)O,,,,,,
982,440983,"2,3-Dihydroxybenzenesulfonic acid",C1=CC(=C(C(=C1)S(=O)(=O)O)O)O,,,,,,
983,440984,"5,6-Dihydroquinoline-2,5,6-triol",C1=CC2=C(C=CC(=O)N2)C(C1O)O,,,,,,
984,440985,"7alpha,27-Dihydroxycholesterol",C[C@H](CCCC(C)CO)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C=C4[C@@]3(CC[C@@H](C4)O)C)O)C,,,,,,
985,440986,"3-Methyl-quinolin-2,8-diol",CC1=CC2=C(C(=CC=C2)O)NC1=O,,,,,,
986,440987,"3-Methyl-1,2-dihydroquinolin-2-one",CC1=CC2=CC=CC=C2NC1=O,,,,,,
987,440988,(+)-Higenamine,C1CN[C@@H](C2=CC(=C(C=C21)O)O)CC3=CC=C(C=C3)O,,,,,,
988,440989,(R)-Coclaurine,COC1=C(C=C2[C@H](NCCC2=C1)CC3=CC=C(C=C3)O)O,,,,,,
989,440990,(R)-Norlaudanosoline,C1CN[C@@H](C2=CC(=C(C=C21)O)O)CC3=CC(=C(C=C3)O)O,,,,,,
990,440991,"2,3',4,6-Tetrahydroxybenzophenone",C1=CC(=CC(=C1)O)C(=O)C2=C(C=C(C=C2O)O)O,,,,,,
991,440992,2-deoxy-D-glucopyranose 6-phosphate,C1[C@H]([C@@H]([C@H](OC1O)COP(=O)(O)O)O)O,,,,,,
992,440993,Lacto-N-tetraose,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O[C@H]2[C@H]([C@H](O[C@H]([C@@H]2O)O[C@@H]3[C@H](OC([C@@H]([C@H]3O)O)O)CO)CO)O)CO)O)O[C@H]4[C@@H]([C@H]([C@H]([C@H](O4)CO)O)O)O,,,,,,
993,440994,"Galbeta1,3GlcNAc",CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](OC1O)CO)O)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O)O,,,,,,
994,440995,Lactobiose,C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](OC([C@@H]([C@H]2O)O)O)CO)O)O)O)O,,,,,,
995,440996,N-Acetyl-D-glucosamine 6-phosphate,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](OC1O)COP(=O)(O)O)O)O,,,,,,
996,440997,D-glucosamine 6-phosphate,C([C@@H]1[C@H]([C@@H]([C@H](C(O1)O)N)O)O)OP(=O)(O)O,,,,,,
997,440998,N-(Carboxyaminomethyl)urea,C(NC(=O)N)NC(=O)O,,,,,,
998,440999,N-(Aminomethyl)urea,C(N)NC(=O)N,,,,,,
999,441000,Dimethylenetriurea,C(NC(=O)N)NC(=O)NCNC(=O)N,,,,,,
1000,441001,Trimethylenetetraurea,C(NC(=O)N)NC(=O)NCNC(=O)NCNC(=O)N,,,,,,
1001,441002,"S-[2-[3-[[4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] 4-chlorobenzenecarbothioate",CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)C4=CC=C(C=C4)Cl)O,,,,,,
1002,441003,"1-[(3S,8S,9S,10R,13S,16R)-3,16-dihydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone",CC(=O)C1[C@@H](CC2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C)O,,,,,,
1003,441004,"1-[(3S,8R,9S,10R,13S)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone",CC(=O)C1=CCC2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,,,,,
1004,441005,(+)-delta-Cadinene,CC1=C[C@H]2[C@@H](CCC(=C2CC1)C)C(C)C,,,,,,
1005,441006,ADP-D-glycero-D-manno-heptose,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OC4[C@H]([C@H]([C@@H]([C@H](O4)[C@@H](CO)O)O)O)O)O)O)N,,,,,,
1006,441007,ADP-L-glycero-D-manno-heptose,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OC4[C@H]([C@H]([C@@H]([C@H](O4)[C@H](CO)O)O)O)O)O)O)N,,,,,,
1007,441008,"3-[(1R,2S,3S,7S,8S,13S,17R,18R)-3,13,17-tris(2-carboxyethyl)-2,7,18-tris(carboxymethyl)-1,2,5,7,12,12,15,17-octamethyl-3,8,13,18,19,22-hexahydrocorrin-8-yl]propanoic acid",CC1=C2[C@@]([C@@H](C(=CC3=NC(=C(C4=NC([C@@H]([C@@]4(C)CCC(=O)O)CC(=O)O)[C@]5([C@@]([C@@H](C1=N5)CCC(=O)O)(C)CC(=O)O)C)C)[C@H](C3(C)C)CCC(=O)O)N2)CCC(=O)O)(C)CC(=O)O,,,,,,
1008,441009,Glc(a1-4)Hex(?1-1?)Glc,C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)OC2[C@H](O[C@@H]([C@@H]([C@H]2O)O)OC3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)CO)O)O)O)O,,,,,,
1009,441010,CID 441010,C[C@@]12CC(=O)O[C@@]13[C@@](C4=C(C(=C(N4)CC5=C(C(=C(N5)C=C6[C@H]([C@](C(=CC(=N3)[C@H]2CCC(=O)O)N6)(C)CC(=O)O)CCC(=O)O)CC(=O)O)CCC(=O)O)CCC(=O)O)CC(=O)O)(C)O,,,,,,
1010,441011,CID 441011,CC(=O)C12C3=C([C@@](C(=N3)CC4=C(C(=C(N4)CC5=C([C@](C(=N5)C=C(N1)[C@H]([C@]2(C)CC(=O)O)CCC(=O)O)(C)CC(=O)O)CCC(=O)O)CC(=O)O)CCC(=O)O)(C)CCC(=O)O)CC(=O)O,,,,,,
1011,441012,CID 441012,C[C@H]1C2=N[C@@](CC3=NC(=C(C4=N[C@@](C5[C@@H]([C@@](C1=N5)(C)CCC(=O)O)CC(=O)O)([C@@]([C@@H]4CCC(=O)O)(C)CC(=O)O)C)C)[C@@]([C@@H]3CCC(=O)O)(C)CC(=O)O)(C(=C2CCC(=O)O)C)C,,,,,,
1012,441013,CID 441013,CC(=O)C12C3=C([C@@](C(=N3)CC4=N[C@@](CC5=C([C@](C(=N5)C=C(N1)[C@H]([C@]2(C)CC(=O)O)CCC(=O)O)(C)CC(=O)O)CCC(=O)O)(C(=C4CCC(=O)O)CC(=O)O)C)(C)CCC(=O)O)CC(=O)O,,,,,,
1013,441014,4-O-beta-D-glucopyranosyl-alpha-D-glucopyranose,C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](O[C@@H]([C@@H]([C@H]2O)O)O)CO)O)O)O)O,,,,,,
1014,441015,"2-[(2S,3S,4S)-3,4-dihydroxy-5-oxo-tetrahydrofuran-2-yl]-2-hydroxy-acetaldehyde",C(=O)C([C@@H]1[C@H]([C@@H](C(=O)O1)O)O)O,,,,,,
1015,441016,5'-Benzoylphosphoadenosine,C1=CC=C(C=C1)C(=O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=CN=C43)N)O)O,,,,,,
1016,441017,CID 441017,CCCC(=O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C2NC=NC3=O)O)O,,,,,,
1017,441018,5'-Butyrylphosphouridine,CCCC(=O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=CC(=O)NC2=O)O)O,,,,,,
1018,441019,"2-Dehydro-D-glucono-1,5-lactone",C([C@@H]1[C@H]([C@@H](C(=O)C(=O)O1)O)O)O,,,,,,
1019,441020,"(3R,4S)-2-(Phosphonooxymethyl)tetrahydrofuran-2,3,4-triol",C1[C@@H]([C@H](C(O1)(COP(=O)(O)O)O)O)O,,,,,,
1020,441021,(2S)-4-(acetylamino)-2-aminobutanoic acid,CC(=O)NCC[C@@H](C(=O)O)N,,,,,,
1021,441022,"Benzoyldehydro-2,3-dihydroxy-benzone",C1=CC=C(C=C1)NC(C2=C(C(=CC=C2)O)O)O,,,,,,
1022,441023,"6-(2,3-Dihydroxybenzoylamino)-2-(alpha,2,3-trihydroxybenzylamino)hexanoic acid",C1=CC(=C(C(=C1)O)O)C(NC(CCCCNC(=O)C2=C(C(=CC=C2)O)O)C(=O)O)O,,,,,,
1023,441024,"6-(2,3-Dihydroxybenzoylamino)-2-(alpha,2,3-trihydroxybenzylamino)hexanamide",C1=CC(=C(C(=C1)O)O)C(NC(CCCCNC(=O)C2=C(C(=CC=C2)O)O)C(=O)N)O,,,,,,
1024,441025,Myxochlin A,C1=CC(=C(C(=C1)O)O)C(NC(CCCCNC(=O)C2=C(C(=CC=C2)O)O)CO)O,,,,,,
1025,441026,Myxochlin B,C1=CC(=C(C(=C1)O)O)C(NC(CCCCNC(=O)C2=C(C(=CC=C2)O)O)CN)O,,,,,,
1026,441027,Myxochlin C,C1=CC(=C(C(=C1)O)O)C(NC(CCCCNC(=O)C2=C(C(=CC=C2)O)O)CNC(=O)C3=C(C(=CC=C3)O)O)O,,,,,,
1027,441028,2-Hydroxypropylphosphonic acid,CC(CP(=O)(O)O)O,,,,,,
1028,441029,"(2S,3R)-3-Methyloxiran-2-ylphosphonic acid",C[C@@H]1[C@@H](O1)P(=O)(O)O,,,,,,
1029,441030,CID 441030,CCCCCC=CCC=CC=CC=C[C@H]([C@H](CCCC(=O)O)O)SC[C@@H](C(=O)O)NC(=O)CC[C@@H](C(=O)O)N,,,,,,
1030,441031,"(3S,4R)-oxolane-2,3,4-triol",C1[C@H]([C@@H](C(O1)O)O)O,,,,,,
1031,441032,D-Altrose,C([C@@H]1[C@H]([C@H]([C@@H](C(O1)O)O)O)O)O,,,,,,
1032,441033,D-Gulose,C([C@@H]1[C@@H]([C@H]([C@H](C(O1)O)O)O)O)O,,,,,,
1033,441034,D-Idose,C([C@@H]1[C@@H]([C@H]([C@@H](C(O1)O)O)O)O)O,,,,,,
1034,441035,D-Talose,C([C@@H]1[C@@H]([C@@H]([C@@H](C(O1)O)O)O)O)O,,,,,,
1035,441036,D-Psicose,C1[C@H]([C@H]([C@H](C(O1)(CO)O)O)O)O,,,,,,
1036,441037,Neuraminic acid,C1[C@@H]([C@H]([C@@H](OC1(C(=O)O)O)[C@@H]([C@@H](CO)O)O)N)O,,,,,,
1037,441038,Muramic acid,C[C@H](C(=O)O)O[C@H]1[C@@H]([C@H](OC([C@@H]1N)O)CO)O,,,,,,
1038,441039,L-Iduronic Acid,[C@@H]1([C@@H]([C@@H](OC([C@@H]1O)O)C(=O)O)O)O,,,,,,
1039,441040,CID 441040,C1[C@H]([C@@H]([C@H](O1)[C@@H](C=O)O)O)O,,,,,,
1040,441041,"(2R,3S,4S,5S)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid",[C@@H]1([C@@H]([C@@H](OC([C@H]1O)O)C(=O)O)O)O,,,,,,
1041,441042,"(2S)-2-[(2S,3R,4R)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyacetaldehyde",C1[C@H]([C@H]([C@H](O1)[C@@H](C=O)O)O)O,,,,,,
1042,441043,"(3S,4S)-3,4,6-trihydroxy-2,5-dioxohexanal",C(C(=O)[C@H]([C@@H](C(=O)C=O)O)O)O,,,,,,
1043,441044,CID 441044,C[C@@H]([C@@H]([C@H]1CNC2=C(N1)C(=O)N=CN2)O)O,,,,,,
1044,441045,"(1R,2S)-1-(7,8-dihydropteridin-6-yl)propane-1,2-diol",C[C@@H]([C@@H](C1=NC2=CN=CN=C2NC1)O)O,,,,,,
1045,441046,XV638,C1=CC=C(C=C1)C[C@@H]2[C@@H]([C@H]([C@H](N(C(=O)N2CC3=CC(=CC=C3)C(=O)NC4=NC=CS4)CC5=CC(=CC=C5)C(=O)NC6=NC=CS6)CC7=CC=CC=C7)O)O,,,,,,
1046,441047,"5-(5-(2,6-Dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)pentyl)-3-(hydroxyethyl oxymethyleneoxymethyl) isoxazole",C1COC(=N1)C2=CC(=C(C(=C2)Cl)OCCCCCC3=CC(=NO3)COCOCCO)Cl,,,,,,
1047,441048,"5-(5-(2,6-Dichloro-4-(4,5-Dihydro-2-Oxazoly)phenoxy)pentyl)-3-Methyl Isoxazole",CC1=NOC(=C1)CCCCCOC2=C(C=C(C=C2Cl)C3=NCCO3)Cl,,,,,,
1048,441049,"5-[7-[4-(4-Ethyl-4,5-dihydrooxazol-2-yl)phenoxy]heptyl]-3-methyl-isoxazole",CCC1COC(=N1)C2=CC=C(C=C2)OCCCCCCCC3=CC(=NO3)C,,,,,,
1049,441050,"3-[(1R,2S,3S,7S,8S,13S,17R,18R)-2,7-bis(2-amino-2-oxoethyl)-3,13,17-tris(2-carboxyethyl)-18-(carboxymethyl)-1,2,5,7,12,12,15,17-octamethyl-3,8,13,18,19,22-hexahydrocorrin-8-yl]propanoic acid",CC1=C2[C@@]([C@@H](C(=CC3=NC(=C(C4=NC([C@@H]([C@@]4(C)CCC(=O)O)CC(=O)O)[C@]5([C@@]([C@@H](C1=N5)CCC(=O)O)(C)CC(=O)N)C)C)[C@H](C3(C)C)CCC(=O)O)N2)CCC(=O)O)(C)CC(=O)N,,,,,,
1050,441051,CID 441051,CC1=C2[C@H]([C@]([C@@]([N-]2)([C@H]3[C@@H]([C@@](C(=N3)C(=C4[C@H](C(C(=N4)C=C5[C@H]([C@](C1=N5)(C)CC(=O)N)CCC(=O)O)(C)C)CCC(=O)O)C)(C)CCC(=O)O)CC(=O)O)C)(C)CC(=O)N)CCC(=O)O.[Co+2],,,,,,
1051,441052,"3-[(1R,2S,3S,7S,8S,13S,17R,18R,19R)-2,7-bis(2-amino-2-oxoethyl)-3,13,17-tris(2-carboxyethyl)-18-(carboxymethyl)-1,2,5,7,12,12,15,17-octamethyl-3,8,13,18,19,22-hexahydrocorrin-8-yl]propanoic acid",CC1=C2[C@@]([C@@H](C(=CC3=NC(=C(C4=N[C@H]([C@@H]([C@@]4(C)CCC(=O)O)CC(=O)O)[C@]5([C@@]([C@@H](C1=N5)CCC(=O)O)(C)CC(=O)N)C)C)[C@H](C3(C)C)CCC(=O)O)N2)CCC(=O)O)(C)CC(=O)N,,,,,,
1052,441053,CID 441053,CC1=C2[C@@]([C@@H](C(=N2)C=C3C([C@@H](C(=N3)C(=C4[C@]([C@H](C([N-]4)[C@]5([C@@]([C@@H](C1=N5)CCC(=O)O)(C)CC(=O)N)C)CC(=O)O)(C)CCC(=O)O)C)CCC(=O)O)(C)C)CCC(=O)O)(C)CC(=O)N.[Co+2],,,,,,
1053,441054,CID 441054,C/C/1=C/2\[C@@]([C@@H](C(=N2)/C=C/3\C([C@@H](C(=N3)/C(=C\4/[C@@]([C@@H](C([N-]4)[C@@]5([C@]([C@@H](C1=N5)CCC(=O)O)(C)CC(=O)N)C)CC(=O)O)(C)CCC(=O)O)/C)CCC(=O)O)(C)C)CCC(=O)O)(C)CC(=O)N.[CH2-][C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O.[Co+3],,,,,,
1054,441055,CID 441055,C/C/1=C/2\[C@@]([C@@H](C(=N2)/C=C/3\C([C@@H](C(=N3)/C(=C\4/[C@@]([C@@H](C([N-]4)[C@@]5([C@]([C@@H](C1=N5)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)(C)CCC(=O)O)/C)CCC(=O)N)(C)C)CCC(=O)N)(C)CC(=O)N.[CH2-][C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O.[Co+3],,,,,,
1055,441056,CID 441056,CC1=C2[C@@]([C@@H](C(=CC3=NC(=C(C4=NC([C@@H]([C@@]4(C)CCC(=O)O)CC(=O)N)[C@]5([C@@]([C@@H](C1=N5)CCC(=O)N)(C)CC(=O)N)C)C)[C@H](C3(C)C)CCC(=O)N)N2)CCC(=O)N)(C)CC(=O)N,,,,,,
1056,441057,CID 441057,C/C/1=C/2\[C@@]([C@@H](C(=N2)/C=C/3\C([C@@H](C(=N3)/C(=C\4/[C@@]([C@@H](C([N-]4)[C@@]5([C@]([C@@H](C1=N5)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)(C)CCC(=O)NCC(C)O)/C)CCC(=O)N)(C)C)CCC(=O)N)(C)CC(=O)N.[CH2-][C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O.[Co+3],,,,,,
1057,441058,CID 441058,CC1=C2[C@@]([C@@H](C(=CC3=NC(=C(C4=NC([C@@H]([C@@]4(C)CCC(=O)NCC(C)O)CC(=O)N)[C@]5([C@@]([C@@H](C1=N5)CCC(=O)N)(C)CC(=O)N)C)C)[C@H](C3(C)C)CCC(=O)N)N2)CCC(=O)N)(C)CC(=O)N,,,,,,
1058,441059,CID 441059,C/C/1=C/2\[C@@]([C@@H](C(=N2)/C=C/3\C([C@@H](C(=N3)/C(=C\4/[C@@]([C@@H](C([N-]4)[C@@]5([C@]([C@@H](C1=N5)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)(C)CCC(=O)NCC(C)OP(=O)(O)O)/C)CCC(=O)N)(C)C)CCC(=O)N)(C)CC(=O)N.[CH2-][C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O.[Co+2],,,,,,
1059,441060,CID 441060,CC1=C2[C@@]([C@@H](C(=CC3=NC(=C(C4=NC([C@@H]([C@@]4(C)CCC(=O)NCC(C)OP(=O)(O)O)CC(=O)N)[C@]5([C@@]([C@@H](C1=N5)CCC(=O)N)(C)CC(=O)N)C)C)[C@H](C3(C)C)CCC(=O)N)N2)CCC(=O)N)(C)CC(=O)N,,,,,,
1060,441061,CID 441061,CC1=C2[C@@]([C@@H](C(=N2)C=C3C([C@@H](C(=N3)C(=C4[C@@]([C@@H](C([N-]4)[C@@]5([C@]([C@@H](C1=N5)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)(C)CCC(=O)NCC(C)OP(=O)(O)OP(=O)(O)OC[C@H]6[C@@H]([C@H]([C@@H](O6)N7C=NC8=C7NC(=NC8=O)N)O)O)C)CCC(=O)N)(C)C)CCC(=O)N)(C)CC(=O)N.[CH2-][C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O.[Co+2],,,,,,
1061,441062,CID 441062,CC1=C2[C@@]([C@@H](C(=CC3=NC(=C(C4=NC([C@@H]([C@@]4(C)CCC(=O)NCC(C)OP(=O)(O)OP(=O)(O)OC[C@@H]5[C@H]([C@H]([C@@H](O5)N6C=NC7=C6NC(=NC7=O)N)O)O)CC(=O)N)[C@]8([C@@]([C@@H](C1=N8)CCC(=O)N)(C)CC(=O)N)C)C)[C@H](C3(C)C)CCC(=O)N)N2)CCC(=O)N)(C)CC(=O)N,,,,,,
1062,441063,2'-Norberbamunine,CN1CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C=C3)O)OC4=CC=C(C=C4)C[C@H]5C6=CC(=C(C=C6CCN5)OC)O)O)OC,,,,,,
1063,441064,Obamegine,CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)C[C@@H]6C7=C(O3)C(=C(C=C7CCN6C)OC)O)O)OC,,,,,,
1064,441065,"(9R,26S)-15,20-dimethoxy-10,25-dimethyl-2-oxa-10,25-diazaheptacyclo[26.2.2.13,7.19,13.118,22.017,34.026,33]pentatriaconta-1(30),3,5,7(35),13,15,17(34),18(33),19,21,28,31-dodecaene-4,16,19-triol",CN1CCC2=CC(=C(C3=C2[C@@H]1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)C[C@@H]6C7=C3C(=C(C=C7CCN6C)OC)O)O)O)OC,,,,,,
1065,441066,(R)-Norreticuline,COC1=C(C=C(C=C1)C[C@@H]2C3=CC(=C(C=C3CCN2)OC)O)O,,,,,,
1066,441067,(S)-6-O-Methylnorlaudanosoline,COC1=C(C=C2[C@@H](NCCC2=C1)CC3=CC(=C(C=C3)O)O)O,,,,,,
1067,441068,(S)-Nororientaline,COC1=C(C=C2[C@@H](NCCC2=C1)CC3=CC(=C(C=C3)O)OC)O,,,,,,
1068,441069,(S)-Norreticuline,COC1=C(C=C(C=C1)C[C@H]2C3=CC(=C(C=C3CCN2)OC)O)O,,,,,,
1069,441070,Cuskhygrine,CN1CCCC1CC(=O)CC2CCCN2C,,,,,,
1070,441071,Strychnine,C1CN2CC3=CCO[C@H]4CC(=O)N5[C@H]6[C@H]4[C@H]3C[C@H]2[C@@]61C7=CC=CC=C75,,,"['Substances used for their pharmacological actions on glycinergic systems. Glycinergic agents include agonists, antagonists, degradation or uptake inhibitors, depleters, precursors, and modulators of receptor function. (See all compounds classified as Glycine Agents.)', 'Substances which, when ingested, inhaled, or absorbed, or when applied to, injected into, or developed within the body in relatively small amounts may, by their chemical action, cause damage to structure or disturbance of function. (From Dorland, 27th ed) (See all compounds classified as Poisons.)', 'Substances that act in the brain stem or spinal cord to produce tonic or clonic convulsions, often by removing normal inhibitory tone. They were formerly used to stimulate respiration or as antidotes to barbiturate overdose. They are now most commonly used as experimental tools. (See all compounds classified as Convulsants.)']","['A rapid, specific and sensitive liquid chromatography-tandem mass spectrometric (LC-MS/MS) method was developed and validated for the simultaneous determination of strychnine, brucine, strychnine N-oxide and brucine N-oxide in rat plasma. Plasma samples were pretreated via simple protein precipitation with methanol and ephedrine hydrochloride was used as internal standard. Chromatographic separation was carried out on an ZORBAX Eclipse XDB-C18 column (2.1 x 150 mm, 3.5 um) by gradient elution with methanol and 10mM ammonium acetate (adjusted to pH 4.0 with formic acid). The quantification of the analytes was performed by mass spectrometry with TurboIonSpray ionization (ESI) inlet in the positive ion multiple reaction monitoring (MRM) mode. The results showed that the calibration curve was linear in the concentration range of 0.510 to approximately 306.3 ng/mL for strychnine, brucine and 0.102 to approximately 306.0 ng/mL for strychnine N-oxide and brucine N-oxide, respectively. The intra- and inter-day precisions were less than 14.9%, and the accuracy ranged from 89.4 to 113% at three QC levels for the 4 analytes. The validated method was successfully applied to the pharmacokinetic study of strychnine, brucine, strychnine N-oxide and brucine N-oxide in rat plasma after oral administration of each monomer and the total alkaloids from Semen Strychni. After single oral administration of the total alkaloids from Semen Strychni at 4 dose levels, Cmax, AUC0-t of strychnine and brucine increased and were proportional to the oral doses. In comparative pharmacokinetics studies, no significant difference was found between each monomer and the total strychnos alkaloids on the pharmacokinetic parameters such as Cmax and AUC. Mean Cmax and AUC of strychnine and brucine were slight increased in the monomer groups in comparison to the total strychnos alkaloids groups, which suggested that some other alkaloids in the Semen Strychni may decrease the absorption of strychnine and brucine in body.', 'To study the effect of liquiritin (Liq) on the transport of strychnine (Str) in Caco-2 cell monolayer model, the transport parameters of Str, such as apparent permeability coefficient (P app (B-->A) and P app (A-->B)) and cumulative transport amount (TRcum), were determined and comparatively analyzed when Str was used solely and co-used with Liq. The effect of drug concentrations, conveying times, P-glycoprotein (P-gp) inhibitor verapamil and conveying liquor pH values on the transport of Str were also investigated. The results indicated that the absorption of Str in Caco-2 cell monolayer model was well and the passive transference was the main intestinal absorption mechanism of Str in the Caco-2 monolayer model, along with the excretion action mediated by P-gp. Liq enhanced the absorption of Str. Meanwhile, conveying liquor pH value had significant influence on the excretion transport of Str.', 'A simple and low-cost HPLC method with UV absorbance detection was developed and validated to simultaneously determine strychnine and brucine, the most abundant alkaloids in the processed Semen Strychni, in rat tissues (kidney, liver, spleen, lung, heart, stomach, small intestine, brain and plasma). The tissue samples were treated with a simple liquid-liquid extraction prior to HPLC. The LOQs were in the range of 0.039-0.050 ug/mL for different tissue or plasma samples. The extraction recoveries varied from 71.63 to 98.79%. The linear range was 0.05-2 ug/mL with correlation coefficient of over 0.991. The intra- and inter-day precision was less than 15%. Then the method was used to measure the tissue distribution of strychnine and brucine after intravenous administration of 1 mg/kg crude alkaloids fraction (CAF) extracted from the processed Semen Strychni. The results revealed that strychnine and brucine possessed similar tissue distribution characterization. The highest level was observed in kidney, while the lowest level was found in brain. It was indicated that kidney might be the primary excretion organ of prototype strychnine and brucine. It was also deduced that strychnine and brucine had difficulty in crossing the blood-brain barrier. Furthermore, no long-term accumulation of strychnine and brucine was found in rat tissues.', 'Strychnine is rapidly absorbed from the gastrointestinal tract and nasal mucosa but not through the skin. Distribution of the drug in tissues is also rapid as is its metabolism to several nontoxic polar products bu hepatic enzymes. Only 5-20% of the intact alkaloid is excreted in urine.', 'For more Absorption, Distribution and Excretion (Complete) data for Strychnine (7 total), please visit the HSDB record page.']","['Within a few minutes of ingestion, strychnine appears unchanged in the urine, but the major route for removal and detoxification is oxidative hepatic metabolism.', 'Studies on the binding spectra of certain alkaloids with rat liver microsomes revealed that brucine, scopolamine and strychnine are type I compounds, whereas boldine, emetine, nicotine, reserpine and sanguinarine show type II binding.', 'The in vitro metabolism of strychnine was studied in 9000-g supernatant fractions from rat and rabbit livers. The metabolism was markedly inhibited by cytochrome p450 inhibitors (SKF-525A and octylamine), but only slightly inhibited by a microsomal Flavine Adenine Dinucleotide containing monooxygenase inhibitor (methimazole). Five metabolites formed in vitro by rabbit liver were isolated and purified. Three of them were identified as 2-hydroxystrychnine, strychnine N-oxide, and 21alpha,22alpha-dihydroxy-22-hydrostrychnine, by comparison with authentic samples by means of UV, NMR, and mass spectrometries. Additionally, 2 other metabolities were tentatively identified as strychnine 21,22-epoxide and 11,12-dehydrostrychnine by spectral measurements. ... The in vitro formation of these metabolites by rabbit liver was detected by high performance liquid chromatography after partial purification. Strychnine N-oxide was the major metabolite and accounted for approximately 15% of the metabolized strychnine. All other metabolites accounted for < 1%. ...']","['In nonfatal human poisoning cases, strychnine disappearance followed first-order kinetics with a half-life of 10 hr or 16 hr.', '... A 42-year-old man presented shortly after ingestion of an unknown quantity of strychnine powder. After a respiratory arrest, with intensive supportive management requiring admission to an intensive care unit, he survived. Eight serum samples were taken over the first 5 days and analyzed subsequently for strychnine concentrations. ... Serum concentrations followed a monoexponential elimination curve with a calculated elimination half-life of 12 hours. ...']"
1071,441072,(S)-2-Propylpiperidine,CCC[C@H]1CCCCN1,,,,,,
1072,441073,"4-[(R)-[(2S,4R,5R)-5-Vinyl-1-azabicyclo[2.2.2]octane-2-yl]hydroxymethyl]-6-methoxyquinoline",COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@H]4CCN3C[C@@H]4C=C)O,,,,"['Following oral administration of a single 600-mg dose of quinine sulfate in healthy adults, the mean plasma clearance was 0.08-0.47 L/hour per kg (median: 0.17 L/hour per kg) and the mean plasma elimination half-life was 9.7-12.5 hours. Following oral administration of 10 mg/kg of quinine sulfate in patients with uncomplicated malaria, mean total clearance of quinine was decreased (approximately 0.09 L/hour per kg) during the acute phase of the infection and increased (approximately 0.16 L/hour per kg) during the recovery or convalescent phase.', 'Following oral administration of a single 600-mg dose of quinine sulfate in geriatric and younger adults, the mean clearance of the drug was decreased (0.06 versus 0.08 L/hour per kg) and the mean elimination half-life was significantly increased (18.4 versus 10.5 hours) in geriatric adults compared with younger adults. Although renal clearance of quinine was similar in geriatric and younger adults, geriatric adults excreted a larger proportion of the dose in urine as unchanged drug compared with younger adults (16.6 versus 11.2%). The steady-state pharmacokinetics after a quinine sulfate dosage of 648 mg 3 times daily for 7 days were similar in healthy geriatric adults 65-78 years of age and healthy younger adults 20-39 years of age; however, the mean elimination half-life was 24 hours in the geriatric individuals compared with 20 hours in the younger adults.', 'Following oral administration of a single dose of 10 mg/kg of quinine sulfate in healthy children or pediatric patients 1.5-12 years of age with uncomplicated Plasmodium falciparum malaria, the mean total clearance (0.06 versus 0.3 L/hour per kg) is reduced and the plasma elimination half-life increased (12.1 versus 3.21 hours) in pediatric patients with malaria as compared to that observed in healthy children.', 'In 15 patients with uncomplicated malaria who received a 10 mg/kg oral dose of quinine sulfate, the mean total clearance of quinine was slower (approximately 0.09 L/hr/kg) during the acute phase of the infection, and faster (approximately 0.16 L/hr/kg) during the recovery or convalescent phase.', 'For more Absorption, Distribution and Excretion (Complete) data for QUININE (19 total), please visit the HSDB record page.']","['In vitro studies using human liver microsomes and recombinant P450 enzymes have shown that quinine is metabolized mainly by CYP3A4. Depending on the in vitro experimental conditions, other enzymes, including CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP2E1 were shown to have some role in the metabolism of quinine.', ""Quinine is metabolized almost exclusively via hepatic oxidative cytochrome P450 (CYP) pathways, resulting in four primary metabolites, 3-hydroxyquinine, 2'-quinone, O-desmethylquinine, and 10,11-dihydroxydihydroquinine. Six secondary metabolites result from further biotransformation of the primary metabolites. The major metabolite, 3-hydroxyquinine, is less active than the parent drug.""]","['Compared with administration of quinine alone, administration of a single 600-mg dose of quinine sulfate in healthy individuals who were receiving ritonavir (200 mg every 12 hours) resulted in an increased quinine mean elimination half-life (11.2 hours versus 13.4 hours).', 'The plasma elimination half-life of quinine reportedly averages 8-21 hours in adults with malaria and 7-12 hours in healthy or convalescing adults.', 'The steady-state pharmacokinetics after a quinine sulfate dosage of 648 mg 3 times daily for 7 days were similar in healthy geriatric adults 65-78 years of age and healthy younger adults 20-39 years of age; however, the mean elimination half-life was 24 hours in the geriatric individuals compared with 20 hours in the younger adults.', 'In children 1-12 years of age, the plasma elimination half-life of quinine reportedly averages 11-12 hours in those with malaria and 6 hours in those convalescing from the disease.', 'At toxic levels elimination half life is reported to be 26.5 + or - 5.8 hrs.']"
1073,441074,Quinidex,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,['For the treatment of ventricular pre-excitation and cardiac dysrhythmias'],"['Quinidine, a hydantoin anticonvulsant, is used alone or with phenobarbital or other anticonvulsants to manage tonic-clonic seizures, psychomotor seizures, neuropathic pain syndromes including diabetic neuropathy, digitalis-induced cardiac arrhythmias, and cardiac arrhythmias associated with QT-interval prolongation.']","['Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)', 'Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) (See all compounds classified as Antimalarials.)', 'Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP2D6. (See all compounds classified as Cytochrome P-450 CYP2D6 Inhibitors.)', 'A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS. (See all compounds classified as Voltage-Gated Sodium Channel Blockers.)', 'Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. (See all compounds classified as Adrenergic alpha-Antagonists.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)']","['When the urine pH is less than 7, about 20% of administered quinidine appears unchanged in the urine, but this fraction drops to as little as 5% when the urine is more alkaline.', '2 to 3 L/kg', '3 – 5 mL/min/kg [adults]', 'The volume of distribution of quinidine is 2 to 3 L/kg in healthy young adults, but this may be reduced to as little as 0.5 L/kg in patients with congestive heart failure, or increased to 3 or 5 L/kg in patients with cirrhosis of the liver. At concentrations of 2 to 5 mg/L (6.5 to 16.2 umol/L), the fraction of quinidine bound to plasma proteins (mainly to (alpha)1-acid glycoprotein and to albumin) is 80 to 88% in adults and older children, but it is lower in pregnant women, and in infants and neonates it may be as low as 50 to 70%. Because (alpha)1-glycoprotein levels are increased in response to stress, serum levels of total quinidine may be greatly increased in settings such as acute myocardial infarction, even though the serum content of unbound (active) drug may remain normal. Protein binding is also increased in chronic renal failure, but binding abruptly descends toward or below normal when heparin is administered for hemodialysis.', '...Essentially completely absorbed after oral admin; max effects occur within 1-3 hr, and persist for 6-8 more hr. Large fluctuations in plasma concentration... if repeated doses are given at this interval. ...IM admin... gluconate yields peak effects in 30-90 min.', '...All administered compound is excreted by kidney, and about 10-50% appears in urine as unchanged quinidine, within 24 hr.', 'The bioavailability of quinidine is 70 to 80% after oral use but varies between individuals and preparations. The sulfate salt is rapidly absorbed in 60 to 90 minutes. Polygalacturonate salts produce peak quinidine concentrations in 5 to 6 hours; gastrointestinal absorption of gluconate salts is intermediate (peak 3-4 hours).', 'For more Absorption, Distribution and Excretion (Complete) data for QUINIDINE (14 total), please visit the HSDB record page.']","['Lactate conjugates of quinidine and its 3-hydroxy metabolite were detected in overdose suicide patient.', 'Quinidine is metabolized in the liver, principally via hydroxylation to 3-hydroxyquinidine and 2-quinidinone. Some metabolites have antiarrhythmic activity. Approximately 10-50% of a dose is excreted in urine (probably by glomerular filtration) as unchanged drug within 24 hr.', ""Quinidine metabolites include 3-hydroxyquinidine N-oxide, 2'-oxoquinidinone, desmethylquinidine, and quinidine N-oxide. While metabolism is highly variable between individuals, at least in cases of quinidine-induced torsade de pointes, the metabolites do not appear to contribute to the formation of dysrhythmias."", 'Quinidine undergoes extensive hepatic oxidative metabolism... One metabolite, 3-hydroxyquinidine, is nearly as potent as quinidine in blocking cardiac sodium channels or prolonging action potentials.', 'Most quindiidne is eliminated hepatically via the action of cytochrome P450 IIIA.', 'Quinidine has known human metabolites that include 3-Hydroxyquinidine and Quinidine-N-oxide.']","['6-8 hours', 'Quinidine generally has a plasma half-life of 6-8 hr in healthy inividuals, but half-life may range from 3-16 hr or longer. In one study in patients with Plasmodium falciparum malaria, the elimination half-life of the drug averaged 12.8 hr (range: 6.6-24.8 hr).', 'The usual plasma half-life of approximately 7 hours after intravenous administration is increased in the presence of chronic liver disease.']"
1074,441075,"4-[(R)-[(2S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-hydroxymethyl]quinolin-6-ol",C=C[C@H]1CN2CCC1C[C@H]2[C@@H](C3=C4C=C(C=CC4=NC=C3)O)O,,,,,,
1075,441076,alpha-Erythroidine,CO[C@@H]1C[C@@]23C(=CCN2CC[C@H]4C3=CC(=O)OC4)C=C1,,,,,,
1076,441077,CID 441077,CC(=O)O[C@H]1C=C[C@H]2[C@@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)OC(=O)C)CCN3C,,,,,,
1077,441078,CID 441078,C[C@@]12C[NH+](C[C@@H]1[NH+](C3=C2C=C(C=C3)OC(=O)NC)C)C.C1=CC=C(C(=C1)C(=O)[O-])[O-],,,,,,
1078,441079,CID 441079,C[C@@]12CN(CC1N(C3=C2C=C(C=C3)OC(=O)NC)C)C,,,,,,
1079,441080,"(5aR,6S,8S,10S,11S,11aS,12aR,13R)-5-methyl-5a,6,8,9,10,11,11a,12-octahydro-5H-6,10:11,12a-dimethanoindolo[3,2-b]quinolizine-8,13-diol",CC[C@H]1[C@@H]2C[C@H]3[C@H]4[C@@]5(C[C@@H](C2[C@H]5O)N3[C@@H]1O)C6=CC=CC=C6N4C,['For use as an antiarrhythmic agent.'],"['Ajmaline is a class 1A antiarrhythmic agent. By interfering with the sodium channels, this drug allows for improvement in abnormal rhythms of the heart']",,,,
1080,441081,"[(1R,10R,11S,12S,14R,23S,25R)-1,10,11,12,14,23-hexahydroxy-6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.02,11.04,9.015,25.018,23.019,25]hexacosan-22-yl] 3,4-dimethoxybenzoate",CC1CCC2[C@@]([C@]3([C@H](C[C@]4(C5CCC6[C@]7(C(CCC6([C@@]5(O7)C[C@]4(C3CN2C1)O)C)OC(=O)C8=CC(=C(C=C8)OC)OC)O)O)O)O)(C)O,,,,"['DATA GIVEN FOR LIPID SOLUBILITY, BINDING TO HUMAN ALBUMIN, & URINARY EXCRETION AFTER ORAL ADMIN TO HUMANS. STRUCTURE-ACTIVITY CORRELATIONS ARE DISCUSSED WITH RESPECT TO LIPID SOLUBILITY & PHARMACOLOGICAL PROPERTIES.']",,
1081,441082,Conessine,C[C@H]1[C@H]2CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC=C5[C@@]4(CC[C@@H](C5)N(C)C)C)CN1C,,,,,,
1082,441083,N-Isopropylammelide,CC(C)NC1=NC(=O)NC(=O)N1,,,,,,
1083,441084,Cephemimycin,CO[C@@]1([C@@H]2N(C1=O)C(=C(CS2)COC(=O)N)C(=O)O)NC(=O)CCC[C@H](C(=O)O)N,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
1084,441085,7a-Hydroxy-o-carbamoyl-deacetylcephalosporin C,C1C(=C(N2[C@H](S1)[C@@](C2=O)(NC(=O)CCC[C@H](C(=O)O)N)O)C(=O)O)COC(=O)N,,,,,,
1085,441086,"20-[(3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-4,6,8,11,12,16,18,36-octahydroxy-35,37,38-trimethyl-2,14-dioxo-1-oxacyclooctatriaconta-21,23,25,27,31,33-hexaene-17-carboxylic acid",C[C@@H]1[C@H]([C@@H]([C@@H](C(O1)OC2CC(C(C(CC(=O)CC(C(CCC(CC(CC(CC(=O)OC(C(C(C(C=CC=CCCC=CC=CC=CC=C2)C)O)C)C)O)O)O)O)O)O)C(=O)O)O)O)N)O,,,,,,
1086,441087,CID 441087,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)[O-])C.[Na+],,,,,,
1087,441088,"cis-5,6-Dihydroxy-4-isopropylcyclohexa-1,3-dienecarboxylic acid",CC(C)C1=CC=C([C@H]([C@H]1O)O)C(=O)O,,,,,,
1088,441089,CID 441089,CC(C)C(=O)C=CC(=C(O)O)C(=O)C(=O)O,,,,,,
1089,441090,"(1S,2R)-3-(4-chlorophenyl)cyclohexa-3,5-diene-1,2-diol",C1=C[C@@H]([C@@H](C(=C1)C2=CC=C(C=C2)Cl)O)O,,,,,,
1090,441091,"4'-Chlorobiphenyl-2,3-diol",C1=CC(=C(C(=C1)O)O)C2=CC=C(C=C2)Cl,,,,,,
1091,441092,"3-Phenylcyclohexa-3,5-diene-1,2-diol",C1=CC=C(C=C1)C2=CC=CC(C2O)O,,,,,,
1092,441093,gamma-Pentachlorocyclohexene,C1=C([C@@H]([C@H]([C@H]([C@@H]1Cl)Cl)Cl)Cl)Cl,,,,,,
1093,441094,"(3R,6R)-1,3,4,6-tetrachlorocyclohexa-1,4-diene",C1=C([C@@H](C=C([C@@H]1Cl)Cl)Cl)Cl,,,,,,
1094,441095,"(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-4-[(4R,5S,6S)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-6-[(3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione",CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)OC2C[C@@]([C@H]([C@@H](O2)C)O)(C)O)C)OC3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,,,"['Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)', 'Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)', 'Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. (See all compounds classified as Gastrointestinal Agents.)']",,,
1095,441096,dTDP-3-dehydro-6-deoxy-alpha-D-glucose,C[C@@H]1[C@H](C(=O)[C@H]([C@H](O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)O)O,,,,,,
1096,441097,"[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl (2R,3S,6R)-3-hydroxy-6-methyl-4-oxotetrahydro-2H-pyran-2-yl dihydrogen diphosphate",C[C@@H]1CC(=O)[C@H]([C@H](O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)O,,,,,,
1097,441098,"dTDP-3-amino-3,4,6-trideoxy-alpha-D-glucose",C[C@@H]1C[C@@H]([C@H]([C@H](O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)O)N,,,,,,
1098,441099,"dTDP-3,4-didehydro-2,6-dideoxy-alpha-D-glucose",C[C@@H]1C(=O)C(=O)C[C@H](O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O,,,,,,
1099,441100,"dTDP-4-oxo-2,6-dideoxy-alpha-D-glucose",C[C@@H]1C(=O)[C@@H](C[C@H](O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)O,,,,,,
1100,441101,"dTDP-4-dehydro-2,6-dideoxy-beta-L-glucose",C[C@H]1C(=O)[C@@H](C[C@H](O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)O,,,,,,
1101,441102,"dTDP-4-dehydro-3-methyl-2,6-dideoxy-beta-L-glucose",C[C@H]1C(=O)[C@](C[C@H](O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)(C)O,,,,,,
1102,441103,"S-[2-[3-[[4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] 3-amino-3-oxopropanethioate",CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)CC(=O)N)O,,,,,,
1103,441104,CID 441104,CC1=C2CC3C(=O)C(=O)C(=C(N)O)C(=O)[C@]3(C(=O)C2=C(C4=C(C=CC(=C14)Cl)O)O)O,,,,,,
1104,441105,CID 441105,CC1=C2C=CC=C(C2=C(C3=C1CC4C(=O)C(=O)C(=C(N)O)C(=O)[C@]4(C3=O)O)O)O,,,,,,
1105,441106,"1,3,4,10,11,12-Hexahydroxy-6-methyltetracene-2-carboxamide",CC1=C2C=CC=C(C2=C(C3=C(C4=C(C=C13)C(=C(C(=C4O)C(=O)N)O)O)O)O)O,,,,,,
1106,441107,"1,3,10,11,12-Pentahydroxy-6-methyltetracene-2-carboxamide",CC1=C2C=CC=C(C2=C(C3=C1C=C4C=C(C(=C(C4=C3O)O)C(=O)N)O)O)O,,,,,,
1107,441108,3-O-alpha-mycarosylerythronolide B,CC[C@@H]1[C@@H]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)O)C)O)(C)O)C)C)O)C,,,,,,
1108,441109,dTDP-beta-L-mycarose,C[C@H]1[C@@H]([C@](C[C@H](O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)(C)O)O,,,,,,
1109,441110,dTDP-alpha-D-desosamine,C[C@@H]1C[C@@H]([C@H]([C@H](O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)O)N(C)C,,,,,,
1110,441111,CID 441111,CC[C@H]1[C@@H]([C@@H]([C@@H](C(=O)[C@H](C[C@@]([C@@H]([C@@H]([C@@H]([C@@H](C(=O)O1)C)OC2C[C@@]([C@@H]([C@@H](O2)C)O)(C)O)C)OC3[C@@H]([C@@H](C[C@@H](O3)C)N(C)C)O)(C)O)C)C)O)C,,,,,,
1111,441112,CID 441112,CC[C@H]1[C@]([C@@H]([C@@H](C(=O)[C@H](C[C@@]([C@@H]([C@@H]([C@H]2[C@@H](COC3(O2)C[C@@]([C@@H]([C@@H](O3)C)O)(C)OC)C(=O)O1)C)OC4[C@@H]([C@@H](C[C@@H](O4)C)N(C)C)O)(C)O)C)C)O)(C)O,,,,,,
1112,441113,Erythronolide B,CC[C@@H]1[C@@H]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O)C)O)(C)O)C)C)O)C,,,,,,
1113,441114,"1,1-Dichloro-2-(4-chloro-2,3-dihydroxyphenyl)-2-(4-chlorophenyl)ethylene",C1=CC(=CC=C1C(=C(Cl)Cl)C2=C(C(=C(C=C2)Cl)O)O)Cl,,,,,,
1114,441115,"3,8,8-Trichloro-7-(4-chlorophenyl)-2-hydroxy-6-oxoocta-2,4,7-trienoic acid",C1=CC(=CC=C1C(=C(Cl)Cl)C(=O)C=CC(=C(C(=O)O)O)Cl)Cl,,,,,,
1115,441116,"3,3-Dichloro-2-(4-chlorophenyl)prop-2-enoic acid",C1=CC(=CC=C1C(=C(Cl)Cl)C(=O)O)Cl,,,,,,
1116,441117,"(1S,2S)-DDT-2,3-dihydrodiol",C1=CC(=CC=C1C(C2=CC=C([C@H]([C@H]2O)O)Cl)C(Cl)(Cl)Cl)Cl,,,,,,
1117,441118,"3-Chloro-6-[2,2,2-trichloro-1-(4-chlorophenyl)ethyl]benzene-1,2-diol",C1=CC(=CC=C1C(C2=C(C(=C(C=C2)Cl)O)O)C(Cl)(Cl)Cl)Cl,,,,,,
1118,441119,"3,8,8,8-Tetrachloro-7-(4-chlorophenyl)-2-hydroxy-6-oxoocta-2,4-dienoic acid",C1=CC(=CC=C1C(C(=O)C=CC(=C(C(=O)O)O)Cl)C(Cl)(Cl)Cl)Cl,,,,,,
1119,441120,CID 441120,CC[C@H]1[C@@H]([C@@H]([C@@H](C(=O)[C@H](C[C@@]([C@@H]([C@@H]([C@@H]([C@@H](C(=O)O1)C)OC2C[C@@]([C@@H]([C@@H](O2)C)O)(C)OC)C)OC3[C@@H]([C@@H](C[C@@H](O3)C)N(C)C)O)(C)O)C)C)O)C,,,,,,
1120,441121,CID 441121,CC1=C2C=CC=C(C2=C(C3=C1CC4[C@@H](C(=O)C(=C(N)O)C(=O)[C@]4(C3=O)O)N)O)O,,,,,,
1121,441122,2-(2-Carboxyethylamino)-5-(diaminomethylideneamino)pentanoic acid,C(CC(C(=O)O)NCCC(=O)O)CN=C(N)N,,,,,,
1122,441123,Deoxyguanidinoproclavaminic acid,C1CN(C1=O)[C@@H](CCCN=C(N)N)C(=O)O,,,,,,
1123,441124,Amidinoproclavaminic acid,C1CN(C1=O)[C@@H]([C@@H](CCN=C(N)N)O)C(=O)O,,,,,,
1124,441125,Dihydroclavaminic acid,C1[C@H]2N(C1=O)[C@@H]([C@H](O2)CCN)C(=O)O,,,,,,
1125,441126,CID 441126,C1[C@H]2N(C1=O)[C@@H](C(=CCN)O2)C(=O)O,,,,,,
1126,441127,"(2R,5R)-7-oxo-3-(2-oxoethylidene)-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid",C1[C@@H]2N(C1=O)[C@H](C(=CC=O)O2)C(=O)O,,,,,,
1127,441128,Thienamycin,C[C@H]([C@@H]1[C@H]2CC(=C(N2C1=O)C(=O)O)SCCN)O,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
1128,441129,Meropenem trihydrate,C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)N(C)C)C(=O)O)[C@@H](C)O.O.O.O,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
1129,441130,Meropenem,C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)N(C)C)C(=O)O)[C@@H](C)O,"['For use as single agent therapy for the treatment of the following infections when caused by susceptible isolates of the designated microorganisms: <b>complicated skin and skin structure infections</b> due to <i>Staphylococcus aureus</i> (b-lactamase and non-b-lactamase producing, methicillin-susceptible isolates only), <i>Streptococcus pyogenes</i>, <i>Streptococcus agalactiae</i>, viridans group streptococci, <i>Enterococcus faecalis</i> (excluding vancomycin-resistant isolates), <i>Pseudomonas aeruginosa</i>, <i>Escherichia coli</i>, <i>Proteus mirabilis</i>, <i>Bacteroides fragilis</i> and <i>Peptostreptococcus</i> species; <b>complicated appendicitis and peritonitis</b> caused by viridans group streptococci, <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, <i>Pseudomonas aeruginosa</i>, <i>Bacteroides fragilis</i>, <i>B. thetaiotaomicron</i>, and <i>Peptostreptococcus</i> species. Also for use in the treatment of bacterial meningitis caused by <i>Streptococcus pneumoniae</i>, <i>Haemophilus influenzae</i> (b-lactamase and non-b-lactamase-producing isolates), and <i>Neisseria meningitidis</i>.']","['Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.']",['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],"['Approximately 70% of the intravenously administered dose is recovered as unchanged meropenem in the urine over 12 hours, after which little further urinary excretion is detectable.', 'Approximately 70% of the intravenously administered dose is recovered as unchanged meropenem in the urine over 12 hours, after which little further urinary excretion is detectable. Urinary concentrations of meropenem in excess of 10 ug/mL are maintained for up to 5 hours after a 500 mg dose.', 'Meropenem is distributed into most body tissues and fluids, including bronchial mucosa, lung, bile, gynecologic tissue (endometrium, myometrium, ovary, cervix, fallopian tube), muscle, heart valves, skin, interstitial and peritoneal fluid, and CSF. Plasma protein binding is approximately 2%. The drug is partially metabolized to at least one microbiologically inactive metabolite. About 70% of an IV dose is eliminated in urine as unchanged drug by tubular secretion and glomerular filtration.', 'At the end of a 30 minute intravenous infusion of a single dose of Meropenem for injection (IV) in healthy volunteers, mean peak plasma concentrations of meropenem are approximately 23 ug/mL (range 14-26) for the 500 mg dose and 49 ug/mL (range 39-58) for the 1 g dose. A 5-minute intravenous bolus injection of Meropenem for injection (IV) in healthy volunteers results in mean peak plasma concentrations of approximately 45 ug/mL (range 18-65) for the 500 mg dose and 112 ug/mL (range 83-140) for the 1 g dose.  Following intravenous doses of 500 mg, mean plasma concentrations of meropenem usually decline to approximately 1 ug/mL at 6 hours after administration.  No accumulation of meropenem in plasma was observed with regimens using 500 mg administered every 8 hours or 1 g administered every 6 hours in healthy volunteers with normal renal function.']","['Primarily excreted unchanged. There is one metabolite which is microbiologically inactive.', 'There is one metabolite of meropenem that is microbiologically inactive.']","['Approximately 1 hour in adults and children 2 years of age and older with normal renal function. Approximately 1.5 hours in children 3 months to 2 years of age.', 'The plasma half-life of meropenem is approximately 1 hour in adults with normal renal function and 1.5 hours in children 3 months to 2 years of age. Plasma half-life is increased and clearance of the drug is decreased in patients with renal impairment.']"
1130,441131,Clavamycin A,C1[C@H]2N(C1=O)C[C@@H](O2)C(C(C(=O)NC(C([C@H]3CN4[C@@H](O3)CC4=O)O)C(=O)O)N)O,,,,,,
1131,441132,Valclavam,CC(C)[C@@H](C(=O)NC(C(C[C@H]1CN2[C@@H](O1)CC2=O)O)C(=O)O)N,,,,,,
1132,441133,Carbapenem-3-carboxylic acid,C1C=C(N2[C@H]1CC2=O)C(=O)O,,,,,,
1133,441134,"2,4-Dichlorobenzoyl-CoA; (Acyl-CoA); [M+H]+",CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)C4=C(C=C(C=C4)Cl)Cl)O,,,,,,
1134,441135,4-Carboxy-4'-sulfoazobenzene,C1=CC(=CC=C1C(=O)O)N=NC2=CC=C(C=C2)S(=O)(=O)O,,,,,,
1135,441136,"3-Sulfohexa-2,4-dienedioic acid",C(=CC(=O)O)C(=CC(=O)O)S(=O)(=O)O,,,,,,
1136,441137,2-(5-oxo-3-sulfo-2H-furan-2-yl)acetic acid,C1=C(C(OC1=O)CC(=O)O)S(=O)(=O)O,,,,,,
1137,441138,4-(Hydroxymethyl)benzenesulfonic acid,C1=CC(=CC=C1CO)S(=O)(=O)O,,,,,,
1138,441139,cyclo[OAla-Val-D-OVal-D-Val-OAla-Val-D-OVal-D-Val-OAla-Val-D-OVal-DL-Val],C[C@H]1C(=O)N[C@H](C(=O)O[C@@H](C(=O)NC(C(=O)O[C@H](C(=O)N[C@H](C(=O)O[C@@H](C(=O)N[C@@H](C(=O)O[C@H](C(=O)N[C@H](C(=O)O[C@@H](C(=O)N[C@@H](C(=O)O1)C(C)C)C(C)C)C(C)C)C)C(C)C)C(C)C)C(C)C)C)C(C)C)C(C)C)C(C)C,,,"['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)', 'Chemical agents that increase the permeability of biological or artificial lipid membranes to specific ions. Most ionophores are relatively small organic molecules that act as mobile carriers within membranes or coalesce to form ion permeable channels across membranes. Many are antibiotics, and many act as uncoupling agents by short-circuiting the proton gradient across mitochondrial membranes. (See all compounds classified as Ionophores.)']",,,
1139,441140,Griseofulvin,C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC,"['For the treatment of ringworm infections of the skin, hair, and nails, namely: tinea corporis, tinea pedis, tinea cruris, tinea barbae, cradle cap or other conditions caused by <i>Trichophyton</i> or <i>Microsporum</i> fungi.']","['Griseofulvin is a mycotoxic metabolic product of <i>Penicillium spp.</i> It was the first available oral agent for the treatment of dermatophytoses and has now been used for more than forty years. Griseofulvin is fungistatic with in vitro activity against various species of Microsporum Epidermophyton, and Trichophyton. It has no effect on bacteria or on other genera of fungi. Following oral administration, griseofulvin is deposited in the keratin precursor cells and has a greater affinity for diseased tissue. The drug is tightly bound to the new keratin which becomes highly resistant to fungal invasions. Once the keratin-Griseofulvin complex reaches the skin site of action, it binds to fungal microtubules (tubulin) thus altering fungal mitosis.']","['Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)']","['Poorly absorbed from GI ranging from 25 to 70% of an oral dose. Absorption is significantly enhanced by administration with or after a fatty meal.', 'IN RATS GIVEN ORAL DOSES OF 100 MG/KG BODY WT (36)CL-GRISEOFULVIN, 10% OF ACTIVITY WAS FOUND IN URINE AFTER 24 HR & 4% DURING 24-48 HR. ...IN ANOTHER STUDY, WITHIN 24-HR PERIOD ONLY 0.14% OF SIMILAR ORAL DOSES IN RATS WAS FOUND IN URINE, & 16% WAS RECOVERED IN FECES. FOLLOWING ITS IV INJECTION GRISEOFULVIN WAS DISTRIBUTED EVENLY THROUGHOUT TISSUES, ALTHOUGH HIGHER LEVELS WERE FOUND IN SKIN & LUNG.', 'Microsize - variable, ranging from 25 to 70% of an oral dose. Ultramicrosize - Almost completely absorbed. Absorption is significantly enhanced by administration with or after a fatty meal.', 'Griseofulvin is deposited in varying concentrations in the keratin layer of the skin, hair, and nails. It can be detected in the stratum corneum of the skin within a few hours following administration. Only a very small fraction of an oral dose is distributed in the body fluids and tissues.', 'Elimination: Renal. less than 1% of a dose is excreted as unchanged drug in the urine. Approximately 36% of griseofulvin is excreted unchanged in the feces.', 'GRISEOFULVIN IS PROBABLY DEPOSITED IN BASAL CELLS AND IS CARRIED OUTWARDS INTO EPIDERMIS AS NORMAL SKIN GROWTH PROCEEDS. THIS...MAKES FOR LONG LATENCY FROM TIME MEDICATION IS BEGUN UNTIL EVIDENCE OF IMPROVEMENT OCCURS.']","['Primarily hepatic with major metabolites being 6-methyl-griseofulvin and its glucuronide conjugate.', 'Griseofulvin is mainly metabolized to 6-dimethylgriseofulvin and its glucuronide.', ""...IT HAS BEEN REPORTED THAT 6-DEMETHYLGRISEOFULVIN IS THE MAJOR URINARY METABOLITE...IN MAN, THE PREVIOUSLY REPORTED 4-DEMETHYL-GRISEOFULVIN WAS ABSENT. GRISEOFULVIC ACID (7-CHLORO-4,6-DIMETHOXY-6'-METHYLGRISAN-2',3,4'-TRIONE) WAS IDENTIFIED...""]","['9-21 hours', 'DRUG HAS A HALF-LIFE IN PLASMA OF ABOUT 1 DAY, & APPROX 50% OF ORAL DOSE CAN BE DETECTED IN THE URINE WITHIN 5 DAYS, MOSTLY IN THE FORM OF METABOLITES /SRP: 36% IN THE FECES WITHIN 5 DAYS/.', 'The half-life of griseofulvin in canine plasma was found to be 47 minutes ... .']"
1140,441141,"(1S,2R,18R,22S,25R,28R,40R)-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5S,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carboxylic acid",C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H](C(C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,,,,"['Vancomycin hydrochloride is not appreciably absorbed from the GI tract in most patients and must be given parenterally for the treatment of systemic infections. Oral bioavailability usually is less than 5%; however, limited data suggest that clinically important serum concentrations of the drug may result following enteral or oral administration of vancomycin in some patients with colitis and/or in those with renal impairment.', 'In adults with normal renal function who received multiple 1 g doses of vancomycin (15 mg/kg) given by IV infusion over 1 hour, mean plasma concentrations immediately after completion of the infusion are approximately 63 ug/mL and mean plasma concentrations 2 and 11 hours later are approximately 23 or 8 ug/mL, respectively. When multiple 500-mg doses are given by IV infusion over 30 minutes, mean plasma concentrations are about 49 ug/mL immediately following the infusion and about 10 ug/mL 6 hours after infusion.', 'Vancomycin is distributed into milk following IV administration. Systemic absorption of oral vancomycin is very low and it is not known whether the drug distributes into human milk following oral administration.', 'Vancomycin readily crosses the placenta and is distributed into cord blood.', 'Vancomycin is approximately 55% serum protein bound as measured by ultrafiltration at vancomycin serum concentrations of 10 to 100 mcg/mL. After IV administration of vancomycin hydrochloride, inhibitory concentrations are present in pleural, pericardial, ascitic, and synovial fluids; in urine; in peritoneal dialysis fluid; and in atrial appendage tissue. Vancomycin hydrochloride does not readily diffuse across normal meninges into the spinal fluid; but, when the meninges are inflamed, penetration into the spinal fluid occurs.']",,"['The mean elimination half-life of vancomycin from plasma is 4 to 6 hours in subjects with normal renal function.', 'In anephric patients, the average half-life of elimination is 7.5 days.']"
1141,441142,"33-[(3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-17-[7-(4-aminophenyl)-5-hydroxy-4-methyl-7-oxoheptan-2-yl]-1,3,5,7,37-pentahydroxy-18-methyl-9,13,15-trioxo-16,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid",C[C@@H]1[C@H]([C@@H]([C@@H](C(O1)OC2CC3C(C(CC(O3)(CC(CC(CC(CC(=O)CCCC(=O)CC(=O)OC(C(C=CC=CC=CC=CC=CC=CC=C2)C)C(C)CC(C)C(CC(=O)C4=CC=C(C=C4)N)O)O)O)O)O)O)C(=O)O)O)N)O,,,,,,
1142,441143,Actinorhodin,C[C@@H]1C2=C(C[C@H](O1)CC(=O)O)C(=O)C3=C(C2=O)C(=O)C(=CC3=O)C4=CC(=C5C(=C4O)C(=C6[C@H](O[C@@H](CC6=C5O)CC(=O)O)C)O)O,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
1143,441144,"2-[(2-amino-5-carbamoyloxy-3,4-dihydroxy-pentanoyl)amino]-2-[(2R,3S,4R,5R)-3,4-dihydroxy-5-[5-(hydroxymethyl)-2,4-dioxo-pyrimidin-1-yl]tetrahydrofuran-2-yl]acetic acid",C1=C(C(=O)NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)C(C(=O)O)NC(=O)C(C(C(COC(=O)N)O)O)N)O)O)CO,,,,,,
1144,441145,Monensin,CC[C@]1(CC[C@@H](O1)[C@@]2(CC[C@@]3(O2)C[C@@H]([C@H]([C@H](O3)[C@@H](C)[C@H]([C@H](C)C(=O)O)OC)C)O)C)[C@H]4[C@H](C[C@@H](O4)[C@@H]5[C@H](C[C@H]([C@@](O5)(CO)O)C)C)C,['For the reduction in the incidence of ketosis in the peri-parturient dairy cow/heifer which is expected to develop ketosis.'],,"['Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)', 'Agents useful in the treatment or prevention of COCCIDIOSIS in man or animals. (See all compounds classified as Coccidiostats.)', 'Chemical agents that increase the permeability of CELL MEMBRANES to SODIUM ions. (See all compounds classified as Sodium Ionophores.)', 'Substances that are destructive to protozoans. (See all compounds classified as Antiprotozoal Agents.)', 'Chemical agents that increase the permeability of CELL MEMBRANES to PROTONS. (See all compounds classified as Proton Ionophores.)']","['The pharmacokinetics of monensin, including half-life, apparent volume of distribution, total body clearance, systemic bioavailability and tissue residues were determined in broiler chickens. The drug was given by intracrop and intravenous routes in a single dose of 40 mg/kg body weight. Following intravenous injection the kinetic disposition of monensin followed a two compartments open model with absorption half life of 0.59 hr, volume of distribution of 4.11 l/kg and total body clearance of 28.36 ml/kg/min. The highest serum concentrations of monensin were reached 0.5 hr after intracrop dosage with an absorption half-life of 0.27 hr and an elimination half life of 2.11 hr. The systemic bioavailability was 65.1% after intracrop administration. Serum protein-binding tendency of monensin calculated in vitro was 22.8%. Monensin concentrations in the serum and tissues of chickens after a single intracrop dose of pure monensin (40 mg/kg body weight) were higher than those after feeding a supplemented monensin premix (120 mg/kg) for 2 weeks. Monensin residues were detected in tested body tissues, collected 2, 4, 6 and 8 hr after oral administration. The highest concentration was found in the liver. In addition, monensin residues were detected only in liver, kidney and fat 24 hr after the last oral dose. No monensin residues could be detected in tissues after 48 hr, except in liver which cleared completely by 72 hr.', 'Six chickens were exposed to (3)H-monensin sodium at 121 mg/kg in the diet for 2 days. Only 52-73% of the radioactivity was recovered; of this, 97% was found in the faeces. The reason for poor radioactivity balance was unknown. /Monensin sodium/', 'Broiler chickens were administered (14)C-monensin sodium at a concentration of 120 mg/kg in the diet for 4 days (two males, three females) or 6 days (three males, three females). Six hours after withdrawal from the treated feed, radioactivity was detected in the liver, kidney, fat and skin, with the highest level detected in the liver (0.5 mg/kg liver). No radioactivity was detected in the muscle tissue. /Monensin sodium/', 'Ten White Leghorn roosters and two White Leghorn hens were exposed orally to a single dose of (14)C-monensin in a gelatine capsule (dose range: 2.6-100 mg). Some birds were colostomized, whereas others had bile cannulae inserted. Absorption in the chickens ranged from 11% to 31% of the ingested (14)C-monensin. The primary route of excretion was in the faeces, with a small proportion excreted in the urine and by respiration.', 'For more Absorption, Distribution and Excretion (Complete) data for MONENSIN (21 total), please visit the HSDB record page.']","['The oxidative metabolism of monensin, an ionophore antibiotic extensively used in veterinary practice as a coccidiostat and a growth promoter, was studied in hepatic microsomal preparations from horses, pigs, broiler chicks, cattle and rats. As assayed by the measurement of the amount of the released formaldehyde, the rate of monensin O-demethylation was nearly of the same order of magnitude in all species, but total monensin metabolism, which was estimated by measuring the rate of substrate disappearance by a high-performance liquid chromatography (HPLC) method, was highest in cattle, intermediate in rats, chicks and pigs, and lowest in horses. When expressed as turnover number (nmol of metabolized monensin/min nmol cytochrome P450-1), the catalytic efficiency (chick >> cattle >> pig approximately rat > horse) was found to correlate inversely with the well known interspecies differences in the susceptibility to the toxic effects of the ionophore, which is characterized by an oral LD50 of 2-3 mg/kg bodyweight (bw) in horses, 50-80 mg/kg bw in cattle and 200 mg/kg bw in chicks. Chick and cattle microsomes also displayed both the highest catalytic efficiency toward two P450 3A dependent substrates (erythromycin and triacetyloleandomycin) and the highest immunodetectable levels of proteins cross-reacting with anti rat P450 3A1/2. ...', 'The O-demethylation of monensin is greater in microsomes from phenobarbital-treated rats than in untreated rats and is dependent on reduced nicotinamide adenine dinucleotide phosphate (NADPH), suggesting that monensin is a cytochrome P450 (CYP) enzyme substrate. The oxidative metabolism of monensin appears to occur at least in part by CYP3A, since treatment of rat hepatic microsomes with chemical inducers of CYP3A significantly increased monensin O-demethylation. It has been speculated that competition between monensin and other CYP3A substrates may explain accidental poisonings that have occurred in several domestic species following coadministration of monensin and other chemotherapeutic agents, since monensin metabolism is significantly decreased in the presence of other CYP3A substrates in rats.', 'Monensin metabolites result mainly from O-demethylation at the methoxylic group and/or hydroxylation at several places on the ionophore backbone. ... Although it is difficult to obtain sufficient monensin metabolites to test activity, four metabolites generated by rat liver microsomes, including a by-product of monensin production (O-desmethylmonensin), have been tested and have at least 10- to 20-fold less antibacterial, anticoccidial, cytotoxic, cardiotonic and ionophoric activity than the parent compound, indicating that metabolism eliminates most of the biological activity of monensin.', 'Monensin is extensively metabolized in the liver, producing more than 50 different metabolites that have been detected in the liver, bile and faeces of chickens, cattle, rats, pigs, dogs, turkeys, sheep and horses. In most species (chickens, rats, dogs, turkeys and pigs), less than 10% of monensin is excreted as the parent compound, whereas a study in calves indicated that 50-68% of the (14)C identified in the feces was unmetabolized monensin. This difference in amount of metabolized monensin may have been a result of differences in absorption of the molecule in different species. Total microsomal monensin metabolism, estimated by measuring the rate of substrate disappearance by a high-performance liquid chromatographic (HPLC) analytical method, is highest in cattle, intermediate in rats, chickens and pigs, and lowest in horses. The pattern of metabolites is qualitatively similar between laboratory and non-laboratory animal species, although quantitative differences exist. No single metabolite dominates the metabolic profile.', 'The metabolism of monensin sodium in human liver microsomes has been compared with metabolism in the microsomes of horses and dogs. A pooled human microsomal sample from multiple donors (male and female, Caucasian, Hispanic and African American, 15-66 years old), pooled dog microsome sample and equine microsomes from a single donor were incubated with 0.5, 1 and 10 ug monensin/mL in the presence or absence of NADPH. The metabolite profiles were examined at 0, 5, 10, 20, 40 and 60 min by liquid chromatography/mass spectrometry (LC-MS) analysis. Monensin was metabolized by first-order kinetics in all species, and metabolism was extensive (93-99% by 60 min). The turnover of monensin in humans was similar to that in dogs, whereas the turnover in horses was only 10% of that in dogs and humans.']","['The pharmacokinetics of monensin, including half-life, apparent volume of distribution, total body clearance, systemic bioavailability and tissue residues were determined in broiler chickens. The drug was given by intracrop and intravenous routes in a single dose of 40 mg/kg body weight. Following intravenous injection the kinetic disposition of monensin followed a two compartments open model with absorption half life of 0.59 hr ... .The highest serum concentrations of monensin were reached 0.5 hr after intracrop dosage with an absorption half-life of 0.27 hr and an elimination half life of 2.11 hr. ...']"
1145,441146,3-Hydroxypimelyl-CoA,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)CC(CCCC(=O)O)O)O,,,,,,
1146,441147,3-oxopimelyl-CoA,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)CC(=O)CCCC(=O)O)O,,,,,,
1147,441148,Mycothiol,CC(=O)N[C@@H](CS)C(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1OC2[C@@H]([C@H](C([C@H]([C@H]2O)O)O)O)O)CO)O)O,,,,,,
1148,441149,"1,6-Dihydroxy-5-methylcyclohexa-2,4-dienecarboxylate",CC1=CC=C[C@@]([C@H]1O)(C(=O)O)O,,,,,,
1149,441150,"(1S,2R)-1,2-dihydrodibenzothiophene-1,2-diol",C1=CC=C2C(=C1)C3=C(S2)C=C[C@H]([C@H]3O)O,,,,,,
1150,441151,"1,2-Dihydroxydibenzothiophene",C1=CC=C2C(=C1)C3=C(S2)C=CC(=C3O)O,,,,,,
1151,441152,CID 441152,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)C=CCCCC(=O)O)O,,,,,,
1152,441153,CID 441153,CC1=C(NC2=CC=C(C(=O)C2=C1)O)O,,,,,,
1153,441154,"5,6-dihydroxy-3-methyl-5,6-dihydroquinolin-2(1H)-one",CC1=CC2=C(C=CC(C2O)O)NC1=O,,,,,,
1154,441155,"cis-1,2-Dihydro-3-ethylcatechol",CCC1=CC=C[C@@H]([C@@H]1O)O,,,,,,
1155,441156,"1,6-Dihydroxy-4-methylcyclohexa-2,4-diene-1-carboxylic acid",CC1=CC(C(C=C1)(C(=O)O)O)O,,,,,,
1156,441157,"1,6-Dihydroxy-2-methylcyclohexa-2,4-dienecarboxylic acid",CC1=CC=CC(C1(C(=O)O)O)O,,,,,,
1157,441158,2-Amino-3-(1H-indol-3-yl)-2-propenoic acid,C1=CC=C2C(=C1)C(=CN2)C=C(C(=O)O)N,,,,,,
1158,441159,"5,9-Dimethyl-11-(2,6,6-trimethylcyclohexen-1-yl)undeca-2,4,6,8,10-pentaenal",CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC=CC=O)C)C,,,,,,
1159,441160,CID 441160,CCC=CCCCCCCCCCC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
1160,441161,"2'-Hydroxy-1,1'-biphenyl-2-sulfinic acid",C1=CC=C(C(=C1)C2=CC=CC=C2S(=O)O)O,,,,,,
1161,441162,6-Hydroxycyclohex-1-ene-1-carboxyl-CoA,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)C4=CCCCC4O)O,,,,,,
1162,441163,"2,4-Hexadienoic acid, 2-hydroxy-5-methyl-6-oxo-, (Z,Z)-",CC(=CO)C=CC(=O)C(=O)O,,,,,,
1163,441164,4-Hydroxy-2-oxohexanoic acid,CCC(CC(=O)C(=O)O)O,,,,,,
1164,441165,Tetranactin,CC[C@H]1C[C@@H]2CC[C@@H](O2)[C@H](C(=O)O[C@@H](C[C@H]3CC[C@H](O3)[C@@H](C(=O)O[C@H](C[C@@H]4CC[C@@H](O4)[C@H](C(=O)O[C@@H](C[C@H]5CC[C@H](O5)[C@@H](C(=O)O1)C)CC)C)CC)C)CC)C,,,,,,
1165,441166,"(2S,3S,4R,5R,6R)-5-[(2S,3R,4R,5S,6R)-3-acetamido-5-[(2S,3R,4R,5S,6R)-3-acetamido-4-hydroxy-6-methyl-5-[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-[(2-hydroxy-5-oxocyclopenten-1-yl)carbamoyl]oxan-2-yl]oxyoxan-2-yl]oxy-4-hydroxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-4-carbamoyloxy-6-[[(2R)-2-carboxy-2-(3,8,8,14,18-pentamethyl-11-methylidenenonadeca-2,6,13,17-tetraenoxy)ethoxy]-hydroxyphosphoryl]oxy-3-hydroxy-3-methyloxane-2-carboxylic acid",C[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2O)NC(=O)C)O[C@@H]3[C@H]([C@]([C@H](O[C@@H]3OP(=O)(O)OC[C@H](C(=O)O)OCC=C(C)CCC=CC(C)(C)CCC(=C)CC=C(C)CCC=C(C)C)C(=O)O)(C)O)OC(=O)N)CO[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)NC(=O)C)O)O[C@H]5[C@@H]([C@H]([C@H]([C@H](O5)C(=O)NC6=C(CCC6=O)O)O)O)O,,,,,,
1166,441167,Vibriobactin,C[C@H]1[C@@H](N=C(O1)C2=C(C(=CC=C2)O)O)C(=O)NCCCN(CCCNC(=O)C3=C(C(=CC=C3)O)O)C(=O)[C@@H]4[C@H](OC(=N4)C5=C(C(=CC=C5)O)O)C,,,"['Low-molecular-weight compounds produced by microorganisms that aid in the transport and sequestration of ferric iron. (The Encyclopedia of Molecular Biology, 1994) (See all compounds classified as Siderophores.)']",,,
1167,441168,11-O-Demethylpradinone II,CC1=CC2=C(C3=C([C@@H]([C@H]2O)O)C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC(=C5)O)O)O)C(=C1C(=O)O)O,,,,,,
1168,441169,11-O-Demethyl-7-methoxypradinone II,CC1=CC2=C(C3=C([C@@H]([C@H]2O)O)C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC(=C5)O)O)OC)C(=C1C(=O)O)O,,,,,,
1169,441170,11-O-Demethylpradimicinone I,CC1=CC2=C(C3=C(C4=C(C=C3[C@@H]([C@H]2O)O)C(=O)C5=C(C4=O)C=C(C=C5O)O)O)C(=C1C(=O)NC(C)C(=O)O)O,,,,,,
1170,441171,"2-[[(5S,6S)-1,5,6,9,14-pentahydroxy-11-methoxy-3-methyl-8,13-dioxo-5,6-dihydrobenzo[a]tetracene-2-carbonyl]amino]propanoic acid",CC1=CC2=C(C3=C(C4=C(C=C3[C@@H]([C@H]2O)O)C(=O)C5=C(C4=O)C=C(C=C5O)OC)O)C(=C1C(=O)NC(C)C(=O)O)O,,,,,,
1171,441172,11-O-Demethylpradimicinone II,CC1=CC2=C(C3=C([C@@H]([C@H]2O)O)C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC(=C5)O)O)O)C(=C1C(=O)NC(C)C(=O)O)O,,,,,,
1172,441173,11-O-Demethyl-7-methoxypradimicinone II,CC1=CC2=C(C3=C([C@@H]([C@H]2O)O)C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC(=C5)O)O)OC)C(=C1C(=O)NC(C)C(=O)O)O,,,,,,
1173,441174,Pradimicinone II,CC1=CC2=C(C3=C([C@@H]([C@H]2O)O)C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC(=C5)OC)O)O)C(=C1C(=O)NC(C)C(=O)O)O,,,,,,
1174,441175,7-Methoxypradimicinone II,CC1=CC2=C(C3=C([C@@H]([C@H]2O)O)C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC(=C5)OC)O)OC)C(=C1C(=O)NC(C)C(=O)O)O,,,,,,
1175,441176,7-Hydroxylpradimicin A,C[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](C3=C(C4=C2C=C(C(=C4O)C(=O)NC(C)C(=O)O)C)C(=C5C(=C3O)C(=O)C6=C(C5=O)C=C(C=C6O)OC)O)O)O)O[C@H]7[C@@H]([C@H]([C@@H](CO7)O)O)O)NC,,,,,,
1176,441177,"2-[[(5S,6S)-5-[(2S,3R,4S,5R,6R)-3,4-dihydroxy-6-methyl-5-(methylamino)oxan-2-yl]oxy-1,6,9,14-tetrahydroxy-11-methoxy-3-methyl-8,13-dioxo-5,6-dihydrobenzo[a]tetracene-2-carbonyl]amino]propanoic acid",C[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](C3=CC4=C(C(=C3C5=C2C=C(C(=C5O)C(=O)NC(C)C(=O)O)C)O)C(=O)C6=C(C4=O)C(=CC(=C6)OC)O)O)O)O)NC,,,,,,
1177,441178,"2-[[(5S,6S)-1,6,9,14-tetrahydroxy-5-[(2S,3R,4S,5S,6R)-3-hydroxy-6-methyl-5-(methylamino)-4-[(2S,3R,4S,5R)-3,4,5-trihydroxytetrahydropyran-2-yl]oxy-tetrahydropyran-2-yl]oxy-11-methoxy-3-methyl-8,13-dioxo-5,6-dihydrobenzo[a]tetracene-2-carbonyl]amino]propanoic acid",C[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](C3=CC4=C(C(=C3C5=C2C=C(C(=C5O)C(=O)NC(C)C(=O)O)C)O)C(=O)C6=C(C4=O)C(=CC(=C6)OC)O)O)O)O[C@H]7[C@@H]([C@H]([C@@H](CO7)O)O)O)NC,,,,,,
1178,441179,Dexylosylpradimicin C,C[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](C3=CC4=C(C(=C3C5=C2C=C(C(=C5O)C(=O)NC(C)C(=O)O)C)O)C(=O)C6=C(C4=O)C(=CC(=C6)OC)O)O)O)O)N,,,,,,
1179,441180,"2-[[(5S,6S)-5-[(2S,3R,4S,5S,6R)-5-amino-3-hydroxy-6-methyl-4-[(2S,3R,4S,5R)-3,4,5-trihydroxytetrahydropyran-2-yl]oxy-tetrahydropyran-2-yl]oxy-1,6,9,14-tetrahydroxy-11-methoxy-3-methyl-8,13-dioxo-5,6-dihydrobenzo[a]tetracene-2-carbonyl]amino]propanoic acid",C[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](C3=CC4=C(C(=C3C5=C2C=C(C(=C5O)C(=O)NC(C)C(=O)O)C)O)C(=O)C6=C(C4=O)C(=CC(=C6)OC)O)O)O)O[C@H]7[C@@H]([C@H]([C@@H](CO7)O)O)O)N,,,,,,
1180,441181,"2-[[(5S,6S)-1,6,9,14-tetrahydroxy-11-methoxy-3-methyl-8,13-dioxo-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-5,6-dihydrobenzo[a]tetracene-2-carbonyl]amino]propanoic acid",C[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](C3=CC4=C(C(=C3C5=C2C=C(C(=C5O)C(=O)NC(C)C(=O)O)C)O)C(=O)C6=C(C4=O)C(=CC(=C6)OC)O)O)O)O)O,,,,,,
1181,441182,"2-[[(5S,6S)-5-[(2S,3R,4S,5S,6R)-3,5-dihydroxy-6-methyl-4-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-1,6,9,14-tetrahydroxy-11-methoxy-3-methyl-8,13-dioxo-5,6-dihydrobenzo[a]tetracene-2-carbonyl]amino]propanoic acid",C[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](C3=CC4=C(C(=C3C5=C2C=C(C(=C5O)C(=O)NC(C)C(=O)O)C)O)C(=O)C6=C(C4=O)C(=CC(=C6)OC)O)O)O)O[C@H]7[C@@H]([C@H]([C@@H](CO7)O)O)O)O,,,,,,
1182,441183,Litomycin,C[C@@H]1[C@]2([C@@H](C[C@@H](O1)C3=C2C(=O)C4=C(C5=C([C@H]6[C@H](CC(=O)O6)OC5C)C(=C4C3=O)O)O)O)O,,,"['Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. (See all compounds classified as Antibiotics, Antineoplastic.)']",,,
1183,441184,Acarbosum,C[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@H](O[C@@H]([C@@H]([C@H]2O)O)O[C@@H]3[C@H](O[C@H]([C@@H]([C@H]3O)O)O)CO)CO)O)O)N[C@H]4C=C([C@@H]([C@@H]([C@H]4O)O)O)CO,,,['Compounds that inhibit or block the activity of GLYCOSIDE HYDROLASES such as ALPHA-AMYLASES and ALPHA-GLUCOSIDASES. (See all compounds classified as Glycoside Hydrolase Inhibitors.)'],"['In a study of 6 healthy men, less than 2% of an oral dose of acarbose was absorbed as active drug, while approximately 35% of total radioactivity from a 14C-labeled oral dose was absorbed. An average of 51% of an oral dose was excreted in the feces as unabsorbed drug-related radioactivity within 96 hours of ingestion. Because acarbose acts locally within the gastrointestinal tract, this low systemic bioavailability of parent compound is therapeutically desired.', 'Following oral dosing of healthy volunteers with 14C-labeled acarbose, peak plasma concentrations of radioactivity were attained 14-24 hours after dosing, while peak plasma concentrations of active drug were attained at approximately 1 hour. The delayed absorption of acarbose-related radioactivity reflects the absorption of metabolites that may be formed by either intestinal bacteria or intestinal enzymatic hydrolysis.', 'Acarbose is metabolized exclusively within the gastrointestinal tract, principally by intestinal bacteria, but also by digestive enzymes. A fraction of these metabolites (approximately 34% of the dose) was absorbed and subsequently excreted in the urine.', 'The fraction of acarbose that is absorbed as intact drug is almost completely excreted by the kidneys. When acarbose was given intravenously, 89% of the dose was recovered in the urine as active drug within 48 hours. In contrast, less than 2% of an oral dose was recovered in the urine as active (i.e., parent compound and active metabolite) drug. This is consistent with the low bioavailability of the parent drug.', 'For more Absorption, Distribution and Excretion (Complete) data for Acarbose (6 total), please visit the HSDB record page.']","['Acarbose is metabolized exclusively within the gastrointestinal tract, principally by intestinal bacteria, but also by digestive enzymes.  ... At least 13 metabolites have been separated chromatographically from urine specimens. The major metabolites have been identified as 4-methylpyrogallol derivatives (i.e., sulfate, methyl, and glucuronide conjugates). One metabolite (formed by cleavage of a glucose molecule from acarbose) also has alpha-glucosidase inhibitory activity. This metabolite, together with the parent compound, recovered from the urine, accounts for less than 2% of the total administered dose.']",['The plasma elimination half-life of acarbose activity is approximately 2 hours in healthy volunteers.']
1184,441185,1-[10-[3-[4-(2-Hydroxyethyl)piperazin-1-yl]propyl]phenothiazin-3-yl]ethanone,CC(=O)C1=CC2=C(C=C1)N(C3=CC=CC=C3S2)CCCN4CCN(CC4)CCO,,,,,,
1185,441186,"(4R)-N-[(1R,2R)-2-hydroxy-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide;hydrate;hydrochloride",CCC[C@@H]1CC(N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@@H](C)O.O.Cl,,,,,,
1186,441187,D-xylose 5-phosphate,C([C@H]([C@@H]([C@H](C=O)O)O)O)OP(=O)(O)O,,,,,,
1187,441188,"(2S)-4-amino-N-[(2S,3S,4R,5S)-5-amino-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide",C1[C@@H]([C@H]([C@@H]([C@H](C1NC(=O)[C@H](CCN)O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)O)N,,,,,,
1188,441189,Euphylline,CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N,,,"['Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)', 'Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)', 'Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases. (See all compounds classified as Phosphodiesterase Inhibitors.)', 'Compounds that bind to and block the stimulation of PURINERGIC P1 RECEPTORS. (See all compounds classified as Purinergic P1 Receptor Antagonists.)']",,,
1189,441190,Azithromycin hydrate,CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H](C([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O.O.O,,,,,,
1190,441191,CID 441191,CC1=C(N=C(N=C1N)[C@H](CC(=O)N)NC[C@@H](C(=O)N)N)C(=O)N[C@@H]([C@@H](C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)N[C@H](C)[C@H]([C@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O.OS(=O)(=O)[O-],,,,,,
1191,441192,CID 441192,CC1=C(N=C(N=C1N)[C@H](CC(=O)N)NC[C@@H](C(=O)N)N)C(=O)N[C@@H]([C@H](C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)N[C@@H](C)[C@H]([C@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O,,,,,,
1192,441193,Carbidopa-levodopa,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN.C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O,,,,,,
1193,441194,"(6R,7R)-7-[[2-amino-2-(4-hydroxyphenyl)-1-oxoethyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)C(C3=CC=C(C=C3)O)N)SC1)C(=O)O,,,,,,
1194,441195,CID 441195,CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)C(C4=CC=CC=C4)O)SC2)C(=O)[O-].[Na+],,,,,,
1195,441196,CID 441196,CC1=NN=C(S1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)CN4C=NN=N4)SC2)C(=O)[O-].O.O.O.O.O.[Na+],,,,,,
1196,441197,CID 441197,C=CC1=C(N2[C@H]([C@H](C2=O)NC(=O)C(=NOCC(=O)O)C3=CSC(=N3)N)SC1)C(=O)O,,,,,,
1197,441198,Cefotetan (disodium),CN1C(=NN=N1)SCC2=C(N3C([C@@](C3=O)(NC(=O)C4SC(=C(C(=O)N)C(=O)[O-])S4)OC)SC2)C(=O)[O-].[Na+].[Na+],,,,,,
1198,441199,Cefoxitin,CO[C@@]1([C@@H]2N(C1=O)C(=C(CS2)COC(=O)N)C(=O)O)NC(=O)CC3=CC=CS3,['For the treatment of serious infections caused by susceptible strains microorganisms.'],"['Cefoxitin is a cephamycin antibiotic often grouped with the second-generation cephalosporins. It is active against a broad range of gram-negative bacteria including anaerobes. The methoxy group in the 7a position provides cefoxitin with a high degree of stability in the presence of beta-lactamases, both penicillinases and cephalosporinases, of gram-negative bacteria.']",['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],"['Approximately 85 percent of cefoxitin is excreted unchanged by the kidneys over a 6-hour period, resulting in high urinary concentrations. Cefoxitin passes into pleural and joint fluids and is detectable in antibacterial concentrations in bile.']",['Minimal (approximately 85 percent of cefoxitin is excreted unchanged by the kidneys over a 6-hour period).'],['The half-life after an intravenous dose is 41 to 59 minutes.']
1199,441200,"(4R,5S,6R)-2,4,5,6-tetrahydroxycyclohex-2-en-1-one",C1=C(C(=O)[C@@H]([C@H]([C@@H]1O)O)O)O,,,,,,
1200,441201,2-deoxy-D-gluc-5-ulosonic acid,C([C@H]([C@@H](C(=O)CO)O)O)C(=O)O,,,,,,
1201,441202,6-phospho-5-dehydro-2-deoxy-D-gluconic acid,C([C@H]([C@@H](C(=O)COP(=O)(O)O)O)O)C(=O)O,,,,,,
1202,441203,trans-Platinum(II) diamminedichloride,N.N.Cl[Pt+2]Cl,"['For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.']","['Cisplatin is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands - directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Alkylating agents are cell cycle-nonspecific. Alkylating agents work by three different mechanisms all of which achieve the same end result - disruption of DNA function and cell death.']","['Reagents with two reactive groups, usually at opposite ends of the molecule, that are capable of reacting with and thereby forming bridges between side chains of amino acids in proteins; the locations of naturally reactive areas within proteins can thereby be identified; may also be used for other macromolecules, like glycoproteins, nucleic acids, or other. (See all compounds classified as Cross-Linking Reagents.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells. (See all compounds classified as Radiation-Sensitizing Agents.)']","['Following cisplatin doses of 20 to 120 mg/m^2, the concentrations of platinum are highest in liver, prostate, and kidney; somewhat lower in bladder, muscle, testicle, pancreas, and spleen; and lowest in bowel, adrenal, heart, lung, cerebrum, and cerebellum. Platinum is present in tissues for as long as 180 days after the last administration.', 'The parent compound, cisplatin, is excreted in the urine. Although small amounts of platinum are present in the bile and large intestine after administration of cisplatin, the fecal excretion of platinum appears to be insignificant.', 'Volume of distribution at steady state = 11-12 L/m^2', '15-16 L/h/m^2 [total body clearance, 7-hour infusion of 100 mg/m^2]']",,['Cisplatin decays monoexponentially with a half life of 20 to 30 minutes following administrations of 50 or 100 mg/m^2.  Cisplatin has a plasma half-life of 30 minutes. The complexes between albumin and the platinum from cisplatin do not dissociate to a significant extent and are slowly eliminated with a minimum half-life of five days or more.']
1203,441204,Dalacin (TN),CCC[C@@H]1C[C@H](N(C1)C)C(=O)NC([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)C(C)Cl.Cl,,,"['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)', 'Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)']",,,
1204,441205,"N-[2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide",CCCC1CC(N(C1)C)C(=O)NC([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)C(C)Cl,,,,,,
1205,441206,CID 441206,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC5C(C[C@]34C)C=NO5,,,,,,
1206,441207,Digitoxin,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5CC[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)C)C)C)O)O,"['For the treatment and management of congestive cardiac insufficiency, arrhythmias and heart failure.']","['Digitoxin is a cardiac glycoside sometimes used in place of DIGOXIN. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting (From Martindale, The Extra Pharmacopoeia, 30th ed, p665). It is eliminated hepatically making it useful in patients with poor or erratic kidney function, although it is now rarely used in practice. Digitoxin lacks the strength of evidence that digoxin has in the management of heart failure.']","['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)']","['Postmortem digitoxin levels in the choroid-retina and vitreous humor of patients who had undergone digitoxin therapy (therapeutic group) and in one case of suicidal digitoxin poisoning were measured and compared with levels in femoral vein blood, myocardium, kidney and liver. The results were interpreted in light of the medical history of each patient. The digitoxin level in the choroid-retina of the single case of suicidal poisoning was far higher than the choroid-retinal levels in the therapeutic group. In the latter, variation in choroid-retinal levels was comparable to that in the other tissues. In cases where the choroid-retina of the right and left eyes were examined, digitoxin levels in both eyes were essentially equal. There was no indication of significant changes in choroid-retinal levels due to postmortem diffusion of digitoxin into the vitreous body. Based on these results, determination of digitoxin levels in the choroid-retina could contribute to improving postmortem diagnosis of lethal digitoxin poisoning.', 'In cats ... 100% of digitoxin is absorbed in 80-100 min following duodenal admin ... digitalis glycosides are transported by blood ... bound to ... albumin, and in part free. ... Tissue distribution is not primarily to heart ... /highest concentration/ ... in excretory organs (liver, bile, intestinal tract, kidney) ... .', 'It is not predictably absorbed from gut of dogs... .', '...Prolonged biological half-life of digitoxin and its metabolites appears to depend on recirculation of free drug molecules after biliary excretion as glucuronide and sulfate conjugate.', 'For more Absorption, Distribution and Excretion (Complete) data for Digitoxin (14 total), please visit the HSDB record page.']","['Hepatic.', 'Eliminated by hepatic degradation ...to inactive genins ...Stepwise hydrolysis of 3 molecules of digitoxose converts glycoside to aglycone digitoxigenin, which is ...converted to inactive epidigitoxigenin. Because enterohepatic recirculation occurs, approx 25% of metabolic end products appear in stool.', 'Studies with various tissues of guinea pig showed that liver, kidney, and adrenal tissues converted digitoxin to digoxin.', 'Digitoxin in bile of rats was excreted largely in form of glucuronide of digitoxigenin monodigitoxoside.', 'Cardiac glycosides undergo varying degrees of hepatic metabolism, enterohepatic circulation, and renal filtration and reabsorption depending on their polarity and lipid solubility. ... Less polar glycosides such as digitoxin are metabolized extensively before they are excreted. Metabolism includes stepwise cleavage of the sugar molecules, hydroxylation, epimerization, and formation of glucuronide and sulfate conjugates. /Cardiac glycosides/', 'For more Metabolism/Metabolites (Complete) data for Digitoxin (6 total), please visit the HSDB record page.']","['The digitoxin half-life in elderly patients in the eight and ninth decade was more prolonged (mean +/- SD: 25 +/- 9 days) than in younger people (6.7 +/- 1.7). These elderly patients accumulated digitoxin even on a dose of 0.05 mg/ day. The symptoms of digitoxin intoxication disappeared on discontinuation of medication. When digitoxin is used in the treatment for heart failure in the very elderly patients, one should be aware of the possibility of digitoxin intoxication, even on a low dose.', 'After administration of 0.6 mg digitoxin mean serum digitoxin half-life of 4.3 days and 8.1 days respectively observed in cholecystectomized heart patients and control subjects.', 'The elimination half-life of digitoxin is usually 5-7 days, but may range from 4-14 days. The elimination half-life of digitoxin is generally unchanged in patients with renal failure. In patients with biliary fistulas, plasma half-life is decreased by about 50%. Variability among patients in the degree of enterohepatic recycling of digitoxin may account for part of the variability in plasma half-life in some patients. The elimination half-life of digitoxin is prolonged in hypothyroid patients and decreased in hyperthyroid patients.']"
1207,441208,(2S)-1-[(2R)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H](C)C(=O)N2CCC[C@H]2C(=O)O,,,,,,
1208,441209,Spirodilactone,C1CC2(C3=CC=CC=C3C(=O)O2)OC1=O,,,,,,
1209,441210,"(1S,2S,8S,9S,11S,12S,13R,19S)-19-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one",C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC4[C@]2(OC(O4)(C)C)C(=O)CO)C[C@@H](C5=CC(=O)C=C[C@]35C)F)O,,,,,,
1210,441211,But-2-enedioic acid;2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethanol,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO.C(=CC(=O)O)C(=O)O,,,,,,
1211,441212,3'-dehydro-ATP,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H](C(=O)[C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)N,,,,,,
1212,441213,3'-Keto-3'-deoxy-AMP,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H](C(=O)[C@H](O3)COP(=O)(O)O)O)N,,,,,,
1213,441214,"[(2S,4R,5R)-3-amino-5-(6-aminopurin-9-yl)-4-hydroxyoxolan-2-yl]methyl dihydrogen phosphate",C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H](C([C@H](O3)COP(=O)(O)O)N)O)N,,,,,,
1214,441215,"[(2S,4R,5R)-3-[[2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-5-(6-aminopurin-9-yl)-4-hydroxyoxolan-2-yl]methyl dihydrogen phosphate",C1=CC(=CC=C1CC(C(=O)NC2[C@H](O[C@H]([C@@H]2O)N3C=NC4=C(N=CN=C43)N)COP(=O)(O)O)N)O,,,,,,
1215,441216,"[(2S,4R,5R)-3-[[2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-5-(6-aminopurin-9-yl)-4-hydroxyoxolan-2-yl]methyl dihydrogen phosphate",CC(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC2[C@H](O[C@H]([C@@H]2O)N3C=NC4=C(N=CN=C43)N)COP(=O)(O)O,,,,,,
1216,441217,"[(2S,4R,5R)-3-[[2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-4-hydroxy-5-[6-(methylamino)purin-9-yl]oxolan-2-yl]methyl dihydrogen phosphate",CC(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC2[C@H](O[C@H]([C@@H]2O)N3C=NC4=C(N=CN=C43)NC)COP(=O)(O)O,,,,,,
1217,441218,"[(2S,4R,5R)-3-[[2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-5-[6-(dimethylamino)purin-9-yl]-4-hydroxyoxolan-2-yl]methyl dihydrogen phosphate",CC(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC2[C@H](O[C@H]([C@@H]2O)N3C=NC4=C3N=CN=C4N(C)C)COP(=O)(O)O,,,,,,
1218,441219,"2-acetamido-N-[(2S,4R,5R)-5-[6-(dimethylamino)purin-9-yl]-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]-3-(4-hydroxyphenyl)propanamide",CC(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC2[C@H](O[C@H]([C@@H]2O)N3C=NC4=C3N=CN=C4N(C)C)CO,,,,,,
1219,441220,"2-acetamido-N-[(2S,4R,5R)-5-[6-(dimethylamino)purin-9-yl]-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]-3-(4-methoxyphenyl)propanamide",CC(=O)NC(CC1=CC=C(C=C1)OC)C(=O)NC2[C@H](O[C@H]([C@@H]2O)N3C=NC4=C3N=CN=C4N(C)C)CO,,,,,,
1220,441221,CID 441221,C[C@@H](C1[C@H]2CC(=C(N2C1=O)C(=O)O)SCCN=CN)O.CC1(C[C@@H]1C(=O)NC(=CCCCCSC[C@H](C(=O)O)N)C(=O)O)C,,,,,,
1221,441222,CID 441222,C[C@@H](C1[C@H]2CC(=C(N2C1=O)C(=O)O)SCCN=CN)O,,,,,,
1222,441223,"1,4:3,6-Dianhydro-L-glucitol",C1[C@H]([C@H]2[C@@H](O1)[C@H](CO2)O)O,,,,,,
1223,441224,"trans-2-Hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane",C1[C@@H](O[C@H](S1)CO)N2C=CC(=NC2=O)N,,,,,,
1224,441225,"3-Ethenylcyclohexa-3,5-diene-1,2-diol",C=CC1=CC=CC(C1O)O,,,,,,
1225,441226,"2,3-Dihydroxy Styrene",C=CC1=C(C(=CC=C1)O)O,,,,,,
1226,441227,"2-Hydroxy-6-oxo-octa-2,4,7-trienoic acid",C=CC(=O)C=CC=C(C(=O)O)O,,,,,,
1227,441228,"3,5-Cyclohexadiene-1,2-diol, 3,6-dichloro-",C1=C(C(C(C(=C1)Cl)O)O)Cl,,,,,,
1228,441229,CID 441229,C(=C(C(=O)O)Cl)C=C(C(=O)O)Cl,,,,,,
1229,441230,Benzoyl acetyl-CoA; (Acyl-CoA); [M+H]+,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)CC(=O)C4=CC=CC=C4)O,,,,,,
1230,441231,"2-Hydroxy-6-oxoocta-2,4-dienoic acid",CCC(=O)C=CC=C(C(=O)O)O,,,,,,
1231,441232,S-Tipc,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@H](C3=CSC=C3)C(=O)O)C(=O)O)C,,,,,,
1232,441233,(1R)-2-phenylcyclopropan-1-amine,C1[C@H](C1C2=CC=CC=C2)N,,,"['Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)', 'Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. (See all compounds classified as Antidepressive Agents.)', 'A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed, p414) (See all compounds classified as Monoamine Oxidase Inhibitors.)']","['THE MAO INHIBITORS ARE ABSORBED READILY WHEN GIVEN BY MOUTH. THESE DRUGS PRODUCE MAXIMAL INHIBITION OF MAO WITHIN 5-10 DAYS. ... ALTHOUGH THEIR BIOLOGICAL ACTIVITY IS PROLONGED BECAUSE OF THE CHARACTERISTICS OF THEIR INTERACTION WITH THE ENZYME, THEIR CLINICAL EFFICACY APPEARS TO BE REDUCED WHEN THE DRUG IS GIVEN LESS FREQUENTLY THAN ONCE DAILY. /MAO INHIBITORS/']",,
1233,441234,"(2,2,3-Trimethyl-5-oxocyclopent-3-en-1-yl)acetic acid",CC1=CC(=O)C(C1(C)C)CC(=O)O,,,,,,
1234,441235,c0411; (Acyl-CoA); [M+H]+,CC1=CC(=O)C(C1(C)C)CC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=CN=C43)N)O)OP(=O)(O)O)O,,,,,,
1235,441236,Trimeprazine tartrate,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)CN(C)C.CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)CN(C)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,,,"['Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)']",,,
1236,441237,CID 441237,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C3=C(C=CC=C3OC)OC)C(=O)[O-])C.O.[Na+],,,,,,
1237,441238,"[[(2S,3S,5R)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]amino]azaniumylideneazanide",CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N[NH+]=[N-],,,,,,
1238,441239,"1-[(2R,4S,5S)-4-(aminodiazenyl)-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione",CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=NN,,,,,,
1239,441240,(4R)-4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one,CN(C)CCC1=CNC2=C1C=C(C=C2)C[C@@H]3COC(=O)N3,,,,,,
1240,441241,CID 441241,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)NC(=O)N4CCN(C4=O)S(=O)(=O)C)C(=O)[O-])C.[Na+],,,,,,
1241,441242,Moxalactam disodium,CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)C(C4=CC=C(C=C4)O)C(=O)[O-])OC)OC2)C(=O)[O-].[Na+].[Na+],,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
1242,441243,Saquinavir,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,"['Saquinavir is indicated, in combination with ritonavir and other antiretroviral agents, for the treatment of HIV-1 infection in patients 16 years of age and older.']","['Saquinavir exerts its antiviral activity by inhibiting an enzyme critical for the HIV-1 viral lifecycle. Like other protease inhibitors, saquinavir has a propensity for participating in drug interactions - use caution when administering saquinavir to patients maintained on other pharmaceutical agents as pharmacodynamic and pharmacokinetic interactions are common. Saquinavir is known to increase the QTc-interval in otherwise healthy individuals, and should therefore be used with caution in patients maintained on other QTc-prolonging medications or for whom prolongation of the QTc-interval may be of particular consequence (e.g. patients with pre-existing heart disease). Careful and regular monitoring of patient bloodwork is recommended, as saquinavir has been associated with the development of metabolic complications (e.g. diabetes mellitus, hyperlipidemia) and worsening of pre-existing liver disease.']","['Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP3A. (See all compounds classified as Cytochrome P-450 CYP3A Inhibitors.)', 'Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. (See all compounds classified as HIV Protease Inhibitors.)']","[""The absolute bioavailability of orally administered saquinavir is only ~4%, thought to be a consequence of incomplete absorption and extensive first-pass metabolism. It is co-administered with ritonavir, another protease inhibitor and a potent inhibitor of the enzymes responsible for saquinavir's first-pass metabolism, in order to dramatically boost its serum concentrations and, by extension, its therapeutic efficacy. Following administration of saquinavir 1000mg twice daily with ritonavir 100mg twice daily the AUC<sub>24h</sub> at steady-state was 39026 ng.h/mL."", ""The primary means of elimination of saquinavir appears to be extensive hepatic metabolism followed by fecal excretion of both the parent drug and metabolic products. Following the administration of radiolabeled saquinavir (both orally and intravenously), approximately 81-88% of radioactivity is recovered in the feces within 5 days of dosing while only 1-3% is recovered in the urine. Mass balance studies indicate that only 13% of orally-administered plasma radioactivity is attributed to unchanged parent drug, with the remainder comprising metabolic products of saquinavir's hepatic metabolism. In contrast, intravenous administration resulted in approximately 66% of the circulating plasma radioactivity being attributed to unchanged parent drug, suggesting a high degree of first-pass metabolism with oral administration."", 'The steady-state volume of distribution of saquinavir is approximately 700 L, suggesting extensive distribution into tissues.', 'The systemic clearance of saquinavir is approximately 1.14 L/h/kg following intravenous administration.', 'Following administration of saquinavir in a dosage of 1200 mg 3 times daily as liquid-filled capsules, mean steady-state AUC at 3 weeks was 7249 ngh/mL compared with an AUC of 866 ngh/mL reported following administration of saquinavir hard gelatin capsules in a dosage of 600 mg 3 times daily. While the AUC of saquinavir in adults receiving liquid-filled capsules was lower at week 61-69 compared with the AUC at week 3, the AUC at week 61-69 was greater than the AUC at the same time point in HIV-infected adults receiving saquinavir as hard gelatin capsules (600 mg 3 times daily).', 'The relative oral bioavailability of saquinavir from liquid-filled (soft gelatin) capsules is estimated to average 331% (range: 207-530%) of that achieved with hard gelatin capsules of the drug when single 600-mg doses are administered. This would represent a calculated average oral bioavailability from the liquid-filled capsules of about 13% based on an average absolute bioavailability of 4% from the hard capsules; however, these are calculated estimates and not based on actual determination of absolute oral bioavailability from the liquid-filled capsules.', 'Saquinavir and its metabolites are eliminated from the body primarily through the biliary system and feces (more than 95% of the drug), with minimal urinary excretion (less than 3% of administered drug).', 'Oral bioavailability of the hard-gelatin capsule formulation of saquinavir (saquinavir mesylate, invirase) is only 4% due to limited absorption and extensive first-pass metabolism, with considerable interpatient variability. ... Absorption of saquinavir may be enhanced when the drug is taken with a high-calorie, high-fat meal. In addition, saquinavir demonstrates a greater than dose-proportional increase in exposure. For example, tripling the oral dose of saquinavir is associated with an eightfold increase in exposure.', 'For more Absorption, Distribution and Excretion (Complete) data for SAQUINAVIR (10 total), please visit the HSDB record page.']","['Saquinavir is extensively metabolized in the liver following oral administration, and _in vitro_ studies have shown that >90% of its biotransformation is mediated by the CYP3A4 isoenzyme. Saquinavir is rapidly metabolized to a number of inactive mono- and di-hydroxylated compounds.', 'Results of in vitro studies indicate that saquinavir is rapidly metabolized in the liver to several monohydroxylated and dihydroxylated inactive metabolites. Metabolism of saquinavir is mediated by cytochrome P450; the isoenzyme CYP3A4 is involved in more than 90% of this metabolism. Orally administered saquinavir appears to undergo substantial metabolism on first pass through the liver.', 'Saquinavir is metabolized primarily by hepatic CYP3A4. The metabolites of saquinavir are not active against HIV-1.', 'Saquinavir has known human metabolites that include (2S)-N-[(2S,3R)-4-[(3S,4aR,8aS)-3-(tert-butylcarbamoyl)-6-hydroxy-decahydroisoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-[(quinolin-2-yl)formamido]butanediamide, (2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-7-hydroxy-decahydroisoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-[(quinolin-2-yl)formamido]butanediamide, and (2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-[(1-hydroxy-2-methylpropan-2-yl)carbamoyl]-decahydroisoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-[(quinolin-2-yl)formamido]butanediamide.']",
1243,441244,Silver sulfadiazine,C1=CN=C(N=C1)[N-]S(=O)(=O)C2=CC=C(C=C2)N.[Ag+],['Indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second- and third-degree burns.'],['Silver sulfadiazine has broad antimicrobial activity. It is bactericidal for many gram- negative and gram-positive bacteria as well as being effective against yeast. Silver sulfadiazine is not a carbonic anhydrase inhibitor and may be useful in situations where such agents are contraindicated.'],"['Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from DISINFECTANTS, which are used on inanimate objects. (See all compounds classified as Anti-Infective Agents, Local.)']",['Very limited penetration through the skin. Only when applied to very large area burns is absorption into the body generally an issue.'],,
1244,441245,"Limonene-1,2-epoxide",CC(=C)[C@@H]1CCC2(C(C1)O2)C,,,,,,
1245,441246,"(1S,2S,4R)-Limonene-1,2-diol",CC(=C)[C@@H]1CC[C@]([C@H](C1)O)(C)O,,,,,,
1246,441247,thymidine 5'-[3-(6-deoxy-D-galactopyranosyl) dihydrogen diphosphate],C[C@@H]1[C@@H]([C@@H]([C@H](C(O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)O)O)O,,,,,,
1247,441248,beta-D-Galp-(1->3)-D-GalpNAc,CC(=O)N[C@@H]1[C@H]([C@H]([C@H](OC1O)CO)O)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O)O,,,,,,
1248,441249,(1->3)-beta-D-Galactopyranans,C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)OC2[C@H]([C@H](O[C@H]([C@@H]2O)O)CO)O)O)OC3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)O)O)O)O,,,,,,
1249,441250,CID 441250,C1[C@@H]([C@@H]([C@H](C(O1)O[C@H]2[C@H]([C@H](OC([C@@H]2O)O)CO)O)O)O)O,,,,,,
1250,441251,7-O-Methylluteone,CC(=CCC1=C(C=C2C(=C1O)C(=O)C(=CO2)C3=C(C=C(C=C3)O)O)OC)C,,,,,,
1251,441252,"4,8,12-Trimethyltridecanoyl-CoA; (Acyl-CoA); [M+H]+",CC(C)CCCC(C)CCCC(C)CCC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
1252,441253,3-Oxopristanoyl-CoA; (Acyl-CoA); [M+H]+,CC(C)CCCC(C)CCCC(C)CCC(=O)C(C)C(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
1253,441254,(R)-Mandelamide,C1=CC=C(C=C1)[C@H](C(=O)N)O,,,,,,
1254,441255,3-Hydroxy-3-(3-hydroxy-4-methoxyphenyl)propionyl-CoA,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)CC(C4=CC(=C(C=C4)OC)O)O)O,,,,,,
1255,441256,CID441256; (Acyl-CoA); [M+H]+,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)CC(C4=CC(=C(C=C4)O)OC)O)O,,,,,,
1256,441257,Deacetylisoipecoside,COC(=O)C1=CO[C@H]([C@@H]([C@@H]1C[C@H]2C3=CC(=C(C=C3CCN2)O)O)C=C)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O,,,,,,
1257,441258,Octreotide diacetate,CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O.CC(=O)O.CC(=O)O,,,,,,
1258,441259,Deacetylipecoside,COC(=O)C1=CO[C@H]([C@@H]([C@@H]1C[C@@H]2C3=CC(=C(C=C3CCN2)O)O)C=C)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O,,,,,,
1259,441260,(2S)-2-amino-3-oxo-4-(phosphonooxy)butanoic acid,C(C(=O)[C@@H](C(=O)O)N)OP(=O)(O)O,,,,,,
1260,441261,"2-[2-(4-Dibenzo[b, f][1,4]thiazepin-11-ylpiperazin-1-yl)ethoxy]ethanol hemifumarate",C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C(=CC(=O)O)C(=O)O,,,"['Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)', 'Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. (See all compounds classified as Antidepressive Agents.)']",,,
1261,441262,"9,12-Octadecadienoic acid, 11-hydroperoxy-, (9Z,11S,12Z)-",CCCCCC=C[C@@H](C=CCCCCCCCC(=O)O)OO,,,,,,
1262,441263,"{[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-2-({[hydroxy({hydroxy[3-hydroxy-3-({2-[(2-{[(3S,7R,11R)-2-hydroxy-3,7,11,15-tetramethylhexadecanoyl]sulfanyl}ethyl)carbamoyl]ethyl}carbamoyl)-2,2-dimethylpropoxy]phosphoryl}oxy)phosphoryl]oxy}methyl)oxolan-3-yl]oxy}phosphonic acid",C[C@H](CCC[C@H](C)CCCC(C)C)CCC[C@H](C)C(C(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O)O,,,,,,
1263,441264,"(3S,4R,6S)-3-ethenyl-6-[(R)-hydroxy(6-methoxyquinolin-4-yl)methyl]-1-azabicyclo[2.2.2]octan-3-ol",COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@H]4CCN3C[C@@]4(C=C)O)O,,,,,,
1264,441265,Trimethyl(2-oxoethyl)azanium;hydrate,C[N+](C)(C)CC=O.O,,,,,,
1265,441266,Thiophene-2-carbonyl-CoA; (Acyl-CoA); [M+H]+,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)C4=CC=CS4)O,,,,,,
1266,441267,"S-[2-[3-[[4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] 5-hydroxythiophene-2-carbothioate",CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)C4=CC=C(S4)O)O,,,,,,
1267,441268,CID 441268,CC12[C@H]([C@H](CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)NC)O,,,,,,
1268,441269,"3-Methyl-1-(2,4,6-trihydroxyphenyl)butan-1-one",CC(C)CC(=O)C1=C(C=C(C=C1O)O)O,,,,,,
1269,441270,CID 441270,CCCCCC=CCC=C[C@@H]([C@@H](CCCCCC(=O)O)O)O,,,,,,
1270,441271,CID 441271,CCCCCCCCC=C[C@@H]([C@@H](CCCCCC(=O)O)O)O,,,,,,
1271,441272,CID 441272,CCC=CCC=CCC=C[C@@H]([C@@H](CCCCCC(=O)O)O)O,,,,,,
1272,441273,CID 441273,CC(C)NC(=O)C1=CC=C(C=C1)CN[NH2+]C.[Cl-],,,,,,
1273,441274,Dextropropoxyphene (isomer hydrochloride),CCC(=O)O[C@](CC1=CC=CC=C1)(C2=CC=CC=C2)[C@@H](C)CN(C)C.Cl,,,,,,
1274,441275,Isopropoxyphene,CCC(=O)O[C@](CC1=CC=CC=C1)(C2=CC=CC=C2)[C@@H](C)CN(C)C,,,,,,
1275,441276,Pharmakon1600-01503908,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@](C3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,,,,,,
1276,441277,Pentazocine hydrochloride,C[C@H]1[C@H]2CC3=C([C@@]1(CCN2CC=C(C)C)C)C=C(C=C3)O.Cl,,,"['Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)', 'Agents inhibiting the effect of narcotics on the central nervous system. (See all compounds classified as Narcotic Antagonists.)', 'Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. (See all compounds classified as Narcotics.)', 'Agents that are administered in association with anesthetics to increase effectiveness, improve delivery, or decrease required dosage. (See all compounds classified as Adjuvants, Anesthesia.)']",,,
1277,441278,Pentazocine,C[C@H]1[C@H]2CC3=C([C@@]1(CCN2CC=C(C)C)C)C=C(C=C3)O,['For the relief of moderate to severe pain.'],"['Pentazocine is a potent analgesic which when administered orally in a 50 mg dose appears equivalent in analgesic effect to 60 mg (1 grain) of codeine. Onset of significant analgesia usually occurs between 15 and 30 minutes after oral administration, and duration of action is usually three hours or longer. Onset and duration of action and the degree of pain relief are related both to dose and the severity of pretreatment pain. Pentazocine weakly antagonizes the analgesic effects of morphine and meperidine; in addition, it produces incomplete reversal of cardiovascular, respiratory, and behavioral depression induced by morphine and meperidine. Pentazocine has about 1/50 the antagonistic activity of nalorphine. It also has sedative activity.']","['Agents that are administered in association with anesthetics to increase effectiveness, improve delivery, or decrease required dosage. (See all compounds classified as Adjuvants, Anesthesia.)', 'Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)', 'Agents inhibiting the effect of narcotics on the central nervous system. (See all compounds classified as Narcotic Antagonists.)', 'Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. (See all compounds classified as Narcotics.)']","['Well absorbed from the gastro-intestinal tract.', 'TRACE AMT OF PENTAZOCINE AND ITS METABOLITES CAN BE DETECTED IN URINE FOR SEVERAL DAYS AFTER A SINGLE ADMIN OF THE DRUG. /PENTAZOCINE LACTATE/', '... DOSE FOR DOSE, BLOOD CONCN & URINARY EXCRETION RATES OF PENTAZOCINE WERE LOWER AFTER ORAL & RECTAL DOSAGE THAN AFTER IV DOSAGE TO MAN. FECAL RECOVERY WAS LOW EVEN AFTER RECTAL DOSING, SUGGESTING THAT REDUCED AVAILABILITY MAY BE DUE TO INTESTINAL OR HEPATIC CLEARANCE DURING ABSORPTION.', 'PENTAZOCINE ENTERS THE CSF RAPIDLY FROM PLASMA AND CSF:PLASMA RATIOS, WHICH VARIED FROM 0.2 TO 0.6 BETWEEN 2 AND 3 HR AFTER IV DOSES, AGREED WELL WITH THE RATIO OF UNBOUND:TOTAL PENTAZOCINE IN PLASMA.', 'PENTAZOCINE IS WELL ABSORBED BY ALL ROUTES OF ADMIN, BUT THERE IS CONSIDERABLE INDIVIDUAL VARIATION. BIOAVAILABILITY AFTER ORAL ADMIN IS 18.4% +/- 7.8%; THE REDUCTION IS DUE TO FIRST-PASS METABOLISM.', 'For more Absorption, Distribution and Excretion (Complete) data for PENTAZOCINE (7 total), please visit the HSDB record page.']","['Hepatic', 'PENTAZOCINE YIELDS 1,2,3,4,5,6-HEXAHYDRO-8-HYDROXY- ALPHA,6(EQ),11(AX)-TRIMETHYL-2,6-METHANO-3-BENZAZOCINE-3-CIS-2-BUTEN-1-OL & 1,2,3,4,5,6-HEXAHYDRO-8-HYDROXY-ALPHA,6(EQ),11(AX)- TRIMETHYL-2,6-METHANO-3-BENZAZOCINE-3-TRANS-2-BUTEN-1-OL IN MONKEY & MOUSE. /FROM TABLE/', '... RATE OF METABOLISM OF PENTAZOCINE HAS BEEN SHOWN TO DIFFER /BETWEEN/ SMOKERS & NON-SMOKERS.', 'IN THE RAT, AFTER ORAL ADMIN OF PENTAZOCINE, MAINLY PENTAZOCINE & ITS GLUCURONIDE CONJUGATES WERE FOUND IN URINE. ALTHOUGH EIGHT METABOLITES WERE EXTRACTED FROM URINE & CHARACTERIZED ... THE AMOUNTS WERE SMALL AND INDICATED HYDROXYLATION AND METHOXYLATION OF THE AROMATIC RING, WITH SOME OXIDN OF THE DIMETHYLALLYL SIDE-CHAIN.', 'Pentazocine is metabolized in the liver, mainly by oxidation of the terminal methyl groups of the dimethyl alkyl side chain to form alcoholic and carboxylic acid metabolites; glucuronide conjugation also occurs.']","['2 to 3 hours', 'THE HALF-LIFE IN PLASMA IS 4-5 HR.', 'The elimination half-life is 203 +/- 71 min following iv admin & 177 +/- 34 min following oral admin. /Pentazocine hydrochloride; pentazocine lactate/']"
1278,441279,CID 441279,C[NH2+]C[C@@H](C1=CC(=CC=C1)O)O.[Cl-],,,,,,
1279,441280,diaminomethylidene-[2-(1H-imidazol-5-yl)ethyl]azanium,C1=C(NC=N1)CC[NH+]=C(N)N,,,,,,
1280,441281,"2-(diphenylmethoxy)-N,N-dimethylethanaminium 8-chloro-1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydropurin-7-ide",CN1C(=C2C(=NC(=N2)Cl)N(C1=O)C)[O-].C[NH+](C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
1281,441282,CID 441282,CC(=C(O)O)C=CC(=O)C(=O)O,,,,,,
1282,441283,2-Methyl-5-oxohex-3-enedioic acid,CC(C=CC(=O)C(=O)O)C(=O)O,,,,,,
1283,441284,6-Methylergoline,CN1CCC[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34,,,,,,
1284,441285,"6-Methyl-9,10-didehydroergoline-8-carboxylic acid",CN1CC(C=C2[C@H]1CC3=CNC4=CC=CC2=C34)C(=O)O,,,,,,
1285,441286,"Ergoline-8-carboxamide, 9,10-didehydro-N-(2-hydroxy-1-methylethyl)-6-methyl-, (8beta)-",CC(CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C,,,,,,
1286,441287,"(6aR,9R)-N-[(1S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide",CC1(C(=O)N2C(C(=O)N3CCC[C@H]3C2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C,,,,,,
1287,441288,"(6aR,9R)-N-[(1S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide",CC(C)CC1C(=O)N2CCC[C@H]2C3(N1C(=O)C(O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=CNC7=CC=CC(=C67)C5=C4)C)O,,,,,,
1288,441289,Pancuronium,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1[N+]4(CCCCC4)C)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C,['Used as a muscle relaxant during anesthesia and surgical procedures.'],"['Pancuronium is a non-depolarising muscle relaxant similar to curare. It acts as a competitive acetylcholine antagonist on neuromuscular junctions, displacing acetylcholine (hence competitive) from its post-synaptic nicotinic acetylcholine receptors. It is, unlike suxamethonium, a non-depolarising agent, which means, that it causes no spontaneous depolarisations upon association with the nicotinic receptor in neuromuscular junction, thus producing no muscle fasciculations upon administration. Pancuronium has no hormonal activity. It exerts slight vagolytic activity (i.e. diminishing activity of the vagus nerve) and no ganglioplegic (i.e., blocking ganglions) activity.']","['Drugs that bind to nicotinic cholinergic receptors (RECEPTORS, NICOTINIC) and block the actions of acetylcholine or cholinergic agonists. Nicotinic antagonists block synaptic transmission at autonomic ganglia, the skeletal neuromuscular junction, and at central nervous system nicotinic synapses. (See all compounds classified as Nicotinic Antagonists.)', 'Drugs that interrupt transmission at the skeletal neuromuscular junction without causing depolarization of the motor end plate. They prevent acetylcholine from triggering muscle contraction and are used as muscle relaxants during electroshock treatments, in convulsive states, and as anesthesia adjuvants. (See all compounds classified as Neuromuscular Nondepolarizing Agents.)']","['241 to 280 mL/kg', 'Plasma cl=1.1–1.9 mL/minute/kg', 'BOTH LIVER & KIDNEYS ARE INVOLVED IN DEGRADATION & EXCRETION OF ... PANCURONIUM ...', 'AFTER IV INJECTION, EFFECTS...BECOME MAXIMAL IN LESS THAN 3 MIN IN ADULTS & 90 SEC IN CHILDREN. ... PLASMA HALF-LIFE IS PROBABLY SLIGHTLY LESS THAN 2 HR. PANCURONIUM IS MOSTLY EXCRETED UNCHANGED INTO URINE.', 'PLACENTAL TRANSFER OF...PANCURONIUM BROMIDE...OCCURS RAPIDLY AFTER ADMIN TO MOTHERS, BUT FETAL:MATERNAL DRUG CONCN RATIO ARE VERY LOW.', 'PLASMA LEVELS OF PANCURONIUM OBEYED TWO-COMPARTMENT KINETICS IN SEVEN PATIENTS ON IV INJECTION & THE BETA-PHASE HALF-TIME VARIED BETWEEN 90 AND 162 MIN. THE MEAN VOLUME OF THE CENTRAL COMPARTMENT WAS 100 ML/KG, WHILE THE OVERALL DISTRIBUTION VOLUME WAS 261 MG/KG. IN PATIENTS WITH CHRONIC RENAL FAILURE, THE PLASMA CLEARANCE...WAS SIGNIFICANTLY REDUCED, WHILE VOLUMES OF BOTH THE OVERALL & CENTRAL COMPARTMENTS WERE SIGNIFICANTLY INCREASED.', 'For more Absorption, Distribution and Excretion (Complete) data for PANCURONIUM BROMIDE (6 total), please visit the HSDB record page.']","['Hepatic.', 'IN CATS, 8 HR AFTER IV INJECTION OF PANCURONIUM BROMIDE, UNCHANGED PANCURONIUM BROMIDE IN URINE, BILE, & LIVER ACCOUNTED FOR 58% OF DOSE, 3-HYDROXY-DERIV FOR 14.5%, 17-HYDROXY-DERIV FOR 7% & 3,17-DIHYDROXY-DERIV FOR 4.5%.']","['1.5 to 2.7 hours.', 'PLASMA HALF-LIFE IS PROBABLY SLIGHTLY LESS THAN 2 HR.']"
1289,441290,Rocuronium,CC(=O)O[C@H]1[C@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C,"['For inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.']","['Neuromuscular blocking agents are drugs that cause skeletal muscle relaxation primarily by causing a decreased response to the neurotransmitter acetylcholine (ACh) at the myoneural (neuromuscular) junction of skeletal muscle. At that site, ACh normally produces electrical depolarization of the postjunctional membrane of motor end-plate, which leads to conduction of muscle action potential and subsequently induces skeletal muscle contraction. Neuromuscular agents are classified as depolarizing or nondepolarizing. Rocuronium is a nondepolarizing neuromuscular blocking agent with a rapid to intermediate onset depending on dose and intermediate duration. Rocuronium, like vecuronium is longer acting in infants than in children. However, unlike vecuronium, rocuronium retains the characteristics of an intermediate-acting NMBD in infants.']","['Drugs that interrupt transmission at the skeletal neuromuscular junction without causing depolarization of the motor end plate. They prevent acetylcholine from triggering muscle contraction and are used as muscle relaxants during electroshock treatments, in convulsive states, and as anesthesia adjuvants. (See all compounds classified as Neuromuscular Nondepolarizing Agents.)']","['Poorly absorbed from the GI tract.', 'Studies of distribution, metabolism, and excretion in cats and dogs indicate that rocuronium is eliminated primarily by the liver.', '0.3 L/kg [3 to <12 mos]', '0.25 L/kg/hr [Adults (Ages 27 to 58 years)]']","['Rocuronium is metabolized to a less active metabolite, 17-desacetyl-rocuronium, and is eliminated primarily by the liver.']","['The rapid distribution half-life is 1-2 minutes and the slower distribution half-life is 14-18 minutes. Renal impairment has no net effect on half-life, however, half-life is almost doubled in patients with impaired liver function.']"
1290,441291,"3-(3,4-Dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrate",CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN.O,,,,,,
1291,441292,N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentyl]-N'-(5-aminopentyl)-N'-hydroxybutanediamide;iron(3+),CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O.[Fe+3],,,"['Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)', 'Organic chemicals that form two or more coordination links with an iron ion. Once coordination has occurred, the complex formed is called a chelate. The iron-binding porphyrin group of hemoglobin is an example of a metal chelate found in biological systems. (See all compounds classified as Iron Chelating Agents.)']",,,
1292,441293,"(1R,3R,8S,10R,13S,16S,17R)-8-tert-butyl-6,17-dihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione",C[C@@H]1C(=O)O[C@@H]2[C@]1([C@@]34C(=O)O[C@H]5C3(C2)C6([C@@H](C5)C(C)(C)C)[C@H](O4)OC(=O)C6O)O,,,,,,
1293,441294,"(1R,3R,8S,10R,13S,16S,17R)-8-tert-butyl-6,12,17-trihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione",C[C@@H]1C(=O)O[C@@H]2[C@]1([C@@]34C(=O)O[C@H]5C3(C2O)C6([C@@H](C5)C(C)(C)C)[C@H](O4)OC(=O)C6O)O,,,['Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. (See all compounds classified as Fibrinolytic Agents.)'],,,
1294,441295,CID 441295,C[C@@H]1C(=O)O[C@@H]2[C@]1([C@@]34C(=O)O[C@H]5C3(C2O)C6([C@@H]([C@H]5O)C(C)(C)C)[C@H](O4)OC(=O)C6O)O,,,,,,
1295,441296,CID 441296,C[C@@H]1C(=O)O[C@@H]2[C@]1([C@@]34C(=O)O[C@H]5C3(C2)C6([C@@H]([C@H]5O)C(C)(C)C)[C@H](O4)OC(=O)C6O)O,,,,,,
1296,441297,"(1S,4S,9R,11S)-9-tert-butyl-7,9-dihydroxy-3,5,12-trioxatetracyclo[6.6.0.01,11.04,8]tetradecane-2,6,13-trione",CC(C)(C)[C@@]1(C[C@H]2[C@@]3(C14[C@H](OC(=O)C4O)OC3=O)CC(=O)O2)O,,,,,,
1297,441298,Hyperforin,CC(C)C(=O)[C@]12C(=O)C(=C([C@](C1=O)(C[C@@H]([C@@]2(C)CCC=C(C)C)CC=C(C)C)CC=C(C)C)O)CC=C(C)C,,"[""Hyperforin is believed to be the primary active constituent responsible for the antidepressant and anxiolytic properties of the extracts of St. John's wort. It acts as a reuptake inhibitor of monoamines, including serotonin, norepinephrine, dopamine, and of GABA and glutamate, with IC50 values of 0.05-0.10 mcg/ml for all compounds, with the exception of glutamate, which is in the 0.5 mcg/ml range. It appears to exert these effects by activating the transient receptor potential ion channel TRPC6. Activation of TRPC6 induces the entry of sodium and calcium into the cell which causes inhibition of monoamine reuptake. Hyperforin is also thought to be responsible for the induction of the cytochrome P450 enzymes CYP3A4 and CYP2C9 by binding to and activating the pregnane X receptor (PXR).""]",,"['Validated analytical methods suitable for determining hyperforin in plasma after administration of alcoholic Hypericum perforatum extracts containing hyperforin are described. After oral administration of 300 mg/kg Hypericum extract (WS 5572, containing 5% hyperforin) to rats maximum plasma levels of approximately 370 ng/ml (approx. 690 nM) were reached after 3 hr, as quantified by a HPLC and UV detection method. Estimated half-life and clearance values were 6 hr and 70 ml/min/kg respectively. Since therapeutic doses of Hypericum extracts are much lower than that used in rats, a more sensitive LC/MS/MS method was developed. The lower limit of quantification of this method was 1 ng/ml. Using this method, plasma levels of hyperforin could be followed for up to 24 hr in healthy volunteers after administration of film coated tablets containing 300 mg hypericum extracts representing 14.8 mg hyperforin. The maximum plasma levels of approximately 150 ng/ml (approx. 280 nM) were reached 3.5 hr after administration. Half-life and mean residence time were 9 and 12 hr respectively. Hyperforin pharmacokinetics were linear up to 600 mg of the extract. Increasing the doses to 900 or 1200 mg of extract resulted in lower Cmax and AUC values than those expected from linear extrapolation of data from lower doses. Plasma concentration curves in volunteers fitted well in an open two-compartment model. In a repeated dose study, no accumulation of hyperforin in plasma was observed. Using the observed AUC values from the repeated dose study, the estimated steady state plasma concentrations of hyperforin after 3 x 300 mg/day of the extract, i.e., after normal therapeutic dose regimen, was approximately 100 ng/ml (approx. 180 nM).', 'After oral administration of 300 mg/kg Hypericum extract (WS 5572, containing 5% hyperforin) to rats maximum plasma levels of approximately 370 ng/ml (approx. 690 nM) were reached after 3 hr, as quantified by a HPLC and UV detection method. Estimated half-life and clearance values were 6 h and 70 ml/min/kg respectively. Since therapeutic doses of Hypericum extracts are much lower than that used in rats, a more sensitive LC/MS/MS method was developed. The lower limit of quantification of this method was 1 ng/ml. Using this method, plasma levels of hyperforin could be followed for up to 24 hr in healthy volunteers after administration of film coated tablets containing 300 mg hypericum extracts representing 14.8 mg hyperforin. The maximum plasma levels of approximately 150 ng/ml (approx. 280 nM) were reached 3.5 h after administration. Half-life and mean residence time were 9 and 12 hr respectively. Hyperforin pharmacokinetics were linear up to 600 mg of the extract. Increasing the doses to 900 or 1200 mg of extract resulted in lower Cmax and AUC values than those expected from linear extrapolation of data from lower doses. Plasma concentration curves in volunteers fitted well in an open two-compartment model. In a repeated dose study, no accumulation of hyperforin in plasma was observed. Using the observed AUC values from the repeated dose study, the estimated steady state plasma concentrations of hyperforin after 3 x 300 mg/day of the extract, i.e., after normal therapeutic dose regimen, was approximately 100 ng/ml (approx. 180 nM).']","[""Hyperforin is an important active component of St. John's wort (Hypericum perforatum) that has been suggested to be responsible for the St. John's wort antidepressive effects and herbal-drug interactions. In this study, the in vitro metabolism profile of hyperforin was investigated using liver microsomes from male and female Sprague-Dawley rats, with or without induction by phenobarbital or dexamethasone. Four major Phase I metabolites, named 19-hydroxyhyperforin, 24-hydroxyhyperforin, 29-hydroxyhyperforin, and 34-hydroxyhyperforin, were isolated by high performance liquid chromatography and identified by mass spectrometry and NMR. Results suggest that hydroxylation is a major biotransformation of the hyperforin pathway in rat liver and that inducible cytochrome P450 3A (CYP450 3A) and/or CYP2B may be the major cytochrome P450 isoforms catalyzing these hydroxylation reactions."", 'Repeated examination of the aerial parts of Hypericum perforatum yielded a new degradation product of hyperforin (1) namely deoxyfurohyperforin A (2), together with the previously identified furohyperforin (3), furoadhyperforin (4), furohyperforin A (5a and 5b), pyrano[7,28-b]hyperforin (6) and 3-methyl-4,6-di(3-methyl-2-butenyl)-2-(2-methyl-1-oxopropyl)-3-(4-methyl-3-pentenyl)-cyclohexanone (7).']","['9 hours', 'After oral administration of 300 mg/kg Hypericum extract (WS 5572, containing 5% hyperforin) to rats ... Estimated half-life and clearance values were 6 hr and 70 mL/min/kg respectively ... Half-life and mean residence time were 9 and 12 hr respectively.']"
1298,441299,"2-(2-Cyclohexa-1,5-dien-1-ylethenyl)-4-methoxy-2,3-dihydropyran-6-one",COC1=CC(=O)OC(C1)C=CC2=CCCC=C2,,,,,,
1299,441300,Abacavir,C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)[C@@H]4C[C@@H](C=C4)CO,"['For the treatment of HIV-1 infection, in combination with other antiretroviral agents.']","['Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Abacavir is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. The concentration of drug necessary to effect viral replication by 50 percent (EC50) ranged from 3.7 to 5.8 μM (1 μM = 0.28 mcg/mL) and 0.07 to 1.0 μM against HIV-1IIIB and HIV-1BaL, respectively, and was 0.26 ± 0.18 μM against 8 clinical isolates.  Abacavir had synergistic activity in cell culture in combination with the nucleoside reverse transcriptase inhibitor (NRTI) zidovudine, the non-nucleoside reverse transcriptase inhibitor (NNRTI) nevirapine, and the protease inhibitor (PI) amprenavir; and additive activity in combination with the NRTIs didanosine, emtricitabine, lamivudine, stavudine, tenofovir, and zalcitabine.']","['Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. (See all compounds classified as Reverse Transcriptase Inhibitors.)', 'Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. (See all compounds classified as Anti-HIV Agents.)']","['Rapid and extensive after oral administration (83% bioavailability, tablet). When a 300 mg tablet is given twice daily to subjects, the peak plasma concentration (Cmax) was 3.0 ± 0.89 mcg/mL and the area under the curve (AUC 0-12 hours) was 6.02 ± 1.73 mcg•hr/mL.', 'Elimination of abacavir was quantified in a mass balance study following administration of a 600-mg dose of 14C-abacavir: 99% of the radioactivity was recovered, 1.2% was excreted in the urine as abacavir, 30% as the 5′-carboxylic acid metabolite, 36% as the 5′-glucuronide metabolite, and 15% as unidentified minor metabolites in the urine. Fecal elimination accounted for 16% of the dose. Renal excretion of unchanged abacavir is a minor route of elimination in humans.', '0.86 ± 0.15 L/kg [IV administration]', '0.80 ± 0.24 L/hr/kg [asymptomatic, HIV-1-infected adult patients receiving single (IV dose of 150\xa0mg]', 'Following oral administration of a 600-mg dose of radiolabeled abacavir, 82.2% of the dose is excreted in urine and 16% of the dose is excreted in feces. The 5-carboxylic acid metabolite, 5-glucuronide metabolite, and unchanged abacavir accounted for 30, 36, and 1.2%, respectively, of recovered radioactivity in urine; unidentified minor metabolites accounted for 15% of recovered radioactivity in urine.', 'It is not known whether abacavir is distributed into human milk; the drug is distributed into milk in rats.', 'Abacavir crosses the placenta in rats.', 'The oral bioavailability of abacavir is high with or without food; the CSF-to-plasma AUC ratio is approximately 0.3.', 'For more Absorption, Distribution and Excretion (Complete) data for ABACAVIR SULFATE (7 total), please visit the HSDB record page.']","['Hepatic, by alcohol dehydrogenase and glucuronosyltransferase to a 5&prime;-carboxylic acid metabolite and 5&prime;-glucuronide metabolite, respectively. These metabolites have no antiviral activity. Abacavir is not significantly metabolized by cytochrome P450 enzymes.', ""Abacavir is partially metabolized by alcohol dehydrogenase (to form the 5'-carboxylic acid) and glucuronidation (to form the 5'-glucuronide)."", 'The metabolic fate of abacavir has not been fully determined, but the drug is metabolized in the liver. Abacavir is metabolized by alcohol dehydrogenase to form the 5-carboxylic acid and by glucuronyltransferase to form the 5-glucuronide; these metabolites do not appear to have any antiviral activity. Any involvement of cytochrome p450 isoenzymes in the metabolism of abacavir is limited.', 'Intracellularly, abacavir is phosphorylated to abacavir monophosphate by adenosine phosphotransferase; abacavir monophosphate is then converted to carbovir monophosphate in a reaction catalyzed by cytosolic enzymes and then to carbovir triphosphate by cellular kinases. Intracellular (host cell) conversion of abacavir to carbovir triphosphate is necessary for the antiviral activity of the drug. The in vitro intracellular half-life of carbovir triphosphate in CD4+ CEM cells is 3.3 hours.']","['1.54 ± 0.63 hours', 'The in vitro intracellular half-life of carbovir triphosphate /SRP: a metabolite of abacavir sulfate,/ in CD4+ CEM cells is 3.3 hours.', 'The plasma elimination half-life of abacavir following a single oral dose (given as abacavir sulfate) is about 1.5 hours. In HIV-infected children 3 months to 13 years of age who received 8 mg/kg of abacavir every 12 hours (given as an oral solution containing abacavir sulfate), steady-state plasma elimination half-life averaged 1.3 hours and was essentially the same as that reported after a single dose. Following oral administration of a single 300-mg dose of abacavir to an individual with renal failure (glomerular filtration rate less than 10 mL/minute) undergoing peritoneal dialysis, the plasma elimination half-life of the drug was 1.33 hours.']"
1300,441301,Androstanediol,C[C@]12CC[C@H](C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4O)C)O,,,,,,
1301,441302,Epiandrosterone,C[C@]12CC[C@@H](C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C)O,,,,,,
1302,441303,CID 441303,C(C(C(C(C(C(=O)[O-])O)O)O)O)O.C(C(C(C(C(C(=O)[O-])O)O)O)O)O.O.O.O.O.O.O.O.O.O.O.O.[OH-].[Na+].[Na+].[Na+].[SbH3].[SbH3],,,,,,
1303,441304,5-Deoxy-2-O-[2-deoxy-2-(methylamino)hexopyranosyl]-3-C-formylpentofuranose,C[C@H]1[C@@]([C@H]([C@@H](O1)O)O[C@H]2[C@H]([C@@H]([C@H]([C@@H](O2)CO)O)O)NC)(C=O)O,,,,,,
1304,441305,Gentamycin C1,CC([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@](CO3)(C)O)NC)O)N)N)N)NC,,,"['Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)', 'Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)']","['/MILK/ Gentamicin is distributed into milk following IM administration.', 'Gentamicin is distributed into cerebrospinal fluid (CSF) in low concentrations following IM or IV administration. CSF concentrations of gentamicin following intrathecal administration depend on the dose administered, the site of injection, the volume in which the dose is diluted, and the presence or absence of obstruction to CSF flow. There may be considerable interpatient variation in concentrations achieved. In one study, intrathecal administration of 4 mg of gentamicin resulted in CSF concentrations of the drug of 19-46 ug/mL for 8 hours and less than 3 ug/mL at 20 hours. Gentamicin crosses the placenta.', 'Following parenteral administration of usual dosages of gentamicin, the drug can be detected in lymph, subcutaneous tissue, lung, sputum, and bronchial, pleural, pericardial, synovial, ascitic, and peritoneal fluids. Concentrations in bile may be low, suggesting minimal biliary excretion. In patients with ventilator-associated pneumonia receiving IV gentamicin (240 mg once daily), drug concentrations in alveolar lining fluid were 32% of serum concentrations and averaged 4.24 ug/mL 2 hours after a dose. Only minimal concentrations of gentamicin are attained in ocular tissue following IM or IV administration.', 'Accumulation of gentamicin does not appear to occur in patients with normal renal function receiving 1-mg/kg doses every 8 hours for 7-10 days. However, accumulation may occur with higher doses and/or when the drug is given for prolonged periods, especially in patients with renal impairment.', 'For more Absorption, Distribution and Excretion (Complete) data for Gentamicin (18 total), please visit the HSDB record page.']","['Gentamicin is not metabolized. It is excreted by glomerular filtration in an active, unchanged form.']","['The plasma elimination half-life of gentamicin is usually 2-4 hours in adults with normal renal function and is reported to range from 24-60 hours in adults with severe renal impairment. The serum half-life of gentamicin averages 3-3.5 hours in infants 1 week to 6 months of age and 5.5 hours in full-term infants and large premature infants less than 1 week of age. In small premature infants, the plasma half-life is approximately 5 hours in those weighing over 2 kg, 8 hours in those weighing 1.5-2 kg, and 11.5 hours in those weighing less than 1.5 kg.', '... terminal elimination half-lives of greater than 100 hours have been reported in adults with normal renal function following repeated IM or IV administration of the drug.']"
1305,441306,Netilmicin,CCN[C@@H]1C[C@@H]([C@H]([C@@H]([C@H]1O[C@@H]2[C@@H]([C@H]([C@@](CO2)(C)O)NC)O)O)O[C@@H]3[C@@H](CC=C(O3)CN)N)N,"['For the treatment of bacteremia, septicaemia, respiratory tract infections, skin and soft-tissue infection, burns, wounds, and peri-operative infections caused by susceptible strains.']","['Netilmicin is a semisynthetic, water soluble antibiotic of the aminoglycoside group, produced by the fermentation of Micromonospora inyoensis, a species of actinomycete. Aminoglycosides are useful primarily in infections involving aerobic, Gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter. It is active at low concentrations against a wide variety of pathogenic bacteria including <i>Escherichia coli</i>, bacteria of the <i>Klebsiella-Enterobacter-Serratia </i>group, <i>Citrobacter </i>sp., <i>Proteus </i>sp. (indole-positive and indole-negative), including <i>Proteus mirabilis</i>, <i>P. morganii, P. rettgrei, P. vulgaris, Pseudomonas aeruginosa </i>and <i>Neisseria gonorrhoea</i>. Netilmicin is also active <i>in vitro </i>against isolates of <i>Hemophilus influenzae, Salmonella </i>sp., <i>Shigella </i>sp. and against penicillinase and non-penicillinase-producing <i>Staphylococcus </i>including methicillin-resistant strains. Some strains of <i>Providencia </i>sp., <i>Acinetobacter </i>sp. and <i>Aeromonas </i>sp. are also sensitive to netilmicin. Many strains of the above organisms which are found to be resistant to other aminoglycosides, such as kanamycin, gentamicin, tobramycin and sisomicin, are susceptible to netilmicin <i>in vitro</i>. Occasionally, strains have been identified which are resistant to amikacin but susceptible to netilmicin. The combination of netilmicin and penicillin G has a synergistic bactericidal effect against most strains of <i>Streptococcus faecalis</i> (enterococcus). The combined effect of netilmicin and carbenicillin or ticarcillin is synergistic for many strains of <i>Pseudomonas aeruginosa</i>. In addition, many isolates of <i>Serratia</i>, which are resistant to multiple antibiotics, are inhibited by synergistic combinations of netilmicin with carbenicillin, azlocillin, mezlocillin, cefamandole, cefotaxime or moxalactam. Aminoglycosides are mostly ineffective against anaerobic bacteria, fungi and viruses.']","['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)', 'Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)']","['Rapidly and completely absorbed after IM administration, peak serum levels were achieved within 30-60 minutes. Aminoglycosides are poorly absorbed orally. Topical absorption is also poor unless severe skin damage is present.', 'Netilmicin is poorly absorbed from the intact GI tract following oral administration. The drug is rapidly and completely absorbed following IM administration.', 'Following absorption, netilmicin rapidly distributes into tissues, sputum, and pericardial, synovial, and peritoneal fluids. ...distributed principally in the extracellular fluid volume... The volume of distribution ...is approximately 20% of body weight. The drug is reportedly 0-30% protein bound.', 'Netilmicin crosses the placenta and has been detected in cord blood. Small amounts of the drug are distributed into milk.', '...is not metabolized and is excreted unchanged in urine mainly by glomerular filtration. In adults with normal renal function, 74% of a 2 mg/kg dose of netilmicin is excreted unchanged within 24 horus: in adults with creatinine clearances of 30-80 or 10-30 mL/min or in anephric adults, 55, 25, or 15% of the dose is excreted in urine within 24 hours, respectively.', 'Netilmicin is removed by hemodialysis. The drug is also removed by peritoneal dialysis but less readily than by hemodialysis.']","['No evidence of metabolic transformation, typically 80% is recoverable in the urine within 24 hours']","['2.5 hours', 'The plasma elimination half-life on netilmicin is about 2-2.5 hr following IV or IM administration of a single dose in adults with normal renal function. The serum half-life is reported to be 18 hr in adults with creatinine clearances of 10-30 mL/min and more than 30 hr in anephric adults. The plasma elimination half-life of netilmicin in neonates is inversely related to birthweight and gestational and postnatal age and has been reported to be about 8 or 4.5 hr in neonates less than 7 days of age weighing 1.5-2 or 3-4 kg, respectively. The plasma elimination half-life for children 6 weeks of age and older is 1.5-2 hr.']"
1306,441307,Acebutolol hydrochloride,CCCC(=O)NC1=CC(=C(C=C1)OCC(CNC(C)C)O)C(=O)C.Cl,,,"['Drugs that bind to and block the activation of ADRENERGIC BETA-1 RECEPTORS. (See all compounds classified as Adrenergic beta-1 Receptor Antagonists.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']","['Distribution of acebutolol hydrochloride into body tissue and fluids has not been fully characterized. Following IV administration in rats, acebutolol is distributed extensively into many tissues, including heart, liver, kidneys, lungs, intestines, stomach, and salivary glands, but only minimally into CSF or testes. Following oral administration of acebutolol hydrochloride in healthy individuals, acebutolol and, to a lesser extent, diacetolol, are distributed into saliva and minimally into CSF. Following oral administration of a single 300-mg dose of acebutolol hydrochloride, about 3-9% of the dose is distributed into bile within 24 hours, in approximately equivalent amounts as acebutolol and diacetolol. Peak biliary concentrations of acebutolol are approximately 60-100 times greater than peak plasma concentrations.', 'Acebutolol and diacetolol readily cross the placenta and can accumulate in the fetus. In pregnant women receiving acebutolol, the mean acebutolol and diacetolol ratios of umbilical venous to maternal venous plasma concentrations were 0.8 (range: 0.5-1) and 0.6 (range: 0.3-0.8), respectively.', 'Following IV administration, acebutolol is rapidly and widely distributed into the extravascular space and the apparent volume of distribution of the drug in healthy adults is approximately 1.6-3 l/kg (range: 1-3.8 l/kg). In healthy individuals, the volume of distribution in the central compartment and at steady state averages 0.16-0.22 and approximately 1.2 l/kg, respectively, following IV administration. The apparent volume distribution may be decreased in geriatric patients.', 'In vitro, acebutolol and diacetolol are approximately 11-35 and 6-9% bound, respectively, to plasma proteins at plasma acebutolol concentrations of 20-9,000 ng/ml. Acebutolol is approximately 50% bound to erythrocytes.', 'For more Absorption, Distribution and Excretion (Complete) data for ACEBUTOLOL HYDROCHLORIDE (16 total), please visit the HSDB record page.']","['Acebutolol is rapidly and extensively metabolized in the liver. Acebutolol undergoes extensive hydrolysis of the butyramide group to form the desbutyl primary amine, acetolol, which is almost completely converted via N-acetylation to diacetolol. The extent of metabolism of acebutolol to diacetolol appears to be independent of the genetic acetylator phenotype of the patient. Diacetolol is equipotent to acebutolol and has a similar pharmacologic profile.']","['Following single or mutiple oral doses of acebutolol hydrochloride, the elimination half-life of diacetolol reportedly averages 21.5 hours (range: 11-49 hours) or 32 hours (range: 17-54 hours) in patients with creatinine clearances of 6-56 or less than 5 ml/minute, respectively.', 'Following a single oral dose in healthy adults, the half-life of acebutolol in the initial distrubution phase (t1/2 alpha) is about 3 hours and the half-life in the terminal phase (t1/2 beta) has been reported to average 11 hours (range: 6-12 hours). The half-lives of the two identified metabolites, diacetolol and acetolol, average 7.5 (range: 7-11 hours) and 3 hours, respectively, following a single oral dose of the drug. The half-life of acebutolol tends to be slightly prolonged following multiple rather than single doses. Following multiple-dose oral administration of acebutolol hyrochloride in healthy individuals (400 mg twice daily for 56 days), the elimination half-life of acebutolol average 13 hours (range: 9-20 hours). The elimination half-lives of acebutolol and diacetolol may be slightly iincreased in geriatric patients.', 'The plasma elimination half-lives of acebutolol and diacetolol in neonates born to women receiving the drug during pregnancy ranged from 6-14 and from 24-30 hours, respectively, in the first 24 hours after birth; the half-life of diacetolol decreased to 12-16 hours during the second day. Neonatal urinary excretion of the drug and diacetolol was maximal during the first 24 hours after birth.']"
1307,441308,Metoprolol tartrate,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O.CC(C)NCC(COC1=CC=C(C=C1)CCOC)O.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,,,"['Drugs that bind to and block the activation of ADRENERGIC BETA-1 RECEPTORS. (See all compounds classified as Adrenergic beta-1 Receptor Antagonists.)', 'Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here. (See all compounds classified as Sympatholytics.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']",,,
1308,441309,(2R)-1-(tert-butylamino)-3-(2-cyclopentylphenoxy)propan-2-ol;sulfuric acid,CC(C)(C)NC[C@H](COC1=CC=CC=C1C2CCCC2)O.CC(C)(C)NC[C@H](COC1=CC=CC=C1C2CCCC2)O.OS(=O)(=O)O,,,,,,
1309,441310,Trimethaphan camsylate,CC1(C2CCC1(C(=O)C2)CS(=O)(=O)[O-])C.C1CC2C3C(C[S+]2C1)N(C(=O)N3CC4=CC=CC=C4)CC5=CC=CC=C5,,,['Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)'],,,
1310,441311,CID 441311,[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[N-]=O.O.O.[Na+].[Na+].[Fe],,,,,,
1311,441312,CID 441312,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H](C)C(=O)N2CCC[C@H]2C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
1312,441313,Perindopril erbumine,CCC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O.CC(C)(C)N,,,"['A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (See all compounds classified as Angiotensin-Converting Enzyme Inhibitors.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']",,,
1313,441314,Miglitol,C1[C@@H]([C@H]([C@@H]([C@H](N1CCO)CO)O)O)O,['For use as an adjunct to diet to improve glycemic control in patients with non-insulin-dependent diabetes mellitus (NIDDM) whose hyperglycemia cannot be managed with diet alone.'],"['Miglitol, an oral alpha-glucosidase inhibitor, is a desoxynojirimycin derivative that delays the digestion of ingested carbohydrates, thereby resulting in a smaller rise in blood glucose concentration following meals. As a consequence of plasma glucose reduction, miglitol reduce levels of glycosylated hemoglobin in patients with Type II (non-insulin-dependent) diabetes mellitus. Systemic nonenzymatic protein glycosylation, as reflected by levels of glycosylated hemoglobin, is a function of average blood glucose concentration over time. Because its mechanism of action is different, the effect of miglitol to enhance glycemic control is additive to that of sulfonylureas when used in combination. In addition, miglitol diminishes the insulinotropic and weight-increasing effects of sulfonylureas. Miglitol has minor inhibitory activity against lactase and consequently, at the recommended doses, would not be expected to induce lactose intolerance.']","['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Compounds that inhibit or block the activity of GLYCOSIDE HYDROLASES such as ALPHA-AMYLASES and ALPHA-GLUCOSIDASES. (See all compounds classified as Glycoside Hydrolase Inhibitors.)', 'Substances which lower blood glucose levels. (See all compounds classified as Hypoglycemic Agents.)']","['Absorption of miglitol is saturable at high doses with 25 mg being completely absorbed while a 100-mg dose is only 50-70% absorbed. No evidence exists to show that systemic absorption of miglitol adds to its therapeutic effect.', 'Miglitol is not metabolized in man or in any animal species studied. It is eliminated by renal excretion as an unchanged drug.', '0.18 L/kg', 'Absorption of miglitol is saturable at high doses: a dose of 25 mg is completely absorbed, whereas a dose of 100 mg is only 50% - 70% absorbed. For all doses, peak concentrations are reached in 2-3 hours.', 'Therapeutic effects principally result from local actions on the small intestine; there is no evidence that systemic absorption contributes to therapeutic response.', 'The protein binding of miglitol is negligible (<4.0%). Miglitol has a volume of distribution of 0.18 L/kg, consistent with distribution primarily into the extracellular fluid.', 'Miglitol is distributed principally into extracellular fluid and concentrated in enterocytes of the small intestine.', 'For more Absorption, Distribution and Excretion (Complete) data for Miglitol (9 total), please visit the HSDB record page.']","['Miglitol is not metabolized in man or in any animal species studied.', 'Miglitol is not metabolized in man or in any animal species studied. No metabolites have been detected in plasma, urine, or feces, indicating a lack of either systemic or pre-systemic metabolism.']","['The elimination half-life of miglitol from plasma is approximately 2 hours.', '... Miglitol is rapidly eliminated from plasma with apparent elimination half-lives of 0.4-1.8 hr. ... At very low concentration levels a terminal elimination phase of radioactivity characterized by half-lives of 50-110 hr...', 'The elimination half-life of miglitol from plasma is approximately 2 hours.']"
1314,441315,CID 441315,CC(CC[C@H](C(C)(C)O)O)C1CCC2[C@@]1(CCCC2=CC=C3C[C@H](CCC3=C)O)C,,,,,,
1315,441316,"3,4-Dihydroxyfluorene",C1C2=C(C3=CC=CC=C31)C(=C(C=C2)O)O,,,,,,
1316,441317,"2-Hydroxy-4-(1-oxo-1,3-dihydro-2H-inden-2-ylidene)-but-2-enoic acid",C1C2=CC=CC=C2C(=C1C=CC(=O)C(=O)O)O,,,,,,
1317,441318,2-Formyl-1-indanone,C1C(C(=O)C2=CC=CC=C21)C=O,,,,,,
1318,441319,"(+)-(3S,4R)-3,4-dihydroxy-3,4-dihydrofluorene",C1C2=C([C@H]([C@H](C=C2)O)O)C3=CC=CC=C31,,,,,,
1319,441320,"3,4-Dihydroxy-3,4-dihydro-9-fluorenone",C1=CC=C2C(=C1)C3=C(C2=O)C=CC(C3O)O,,,,,,
1320,441321,"1,2-Dihydroxyfluorene",C1C2=CC=CC=C2C3=C1C(=C(C=C3)O)O,,,,,,
1321,441322,2-Hydroxy-4-(2-oxo-indan-1-ylidene)-2-butenoic acid,C1C2=CC=CC=C2C(=CC=C(C(=O)O)O)C1=O,,,,,,
1322,441323,1-Formyl-2-indanone,C1C2=CC=CC=C2C(C1=O)C=O,,,,,,
1323,441324,CID 441324,C1=CC=C(C(=C1)O)OC(=CC=CC(=O)C(=O)O)O,,,,,,
1324,441325,Amiodarone hydrochloride,CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I.Cl,,,"['A class of drugs that act by inhibition of potassium efflux through cell membranes. Blockade of potassium channels prolongs the duration of ACTION POTENTIALS. They are used as ANTI-ARRHYTHMIA AGENTS and VASODILATOR AGENTS. (See all compounds classified as Potassium Channel Blockers.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)', 'Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP1A2. (See all compounds classified as Cytochrome P-450 CYP1A2 Inhibitors.)', 'Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP3A. (See all compounds classified as Cytochrome P-450 CYP3A Inhibitors.)', 'A class of drugs that act by inhibition of sodium influx through cell membranes. Blockade of sodium channels slows the rate and amplitude of initial rapid depolarization, reduces cell excitability, and reduces conduction velocity. (See all compounds classified as Sodium Channel Blockers.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP2C9. (See all compounds classified as Cytochrome P-450 CYP2C9 Inhibitors.)', 'Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP2D6. (See all compounds classified as Cytochrome P-450 CYP2D6 Inhibitors.)']","['Plasma concentration of amiodarone appear to decline in at least a biphasic manner, although more complex, multicompartmental pharmacokinetics have been described. Following a single IV dose in healthy adults, the half-life of the drug in the terminal elimination phase has been reported to average 25 days (range 9-47 days). The elimination half-life of the major metabolite, N-desethylamiodarone, is equal to or longer than that of the parent drug. Following single dose admin of amiodarone in a limited number of healthy individuals, amiodarone exhibits multicompartmental pharmacokinetics; the mean apparent terminal plasma elimination half-life of amiodarone and N-desethylamiodarone were 58 (range: 15-142) and 36 (range: 14-75) days, respectively. The half-life of amiodarone appears to be substantially more prolonged following multiple rather than single doses. It has been suggested that differences in reported elimination half-lives may result in part from misinterpretation of slow distribution phases as elimination phases following IV administration of the drug. Following chronic oral administration of amiodarone hydrochloride in patients with cardiac arrhythmias (200-600 mg daily for 2-52 months), the drug appears to be eliminated in a biphasic manner with an initial elimination half-life of about 2.5-10 days, which is followed by a terminal elimination half-life averaging 53 days (range: 26-107 days), with most patients exhibiting a terminal elimination half-life in the range of 40-55 days. The elimination half-life of the major metabolite, N-desethylamiodarone, averages 57-61 days (range 20-118 days) following long-term oral administration of amiodarone. The elimination profile of amiodarone may reflect an initial elimination of the drug from well-perfused tissues followed by prolonged elimination from poorly perfused tissues such as adipose tissue.', 'Following iv administration of amiodarone in healthy individuals, total plasma clearance of the drug averages approximately 1.9 ml/min/kg (range: 1.4-2.5 ml/min/kg). Although not clearly established, total apparent plasma clearance of the drug appears to decrease with time. Clinical experience suggests that clearance of amiodarone may be more rapid in pediatric patients; however, further studies are needed to fully determine the effects of age on clearance of the drug. Factors of age, gender, or renal or hepatic disease appear to have no effect on the disposition of amiodarone or its major metabolite, N-desethylamiodarone.', 'Amiodarone hydrochloride is slowly and variably absorbed from the GI tract following oral administration. The absolute bioavailability of commercially available amiodarone hydrochloride tablets averages approximately 50%, but varies considerably, ranging from 22-86%.', 'Following oral administration, peak plasma amiodarone concentrations usually occur within 3-7 hours (range: 2-12 hours). Following oral administration of a single 400 mg dose of amiodarone hydrochloride in fasting, healthy adults, peak plasma amiodarone concentration of approximately 0.15-0.7 ug/ml are attained. Within the oral dosage range of 100-600 mg daily, steady state plasma concentrations of the drug are approximately proportional to dosage, increasing by an average of 0.5 ug/ml per 100 mg increment in dosage; however, there is considerable interindividual variation in plasma concentrations attained with a given dosage. Following continuous oral administration of the drug in the absence of an initial loading dose regimen, steady state plasma amiodarone concentrations would not be attained for at least 1 month and generally not for up to 5 months or longer. Following chronic oral administration of amiodarone, plasma concentrations of N-desethylamiodarone, the major metabolite of the drug, are approximately 0.5-2 times those of unchanged drug.', 'For more Absorption, Distribution and Excretion (Complete) data for AMIODARONE HYDROCHLORIDE (11 total), please visit the HSDB record page.']","['The drug appears to be extensively metabolized, probably in the liver and possibly in the intestinal lumen and/or GI mucosa, to at least one major metabolite. The major metabolite, N-desethylamiodarone, is formed by N-deethylation. Although not clearly established, limited data in animals indicate that the desethyl metabolite may possess some antiarrhythmic activity. ... A minor metabolite of amiodarone, di-N-desethylamiodarone, has been identified in animals following chronic administration of the drug. Amiodarone and N-desethylamiodarone may undergo deiodination to form deiodoamiodarone and deiodo-N-desethylamiodarone, respectively; iodine (in the form of iodide); and possibly other iodine containing metabolites. It is not known whether deiodinated metabolites are pharmacologically active.', 'Amiodarone undergoes hepatic metabolism by cytochrome P450 3A4 to desethyl-amiodarone.']","['Following a single IV dose in healthy adults, the half-life of the drug in the terminal elimination phase has been reported to average 25 days (range 9-47 days). The elimination half-life of the major metabolite, N-desethylamiodarone, is equal to or longer than that of the parent drug.', 'Following single dose admin of amiodarone in a limited number of healthy individuals, amiodarone exhibits multicompartmental pharmacokinetics; the mean apparent terminal plasma elimination half-life of amiodarone and N-desethylamiodarone were 58 (range: 15-142) and 36 (range: 14-75) days, respectively.', 'Following chronic oral administration of amiodarone hydrochloride in patients with cardiac arrhythmias (200-600 mg daily for 2-52 months), the drug appears to be eliminated in a biphasic manner with an initial elimination half-life of about 2.5-10 days, which is followed by a terminal elimination half-life averaging 53 days (range: 26-107 days), with most patients exhibiting a terminal elimination half-life in the range of 40-55 days.', 'The elimination half-life of the major metabolite, N-desethylamiodarone, averages 57-61 days (range 20-118 days) following long-term oral administration of amiodarone.']"
1325,441326,Quinidine sulphate,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O.COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O.OS(=O)(=O)O,,,"['Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)', 'Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) (See all compounds classified as Antimalarials.)', 'Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP2D6. (See all compounds classified as Cytochrome P-450 CYP2D6 Inhibitors.)', 'A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS. (See all compounds classified as Voltage-Gated Sodium Channel Blockers.)', 'Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. (See all compounds classified as Adrenergic alpha-Antagonists.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)']","['ABOUT 90% OF QUINIDINE IN PLASMA IS BOUND TO PLASMA PROTEINS (ALPHA/ACID GLYCOPROTEIN AND ALBUMIN) THE DRUG ENTERS ERYTHROCYTES & ... BINDS TO HEMOGLOBIN; AT STEADY STATE, CONCN OF QUINIDINE IN PLASMA & ERYTHROCYTES ARE APPROXIMATELY EQUAL. QUINIDINE ACCUMULATES RAPIDLY IN MOST TISSUES EXCEPT BRAIN, & ... VOL OF DISTRIBUTION IS 2-3 L/KG. /QUINIDINE/', 'METABOLITES AND SOME OF THE PARENT DRUG (20%) ARE EXCRETED IN URINE; ELIMINATION HALF-TIME IS ABOUT 6 HR. /QUINIDINE/', 'LIVER METABOLISM & RENAL EXCRETION ARE THE MAIN ROUTES OF ELIMINATION. ENTEROHEPATIC CIRCULATION WOULD NOT SIGNIFICANTLY ALTER ABSORPTION KINETICS AS REFLECTED BY BLOOD CONCENTRATION.', 'PEAK PLASMA CONCN OF 0.29 UG/ML OF QUINIDINE WERE MEASURED @ 4 HR AFTER ADMIN OF SUSTAINED RELEASE CAPSULE (250 MG QUINIDINE BISULFATE) AND DECLINED STEADILY DURING THE NEXT 8 HR, WHILE AFTER ADMIN OF SUSTAINED RELEASE TABLET (300 MG QUINIDINE SULFATE) THEY WERE FAIRLY EVEN DURING 2-10 HR AFTER DOSING. PLASMA CONCENTRATIONS WERE HIGHER AT LATER TIMES FOR THE CAPSULE THAN FOR THE TABLET. THE BIOAVAILABILITY OF QUINIDINE FROM THE CAPSULES DURING 12 HR WAS 184% COMPARED TO THE TABLET. MEAN QUINIDINE PLASMA CONCN WERE SIGNIFICANTLY GREATER @ 3, 4, 6, 8, & 10 HR AFTER ADMIN OF THE CAPSULE THAN AFTER THE TABLET.', 'For more Absorption, Distribution and Excretion (Complete) data for QUINIDINE SULFATE (24 total), please visit the HSDB record page.']","[""QUINIDINE YIELDS 2'-HYDROXYQUINIDINE AS METABOLITE IN MAN. /QUINIDINE; FROM TABLE/"", 'MOST URINARY METABOLITES ARE HYDROXYLATED AT ONLY ONE SITE, EITHER ON THE QUINOLINE RING OR ON THE QUINUCLIDINE RING; SMALL AMOUNTS OF DIHYDROXY COMPOUNDS ARE ALSO FOUND. THE FRACTION OF A DOSE OF QUINIDINE THAT IS METABOLIZED & THE METABOLIC PATHWAY APPEAR TO VARY CONSIDERABLY FROM PATIENT TO PATIENT.', 'Quinidine is metabolized in the liver, principally via hydroxylation to 3-hydroxyquinidine and 2-quinidinone. The metabolites may be pharmacologically active. Approximately 10-50% of a dose is excreted in urine (probably by glomerular filtration) as unchanged drug within 24 hr. /Quinidine/']","['THE ELIMINATION HALF-LIFE OF QUINIDINE RANGES FROM 4 TO 10 HR IN HEALTHY PERSONS, WITH USUAL MEAN VALUE OF 6 TO 7 HR. HALF-LIFE IS SIGNIFICANTLY PROLONGED IN ELDERLY PERSONS, EVEN WHEN THEY ARE APPARENTLY HEALTHY. /QUINIDINE/', '... EXCRETED IN URINE; ELIMINATION HALF-TIME IS ABOUT 6 HR. /QUINIDINE/', 'Quinidine generally has a plasma half-life of 6-8 hr in healthy individuals, but half-life may range from 3-16 hr or longer. In one study in patients with Plasmodium falciparum malaria, the elimination half-life of the drug averaged 12.8 hr (range: 6.6-24.8 hr). /Quinidine/']"
1326,441327,Quinidine galacturonate,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O.C(=O)[C@@H]([C@H]([C@H]([C@@H](C(=O)O)O)O)O)O,,,,,,
1327,441328,7-Aminocephalosporanic acid,CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)N)SC1)C(=O)O,,,,,,
1328,441329,CID 441329,CC1(C(N2[C@H](S1(=O)=O)CC2=O)C(=O)[O-])C.[Na+],,,,,,
1329,441330,Emedastine (difumarate),CCOCCN1C2=CC=CC=C2N=C1N3CCCN(CC3)C.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
1330,441331,CID 441331,CCCCC[C@@](C)(C=C[C@H]1[C@@H](C[C@@H]([C@@H]1CC=CCCCC(=O)O)O)O)O.C(C(CO)(CO)N)O,,,,,,
1331,441332,"7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3S)-3-hydroxy-3-methyloct-1-enyl]cyclopentyl]hept-5-enoic acid",CCCCC[C@@](C)(C=C[C@H]1[C@@H](C[C@@H]([C@@H]1CC=CCCCC(=O)O)O)O)O,,,,,,
1332,441333,Metaproterenol sulfate,CC(C)NCC(C1=CC(=CC(=C1)O)O)O.CC(C)NCC(C1=CC(=CC(=C1)O)O)O.OS(=O)(=O)O,,,"['Drugs that prevent preterm labor and immature birth by suppressing uterine contractions (TOCOLYSIS). Agents used to delay premature uterine activity include magnesium sulfate, beta-mimetics, oxytocin antagonists, calcium channel inhibitors, and adrenergic beta-receptor agonists. The use of intravenous alcohol as a tocolytic is now obsolete. (See all compounds classified as Tocolytic Agents.)', 'Compounds bind to and activate ADRENERGIC BETA-2 RECEPTORS. (See all compounds classified as Adrenergic beta-2 Receptor Agonists.)', 'Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)', 'Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)']",,,
1333,441334,Terbutaline sulfate,CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O.CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O.OS(=O)(=O)O,,,"['Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)', 'Compounds bind to and activate ADRENERGIC BETA-2 RECEPTORS. (See all compounds classified as Adrenergic beta-2 Receptor Agonists.)', 'Drugs that prevent preterm labor and immature birth by suppressing uterine contractions (TOCOLYSIS). Agents used to delay premature uterine activity include magnesium sulfate, beta-mimetics, oxytocin antagonists, calcium channel inhibitors, and adrenergic beta-receptor agonists. The use of intravenous alcohol as a tocolytic is now obsolete. (See all compounds classified as Tocolytic Agents.)', 'Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)']",,,
1334,441335,Mometasone,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CCl)O)C)O)Cl)C,['The inhaler is indicated for the maintenance treatment of asthma as prophylactic therapy. The nasal spray is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis.'],"['Mometasone is a medium-potency synthetic corticosteroid with antiinflammatory, antipruritic, and vasoconstrictive properties. Studies in asthmatic patients have demonstrated that mometasone provides a favorable ratio of topical to systemic activity due to its primary local effect along with the extensive hepatic metabolism and the lack of active metabolites. Though effective for the treatment of asthma, glucocorticoids do not affect asthma symptoms immediately. Maximum improvement in symptoms following inhaled administration of mometasone furoate may not be achieved for 1 to 2 weeks or longer after starting treatment. When glucocorticoids are discontinued, asthma stability may persist for several days or longer. Mometasone has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor which is approximately 12 times that of dexamethasone, 7 times that of triamcinolone acetonide, 5 times that of budesonide, and 1.5 times that of fluticasone. The clinical significance of these findings is unknown.']","['Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)', 'Drugs used to treat or prevent skin disorders or for the routine care of skin. (See all compounds classified as Dermatologic Agents.)', 'Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)']",['Nasal spray is virtually undetectable in plasma'],"['Hepatic. Extensive metabolism to multiple metabolites. There are no major metabolites detectable in plasma. Upon in vitro incubation, one of the minor metabolites formed is 6&szlig;-hydroxy-mometasone furoate. In human liver microsomes, the formation of the metabolite is regulated by cytochrome P-450 3A4.']",['5.8 hours']
1335,441336,Mometasone furoate,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CCl)OC(=O)C5=CC=CO5)C)O)Cl)C,"['There are 3 formulations of mometasone furoate with various indications. The inhaler is indicated for prophylaxis of asthma in patients ≥4 years. The nasal spray is indicated for treating nasal symptoms of allergic rhinitis in patients ≥2 years, treating symptoms of nasal congestion from seasonal allergic rhinitis in patients ≥2 years, treating nasal polyps in patients ≥18 years, and prophylaxis of seasonal allergic rhinitis in patients ≥12 years. The ointment is indicated for symptomatic treatment of dermatitis and pruritis in patients ≥2 years.']","['Mometasone is a synthetic corticosteroid with an affinity for glucocorticoid receptors 22 times higher than that of [dexamethasone]. Mometasone furoate also has a lower affinity to mineralocorticoid receptors than natural corticosteroids, making it more selective in its action. Mometasone furoate diffuses across cell membranes to activate pathways responsible for reducing inflammation.']","['Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)', 'Drugs used to treat or prevent skin disorders or for the routine care of skin. (See all compounds classified as Dermatologic Agents.)', 'Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)']","['The mean time to peak concentration is 1.0 to 2.5 hours. Bioavailability has been reported as <1% but studies of repeat doses of inhaled corticosteroids suggest a bioavailability of 11%. The 0.1% ointment may have a bioavailability of 0.7%.', 'For an inhaled dose, approximately 74% is excreted in the feces and 8% is excreted in the urine.', 'Steady state volume of distribution of 152L.', 'The clearance rate of mometasone furoate is not readily available, though it may be close to 90L/h.']",['Metabolism of mometasone furoate is largely performed hepatically by cytochrome P450 3A4 producing a number of metabolites. Some of these metabolites include free mometasone and 6-beta-hydroxy-mometasone furoate.'],['The terminal half life of an inhaled dose is approximately 5 hours though it has been reported as 5.8 hours by other sources.']
1336,441337,Ipratropium bromide hydrate,CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.O.[Br-],,,"['Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)', 'Drugs that bind to but do not activate CHOLINERGIC RECEPTORS, thereby blocking the actions of ACETYLCHOLINE or cholinergic agonists. (See all compounds classified as Cholinergic Antagonists.)']",,,
1337,441338,Stilnox,CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C.CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,,,"['Endogenous compounds and drugs that bind to and activate GABA-A RECEPTORS. (See all compounds classified as GABA-A Receptor Agonists.)', 'Drugs used to induce SLEEP, prevent SLEEPLESSNESS, or treat SLEEP INITIATION AND MAINTENANCE DISORDERS. (See all compounds classified as Sleep Aids, Pharmaceutical.)']",,,
1338,441339,D-Glycero-D-manno-heptose 7-phosphate,C([C@H]([C@@H]1[C@H]([C@@H]([C@@H](C(O1)O)O)O)O)O)OP(=O)(O)O,,,,,,
1339,441340,D-Glycero-D-manno-heptose 1-phosphate,C([C@H]([C@@H]1[C@H]([C@@H]([C@@H](C(O1)OP(=O)(O)O)O)O)O)O)O,,,,,,
1340,441341,(2R)-2-(2-oxopyrrolidin-1-yl)butanamide,CC[C@H](C(=O)N)N1CCCC1=O,,,"['Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)', 'Drugs used to specifically facilitate learning or memory, particularly to prevent the cognitive deficits associated with dementias. These drugs act by a variety of mechanisms. (See all compounds classified as Nootropic Agents.)']",,,
1341,441342,"[(1S,5S)-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] 3-hydroxy-2-phenylpropanoate;bromide",C[N+]1([C@H]2CC(C[C@H]1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4)C.[Br-],,,,,,
1342,441343,"[(1S,5S)-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] 3-hydroxy-2-phenylpropanoate",C[N+]1([C@H]2CC(C[C@H]1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4)C,,,,,,
1343,441344,Dicyclomine hydrochloride,CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2.Cl,,,"['Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)', 'Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)']",,,
1344,441345,Flavoxate hydrochloride,CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OCCN3CCCCC3)C4=CC=CC=C4.Cl,,,"['Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)', 'Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS. (See all compounds classified as Urological Agents.)']",,,
1345,441346,Anzemet hydrate,CS(=O)(=O)O.C1C2CC3CC(CC1N3CC2=O)OC(=O)C4=CNC5=CC=CC=C54,,,"['Drugs that bind to but do not activate SEROTONIN 5-HT3 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT3 RECEPTOR AGONISTS. (See all compounds classified as Serotonin 5-HT3 Receptor Antagonists.)', 'Drugs used to prevent NAUSEA or VOMITING. (See all compounds classified as Antiemetics.)']",,,
1346,441347,Reglan,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl.O.Cl,,,"['Drugs used to prevent NAUSEA or VOMITING. (See all compounds classified as Antiemetics.)', 'Compounds and drugs that bind to and inhibit or block the activation of DOPAMINE D2 RECEPTORS. (See all compounds classified as Dopamine D2 Receptor Antagonists.)']",,,
1347,441348,Chloroprocaine hydrochloride,CCN(CC)CCOC(=O)C1=C(C=C(C=C1)N)Cl.Cl,['Intrathecal anaesthesia'],,"['Drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They act on any part of the nervous system and on every type of nerve fiber. In contact with a nerve trunk, these anesthetics can cause both sensory and motor paralysis in the innervated area. Their action is completely reversible. (From Gilman AG, et. al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed) Nearly all local anesthetics act by reducing the tendency of voltage-dependent sodium channels to activate. (See all compounds classified as Anesthetics, Local.)']",,,
1348,441349,CID 441349,C[C@@H]1CCC2C[C@@H](C(=CC=CC=C[C@H](C[C@H](C(=O)[C@@H]([C@@H](C(=C[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)C)O)OC)C)C)C)OC,,,,,,
1349,441350,Metyrosine,C[C@](CC1=CC=C(C=C1)O)(C(=O)O)N,"['For use in the treatment of patients with pheochromocytoma, for preoperative preparation of patients for surgery, management of patients when surgery is contraindicated, and chronic treatment of patients with malignant pheochromocytoma.']","['In patients with pheochromocytoma, who produce excessive amounts of norepinephrine and epinephrine, administration of one to four grams of metyrosine per day has reduced catecholamine biosynthesis from about 35 to 80 percent as measured by the total excretion of catecholamines and their metabolites (metanephrine and vanillylmandelic acid). The maximum biochemical effect usually occurs within two to three days, and the urinary concentration of catecholamines and their metabolites usually returns to pretreatment levels within three to four days after metyrosine is discontinued. Most patients with pheochromocytoma treated with metyrosine experience decreased frequency and severity of hypertensive attacks with their associated headache, nausea, sweating, and tachycardia. In patients who respond, blood pressure decreases progressively during the first two days of therapy with metyrosine; after withdrawal, blood pressure usually increases gradually to pretreatment values within two to three days.']",['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],"['Well absorbed from the gastrointestinal tract.', 'Because the first step is also the rate-limiting step, blockade of tyrosine hydroxylase activity results in decreased endogenous levels of catecholamines, usually measured as decreased urinary excretion of catecholamines and their metabolites.']","['Little biotransformation, with catechol metabolites accounting for less than 1% of the administered dose.']",['3.4 to 3.7 hours']
1350,441351,Rocuronium bromide,CC(=O)O[C@H]1[C@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C.[Br-],,,"['Drugs that interrupt transmission at the skeletal neuromuscular junction without causing depolarization of the motor end plate. They prevent acetylcholine from triggering muscle contraction and are used as muscle relaxants during electroshock treatments, in convulsive states, and as anesthesia adjuvants. (See all compounds classified as Neuromuscular Nondepolarizing Agents.)']",,,
1351,441352,(5R)-3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane;methanesulfonic acid,CN1[C@@H]2CCC1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4.CS(=O)(=O)O,,,,,,
1352,441353,(5R)-3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane,CN1[C@@H]2CCC1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
1353,441354,But-2-enedioic acid;1-[10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazin-2-yl]ethanone,CC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCN(CC4)CCO.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
1354,441355,CID 441355,CCC(C)[C@@H]1[C@H](CC[C@@]2(O1)C[C@@H]3C[C@H](O2)CC=C([C@H]([C@H](C=CC=C4CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)C)C.C[C@H]1CC[C@]2(C[C@@H]3C[C@H](O2)CC=C([C@H]([C@H](C=CC=C4CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)C)O[C@@H]1C(C)C,,,,,,
1355,441356,CID 441356,CCC(C)[C@@H]1[C@H](CC[C@@]2(O1)C[C@@H]3C[C@H](O2)CC=C([C@H]([C@H](C=CC=C4CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)C)C,,,,,,
1356,441357,CID 441357,C[C@@H]1CC[C@]2(C[C@H]3C[C@H](O2)CC=C([C@H]([C@@H](C=CC=C4CO[C@H]5[C@@]4([C@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@@H]6C[C@H]([C@H](C(O6)C)O[C@@H]7C[C@H]([C@H](C(O7)C)O)OC)OC)C)O[C@H]1C(C)C,,,,,,
1357,441358,Nortriptyline hydrochloride,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,,,"['Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However, the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system. (See all compounds classified as Antidepressive Agents, Tricyclic.)', 'Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin. (See all compounds classified as Adrenergic Uptake Inhibitors.)']",,,
1358,441359,[(1S)-2-phenylcyclopropyl]azanium;[(1R)-2-phenylcyclopropyl]azanium;sulfate,C1[C@H](C1C2=CC=CC=C2)[NH3+].C1[C@@H](C1C2=CC=CC=C2)[NH3+].[O-]S(=O)(=O)[O-],,,,,,
1359,441360,(1S)-2-phenylcyclopropan-1-amine,C1[C@@H](C1C2=CC=CC=C2)N,,,,,,
1360,441361,Vaniqa,C(CC(C(F)F)(C(=O)O)N)CN.O.Cl,['Treatment of facial hirsutism in women.'],,"['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Substances and drugs that inhibit or block the activity of ORNITHINE DECARBOXYLASE. (See all compounds classified as Ornithine Decarboxylase Inhibitors.)', 'Agents destructive to the protozoal organisms belonging to the suborder TRYPANOSOMATINA. (See all compounds classified as Trypanocidal Agents.)']",,,
1361,441362,Mephaquin; Racemic mefloquine; Ro 21-5998; WR 142490,C1CCNC(C1)C(C2=CC(=NC3=C2C=CC=C3C(F)(F)F)C(F)(F)F)O.Cl,,,,,,
1362,441363,"(1S,2S,6R,14R,16R)-5-(cyclopropylmethyl)-16-(2-hydroxy-3,3-dimethylbutan-2-yl)-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol",CC(C)(C)C(C)([C@H]1C[C@@]23CCC1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O,,,,,,
1363,441364,"(1S,2S,6R,14R,16R)-5-(cyclopropylmethyl)-16-(2-hydroxy-3,3-dimethylbutan-2-yl)-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol;hydrochloride",CC(C)(C)C(C)([C@H]1C[C@@]23CCC1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O.Cl,"['Sixmo is indicated for substitution treatment for opioid dependence in clinically stable adult patients who require no more than 8 mg/day of sublingual buprenorphine, within a framework of medical, social and psychological treatment.']",,"['Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)', 'Agents inhibiting the effect of narcotics on the central nervous system. (See all compounds classified as Narcotic Antagonists.)', 'Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. (See all compounds classified as Narcotics.)']",,,
1364,441365,"(1S,9S,10S)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene-4,10-diol;(2R,3R)-2,3-dihydroxybutanedioic acid",C1CC[C@]2([C@@H]3CC4=C([C@]2(C1)CCN3CC5CCC5)C=C(C=C4)O)O.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,,,,,,
1365,441366,"(4S,4aR,7aR,12bS)-9-hydroxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one;hydrochloride",CN1CC[C@]23[C@@H]4[C@@H]1CC5=C2C(=C(C=C5)O)O[C@H]3C(=O)CC4.Cl,,,,,,
1366,441367,CID 441367,CN1CC[C@]23[C@@H]4C(=O)CCC2[C@@H]1CC5=C3C(=C(C=C5)O)O4,,,,,,
1367,441368,CID 441368,C[NH+]1CC[C@]23[C@@H]4[C@@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O.C[NH+]1CC[C@]23[C@@H]4[C@@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O.[O-]S(=O)(=O)[O-],,,,,,
1368,441369,CID 441369,CN1CC[C@]23[C@@H]4[C@@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3C(=O)CC4.CN1CC[C@]23[C@@H]4[C@@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3C(=O)CC4.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.O.O.O.O.O,,,,,,
1369,441370,"(4S,4aS,7aR,12bS)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one;hydrochloride",CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@@H]1CC5=C3C(=C(C=C5)OC)O4)O.Cl,,,,,,
1370,441371,Erythromycin estolate,CCCCCCCCCCCCOS(=O)(=O)O.CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)CC)(C)O)C)C)O)(C)O,,,"['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)', 'Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. (See all compounds classified as Gastrointestinal Agents.)', 'Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)']",,,
1371,441372,CID 441372,CC[C@H]1C(=O)N2CCC[C@H]2C(=O)N([C@H](C(=O)N3CC(C(=O)CC3C(=O)N[C@H](C(=O)O[C@@H]([C@@H](C(=O)N1)NC(=O)C4=C(C=CC=N4)O)C)C5=CC=CC=C5)CS[C@@H]6CN7CCC6CC7)CC8=CC=C(C=C8)N(C)C)C,,,,,,
1372,441373,Merbromin,C1=CC=C(C(=C1)C2=C3C=C(C(=O)C=C3OC4=C(C(=C(C=C24)Br)[O-])[Hg])Br)C(=O)[O-].O.[Na+].[Na+],,,,,,
1373,441374,Kanamycin sulfate,C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)N)O)N.OS(=O)(=O)O,,,"['Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)', 'Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)']",,,
1374,441375,Paromomycin sulfate,C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O)O)N)O)O)N.OS(=O)(=O)O,,,"['Substances that are destructive to protozoans. (See all compounds classified as Antiprotozoal Agents.)', 'Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)']",,,
1375,441376,CID 441376,CC(=NS(=O)(=O)C1=CC=C(C=C1)N)[O-].[Na+],,,,,,
1376,441377,"7-(1,2,3,4,4a,5,7,7a-Octahydropyrrolo[3,4-b]pyridin-6-yl)-1-cyclopropyl-6-fluoranyl-8-methoxy-4-oxidanylidene-quinoline-3-carboxylic acid hydrochloride",COC1=C2C(=CC(=C1N3CC4CCCNC4C3)F)C(=O)C(=CN2C5CC5)C(=O)O.Cl,,,,,,
1377,441378,CID 441378,C[C@@H]1C=CC=C(C(=O)N=C2C(=CNN3CCN(CC3)C4CCCC4)C(=C5C(=C2O)C(=C(C6=C5C(=O)[C@](O6)(OC=C[C@@H]([C@H]([C@H]([C@H]([C@H]([C@@H]([C@@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C,,,,,,
1378,441379,"2'-Aminobiphenyl-2,3-diol",C1=CC=C(C(=C1)C2=C(C(=CC=C2)O)O)N,,,,,,
1379,441380,"2,4-Hexadienoic acid, 6-(2-aminophenyl)-2-hydroxy-6-oxo-",C1=CC=C(C(=C1)C(=CC=CC(=O)C(=O)O)O)N,,,,,,
1380,441381,Saponarin,C1=CC(=CC=C1C2=CC(=O)C3=C(C(=C(C=C3O2)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O)O,,,,,,
1381,441382,"(1R,3S,5R,7R,12R,22R,24S,25R,26S)-22-[(3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.05,7]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid",C[C@@H]1CC=CC=CC=CC=C[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@@H]3[C@H](O3)C=CC(=O)O1)O)O)O)C(=O)O)OC4[C@H]([C@H]([C@@H]([C@H](O4)C)O)N)O,,,,,,
1382,441383,Terconazole,CC(C)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=NC=N4)C5=C(C=C(C=C5)Cl)Cl,['For the treatment of candidiasis (a yeast-like fungal infection) of the vulva and vagina.'],"['Terconazole is a triazole antifungal agent available for intravaginal use. It is structurally related to imidazole-derivative antifungal agents, although terconazole and other triazoles have 3 nitrogens in the azole ring. By inhibiting the 14-alpha-demethylase (lanosterol 14-alpha-demethylase), Terconazole inhibits ergosterol synthesis. Depletion of ergosterol in fungal membrane disrupts the structure and many functions of fungal membrane leading to inhibition of fungal growth.']","['Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)']","['Following intravaginal administration of terconazole in humans, absorption ranged from 5-8% in three hysterectomized subjects and 12-16% in two non-hysterectomized subjects with tubal ligations', 'Following oral (30 mg) administration of 14C-labelled terconazole, excretion of radioactivity was both by renal (32-56%) and fecal (47-52%) routes.']","['Systemically absorbed drug appears to be rapidly and extensively metabolized. Terconazole primarily undergoes oxidatative N- and O-dealkylation, dioxolane ring cleavage, and conjugation.']",['6.9 hours (range 4.0-11.3)']
1383,441384,Abacavir sulfate,C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)[C@@H]4C[C@@H](C=C4)CO.C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)[C@@H]4C[C@@H](C=C4)CO.OS(=O)(=O)O,"['Ziagen is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults, adolescents and children.']",,"['Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. (See all compounds classified as Reverse Transcriptase Inhibitors.)', 'Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. (See all compounds classified as Anti-HIV Agents.)']","['Following oral administration of a 600-mg dose of radiolabeled abacavir, 82.2% of the dose is excreted in urine and 16% of the dose is excreted in feces. The 5-carboxylic acid metabolite, 5-glucuronide metabolite, and unchanged abacavir accounted for 30, 36, and 1.2%, respectively, of recovered radioactivity in urine; unidentified minor metabolites accounted for 15% of recovered radioactivity in urine.', 'It is not known whether abacavir is distributed into human milk; the drug is distributed into milk in rats.', 'Abacavir crosses the placenta in rats.', 'The oral bioavailability of abacavir is high with or without food; the CSF-to-plasma AUC ratio is approximately 0.3.', 'For more Absorption, Distribution and Excretion (Complete) data for ABACAVIR SULFATE (7 total), please visit the HSDB record page.']","[""Abacavir is partially metabolized by alcohol dehydrogenase (to form the 5'-carboxylic acid) and glucuronidation (to form the 5'-glucuronide)."", 'The metabolic fate of abacavir has not been fully determined, but the drug is metabolized in the liver. Abacavir is metabolized by alcohol dehydrogenase to form the 5-carboxylic acid and by glucuronyltransferase to form the 5-glucuronide; these metabolites do not appear to have any antiviral activity. Any involvement of cytochrome p450 isoenzymes in the metabolism of abacavir is limited.', 'Intracellularly, abacavir is phosphorylated to abacavir monophosphate by adenosine phosphotransferase; abacavir monophosphate is then converted to carbovir monophosphate in a reaction catalyzed by cytosolic enzymes and then to carbovir triphosphate by cellular kinases. Intracellular (host cell) conversion of abacavir to carbovir triphosphate is necessary for the antiviral activity of the drug. The in vitro intracellular half-life of carbovir triphosphate in CD4+ CEM cells is 3.3 hours.']","['The in vitro intracellular half-life of carbovir triphosphate /SRP: a metabolite of abacavir sulfate,/ in CD4+ CEM cells is 3.3 hours.', 'The plasma elimination half-life of abacavir following a single oral dose (given as abacavir sulfate) is about 1.5 hours. In HIV-infected children 3 months to 13 years of age who received 8 mg/kg of abacavir every 12 hours (given as an oral solution containing abacavir sulfate), steady-state plasma elimination half-life averaged 1.3 hours and was essentially the same as that reported after a single dose. Following oral administration of a single 300-mg dose of abacavir to an individual with renal failure (glomerular filtration rate less than 10 mL/minute) undergoing peritoneal dialysis, the plasma elimination half-life of the drug was 1.33 hours.']"
1384,441385,"[(3S)-oxolan-3-yl] N-[(2S,3S)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate",CC(C)CN(C[C@@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)O)S(=O)(=O)C3=CC=C(C=C3)N,,,,,,
1385,441386,Delavirdine mesylate,CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C.CS(=O)(=O)O,,,"['Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. (See all compounds classified as Anti-HIV Agents.)', 'Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. (See all compounds classified as Reverse Transcriptase Inhibitors.)']","['Elimination: Fecal: 44% following multiple doses of 330 mg three times a day in healthy volunteers. Renal: 51%, following multiple doses of 330 mg three times a day in healthy volunteers. Less than 5% of the dose is recovered unchanged in urine.', 'Delavirdine is distributed predominantly into blood plasma.', 'Delavirdine is well absorbed, especially at pH less than 2.0.', 'Delavirdine mesylate is rapidly absorbed following oral administration, and peak plasma concentrations of the drug are attained approximately 1 hour after the dose. Following oral administration of 400 mg of delavirdine mesylate 3 times daily in HIV-infected adults, mean steady-state peak plasma concentrations of the drug are 15.98 ug/ml (range: 0.91-45.66 ug/ml), mean trough plasma concentrations are 6.85 ug/ml (range: 0.05-20.55 ug/ml), and mean AUC is 82.19 ughour/ml.', 'For more Absorption, Distribution and Excretion (Complete) data for DELAVIRDINE MESYLATE (8 total), please visit the HSDB record page.']","['Delavirdine binds extensively to plasma proteins and primarily is metabolized by CYP3A4. The major metabolic pathway results in N-dealkylation. There is considerable intersubject variability in plasma delavirdine concentrations related to differences in CYP3A activity. The CSF-to-plasma ratio is 0.02.', ""The metabolism of delavirdine in the mouse was extensive and involved amide bond cleavage, N-desalkylation, hydroxylation at the C-6' position of the pyridine ring, and pyridine ring-cleavage as determined by MS and/or 1H and 13C NMR spectroscopies. N-desalkylation and amide bond cleavage were the primary metabolic pathways at low drug doses and, as the biotransformation of delavirdine to desalkyl delavirdine reached saturation or inhibition, amide bond cleavage became the predominant pathway at higher doses and after multiple doses.""]","['The apparent plasma half-life of delavirdine increases with dose. The mean plasma half-life of delavirdine is 5.8 hours (range: 2-11 hours) in adults receiving a dosage of 400 mg 3 times daily.', 'Elimination from plasma: Mean, 5.8 hours (range, 2 to 11 hours) following treatment with 400 mg three times a day. The apparent half-life increases with dose.']"
1386,441387,CID 441387,CC1=NN=C(S1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)CN4C=NN=N4)SC2)C(=O)[O-].[Na+],,,,,,
1387,441388,CID 441388,CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CSC3=CC=NC=C3)SC1)C(=O)[O-].[Na+],,,,,,
1388,441389,CID 441389,CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)C(C4=CC=CC=C4)OC=O)SC2)C(=O)[O-].[Na+],,,,,,
1389,441390,"(6R-(6alpha,7beta))-7-((Formyloxy)phenylacetamido)-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid",CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)C(C4=CC=CC=C4)OC=O)SC2)C(=O)O,,,,,,
1390,441391,"disodium;(6R,7R)-7-[(2-hydroxy-2-phenylacetyl)amino]-8-oxo-3-[[1-(sulfonatomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate",C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)O)C(=O)[O-])CSC4=NN=NN4CS(=O)(=O)[O-].[Na+].[Na+],,,,,,
1391,441392,CID 441392,CO[C@@]1([C@@H]2N(C1=O)C(=C(CS2)COC(=O)N)C(=O)[O-])NC(=O)CC3=CC=CS3.[Na+],,,,,,
1392,441393,"(6R,7R)-7-[[2-(2-amino-4-thiazolyl)-2-methoxyimino-1-oxoethyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-[oxo(propan-2-yloxy)methoxy]ethyl ester",CC(C)OC(=O)OC(C)OC(=O)C1=C(CS[C@H]2N1C(=O)[C@H]2NC(=O)C(=NOC)C3=CSC(=N3)N)COC,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
1393,441394,CID 441394,CON=C(C1=CSC(=N1)N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=CCS3)C(=O)[O-].[Na+],,,,,,
1394,441395,"2-amino-2-(hydroxymethyl)propane-1,3-diol;[(2S,3R)-3-methyloxiran-2-yl]phosphonic acid",C[C@@H]1[C@@H](O1)P(=O)(O)O.C(C(CO)(CO)N)O,,,,,,
1395,441396,"(1S,2R,18R,22S,25R,28R,40R)-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5S,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carboxylic acid;hydrochloride",C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H](C(C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O.Cl,,,,,,
1396,441397,Bacampicillin,CCOC(=O)OC(C)OC(=O)[C@H]1C(S[C@H]2N1C(=O)[C@H]2NC(=O)[C@@H](C3=CC=CC=C3)N)(C)C,"['For infections at the following sites: upper and lower respiratory tract; skin and soft tissue; urinary tract and acute uncomplicated gonococcal urethritis, when due to sensitive strains of the following organisms:  Gram-positive: streptococci (including <i>S. faecalis</i> and <i>S. pneumoniae</i>) and nonpenicillinase-producing staphylococci; Gram-negative: <i>H. influenzae</i>, <i>N. gonorrhoeae</i>, <i>E. coli</i>, <i>P. mirabilis</i>, <i>Salmonellae</i> and <i>Shigellae</i>.']",['Bacampicillin is a prodrug of ampicillin and is microbiologically inactive.'],['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],['Absorbed following oral administration.'],,
1397,441398,Bacampicillin hydrochloride,CCOC(=O)OC(C)OC(=O)[C@H]1C(S[C@H]2N1C(=O)[C@H]2NC(=O)[C@@H](C3=CC=CC=C3)N)(C)C.Cl,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
1398,441399,CID 441399,CC1=C(C(=NO1)C2=CC=CC=C2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)[O-].O.[Na+],,,,,,
1399,441400,Sodium;(4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid;trihydrate,C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN.O.O.O.[Na+],,,,,,
1400,441401,Linezolid,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,"['Linezolid is indicated in adults and children for the treatment of infections caused by susceptible Gram-positive bacteria, including nosocomial pneumonia, community-acquired pneumonia, skin and skin structure infections, and vancomycin-resistant _Enterococcus faecium_ infections. Examples of susceptible bacteria include _Staphylococcus aureus_, _Streptococcus pneumoniae_, _Streptococcus pyogenes_, and _Streptococcus agalactiae_.  Linezolid is not indicated for the treatment of Gram-negative infections, nor has it been evaluated for use longer than 28 days.']","['Linezolid is an oxazolidinone antibacterial agent effective against most strains of aerobic Gram-positive bacteria and mycobacteria. It appears to be bacteriostatic against both staphylococci and enterococci and bactericidal against most isolates of streptococci. Linezolid has shown some _in vitro_ activity against Gram-negative and anaerobic bacteria but is not considered efficacious against these organisms.  Linezolid is a reversible and non-selective inhibitor of monoamine oxidase (MAO) enzymes and can therefore contribute to the development of serotonin syndrome when administered alongside serotonergic agents such as selective serotonin re-uptake inhibitors (SSRIs) or tricyclic antidepressants (TCAs). Linezolid should not be used for the treatment of catheter-related bloodstream infections or catheter-site infections, as the risk of therapy appears to outweigh its benefits under these circumstances.']","['Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)', 'Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)']","['Linezolid is extensively absorbed following oral administration and has an absolute bioavailability of approximately 100%. Maximum plasma concentrations are reached within approximately 1 to 2 hours after dosing (T<sub>max</sub>) and range from 8.1-12.9 mcg/mL after single doses and 11.0-21.2 mcg/mL after multiple dosing.  The absorption of orally administered linezolid is not significantly affected by co-administration with food and it may therefore be given without regard to the timing of meals.', 'Urinary excretion is the primary means by which linezolid and its metabolic products are excreted. Following the administration of a radiolabeled dose of linezolid under steady-state conditions, approximately 84% of radioactivity was recovered in the urine, of which approximately 30% is unchanged parent drug, 40% is the hydroxyethyl glycine metabolite, and 10% is the aminoethoxyacetic acid metabolite. Fecal elimination is comparatively minor, with no parent drug observed in feces and only 6% and 3% of an administered dose found in the feces as the hydroxyethyl glycine metabolite and the aminoethoxyacetic acid metabolite, respectively.', 'At steady-state, the volume of distribution of linezolid in healthy adults is approximately 40-50 liters.', 'Total clearance of linezolid is estimated to be 100-200 mL/min, the majority of which appears to be non-renal. Mean renal clearance is approximately 40 mL/min, which suggests net tubular reabsorption, while non-renal clearance is estimated to account for roughly 65% of total clearance, or 70-150 mL/min on average. Variability in linezolid clearance is high, particularly for non-renal clearance.', 'Distributed to well-perfused tissues; volume of distribution slightly lower in women than men. VolD (steady state) - 40 to 50 L.', 'AUC is lower for pediatric patients compared with adults and a wider variability of linezolid AUC cross all pediatric age groups as compared with adults. Most pre-term neonates less than 7 days of age (gestational age less than 34 weeks) have larger AUC values than many full-term neonates and  older infants.', 'Linezolid was rapidly absorbed after p.o. dosing with an p.o. bioavailability of > 95% in rat and dog, and > 70% in mouse. Twenty-eight-day i.v./p.o. toxicokinetic studies in rat (20-200 mg kg(-1) day(-1)) and dog (10-80 mg kg(-1) day(-1)) revealed neither a meaningful increase in clearance nor accumulation upon multiple dosing. Linezolid had limited protein binding (<35%) and was very well distributed to most extravascular sites, with a volume of distribution at steady-state (V(ss)) approximately equal to total body water. Linezolid circulated mainly as parent drug and was excreted mainly as parent drug and two inactive carboxylic acids, PNU-142586 and PNU-142300. Minor secondary metabolites were also characterized. In all species, the clearance rate was determined by metabolism. Radioactivity recovery was essentially complete within 24-48 hr. Renal excretion of parent drug and metabolites was a major elimination route. Parent drug underwent renal tubular reabsorption, significantly slowing parent drug excretion and allowing a slow metabolic process to become rate-limiting in overall clearance. It is concluded that ADME data were relatively consistent across species and supported the rat and dog as the principal non-clinical safety species.', 'In two randomized, double-blind, placebo-controlled, dose-escalating trials, subjects were exposed either to oral (375, 500 or 625 mg) or intravenous (500 or 625 mg) linezolid or placebo twice daily. Serial blood and urine samples were obtained after the first- and multiple-dose administrations for up to 18 days. Non-compartmental pharmacokinetic analyses were used to describe the disposition of linezolid. Plasma linezolid concentrations and area under the concentration-time curves (AUC) increased proportionally with dose irrespective of the route of administration. Plasma linezolid concentrations remained above the MIC90 for susceptible target pathogens (4.0 mg/L) for the majority of the 12 hr dosing interval. Mean clearance, half-life and volume of distribution were similar irrespective of dose for both the oral and intravenous routes. Linezolid was well tolerated and the frequency of drug-related adverse events was similar between the linezolid and placebo groups. Oral and intravenous linezolid exhibit linear pharmacokinetics, with concentrations remaining above the target MIC90 /minimal inhibitory concentration/ for most of the dosing interval. These results support a twice-daily schedule for linezolid and demonstrate the feasibility of converting from intravenous to oral dosing without a dose adjustment.', 'For more Absorption, Distribution and Excretion (Complete) data for LINEZOLID (16 total), please visit the HSDB record page.']","['Linezolid is primarily metabolized to two inactive metabolites: an aminoethoxyacetic acid metabolite (PNU-142300) and a hydroxyethyl glycine metabolite (PNU-142586), both of which are the result of morpholine ring oxidation. The hydroxyethyl glycine metabolite - the most abundant of the two metabolites - is likely generated via non-enzymatic processes, though further detail has not been elucidated.  While the specific enzymes responsible for the biotransformation of linezolid are unclear, it does not appear to be subject to metabolism via the CYP450 enzyme system, nor does it meaningfully inhibit or induce these enzymes. Linezolid is, however, a reversible and non-selective inhibitor of monoamine oxidase enzymes.', 'In vitro studies have not shown that linezolid is metabolized by human cytochrome p450 enzymes. Linezolid does not inhibit the cytochrome p450 enzymes.', 'Linezolid is primarily metabolized via oxidation of the morpholine ring. Two inactive metabolites are formed: the aminoethoxyacetic acid metabolite and the hydroxyethyl glycine metabolite. The hydroxyethyl glycine metabolite is formed via a non-enzymatic chemical oxidation mechanism in vitro.', 'The drug is metabolized principally via oxidation to 2 inactive metabolites; an aminoethoxyacetic acid metabolite and a hydroxyethyl glycine metabolite. Linezolid is not metabolized to any measurable extent by the cytochrome p450 (CYP) enzyme system. Linezolid does not inhibit CYP isoenzymes 1A2, 2C9, 2C19, 2D6, 2E1, or 3A4 and is not an enzyme inducer, suggesting that the drug is unlikely to alter the pharmacokinetics of drugs metabolized by these enzymes.', 'In vitro studies were conducted to identify the hepatic enzyme(s) responsible for the oxidative metabolism of linezolid. In human liver microsomes, linezolid was oxidized to a single metabolite, hydroxylinezolid (M1). Formation of M1 was determined to be dependent upon microsomal protein and NADPH. Over a concentration range of 2 to 700 uM, the rate of M1 formation conformed to first-order (nonsaturable) kinetics. Application of conventional in vitro techniques were unable to identify the molecular origin of M1 based on the following experiments: a) inhibitor/substrates for various cytochrome P-450 (CYP) enzymes were unable to inhibit M1 formation; b) formation of M1 did not correlate (r(2) < 0.23) with any of the measured catalytic activities across a population of human livers (n = 14); c) M1 formation was not detectable in incubations using microsomes prepared from a baculovirus insect cell line expressing CYPs 1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4, 3A5, and 4A11. In addition, results obtained from an in vitro P-450 inhibition screen revealed that linezolid was devoid of any inhibitory activity toward the following CYP enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4). Additional in vitro studies excluded the possibility of flavin-containing monooxygenase and monoamine oxidase as potential enzymes responsible for metabolite formation. However, metabolite formation was found to be optimal under basic (pH 9.0) conditions, which suggests the potential involvement of either an uncharacterized P-450 enzyme or an alternative microsomal mediated oxidative pathway.', 'Linezolid is primarily metabolized by oxidation of the morpholine ring, which results in two inactive ring-opened carboxylic acid metabolites: the aminoethoxyacetic acid metabolite (A), and the hydroxyethyl glycine metabolite (B). Formation of metabolite B is mediated by a non-enzymatic chemical oxidation mechanism in vitro. Linezolid is not an inducer of cytochrome P450 (CYP) in rats, and it has been demonstrated from in vitro studies that linezolid is not detectably metabolized by human cytochrome P450 and it does not inhibit the activities of clinically significant human CYP isoforms (1A2, 2C9, 2C19, 2D6, 2E1, 3A4).']","['The elimination half-life is estimated to be between 5 and 7 hours.', '... A significant although weak correlation between age and total body clearance was observed. The mean (+ or - SD) values for elimination half-life, total clearance and apparent volume of distribution were 3.0 + or - 1.1 hr, 0.34 + or - 0.15 liter/h/kg and 0.73 + or - 0.18 liter/kg, respectively. ...', 'The following are elimination half live values of linezolid doses in adults: 400 mg tablet (single dose) - 5.2 hours; 400 mg tablet every 12 hours - 4.69 hours; 600 mg tablet (single dose) - 4.26 hours; 600 mg tablet every 12 hours - 5.4 hours; 600 mg oral suspension (single dose) - 4.6 hours; 600 mg intravenous injection (single dose) - 4.4 hours; 600 mg intravenous injection every 12 hours - 4.8 hours;. Pediatrics ranging in age from greater than 7 days of age to 11 years of age have a shorter half-life compared with adults.']"
1401,441402,CID 441402,CC12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)O.C1CNCCN1,,,,,,
1402,441403,CID 441403,CC12CC[C@H]3[C@H](C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)O,,,,,,
1403,441404,Testosterone cypionate,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)CCC4CCCC4)CCC5=CC(=O)CC[C@]35C,"['Testosterone cypionate is used in males that present conditions derived from a deficiency or absence of endogenous testosterone. These conditions are 1) primary hypogonadism, defined as the testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome or orchidectomy; and 2) hypogonadotropic hypogonadism characterized by idiopathic gonadotropin, LHRH deficiency or pituitary-hypothalamic injury from tumors, trauma or radiation.']",['Administration of ester derivatives of testosterone as testosterone cypionate generates an increase in serum testosterone to levels reaching 400% from the baseline within 24 hours of administration. These androgen levels remain elevated for 3-5 days after initial administration. The continuous variation in plasma testosterone after intramuscular administration of testosterone cypionate results in fluctuations in mood and libido as well as some local inflammation.'],"['Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power. (See all compounds classified as Androgens.)', 'These compounds stimulate anabolism and inhibit catabolism. They stimulate the development of muscle mass, strength, and power. (See all compounds classified as Anabolic Agents.)']","['Testosterone cypionate is an esterified anabolic which allows it to present a greater degree of solubility in fats and thus, the release and absorption occur in a slow rate compare to homologous molecules. Intramuscular administration of 200 mg of testosterone cypionate produced a mean supratherapeutic Cmax of 1122 ng/dl which occurred 4-5 days post-injection. After the fifth day, the levels of testosterone cypionate in plasma went down reaching an average of 400 ng/dl.', 'About 90% of a dose of testosterone given intramuscularly is excreted in the urine as glucuronic and sulfuric acid conjugates of testosterone and its metabolites; about 6% of a dose is excreted in the feces, mostly in the unconjugated form.', 'The volume of distribution following intravenous administration of testosterone is of approximately 1 L/kg.', 'Testosterone cypionate presents a lower clearance rate after intramuscular administration compared to other analogs of testosterone.']","['To start its activity, testosterone cypionate has to be processed by enzymes in the bloodstream. These enzymes will break the bond between the cypionate ester moiety and the testosterone. Once separated, testosterone is metabolized to 17-keto steroids through two different pathways. The major active metabolites are estradiol and dihydrotestosterone (DHT). Testosterone is metabolized to DHT by steroid 5α-reductase in skin, liver and urogenital tract. In reproductive tissues DHT is further metabolized to androstanediol.']","['The half-life of testosterone cypionate is one of the longest, being approximately of 8 days.']"
1404,441405,(S)-Bicalutamide,C[C@@](CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O,,,,,,
1405,441406,Hydrocortisone sodium phosphate,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)COP(=O)([O-])[O-])O)C)O.[Na+].[Na+],,,,,,
1406,441407,Hydrocortisone phosphate,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)COP(=O)(O)O)O)C)O,"[""For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.""]","['Hydrocortisone is the most important human glucocorticoid. It is essential for life and regulates or supports a variety of important cardiovascular, metabolic, immunologic and homeostatic functions. Topical hydrocortisone is used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Glucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic effects. Glucocorticoids are distinguished from mineralocorticoids and sex steroids by having different receptors, target cells, and effects. Technically, the term corticosteroid refers to both glucocorticoids and mineralocorticoids, but is often used as a synonym for glucocorticoid. Glucocorticoids suppress cell-mediated immunity. They act by inhibiting genes that code for the cytokines IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8 and TNF-alpha, the most important of which is the IL-2. Reduced cytokine production limits T cell proliferation. Glucocorticoids also suppress humoral immunity, causing B cells to express lower amounts of IL-2 and IL-2 receptors. This diminishes both B cell clonal expansion and antibody synthesis. The diminished amounts of IL-2 also leads to fewer T lymphocyte cells being activated.']",,"['Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption.', 'Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.']",['Primarily hepatic via CYP3A4'],['6-8 hours']
1407,441408,CID 441408,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)COC(=O)CCC(=O)[O-])O)C)O.[Na+],,,,,,
1408,441409,Prednisolone sodium phosphate,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)COP(=O)([O-])[O-])O)CCC4=CC(=O)C=C[C@]34C)O.[Na+].[Na+],,,"['A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. (See all compounds classified as Glucocorticoids.)']",,,
1409,441410,Leuprorelin acetate,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O,,,,,,
1410,441411,Epinephrine Hydrochloride,CNC[C@@H](C1=CC(=C(C=C1)O)O)O.Cl,,,"['Drugs that selectively bind to and activate beta-adrenergic receptors. (See all compounds classified as Adrenergic beta-Agonists.)', 'Drugs that selectively bind to and activate alpha adrenergic receptors. (See all compounds classified as Adrenergic alpha-Agonists.)', 'Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)', 'Drugs used to cause constriction of the blood vessels. (See all compounds classified as Vasoconstrictor Agents.)', 'Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)', 'Agents that dilate the pupil. They may be either sympathomimetics or parasympatholytics. (See all compounds classified as Mydriatics.)']","['.../ELIMINATION OF GELATINE USED AS PLASMA SUBSTITUTE/ IS RAPID & CONSTITUTES NO DRAWBACK TO USING THESE SOLN.', '...IT IS COMPLETELY ABSORBED IN 4 TO 6 WK, IT MAY BE LEFT IN PLACE AFTER CLOSURE OF OPERATIVE WOUND.', 'INTRAVASCULAR RETENTION, DISPERSAL, EXCRETION, & BREAK-DOWN OF GELATIN PLASMA SUBSTITUTES ARE DISCUSSED.']",,
1411,441412,Propiverine hydrochloride,CCCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OC3CCN(CC3)C.Cl,,,"['Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS. (See all compounds classified as Urological Agents.)', 'Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)', 'Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)']",,,
1412,441413,"(1R,3S)-5-[2-[(1R,3aS,7aR)-1-[(2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol",C[C@H](C=C[C@H](C)C(C)C)[C@H]1CC[C@@H]2[C@@]1(CCCC2=CC=C3C[C@H](C[C@@H](C3=C)O)O)C,,,,,,
1413,441414,Metaraminol bitartrate,C[C@@H]([C@@H](C1=CC(=CC=C1)O)O)N.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,,,"['Compounds that bind to and activate ADRENERGIC ALPHA-1 RECEPTORS. (See all compounds classified as Adrenergic alpha-1 Receptor Agonists.)', 'Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)', 'Drugs used to cause constriction of the blood vessels. (See all compounds classified as Vasoconstrictor Agents.)']",,,
1414,441415,Levobunolol hydrochloride,CC(C)(C)[NH2+]C[C@@H](COC1=CC=CC2=C1CCCC2=O)O.[Cl-],,,"['Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here. (See all compounds classified as Sympatholytics.)', 'Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)']",,,
1415,441416,CID 441416,CC1=CC2=C(C=C1C)N(C=N2)[C@@H]3[C@@H]([C@@H]([C@H](O3)CO)OP(=O)([O-])O[C@@H](C)CNC(=O)CC[C@@]4([C@H](C5[C@]6([C@@]([C@@H](C(=N6)C(=C7[C@@]([C@@H](C(=N7)C=C8C([C@@H](C(=N8)C(=C4[N-]5)C)CCC(=O)N)(C)C)CCC(=O)N)(C)CC(=O)N)C)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)C)O.O.[Co],,,,,,
1416,441417,beta-Cymaropyranose,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O)OC)O,,,,,,
1417,441418,beta-D-Digitalopyranose,C[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O)O)OC)O,,,,,,
1418,441419,alpha-D-manno-heptulopyranose,C([C@@H]1[C@H]([C@@H]([C@@H]([C@@](O1)(CO)O)O)O)O)O,,,,,,
1419,441420,beta-L-Oleandropyranose,C[C@H]1[C@@H]([C@H](C[C@H](O1)O)OC)O,,,,,,
1420,441421,Ajugose,C([C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)OC[C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)OC[C@@H]3[C@@H]([C@@H]([C@H]([C@H](O3)OC[C@@H]4[C@@H]([C@@H]([C@H]([C@H](O4)OC[C@@H]5[C@H]([C@@H]([C@H]([C@H](O5)O[C@]6([C@H]([C@@H]([C@H](O6)CO)O)O)CO)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O,,,,,,
1421,441422,beta-Gentiobiose,C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)O)O)O)O)O)O)O)O,,,,,,
1422,441423,CID 441423,C[C@H]1[C@@H]([C@H]([C@H]([C@H](O1)O)O[C@@H]2[C@@H]([C@H](C=C(O2)C(=O)[O-])O)O)O)O.[Na+],,,,,,
1423,441424,CID 441424,C[C@H]1[C@@H]([C@H]([C@H]([C@H](O1)O)O[C@@H]2[C@@H](C(C=C(O2)C(=O)O)O)O)O)O,,,,,,
1424,441425,"(2S,3R,4S,5R,6S)-6-[[(2S,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyoxolan-2-yl]methoxy]-4-(hydroxymethyl)oxane-2,3,5-triol",C([C@H]1[C@H]([C@H](O[C@@H]([C@@H]1O)OC[C@@]2([C@H]([C@@H]([C@H](O2)CO)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO[C@@H]4[C@@H]([C@H]([C@H]([C@H](O4)CO)O)O)O)O)O)O)O)O)O,,,,,,
1425,441426,2-O-alpha-L-Rhamnopyranosyl-D-glucopyranose,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2O)CO)O)O)O)O)O,,,,,,
1426,441427,6-O-(beta-D-xylopyranosyl)-D-glucopyranose,C1[C@H]([C@@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H](C(O2)O)O)O)O)O)O)O,,,,,,
1427,441428,Robinose,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@@H]([C@@H]([C@H]([C@@H](O2)O)O)O)O)O)O)O,,,,,,
1428,441429,6-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranose,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)O)O)O)O)O)O)O,,,,,,
1429,441430,Sesamose,C([C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)OC[C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)OC[C@@H]3[C@H]([C@@H]([C@](O3)(CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O)O)O)O)O)O)O)O,,,,,,
1430,441431,"[(2R,3S,5R)-3-hydroxy-5-(2H-pyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate",C1[C@@H]([C@H](O[C@H]1N2CN=CC=C2)COP(=O)(O)O)O,,,,,,
1431,441432,2-O-beta-D-Glucopyranosyl-beta-D-glucopyranose,C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O)O,,,,,,
1432,441433,Umbelliferose,C([C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@@H]2O[C@]3([C@H]([C@@H]([C@H](O3)CO)O)O)CO)CO)O)O)O)O)O)O,,,,,,
1433,441434,Verbascose,C([C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)OC[C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)OC[C@@H]3[C@@H]([C@@H]([C@H]([C@H](O3)OC[C@@H]4[C@H]([C@@H]([C@H]([C@H](O4)O[C@]5([C@H]([C@@H]([C@H](O5)CO)O)O)CO)O)O)O)O)O)O)O)O)O)O)O)O)O,,,,,,
1434,441435,Clusianose,C([C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)OC[C@](CO)([C@@H]([C@@H](CO)O)O)O)O)O)O)O,,,,,,
1435,441436,Perseitol,C([C@H]([C@H](C([C@@H]([C@H](CO)O)O)O)O)O)O,,,,,,
1436,441437,Quercitol,C1[C@H]([C@@H](C([C@H]([C@@H]1O)O)O)O)O,,,,,,
1437,441438,(-)-Viburnitol,C1[C@H]([C@H](C([C@H]([C@@H]1O)O)O)O)O,,,,,,
1438,441439,Volemitol,C([C@H]([C@H](C([C@@H]([C@@H](CO)O)O)O)O)O)O,,,,,,
1439,441440,Beta-alanine betaine,C[N+](C)(C)CCC(=O)[O-],,,,,,
1440,441441,"2-Amino-4-((carboxycarbonyl)amino)butanoic acid, (2S)-",C(CNC(=O)C(=O)O)[C@@H](C(=O)O)N,,,,,,
1441,441442,"(S)-4,5-Didehydropipecolic acid",C1C=CCN[C@@H]1C(=O)O,,,,,,
1442,441443,Canaline,C(CON)[C@@H](C(=O)O)N,,,,,,
1443,441444,"2,5-Dihydrophenylalanine",C1C=CCC(=C1)C[C@@H](C(=O)O)N,,,,,,
1444,441445,Hypoglycine B,C=C1C[C@H]1C[C@@H](C(=O)O)NC(=O)CC[C@@H](C(=O)O)N,,,,,,
1445,441446,Chaulmoogric acid,C1C[C@@H](C=C1)CCCCCCCCCCCCC(=O)O,,,,,,
1446,441447,Homostachydrine,C[N+]1(CCCC[C@H]1C(=O)[O-])C,,,,,,
1447,441448,"1,1-Dimethyl-2-carboxylatopiperidinium",C[N+]1(CCCCC1C(=O)O)C,,,,,,
1448,441449,"10,16-Dihydroxyhexadecanoic acid",C(CCCCC(=O)O)CCCC(CCCCCCO)O,,,,,,
1449,441450,(+)-gamma-Hydroxy-L-homoarginine,C(CN=C(N)N)[C@H](C[C@@H](C(=O)O)N)O,,,,,,
1450,441451,Hypoglycin A,C=C1C[C@H]1C[C@@H](C(=O)O)N,,,,,"['TRANSAMINATION RESULTS IN FORMATION OF METHYLENECYCLOPROPANEPYRUVIC ACID,  WHICH UNDERGOES DECARBOXYLATION TO METHYLENECYCLOPROPANE ACETIC ACID; PYRIDOXAL PHOSPHATE PLUS  MG(2+) IONS AND THIAMINE PYROPHOSPHATE, MG(2+) IONS PLUS COENZYME-A ARE THE COFACTORS INVOLVED  IN THE TWO REACTION STEPS.', 'Numerous abnormal metabolites were identified in large amounts in the urine of  hypoglycin-treated rats... .  analysis. ... Ten of them have not been previously associated with hypoglycin administration: these are  several hydroxy compounds, including those from the valine and isoleucine pathways,  2-oxo-adipic acid, n-butyrylglycine and isovaleryl glucuronide. These results indicate that  the pathways of isoleucine and valine metabolism are inhibited at their respective acyl-CoA  dehydrogenation steps, as is the case for fatty acid, leucine and lysine metabolism, as  previously shown.', '... 14C- and 3H-labelled palmitic acid  was administered with hypoglycin to rats, and radioactivity was measured in urinary  dicarboxylic acids... . Both isotopes were  incorporated into adipic and sebacic acids, indicating a precursor-product relationship.  Glutaric acid was, essentially, unlabelled. Preferential incorporation of C-16, relative to  C-1 of palmitate ...  could be deduced ... . It  thus appears that omega-oxidation of the fatty acid intervenes predominantly at an  intermediate stage of chain-shortening, when inhibition of beta-oxidation by hypoglycin  becomes more pronounced.', 'Hypoglycin A, which is now simply called hypoglycin, is metabolized by means of transamination  and oxidative decarboxylation to methylene cyclopropyl acetic acid (MCPA).[']",
1451,441452,(S)-2-Amino-2-[(S)-2-methylenecyclopropyl]acetic acid,C=C1C[C@@H]1[C@@H](C(=O)O)N,,,,,,
1452,441453,(2S)-4-hydroxy-2-(oxaloamino)butanoic acid,C(CO)[C@@H](C(=O)O)NC(=O)C(=O)O,,,,,,
1453,441454,S-n-Propenyl-L-cystein-S-oxid,CC=CS(=O)C[C@@H](C(=O)O)N,,,,,,
1454,441455,L-Selenocystathionine,C(C[Se]C[C@@H](C(=O)O)N)[C@@H](C(=O)O)N,,,,,,
1455,441456,alpha-Amino-3-oxo-5-isoxazolidineacetic acid,C1[C@H](ONC1=O)[C@@H](C(=O)O)N,,,,,,
1456,441457,Cathine,C[C@@H]([C@H](C1=CC=CC=C1)O)N,['Used to decrease appetite.'],"['Closely related to ephedrine, cathinone and other amphetamines, it may contribute to the stimulant effect of <i>Catha edulis</i>, although another constituent, cathinone appears to show stronger activity.']",['Agents that are used to suppress appetite. (See all compounds classified as Appetite Depressants.)'],"['The mucosa of the oral cavity is considered to be the first absorption segment, where the major proportion of the alkaloids is absorbed (mean +/- SD: 84 +/- 6% for cathine). [PMID: 12848785]']",,['5.2 +/- 3.4 hours']
1457,441458,"(2R,3R)-N-[4-(diaminomethylideneamino)butyl]-5-[3-[4-(diaminomethylideneamino)butylamino]-3-oxoprop-1-enyl]-2-(4-hydroxyphenyl)-2,3-dihydro-1-benzofuran-3-carboxamide",C1=CC(=CC=C1[C@H]2[C@@H](C3=C(O2)C=CC(=C3)C=CC(=O)NCCCCN=C(N)N)C(=O)NCCCCN=C(N)N)O,,,,,,
1458,441459,"(2R,3R)-N-[4-(diaminomethylideneamino)butyl]-5-[3-[4-(diaminomethylideneamino)butylamino]-3-oxoprop-1-enyl]-2-(4-hydroxyphenyl)-7-methoxy-2,3-dihydro-1-benzofuran-3-carboxamide",COC1=CC(=CC2=C1O[C@H]([C@@H]2C(=O)NCCCCN=C(N)N)C3=CC=C(C=C3)O)C=CC(=O)NCCCCN=C(N)N,,,,,,
1459,441460,"(9S,10R)-dihydroxyoctadecanoic acid",CCCCCCCC[C@H]([C@H](CCCCCCCC(=O)O)O)O,,,,,,
1460,441461,"8(r)-Hydroxy-9,12-octadecadienoic acid",CCCCCC=CCC=C[C@@H](CCCCCCC(=O)O)O,,,,,,
1461,441462,Neoamygdalin,C1=CC=C(C=C1)[C@@H](C#N)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O)O,,,"['Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. (See all compounds classified as Antineoplastic Agents, Phytogenic.)']",['THE MAX CYANIDE LEVEL AFTER ORAL ADMIN OF AMYGDALIN TO MICE WAS REACHED AT ABOUT 1 1/2-2 HR & WAS WITHIN THE RANGE OF VALUES SEEN AFTER KCN ADMIN. THE ABILITY OF THE CONTENTS OF VARIOUS REGIONS OF THE GI TRACT & OF TUMOR TISSUE TO RELEASE CYANIDE FROM AMYGDALIN WAS ASSESSED. THE STOMACH & UPPER INTESTINE HAD LITTLE ACTIVITY WHILE THE LOWER INTESTINE & FECES RELEASED LARGE AMOUNTS. THERE WAS A LARGE VARIATION BETWEEN MICE.'],"['AMYGDALIN IS A CHEMICAL COMBINATION OF GLUCOSE, BENZALDEHYDE, & CYANIDE FROM WHICH THE LATTER CAN BE RELEASED BY THE ACTION OF BETA-GLUCOSIDASE OR EMULSIN. ALTHOUGH THESE ENZYMES ARE NOT FOUND IN MAMMALIAN TISSUES, THE HUMAN INTESTINAL MICROFLORA APPEARS TO POSSESS THESE OR SIMILAR ENZYMES CAPABLE OF EFFECTING CYANIDE RELEASE RESULTING IN HUMAN POISONING. FOR THIS REASON AMYGDALIN MAY BE AS MUCH AS 40 TIMES MORE TOXIC BY THE ORAL ROUTE AS COMPARED WITH IV INJECTION.', '...PLANT GLYCOSIDES ARE CHARACTERIZED BY PRODN OF CYANIDE, TOGETHER WITH A SUGAR & AROMATIC ALDEHYDE, ON ENZYMIC OR ACID HYDROLYSIS. COMMON EXAMPLES ARE AMYGDALIN (GENTIOBIOSE + BENZALDEHYDE + HCN) WHICH IS PRESENT IN BITTER ALMONDS... AN ENZYME COMPLEX, EMULSIN, IS PRESENT TOGETHER WITH GLYCOSIDES IN PLANT TISSUES & CATALYZES THE HYDROLYSIS OF GLYCOSIDES, FIRST TO MANDELONITRILE OR P-HYDROXYMANDELONITRILE, & THEN TO BENZALDEHYDE OR P-HYDROXYBENZALDEHYDE, & HCN. ... THE ALDEHYDES ARE OXIDIZED TO CORRESPONDING AROMATIC ACIDS & EXCRETED AS PEPTIDE CONJUGATES.', '...VARIOUS PRUNUS SPECIES CONTAIN...AMYGDALIN, WHICH IS HYDROLYZED BY ENZYME EMULSIN... IN INTACT PLANT NO SUCH ACTION TAKES PLACE; IT IS NOT UNTIL PLANT TISSUE IS DAMAGED OR STARTS TO DECAY THAT LIBERATION OF HCN BEGINS.', 'BREAKDOWN /OF GLYCOSIDES/ OFTEN OCCURS MORE READILY OR MORE RAPIDLY IN RUMEN THAN IN DIGESTIVE TRACT OF MONOGASTRIC ANIMALS. ALSO, SMALL MOLECULES CAN BE ABSORBED AT THE RUMEN & THUS ENTER CIRCULATION RAPIDLY. BREAKDOWN OF CYANOGENIC GLYCOSIDES, SUCH AS AMYGDALIN, FROM MEMBERS OF ROSE FAMILY...IS AN EXAMPLE.', 'For more Metabolism/Metabolites (Complete) data for AMYGDALIN (9 total), please visit the HSDB record page.']","['PLASMA & URINE CONCN OF AMYGDALIN, WHOLE-BLOOD CONCN OF CN- & SCN- CONCN IN SERUM & URINE WERE DETERMINED IN CANCER PT FOLLOWING IV (4.5 G/SQUARE M) & ORAL (500-MG TABLET) ADMIN OF AMYGDALIN. FOLLOWING IV ADMIN, CONCN OF PARENT DRUG AS HIGH AS 1401 MUG/ML WERE OBSERVED WITH NO INCR IN PLASMA CONCN OF CN- OR SERUM CONCN OF SCN-. PLASMA ELIM OF AMYGDALIN WAS BEST DESCRIBED BY 2-COMPARTMENT OPEN MODEL WITH MEAN DISTRIBUTIVE PHASE T/2 OF 6.2 MIN, MEAN ELIM PHASE T/2 OF 120.3 MIN, & MEAN CLEARANCE OF 99.3 ML/MIN. FOLLOWING ORAL ADMIN OF AMYGDALIN, PLASMA CONCN WERE MUCH LOWER, WITH PEAK VALUES OF LESS THAN 525 NG/ML. CN- CONCN INCR TO VALUES AS HIGH AS 2.1 MUG/ML WHOLE BLOOD. SCN- CONCN DID NOT INCR FOR SEVERAL DAYS, PLATEAUING AT VALUES AS HIGH AS 38 MUG/ML SERUM.']"
1462,441463,CID 441463,C1[C@H]([C@H]([C@H]([C@H](O1)OC[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)O[C@H](C#N)C3=CC=CC=C3)O)O)O)O)O)OC(=O)C=CC4=CC=C(C=C4)O[C@@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)CO)O)O)O,,,,,,
1463,441464,"(2R)-3-(hydroxymethyl)-2-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybut-3-enenitrile",C=C(CO)[C@H](C#N)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1464,441465,p-Glucosyloxymandelonitrile,C1=CC(=CC=C1C(C#N)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O,,,,,,
1465,441466,"2-Cyclopentene-1-carbonitrile, 1-(beta-D-glucopyranosyloxy)-4,5-dihydroxy-,(1alpha,4alpha,5beta)-",C1=C[C@]([C@@H]([C@H]1O)O)(C#N)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O,,,,,,
1466,441467,Lotaustralin,CC[C@](C)(C#N)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1467,441468,Epilucumin,C1[C@H]([C@@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)O[C@H](C#N)C3=CC=CC=C3)O)O)O)O)O)O,,,,,,
1468,441469,CID 441469,CC(=C)[C@H](C#N)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO[C@H]2[C@@H]([C@H]([C@H](CO2)O)O)O)O)O)O,,,,,,
1469,441470,"3-Butenenitrile, 2-(beta-D-glucopyranosyloxy)-3-methyl-, (R)-",CC(=C)[C@H](C#N)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1470,441471,CID 441471,C1=CC(=CC=C1[C@H](C#N)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
1471,441472,Sarmentosin epoxide,C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)OCC2C(O2)(CO)C#N)O)O)O)O,,,,,,
1472,441473,Zierin,C1=CC(=CC(=C1)O)[C@@H](C#N)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O,,,,,,
1473,441474,beta-D-Apiose,C1[C@@]([C@H]([C@@H](O1)O)O)(CO)O,,,,,,
1474,441475,2-Deoxy-alpha-D-ribopyranose,C1[C@@H]([C@@H](CO[C@@H]1O)O)O,,,,,,
1475,441476,Pectin,[C@@H]1([C@H]([C@H](O[C@H]([C@@H]1O)O)C(=O)O)O)O,"['Pectin is used in food as a gelling agent and stabilizer. As a medical drug, it has obtained a great interest in its potential use as a source of dietary fiber, lipid, cholesterol, serum glucose and insulin level lowering effect, gastric emptying delay. Some recent studies have researched the possibility of using pectin for the formation of nanoparticles as a delivery vehicle of drugs.']","['Pectin increases viscosity and volume of stools which helps it to be used for constipation and diarrhea. It is reported as well to present lowering effects of different body components. This effect depends on the type of pectin which indicated that this effect is related to the composition of the correspondent pectin. Nonetheless, this data is still unclear and more studies need to be performed to conclude this effect of pectin.']",['Substances used in the processing or storage of foods or animal feed including ANTIOXIDANTS; FOOD PRESERVATIVES; FOOD COLORING AGENTS; FLAVORING AGENTS; ANTI-INFECTIVE AGENTS; EXCIPIENTS and other similarly used substances. Many of the same substances are used as PHARMACEUTIC AIDS. (See all compounds classified as Food Additives.)'],"['Pectin is not absorbed and it is not distributed in the body.', 'Pectin is completely excreted in the feces, including a small amount of trigalacturonic acid that can be found in the colon.', 'Pharmacokinetic studies have not been performed as pectin is not absorbed.', 'Pharmacokinetic studies have not been performed as pectin is not absorbed.']",['Pectin is depolymerized and de-esterified to a very small extent. It passes to the small intestine as a macromolecule and the majority of the pectin is eliminated unchanged.'],['Pharmacokinetic studies have not been performed as pectin is not absorbed.']
1476,441477,beta-D-Glucosamine,C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)N)O)O)O,,,,,,
1477,441478,beta-D-Glucopyranuronic acid,[C@@H]1([C@@H]([C@H](O[C@H]([C@@H]1O)O)C(=O)O)O)O,,,,,,
1478,441479,beta-D-hamamelose,C1[C@H]([C@H]([C@@]([C@@H](O1)O)(CO)O)O)O,,,,,,
1479,441480,alpha-D-Quinovopyranose,C[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O)O)O)O,,,,,,
1480,441481,beta-D-Ribopyranose,C1[C@H]([C@H]([C@H]([C@@H](O1)O)O)O)O,,,,,,
1481,441482,alpha-D-Ribulose,C1[C@H]([C@H]([C@@](O1)(CO)O)O)O,,,,,,
1482,441483,beta-D-Sedoheptulopyranose,C([C@@H]1[C@H]([C@H]([C@@H]([C@](O1)(CO)O)O)O)O)O,,,,,,
1483,441484,alpha-L-Sorbopyranose,C1[C@@H]([C@H]([C@@H]([C@](O1)(CO)O)O)O)O,,,,,,
1484,441485,2-Methoxyestrone 3-sulfate,C[C@]12CC[C@@H]3[C@H]([C@H]1CCC2=O)CCC4=CC(=C(C=C34)OC)OS(=O)(=O)O,,,,,,
1485,441486,2-Methoxyestradiol-17beta 3-sulfate,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=C(C=C34)OC)OS(=O)(=O)O,,,,,,
1486,441487,"WURCS=2.0/2,2,1/[a2122h-1b_1-5][a211h-1a_1-5]/1-2/a6-b1",C1[C@@H]([C@@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)O)O)O)O)O)O)O,,,,,,
1487,441488,"Dodeca-3,6,9-trien-1-ol",CCC=CCC=CCC=CCCO,,,,,,
1488,441489,"Hentriacontane-14,16-dione",CCCCCCCCCCCCCCCC(=O)CC(=O)CCCCCCCCCCCCC,,,,,,
1489,441490,Nonacosan-10-one,CCCCCCCCCCCCCCCCCCCC(=O)CCCCCCCCC,,,,,,
1490,441491,Propanethial S-oxide,CCC=S=O,,,,,,
1491,441492,"N-(2-methylpropyl)-2,4-tetradecadiene-8,10-diynamide",CCCC#CC#CCCC=CC=CC(=O)NCC(C)C,,,,,,
1492,441493,CID 441493,CS(=O)CCCCCC(=NOS(=O)(=O)[O-])S[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1493,441494,CID 441494,CS(=O)CCCCCC(=NOS(=O)(=O)O)S[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1494,441495,CID 441495,CSCCCCCC(=NOS(=O)(=O)[O-])S[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1495,441496,CID 441496,CSCCCCCC(=NOS(=O)(=O)O)S[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1496,441497,CID 441497,C=CCCCC(=NOS(=O)(=O)[O-])S[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1497,441498,CID 441498,CC(=NOS(=O)(=O)[O-])S[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1498,441499,CID 441499,CC(=NOS(=O)(=O)O)S[C@@H]1[C@@H]([C@H]([C@@H](C(O1)CO)O)O)O,,,,,,
1499,441500,CID 441500,CS(=O)(=O)CCCC(=NOS(=O)(=O)[O-])S[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1500,441501,CID 441501,CC[C@@](C)(CC(=NOS(=O)(=O)[O-])S[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)O,,,,,,
1501,441502,CID 441502,CC[C@@](C)(CC(=NOS(=O)(=O)O)S[C@@H]1[C@@H]([C@H]([C@@H](C(O1)CO)O)O)O)O,,,,,,
1502,441503,CID 441503,CC[C@H](C)C(=NOS(=O)(=O)[O-])S[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1503,441504,CID 441504,CC[C@H](C)C(=NOS(=O)(=O)O)S[C@@H]1[C@@H]([C@H]([C@@H](C(O1)CO)O)O)O,,,,,,
1504,441505,CID 441505,CC(C)(CC(=NOS(=O)(=O)[O-])S[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)O,,,,,,
1505,441506,CID 441506,CC(C)(CC(=NOS(=O)(=O)O)S[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)O,,,,,,
1506,441507,CID 441507,CSCCCCC(=NOS(=O)(=O)[O-])S[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1507,441508,CID 441508,CS(=O)(=O)CCCCC(=NOS(=O)(=O)[O-])S[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1508,441509,CID 441509,CS(=O)(=O)CCCCC(=NOS(=O)(=O)O)S[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1509,441510,CID 441510,CS(=O)CCCC(=NOS(=O)(=O)[O-])S[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1510,441511,CID 441511,CS(=O)CCCC(=NOS(=O)(=O)O)S[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1511,441512,CID 441512,CSCCCC(=NOS(=O)(=O)[O-])S[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1512,441513,CID 441513,CSCCCC(=NOS(=O)(=O)O)S[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1513,441514,CID 441514,CCC(=NOS(=O)(=O)[O-])S[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1514,441515,CID 441515,CCC(=NOS(=O)(=O)O)S[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1515,441516,CID 441516,COC1=CC=CC(=C1)CC(=NOS(=O)(=O)[O-])S[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O,,,,,,
1516,441517,CID 441517,COC1=CC=CC(=C1)CC(=NOS(=O)(=O)O)S[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O,,,,,,
1517,441518,CID 441518,C=CCCC(=NOS(=O)(=O)[O-])S[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1518,441519,CID 441519,C=CCCC(=NOS(=O)(=O)O)S[C@@H]1[C@@H]([C@H]([C@@H](C(O1)CO)O)O)O,,,,,,
1519,441520,CID 441520,C=CC[C@@H](CC(=NOS(=O)(=O)[O-])S[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)O,,,,,,
1520,441521,CID 441521,C=CC[C@@H](CC(=NOS(=O)(=O)O)S[C@@H]1[C@@H]([C@H]([C@@H](C(O1)CO)O)O)O)O,,,,,,
1521,441522,CID 441522,C1=CC=C(C=C1)CCC(=NOS(=O)(=O)[O-])S[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O,,,,,,
1522,441523,"[[2-methyl-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanylpropylidene]amino] sulfate",CC(C)C(=NOS(=O)(=O)[O-])S[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1523,441524,Glucoputranjivin,CC(C)C(=NOS(=O)(=O)O)S[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1524,441525,CID 441525,CS(=O)CCCCC(=NOS(=O)(=O)[O-])S[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1525,441526,CID 441526,CS(=O)CCCCC(=NOS(=O)(=O)O)S[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1526,441527,CID 441527,CS(=O)C=CCCC(=NOS(=O)(=O)[O-])S[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1527,441528,CID 441528,CS(=O)C=CCCC(=NOS(=O)(=O)O)S[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1528,441529,CID 441529,C1=CC2=C(C(=C1)O)C(=CN2)CC(=NOS(=O)(=O)[O-])S[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
1529,441530,CID 441530,COC1=CC=CC2=C1C(=CN2)CC(=NOS(=O)(=O)[O-])S[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
1530,441531,CID 441531,CON1C=C(C2=CC=CC=C21)CC(=NOS(=O)(=O)[O-])S[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
1531,441532,CID 441532,C=C[C@@H](CC(=NOS(=O)(=O)[O-])S[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)O,,,,,,
1532,441533,CID 441533,C=C[C@@H](CC(=NOS(=O)(=O)O)SC1[C@@H]([C@H](C([C@H](O1)CO)O)O)O)O,,,,,,
1533,441534,CID 441534,C1=CC(=CC=C1CC(=NOS(=O)(=O)[O-])S[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O,,,,,,
1534,441535,CID 441535,C=CCC(=NOS(=O)(=O)[O-])S[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1535,441536,"3-[2-sulfonatooxyimino-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanylethyl]indole-1-sulfonate",C1=CC=C2C(=C1)C(=CN2S(=O)(=O)[O-])CC(=NOS(=O)(=O)[O-])S[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
1536,441537,Sulfoglucobrassicin,C1=CC=C2C(=C1)C(=CN2S(=O)(=O)O)CC(=NOS(=O)(=O)O)S[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
1537,441538,Clitidine 5'-phosphate,C1=CN(C=C(C1=N)C(=O)O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O,,,,,,
1538,441539,Amataine,COC1=CC=CC2=C1N3C[C@@]45C[C@H]6[C@]3([C@]27CCN8[C@H]7[C@@]9(C6)CCO[C@H]9CC8)O[C@H]4N1CC[C@@]23[C@@H]1[C@@]1([C@H]5OCC1)CC(=C2NC1=CC=CC=C31)C(=O)OC,,,,,,
1539,441540,"3H-Purin-6-amine, 3-(3-methyl-2-butenyl)-",CC(=CC[N+]1=C2C(=C(N=C1)N)NC=N2)C,,,,,,
1540,441541,alpha-Amanitin,CC[C@H](C)[C@H]1C(=O)NCC(=O)N[C@H]2CS(=O)C3=C(C[C@@H](C(=O)NCC(=O)N1)NC(=O)[C@@H](NC(=O)[C@@H]4C[C@H](CN4C(=O)[C@@H](NC2=O)CC(=O)N)O)[C@@H](C)[C@H](CO)O)C5=C(N3)C=C(C=C5)O,,,"['Compounds that inhibit cell production of DNA or RNA. (See all compounds classified as Nucleic Acid Synthesis Inhibitors.)', 'Substances which, when ingested, inhaled, or absorbed, or when applied to, injected into, or developed within the body in relatively small amounts may, by their chemical action, cause damage to structure or disturbance of function. (From Dorland, 27th ed) (See all compounds classified as Poisons.)']",,,
1541,441542,Phalloidine,C[C@H]1C(=O)N[C@H]2CC3=C(NC4=CC=CC=C34)SC[C@@H](C(=O)N5C[C@H](C[C@H]5C(=O)N1)O)NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)C[C@](C)(CO)O)C)[C@H](C)O,,,"['Substances which, when ingested, inhaled, or absorbed, or when applied to, injected into, or developed within the body in relatively small amounts may, by their chemical action, cause damage to structure or disturbance of function. (From Dorland, 27th ed) (See all compounds classified as Poisons.)']","['THE UPTAKE, BINDING AND ELIMINATION OF PHALLOIDIN BY LIVER WAS COMPARED IN ADULT AND BABY (17-19 DAYS OLD) RATS IN VIVO AND IN VITRO. IN BOTH GROUPS, THERE WAS NO RELATION BETWEEN THE CONCENTRATION OF THE POISON IN THE LIVER AND THE TOXICITY. ALTHOUGH BABY RATS SHOWED A SIGNIFICANTLY HIGHER TOLERANCE AGAINST PHALLOIDIN THAN THE ADULT ANIMALS, THE CONCENTRATION OF THE POISON IN THE LIVER OF BABY RATS WAS HIGHER, AND THE ELIMINATION WAS SIGNIFICANTLY SLOWER THAN IN ADULT RATS. THE VERY TIGHT BINDING AND CONCENTRATION OF PHALLOIDIN IN THE LIVER WAS EXPLAINED BY AN EXTREMELY LOW DISSOCIATION CONSTANT.', 'PHALLOIN AND GAMMA-AMANITIN WERE DETECTED WITHIN THE FIRST DAY AND PHALLOIDIN WITHIN THE SECOND DAY IN THE URINE OF RATS AFTER ADMINISTRATION OF AMANITA PHALLOIDES EXTRACTS.']","['VARIOUS OBSERVATIONS SUGGESTED THAT PHALLOIDINE, A POISONOUS CONSTITUENT OF THE GREEN MUSHROOM, AMANITA PHALLOIDES, WOULD NOT BE TOXIC PER SE, BUT WOULD UNDERGO BIOACTIVATION IN THE LIVER. USING (3)H-DEMETHYLPHALLOIN, A TOXIC DERIVATIVE OF PHALLOIDINE, /IT WAS CONCLUDED/...THAT (3)H-DEMETHYLPHALLOIN, AND MOST PROBABLY ALSO PHALLOIDINE, ARE UNMETABOLIZED IN THE LIVERS OF RATS AND MICE. A SECONDARY EXCRETORY PRODUCT IN THE URINE OF TREATED ANIMALS WAS FOUND TO BE AN AUTODEGRADATION COMPOUND OF THE (3)H-LABELED DERIVATIVE.']",
1542,441543,CID 441543,C[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CCCNP(=N)(N)NS(=O)(=O)O)N,,,,,,
1543,441544,CID 441544,CC(C)[C@@H]1[C@@H](C(=O)NC(=CCl)C(=O)N[C@H](CC2=C(O1)CC(C2=O)O)C(=O)O)NC(=O)[C@H]([C@@H](CCCN)O)NC(=O)[C@H](CC(C)C(Cl)Cl)NC(=O)C(O)O,,,,,,
1544,441545,"Heptadeca-1,9,16-trien-4,6-diyn-3-one",C=CCCCCCC=CCC#CC#CC(=O)C=C,,,,,,
1545,441546,"(2R)-tridec-11-en-3,5,7,9-tetrayne-1,2-diol",CC=CC#CC#CC#CC#C[C@H](CO)O,,,,,,
1546,441547,"1,9-Heptadecadiene-4,6-diyne-3,8-diol, (3R,8S,9Z)-",CCCCCCCC=C[C@@H](C#CC#C[C@@H](C=C)O)O,,,,,,
1547,441548,CID 441548,CC#CC#CC=C[C@H]1[C@@H](CCCO1)O,,,,,,
1548,441549,"N-(2-methylpropyl)hexadeca-2,6,8-trien-10-ynamide",CCCCCC#CC=CC=CCCC=CC(=O)NCC(C)C,,,,,,
1549,441550,"(2S)-trideca-3,11-dien-5,7,9-triyne-1,2-diol",CC=CC#CC#CC#CC=C[C@@H](CO)O,,,,,,
1550,441551,Thiarubrine B,CC#CC#CC1=CC=C(SS1)C#CC=C,,,,,,
1551,441552,"1-Tridecene-3,5,7,9,11-pentayne",CC#CC#CC#CC#CC#CC=C,,,,,,
1552,441553,Methyl 3-(5-hept-4-en-2-ynoylfuran-2-yl)prop-2-enoate,CCC=CC#CC(=O)C1=CC=C(O1)C=CC(=O)OC,,,,,,
1553,441554,3-(5-Hept-4-en-2-ynoylfuran-2-yl)prop-2-enoic acid,CCC=CC#CC(=O)C1=CC=C(O1)C=CC(=O)O,,,,,,
1554,441555,"(2S)-4-[(2S,13R)-2,13-dihydroxy-13-[(2R,5R)-5-[(2R,5R)-5-[(1R)-1-hydroxyundecyl]oxolan-2-yl]oxolan-2-yl]tridecyl]-2-methyl-2H-furan-5-one",CCCCCCCCCC[C@H]([C@H]1CC[C@@H](O1)[C@H]2CC[C@@H](O2)[C@@H](CCCCCCCCCC[C@@H](CC3=C[C@@H](OC3=O)C)O)O)O,,,"['Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. (See all compounds classified as Antineoplastic Agents, Phytogenic.)', 'Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']",,,
1555,441556,Acremoauxin A,C[C@H](C1=CNC2=CC=CC=C21)C(=O)OC[C@H]([C@@H]([C@@H](CO)O)O)O,,,,,,
1556,441557,Bullatacinone,CCCCCCCCCC[C@@H]([C@H]1CC[C@@H](O1)[C@H]2CC[C@@H](O2)[C@@H](CCCCCCCCCC[C@@H]3C[C@H](C(=O)O3)CC(=O)C)O)O,,,,,,
1557,441558,Chalcogran,CC[C@H]1CC[C@]2(O1)CCCO2,,,,,,
1558,441559,N-(4-hydroxycinnamoyl)-5-hydroxyanthranilic acid,C1=CC(=CC=C1C=CC(=O)NC2=C(C=C(C=C2)O)C(=O)O)O,,,,,,
1559,441560,Coronarian,C(C[N+](=O)[O-])C(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O)OC(=O)CC[N+](=O)[O-])O)O,,,,,,
1560,441561,Cucumopine,C1[C@H](N[C@](C2=C1NC=N2)(CCC(=O)O)C(=O)O)C(=O)O,,,,,,
1561,441562,Dianthramine,C1=CC(=C(C=C1O)NC2=C(C=CC(=C2)O)C(=O)O)C(=O)O,,,,,,
1562,441563,DIMBOA glucoside,COC1=CC2=C(C=C1)N(C(=O)[C@H](O2)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O,,,,,,
1563,441564,Indican,C1=CC=C2C(=C1)C(=CN2)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
1564,441565,"2-[(1R,2S,3S)-3-hydroxy-2-pent-2-enylcyclopentyl]acetic acid",CCC=CC[C@H]1[C@H](CC[C@@H]1O)CC(=O)O,,,,,,
1565,441566,CID 441566,CCC[C@H]1[C@@H](C(=O)C[C@@H](C(=CC)CC2=C1C(=O)OC2=O)O)O,,,,,,
1566,441567,4-[12-(3-hexadec-3-enyloxiran-2-yl)dodecyl]-2-methyl-2H-furan-5-one,CCCCCCCCCCCCC=CCCC1C(O1)CCCCCCCCCCCCC2=CC(OC2=O)C,,,,,,
1567,441568,CID 441568,CCCCCCCCCCC=CCCC(C(CCC=CCC[C@@H](CCCCCC(CC1=CC(OC1=O)C)O)O)O)O,,,,,,
1568,441569,"Hexa-3,5-dienyl butanoate",CCCC(=O)OCCC=CC=C,,,,,,
1569,441570,Isotan B,C1=CC=C2C(=C1)C(=CN2)OC(=O)C3[C@H]([C@@H]([C@](O3)(CO)O)O)O,,,,,,
1570,441571,Lycomarasmine,C([C@@H](C(=O)O)NCC(C(=O)O)NCC(=O)N)C(=O)O,,,,,,
1571,441572,"(2S,2'S,5'S)-Lilac aldehyde",C[C@H](C=O)[C@@H]1CC[C@@](O1)(C)C=C,,,,,,
1572,441573,(2S)-6-amino-2-[[(1S)-1-carboxyethyl]amino]hexanoic acid,C[C@@H](C(=O)O)N[C@@H](CCCCN)C(=O)O,,,,,,
1573,441574,(S)-4-Nonanolide,CCCCC[C@H]1CCC(=O)O1,,,,,,
1574,441575,Parasorbic acid,C[C@H]1CC=CC(=O)O1,,,,,,
1575,441576,"(3,4-Dihydroxy-10-oxo-2-propyl-2,3,4,7,8,9-hexahydrooxecin-9-yl) hexa-2,4-dienoate",CCCC1C(C(C=CCCC(C(=O)O1)OC(=O)C=CC=CC)O)O,,,,,,
1576,441577,(2S)-2-[[(1R)-1-carboxy-4-(diaminomethylideneamino)butyl]amino]pentanedioic acid,C(C[C@H](C(=O)O)N[C@@H](CCC(=O)O)C(=O)O)CN=C(N)N,,,,,,
1577,441578,CID 441578,CCCC1CC=C[C@H](CCCC(=O)O1)O,,,,,,
1578,441579,Ruscopine,COC1=C(C=C(C=C1)CCC(CCCN=CN)N=CN)OC,,,,,,
1579,441580,"(5S)-3-acetyl-5-[(2S)-butan-2-yl]pyrrolidine-2,4-dione",CC[C@H](C)[C@H]1C(=O)C(C(=O)N1)C(=O)C,,,,,,
1580,441581,Ranunculin,C1=CC(=O)O[C@@H]1CO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O,,,,,,
1581,441582,3-Acetylnerbowdine,CC(=O)O[C@@H]1C[C@@H]2[C@@]3(CCN2CC4=C(C5=C(C=C43)OCO5)OC)[C@@H](C1)O,,,,,,
1582,441583,Albomaculine,CN1CCC2=CC[C@@H]3[C@H]([C@@H]21)C4=CC(=C(C(=C4C(=O)O3)OC)OC)OC,,,,,,
1583,441584,CID 441584,CO[C@@H]1C[C@@H]2[C@@]3(CCN2CC4=C(C(=C(C=C43)O)OC)OC)C=C1,,,,,,
1584,441585,"Crinan-12-ol, 1,2-didehydro-3alpha,7-dimethoxy-",CO[C@@H]1C[C@@H]2[C@]3(C=C1)[C@@H](CN2CC4=C(C5=C(C=C34)OCO5)OC)O,,,,,,
1585,441586,Belladine,CN(CCC1=CC=C(C=C1)OC)CC2=CC(=C(C=C2)OC)OC,,,,,,
1586,441587,Brunsvigine,C1[C@H]([C@H](C=C2[C@H]1N3C[C@H]2C4=CC5=C(C=C4C3)OCO5)O)O,,,,,,
1587,441588,Candimine,CN1CCC2=C[C@@H]([C@@H]3[C@H]([C@@H]21)C4=CC5=C(C(=C4C(=O)O3)OC)OCO5)O,,,,,,
1588,441589,Caranine,C1CN2CC3=CC4=C(C=C3[C@H]5[C@H]2C1=CC[C@H]5O)OCO4,,,,,,
1589,441590,Caribine,C1C[C@H]2C=C3[C@@H]4[C@@H]([C@H]2NC1)C5=CC6=C(C=C5CN4CC3O)OCO6,,,,,,
1590,441591,Carinatine,COC1=C(C=C2[C@@H]3[C@@H]([C@H](C=C4[C@H]3N(CC4)CC2=C1)CO)O)O,,,,,,
1591,441592,Cavinine,CO[C@@H]1C[C@@H]2[C@@]3([C@@H](CN2CC4=C(C5=C(C=C43)OCO5)OC)O)[C@@H]6[C@H]1O6,,,,,,
1592,441593,Haemanthamine,CO[C@H]1C[C@H]2[C@@]3(C=C1)[C@H](CN2CC4=CC5=C(C=C34)OCO5)O,,,,,,
1593,441594,Hippeastrine,CN1CCC2=C[C@@H]([C@@H]3[C@H]([C@@H]21)C4=CC5=C(C=C4C(=O)O3)OCO5)O,,,,,,
1594,441595,Kalbreclasine,C1OC2=C(O1)C(=C3C(=C2)C4=C[C@@H]([C@H]([C@H]([C@@H]4NC3=O)O)O)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O,,,,,,
1595,441596,(+)-Narwedine,CN1CC[C@]23C=CC(=O)C[C@H]2OC4=C(C=CC(=C34)C1)OC,,,,,,
1596,441597,Pancratistatin,C1OC2=C(O1)C(=C3C(=C2)[C@@H]4[C@H]([C@@H]([C@@H]([C@H]([C@@H]4O)O)O)O)NC3=O)O,,,,,,
1597,441598,CID 441598,C1[C@H](NC(=CC1=CC=[N+]2[C@@H](CC3=CC(=C(C=C32)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)C(=O)O)O)O)O)C(=O)[O-])C(=O)O)C(=O)O,,,,,,
1598,441599,CID 441599,C1[C@H](NC(=CC1=CC=[N+]2[C@@H](CC3=CC(=C(C=C32)O)OC4C([C@H]([C@@H]([C@H](O4)CO)O)O)OC5C([C@H]([C@@H]([C@H](O5)C(=O)O)O)O)O)C(=O)O)C(=O)O)C(=O)O,,,,,,
1599,441600,"(2S)-4-(2-oxoethylidene)-2,3-dihydro-1H-pyridine-2,6-dicarboxylic acid",C1[C@H](NC(=CC1=CC=O)C(=O)O)C(=O)O,,,,,,
1600,441601,CID 441601,C1[C@H](NC(=CC1=CC=[N+]2[C@@H](CC3=CC(=C(C=C32)O)O)C(=O)[O-])C(=O)O)C(=O)O,,,,,,
1601,441602,"(2S)-1-[2-[(2S)-2,6-Dicarboxy-1,2,3,4-tetrahydropyridine-4-ylidene]ethylidene]-2-carboxylato-5,6-dihydroxyindoline-1-ium",C1[C@H](NC(=CC1=CC=[N+]2[C@@H](CC3=CC(=C(C=C32)O)O)C(=O)O)C(=O)O)C(=O)O,,,,,,
1602,441603,"(2S)-1-[2-[(2S)-2,6-dicarboxy-2,3-dihydro-1H-pyridin-4-ylidene]ethylidene]-6-hydroxy-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3-dihydroindol-1-ium-2-carboxylate",C1[C@H](NC(=CC1=CC=[N+]2[C@@H](CC3=CC(=C(C=C32)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)C(=O)[O-])C(=O)O)C(=O)O,,,,,,
1603,441604,"(2S)-1-[2-[(2S)-1,2,3,4-Tetrahydro-2,6-dicarboxypyridine-4-ylidene]ethylidene]-2alpha-carboxy-5-(beta-D-glucopyranosyloxy)-6-hydroxyindoline-1-ium",C1[C@H](NC(=CC1=CC=[N+]2[C@@H](CC3=CC(=C(C=C32)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)C(=O)O)C(=O)O)C(=O)O,,,,,,
1604,441605,CID 441605,C1[C@H](NC(=CC1=CC=[N+]2[C@@H](CC3=CC(=C(C=C32)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)C(=O)[O-])C(=O)O)C(=O)O,,,,,,
1605,441606,CID 441606,C1[C@H](NC(=CC1=CC=[N+]2[C@@H](CC3=CC(=C(C=C32)O)O[C@H]4[C@@H]([C@H]([C@@H](C(O4)CO)O)O)O[C@H]5[C@@H]([C@H]([C@@H](C(O5)CO)O)O)O)C(=O)O)C(=O)O)C(=O)O,,,,,,
1606,441607,CID 441607,COC1=C(C=CC(=C1)C=CC(=O)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2O[C@@H]3[C@H]([C@@H]([C@H](O[C@H]3OC4=C(C=C5C(=C4)C[C@H]([N+]5=CC=C6C[C@H](NC(=C6)C(=O)O)C(=O)O)C(=O)[O-])O)CO)O)O)C(=O)O)O)O)O,,,,,,
1607,441608,CID 441608,COC1=C(C=CC(=C1)C=CC(=O)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2O[C@@H]3[C@H]([C@@H]([C@H](O[C@H]3OC4=C(C=C5C(=C4)C[C@H]([N+]5=CC=C6C[C@H](NC(=C6)C(=O)O)C(=O)O)C(=O)O)O)CO)O)O)C(=O)O)O)O)O,,,,,,
1608,441609,CID 441609,C1[C@H](N=C(C=C1C=CN[C@@H](CC2=CC(=C(C=C2)O)O)C(=O)O)C(=O)O)C(=O)O,,,,,,
1609,441610,CID 441610,C1[C@H](NC(=CC1=CC=[N+]2[C@@H](CC3=CC(=C(C=C32)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)C(=O)[O-])C(=O)O)C(=O)O,,,,,,
1610,441611,CID 441611,C1[C@H](NC(=CC1=CC=[N+]2[C@@H](CC3=CC(=C(C=C32)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)C(=O)O)C(=O)O)C(=O)O,,,,,,
1611,441612,Squamocin,CCCCCC[C@@H](CCC[C@@H]([C@H]1CC[C@@H](O1)[C@H]2CC[C@@H](O2)[C@@H](CCCCCCCCCCCCC3=C[C@@H](OC3=O)C)O)O)O,,,,,,
1612,441613,"2-Butenoic acid, 2-methyl-, 2-methyl-2-butenyl ester",CC=C(C)COC(=O)C(=CC)C,,,,,,
1613,441614,CID 441614,COC1=C(C=CC(=C1)C=CC(=O)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(C=C4C[C@H]([N+](=CC=C5C[C@H](NC(=C5)C(=O)O)C(=O)O)C4=C3)C(=O)[O-])O)O)O)O)O,,,,,,
1614,441615,CID 441615,COC1=C(C=CC(=C1)C=CC(=O)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(C=C4C[C@H]([N+](=CC=C5C[C@H](NC(=C5)C(=O)O)C(=O)O)C4=C3)C(=O)O)O)O)O)O)O,,,,,,
1615,441616,CID 441616,C1[C@@H](N=C(C=C1C=CN[C@@H](CCCO)C(=O)O)C(=O)O)C(=O)O,,,,,,
1616,441617,CID 441617,C1C[C@H]([N+](=CC=C2C[C@H](NC(=C2)C(=O)O)C(=O)O)C1)C(=O)[O-],,,,,,
1617,441618,"4-[2-(2-carboxypyrrolidin-1-ium-1-ylidene)ethylidene]-2,3-dihydro-1H-pyridine-2,6-dicarboxylic acid",C1CC([N+](=CC=C2CC(NC(=C2)C(=O)O)C(=O)O)C1)C(=O)O,,,,,,
1618,441619,CID 441619,C[C@@](CC(=O)O)(CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)OC2=C(C=C3C(=C2)C[C@H]([N+]3=CC=C4C[C@H](NC(=C4)C(=O)O)C(=O)O)C(=O)[O-])O)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)C(=O)O)O)O)O)O)O)O,,,,,,
1619,441620,CID 441620,C[C@@](CC(=O)O)(CC(=O)OCC1[C@H]([C@@H]([C@H]([C@@H](O1)OC2=C(C=C3C(=C2)C[C@H]([N+]3=CC=C4C[C@H](NC(=C4)C(=O)O)C(=O)O)C(=O)O)O)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)C(=O)O)O)O)O)O)O)O,,,,,,
1620,441621,CID 441621,C1[C@@H](NC(=CC1=CC=[N+]2[C@@H](CC3=CC(=C(C=C32)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)C(=O)[O-])C(=O)O)C(=O)O,,,,,,
1621,441622,"(2R)-4-[2-[(2S)-2alpha-Carboxy-5-(beta-D-glucopyranosyloxy)-6-hydroxy-1-azoniaindoline-1-ylidene]ethylidene]-1,2,3,4-tetrahydro-2,6-pyridinedicarboxylic acid",C1[C@@H](NC(=CC1=CC=[N+]2[C@@H](CC3=CC(=C(C=C32)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)C(=O)O)C(=O)O)C(=O)O,,,,,,
1622,441623,CID 441623,COC1=C(C=CC(=C1)C=CC(=O)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(C=C4C(=C3)C[C@H]([N+]4=CC=C5C[C@H](NC(=C5)C(=O)O)C(=O)O)C(=O)[O-])O)O)O)O)O,,,,,,
1623,441624,"(2S)-4-[2-[(2S)-2-carboxy-6-hydroxy-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyloxymethyl]oxan-2-yl]oxy-2,3-dihydroindol-1-ium-1-ylidene]ethylidene]-2,3-dihydro-1H-pyridine-2,6-dicarboxylic acid",COC1=C(C=CC(=C1)C=CC(=O)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(C=C4C(=C3)C[C@H]([N+]4=CC=C5C[C@H](NC(=C5)C(=O)O)C(=O)O)C(=O)O)O)O)O)O)O,,,,,,
1624,441625,CID 441625,CS(=O)CCC(C(=O)O)NC=CC1=CC(=NC(C1)C(=O)O)C(=O)O,,,,,,
1625,441626,CID 441626,C1C(N=C(C=C1C=CNC(CC(=O)O)C(=O)O)C(=O)O)C(=O)O,,,,,,
1626,441627,CID 441627,C1C(N=C(C=C1C=CNCCC2=CC=C(C=C2)O)C(=O)O)C(=O)O,,,,,,
1627,441628,CID 441628,C1C(N=C(C=C1C=CNCCC2=CC(=C(C=C2)O)O)C(=O)O)C(=O)O,,,,,,
1628,441629,CID 441629,C1CC(=O)[C@@H]([C@H]1CC(=O)O)CC=CCCO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O,,,,,,
1629,441630,CID 441630,C1[C@H](N=C(C=C1C=CN[C@@H](C2=CC(=O)NO2)C(=O)O)C(=O)O)C(=O)O,,,,,,
1630,441631,CID 441631,C1[C@H](N=C(C=C1C=CN[C@@H](CC2=CC(=O)OC(=C2)C(=O)O)C(=O)O)C(=O)O)C(=O)O,,,,,,
1631,441632,Musca-aurin VII,C1[C@H](N=C(C=C1C=C[N+]2=CNC(=C2)C[C@@H](C(=O)[O-])N)C(=O)O)C(=O)O,,,,,,
1632,441633,"(2S)-4-[2-[5-[(2S)-2-amino-2-carboxyethyl]-1H-imidazol-3-ium-3-yl]ethenyl]-2,3-dihydropyridine-2,6-dicarboxylic acid",C1[C@H](N=C(C=C1C=C[N+]2=CNC(=C2)C[C@@H](C(=O)O)N)C(=O)O)C(=O)O,,,,,,
1633,441634,CID 441634,C1[C@H](NC(=CC1=CC=[N+]2[C@@H](CC3=C2C(=O)OC(=C3)C(=O)O)C(=O)[O-])C(=O)O)C(=O)O,,,,,,
1634,441635,CID 441635,C1[C@H](NC(=CC1=CC=[N+]2[C@@H](CC3=C2C(=O)OC(=C3)C(=O)O)C(=O)O)C(=O)O)C(=O)O,,,,,,
1635,441636,CID 441636,C1[C@H](C[N+](=CC=C2C[C@H](NC(=C2)C(=O)O)C(=O)O)[C@@H]1C(=O)[O-])O,,,,,,
1636,441637,CID 441637,C1[C@H](C[N+](=CC=C2C[C@H](NC(=C2)C(=O)O)C(=O)O)[C@@H]1C(=O)O)O,,,,,,
1637,441638,CID 441638,C1[C@H](N=C(C=C1C=CN[C@@H](CC2=CC=C(C=C2)O)C(=O)O)C(=O)O)C(=O)O,,,,,,
1638,441639,CID 441639,C1[C@H](N=C(C=C1C=CNCC(=O)O)C(=O)O)C(=O)O,,,,,,
1639,441640,"[(2R,3S,4S,5R,6S)-6-[[(2S)-2-carboxy-1-[2-[(2R)-2,6-dicarboxy-2,3-dihydro-1H-pyridin-4-ylidene]ethylidene]-6-hydroxy-2,3-dihydroindol-1-ium-5-yl]oxy]-3,4,5-trihydroxyoxan-2-yl]methyl sulfate",C1[C@@H](NC(=CC1=CC=[N+]2[C@@H](CC3=CC(=C(C=C32)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)COS(=O)(=O)[O-])O)O)O)C(=O)O)C(=O)O)C(=O)O,,,,,,
1640,441641,"(2R)-4-[2-[(2S)-2-carboxy-6-hydroxy-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(sulfooxymethyl)oxan-2-yl]oxy-2,3-dihydroindol-1-ium-1-ylidene]ethylidene]-2,3-dihydro-1H-pyridine-2,6-dicarboxylic acid",C1[C@@H](NC(=CC1=CC=[N+]2[C@@H](CC3=CC(=C(C=C32)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)COS(=O)(=O)O)O)O)O)C(=O)O)C(=O)O)C(=O)O,,,,,,
1641,441642,CID 441642,C1[C@H](N=C(C=C1C=CN[C@@H](CCC(=O)O)C(=O)O)C(=O)O)C(=O)O,,,,,,
1642,441643,Tuliposide B,C=C(C(CO)O)C(=O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1643,441644,(5S)-5-heptyloxolan-2-one,CCCCCCC[C@H]1CCC(=O)O1,,,,,,
1644,441645,Uvaricin,CCCCCCCCCC[C@@H]([C@H]1CC[C@@H](O1)[C@H]2CC[C@@H](O2)[C@@H](CCCCCCCCCCCCC3=C[C@@H](OC3=O)C)O)OC(=O)C,,,,,,
1645,441646,"2',4,4'-Trihydroxy-3,5-diprenylchalcone",CC(=CCC1=CC(=CC(=C1O)CC=C(C)C)C=CC(=O)C2=C(C=C(C=C2)O)O)C,,,,,,
1646,441647,"2-(4-Hydroxyphenyl)chromenylium-5,7-diol",C1=CC(=CC=C1C2=[O+]C3=CC(=CC(=C3C=C2)O)O)O,,,,,,
1647,441648,Aurantinidin,C1=CC(=CC=C1C2=C(C=C3C(=[O+]2)C=C(C(=C3O)O)O)O)O,,,,,,
1648,441649,"3,5,6-Trihydroxy-2-(4-hydroxyphenyl)chromen-7-one",C1=CC(=CC=C1C2=C(C=C3C(=CC(=O)C(=C3O)O)O2)O)O,,,,,,
1649,441650,"4,6-Dihydroxy-2-[(3,4,5-trihydroxyphenyl)methylidene]-1-benzofuran-3-one",C1=C(C=C(C(=C1O)O)O)C=C2C(=O)C3=C(C=C(C=C3O2)O)O,,,,,,
1650,441651,"(6S)-6-hydroxy-3-[18-[(4S)-4-hydroxy-2,6,6-trimethyl-3-oxocyclohexen-1-yl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-2,4,4-trimethylcyclohex-2-en-1-one",CC1=C(C(C[C@@H](C1=O)O)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC2=C(C(=O)[C@H](CC2(C)C)O)C)C)C,,,,,,
1651,441652,CID 441652,CC(=CC=CC=C(C)C=CC(=O)O)C=CC=C(C)C=C[C@@]1([C@](CCCC1(C)C)(C)O)O,,,,,,
1652,441653,"19-[(4R)-4-hydroxy-2,6,6-trimethylcyclohexen-1-yl]-1-[(1R,4S)-4-hydroxy-1,2,2-trimethylcyclopentyl]-4,8,13,17-tetramethylnonadeca-2,4,6,8,10,12,14,16,18-nonaen-1-one",CC1=C(C(C[C@@H](C1)O)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC(=O)[C@@]2(C[C@H](CC2(C)C)O)C)C)C,,,,,,
1653,441654,"1,20-bis[(1R,4S)-4-hydroxy-1,2,2-trimethylcyclopentyl]-4,8,13,17-tetramethylicosa-2,4,6,8,10,12,14,16,18-nonaene-1,20-dione",CC(=CC=CC=C(C)C=CC=C(C)C=CC(=O)[C@@]1(C[C@H](CC1(C)C)O)C)C=CC=C(C)C=CC(=O)[C@@]2(C[C@H](CC2(C)C)O)C,,,,,,
1654,441655,"(6R)-6-(3,7,12,16,20,24-hexamethylpentacosa-1,3,5,7,9,11,13,15,17,19,23-undecaenyl)-1,5,5-trimethylcyclohexene",CC1=CCCC([C@H]1C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC=C(C)CCC=C(C)C)C)C)(C)C,,,,,,
1655,441656,"(1S)-4-[18-[(4S)-4-hydroxy-2,6,6-trimethylcyclohex-2-en-1-ylidene]-3,7,12,16-tetramethyloctadeca-2,4,6,8,10,12,14,16-octaenylidene]-3,5,5-trimethylcyclohex-2-en-1-ol",CC1=C[C@H](CC(C1=CC=C(C)C=CC=C(C)C=CC=CC(=CC=CC(=CC=C2C(=C[C@H](CC2(C)C)O)C)C)C)(C)C)O,,,,,,
1656,441657,"(2R,6S,7aR)-2-[17-[(1R,4R)-4-hydroxy-2,6,6-trimethylcyclohex-2-en-1-yl]-6,11,15-trimethylheptadeca-2,4,6,8,10,12,14,16-octaen-2-yl]-4,4,7a-trimethyl-2,5,6,7-tetrahydro-1-benzofuran-6-ol",CC1=C[C@@H](CC([C@H]1C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)[C@H]2C=C3[C@](O2)(C[C@H](CC3(C)C)O)C)C)C)(C)C)O,,,,,,
1657,441658,Capensinidin,COC1=CC(=CC(=C1O)OC)C2=C(C=C3C(=CC(=CC3=[O+]2)O)OC)O,,,,,,
1658,441659,CID 441659,COC1=CC(=CC(=C1O)OC)C2=C(C=C3C(=CC(=O)C=C3OC)O2)O,,,,,,
1659,441660,Xanthophyll dipalmitate,CCCCCCCCCCCCCCCC(=O)O[C@@H]1CC(=C(C(C1)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=C[C@H]2C(=C[C@@H](CC2(C)C)OC(=O)CCCCCCCCCCCCCCC)C)C)C)C,,,,,,
1660,441661,"5-hydroxy-4-[3-(4-hydroxyphenyl)prop-2-enoyl]-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycyclohexa-3,5-diene-1,2-dione",C1=CC(=CC=C1C=CC(=O)C2=C(C(=O)C(=O)C=C2O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O,,,,,,
1661,441662,"(1R,4R)-4-[18-[(1R,4R)-4-hydroxy-2,6,6-trimethylcyclohex-2-en-1-yl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-3,5,5-trimethylcyclohex-2-en-1-ol",CC1=C[C@@H](CC([C@H]1C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=C[C@H]2C(=C[C@@H](CC2(C)C)O)C)C)C)(C)C)O,,,,,,
1662,441663,Silandrin,COC1=C(C=CC(=C1)[C@@H]2[C@H](OC3=C(O2)C=CC(=C3)[C@@H]4CC(=O)C5=C(C=C(C=C5O4)O)O)CO)O,,,,,,
1663,441664,CID 441664,CC1=C(C(C[C@@H](C1)O)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=C[C@H]2C(=C[C@@H](CC2(C)C)O)C)C)C,,,,,,
1664,441665,CID 441665,CC1=C[C@@H](CC([C@H]1C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=C[C@]23[C@](O2)(C[C@H](CC3(C)C)O)C)C)C)(C)C)O,,,,,,
1665,441666,"2,6,10,14,19,23,27,31-Octamethyldotriaconta-2,6,8,10,12,14,16,18,20,22,24,26,30-tridecaen-1-ol",CC(=CCCC(=CC=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC=C(C)CCC=C(C)CO)C)C)C)C,,,,,,
1666,441667,Kuromanin,C1=CC(=C(C=C1C2=[O+]C3=CC(=CC(=C3C=C2O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O)O)O,,,,,,
1667,441668,Mutatochrome,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C2C=C3C(CCCC3(O2)C)(C)C)C)C,,,,,,
1668,441669,CID 441669,CCCCCCCCCCCCCCCC(=O)O[C@@H]1CC(=C(C(C1)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC2=C(C[C@H](CC2(C)C)OC(=O)CCCCCCCCCCCCCCC)C)C)C)C,,,,,,
1669,441670,"(1R)-4-(3,7,12,16,20,24-hexamethylpentacosa-1,3,5,7,9,11,13,15,17,19,23-undecaenyl)-3,5,5-trimethylcyclohex-3-en-1-ol",CC1=C(C(C[C@@H](C1)O)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC=C(C)CCC=C(C)C)C)C,,,,,,
1670,441671,cyanidin 3-O-(6-O-glucosyl-2-O-xylosylgalactoside),C1[C@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@H]([C@H](O[C@H]2OC3=CC4=C(C=C(C=C4[O+]=C3C5=CC(=C(C=C5)O)O)O)O)CO[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)O)O)O)O)O,,,,,,
1671,441672,CID 441672,C1[C@H]([C@H]([C@H]([C@H](O1)O[C@@H]2[C@@H]([C@H]([C@@H](O[C@@H]2OC3=C(OC4=CC(=O)C=C(C4=C3)O)C5=CC(=C(C=C5)O)O)CO[C@@H]6[C@@H]([C@@H]([C@H]([C@@H](O6)CO)O)O)O)O)O)O)O)O,,,,,,
1672,441673,"2-(3,7,12,16,20,24-Hexamethylpentacosa-1,3,5,7,9,11,13,15,17,19,21,23-dodecaenyl)-1,3,3-trimethylcyclohexene",CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC=C(C)C=CC=C(C)C)C)C,,,,,,
1673,441674,Cyanidin 3-O-rutinoside,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=CC4=C(C=C(C=C4[O+]=C3C5=CC(=C(C=C5)O)O)O)O)O)O)O)O)O)O,,,,,,
1674,441675,Dammarenediol-I,CC(=CCC[C@](C)([C@H]1CC[C@@]2([C@@H]1CC[C@H]3[C@]2(CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)C)C)O)C,,,,,,
1675,441676,Dipterocarpol,CC(=CCC[C@@](C)([C@H]1CC[C@@]2([C@@H]1CC[C@H]3[C@]2(CC[C@@H]4[C@@]3(CCC(=O)C4(C)C)C)C)C)O)C,,,,,,
1676,441677,alpha-Elemolic acid,CC(=CCC[C@@H]([C@@H]1CC[C@]2([C@]1(CCC3=C2CC[C@@H]4[C@@]3(CC[C@H](C4(C)C)O)C)C)C)C(=O)O)C,,,,,,
1677,441678,Euphol,C[C@H](CCC=C(C)C)[C@@H]1CC[C@]2([C@]1(CCC3=C2CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)C)C,,,,,,
1678,441679,Fernene,CC(C)[C@H]1CC[C@@H]2[C@@]1(CC[C@]3([C@]2(CC=C4[C@@H]3CC[C@@H]5[C@@]4(CCCC5(C)C)C)C)C)C,,,,,,
1679,441680,Hopane-29-acetate,CC(COC(=O)C)[C@H]1CC[C@]2([C@H]1CC[C@@]3([C@@H]2CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CCCC5(C)C)C)C)C)C,,,,,,
1680,441681,"cyanidin 3,3',5-tri-O-glucoside",C1=CC(=C(C=C1C2=C(C=C3C(=CC(=CC3=[O+]2)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)O,,,,,,
1681,441682,CID 441682,C1=CC(=C(C=C1C2=C(C=C3C(=CC(=O)C=C3O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O2)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)O,,,,,,
1682,441683,Papyriferic acid,CC(=O)O[C@@H]1C[C@@H]2[C@]3(CC[C@H](C([C@@H]3CC[C@]2([C@]4([C@H]1[C@H](CC4)[C@@]5(CC[C@@H](O5)C(C)(C)O)C)C)C)(C)C)OC(=O)CC(=O)O)C,,,,,,
1683,441684,Sapelin A,C[C@@]12CC[C@H]3C(=CC[C@@H]4[C@@]3(CC[C@H](C4(C)C)O)C)[C@]1(CC[C@H]2[C@@H]5C[C@H]([C@@H](OC5)C(C)(C)O)O)C,,,,,,
1684,441685,Taccalonolide A,C[C@@H]1C=C2[C@@]([C@H]3[C@H]1[C@@]4([C@@H]([C@H]3OC(=O)C)[C@H]5[C@H]([C@@H]([C@@H]4OC(=O)C)OC(=O)C)[C@@]6([C@H](C[C@H]7[C@@H]([C@@H]6OC(=O)C)O7)C(=O)[C@@H]5O)C)C)([C@](C(=O)O2)(C)O)C,,,,,,
1685,441686,"(3S,4aR,6aR,6aR,6bR,8aR,12S,12aS,14aR,14bR)-4,4,6a,6b,8a,12,14b-heptamethyl-11-methylidene-1,2,3,4a,5,6,6a,7,8,9,10,12,12a,13,14,14a-hexadecahydropicen-3-ol",C[C@H]1[C@H]2[C@H]3CC[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC[C@]2(CCC1=C)C)C)C)(C)C)O)C,,,,,,
1686,441687,"(6aR,6bR,8aS,11R,12aR,14aR)-3-hydroxy-4,6a,6b,8a,11,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione",C[C@@H]1C[C@@H]2[C@@](CC[C@@]3([C@@]2(CC[C@@]4(C3=CC=C5C4=CC(=O)C(=C5C)O)C)C)C)(CC1=O)C,,,"['Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. (See all compounds classified as Antineoplastic Agents, Phytogenic.)']",,,
1687,441688,Cyanin,C1=CC(=C(C=C1C2=C(C=C3C(=CC(=CC3=[O+]2)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O)O,,,,,,
1688,441689,"Delphinidin 3,3',5'-tri-O-glucoside",C1=C(C=C(C(=C1O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)C4=[O+]C5=CC(=CC(=C5C=C4O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)O)O,,,,,,
1689,441690,CID 441690,C1=C(C=C(C(=C1O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)C4=C(C=C5C(=CC(=O)C=C5O4)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O,,,,,,
1690,441691,"2-[3,4-Dihydroxy-5-[6-O-(3,4-dihydroxy-trans-cinnamoyl)-beta-D-glucopyranosyloxy]phenyl]-3-(beta-D-glucopyranosyloxy)-5-[6-O-(3,4-dihydroxy-cis-cinnamoyl)-beta-D-glucopyranosyloxy]-7-hydroxy-1-benzopyrylium",C1=CC(=C(C=C1C=CC(=O)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=CC(=CC(=C3O)O)C4=C(C=C5C(=CC(=CC5=[O+]4)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)COC(=O)C=CC7=CC(=C(C=C7)O)O)O)O)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O)O)O)O)O,,,,,,
1691,441692,CID 441692,COC1=C(C=CC(=C1)C2=C(C=C3C(=CC(=[OH+])C=C3O[C@@H]4[C@@H]([C@@H]([C@H]([C@@H](O4)CO)O)O)O)O2)O[C@@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)COC(=O)C=CC6=CC(=C(C=C6)O[C@@H]7[C@@H]([C@@H]([C@H]([C@@H](O7)CO)O)O)OC(=O)C=CC8=CC(=C(C=C8)O)O[C@@H]9[C@@H]([C@@H]([C@H]([C@@H](O9)CO)O)O)O)O)O)O)O[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)CO)O)O)OC(=O)C=CC1=CC(=C(C=C1)O)O[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)CO)O)O)O)O,,,,,,
1692,441693,CID 441693,COC1=C(C=CC(=C1)C2=C(C=C3C(=CC(=O)C=C3O[C@@H]4[C@@H]([C@@H]([C@H]([C@@H](O4)CO)O)O)O)O2)O[C@@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)COC(=O)C=CC6=CC(=C(C=C6)O[C@@H]7[C@@H]([C@@H]([C@H]([C@@H](O7)CO)O)O)OC(=O)C=CC8=CC(=C(C=C8)O)O[C@@H]9[C@@H]([C@@H]([C@H]([C@@H](O9)CO)O)O)O)O)O)O)O[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)CO)O)O)OC(=O)C=CC1=CC(=C(C=C1)O)O[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)CO)O)O)O)O,,,,,,
1693,441694,Hirsutidin,COC1=CC(=C2C=C(C(=[O+]C2=C1)C3=CC(=C(C(=C3)OC)O)OC)O)O,,,,,,
1694,441695,CID 441695,COC1=CC(=O)C2=CC(=C(OC2=C1)C3=CC(=C(C(=C3)OC)O)OC)O,,,,,,
1695,441696,(S)-2-Hydroxy-2-methylsuccinic acid,C[C@](CC(=O)O)(C(=O)O)O,,,,,,
1696,441697,6-Hydroxycyanidin,C1=CC(=C(C=C1C2=C(C=C3C(=[O+]2)C=C(C(=C3O)O)O)O)O)O,,,,,,
1697,441698,CID 441698,C1=CC(=C(C=C1C2=C(C=C3C(=CC(=O)C(=C3O)O)O2)O)O)O,,,,,,
1698,441699,Cyanidin 3-O-galactoside,C1=CC(=C(C=C1C2=[O+]C3=CC(=CC(=C3C=C2O[C@H]4[C@@H]([C@H]([C@H]([C@H](O4)CO)O)O)O)O)O)O)O,,,,,,
1699,441700,"2-[(3,4-Dihydroxyphenyl)methylidene]-6-hydroxy-7-methoxy-1-benzofuran-3-one",COC1=C(C=CC2=C1OC(=CC3=CC(=C(C=C3)O)O)C2=O)O,,,,,,
1700,441701,Luteolinidin,C1=CC(=C(C=C1C2=[O+]C3=CC(=CC(=C3C=C2)O)O)O)O,,,,,,
1701,441702,"3',4',5',7-Tetrahydroxy-3-[6-O-(4-hydroxy-cis-cinnamoyl)-beta-D-glucopyranosyloxy]-5-[6-O-(3-hydroxy-1,3-dioxopropyl)-beta-D-glucopyranosyloxy]flavylium",C1=CC(=CC=C1C=CC(=O)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C([O+]=C4C=C(C=C(C4=C3)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)COC(=O)CC(=O)O)O)O)O)O)C6=CC(=C(C(=C6)O)O)O)O)O)O)O,,,,,,
1702,441703,CID 441703,C1=CC(=CC=C1C=CC(=O)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=CC(=O)C=C(C4=C3)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)COC(=O)CC(=O)O)O)O)O)C6=CC(=C(C(=C6)O)O)O)O)O)O)O,,,,,,
1703,441704,14-O-Acetylbrowniine,CCN1C[C@@]2(CC[C@@H]([C@@]34[C@@H]2[C@@H]([C@@](C31)([C@]5(C[C@@H]([C@H]6C[C@@H]4[C@@H]5[C@H]6OC(=O)C)OC)O)O)OC)OC)COC,,,,,,
1704,441705,Aconifine,CCN1C[C@@]2([C@@H](C[C@@H]([C@@]34[C@@H]2[C@H]([C@@H](C31)[C@@]5([C@@H]6[C@]4(C[C@@]([C@@H]6OC(=O)C7=CC=CC=C7)([C@H]([C@@H]5O)OC)O)O)OC(=O)C)OC)OC)O)COC,,,,,,
1705,441706,Ajaconine,C[C@@]12CCC[C@]34[C@@H]1C[C@H]([C@]56[C@H]3C[C@H](CC5)C(=C)[C@H]6O)OC4N(C2)CCO,,,,,,
1706,441707,Anhwiedelphinine,C[C@H]1CC(=O)N(C1=O)C2=CC=CC=C2C(=O)OC[C@@]34CC[C@@H]([C@@]56[C@@H]3[C@@H]([C@@](C5N=C4)([C@]7(C[C@@H]([C@H]8C[C@@H]6[C@@H]7[C@H]8OC)OC)O)O)OC)OC,,,,,,
1707,441708,Anthranoyllycoctonine,CCN1C[C@@]2(CC[C@@H]([C@@]34[C@@H]2[C@@H]([C@@](C31)([C@]5(C[C@@H]([C@H]6C[C@@H]4[C@@H]5[C@H]6OC)OC)O)O)OC)OC)COC(=O)C7=CC=CC=C7N,,,,,,
1708,441709,Atisine,C[C@@]12CCC[C@@]3([C@@H]1CC[C@]45[C@H]3C[C@H](CC4)C(=C)[C@H]5O)C6N(C2)CCO6,,,,,,
1709,441710,Avadharidine,CCN1C[C@@]2(CC[C@@H]([C@@]34[C@@H]2[C@H]([C@@](C31)([C@]5(C[C@@H]([C@H]6C[C@@H]4[C@@H]5[C@H]6OC)OC)O)O)OC)OC)COC(=O)C7=CC=CC=C7NC(=O)CCC(=O)N,,,,,,
1710,441711,"Aconitan-14-one, 7,8-dihydroxy-20-ethyl-4-(((2-(3-methyl-2,5-dioxo-1-pyrrolidinyl)benzoyl)oxy)methyl)-1,6,16-trimethoxy-, (1-alpha,4(S),6-beta,16-beta)-",CCN1C[C@@]2(CC[C@@H]([C@@]34[C@@H]2[C@@H]([C@@](C31)([C@]5(C[C@@H]([C@H]6C[C@@H]4[C@@H]5C6=O)OC)O)O)OC)OC)COC(=O)C7=CC=CC=C7N8C(=O)C[C@@H](C8=O)C,,,,,,
1711,441712,10-Hydroxy mesaconitine,CC(=O)O[C@@]12[C@H]3[C@@H]([C@@H]4[C@@]5(CN(C3[C@]4([C@H](C[C@H]5O)OC)[C@]6([C@@H]1[C@H]([C@](C6)([C@H]([C@@H]2O)OC)O)OC(=O)C7=CC=CC=C7)O)C)COC)O,,,,,,
1712,441713,Bikhaconitine,CCN1C[C@@]2(CC[C@@H]([C@@]34[C@@H]2[C@H]([C@@H](C31)[C@]5(C[C@@H]([C@]6(C[C@@H]4[C@@H]5[C@H]6OC(=O)C7=CC(=C(C=C7)OC)OC)O)OC)OC(=O)C)OC)OC)COC,,,,,,
1713,441714,"Aconitane-7,8,14-triol, 20-ethyl-4-(methoxymethyl)-1,6,16-trimethoxy-, (1-alpha,6-beta,14-alpha,16-beta)-",CCN1C[C@@]2(CC[C@@H]([C@@]34[C@@H]2[C@@H]([C@@](C31)([C@]5(C[C@@H]([C@H]6C[C@@H]4[C@@H]5[C@H]6O)OC)O)O)OC)OC)COC,,,,,,
1714,441715,Cammaconine,CCN1C[C@@]2(CC[C@@H]([C@@]34[C@@H]2C[C@@H](C31)[C@]5(C[C@@H]([C@H]6C[C@@H]4[C@@H]5[C@H]6O)OC)O)OC)CO,,,,,,
1715,441716,Cardiopetalidine,CCN1C[C@@]2(CC[C@@H]([C@@]34[C@@H]2C[C@@](C31)([C@]5(CC[C@H]6C[C@@H]4[C@@H]5[C@H]6O)O)O)O)C,,,,,,
1716,441717,Cashmiradelphine,CCN1C[C@@]2(CC[C@@H]([C@@]34[C@@H]2[C@@H]([C@@](C31)([C@]5(C[C@@H]([C@H]6C[C@@H]4[C@@H]5[C@H]6OC)OC)O)O)OC)OC)COC(=O)C7=CC=CC=C7NC(=O)CCC(=O)OC,,,,,,
1717,441718,"2-(dimethylamino)ethyl 2-[(1R,4aS,4bR,7S,8aR,10S,10aS)-7,10-dihydroxy-1,4b,8,8-tetramethyl-3,4,4a,5,6,7,8a,9,10,10a-decahydro-1H-phenanthren-2-ylidene]acetate",C[C@@H]1[C@H]2[C@H](CCC1=CC(=O)OCCN(C)C)[C@]3(CC[C@@H](C([C@@H]3C[C@@H]2O)(C)C)O)C,,,,,,
1718,441719,"2-(dimethylamino)ethyl 2-[(1R,4aS,4bR,7S,8aR,10aS)-7-hydroxy-1,4b,8,8-tetramethyl-10-oxo-1,3,4,4a,5,6,7,8a,9,10a-decahydrophenanthren-2-ylidene]acetate",C[C@@H]1[C@H]2[C@H](CCC1=CC(=O)OCCN(C)C)[C@]3(CC[C@@H](C([C@@H]3CC2=O)(C)C)O)C,,,,,,
1719,441720,Condelphine,CCN1C[C@@]2(CC[C@@H]([C@@]34[C@@H]2C[C@@H](C31)[C@]5(C[C@@H]([C@H]6C[C@@H]4[C@@H]5[C@H]6OC(=O)C)OC)O)O)COC,,,,,,
1720,441721,"Veatchine,15-deoxy-16,17-dihydro-15-oxo-, (16-beta,20S)-",C[C@@H]1[C@H]2CC[C@@H]3[C@@](C2)(C1=O)CC[C@H]4[C@@]35CCC[C@]4(CN6[C@H]5OCC6)C,,,,,,
1721,441722,14-Deacetylnudicauline,CCN1C[C@@]2(CC[C@@H]([C@@]34[C@@H]2[C@@H]([C@@](C31)([C@]5(C[C@@H]([C@H]6C[C@@H]4[C@@H]5[C@H]6O)OC)O)O)OC)OC)COC(=O)C7=CC=CC=C7N8C(=O)C[C@@H](C8=O)C,,,,,,
1722,441723,Delavaine A,CCN1C[C@@]2(CC[C@@H]([C@@]34[C@@H]2[C@@H]([C@@](C31)([C@]5(C[C@@H]([C@H]6C[C@@H]4[C@@H]5[C@H]6OC)OC)O)O)OC)OC)COC(=O)C7=CC=CC=C7NC(=O)C(C)CC(=O)OC,,,,,,
1723,441724,Delcorine,CCN1C[C@@]2(CC[C@@H]([C@@]34[C@@H]2[C@@H]([C@@]5(C31)[C@]6(C[C@@H]([C@H]7C[C@@H]4[C@@H]6[C@H]7OC)OC)OCO5)O)OC)COC,,,,,,
1724,441725,CID 441725,CCN1C[C@@]2(CC[C@@H]([C@@]34[C@@H]2[C@@H]([C@@](C31)([C@]5(C[C@@H]([C@H]6C[C@@H]4[C@@H]5[C@H]6O)OC)O)O)OC)O)COC,,,,,,
1725,441726,CID 441726,CC(=O)O[C@]12C[C@@H]([C@]3(C[C@H]([C@@H]1[C@H]3OC(=O)C4=CC=CC=C4)[C@]56[C@H](CC[C@@]7([C@H]5[C@H]([C@H]2C6N(C7)C)OC)COC)OC)O)OC,,,,,,
1726,441727,Delsoline,CCN1C[C@@]2(CC[C@@H]([C@@]34[C@@H]2[C@@H]([C@@](C31)([C@]5(C[C@@H]([C@H]6C[C@@H]4[C@@H]5[C@H]6OC)OC)O)O)OC)O)COC,,,,,,
1727,441728,Deltaline,CCN1C[C@@]2(CC[C@@H]([C@@]34[C@@H]2[C@@H]([C@@]5(C31)[C@]6(C[C@@H]([C@H]7C[C@@]4([C@@H]6[C@H]7OC)O)OC)OCO5)OC(=O)C)OC)C,,,,,,
1728,441729,CID 441729,CCN1C[C@@]2(CCC[C@@]34[C@@H]2CC([C@H]31)[C@]56[C@H]4[C@H]([C@H](CC5)C(=C)[C@H]6O)O)C,,,,,,
1729,441730,Elatine,CCN1C[C@@]2(CC[C@@H]([C@@]34[C@@H]2[C@@H]([C@@]5(C31)[C@]6(C[C@@H]([C@H]7C[C@@H]4[C@@H]6[C@H]7OC)OC)OCO5)OC)OC)COC(=O)C8=CC=CC=C8N9C(=O)CC(C9=O)C,,,,,,
1730,441731,"methyl (1S,4aR,4bS,8R,8aS,10R,10aR)-7-[2-[2-(dimethylamino)ethoxy]-2-oxoethylidene]-10-hydroxy-1,4a,8-trimethyl-9-oxo-2,3,4,4b,5,6,8,8a,10,10a-decahydrophenanthrene-1-carboxylate",C[C@@H]1[C@H]2[C@H](CCC1=CC(=O)OCCN(C)C)[C@]3(CCC[C@]([C@@H]3[C@H](C2=O)O)(C)C(=O)OC)C,,,,,,
1731,441732,Falaconitine,CCN1C[C@@]2([C@@H](C[C@@H]([C@@]34[C@@H]2[C@H]([C@@H](C31)C5=C[C@@H]([C@]6(C[C@@H]4[C@@H]5[C@H]6OC(=O)C7=CC(=C(C=C7)OC)OC)O)OC)OC)OC)O)COC,,,,,,
1732,441733,Finaconitine,CCN1C[C@@]2(CC[C@@H]([C@@]34[C@@H]2C[C@@](C31)([C@]5(C[C@@H]([C@H]6C[C@@]4([C@@]5([C@H]6OC)O)O)OC)O)O)OC)COC(=O)C7=CC=CC=C7NC(=O)C,,,,,,
1733,441734,CID 441734,C[C@@]12CCC[C@@]3([C@@H]1CC[C@]45[C@H]3CC[C@@H](C4)C(=C)[C@@H]5O)CN6C2OCC6,,,,,,
1734,441735,"4:1A,6B.Heteratisane",CCN1C[C@@]2(CC[C@@H]([C@@]34[C@@H]2[C@@H]([C@@H](C31)[C@]5(CC[C@@H]6C[C@@H]4[C@@H]5C(=O)O6)O)O)OC)C,,,,,,
1735,441736,CID 441736,C[C@@]12C[C@@H](C[C@]34[C@@H]1C5C[C@]67[C@H]3[C@@H]([C@H]([C@@H](C6C4N5C2)O)C(=C)C7)O)O,,,,,,
1736,441737,Hypaconitine,CC(=O)O[C@@]12[C@@H]3[C@@H](C[C@@]([C@@H]3OC(=O)C4=CC=CC=C4)([C@H]([C@@H]1O)OC)O)[C@]56[C@H](CC[C@@]7([C@H]5[C@H]([C@H]2C6N(C7)C)OC)COC)OC,,,,,,
1737,441738,Icaceine,C[C@]12CC[C@@H]([C@]3([C@@H]1[C@@H](C=C4C2CCC5(C4OCC5N(C)C)C)OC3=O)C)O,,,,,,
1738,441739,Icacine,C[C@@]12CC[C@H]3[C@@]45CC[C@@]([C@]6([C@@H]4[C@@H]([C@H]7[C@]3([C@@H]1OC[C@@H]2N(C)C)O7)OC6=O)C)(OC5)O,,,,,,
1739,441740,Indaconitine,CCN1C[C@@]2([C@@H](C[C@@H]([C@@]34[C@@H]2[C@H]([C@@H](C31)[C@]5(C[C@@H]([C@]6(C[C@@H]4[C@@H]5[C@H]6OC(=O)C7=CC=CC=C7)O)OC)OC(=O)C)OC)OC)O)COC,,,,,,
1740,441741,Jesaconitine,CCN1C[C@@]2([C@@H](C[C@@H]([C@@]34[C@@H]2[C@H]([C@@H](C31)[C@@]5([C@@H]6[C@H]4C[C@@]([C@@H]6OC(=O)C7=CC=C(C=C7)OC)([C@H]([C@@H]5O)OC)O)OC(=O)C)OC)OC)O)COC,,,,,,
1741,441742,Carmicheline,CCN1C[C@@]2(CC[C@@H]([C@@]34[C@@H]2C[C@@H](C31)[C@]5(C[C@@H]([C@H]6C[C@@H]4[C@@H]5[C@H]6O)OC)O)O)C,,,,,,
1742,441743,CID 441743,CCN1C[C@@]2(CC[C@@H]([C@@]34[C@@H]2C[C@@H](C31)[C@]5(C[C@@H]([C@H]6C[C@@H]4[C@@]5([C@H]6OC)O)OC)O)OC)OC(=O)C7=CC=CC=C7NC(=O)C,,,"['A subclass of analgesic agents that typically do not bind to OPIOID RECEPTORS and are not addictive. Many non-narcotic analgesics are offered as NONPRESCRIPTION DRUGS. (See all compounds classified as Analgesics, Non-Narcotic.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'A loosely defined grouping of drugs that have effects on psychological function. Here the psychotropic agents include the antidepressive agents, hallucinogens, and tranquilizing agents (including the antipsychotics and anti-anxiety agents). (See all compounds classified as Psychotropic Drugs.)']",,,
1743,441744,Lindheimerine,CC(=O)O[C@@H]1C(=C)[C@@H]2CC[C@@H]3[C@]1(C2)CC[C@H]4[C@@]35CCC[C@]4(CN=C5)C,,,,,,
1744,441745,Lycaconitine,CCN1C[C@@]2(CC[C@@H]([C@@]34[C@@H]2[C@@H]([C@@](C31)([C@]5(C[C@@H]([C@H]6C[C@@H]4[C@@H]5[C@H]6OC)OC)O)O)OC)OC)COC(=O)C7=CC=CC=C7N8C(=O)CCC8=O,,,,,,
1745,441746,CID 441746,CCN1C[C@@]2(CC[C@@H]([C@@]34[C@@H]2[C@@H]([C@@](C31)([C@]5(C[C@@H]([C@H]6C[C@@H]4[C@@H]5[C@H]6OC)OC)O)O)OC)OC)CO,,,,,,
1746,441747,Mesaconitine,CC(=O)O[C@@]12[C@@H]3[C@@H](C[C@@]([C@@H]3OC(=O)C4=CC=CC=C4)([C@H]([C@@H]1O)OC)O)[C@]56[C@H](C[C@H]([C@@]7([C@H]5[C@H]([C@H]2C6N(C7)C)OC)COC)O)OC,,,,,,
1747,441748,CID 441748,CCN1C[C@@]2(CC[C@@H]([C@@]34[C@@H]2[C@@H]([C@@](C31)([C@]5(C[C@@H]([C@H]6C[C@@H]4[C@@H]5[C@H]6OC)OC)O)O)OC)OC)COC(=O)C7=CC=CC=C7N8C(=O)CC(C8=O)C,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)', 'Drugs that bind to nicotinic cholinergic receptors (RECEPTORS, NICOTINIC) and block the actions of acetylcholine or cholinergic agonists. Nicotinic antagonists block synaptic transmission at autonomic ganglia, the skeletal neuromuscular junction, and at central nervous system nicotinic synapses. (See all compounds classified as Nicotinic Antagonists.)']",,,
1748,441749,Napelline,CCN1C[C@@]2(CC[C@@H]([C@@]34[C@@H]2C[C@@H](C31)[C@]56[C@H]4C[C@@H]([C@@H](C5)C(=C)[C@H]6O)O)O)C,,,,,,
1749,441750,Ipwqjeoncufcor-rnnmqtrdsa-,CCN1C[C@@]2(CC[C@@H]([C@@]34[C@@H]2[C@@H]([C@@](C31)([C@]5(C[C@@H]([C@H]6C[C@@H]4[C@@H]5[C@H]6OC(=O)C)OC)O)O)OC)OC)COC(=O)C7=CC=CC=C7N8C(=O)C[C@@H](C8=O)C,,,,,,
1750,441751,CID 441751,CC(=O)O[C@@H]1C(=C)[C@@H]2CC[C@@H]3[C@]1(C2)CC[C@H]4[C@@]35CCC[C@]4(CN6C5OCC6)C,,,,,,
1751,441752,Pseudoaconitine,CCN1C[C@@]2([C@@H](C[C@@H]([C@@]34[C@@H]2[C@H]([C@@H](C31)[C@]5(C[C@@H]([C@]6(C[C@@H]4[C@@H]5[C@H]6OC(=O)C7=CC(=C(C=C7)OC)OC)O)OC)OC(=O)C)OC)OC)O)COC,,,,,,
1752,441753,Ryania,C[C@H]1CC[C@@]2([C@@]3(C[C@]4([C@]5([C@]([C@H]([C@@]3([C@]5([C@]2([C@@H]1O)O4)O)O)OC(=O)C6=CC=CN6)(C(C)C)O)C)O)C)O,,,,,,
1753,441754,Septentrionine,CCN1C[C@@]2(CC[C@@H]([C@@]34[C@@H]2[C@@H]([C@@](C31)([C@]5(C[C@@H]([C@H]6C[C@@H]4[C@@H]5[C@H]6OC)OC)OC)O)OC)OC)COC(=O)C7=CC=CC=C7NC(=O)CCC(=O)OC,,,,,,
1754,441755,"(1R,2R,5R,7R,8R,9R,13R,16S,17R)-11-ethyl-7,16-dihydroxy-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.15,8.01,10.02,8.013,17]nonadecan-4-one",CCN1C[C@@]2(CC[C@@H]([C@@]34[C@@H]2C[C@@H](C31)[C@]56[C@H]4CC(=O)[C@H](C5)C(=C)[C@H]6O)O)C,,,,,,
1755,441756,Spiradine A,C[C@@]12CCC[C@]34[C@@H]1[C@]5(C[C@]67[C@H]3C(=O)[C@H](CC6C4N5C2)C(=C)C7)O,,,,,,
1756,441757,Spiramine A,CC(=O)O[C@H]1C(=C)[C@H]2CC[C@]13[C@@H](C2)[C@]45CCC[C@@]6([C@H]4C[C@H]3O[C@H]5N7[C@@H]6OCC7)C,,,,,,
1757,441758,CID 441758,CC1=C[C@@]23CC(=O)[C@@H]4[C@@]5(CCC[C@@]46[C@@]2(C[C@@H]1CC3[C@@H]6N7C5OCC7)O)C,,,,,,
1758,441759,CID 441759,C[C@]12CCC[C@]34[C@@H]1C(=O)C[C@]56[C@H]3C(=O)[C@H](CC5[C@@H]4N7C2OCC7)C(=C)C6,,,,,,
1759,441760,CID 441760,C[C@@]12CCC[C@]34[C@@H]1CC[C@]56[C@H]3C[C@H](CC5C4N(C2)C)[C@@]7(C6)CC[C@@]89[C@H]1C8C[C@]2([C@@H]9O7)CCC3=C(C2=C1)C[C@@H]1C[C@]3(CN(C1)C)C,,,,,,
1760,441761,Talatizamine,CCN1C[C@@]2(CC[C@@H]([C@@]34[C@@H]2C[C@@H](C31)[C@]5(C[C@@H]([C@H]6C[C@@H]4[C@@H]5[C@H]6O)OC)O)OC)COC,,,,,,
1761,441762,Thalicsessine,C[C@@]12CCC[C@]34[C@@H]1C(=O)C[C@]56[C@H]3C(=O)[C@H](CC5C4N(C2=O)CCO)C(=C)C6,,,,,,
1762,441763,Tricornine,CCN1C[C@@]2(CC[C@@H]([C@@]34[C@@H]2[C@@H]([C@@](C31)([C@]5(C[C@@H]([C@H]6C[C@@H]4[C@@H]5[C@H]6OC)OC)O)O)OC)OC)COC(=O)C,,,,,,
1763,441764,Silicristin,COC1=C(C=CC(=C1)[C@H]2[C@@H](C3=C(O2)C(=CC(=C3)[C@@H]4[C@H](C(=O)C5=C(C=C(C=C5O4)O)O)O)O)CO)O,,,,,,
1764,441765,"Malvidin-3,5-diglucoside",COC1=CC(=CC(=C1O)OC)C2=C(C=C3C(=CC(=CC3=[O+]2)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O,,,,,,
1765,441766,"2-(4-Oxo-3,5-dimethoxy-2,5-cyclohexadienylidene)-3,5-bis[(beta-D-glucopyranosyl)oxy]-2H-1-benzopyran-7-ol",COC1=CC(=CC(=C1O)OC)C2=C(C=C3C(=CC(=O)C=C3O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O2)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O,,,,,,
1766,441767,Sophoranone,CC(=CCC1=CC(=CC(=C1O)CC=C(C)C)[C@@H]2CC(=O)C3=C(O2)C(=C(C=C3)O)CC=C(C)C)C,,,,,,
1767,441768,"2-(3,4-dihydroxybenzylidene)-6,7-dihydroxy-1-benzofuran-3(2H)-one",C1=CC(=C(C=C1C=C2C(=O)C3=C(O2)C(=C(C=C3)O)O)O)O,,,,,,
1768,441769,"7-Benzylidene-4-hydroxyfuro[2,3-g][1,3]benzodioxol-8-one",C1OC2=C(O1)C3=C(C=C2O)OC(=CC4=CC=CC=C4)C3=O,,,,,,
1769,441770,CID 441770,C1=CC(=CC=C1C=CC(=O)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=CC(=[OH+])C=C(C4=C3)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)COC(=O)CC(=O)O)OC(=O)CC(=O)O)O)O)C6=CC=C(C=C6)O)O)O)O)O,,,,,,
1770,441771,"3-[[(2R,3S,4R,5R,6S)-3-(2-carboxyacetyl)oxy-4,5-dihydroxy-6-[2-(4-hydroxyphenyl)-7-oxo-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[3-(4-hydroxyphenyl)prop-2-enoyloxymethyl]oxan-2-yl]oxychromen-5-yl]oxyoxan-2-yl]methoxy]-3-oxopropanoic acid",C1=CC(=CC=C1C=CC(=O)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=CC(=O)C=C(C4=C3)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)COC(=O)CC(=O)O)OC(=O)CC(=O)O)O)O)C6=CC=C(C=C6)O)O)O)O)O,,,,,,
1771,441772,Pelargonin,C1=CC(=CC=C1C2=C(C=C3C(=CC(=CC3=[O+]2)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O,,,,,,
1772,441773,Peonidin,COC1=C(C=CC(=C1)C2=[O+]C3=CC(=CC(=C3C=C2O)O)O)O,,,,,,
1773,441774,Petunidin,COC1=CC(=CC(=C1O)O)C2=[O+]C3=CC(=CC(=C3C=C2O)O)O,,,,,,
1774,441775,Riccionidin A,C1=C2C=C3C(=C4C(=CC(=CC4=[OH+])O)O3)OC2=CC(=C1O)O,,,,,,
1775,441776,"2,3,6-Trihydroxy-[1]benzofuro[3,2-b]chromen-8-one",C1=C2C=C3C(=C4C(=CC(=O)C=C4O3)O)OC2=CC(=C1O)O,,,,,,
1776,441777,Rosinidin,COC1=CC(=C2C=C(C(=[O+]C2=C1)C3=CC(=C(C=C3)O)OC)O)O,,,,,,
1777,441778,3-Hydroxy-2-(4-hydroxy-3-methoxyphenyl)-7-methoxychromen-5-one,COC1=CC(=O)C2=CC(=C(OC2=C1)C3=CC(=C(C=C3)O)OC)O,,,,,,
1778,441779,1-(4-Hydroxyphenyl)-3-(4-hydroxy-2-methoxyphenyl)propene,COC1=C(C=CC(=C1)O)CC=CC2=CC=C(C=C2)O,,,,,,
1779,441780,Mulbel-rochromene,CC1=C[C@H]2[C@H]3[C@H](C1)C4=C(C=C(C=C4)O)O[C@]3(OC5=CC(=CC(=C25)O)C6=CC7=C(O6)C=C(C=C7)O)C8=C(C=C(C=C8)O)O,,,,,,
1780,441781,beta-Cotonefuran,COC1=C(C(=C2C(=C1)C3=C(O2)C(=C(C=C3)O)OC)OC)OC,,,,,,
1781,441782,"2,8-Dihydroxy-3,4,7-trimethoxydibenzofuran",COC1=C(C=C2C3=CC(=C(C(=C3OC2=C1)OC)OC)O)O,,,,,,
1782,441783,CID 441783,C1=CC(=C(C=C1C[C@H](C(=O)O)OC(=O)C=CC2=C3C(C(OC3=C(C=C2)O)C4=CC(=C(C=C4)O)O)C(=O)O)O)O,,,,,,
1783,441784,CID 441784,CCC(C)C(=O)O[C@@H]1[C@H]2[C@H]([C@H]([C@]3([C@H]4[C@@]2(CO3)[C@@H](C[C@@H]5[C@@]4([C@@H](C(=O)C=C5C)O)C)OC1=O)O)O)C,,,,,,
1784,441785,"dimethyl (1S,4S,5R,6S,7S,8R,11S,12R,14S,15R)-12-acetyloxy-4,7-dihydroxy-6-[(1S,2S,6S,8S,9R,11S)-2-hydroxy-11-methyl-5,7,10-trioxatetracyclo[6.3.1.02,6.09,11]dodec-3-en-9-yl]-6-methyl-14-(2-methylbut-2-enoyloxy)-3,9-dioxatetracyclo[6.6.1.01,5.011,15]pentadecane-4,11-dicarboxylate",CC=C(C)C(=O)O[C@H]1C[C@H]([C@]2(CO[C@@H]3[C@@H]2[C@]14CO[C@@]([C@H]4[C@]([C@@H]3O)(C)[C@@]56[C@@H]7C[C@H]([C@@]5(O6)C)[C@]8(C=CO[C@H]8O7)O)(C(=O)OC)O)C(=O)OC)OC(=O)C,,,,,,
1785,441786,"methyl (1R,2S,3R,6R,8R,13S,14R,15R,16S,17S)-3-(3,4-dimethylpent-2-enoyloxy)-10,15,16-trihydroxy-9,13-dimethyl-4,11-dioxo-5,18-dioxapentacyclo[12.5.0.01,6.02,17.08,13]nonadec-9-ene-17-carboxylate",CC1=C(C(=O)C[C@]2([C@H]1C[C@@H]3[C@]45[C@@H]2[C@H]([C@@H]([C@]([C@@H]4[C@H](C(=O)O3)OC(=O)C=C(C)C(C)C)(OC5)C(=O)OC)O)O)C)O,,,,,,
1786,441787,"methyl (1R,2S,3R,6R,8R,13S,14R,15R,16S,17S)-3-(4-acetyloxy-3,4-dimethylpent-2-enoyl)oxy-10,15,16-trihydroxy-9,13-dimethyl-4,11-dioxo-5,18-dioxapentacyclo[12.5.0.01,6.02,17.08,13]nonadec-9-ene-17-carboxylate",CC1=C(C(=O)C[C@]2([C@H]1C[C@@H]3[C@]45[C@@H]2[C@H]([C@@H]([C@]([C@@H]4[C@H](C(=O)O3)OC(=O)C=C(C)C(C)(C)OC(=O)C)(OC5)C(=O)OC)O)O)C)O,,,,,,
1787,441788,Brucein D,CC1=CC(=O)[C@H]([C@]2([C@H]1C[C@@H]3[C@]45[C@@H]2[C@H]([C@@H]([C@]([C@@]4([C@H](C(=O)O3)O)O)(OC5)C)O)O)C)O,,,,,,
1788,441789,Bruceoside A,C[C@H]1[C@@H]2C[C@@H]3[C@@]45CO[C@@]([C@@H]4[C@H](C(=O)O3)OC(=O)C=C(C)C)([C@H]([C@@H]([C@@H]5[C@]2(C=C(C1=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)O)O)C(=O)OC,,,,,,
1789,441790,Castelanone,C[C@@H]1[C@@H]2[C@H](C(=O)O[C@H]3[C@@]24CO[C@@]([C@@H]1O)([C@@H]4[C@@]5([C@@H](C3)C(=CC(=O)[C@H]5O)C)C)O)OC(=O)CC(C)C,,,,,,
1790,441791,Chaparrin,C[C@@H]1[C@@H]2CC(=O)O[C@H]3[C@@]24CO[C@@]([C@@H]1O)([C@@H]4[C@@]5([C@@H](C3)C(=C[C@@H]([C@H]5O)O)C)C)O,,,,,,
1791,441792,Chaparrolide,C[C@@H]1C[C@@H]([C@H]([C@]2([C@H]1C[C@@H]3[C@@]4([C@@H]2C(=O)[C@H]([C@@H]([C@@H]4CC(=O)O3)C)O)C)C)O)O,,,,,,
1792,441793,Eurycomalactone,C[C@H]1[C@@H]2[C@@H]([C@@H]3[C@@]4([C@@H](CC(=O)[C@]3([C@H]1C(=O)O2)C)C(=CC(=O)[C@H]4O)C)C)O,,,,,,
1793,441794,Simarubaceae,CC[C@@](C)(C(=O)O[C@@H]1[C@H]2[C@H]([C@H]([C@]3([C@H]4[C@@]2(CO3)[C@@H](C[C@@H]5[C@@]4([C@@H]([C@H](C=C5C)O)O)C)OC1=O)O)O)C)O,,,"['Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. (See all compounds classified as Antineoplastic Agents, Phytogenic.)']",,,
1794,441795,6-Methoxy-alpha-pyrufuran,COC1=CC=CC2=C1OC3=C2C(=C(C(=C3OC)OC)O)OC,,,,,,
1795,441796,Glaucarubinone,CC[C@@](C)(C(=O)O[C@@H]1[C@H]2[C@H]([C@H]([C@]3([C@H]4[C@@]2(CO3)[C@@H](C[C@@H]5[C@@]4([C@@H](C(=O)C=C5C)O)C)OC1=O)O)O)C)O,,,,,,
1796,441797,Glaucarubolone,C[C@@H]1[C@@H]2[C@H](C(=O)O[C@H]3[C@@]24CO[C@@]([C@@H]1O)([C@@H]4[C@@]5([C@@H](C3)C(=CC(=O)[C@H]5O)C)C)O)O,,,,,,
1797,441798,"1-(1-Carboxypropan-2-yl)-5-[(3,3-dimethyl-7-oxabicyclo[2.2.1]heptan-1-yl)methyl]-7-hydroxy-1,7a-dimethyl-2,6,7,7a-tetrahydro-1H-indene-4-carboxylic acid",C[C@H](CC(=O)O)[C@@]1(CC=C2[C@]1([C@@H](CC(=C2C(=O)O)C[C@]34CC[C@H](O3)C(C4)(C)C)O)C)C,,,,,,
1798,441799,"methyl 3-[(1R,2R,4S,7S,8S,11R,12R,13R,17S)-7-(furan-3-yl)-13,17-dihydroxy-1,8,12,15,15-pentamethyl-5,14-dioxo-3,6,16-trioxapentacyclo[9.6.0.02,4.02,8.013,17]heptadecan-12-yl]prop-2-enoate",C[C@@]12CC[C@@H]3[C@@]([C@]4(C(=O)C(O[C@]4([C@]3([C@@]15[C@H](O5)C(=O)O[C@H]2C6=COC=C6)C)O)(C)C)O)(C)C=CC(=O)OC,,,,,,
1799,441800,"[(1S,2R,4R,5R,6S,8R,10S,11S,12R,14R,15S,19S,21R)-6-(furan-3-yl)-4,12,16,19-tetrahydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.01,14.02,11.05,10.08,10]henicosan-21-yl] acetate",CC(=O)O[C@@H]1C[C@@H]([C@@]23COC([C@]1([C@@H]2C[C@H]([C@@]4([C@@H]3C(=O)[C@@H]([C@@]5([C@]46[C@H](O6)C[C@H]5C7=COC=C7)C)O)C)O)C)O)O,,,,,,
1800,441801,Ichangin,C[C@@]12CC[C@H]3[C@]([C@@]14[C@H](O4)C(=O)O[C@H]2C5=COC=C5)(C(=O)C[C@H]([C@@]36COC(=O)C[C@@H]6O)C(C)(C)O)C,,,,,,
1801,441802,Isobrucein A,CC1=CC(=O)[C@H]([C@]2([C@H]1C[C@@H]3[C@]45[C@@H]2[C@H]([C@@H]([C@]([C@@H]4[C@H](C(=O)O3)OC(=O)CC(C)C)(OC5)C(=O)OC)O)O)C)O,,,,,,
1802,441803,Nigakihemiacetal A,C[C@@H]1C=C(C(=O)[C@]2([C@H]1C[C@@H]3[C@@]4([C@@H]2[C@@H]([C@H]([C@@]([C@@H]4CC(O3)O)(C)O)OC)O)C)C)OC,,,,,,
1803,441804,Unii-3T62wcm8EK,CC[C@H](C(=O)O[C@@H]1[C@H]2[C@]3([C@H]([C@@H]([C@H]4[C@@]2(CO3)[C@@H](C[C@@H]5[C@@]4([C@@H](C(=O)C=C5C)O)C)OC1=O)O)O)C)OC(=O)C,,,,,,
1804,441805,Rutaevin,C[C@@]12CC[C@H]3[C@]([C@@]14[C@H](O4)C(=O)O[C@H]2C5=COC=C5)([C@H](C(=O)[C@@H]6[C@@]37COC(=O)C[C@@H]7OC6(C)C)O)C,,,,,,
1805,441806,"[(1R,2S,4R,6R,9R,10S,11R,12S,14R,15R,18R)-14-acetyloxy-6-(furan-3-yl)-10-(2-methoxy-2-oxoethyl)-7,9,11,15-tetramethyl-3,17-dioxapentacyclo[9.6.1.02,9.04,8.015,18]octadec-7-en-12-yl] 2-methylbut-2-enoate",CC=C(C)C(=O)O[C@H]1C[C@H]([C@]2(CO[C@@H]3[C@@H]2[C@]1([C@@H]([C@]4([C@@H]3O[C@H]5C4=C([C@@H](C5)C6=COC=C6)C)C)CC(=O)OC)C)C)OC(=O)C,,,,,,
1806,441807,Samaderin A,CC1=CC(=O)[C@]2(C1=CC(=O)[C@]34[C@@H]2[C@H]([C@H]5[C@]([C@@H]3C(=O)O5)(OC4)C)O)C,,,,,,
1807,441808,Simalikilactone D,CC[C@@H](C)C(=O)O[C@@H]1[C@H]2[C@]3([C@H]([C@@H]([C@H]4[C@@]2(CO3)[C@@H](C[C@@H]5[C@@]4([C@@H](C(=O)C=C5C)O)C)OC1=O)O)O)C,,,,,,
1808,441809,Soularubinone,C[C@@H]1[C@@H]2[C@H](C(=O)O[C@H]3[C@@]24CO[C@@]([C@@H]1O)([C@@H]4[C@@]5([C@@H](C3)C(=CC(=O)[C@H]5O)C)C)O)OC(=O)CC(C)(C)O,,,,,,
1809,441810,"[(1S,2R,4S,5R,6S,8R,10S,11S,12R,14R,15S,19R,20R,21S)-20,21-diacetyloxy-6-(furan-3-yl)-4,12,19-trihydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.01,14.02,11.05,10.08,10]henicosan-16-yl] (2R)-2-methylbutanoate",CC[C@@H](C)C(=O)OC1[C@]2([C@@H]3C[C@H]([C@@]4([C@@H]([C@@]3(CO1)[C@H]([C@H]([C@H]2OC(=O)C)OC(=O)C)O)C(=O)[C@H]([C@@]5([C@]46[C@H](O6)C[C@H]5C7=COC=C7)C)O)C)O)C,,,,,,
1810,441811,"[(1S,4R,5R,6R,7S,8R,11S,12R,13S,17S,18S,19R)-8-acetyloxy-4,5,17-trihydroxy-6,14,18-trimethyl-9,16-dioxo-3,10-dioxapentacyclo[9.8.0.01,7.04,19.013,18]nonadec-14-en-12-yl] 2-methylbut-2-enoate",CC=C(C)C(=O)O[C@@H]1[C@H]2C(=CC(=O)[C@H]([C@@]2([C@@H]3[C@@]45[C@@H]1OC(=O)[C@@H]([C@H]4[C@H]([C@H]([C@@]3(OC5)O)O)C)OC(=O)C)C)O)C,,,,,,
1811,441812,Zapoterin,C[C@@]12C[C@@H]([C@@H]3[C@]4(C=CC(=O)OC([C@@H]4CC(=O)[C@]3([C@@]15[C@H](O5)C(=O)O[C@H]2C6=COC=C6)C)(C)C)C)O,,,,,,
1812,441813,"(3S,8S,9R,10R,13R,14S,17R)-17-[(2R)-5,6-dihydroxy-6-methylheptan-2-yl]-3-hydroxy-4,4,9,13,14-pentamethyl-1,2,3,7,8,10,12,15,16,17-decahydrocyclopenta[a]phenanthren-11-one",C[C@H](CCC(C(C)(C)O)O)[C@H]1CC[C@@]2([C@@]1(CC(=O)[C@@]3([C@H]2CC=C4[C@H]3CC[C@@H](C4(C)C)O)C)C)C,,,,,,
1813,441814,CID 441814,C[C@H](CCC=C(C)CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O)O)[C@H]3CC[C@@]4([C@@]3(CC(=O)[C@@]5([C@H]4CC=C6[C@H]5CC[C@@H](C6(C)C)O)C)C)C,,,,,,
1814,441815,CID 441815,C[C@H](CCC=C(C)CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O)O)[C@H]3CC[C@@]4([C@@]3(CC(=O)[C@@]5([C@H]4CC=C6[C@H]5CC[C@@H](C6(C)C)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)C)C)C,,,,,,
1815,441816,CID 441816,C[C@H](CCC=C(C)CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O)O)[C@H]3CC[C@@]4([C@@]3(C[C@H]([C@@]5([C@H]4CC=C6[C@H]5CC[C@@H](C6(C)C)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)C)O)C)C,,,,,,
1816,441817,"(2S,3S,8S,9R,10R,13R,14S,16R,17R)-17-[(2R)-2,6-dihydroxy-6-methyl-3-oxohept-4-en-2-yl]-2,3,16-trihydroxy-4,4,9,13,14-pentamethyl-1,2,3,7,8,10,12,15,16,17-decahydrocyclopenta[a]phenanthren-11-one",C[C@@]12C[C@H]([C@@H]([C@]1(CC(=O)[C@@]3([C@H]2CC=C4[C@H]3C[C@@H]([C@H](C4(C)C)O)O)C)C)[C@](C)(C(=O)C=CC(C)(C)O)O)O,,,,,,
1817,441818,Cucurbitacin H,C[C@@]12C[C@H]([C@@H]([C@]1(CC(=O)[C@@]3([C@H]2CC=C4[C@H]3C[C@@H](C(=O)C4(C)C)O)C)C)[C@](C)(C(=O)CC(C(C)(C)O)O)O)O,,,,,,
1818,441819,Cucurbitacin J,C[C@@]12C[C@H]([C@@H]([C@]1(CC(=O)[C@@]3([C@H]2CC=C4[C@H]3C=C(C(=O)C4(C)C)O)C)C)[C@](C)(C(=O)CC(C(C)(C)O)O)O)O,,,,,,
1819,441820,Cucurbitacin L,C[C@@]12C[C@H]([C@@H]([C@]1(CC(=O)[C@@]3([C@H]2CC=C4[C@H]3C=C(C(=O)C4(C)C)O)C)C)[C@](C)(C(=O)CCC(C)(C)O)O)O,,,,,,
1820,441821,"(2R,3S,8S,9R,10R,13R,14S,16R,17R)-17-[(2R)-2,6-dihydroxy-6-methyl-3-oxohept-4-en-2-yl]-2,3,16-trihydroxy-4,4,9,13,14-pentamethyl-1,2,3,7,8,10,12,15,16,17-decahydrocyclopenta[a]phenanthren-11-one",C[C@@]12C[C@H]([C@@H]([C@]1(CC(=O)[C@@]3([C@H]2CC=C4[C@H]3C[C@H]([C@H](C4(C)C)O)O)C)C)[C@](C)(C(=O)C=CC(C)(C)O)O)O,,,,,,
1821,441822,Cucurbitacin P,C[C@@]12C[C@H]([C@@H]([C@]1(CC(=O)[C@@]3([C@H]2CC=C4[C@H]3C[C@H]([C@H](C4(C)C)O)O)C)C)[C@](C)(C(=O)CCC(C)(C)O)O)O,,,,,,
1822,441823,CID 441823,C[C@@]12CC[C@@]3([C@H]([C@@H](C[C@]3([C@@H]1CC=C4[C@H]2C=C(C(=O)C4(C)C)O)C)O)[C@](C)(C(=O)C=CC(C)(C)O)O)C,,,,,,
1823,441824,Gratiogenin,C[C@]1(CC[C@H](O1)C(C)(C)O)[C@H]2CC[C@@]3([C@@]2(CC(=O)[C@@]4([C@H]3CC=C5[C@H]4CC[C@@H](C5(C)C)O)C)C)C,,,,,,
1824,441825,CID 441825,CC(=O)O[C@H]1CO[C@H]([C@@H]([C@H]1O)OC(=O)C)O[C@@H]2C[C@]3([C@@H]4CC=C5[C@H]([C@@]4(CC[C@@]3([C@H]2[C@](C)(C(=O)C=CC(C)(C)O)O)C)C)C=C(C(=O)C5(C)C)O)C,,,,,,
1825,441826,Ajugasterone C,CC(C)CC[C@H]([C@@](C)([C@H]1CC[C@@]2([C@@]1(C[C@H]([C@H]3C2=CC(=O)[C@H]4[C@@]3(C[C@@H]([C@@H](C4)O)O)C)O)C)O)O)O,,,,,,
1826,441827,"Ergosta-5,22-dien-3beta-ol",C[C@H](C=C[C@H](C)C(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,,,,,
1827,441828,Inokosterone,C[C@H](CC[C@H]([C@@](C)([C@H]1CC[C@@]2([C@@]1(CC[C@H]3C2=CC(=O)[C@H]4[C@@]3(C[C@@H]([C@@H](C4)O)O)C)C)O)O)O)CO,,,,,,
1828,441829,"Ergosta-5,8,22-trien-3beta-ol",C[C@H](C=C[C@H](C)C(C)C)[C@H]1CC[C@@H]2[C@@]1(CCC3=C2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,,,,,
1829,441830,Makisterone B,C[C@H](C[C@H]([C@@](C)([C@H]1CC[C@@]2([C@@]1(CC[C@H]3C2=CC(=O)[C@H]4[C@@]3(C[C@@H]([C@@H](C4)O)O)C)C)O)O)O)C(C)CO,,,,,,
1830,441831,Podecdysone B,C[C@]12CCC3=C(C1=CC[C@@H]2[C@](C)([C@@H](CCC(C)(C)O)O)O)CC(=O)[C@H]4[C@@]3(C[C@@H]([C@@H](C4)O)O)C,,,,,,
1831,441832,Pollinastanol,C[C@H](CCCC(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5)O)C)C,,,,,,
1832,441833,Polypodine b,C[C@]12CC[C@H]3C(=CC(=O)[C@]4([C@@]3(C[C@@H]([C@@H](C4)O)O)C)O)[C@@]1(CC[C@@H]2[C@](C)([C@@H](CCC(C)(C)O)O)O)O,,,,,,
1833,441834,"(3S,8S,9S,10R,13R,14S,17R)-17-[(2R,5R)-5-ethyl-6-methylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol",CC[C@@H](C=C[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C)C(C)C,,,,,,
1834,441835,Poststerone,CC(=O)[C@H]1CC[C@@]2([C@@]1(CC[C@H]3C2=CC(=O)[C@H]4[C@@]3(C[C@@H]([C@@H](C4)O)O)C)C)O,,,,,,
1835,441836,Pterosterone,CC(C)[C@H](C[C@H]([C@@](C)([C@H]1CC[C@@]2([C@@]1(CC[C@H]3C2=CC(=O)[C@H]4[C@@]3(C[C@@H]([C@@H](C4)O)O)C)C)O)O)O)O,,,,,,
1836,441837,Schottenol,CC[C@H](CC[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3C2=CC[C@@H]4[C@@]3(CC[C@@H](C4)O)C)C)C(C)C,,,,,,
1837,441838,Adonitoxin,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3CC[C@]5([C@@]4(C[C@@H]([C@@H]5C6=CC(=O)OC6)O)O)C)C=O)O)O)O,,,,,,
1838,441839,Moracin A,COC1=CC2=C(C=C(O2)C3=CC(=CC(=C3)O)O)C(=C1)OC,,,,,,
1839,441840,Adynerin,C[C@@H]1[C@@H]([C@@H](C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@]45[C@@H]3CC[C@]6([C@]4(O5)CC[C@@H]6C7=CC(=O)OC7)C)C)OC)O,,,,,,
1840,441841,"2-[2-(3,7-Dimethylocta-2,6-dienyl)-5-hydroxy-3-methoxyphenyl]-1-benzofuran-6-ol",CC(=CCCC(=CCC1=C(C=C(C=C1OC)O)C2=CC3=C(O2)C=C(C=C3)O)C)C,,,,,,
1841,441842,alpha-Antiarin,C[C@@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2CC[C@@]3([C@H]4C[C@H]([C@@]5([C@H](CC[C@@]5([C@@H]4CC[C@@]3(C2)O)O)C6=CC(=O)OC6)C)O)C=O)O)O)O,,,,,,
1842,441843,Antioside,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2CC[C@@]3([C@H]4C[C@H]([C@@]5([C@H](CC[C@@]5([C@@H]4CC[C@@]3(C2)O)O)C6=CC(=O)OC6)C)O)C)O)O)O,,,,,,
1843,441844,Asclepin,C[C@@H]1C[C@@H]([C@]2([C@@H](O1)O[C@@H]3C[C@@H]4CC[C@@H]5[C@@H]([C@]4(C[C@H]3O2)C=O)CC[C@]6([C@@]5(CC[C@@H]6C7=CC(=O)OC7)O)C)O)OC(=O)C,,,,,,
1844,441845,Aspecioside,C[C@@H]1[C@H]([C@H]([C@H]([C@@H](O1)O[C@H]2CC[C@]3([C@H](C2)C[C@H]4[C@@]5([C@@H]3C[C@H]([C@]6([C@@]5(CC[C@@H]6C7=CC(=O)OC7)O)C)O)O4)C)O)O)O,,,,,,
1845,441846,"3-[(3S,5S,8R,9S,10R,11R,13R,14S,17R)-3-[(2R,3R,4S,5S,6R)-3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl]oxy-5,11,14-trihydroxy-10,13-dimethyl-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2H-furan-5-one",C[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@H]2CC[C@@]3([C@@H]4[C@@H](CC[C@@]3(C2)O)[C@]5(CC[C@@H]([C@]5(C[C@H]4O)C)C6=CC(=O)OC6)O)C)O)OC)O,,,,,,
1846,441847,CID 441847,C[C@]12C[C@H]([C@H]3[C@H]([C@]1(CC[C@@H]2C4=COC(=O)C=C4)O)CC[C@@]56[C@@]3([C@H]7C[C@H](C5)OC(O7)(O6)C)C=O)O,,,,,,
1847,441848,Bryotoxin A,C[C@@H]1C[C@H]([C@@H]([C@@H](O1)O[C@H]2CC[C@@]3([C@@H]4[C@@H](CC[C@@]3(C2)O)[C@]5(CC[C@@H]([C@]5(C(=O)[C@H]4O)C)C6=COC(=O)C=C6)O)C=O)O)OC(=O)C,,,,,,
1848,441849,Calactin,C[C@@H]1C[C@H]([C@]2([C@@H](O1)O[C@@H]3C[C@@H]4CC[C@@H]5[C@@H]([C@]4(C[C@H]3O2)C=O)CC[C@]6([C@@]5(CC[C@@H]6C7=CC(=O)OC7)O)C)O)O,,,,,,
1849,441850,Thevetin B,C[C@H]1[C@@H]([C@H]([C@@H]([C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3CC[C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)C)O)OC)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O)O)O,,,,,,
1850,441851,Cerbertin,C[C@H]1[C@@H]([C@H]([C@@H]([C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3[C@H]5[C@H](O5)[C@]6([C@@]4(CC[C@@H]6C7=CC(=O)OC7)O)C)C=O)OC(=O)C)OC)O,,,,,,
1851,441852,Convallatoxin,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2CC[C@@]3([C@H]4CC[C@@]5([C@H](CC[C@@]5([C@@H]4CC[C@@]3(C2)O)O)C6=CC(=O)OC6)C)C=O)O)O)O,,,['Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)'],"['The intestinal absorption of 15 cardenolides was examined after the (3)H-labeled substances were injected intraluminally into ligated duodenal loops of cats. Concentrations of (3)H were followed in the portal circulation and in the bile.', 'Isolated, everted rat jejunal preparations absorbed convallatoxin by an active transport mechanism. No relation was observed between the amount of cardiotonic glycoside actively transported and the oxygen consumption of the tissue.', 'Digitalis-like compounds (DLCs), such as digoxin and digitoxin that are derived from digitalis species, are currently used to treat heart failure and atrial fibrillation, but have a narrow therapeutic index. Drug-drug interactions at the transporter level are frequent causes of DLCs toxicity. P-glycoprotein (P-gp, ABCB1) is the primary transporter of digoxin and its inhibitors influence pharmacokinetics and disposition of digoxin in the human body; however, the involvement of P-gp in the disposition of other DLCs is currently unknown. In present study, the transport of fourteen DLCs by human P-gp was studied using membrane vesicles originating from human embryonic kidney (HEK293) cells overexpressing P-gp. DLCs were quantified by liquid chromatography-mass spectrometry (LC-MS). The Lily of the Valley toxin, convallatoxin, was identified as a P-gp substrate (Km: 1.1+/-0.2 mM) in the vesicular assay. Transport of convallatoxin by P-gp was confirmed in rat in vivo, in which co-administration with the P-gp inhibitor elacridar, resulted in increased concentrations in brain and kidney cortex. To address the interaction of convallatoxin with P-gp on a molecular level, the effect of nine alanine mutations was compared with the substrate N-methyl quinidine (NMQ). Phe343 appeared to be more important for transport of NMQ than convallatoxin, while Val982 was particularly relevant for convallatoxin transport. We identified convallatoxin as a new P-gp substrate and recognized Val982 as an important amino acid involved in its transport. ...']","['Helveticoside and convallatoxin were converted hydrolytically into strophanthidine during perfusion through an isolated rat small intestine segment. Also, the C10-aldehyde group of these compounds was reduced enzymatically to helveticosol, convallatoxol, and strophanthidol. This reduction of strophanthidine cardenolides, beside the hydrolysis reaction, appeared to be the most important biotransformation reaction in the rat small intestine.']",
1852,441853,Cymarin,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@@]3([C@H]4CC[C@@]5([C@H](CC[C@@]5([C@@H]4CC[C@@]3(C2)O)O)C6=CC(=O)OC6)C)C=O)OC)O,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)']",,,
1853,441854,Decoside,C[C@H]1[C@@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4C3=C(C(=O)[C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C)OC)O,,,,,,
1854,441855,Diginatin,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(C[C@@H]([C@@H]7C8=CC(=O)OC8)O)O)C)O)C)C)C)O)O,,,,,,
1855,441856,Digitalin,C[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3CC[C@]5([C@@]4(C[C@@H]([C@@H]5C6=CC(=O)OC6)O)O)C)C)O)OC)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O,,,,,,
1856,441857,Divostroside,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3[C@@H](C[C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C)OC)O,,,,,,
1857,441858,Eriocarpin,C[C@@H]1C[C@H]([C@]2([C@@H](O1)O[C@@H]3C[C@@H]4C[C@H]5[C@]6(O5)[C@@H]([C@]4(C[C@H]3O2)C)[C@@H](C(=O)[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)O)O,,,,,,
1858,441859,Hellebrin,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2CC[C@@]3([C@H]4CC[C@@]5([C@H](CC[C@@]5([C@@H]4CC[C@@]3(C2)O)O)C6=COC(=O)C=C6)C)C=O)O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O,,,,,,
1859,441860,Helveticoside,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@@]3([C@H]4CC[C@@]5([C@H](CC[C@@]5([C@@H]4CC[C@@]3(C2)O)O)C6=CC(=O)OC6)C)C=O)O)O,,,,,,
1860,441861,Labriformidin,C[C@@H]1CC(=O)[C@]2([C@@H](O1)O[C@@H]3C[C@@H]4C[C@H]5[C@]6(O5)[C@@H]([C@]4(C[C@H]3O2)C)[C@@H](C(=O)[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)O,,,,,,
1861,441862,Labriformin,C[C@@H]1CC2([C@]3([C@@H](O1)O[C@@H]4C[C@@H]5C[C@H]6[C@]7(O6)[C@@H]([C@]5(C[C@H]4O3)C)[C@@H](C(=O)[C@]8([C@@]7(CC[C@@H]8C9=CC(=O)OC9)O)C)O)O)N=CCS2,,,,,,
1862,441863,Lanceotoxin A,C[C@@H]([C@@H]([C@H]([C@H](C(=O)O[C@H]1CC[C@@]2([C@H]3CC[C@@]4([C@H](CC[C@@]4([C@@H]3CC[C@@]2(C1)OC(=O)C)O)C5=COC(=O)C=C5)C)C=O)O)O)O)O,,,,,,
1863,441864,Lanceotoxin B,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2CC[C@@]3([C@H]4CC[C@@]5([C@H](CC[C@@]5([C@@H]4CC[C@@]3(C2)OC(=O)C)O)C6=COC(=O)C=C6)C)C=O)O)O)O,,,,,,
1864,441865,Lokundjoside,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2CC[C@@]3([C@@H]4[C@@H](CC[C@@]3(C2)O)[C@]5(CC[C@@H]([C@]5(C[C@H]4O)C)C6=CC(=O)OC6)O)C)O)O)O,,,,,,
1865,441866,Sarmutogenin 3-O-beta-D-digitaloside,C[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3C(=O)[C@H]([C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C)O)OC)O,,,,,,
1866,441867,Neriifolin,C[C@H]1[C@@H]([C@H]([C@@H]([C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3CC[C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)C)O)OC)O,,,,,,
1867,441868,Rhodexin A,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3[C@@H](C[C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C)O)O)O,,,,,,
1868,441869,Sarmentoloside,C[C@H]1[C@H]([C@H]([C@H]([C@@H](O1)O[C@H]2CC[C@@]3([C@@H]4[C@@H](CC[C@@]3(C2)O)[C@]5(CC[C@@H]([C@]5(C[C@H]4O)C)C6=CC(=O)OC6)O)CO)O)O)O,,,,,,
1869,441870,Scillaren A,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2CC[C@@]3([C@H]4CC[C@@]5([C@H](CC[C@@]5([C@@H]4CCC3=C2)O)C6=COC(=O)C=C6)C)C)O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O,,,,,,
1870,441871,Scilliroside,CC(=O)O[C@@H]1C[C@@]2([C@H](CC[C@]3([C@@]2(CC[C@@H]3C4=COC(=O)C=C4)O)C)[C@@]5(C1=C[C@H](CC5)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)O,,,,"['Red squill is a little-used rodenticide, consisting of the inner portions of a small cabbage plant grown in eastern Mediterranean countries. Its toxic properties have been known since ancient times and are probably due to cardiac glycosides. For several reasons, mammals other than rodents are unlikely to be poisoned: (1) red squill is intensely nauseant, so that animals which vomit (rodents do not) are unlikely to retain the poison; (2) the glycoside is not efficiently absorbed from the gut; and (3) absorbed glycoside is rapidly excreted. Injection of the glycosides leads to effects typical of digitalis: alterations in cardiac impulse conduction and arrhythmias.']",,
1871,441872,Strophanthidin 3-diglucosylcymarose,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@@]3([C@H]4CC[C@@]5([C@H](CC[C@@]5([C@@H]4CC[C@@]3(C2)O)O)C6=CC(=O)OC6)C)C=O)OC)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O)O,,,,,,
1872,441873,Thevetin A,C[C@H]1[C@@H]([C@H]([C@@H]([C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3CC[C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)C=O)O)OC)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O)O)O,,,,,,
1873,441874,Uscharidin,C[C@@H]1CC(=O)[C@]2([C@@H](O1)O[C@@H]3C[C@@H]4CC[C@@H]5[C@@H]([C@]4(C[C@H]3O2)C=O)CC[C@]6([C@@]5(CC[C@@H]6C7=CC(=O)OC7)O)C)O,,,,,,
1874,441875,Vernadigin,C[C@@H]1[C@@H]([C@@H](C[C@@H](O1)O[C@H]2CC[C@@]3([C@H]4CC[C@@]5([C@H]([C@H](C[C@@]5([C@@H]4CC[C@@]3(C2)O)O)O)C6=CC(=O)OC6)C)C=O)OC)O,,,,,,
1875,441876,Agavoside A,C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(C(=O)C[C@H]5[C@H]4CC[C@@H]6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@H]([C@H](O7)CO)O)O)O)C)C)C)OC1,,,,,,
1876,441877,"(2S,3R,4R,5R,6S)-2-[(2R,3S,4S,5R,6R)-4-hydroxy-2-(hydroxymethyl)-6-[(1S,2S,4S,5'S,6S,7S,8R,9S,12S,13R,16S)-5',7,9,13-tetramethyl-5'-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]spiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxolane]-16-yl]oxy-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]oxy-6-methyloxane-3,4,5-triol",C[C@H]1[C@H]2[C@H](C[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC=C5[C@@]4(CC[C@@H](C5)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O[C@H]7[C@@H]([C@@H]([C@H]([C@@H](O7)C)O)O)O)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)C)C)O[C@]19CC[C@@](O9)(C)CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1877,441878,"(2S,3R,4R,5R,6S)-2-[(2R,3S,4S,5R,6R)-5-[(2S,3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-4-hydroxy-2-(hydroxymethyl)-6-[(1S,2S,4S,5'S,6S,7S,8R,9S,12S,13R,16S)-5',7,9,13-tetramethyl-5'-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]spiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxolane]-16-yl]oxyoxan-3-yl]oxy-6-methyloxane-3,4,5-triol",C[C@H]1[C@H]2[C@H](C[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC=C5[C@@]4(CC[C@@H](C5)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O[C@H]7[C@@H]([C@@H]([C@H]([C@@H](O7)C)O)O)O)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O)C)C)O[C@]11CC[C@@](O1)(C)CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1878,441879,Capsicoside A,C[C@H]1[C@H]2[C@H](C[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC[C@@H]5[C@@]4(C[C@H]([C@@H](C5)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O[C@H]7[C@@H]([C@H]([C@H]([C@H](O7)CO)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O)O)O)C)C)O[C@@]1(CC[C@@H](C)CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)O,,,,,,
1879,441880,Convallagenin A,C[C@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC[C@]6([C@@]5([C@@H](C[C@@H](C6)O)O)C)O)C)C)OC1,,,,,,
1880,441881,Convallamarogenin,C[C@H]1[C@H]2[C@H](C[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC[C@H]5[C@@]4([C@@H](C[C@@H](C5)O)O)C)C)O[C@]16CCC(=C)CO6,,,,,,
1881,441882,Convallamaroside,C[C@H]1[C@H]2[C@H](C[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC[C@H]5[C@@]4([C@@H](C[C@@H](C5)O[C@H]6[C@@H]([C@@H]([C@H]([C@@H](O6)C)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)O)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)C)O)O)O[C@H]9[C@@H]([C@@H]([C@H]([C@@H](O9)C)O)O)O)C)C)O[C@@]1(CCC(=C)CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)O,,,,,,
1882,441883,Convallagenin A 3-O-alpha-L-arabinopyranoside,C[C@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC[C@]6([C@@]5([C@@H](C[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@H](CO7)O)O)O)O)C)O)C)C)OC1,,,,,,
1883,441884,Deltonin,C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC=C6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O)O[C@H]9[C@@H]([C@@H]([C@H]([C@@H](O9)C)O)O)O)C)C)C)OC1,,,,,,
1884,441885,Protodeltonin,C[C@H]1[C@H]2[C@H](C[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC=C5[C@@]4(CC[C@@H](C5)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)O)O[C@H]8[C@@H]([C@@H]([C@H]([C@@H](O8)C)O)O)O)C)C)O[C@@]1(CC[C@@H](C)CO[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O,,,,,,
1885,441886,Digitogenin,C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)[C@H]([C@@H]4[C@@]3(CC[C@H]5[C@H]4CC[C@@H]6[C@@]5(C[C@H]([C@@H](C6)O)O)C)C)O)C)OC1,,,,,,
1886,441887,Gitogenin,C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC[C@@H]6[C@@]5(C[C@H]([C@@H](C6)O)O)C)C)C)OC1,,,,,,
1887,441888,Gitonin,C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC[C@@H]6[C@@]5(C[C@H]([C@@H](C6)O[C@H]7[C@@H]([C@H]([C@H]([C@H](O7)CO)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O[C@H]9[C@@H]([C@H]([C@@H](CO9)O)O)O)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O)O)O)O)O)C)C)C)OC1,,,,,,
1888,441889,Officinalisnin I,C[C@H]1[C@H]2[C@H](C[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC[C@H]5[C@@]4(CC[C@@H](C5)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)C)C)O[C@@]1(CC[C@@H](C)CO[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O,,,,,,
1889,441890,Osladin,C[C@@H]1CCC(O[C@@H]1O[C@H]2[C@@H]([C@@H]([C@H]([C@@H](O2)C)O)O)O)[C@@H](C)C3CC[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC(=O)[C@@H]6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O[C@H]8[C@@H]([C@@H]([C@H]([C@@H](O8)C)O)O)O)C)C,,,,,,
1890,441891,Protodioscin,C[C@H]1[C@H]2[C@H](C[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC=C5[C@@]4(CC[C@@H](C5)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O[C@H]7[C@@H]([C@@H]([C@H]([C@@H](O7)C)O)O)O)O)O[C@H]8[C@@H]([C@@H]([C@H]([C@@H](O8)C)O)O)O)C)C)O[C@@]1(CC[C@@H](C)CO[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O,,,,,,
1891,441892,Protogracillin,C[C@H]1[C@H]2[C@H](C[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC=C5[C@@]4(CC[C@@H](C5)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)O[C@H]8[C@@H]([C@@H]([C@H]([C@@H](O8)C)O)O)O)C)C)O[C@@]1(CC[C@@H](C)CO[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O,,,,,,
1892,441893,Ruscogenin,C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC=C6[C@@]5([C@@H](C[C@@H](C6)O)O)C)C)C)OC1,,,,,,
1893,441894,Ruscoside,C[C@H]1[C@H]2[C@H](C[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC=C5[C@@]4([C@@H](C[C@@H](C5)O[C@H]6[C@@H]([C@H]([C@H](CO6)O)O)O[C@H]7[C@@H]([C@@H]([C@H]([C@@H](O7)C)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O)O)C)C)O[C@@]1(CCC(=C)CO[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O,,,,,,
1894,441895,Sarsaparilloside,C[C@H]1[C@H]2[C@H](C[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC[C@H]5[C@@]4(CC[C@@H](C5)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)O[C@H]8[C@@H]([C@@H]([C@H]([C@@H](O8)C)O)O)O)O)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)C)C)O[C@@]1(CC[C@H](C)CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)O,,,,,,
1895,441896,Asparanin B,C[C@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC[C@H]6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O[C@H]8[C@@H]([C@@H]([C@H]([C@@H](O8)C)O)O)O)O)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)C)C)C)OC1,,,,,,
1896,441897,Tigonin,C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC[C@@H]6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@H]([C@H](O7)CO)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O[C@H]9[C@@H]([C@H]([C@@H](CO9)O)O)O)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O)O)C)C)C)OC1,,,,,,
1897,441898,Tokoronin,C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC[C@H]6[C@@]5([C@@H]([C@@H]([C@H](C6)O)O)O[C@H]7[C@@H]([C@H]([C@H](CO7)O)O)O)C)C)C)OC1,,,,,,
1898,441899,Trigonelloside C,C[C@H]1[C@H]2[C@H](C[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC=C5[C@@]4(CC[C@@H](C5)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O[C@H]7[C@@H]([C@@H]([C@H]([C@@H](O7)C)O)O)O)O)O[C@H]8[C@@H]([C@@H]([C@H]([C@@H](O8)C)O)O)O)C)C)O[C@@]1(CC[C@H](C)CO[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O,,,,,,
1899,441900,Yamogenin,C[C@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC=C6[C@@]5(CC[C@@H](C6)O)C)C)C)OC1,,,,,,
1900,441901,Yamogenin 3-O-neohesperidoside,C[C@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC=C6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O[C@H]8[C@@H]([C@@H]([C@H]([C@@H](O8)C)O)O)O)C)C)C)OC1,,,,,,
1901,441902,"(1S,3R,6S,7S,8R,11S,12S,16R)-7,12,16-Trimethyl-15-[(1S)-1-[(2S)-5-methyl-6-oxo-2,3-dihydropyran-2-yl]ethyl]-6-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentacyclo[9.7.0.01,3.03,8.012,16]octadecane-7-carboxylic acid",CC1=CC[C@H](OC1=O)[C@@H](C)C2CC[C@@]3([C@@]2(CC[C@]45[C@H]3CC[C@@H]6[C@]4(C5)CC[C@@H]([C@@]6(C)C(=O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)C)C,,,,,,
1902,441903,"(2S,3S,4S,5R,6R)-6-[[(3S,4S,4aR,6aR,6bS,8R,8aR,9R,10R,12aS,14aR,14bR)-9-acetyloxy-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-10-(2-methylbut-2-enoyloxy)-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-4-hydroxy-3,5-bis[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy]oxane-2-carboxylic acid",CC=C(C)C(=O)O[C@H]1[C@@H]([C@@]2([C@@H](C[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H]([C@]5(C)CO)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)C)C)[C@@H]2CC1(C)C)C)O)CO)OC(=O)C,,,,,,
1903,441904,Arvensoside A,C[C@]12CC[C@@H](C([C@@H]1CC[C@@]3([C@@H]2CC=C4[C@]3(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)C)(C)C)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O[C@H]8[C@@H]([C@H]([C@H]([C@H](O8)CO)O)O)O)O,,,,,,
1904,441905,Astragaloside III,C[C@]12CC[C@@]34C[C@@]35CC[C@@H](C([C@@H]5[C@H](C[C@H]4[C@@]1(C[C@@H]([C@@H]2[C@]6(CC[C@H](O6)C(C)(C)O)C)O)C)O)(C)C)O[C@H]7[C@@H]([C@H]([C@@H](CO7)O)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O,,,,,,
1905,441906,Astrasieversianin XVI,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H](CO[C@H]2O[C@H]3CC[C@]45C[C@]46CC[C@@]7([C@H]([C@H](C[C@]7([C@@H]6C[C@@H]([C@H]5C3(C)C)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)C)O)[C@]9(CC[C@H](O9)C(C)(C)O)C)C)O)O)O)O)O,,,,,,
1906,441907,Avenacin A-1,C[C@]12CC[C@@H]([C@@]([C@@H]1CC[C@@]3([C@@H]2C[C@@H]4[C@]5([C@]3(C[C@@H]([C@@]6([C@H]5C[C@@]([C@H](C6)OC(=O)C7=CC=CC=C7NC)(C)C=O)C)O)C)O4)C)(C)CO)O[C@H]8[C@@H]([C@H]([C@H](CO8)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1907,441908,Avenacin B-2,C[C@]12CC[C@@H](C([C@@H]1CC[C@@]3([C@@H]2C[C@@H]4[C@]5([C@]3(C[C@@H]([C@@]6([C@H]5C[C@@]([C@H](C6)OC(=O)C7=CC=CC=C7)(C)C=O)C)O)C)O4)C)(C)C)O[C@H]8[C@@H]([C@H]([C@H](CO8)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1908,441909,Azukisaponin III,C[C@]12CC[C@@](C[C@H]1C3=CC[C@@H]4[C@]5(CC[C@@H]([C@]([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)CO)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)C)(C)C(=O)O,,,,,,
1909,441910,Bayogenin 3-O-cellobioside,C[C@@]12CC[C@@H]3[C@@]([C@H]1CC=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)(C[C@@H]([C@@H]([C@@]3(C)CO)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)O)O)O)C,,,,,,
1910,441911,Camellidin I,CC(=O)O[C@@]12CC(CC[C@@H]1C(=O)C[C@@]3(C2=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O[C@H]7[C@@H]([C@H]([C@H]([C@H](O7)CO)O)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O)O[C@H]9[C@@H]([C@H]([C@H]([C@H](O9)CO)O)O)O)C)C)C)(C)C,,,,,,
1911,441912,Camellidin II,C[C@]12CC[C@@H](C([C@@H]1CC[C@@]3([C@@H]2CC=C4[C@]3(CC(=O)[C@@H]5[C@]4(CC(CC5)(C)C)O)C)C)(C)C)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O)O[C@H]7[C@@H]([C@H]([C@H]([C@H](O7)CO)O)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O[C@H]9[C@@H]([C@H]([C@H]([C@H](O9)CO)O)O)O,,,,,,
1912,441913,CID 441913,C[C@@H]1CC2(C3C(O3)(C(O2)O)C)O[C@@H]4[C@H]1[C@]5([C@@H](C[C@@]67C[C@@]68CC[C@@H](C([C@@H]8CC=C7[C@@]5(C4)C)(C)C)O[C@H]9[C@@H]([C@H]([C@@H](CO9)O)O)O)OC(=O)C)C,,,,,,
1913,441914,Colubrin,CC(=C[C@H]1C[C@]([C@@H]2[C@H]3CC[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@]36C[C@@]2(O1)OC6)C)(C)C)O[C@H]7[C@@H]([C@H]([C@H](CO7)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O[C@H]9[C@@H]([C@H]([C@@H](CO9)O)O)O)OC(=O)C)C)(C)O)C,,,,,,
1914,441915,Colubrinoside,CC(=C[C@H]1C[C@]([C@@H]2[C@H]3CC[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@]36C[C@@]2(O1)OC6)C)(C)C)O[C@H]7[C@@H]([C@H]([C@H](CO7)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)OC(=O)C)O[C@H]9[C@@H]([C@H]([C@@H](CO9)O)O)O)O)OC(=O)C)C)(C)O)C,,,,,,
1915,441916,Cyclamin,C[C@@]1(CC[C@@]23CO[C@]4([C@@H]2C1)CC[C@@H]5[C@]6(CC[C@@H](C([C@@H]6CC[C@]5([C@@]4(C[C@H]3O)C)C)(C)C)O[C@H]7[C@@H]([C@H]([C@H](CO7)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O[C@H]1[C@@H]([C@H]([C@@H](CO1)O)O)O)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)C)C=O,,,,,,
1916,441917,Cyclofoetoside B,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)O[C@H]3C[C@]4([C@@H]5CC[C@H]6[C@@]([C@H](CC[C@]67[C@]5(C7)CC[C@@]4(C3[C@H](C)CC[C@@H](C(C)(C)O)O)C)O[C@H]8[C@@H]([C@H]([C@H](CO8)O)O)O)(C)CO)C)O)O)O)O)O)O,,,,,,
1917,441918,Desglucomusennin,C[C@]12CC[C@@H](C([C@@H]1CC[C@@]3([C@@H]2CC=C4[C@]3(C[C@H]([C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)O)C)C)(C)C)O[C@H]6[C@@H]([C@H]([C@H](CO6)O)O)O[C@H]7[C@@H]([C@H]([C@H](CO7)O)O)O[C@H]8[C@@H]([C@H]([C@H](CO8)O)O)O,,,,,,
1918,441919,Dianoside A,C[C@]12CC[C@@H]([C@@]([C@@H]1CC[C@@]3([C@@H]2CC=C4[C@]3(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)C)(C)C(=O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O,,,,,,
1919,441920,"(4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-[(2S,3S,5R)-5-hydroxy-4-oxo-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid",C[C@]12CC[C@@H](C([C@@H]1CC[C@@]3([C@@H]2CC=C4[C@]3(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)C)(C)C)O[C@H]6[C@@H](C(=O)[C@@H](CO6)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O,,,,,,
1920,441921,Ginsenoside Re,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2O[C@H]3C[C@@]4([C@H](C[C@H]([C@H]5[C@]4(CC[C@@H]5[C@](C)(CCC=C(C)C)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)O)[C@@]7([C@@H]3C([C@H](CC7)O)(C)C)C)C)CO)O)O)O)O)O,,,,,,
1921,441922,Ginsenoside Rf,CC(=CCC[C@@](C)([C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(C[C@@H]([C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)O)C)O)C,,,,,,
1922,441923,Ginsenoside RG1,CC(=CCC[C@@](C)([C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(C[C@@H]([C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)C)O)C)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C,,,"['A class of drugs producing both physiological and psychological effects through a variety of mechanisms. They can be divided into &quot;specific&quot; agents, e.g., affecting an identifiable molecular mechanism unique to target cells bearing receptors for that agent, and &quot;nonspecific&quot; agents, those producing effects on different target cells and acting by diverse molecular mechanisms. Those with nonspecific mechanisms are generally further classed according to whether they produce behavioral depression or stimulation. Those with specific mechanisms are classed by locus of action or specific therapeutic use. (From Gilman AG, et al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed, p252) (See all compounds classified as Central Nervous System Agents.)']",,['M1 (20- O -β- D -glucopyranosyl-20( S )- protopanaxadiol ) is a ppd-type monoglucoside ginsenoside metabolized by intestinal bacteria in humans'],
1923,441924,CID 441924,CC=C(C)C(=O)O[C@H]1[C@@H]([C@@]2([C@H](C[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H]([C@@]5(C)CO)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O)O)O)C)C)[C@@H]2CC1(C)C)C)O)COC(=O)C)O,,,,,,
1924,441925,Gypenoside XXV,CC(=CCC[C@@](CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)([C@H]2CC[C@@]3([C@@H]2CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)O[C@H]6[C@@H]([C@H]([C@H](CO6)O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)C=O)C)C)O)C,,,,,,
1925,441926,psi-Rhodomyrtoxin,CCC(C)C(=O)C1=C(C(=C(C2=C1OC3=C2C(=C(C(=C3C(=O)CC(C)C)O)C)O)O)C)O,,,,,,
1926,441927,Gypsogenin 3-O-rhamnosylglucuronide,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2[C@@H]([C@H](O[C@H]([C@@H]2O)O[C@H]3CC[C@]4([C@H]([C@]3(C)C=O)CC[C@@]5([C@@H]4CC=C6[C@]5(CC[C@@]7([C@H]6CC(CC7)(C)C)C(=O)O)C)C)C)C(=O)O)O)O)O)O,,,,,,
1927,441928,Cauloside A,C[C@]12CC[C@@H]([C@@]([C@@H]1CC[C@@]3([C@@H]2CC=C4[C@]3(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)C)(C)CO)O[C@H]6[C@@H]([C@H]([C@H](CO6)O)O)O,,,['Compounds that inhibit the activity of DNA TOPOISOMERASE I. (See all compounds classified as Topoisomerase I Inhibitors.)'],,,
1928,441929,beta-Hederin,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@H](CO[C@H]2O[C@H]3CC[C@]4([C@H](C3(C)C)CC[C@@]5([C@@H]4CC=C6[C@]5(CC[C@@]7([C@H]6CC(CC7)(C)C)C(=O)O)C)C)C)O)O)O)O)O,,,,,,
1929,441930,Helianthoside A,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H](O[C@H]([C@@H]2O)O[C@@H]3[C@H](O[C@H]([C@@H]([C@H]3O)O)O[C@H]4CC[C@]5([C@H](C4(C)C)CC[C@@]6([C@@H]5CC=C7[C@]6(C[C@H]([C@@]8([C@H]7CC(CC8)(C)C)C(=O)O)O)C)C)C)CO[C@H]9[C@@H]([C@H]([C@@H](CO9)O)O)O)C)O)O)O)O,,,,,,
1930,441931,Ilexolide A,C[C@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)O[C@H]6[C@@H]([C@H]([C@H](O6)CO)O)O)C)C)C2=C1C)C)C(=O)O,,,,,,
1931,441932,Medicagenic acid 3-O-triglucoside,C[C@@]12CC[C@@H]3[C@@]([C@H]1CC=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)(C[C@@H]([C@@H]([C@@]3(C)C(=O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O)O)O)O)O)C,,,,,,
1932,441933,Musennin,C[C@]12CC[C@@H](C([C@@H]1CC[C@@]3([C@@H]2CC=C4[C@]3(C[C@H]([C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)O)C)C)(C)C)O[C@H]6[C@@H]([C@H]([C@H](CO6)O)O)O[C@H]7[C@@H]([C@H]([C@H](CO7)O)O)O[C@H]8[C@@H]([C@H]([C@H](CO8)O)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O,,,,,,
1933,441934,Notoginsenoside R1,CC(=CCC[C@@](C)([C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(C[C@@H]([C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H](CO6)O)O)O)C)O)C)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)C,,,,,"['Zebrafish, a common model organism for studies of vertebrate development and gene function, has been used in pharmaceutical research as a new and powerful tool in recent years. In the present study, /the researchers/ applied zebrafish ...in a metabolic study of notoginsenoside (R1), ginsenoside (Rg1) and ginsenoside (Rb1), which are saponins isolated from Panax notoginseng. Metabolites of these three saponin compounds in zebrafish after exposure for 24 hr were identified by high performance liquid chromatography - electrospray mass spectrometry (HPLC-ESI-MS) with a Zorbax C-18 column for separation using a binary gradient elution of 0.05% formic acid acetonitrile - 0.05% formic acid water. The quasi-molecular ions of compounds were detected in negative mode. Step-wise deglycosylation metabolites and hydroxylation metabolites of the three saponins were found, which were /consistant/ with regular methods for metabolic analysis...']",
1934,441935,Olaxoside,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2[C@@H]([C@H]([C@@H](O[C@@H]2C(=O)O)O[C@H]3CC[C@]4([C@H](C3(C)C)CC[C@@]5([C@@H]4CC=C6[C@]5(CC[C@@]7([C@H]6CC(CC7)(C)C)C(=O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)C)C)C)O)O)O)O)O,,,,,,
1935,441936,Pfaffic acid,C[C@]12CC[C@@]3([C@H]1C[C@@]4(C(=CC[C@H]5[C@]4(CC[C@@H]6[C@@]5(CC[C@@H](C6(C)C)O)C)C)[C@@H]3C2)C)C(=O)O,,,,,,
1936,441937,Pfaffoside A,C[C@]12CC[C@@]3([C@H]1C[C@@]4(C(=CC[C@H]5[C@]4(CC[C@@H]6[C@@]5(CC[C@@H](C6(C)C)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)C(=O)O)O)O)O[C@H]8[C@@H]([C@H]([C@@H](CO8)O)O)O)C)C)[C@@H]3C2)C)C(=O)O,,,,,,
1937,441938,Phaseoloside D,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H](O[C@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H]([C@H](CO[C@H]4O[C@H]5[C@@H]([C@H](O[C@H]([C@@H]5O)O[C@H]6CC[C@]7([C@H]([C@@]6(C)CO)CC[C@@]8([C@@H]7CC=C9[C@]8(C=C[C@@]1([C@H]9CC(CC1)(C)C)C)C)C)C)C(=O)O)O)O)O)CO)O[C@H]1[C@@H]([C@H]([C@H]([C@H](O1)CO)O)O)O)O)O)O)O)O,,,,,,
1938,441939,Esculentoside B,C[C@@]1(CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(C[C@@H]([C@@H]([C@@]5(C)CO)O[C@H]6[C@@H]([C@H]([C@@H](CO6)O)O)O)O)C)C)[C@@H]2C1)C)C(=O)O)C(=O)OC,,,,,,
1939,441940,Pittoside A,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2CC[C@]3([C@H](C2(C)C)CC[C@@]4([C@@H]3CC=C5[C@]4([C@H](C[C@@]6([C@H]5CC([C@H]([C@@H]6O)O)(C)C)CO)O)C)C)C)O)O)O[C@H]7[C@@H]([C@H]([C@H](CO7)O)O)O,,,,,,
1940,441941,"(2S,3R,4R,5R,6S)-2-[(2R,3R,4S,5R,6R)-2-[[(3S,4aR,6aR,6bS,8R,8aS,12aS,14aR,14bR)-8-hydroxy-8a-(hydroxymethyl)-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-4-hydroxy-6-(hydroxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyoxan-3-yl]oxy-6-methyloxane-3,4,5-triol",C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@H]([C@H](O[C@H]2O[C@H]3CC[C@]4([C@H](C3(C)C)CC[C@@]5([C@@H]4CC=C6[C@]5(C[C@H]([C@@]7([C@H]6CC(CC7)(C)C)CO)O)C)C)C)CO)O[C@H]8[C@@H]([C@H]([C@H]([C@H](O8)CO[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O)O)O)O)O)O)O,,,,,,
1941,441942,Propapyriogenin A2,C[C@]12CCC(=O)C([C@@H]1CC[C@@]3([C@@H]2[C@@H](C=C4[C@]3(CC[C@@]5([C@H]4CC(C(=O)C5)(C)C)C(=O)O)C)O)C)(C)C,,,,,,
1942,441943,Rotundioside B,C[C@]12CC[C@@H](C([C@@H]1CC[C@@]3([C@@H]2CC=C4[C@]3(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O)O)O)O)O)O)C)C)(C)C)OS(=O)(=O)[O-],,,,,,
1943,441944,CID 441944,C[C@@]12CC[C@H](C([C@@H]1CC[C@]3([C@@H]2CC=C4[C@]3(CC[C@]5([C@H]4CC(CC5)(C)C)C(=O)O[C@@H]6[C@@H]([C@@H](C([C@@H](O6)CO[C@@H]7[C@@H]([C@@H]([C@H]([C@@H](O7)CO)O)O)O[C@@H]8[C@@H]([C@@H]([C@H]([C@@H](O8)CO[C@@H]9[C@@H]([C@@H]([C@H]([C@@H](O9)CO)O)O)O)O)O)O)O)O)O)C)C)(C)C)OS(=O)(=O)O,,,,,,
1944,441945,Saikosaponin BK1,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2O)O)O[C@H]3CC[C@]4([C@H](C3(C)C)CC[C@@]5([C@@H]4C=CC6=C7CC(CC[C@@]7([C@@H](C[C@]65C)O)CO)(C)C)C)C)CO[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O)O)O,,,,,,
1945,441946,Saponoside D,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2[C@@H]([C@H]([C@@H](O[C@@H]2C(=O)O)O[C@H]3CC[C@]4([C@H]([C@@]3(C)C=O)CC[C@@]5([C@@H]4CC=C6[C@]5(CC[C@@]7([C@H]6CC(CC7)(C)C)C(=O)O[C@H]8[C@@H]([C@H]([C@H]([C@H](O8)C)O[C@H]9[C@@H]([C@H]([C@@H](CO9)O)O)O)O[C@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)C)O[C@H]1[C@@H]([C@H]([C@H]([C@H](O1)CO)O)O)O)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)O)C)C)C)O)O[C@H]1[C@@H]([C@H]([C@@H](CO1)O[C@H]1[C@@H]([C@H]([C@H](CO1)O)O)O)O)O[C@H]1[C@@H]([C@H]([C@H]([C@H](O1)CO)O)O)O)O)O)O,,,,,,
1946,441947,"(2S,3R,4S,4aR,6aR,6bR,8aS,12aS,14aR,14bR)-8a-[(2S,3R,4S,5R,6R)-3-[(2S,3R,4S,5R,6S)-5-[(2S,3R,4R,5R)-3,4-dihydroxy-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-5-[3-(3,4-dimethoxyphenyl)prop-2-enoyloxy]-4-hydroxy-6-methyloxan-2-yl]oxycarbonyl-2-hydroxy-6b-(hydroxymethyl)-4,6a,11,11,14b-pentamethyl-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4-carboxylic acid",C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@H]([C@H](O[C@H]2OC(=O)[C@@]34CC[C@@]5(C(=CC[C@H]6[C@]5(CC[C@@H]7[C@@]6(C[C@@H]([C@@H]([C@@]7(C)C(=O)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O)C)C)[C@@H]3CC(CC4)(C)C)CO)C)OC(=O)C=CC9=CC(=C(C=C9)OC)OC)O)O)O)O[C@H]1[C@@H]([C@H]([C@@H](CO1)O[C@H]1[C@@H]([C@H]([C@H]([C@H](O1)CO)O)O)O)O)O,,,,,,
1947,441948,Toxol,CC(=C)[C@H]1[C@@H](C2=C(O1)C=CC(=C2)C(=O)C)O,,,,,,
1948,441949,"[(2S,3R)-5-acetyl-2-prop-1-en-2-yl-2,3-dihydro-1-benzofuran-3-yl] 2-methylbut-2-enoate",CC=C(C)C(=O)O[C@H]1[C@@H](OC2=C1C=C(C=C2)C(=O)C)C(=C)C,,,,,,
1949,441950,Soyasaponin A1,C[C@]12CC[C@@H]([C@]([C@@H]1CC[C@@]3([C@@H]2CC=C4[C@]3(CC[C@@]5([C@H]4CC([C@H]([C@H]5O[C@H]6[C@@H]([C@H]([C@H](CO6)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)O)O)(C)C)C)C)C)(C)CO)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)C(=O)O)O)O)O[C@H]9[C@@H]([C@H]([C@H]([C@H](O9)CO)O)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
1950,441951,Spinasaponin A,C[C@]12CC[C@@H](C([C@@H]1CC[C@@]3([C@@H]2CC=C4[C@]3(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)C)(C)C)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)O,,,,,,
1951,441952,Thalicoside A,C[C@@H]([C@H]1[C@H](C[C@@]2([C@@]1(CC[C@]34[C@@H]2CC[C@@H]5[C@]3(C4)CC[C@@H]([C@@]5(C)CO[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)C)C)O)[C@H](CC=C(C)C)O,,,,,,
1952,441953,CID 441953,CC=C(C)C(=O)O[C@H]1[C@@H]([C@@]2([C@@H](C[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H]([C@@]5(C)CO)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O)O[C@H]7[C@@H]([C@H]([C@H]([C@H](O7)CO)O)O)O)O[C@H]8[C@@H]([C@H]([C@H](CO8)O)O)O[C@H]9[C@@H]([C@H]([C@@H](CO9)O)O)O)C)C)[C@@H]2CC1(C)C)C)O)CO)OC(=O)C,,,,,,
1953,441954,CID 441954,C[C@H]1[C@H]2[C@H]([C@H]([C@@H](O1)O[C@@H]3[C@H]([C@@H](CO[C@H]3OC(=O)[C@]45CC[C@@]6(C(=CC[C@@H]7[C@@]6(CC[C@@H]8[C@]7(C[C@H]([C@H]([C@]8(C)CO)O[C@H]9[C@@H]([C@H]([C@H]([C@@H](O9)CO)O)O)O[C@@H]1[C@@H]([C@@H]([C@@H](CO1)OC(=O)C[C@@](CC(=O)O2)(C)O)O)O)O)C)C)[C@@H]4CC(CC5)(C)C)C)O)O)O)O[C@@H]1[C@@H]([C@@H]([C@@H](CO1)O)O)O,,,,,,
1954,441955,Virgaureasaponin I,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2[C@@H](CO[C@H]([C@@H]2O)O[C@H]3[C@@H](O[C@H]([C@@H]([C@@H]3O)O)O[C@@H]4[C@H]([C@H]([C@H](O[C@H]4OC(=O)C56CCC(C[C@H]5C7=CC[C@H]8[C@]([C@@]7(C[C@H]6O)C)(CC[C@@H]9[C@@]8(C[C@@H]([C@@H]([C@@]9(C)CO)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)O)C)C)(C)C)C)O)O)C)O)O)O)O,,,,,,
1955,441956,Yiamoloside B,C[C@@]1(CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)O[C@H]6[C@@H]([C@H]([C@H]([C@H](O6)CO)O[C@H]7[C@@H]([C@H]([C@H]([C@H](O7)CO)O)O)O)O)O)C)C)[C@@H]2C1)C)C(=O)O)C(=O)OC,,,,,,
1956,441957,Ziziphin,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2CO[C@H]([C@@H]([C@H]2O)O)O[C@H]3CC[C@@]4([C@H]5CC[C@@H]6[C@H]7[C@@](C[C@@H](O[C@@]78C[C@]6([C@@]5(CC[C@H]4C3(C)C)C)CO8)C=C(C)C)(C)O[C@H]9[C@@H]([C@@H]([C@H]([C@@H](O9)C)O)OC(=O)C)OC(=O)C)C)O)O)O,,,,,,
1957,441958,Vignafuran,COC1=CC2=C(C=C1)C=C(O2)C3=C(C=C(C=C3)O)OC,,,,,,
1958,441959,Biflorin,CC1=CC(=O)C2=C(O1)C=C(C(=C2O)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O,,,,,,
1959,441960,Cimifugin,CC(C)([C@@H]1CC2=C(O1)C=C3C(=C2OC)C(=O)C=C(O3)CO)O,,,,,,
1960,441961,"8-(3,3-Dimethylallyl)spatheliachromene",CC1=CC(=O)C2=C(O1)C(=C3C(=C2O)C=CC(O3)(C)C)CC=C(C)C,,,,,,
1961,441962,"2,2-Dimethyl-8-prenylchromene 6-carboxylic acid",CC(=CCC1=CC(=CC2=C1OC(C=C2)(C)C)C(=O)O)C,,,,,,
1962,441963,"2-Butanoyl-4-[(8-butanoyl-5,7-dihydroxy-2,2-dimethylchromen-6-yl)methyl]-3,5-dihydroxy-6,6-dimethylcyclohexa-2,4-dien-1-one",CCCC(=O)C1=C(C(=C(C(C1=O)(C)C)O)CC2=C(C(=C3C(=C2O)C=CC(O3)(C)C)C(=O)CCC)O)O,,,,,,
1963,441964,2-(2-Phenylethyl)chromone,C1=CC=C(C=C1)CCC2=CC(=O)C3=CC=CC=C3O2,,,,,,
1964,441965,Frutinone A,C1=CC=C2C(=C1)C3=C(C(=O)C4=CC=CC=C4O3)C(=O)O2,,,['Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP1A2. (See all compounds classified as Cytochrome P-450 CYP1A2 Inhibitors.)'],,,
1965,441966,Khelloside,COC1=C2C=COC2=CC3=C1C(=O)C=C(O3)CO[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O,,,,,,
1966,441967,CID 441967,CCC1=COC2=CC(=O)C=C(C2=C1O)O,,,,,,
1967,441968,Perforatin A,CC1=CC(=O)C2=C(C=C3C(=C2O1)C=CC(O3)(C)C)OC,,,,,,
1968,441969,"6,7,8-Trimethoxy-2,2-dimethylchromene",CC1(C=CC2=CC(=C(C(=C2O1)OC)OC)OC)C,,,,,,
1969,441970,5-O-Methylvisamminol,CC1=CC(=O)C2=C(C3=C(C=C2O1)O[C@@H](C3)C(C)(C)O)OC,,,,,,
1970,441971,1-Acetylaspidoalbidine,CC(=O)N1[C@@H]2CC[C@@]34CCCN5[C@]3([C@]2(CC5)C6=CC=CC=C61)OCC4,,,,,,
1971,441972,Adifoline,C[C@@H]1[C@@H]2[C@H](CC3=C4N1C5=C(C4=CC(=N3)C(=O)O)C=C(C=C5)O)C(=CO[C@@H]2O)C(=O)OC,,,,,,
1972,441973,CID 441973,CC=C1CN([C@@H]2CC3=C(C(=O)C[C@H]1C2CO)NC4=CC=CC=C34)C,,,,,,
1973,441974,CID 441974,CC=C1CN2[C@H]3C[C@H]1C([C@@H]2CC4=C3N(C5=CC=CC=C45)C)CO,,,,,,
1974,441975,Ajmalicine,C[C@H]1[C@H]2CN3CCC4=C([C@@H]3C[C@@H]2C(=CO1)C(=O)OC)NC5=CC=CC=C45,"['Rauwolfia alkaloids are indicated in the treatment of hypertension. Rauwolfia alkaloids have been used for relief of symptoms in agitated psychotic states such as schizophrenia; however, use as antipsychotics and sedatives have been replaced with the use of more effective, safer agents.']","['Reserpine is used to treat high blood pressure. It also is used to treat severe agitation in patients with mental disorders. Reserpine is in a class of medications called rauwolfia alkaloids. It works by slowing the activity of the nervous system, causing the heart rate to slow and the blood vessels to dilate.']",['Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)'],"['Mean maximum plasma levels of plasma concentrations after 0.5 mg of Reserpine, administered as two 0.25 mg tablets or as an aqueous solution, peaked after 2.5 hours. The mean peak level was approximately 1.1 ng/ml. Bioavailability of Reserpine, has been reported to be approximately 50%.', 'The elimination of reserpine and its metabolites in the feces ranges from 30% after intramuscular administration to  about 60% after oral ingestion, primarily as unmetabolized reserpine, over a 4 day period after the  ingestionof 0.25 mg to 0.50 mg doses. Over the same time period, about 8% of the ingested dose was recovered in the urine, primarily as the trimethoxybenzoic acid metabolite.', 'Hepatically and renally.']","['Reserpine is almost completely metabolized in the body, and only about 1% is excreted as unchanged drug in the urine. Hepatic metabolism accounts for less than 50% of the elimination of reserpine, with the remainder being eliminated  in the faeces, and some unmetabolized reserpine and metabolites being eliminated in the urine. In man, metabolites are methylreserpate and trimethoxybenzoic acid. Metabolism may be more important with intramuscular administration.']","['After oral ingestion, an initial half-life of approximately 5 hours is followed by a terminal half-life of approximately 200 hours.']"
1975,441976,CID 441976,CC=C1CN2CC[C@@]34[C@@H]2C[C@@H]1C(=C3NC5=CC=CC=C45)C(=O)OC,,,,,,
1976,441977,"methyl (1S,12S,14R)-15-ethylidene-13-(hydroxymethyl)-3,17-diazapentacyclo[12.3.1.02,10.04,9.012,17]octadeca-2(10),4,6,8-tetraene-13-carboxylate",CC=C1CN2[C@H]3C[C@H]1C([C@@H]2CC4=C3NC5=CC=CC=C45)(CO)C(=O)OC,,,,,,
1977,441978,CID 441978,CC=C1CN2CC[C@@]34C5=C(C=CC(=C5)O)N([C@@]36[C@@H]2C[C@H]1C4(CO6)C(=O)OC)C,,,,,,
1978,441979,Alstonine,C[C@H]1[C@@H]2CN3C=CC4=C5C=CC=CC5=NC4=C3C[C@@H]2C(=CO1)C(=O)OC,,,,,,
1979,441980,Ptaerochromenol,CC1(C=CC2=C(O1)C=C(C3=C2OC(=CC3=O)CO)O)C,,,,,,
1980,441981,Ptaeroglycol,CC1=CC(=O)C2=C(C3=C(C=C2O1)OCC(C=C3)(CO)O)O,,,,,,
1981,441982,Pulverochromenol,CC(=CCC1=C2C(=CC3=C1OC(=CC3=O)CO)C=CC(O2)(C)C)C,,,,,,
1982,441983,Angustine,C=CC1=CN=CC2=C1C=C3C4=C(CCN3C2=O)C5=CC=CC=C5N4,,,,,,
1983,441984,Apodine,COC(=O)C1=C2[C@]3(CCN4[C@H]3[C@@]5(C1)CC(=O)O[C@H]5CC4)C6=CC=CC=C6N2,,,,,,
1984,441985,CID 441985,CC=C1CN2CC[C@@H]1C(=C)C3=C(C2)C4=CC=CC=C4N3,,,,,,
1985,441986,Aspidoalbine,CCC(=O)N1[C@@H]2CC[C@@]34CCCN5[C@]3([C@]2(CC5)C6=CC(=C(C(=C61)O)OC)OC)OCC4,,,,,,
1986,441987,CID 441987,CC=C1CN[C@H]2C[C@@H]1C([C@@]34[C@@]2(NC5=CC=CC=C53)OCC4)(CO)C(=O)OC,,,,,,
1987,441988,Aspidofractine,COC(=O)[C@@H]1C[C@]23CCCN4[C@@H]2[C@@]5([C@]1(CC3)N(C6=CC=CC=C65)C=O)CC4,,,,,,
1988,441989,"1-[(1R,9R,11R,17R)-18-ethylidene-6-methoxy-8,14-diazapentacyclo[9.5.2.01,9.02,7.014,17]octadeca-2(7),3,5-trien-8-yl]ethanone",CC=C1[C@@H]2CCN3[C@H]1[C@@]4(CC3)[C@@H](C2)N(C5=C4C=CC=C5OC)C(=O)C,,,,,,
1989,441990,Auricularine,CC1=C[C@H]2[C@@H]([C@H]([C@]34[C@]2(NC5=CC=CC=C53)N(CC4)C)C6=C(C7=CC=CC=C7N6)CCN(C)C)C(C1)(C)C,,,,,,
1990,441991,Baloxine,C[C@@H]([C@@]12CC(=O)CN3[C@@H]1[C@@]4(CC3)C5=CC=CC=C5NC4=C(C2)C(=O)OC)O,,,,,,
1991,441992,Bleekerine,C[C@H]1[C@@H]2CN3C=CC4=C5C=C(C(=CC5=NC4=C3C[C@@H]2C(=CO1)C(=O)OC)OC)OC,,,,,,
1992,441993,Spathelia bischromene,CC1=CC(=O)C2=C3C(=C4C(=C2O1)C=CC(O4)(C)C)C=CC(O3)(C)C,,,,,,
1993,441994,Bonafousine,CC[C@H]1C[C@H]2C[C@@]3([C@H]1N(C2)CCC4=C3NC5=C4C=CC(=C5[C@H]6CC[C@@H]7C8=C(CCN7)C9=CC=CC=C9N68)O)C(=O)OC,,,,,,
1994,441995,Borrecapine,CC(=C[C@@H]1C[C@]([C@@H](N1)C(=O)C2=CNC3=CC=CC=C32)(C)C=C)C,,,,,,
1995,441996,Borreline,CC1=N[C@@H]([C@@](C1)(C)C=C)C(=O)C2=CNC3=CC=CC=C32,,,,,,
1996,441997,6-Acetylpicropolin,C[C@@H]1C(=O)[C@@H]([C@@]2([C@@H]([C@@]13C[C@H](OC3=O)C4=COC=C4)CCC[C@]25CO5)COC(=O)C)OC(=O)C,,,,,,
1997,441998,CID 441998,CC(=CCCC(=CCCC(=CCC1=C(OC2=CC(=O)C=CC2=C1O)O)C)C)C,,,,,,
1998,441999,Acutilol A,CC1=C2CC=C([C@H]2[C@@H]([C@@H](CC1)[C@H](C)CCC3C(O3)(C)C)O)C,,,,,,
1999,442000,"(3aR,8bS)-8a-hydroxy-8,8-dimethyl-3-[[(2R)-4-methyl-5-oxo-2H-furan-2-yl]oxymethylidene]-5,6,7,8b-tetrahydro-3aH-indeno[1,2-b]furan-2-one",CC1=C[C@@H](OC1=O)OC=C2[C@H]3C=C4CCCC(C4([C@H]3OC2=O)O)(C)C,,,,,,
2000,442001,Allogibberic acid,CC1=C2[C@@H]([C@@]34CC(=C)[C@@](C3)(CC[C@@H]4C2=CC=C1)O)C(=O)O,,,,,,
2001,442002,3-epi-Aantheridic acid methyl ester,C[C@@]12[C@H](CC[C@@]3([C@@H]1[C@@H](C4=C[C@H]5CC[C@]43[C@H](C5=C)O)C(=O)OC)OC2=O)O,,,,,,
2002,442003,Asebotoxin II,CCC(=O)O[C@@H]1[C@H]2CC[C@@H]3[C@]1(C[C@H]([C@]4([C@H](C3=C)C[C@@H](C4(C)C)O)O)O)C[C@@]2(C)O,,,,,,
2003,442004,Atractyloside,CC(C)CC(=O)O[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O[C@@H]2C[C@H]([C@H]3CC[C@@]45C[C@@H](CC[C@H]4[C@@]3(C2)C)C(=C)[C@@H]5O)C(=O)O)CO)OS(=O)(=O)[O-])OS(=O)(=O)[O-].[K+].[K+],,,['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],,,
2004,442005,CID 442005,CC(C)CC(=O)O[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O[C@@H]2C[C@H]([C@H]3CC[C@@]45C[C@@H](CC[C@H]4[C@@]3(C2)C)C(=C)[C@@H]5O)C(=O)O)CO)OS(=O)(=O)O)OS(=O)(=O)O,,,,,,
2005,442006,Baliospermin,CCCCCCCCCCCC(=O)O[C@@]12C[C@H]([C@@]3([C@@H]4C=C(C(=O)[C@]4([C@@H]([C@@]5([C@H]([C@H]3[C@@H]1C2(C)C)O5)CO)O)O)C)O)C,,,,,,
2006,442007,Callicarpone,C[C@]12CCCC([C@@H]1CC(=O)C3=C2C(=O)[C@@H]4[C@](C3)(O4)C(C)(C)O)(C)C,,,,,,
2007,442008,Candletoxin A,CCC(C)C(=O)OC[C@@]1([C@@H]2[C@]1(C[C@H]([C@]3([C@H]2C=C(C[C@]4([C@H]3C=C(C4=O)C)O)COC(=O)C)O)C)OC(=O)CC5=CC=CC=C5)C,,,,,,
2008,442009,Carnosol,CC(C)C1=C(C(=C2C(=C1)[C@@H]3C[C@@H]4[C@@]2(CCCC4(C)C)C(=O)O3)O)O,,,,,,
2009,442010,Caryoptin,C[C@@H]1C[C@@H]([C@@]2([C@@H]([C@@]1(C)[C@@H]3C[C@H]4C=CO[C@H]4O3)CC[C@H]([C@]25CO5)OC(=O)C)COC(=O)C)OC(=O)C,,,,,,
2010,442011,Cascarillin,C[C@@H]1[C@@H](C[C@@]2([C@@H]([C@]1(C[C@H](C3=COC=C3)O)C=O)CC[C@H]([C@]2(C)O)O)C)OC(=O)C,,,,,,
2011,442012,Chasmanthin,C[C@@]12CC[C@H]3C(=O)O[C@H](C[C@]3([C@@H]1[C@H]4[C@H]5[C@@H]([C@@]2(C(=O)O4)O)O5)C)C6=COC=C6,,,,,,
2012,442013,Clerodendrin A,CC[C@](C)(C(=O)O[C@H]1[C@@H](C[C@@H]2[C@@](C(=C[C@@H]([C@]2([C@@]13CO3)COC(=O)C)OC(=O)C)C)(C)[C@@H]4C[C@H]5C=CO[C@H]5O4)O)OC(=O)C,,,,,,
2013,442014,Clerodin,C[C@@H]1C[C@@H]([C@@]2([C@@H]([C@@]1(C)[C@@H]3C[C@H]4C=CO[C@H]4O3)CCC[C@]25CO5)COC(=O)C)OC(=O)C,,,,,,
2014,442015,"(2S,4AR,6aR,7R,10R,10aS,10bS)-2-(furan-3-yl)-7-hydroxy-6a,10b-dimethyl-4a,5,6,6a,7,10,10a,10b-octahydro-1H-10,7-(epoxymethano)benzo[f]isochromene-4,12(2H)-dione",C[C@@]12CC[C@H]3C(=O)O[C@@H](C[C@]3([C@@H]1[C@H]4C=C[C@@]2(C(=O)O4)O)C)C5=COC=C5,,,,,,
2015,442016,"(2S,3R,4R,5S,6R)-2-[[(3R,8R,9R,10R,11S,14R)-9,14-dihydroxy-14-(methoxymethyl)-3,10-dimethyl-6-propan-2-yl-8-tricyclo[9.3.0.03,7]tetradeca-1,6-dienyl]oxy]-5-[(2R)-1-hydroxy-2-[(2S)-oxiran-2-yl]propan-2-yl]oxy-6-(methoxymethyl)oxane-3,4-diol",C[C@@H]1[C@@H]2CC[C@@](C2=C[C@]3(CCC(=C3[C@H]([C@@H]1O)O[C@@H]4[C@@H]([C@H]([C@@H]([C@H](O4)COC)O[C@](C)(CO)[C@@H]5CO5)O)O)C(C)C)C)(COC)O,,,,,,
2016,442017,Cyathin A3,CC(C)C1=C2[C@H]3C[C@H](C(=CC(=O)[C@@]3(CC[C@]2(CC1)C)C)CO)O,,,,,,
2017,442018,Genkwanine VIII,C[C@@H]1C[C@]2([C@H]3[C@H]4[C@]1([C@@H]5C=C(C(=O)[C@]5([C@@H]([C@@]6([C@H]4O6)CO)O)O)C)OC(O3)(O2)C7=CC=CC=C7)C(=C)C,,,,,,
2018,442019,"7beta,12alpha-Dihydroxykaurenolide",C[C@@]12CCC[C@@]3([C@H]1[C@H]([C@@H]([C@]45[C@H]2C[C@@H]([C@H](C4)C(=C)C5)O)O)OC3=O)C,,,,,,
2019,442020,Borreverine,CC1=C[C@H]2[C@@H]([C@H]([C@]34[C@]2(NC5=CC=CC=C53)N(CC4)C)C6=C(C7=CC=CC=C7N6)CCNC)C(C1)(C)C,,,,,,
2020,442021,Brucine,COC1=C(C=C2C(=C1)[C@]34CCN5[C@H]3C[C@@H]6[C@@H]7[C@@H]4N2C(=O)C[C@@H]7OCC=C6C5)OC,,,"['Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)', 'Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)', 'Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']",,['BRUCINE YIELDS BRUCINE-N-OXIDE IN BACILLUS; YIELDS 2-HYDROXY-3-METHOXYSTRYCHNINE & 3-HYDROXY-2-METHOXYSTRYCHNINE IN RABBITS.'],
2021,442022,CID 442022,CC=C1C[N@@+]2(CC[C@@]34[C@@H]2C[C@@H]1[C@H]5[C@@]3(N([C@H]6[C@@H]5N7C8=CC=CC=C8[C@@]91[C@@]7([C@@H]6[C@H]2C[C@@H]9[N@@+](CC1)(CC2=CC)C)O)C1=CC=CC=C41)O)C,,,,,,
2022,442023,Diterpenoid SP-II,C[C@@]12CCC[C@@]([C@H]1CC[C@]34[C@H]2CC[C@H](C3)[C@](C4)(CO)O)(C)C(=O)O,,,,,,
2023,442024,"methyl (1R,1'R,4'R,6'R,10'S,12R,14'S,15'R,16S,17R,22R)-18'-methoxyspiro[15-oxa-8,19-diazahexacyclo[10.9.1.01,9.02,7.012,16.019,22]docosa-2,4,6,9-tetraene-17,2'-9-oxa-13,16-diazaheptacyclo[11.9.2.01,15.04,15.06,10.06,14.017,22]tetracosa-17(22),18,20-triene]-10-carboxylate",COC1=CC=CC2=C1N[C@]34[C@]25CCN6[C@H]3[C@]7(CCO[C@H]7CC6)C[C@H]4C[C@]58CN9CC[C@@]12[C@@H]9[C@@]3([C@H]8OCC3)CC(=C1NC1=CC=CC=C21)C(=O)OC,,,,,,
2024,442025,Calligonine,C[C@@H]1C2=C(CCN1)C3=CC=CC=C3N2,,,,,,
2025,442026,CID 442026,CCCC=CC=CC=CC(=O)O[C@@]12[C@@H](C1(C)C)[C@@H]3C=C(C[C@H]4[C@H]([C@]3([C@@H]([C@H]2OC(=O)C)C)O)C=C(C4=O)C)CO,,,,,,
2026,442027,Ferruginol,CC(C)C1=C(C=C2C(=C1)CC[C@@H]3[C@@]2(CCCC3(C)C)C)O,,,,,,
2027,442028,"(2S,3R,4S,5S,6R)-2-[[(3R,8R,9R,10R,11S,14S)-9-hydroxy-14-(hydroxymethyl)-3,10-dimethyl-6-propan-2-yl-8-tricyclo[9.3.0.03,7]tetradeca-1,6-dienyl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol",C[C@@H]1[C@@H]2CC[C@@H](C2=C[C@]3(CCC(=C3[C@H]([C@@H]1O)O[C@@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)C(C)C)C)CO,,,,,,
2028,442029,CID 442029,C[C@@H]1[C@H]([C@]2([C@H]3[C@H]4[C@]1([C@@H]5C=C(C(=O)[C@]5([C@@H]([C@@]6([C@H]4O6)CO)O)O)C)OC(O3)(O2)C7=CC=CC=C7)C(=C)C)OC(=O)C=CC8=CC=CC=C8,,,,,,
2029,442030,CID 442030,CCCCCC=CC=CC(=O)O[C@@H]1[C@H]([C@]23[C@@H]4C=C(C(=O)[C@]4([C@@H]([C@@]5([C@H]([C@H]2[C@@H]6[C@]1(OC(O6)(O3)C7=CC=CC=C7)C(=C)C)O5)CO)O)O)C)C,,,,,,
2030,442031,(+)-Calycanthidine,CN1CC[C@]2([C@@H]1NC3=CC=CC=C32)[C@]45CCN([C@H]4N(C6=CC=CC=C56)C)C,,,,,,
2031,442032,Gnididilatin,CCCCCCCCCC12O[C@@H]3[C@@H]4[C@H]5[C@](O5)([C@H]([C@]6([C@H]([C@@]4(O1)[C@@H]([C@H]([C@@]3(O2)C(=C)C)OC(=O)C7=CC=CC=C7)C)C=C(C6=O)C)O)O)CO,,,,,,
2032,442033,CID 442033,CCCC=CC=CC=CC(=O)O[C@@H]1[C@H]([C@]23[C@@H]4C=C(C(=O)[C@]4([C@@H]([C@@]5([C@H]([C@H]2[C@@H]6[C@]1(OC(O6)(O3)C7=CC=CC=C7)C(=C)C)O5)CO)O)O)C)C,,,,,,
2033,442034,CID 442034,CC(=O)O[C@H]1[C@H]2CC[C@@H]3[C@]1(C[C@H]([C@]4([C@H]([C@]3(C)O)C[C@@H](C4(C)C)O)O)O)C[C@@]2(C)O,,,"['Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Drugs that interrupt transmission at the skeletal neuromuscular junction by causing sustained depolarization of the motor end plate. These agents are primarily used as adjuvants in surgical anesthesia to cause skeletal muscle relaxation. (See all compounds classified as Neuromuscular Depolarizing Agents.)']",,,
2034,442035,Hallactone A,CC(C)C1=C2C[C@@H]3[C@H]4[C@]([C@H]([C@H]5[C@@H]([C@@]4(C2=CC(=O)O1)C)O5)O)(C(=O)O3)C,,,,,,
2035,442036,Hallactone B,C[C@]12C[C@H]3[C@H](O3)[C@]4([C@@H]1[C@@H]([C@@H]5[C@]6(C2=CC(=O)O[C@@H]6[C@](C)(CS(=O)(=O)C)O)O5)OC4=O)C,,,,,,
2036,442037,Carapanaubine,C[C@H]1[C@@H]2CN3CC[C@]4([C@@H]3C[C@@H]2C(=CO1)C(=O)OC)C5=CC(=C(C=C5NC4=O)OC)OC,,,,,,
2037,442038,CID 442038,CCCCCCCCCC=CC=CC12O[C@@H]3[C@@H]4[C@H]5[C@](O5)([C@H]([C@]6([C@H]([C@@]4(O1)[C@@H](C[C@@]3(O2)C(=C)C)C)C=C(C6=O)C)O)O)CO,,,,,,
2038,442039,Hymatoxin A,C[C@@]1(CC[C@]2(C(=C[C@@H]3[C@@H]4[C@@]2(CCC[C@@]4(C(=O)O3)C)C)C1)O)CCOS(=O)(=O)[O-],,,,,,
2039,442040,CID 442040,C[C@@]1(CC[C@]2(C(=CC3[C@@H]4[C@@]2(CCC[C@@]4(C(=O)O3)C)C)C1)O)CCOS(=O)(=O)O,,,,,,
2040,442041,"3beta,11beta-Diacetoxy-1alpha-hydroxykaura-16-ene-6,15-dione",CC(=O)O[C@@H]1C[C@@H](C([C@@H]2[C@@]1([C@@H]3[C@@H](C[C@@H]4C[C@@]3(CC2=O)C(=O)C4=C)O)C)(C)C)OC(=O)C,,,,,,
2041,442042,Ingenol,C[C@@H]1C[C@@H]2[C@@H](C2(C)C)[C@@H]3C=C([C@H]([C@]4([C@@]1(C3=O)C=C([C@@H]4O)C)O)O)CO,,,,,,
2042,442043,"Ingenol 3,20-dibenzoate",C[C@@H]1C[C@@H]2[C@@H](C2(C)C)[C@@H]3C=C([C@H]([C@]4([C@@]1(C3=O)C=C([C@@H]4OC(=O)C5=CC=CC=C5)C)O)O)COC(=O)C6=CC=CC=C6,,,,,,
2043,442044,Inumakilactone A glycoside,C[C@@H]([C@@H]1[C@]23[C@H](O2)[C@@H]4[C@H]5[C@]([C@H]([C@@H]6[C@H]([C@@]5(C3=CC(=O)O1)C)O6)O)(C(=O)O4)C)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O,,,,,,
2044,442045,Isodomedin,CC(=O)O[C@H]1C[C@@H]([C@]2([C@@H]3CC[C@@H]4[C@H]([C@@]3([C@@H](C[C@@H]2C1(C)C)O)C(=O)C4=C)O)C)O,,,,,,
2045,442046,"[(8S,9R)-8-[2-(2-methylbut-2-enoyloxy)propan-2-yl]-2-oxo-8,9-dihydrofuro[2,3-h]chromen-9-yl] 2-methylbut-2-enoate",CC=C(C)C(=O)O[C@H]1[C@H](OC2=C1C3=C(C=C2)C=CC(=O)O3)C(C)(C)OC(=O)C(=CC)C,,,,,,
2046,442047,CID 442047,CC(=O)OC[C@@]12[C@H](CCC([C@H]1C=O)(C)C)OC(=O)[C@]34[C@H]2[C@H](C[C@H](C3)C(=C)C4=O)O,,,,,,
2047,442048,Isopimaric acid,C[C@@]1(CC[C@H]2C(=CC[C@@H]3[C@@]2(CCC[C@@]3(C)C(=O)O)C)C1)C=C,,,"['Chemical agents that increase the permeability of biological or artificial lipid membranes to specific ions. Most ionophores are relatively small organic molecules that act as mobile carriers within membranes or coalesce to form ion permeable channels across membranes. Many are antibiotics, and many act as uncoupling agents by short-circuiting the proton gradient across mitochondrial membranes. (See all compounds classified as Ionophores.)']",,,
2048,442049,"[(1S,4R,5S,6R,8R,11R)-5-[(3aS,5S,6aS)-3a,4,5,6a-tetrahydrofuro[2,3-b]furan-5-yl]-4,5-dimethylspiro[9-oxatricyclo[6.2.2.01,6]dodecane-11,2'-oxirane]-10-yl] acetate",C[C@@H]1CC[C@]23[C@@H]([C@@]1(C)[C@@H]4C[C@H]5C=CO[C@H]5O4)C[C@H](C[C@]26CO6)OC3OC(=O)C,,,,,,
2049,442050,Kansuinine B,C[C@H]1[C@H]2[C@@H](O2)C(C(=O)[C@@H]([C@H](C(=C)[C@@H]([C@H]3[C@H]([C@]([C@@H]([C@@]3(C1=O)OC(=O)C)O)(C)O)OC(=O)C)OC(=O)C4=CC=CC=C4)OC(=O)C5=CC=CC=C5)O)(C)C,,,,,,
2050,442051,Athamantin,CC(C)CC(=O)O[C@H]1[C@H](OC2=C1C3=C(C=C2)C=CC(=O)O3)C(C)(C)OC(=O)CC(C)C,,,,,,
2051,442052,2-Ketoepimanool,C[C@]12CC(=O)CC([C@@H]1CCC(=C)[C@@H]2CC[C@@](C)(C=C)O)(C)C,,,,,,
2052,442053,CID 442053,C[C@H]1C[C@]2([C@H]([C@H]1O)[C@@H](C(=C)CC[C@H]3[C@H](C3(C)C)C=C(C2=O)C)O)O,,,,,,
2053,442054,"[(1R,2S,4R,5S,6S,10S,11R,12R,14S,16R)-5,6,11-trihydroxy-4-(hydroxymethyl)-8,12,15,15-tetramethyl-7-oxo-3-oxapentacyclo[9.5.0.02,4.06,10.014,16]hexadec-8-en-14-yl] hexadeca-2,4,6-trienoate",CCCCCCCCCC=CC=CC=CC(=O)O[C@@]12C[C@H]([C@@]3([C@@H]4C=C(C(=O)[C@]4([C@@H]([C@@]5([C@H]([C@H]3[C@@H]1C2(C)C)O5)CO)O)O)C)O)C,,,,,,
2054,442055,"methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(2S)-6-ethyl-8-formyl-2-methoxycarbonyl-4-oxo-8,18-diazatricyclo[9.7.0.012,17]octadeca-1(11),6,12,14,16-pentaen-2-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate",CCC1=CN(CCC2=C([C@](CC(=O)C1)(C3=C(C=C4C(=C3)[C@]56CCN7[C@H]5[C@@](C=CC7)([C@H]([C@@]([C@@H]6N4C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)NC8=CC=CC=C28)C=O,,,,,,
2055,442056,CID 442056,COC1=CC2=C3C=CNC(=C3N=C2C=C1)CC4=CC=C(C=C4)O,,,,,,
2056,442057,Mascaroside,C[C@@]12CC(=O)C3=C([C@H]1CC[C@]45[C@H]2[C@H](C[C@H](C4)[C@]([C@@H]5O)(CO[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)O)O)C=CO3,,,,,,
2057,442058,(+)-Chimonanthine,CN1CC[C@]2([C@@H]1NC3=CC=CC=C32)[C@]45CCN([C@H]4NC6=CC=CC=C56)C,,,,,,
2058,442059,CID 442059,C[C@@H]1[C@H]([C@]2([C@H]3[C@H]4[C@]1([C@@H]5C=C(C(=O)[C@]5([C@@H]([C@@]6([C@H]4O6)CO)O)O)C)OC(O3)(O2)C7=CC=CC=C7)C(=C)C)OC(=O)C=CC=CC8=CC=CC=C8,,,,,,
2059,442060,Montanin,CCCCCCCCCCCC12O[C@@H]3[C@@H]4[C@H]5[C@](O5)([C@H]([C@]6([C@H]([C@@]4(O1)[C@@H](C[C@@]3(O2)C(=C)C)C)C=C(C6=O)C)O)O)CO,,,,,,
2060,442061,Montanin A,C[C@@H]1CC2=C3[C@@H]([C@@]14C[C@H](OC4=O)C5=COC=C5)CCCC3=CO2,,,,,,
2061,442062,CID 442062,C[C@H](CCC[C@]1([C@@H](CCC(=CCO)CO1)O)C)C(=O)C=C(C)C(C)C,,,,,,
2062,442063,CID 442063,CC(C)C1=C2[C@H]([C@@H]3[C@H]4[C@]([C@H]([C@H]5[C@@H]([C@@]4(C2=CC(=O)O1)C)O5)O)(C(=O)O3)C)O,,,,,,
2063,442064,CID 442064,CCCC=CC=CC(=O)O[C@@H]1[C@H]([C@@]2([C@@H]3C=C(C(=O)[C@H]3CC(=C[C@H]2[C@H]4[C@@]1(C4(C)C)OC(=O)C)CO)C)O)C,,,,,,
2064,442065,CID 442065,CC=C1C[N@@+]2(CC[C@@]34[C@@H]2C[C@@H]1C5=CN6C7=CC=CC=C7[C@@]89[C@]61C(=CN([C@@]53O1)C1=CC=CC=C41)[C@H]1C[C@@H]8[N@@+](CC9)(CC1=CC)C)C,,,,,,
2065,442066,"Eburnamenin-14-ol, 14,15-dihydro-, (14alpha)-",CC[C@]12CCCN3[C@H]1C4=C(CC3)C5=CC=CC=C5N4[C@H](C2)O,,,,,,
2066,442067,17-Oxogrindelic acid,C[C@]1(CC[C@@]2(O1)C(=CC[C@@H]3[C@@]2(CCCC3(C)C)C)C=O)CC(=O)O,,,,,,
2067,442068,Palmarin,C[C@@]12CC[C@@H]3C(=O)O[C@H](C[C@]3([C@@H]1[C@H]4[C@H]5[C@@H]([C@@]2(C(=O)O4)O)O5)C)C6=COC=C6,,,,,,
2068,442069,CID 442069,CC=C1C[N@+]2(CC[C@@]34[C@@]2([C@H](C[C@@H]1C3(CO)C(=O)OC)O)NC5=CC=CC=C45)C,,,,,,
2069,442070,Phorbol,C[C@@H]1[C@H]([C@@]2([C@@H](C2(C)C)[C@H]3[C@]1([C@@H]4C=C(C(=O)[C@]4(CC(=C3)CO)O)C)O)O)O,,,,,"['Anaerobic incubation of phorbol (1) from Croton tiglium with human intestinal bacteria afforded five metabolites: isophorbol (2), deoxyphorbol (3), 4beta,9alpha,20-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione (4), 4beta,9alpha,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione (5) and 4beta,9a,20-trihydroxy-14(13-->12)-abeo-12alphaH-1,6-tigliadiene-3,13-dione (6). All these metabolites (2-6) were identified and characterized by spectroscopic means, including two-dimensional (2D)-NMR. Nine defined strains from the human intestine showed an ability to transform 1 to these metabolites.']",
2070,442071,CID 442071,CC=C1CN([C@@H]2CC3=C([C@H](C[C@@H]1C2C(=O)OC)C4=C(C=C5C6=C([C@@]7(C[C@@H]8C[C@@H]([C@@H]7N(C8)CC6)[C@@H](C)O)C(=O)OC)NC5=C4)OC)NC9=CC=CC=C39)C,,,,,,
2071,442072,Lysergamide,CN1C[C@@H](C=C2[C@H]1CC3=CNC4=CC=CC2=C34)C(=O)N,,,,,,
2072,442073,Pimelea factor P2,C[C@@H]1CCCCCCCC23O[C@@H]4[C@@H]5[C@H]6[C@](O6)([C@H]([C@]7([C@@H]([C@@H]1[C@@H]([C@@H]7OC(=O)C8=CC=CC=C8)C)[C@@]5(O2)[C@@H](C[C@@]4(O3)C(=C)C)C)O)O)CO,,,,,,
2073,442074,Plaunol B,C=C1C[C@@H]2[C@@]3([C@@H]([C@@]14C[C@H](OC4=O)C5=COC=C5)CCC=C3C(=O)O2)CO,,,,,,
2074,442075,"(1R,2S,4S,9R,12R,13S)-12-[(2S)-2-(furan-3-yl)-2-hydroxyethyl]-4,13-dihydroxy-11-methylidene-8,14-dioxatetracyclo[7.6.0.01,6.02,12]pentadec-5-en-7-one",C=C1C[C@@H]2[C@]34CO[C@@H]([C@@]1([C@H]3C[C@@H](C=C4C(=O)O2)O)C[C@@H](C5=COC=C5)O)O,,,,,,
2075,442076,CID 442076,C[C@H]1[C@@H]([C@](C[C@H]([C@]2([C@H]3[C@@]1(CCC2C)CCC3=O)C)OC(=O)CO)(C)C=C)O,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
2076,442077,Eseramine,C[C@@]12CCN([C@@H]1N(C3=C2C=C(C=C3)OC(=O)NC)C)C(=O)NC,,,,,,
2077,442078,Podolactone B,C[C@@]12[C@@H]3[C@@H]([C@@H]4[C@]5(O4)[C@H](OC(=O)C=C5[C@]3([C@@H]6[C@H]([C@@H]1O)O6)C)[C@@](C)(CO)O)OC2=O,,,,,,
2078,442079,Ponalactone A,CC(C)[C@@H]1C2=C[C@@H]3[C@H]4[C@]([C@H]([C@H]5[C@@H]([C@@]4(C2=CC(=O)O1)C)O5)O)(C(=O)O3)C,,,,,,
2079,442080,CID 442080,C[C@@H]1C[C@@]2(CC(=CCC[C@@H]2[C@]1(CCC(=CCO)CO)CO)C)C=O,,,,,,
2080,442081,"1,2-Oxazino[6,5-b]indol-6-ol, 2,3,4,4a,9,9a-hexahydro-2,4a,9-trimethyl-, 6-(N-methylcarbamate), (4aR,9aR)-rel-",C[C@]12CCN(O[C@H]1N(C3=C2C=C(C=C3)OC(=O)NC)C)C,,,,,,
2081,442082,"[(1R,2R,6R,10S,11R,15R,17R)-13-benzyl-6-hydroxy-4,17-dimethyl-5-oxo-15-prop-1-en-2-yl-12,14,18-trioxapentacyclo[11.4.1.01,10.02,6.011,15]octadeca-3,8-dien-8-yl]methyl 2-(4-hydroxy-2-methoxyphenyl)acetate",C[C@@H]1C[C@]2([C@H]3[C@H]4[C@]1([C@@H]5C=C(C(=O)[C@]5(CC(=C4)COC(=O)CC6=C(C=C(C=C6)O)OC)O)C)OC(O3)(O2)CC7=CC=CC=C7)C(=C)C,,,,,,
2082,442083,Rhodojaponin IV,CC(=O)O[C@@H]1C[C@@]23C[C@@]([C@@H]([C@H]2OC(=O)C)CC[C@H]3[C@@]([C@H]4[C@]1(C([C@H](C4)O)(C)C)O)(C)O)(C)O,,,,,,
2083,442084,Royleanone,CC(C)C1=C(C2=C(C(=O)C1=O)[C@]3(CCCC([C@@H]3CC2)(C)C)C)O,,,,,,
2084,442085,Shikodonin,C[C@@]12CCC[C@@]3([C@@H]1[C@H](OC2)O)COC(=O)[C@]45[C@H]3[C@@H](C[C@H](C4)C(=C)C5=O)O,,,,,,
2085,442086,"5,5a-Dihydroxy-4a-(hydroxymethyl)-7,9-dimethyl-2-nonyl-10a-(prop-1-en-2-yl)-3a,3b,3c,4a,5,5a,8a,9,10,10a-decahydro-2H,6H-2,8b-epoxyoxireno[6,7]azuleno[5,4-e][1,3]benzodioxol-6-one",CCCCCCCCCC12O[C@@H]3[C@@H]4[C@H]5[C@](O5)([C@H]([C@]6([C@H]([C@@]4(O1)[C@@H](C[C@@]3(O2)C(=C)C)C)C=C(C6=O)C)O)O)CO,,,,,,
2086,442087,"(3aR,8S,8bS)-8-methyl-3-[[(2R)-4-methyl-5-oxo-2H-furan-2-yl]oxymethylidene]-4,5,6,7,8,8b-hexahydro-3aH-indeno[1,2-b]furan-2-one",C[C@H]1CCCC2=C1[C@@H]3[C@H](C2)C(=CO[C@H]4C=C(C(=O)O4)C)C(=O)O3,,,,,,
2087,442088,Evodiamine,CN1[C@@H]2C3=C(CCN2C(=O)C4=CC=CC=C41)C5=CC=CC=C5N3,,,,,,
2088,442089,Stevioside,C[C@@]12CCC[C@@]([C@H]1CC[C@]34[C@H]2CC[C@](C3)(C(=C)C4)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)(C)C(=O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O,,,"['Substances that sweeten food, beverages, medications, etc., such as sugar, saccharine or other low-calorie synthetic products. (From Random House Unabridged Dictionary, 2d ed) (See all compounds classified as Sweetening Agents.)']",,,
2089,442090,(+/-)-Strigol,CC1=C[C@@H](OC1=O)OC=C2[C@H]3CC4=C([C@H]3OC2=O)C(CC[C@@H]4O)(C)C,,,,,,
2090,442091,Fruticosonine,C[C@@H]1CC[C@H](CC1=O)C(C)(C)NCCC2=CNC3=CC=CC=C32,,,,,,
2091,442092,CID 442092,C[C@@H]1C[C@]2([C@H]3[C@H]4[C@@]15[C@@H]6[C@@H](CCCCCCCCCCCCCC=CC(O3)(O2)O5)[C@@H](C(=O)[C@]6([C@@H]([C@@]7([C@H]4O7)CO)O)O)C)C(=C)C,,,,,,
2092,442093,CID 442093,CC[C@H]1C[C@H]2C[C@@]3([C@H]1N(C2)CCC4=C3NC5=CC(=C(C=C45)[C@H]6C[C@@H]7C([C@@H](CC8=C6NC9=CC=CC=C89)NCC7=CC)C(=O)OC)OC)C(=O)OC,,,,,,
2093,442094,CID 442094,CC[C@H]1C[C@H]2C[C@@]3([C@H]1N(C2)CCC4=C3NC5=CC(=C(C=C45)OC)[C@H]6C[C@@H]7C([C@@H](CC8=C6NC9=CC=CC=C89)NCC7=CC)C(=O)OC)C(=O)OC,,,,,,
2094,442095,Geissoschizoline,CC[C@@H]1CN2CC[C@@]34[C@@H]2C[C@@H]1[C@@H]([C@@H]3NC5=CC=CC=C45)CO,,,,,,
2095,442096,CID 442096,CCCCCC=CC=CC12O[C@@H]3[C@@H]4[C@H]5[C@](O5)([C@H]([C@]6([C@H]([C@@]4(O1)[C@@H](C[C@@]3(O2)C(=C)C)C)C=C(C6=O)C)O)O)CO,,,,,,
2096,442097,"methyl (2R)-2-[(2R,12bS)-3-ethylidene-2,4,6,7,12,12b-hexahydro-1H-indolo[2,3-a]quinolizin-2-yl]-2-[(1R,9S,12S,13S,14S,19S,21S)-14-ethyl-10-oxa-8,16-diazahexacyclo[11.5.2.11,8.02,7.016,19.012,21]henicosa-2,4,6-trien-9-yl]acetate",CC[C@@H]1CN2CC[C@@]34[C@@H]2C[C@@H]1[C@H]5[C@@H]3N([C@@H](OC5)[C@@H]([C@H]6C[C@H]7C8=C(CCN7CC6=CC)C9=CC=CC=C9N8)C(=O)OC)C1=CC=CC=C41,,,,,,
2097,442098,"[(1R,2R,6R,10S,11R,15R,17R)-13-benzyl-6-hydroxy-4,17-dimethyl-5-oxo-15-(prop-1-en-2-yl)-12,14,18-trioxapentacyclo[11.4.1.0^{1,10}.0^{2,6}.0^{11,15}]octadeca-3,8-dien-8-yl]methyl 2-(4-hydroxyphenyl)acetate",C[C@@H]1C[C@]2([C@H]3[C@H]4[C@]1([C@@H]5C=C(C(=O)[C@]5(CC(=C4)COC(=O)CC6=CC=C(C=C6)O)O)C)OC(O3)(O2)CC7=CC=CC=C7)C(=C)C,,,,,,
2098,442099,CID 442099,CC[C@@H]1[C@H]2C[C@@H]3[C@]4(C[C@@H]([C@H]2CO3)N1)C5=C(C=C(C=C5)OC)N(C4=O)OC,,,,,,
2099,442100,"(6R)-9-[(2S,3R)-3-hydroxy-6-(2-hydroxyethylidene)-2-methyloxepan-2-yl]-2,6-dimethylnon-2-en-5-one",C[C@H](CCC[C@]1([C@@H](CCC(=CCO)CO1)O)C)C(=O)CC=C(C)C,,,,,,
2100,442101,Cichoriin,C1=CC(=O)OC2=CC(=C(C=C21)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
2101,442102,CID 442102,CN1C[C@@]2([C@H]3[C@H]1[C@@H]4C2C[C@H]([C@@]35C6=CC=CC=C6NC5=O)OC4)C=C,,,,,,
2102,442103,Haplophytine,CN1CC[C@@]2(C3=C(C(=CC=C3)O)N4[C@]1(C2=O)CCC4=O)C5=C(C(=C6C(=C5)[C@@]78CCN9[C@]71[C@@](CCC9)(CC(=O)O1)C=C[C@H]8N6C)OC)OC,,,,,,
2103,442104,(-)-Columbianetin,CC(C)([C@H]1CC2=C(O1)C=CC3=C2OC(=O)C=C3)O,,,,,,
2104,442105,Hodgkinsine,CN1CC[C@]2([C@@H]1NC3=CC=CC=C32)C4=C5C(=CC=C4)[C@]6(CCN([C@H]6N5)C)[C@@]78CCN([C@@H]7NC9=CC=CC=C89)C,,,,,,
2105,442106,Hypaphorine,C[N+](C)(C)[C@@H](CC1=CNC2=CC=CC=C21)C(=O)[O-],,,,,,
2106,442107,[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]-trimethylazanium,C[N+](C)(C)[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O,,,,,,
2107,442108,12-Methoxyibogamine,CC[C@H]1C[C@H]2C[C@@H]3[C@H]1N(C2)CCC4=C3NC5=C4C=C(C=C5)OC,,,"['Drugs capable of inducing illusions, hallucinations, delusions, paranoid ideations, and other alterations of mood and thinking. Despite the name, the feature that distinguishes these agents from other classes of drugs is their capacity to induce states of altered perception, thought, and feeling that are not experienced otherwise. (See all compounds classified as Hallucinogens.)', 'Drugs that bind to but do not activate excitatory amino acid receptors, thereby blocking the actions of agonists. (See all compounds classified as Excitatory Amino Acid Antagonists.)']","['To investigate the pharmacokinetic properties of ibogaine, a putatively anti-addictive alkaloid, levels of this drug were quantified in plasma and tissues for up to 3 hr following i.v. infusion in rats. Immediately following a 31-35 min infusion (20 mg/kg), mean plasma ibogaine levels were 373 ng/mL; these values declined rapidly thereafter in a biexponential manner. The plasma time course in 5 of 7 animals demonstrated an excellent fit to a two-compartment pharmacokinetic model, with alpha and beta half-lives of 7.3 min and 3.3 hr, respectively. Drug clearance was estimated to be 5.9 L/hr (n = 7). Ibogaine levels in brain, liver and kidney 3 hr after the end of drug infusion were 143-170 ng/g, close to simulated values for the peripheral pharmacokinetic compartment. However, 3-hr drug levels in adipose tissue were much higher (3,328 ng/g), implying the need for a more complex pharmacokinetic model. Mechanisms for the initial, rapid disappearance of plasma ibogaine are thought to include metabolic demethylation as well as redistribution to body stores. The sequestration of ibogaine by adipose tissue probably contributes to a protracted persistence of drug in the body. This persistence may be underestimated by the beta half-life reported in the present study.', 'The distribution of the putative anti-addictive substance ibogaine was measured in plasma, brain, kidney, liver and fat after ip and sc administration in rats. One hr after ip dosing (40 mg/kg), drug levels ranged from 106 ng/ml (plasma) to 11,308 ng/g (fat), with significantly higher values after sc administration of the same dose. Drug levels were 10-20 fold lower 12 hr after the same dose. These results suggest that: 1) ibogaine is subject to a substantial ""first pass"" effect after ip dosing, demonstrated by higher drug levels following the sc route, 2) ibogaine shows a large accumulation in adipose tissue, consistent with its lipophilic nature, and 3) persistence of the drug in fat may contribute to a long duration of action.', '/The authors/ report ... the tissue distribution of ibogaine and noribogaine, the main metabolite of ibogaine, in a 48-year-old Caucasian male, with a history of drug abuse, found dead at his home after a poisoning involving the ingestion of root bark from the shrub Tabernanthe iboga. Ibogaine and noribogaine were quantified in tissues and fluids using a fully validated liquid chromatography-electrospray mass spectrometry method. Apart from cardiac tissue, ibogaine and noribogaine were identified in all matrices investigated. The highest concentrations were found in spleen, liver, brain, and lung. The tissue/subclavian blood concentration ratios averaged 1.78, 3.75, 1.16, and 4.64 for ibogaine and 0.83, 2.43, 0.90, and 2.69 for noribogaine for spleen, liver, brain, and lung, respectively. Very low concentrations of the two drugs were found in the prostatic tissue. Both ibogaine and noribogaine are secreted in the bile and cross the blood-brain barrier. Four other compounds were detected in most of the studied matrices. One of them was identified as ibogamine. Unfortunately, /the authors/ were not able to positively identify the other three compounds because of the unavailability of reference substances. Two of them could possibly be attributed to the following oxidation products: iboluteine and desmethoxyiboluteine. The third compound could be ibogaline.']","[""Ibogaine is a psychoactive alkaloid that possesses potential as an agent to treat opiate and cocaine addiction. The primary metabolite arises via O-demethylation at the 12-position to yield 12-hydroxyibogamine. In this report, evidence is presented that the O-demethylation of ibogaine observed in human hepatic microsomes is catalyzed primarily by the polymorphically expressed cytochrome P-4502D6 (CYP2D6). An enzyme kinetic examination of ibogaine O-demethylase activity in pooled human liver microsomes suggested that two (or more) enzymes are involved in this reaction: one with a low KMapp (1.1 uM) and the other with a high KMapp (>200 uM). The low KMapp activity comprised >95% of total intrinsic clearance. Human liver microsomes from three individual donors demonstrated similar enzyme kinetic parameters (mean KMapp = 0.55 +/- 0.09 uM and 310 +/- 10 microM for low and high KM activities, respectively). However, a fourth human microsome sample that appeared to be a phenotypic CYP2D6 poor metabolizer possessed only the high KMapp activity. In hepatic microsomes from a panel of human donors, the low KMapp ibogaine O-demethylase activity correlated with CYP2D6-catalyzed bufuralol 1'-hydroxylase activity but not with other P450 isoform-specific activities. Quinidine, a CYP2D6-specific inhibitor, inhibited ibogaine O-demethylase (IC50 = 0.2 uM), whereas other P450 isoform-specific inhibitors did not inhibit this activity. Also, of a battery of recombinant heterologously expressed human P450 isoforms, only rCYP2D6 possessed significant ibogaine O-demethylase activity. Thus, it is concluded that ibogaine O-demethylase is catalyzed by CYP2D6 and that this isoform is the predominant enzyme of ibogaine O-demethylation in humans. The potential pharmacological implications of these findings are discussed."", '/The authors/ report ... the tissue distribution of ibogaine and noribogaine, the main metabolite of ibogaine, in a 48-year-old Caucasian male, with a history of drug abuse, found dead at his home after a poisoning involving the ingestion of root bark from the shrub Tabernanthe iboga. Ibogaine and noribogaine were quantified in tissues and fluids using a fully validated liquid chromatography-electrospray mass spectrometry method. Apart from cardiac tissue, ibogaine and noribogaine were identified in all matrices investigated. The highest concentrations were found in spleen, liver, brain, and lung. The tissue/subclavian blood concentration ratios averaged 1.78, 3.75, 1.16, and 4.64 for ibogaine and 0.83, 2.43, 0.90, and 2.69 for noribogaine for spleen, liver, brain, and lung, respectively. Very low concentrations of the two drugs were found in the prostatic tissue. Both ibogaine and noribogaine are secreted in the bile and cross the blood-brain barrier. Four other compounds were detected in most of the studied matrices. One of them was identified as ibogamine. Unfortunately, /the authors/ were not able to positively identify the other three compounds because of the unavailability of reference substances. Two of them could possibly be attributed to the following oxidation products: iboluteine and desmethoxyiboluteine. The third compound could be ibogaline.']","['To investigate the pharmacokinetic properties of ibogaine, a putatively anti-addictive alkaloid, levels of this drug were quantified in plasma and tissues for up to 3 hr following i.v. infusion in rats. Immediately following a 31-35 min infusion (20 mg/kg). ... The plasma time course in 5 of 7 animals demonstrated an excellent fit to a two-compartment pharmacokinetic model, with alpha and beta half-lives of 7.3 min and 3.3 hr, respectively. ...']"
2108,442109,Ibogamine,CC[C@H]1C[C@H]2C[C@@H]3[C@H]1N(C2)CCC4=C3NC5=CC=CC=C45,,,,,,
2109,442110,Leurosidine,CC[C@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,,,,"['Vinblastine sulfate is unpredictably absorbed from the GI tract. Following iv administration, the drug is rapidly cleared from the blood and distributed into body tissues. Vinblastine crosses the blood brain barrier poorly and does not appear in the CSF in therapeutic concentrations.', 'The volume of the central compartment is 70% of body weight, probably reflecting very rapid tissue binding to formed elements of the blood. Extensive reversible tissue binding occurs. Low body stores are present at 48 and 72 hours after injection.', 'Following injection of tritiated vinblastine in the human cancer patient, 10% of the radioactivity was found in the feces and 14% in the urine; the remaining activity was not accounted for. Similar studies in dogs demonstrated that, over 9 days, 30% to 36% of radioactivity was found in the bile and 12% to 17% in the urine. A similar study in the rat demonstrated that the highest concentrations of radioactivity were found in the lung, liver, spleen, and kidney 2 hours after injection.', 'It is not known whether this drug is excreted in human milk.', 'For more Absorption, Distribution and Excretion (Complete) data for VINBLASTINE (9 total), please visit the HSDB record page.']","['Vinblastine is reported to be extensively metabolized, primarily in the liver, to desacetylvinblastine, which is more active than the parent compound on a weight basis.', 'Since the major route of excretion may be through the biliary system, toxicity from this drug may be increased when there is hepatic excretory insufficiency. The metabolism of vinca alkaloids has been shown to be mediated by hepatic cytochrome P450 isoenzymes in the CYP 3A subfamily. This metabolic pathway may be impaired in patients with hepatic dysfunction or who are taking concomitant potent inhibitors of these isoenzymes such as erythromycin.']","['Pharmacokinetic studies in patients with cancer have shown a triphasic serum decay pattern following rapid intravenous injection. The initial, middle, and terminal half-lives are 3.7 minutes, 1.6 hours, and 24.8 hours, respectively.', 'The elimination of VLB from the plasma of patients who received it by 5-day iv infusion at 1 to 2 mg/sq m daily was biphasic. In four patients who achieved partial remission, the average plasma half-life of VLB during the terminal phase was 29.4 +/- 14.6 days ...  However, in three patients whose disease merely stabilized, the plasma half-life was 6.4 +/- 1.6 days ...  In contrast, in five patients with refractory disease, this parameters was 2.3 +/- 0.3 days...', 'The pharmacokinetics of vinblastine in humans was examined using a radioimmunoassay specific for both the Vinca alkaloids and aromatic ring [3H]vinblastine. The data were consistent with a three-compartment open model system with the following values, alpha phase: t1/2=3.90+/-1.46 min; Vc=16.8+/-7.1 liters. beta phase:t1/2=53.0+/-13.0 min; Vbeta=79.0+/-52.0 liters; gamma phase:t1/2=1173.0+/-65.0 min; Vgamma=1656.0+/-717.0 liters. ...']"
2110,442111,Vinleurosine,CC[C@]12CN3CCC4=C([C@](C[C@H](C3)[C@H]1O2)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)NC1=CC=CC=C41,,,,,,
2111,442112,Mesembrinol,CN1CC[C@]2([C@@H]1C[C@@H](CC2)O)C3=CC(=C(C=C3)OC)OC,,,,,,
2112,442113,Physovenine,C[C@@]12CCO[C@@H]1N(C3=C2C=C(C=C3)OC(=O)NC)C,,,,,,
2113,442114,"methyl 2-[(3R,6'R,7'S,8'aS)-6'-ethyl-2-oxospiro[1H-indole-3,1'-3,5,6,7,8,8a-hexahydro-2H-indolizine]-7'-yl]-3-methoxyprop-2-enoate",CC[C@H]1CN2CC[C@]3([C@@H]2C[C@@H]1C(=COC)C(=O)OC)C4=CC=CC=C4NC3=O,,,,,,
2114,442115,Roxburghine B,C[C@]12[C@@H]3CN4CCC5=C([C@H]4C[C@@H]3C(=CN1CCC6=C2NC7=CC=CC=C67)C(=O)OC)NC8=CC=CC=C58,,,,,,
2115,442116,"(1S,12S,14S)-15-ethylidene-13-(hydroxymethyl)-3,17-diazapentacyclo[12.3.1.02,10.04,9.012,17]octadeca-2(10),4(9),5,7-tetraen-7-ol",CC=C1CN2[C@H]3C[C@H]1C([C@@H]2CC4=C3NC5=C4C=C(C=C5)O)CO,,,,,,
2116,442117,CID 442117,CC[C@H]1C[C@H]2C[C@@H]3[C@H]1N(C2)CCC4=C3NC5=C4C=CC(=C5)[C@H]6C[C@@H]7C([C@@H](CC8=C6NC9=CC=CC=C89)N(CC7=CC)C)C(=O)OC,,,,,,
2117,442118,(R)-Tetrahydroharmine,C[C@@H]1C2=C(CCN1)C3=C(N2)C=C(C=C3)OC,,,,,,
2118,442119,Thienodolin,C1=CC2=C(C=C1Cl)NC3=C2C=C(S3)C(=O)N,,,,,,
2119,442120,Trichotomine,C1[C@H](N2C(=CC(=C2O)C3=CC4=C5C(=C6C=CC=CC6=N5)C[C@H](N4C3=O)C(=O)O)C7=C1C8=CC=CC=C8N7)C(=O)O,,,,,,
2120,442121,Usambarine,CN1CCC2=C([C@@H]1C[C@H]3C[C@H]4C5=C(CCN4C[C@@H]3C=C)C6=CC=CC=C6N5)NC7=CC=CC=C27,,,,,,
2121,442122,CID 442122,CC[C@H]1C[C@H]2C[C@@]3([C@H]1N(C2)CCC4=C3NC5=CC(=C(C=C45)OC)[C@H]6C[C@@H]7C([C@@H](CC8=C6NC9=CC=CC=C89)N(CC7=CC)C)C(=O)OC)C(=O)OC,,,,,,
2122,442123,CID 442123,CC=C1CN([C@@H]2CC3=C(C(=O)C[C@@H]1C2C(=O)OC)NC4=CC=CC=C34)C,,,,,,
2123,442124,"methyl (1R,1'R,7'S,11'R,12R,13'R,16S,17S,22R,24'R,25'S)-24'-hydroxy-20'-methoxyspiro[15-oxa-8,19-diazahexacyclo[10.9.1.01,9.02,7.012,16.019,22]docosa-2,4,6,9-tetraene-17,15'-8-oxa-4,17-diazaheptacyclo[11.10.1.11,4.07,11.017,24.018,23.011,25]pentacosa-18(23),19,21-triene]-10-carboxylate",COC1=CC2=C(C=C1)[C@]34CCN5[C@H]3[C@]6(CCO[C@H]6CC5)C[C@@H]7[C@@]4(N2C[C@]8(C7)CN9CC[C@@]12[C@@H]9[C@@]3([C@H]8OCC3)CC(=C1NC1=CC=CC=C21)C(=O)OC)O,,,,,,
2124,442125,Decuroside III,CC(C)([C@H]1CC2=C(O1)C=C3C(=C2)C=CC(=O)O3)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O[C@@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O)O,,,,,,
2125,442126,Decursin,CC(=CC(=O)O[C@H]1CC2=C(C=C3C(=C2)C=CC(=O)O3)OC1(C)C)C,,,['Compounds or factors that act on a specific enzyme to increase its activity. (See all compounds classified as Enzyme Activators.)'],,,
2126,442127,Decursinol,CC1([C@H](CC2=C(O1)C=C3C(=C2)C=CC(=O)O3)O)C,,,['Compounds or factors that act on a specific enzyme to increase its activity. (See all compounds classified as Enzyme Activators.)'],,,
2127,442128,Dihydrosamidin,CC(C)CC(=O)O[C@@H]1[C@@H](C2=C(C=CC3=C2OC(=O)C=C3)OC1(C)C)OC(=O)C,,,,,,
2128,442129,Disenecionyl cis-khellactone,CC(=CC(=O)O[C@H]1[C@H](C(OC2=C1C3=C(C=C2)C=CC(=O)O3)(C)C)OC(=O)C=C(C)C)C,,,,,,
2129,442130,"(3'R,4'R)-3'-Epoxyangeloyloxy-4'-acetoxy-3',4'-dihydroseselin",CC1C(O1)(C)C(=O)O[C@@H]2[C@@H](C3=C(C=CC4=C3OC(=O)C=C4)OC2(C)C)OC(=O)C,,,,,,
2130,442131,CID 442131,C1=C2C=C(C(=O)C=C2OC(=C1)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
2131,442132,CID 442132,COC1=CC2=CC=C(OC2=C(C1=O)O[C@H]3[C@@H]([C@@H]([C@@H]([C@H](O3)CO)O)O)O)O,,,,,,
2132,442133,Isosamidin,CC(=CC(=O)O[C@H]1[C@H](C(OC2=C1C3=C(C=C2)C=CC(=O)O3)(C)C)OC(=O)C)C,,,,,,
2133,442134,Leptodactylone,COC1=CC(=C(C2=C1C=CC(=O)O2)O)OC,,,,,,
2134,442135,Libanorin,CC(=CC(=O)OC(C)(C)[C@@H]1CC2=C(O1)C=CC3=C2OC(=O)C=C3)C,,,,,,
2135,442136,CID 442136,CC[C@H]1C[C@H]2C[C@@H]3[C@H]1N(C2)CCC4=C3NC5=C4C=CC(=C5)OC,,,,,,
2136,442137,Peucenidin,CC(=CC(=O)OC(C)(C)[C@@H]1[C@@H](C2=C(O1)C=CC3=C2OC(=O)C=C3)OC(=O)C)C,,,,,,
2137,442138,Absinthin,C[C@H]1[C@@H]2CC[C@]([C@@H]3[C@H]4[C@H]5C=C([C@@]6([C@H]4C(=C3[C@H]2OC1=O)C)[C@@H]5[C@@](CC[C@@H]7[C@@H]6OC(=O)[C@H]7C)(C)O)C)(C)O,,,,,,
2138,442139,"(3R,3aS,9aS,9bS)-3,6,9-trimethyl-3,3a,4,5,9a,9b-hexahydroazuleno[4,5-b]furan-2,7-dione",C[C@@H]1[C@@H]2CCC(=C3[C@@H]([C@H]2OC1=O)C(=CC3=O)C)C,,,,,,
2139,442140,Acroptilin,C[C@@](CCl)(C(=O)O[C@H]1CC(=C)[C@@H]2C[C@@H]([C@]3([C@@H]2[C@@H]4[C@@H]1C(=C)C(=O)O4)CO3)O)O,,,,,,
2140,442141,"[(3aR,4S,11aR)-6,10-bis(hydroxymethyl)-3-methylidene-2-oxo-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-4-yl] 2-methylpropanoate",CC(C)C(=O)O[C@H]1CC(=CCCC(=C[C@@H]2[C@@H]1C(=C)C(=O)O2)CO)CO,,,,,,
2141,442142,Angustibalin,C[C@@H]1C[C@@H]2[C@H]([C@@H]([C@]3([C@H]1C=CC3=O)C)OC(=O)C)C(=C)C(=O)O2,,,,,,
2142,442143,CID 442143,CCC(C)C(=O)O[C@H]1C[C@]([C@H]2[C@@H](C=C([C@H]2[C@H]3[C@@H]1[C@](C(=O)O3)(C)OC(=O)C)C)OC(=O)C(=CC)C)(C)OC(=O)C,,,,,,
2143,442144,"[(3aS,5S,5aR,7S,8aS,9aR)-8a-hydroxy-1,8-dimethylidene-2-oxospiro[4,5a,6,7,9,9a-hexahydro-3aH-azuleno[6,5-b]furan-5,2'-oxirane]-7-yl] acetate",CC(=O)O[C@H]1C[C@H]2[C@@]3(C[C@H]4[C@H](C[C@]2(C1=C)O)C(=C)C(=O)O4)CO3,,,,,,
2144,442145,Arnicolide A,C[C@@H]1C[C@@H]2[C@@H]([C@@H](C(=O)O2)C)[C@@H]([C@]3([C@H]1C=CC3=O)C)OC(=O)C,,,,,,
2145,442146,Artabsin,C[C@H]1[C@@H]2CC[C@](C3=CCC(=C3[C@H]2OC1=O)C)(C)O,,,,,,
2146,442147,Artecanin,C[C@]1(CC[C@@H]2[C@@H]([C@@H]3[C@]14[C@H](O4)[C@H]5[C@@]3(O5)C)OC(=O)C2=C)O,,,,,,
2147,442148,(+)-Rutamarin,CC(=O)OC(C)(C)[C@@H]1CC2=C(O1)C=C3C(=C2)C=C(C(=O)O3)C(C)(C)C=C,,,,,,
2148,442149,Rutarin,CC(C)([C@@H]1CC2=C(O1)C(=C3C(=C2)C=CC(=O)O3)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O,,,,,,
2149,442150,Samidin,CC(=CC(=O)O[C@@H]1[C@@H](C2=C(C=CC3=C2OC(=O)C=C3)OC1(C)C)OC(=O)C)C,,,,,,
2150,442151,Visnadine,CC[C@@H](C)C(=O)O[C@@H]1[C@@H](C2=C(C=CC3=C2OC(=O)C=C3)OC1(C)C)OC(=O)C,,,,,,
2151,442152,Abyssinone I,CC1(C=CC2=C(O1)C=CC(=C2)[C@@H]3CC(=O)C4=C(O3)C=C(C=C4)O)C,,,,,,
2152,442153,Abyssinone V,CC(=CCC1=CC(=CC(=C1O)CC=C(C)C)[C@@H]2CC(=O)C3=C(C=C(C=C3O2)O)O)C,,,,,,
2153,442154,Afzelechin,C1[C@@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC=C(C=C3)O)O,,,,,,
2154,442155,(+)-Adlumine,CN1CCC2=CC(=C(C=C2[C@H]1[C@@H]3C4=C(C5=C(C=C4)OCO5)C(=O)O3)OC)OC,,,,,,
2155,442156,Aknadicine,COC1=C(C2=C(CC[C@@]34[C@@]2(CCN3)CC(=O)C(=C4OC)OC)C=C1)O,,,,,,
2156,442157,Alamarine,C[C@H](C1=C2C=C3C4=CC(=C(C=C4CCN3C(=O)C2=CN=C1)OC)O)O,,,,,,
2157,442158,Alangicine,CC[C@H]1CN2CCC3=C(C(=C(C=C3[C@@H]2C[C@@H]1CC4=NCCC5=CC(=C(C=C54)OC)O)OC)OC)O,,,,,,
2158,442159,Alangimarckine,CC[C@H]1CN2CCC3=C(C(=C(C=C3[C@@H]2C[C@@H]1C[C@@H]4C5=C(CCN4)C6=CC=CC=C6N5)OC)OC)O,,,,,,
2159,442160,Alangimarine,COC1=C(C=C2C(=C1)CCN3C2=CC4=C(C3=O)C=NC=C4C=C)O,,,,,,
2160,442161,Alangiside,COC1=C(C=C2[C@H]3C[C@H]4[C@H]([C@@H](OC=C4C(=O)N3CCC2=C1)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)C=C)O,,,,,,
2161,442162,Alpinine,CN1CCC2=CC(=C(C=C2[C@H]3[C@H]1C4=C([C@H](O3)OC)C(=C(C=C4)OC)OC)OC)OC,,,,,,
2162,442163,CID 442163,C1C(NC2=C(N1)NC(=NC2=O)N)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)NC(CCC(=O)O)C(=O)O)C(=O)O,,,,,,
2163,442164,Amurensine,CN1C[C@@H]2C3=CC(=C(C=C3C[C@H]1C4=CC5=C(C=C24)OCO5)OC)O,,,,,,
2164,442165,"(1R,12S)-16-methoxy-20-methyl-5,7-dioxa-20-azapentacyclo[10.5.3.01,13.02,10.04,8]icosa-2,4(8),9,13,16-pentaen-15-one",CN1CC[C@]23C=C(C(=O)C=C2[C@@H]1CC4=CC5=C(C=C34)OCO5)OC,,,,,,
2165,442166,Ankorine,CC[C@H]1CN2CCC3=C(C(=C(C=C3[C@@H]2C[C@@H]1CCO)OC)OC)O,,,,,,
2166,442167,(-)-Apoglaziovine,CN1CCC2=CC(=C(C3=C2[C@H]1CC4=C3C=C(C=C4)O)O)OC,,,,,,
2167,442168,(-)-Argemonine,CN1[C@H]2CC3=CC(=C(C=C3[C@@H]1CC4=CC(=C(C=C24)OC)OC)OC)OC,,,,,,
2168,442169,(-)-Armepavine,CN1CCC2=CC(=C(C=C2[C@H]1CC3=CC=C(C=C3)O)OC)OC,,,,,,
2169,442170,"(3aS,7R,11aR)-7-hydroxy-10-methyl-3,6-dimethylidene-4,5,7,8,9,11a-hexahydro-3aH-cyclodeca[b]furan-2-one",CC1=C[C@@H]2[C@@H](CCC(=C)[C@@H](CC1)O)C(=C)C(=O)O2,,,,,,
2170,442171,Autumnolide,C[C@@H]1C[C@@H]2[C@H]([C@@H]([C@]3([C@H]1[C@@H]4[C@H]([C@@H]3O)O4)C)O)C(=C)C(=O)O2,,,,,,
2171,442172,CID 442172,CC1=C[C@H](C[C@@]2([C@H](O2)C[C@H]3[C@H](C1)OC(=O)C3=C)C)O,,,,,,
2172,442173,Bakkenolide A,C[C@H]1CCC[C@H]2[C@@]1(C[C@]3(C2)C(=C)COC3=O)C,,,,,,
2173,442174,"[(4R,8R,9R,11R)-2,11-dimethyl-7-methylidene-6,12-dioxo-5,14-dioxatricyclo[9.2.1.04,8]tetradeca-1(13),2-dien-9-yl] 2-methylprop-2-enoate",CC1=C[C@@H]2[C@@H]([C@@H](C[C@@]3(C(=O)C=C1O3)C)OC(=O)C(=C)C)C(=C)C(=O)O2,,,,,,
2174,442175,Canin,C[C@]1(CC[C@@H]2[C@@H]([C@@H]3[C@@]14[C@@H](O4)[C@@H]5[C@]3(O5)C)OC(=O)C2=C)O,,,,,,
2175,442176,CID 442176,CC1=CC[C@H](C(=C[C@H]([C@H]2[C@H](C1)OC(=O)C2=C)O)C)O,,,,,,
2176,442177,CID 442177,CC1=CC[C@H](C(=C[C@H]([C@H]2[C@H](C1)OC(=O)C2=C)OC(=O)C)C)OC(=O)C,,,,,,
2177,442178,Chlorochrymorin,C[C@@H]([C@@H]1C[C@@H]2[C@@H]([C@@H]3[C@]14[C@H](O4)[C@H]([C@]3(C)O)Cl)OC(=O)C2=C)O,,,,,,
2178,442179,"[(3aR,4S,6aR,8R,9S,9aS,9bS)-9-(chloromethyl)-8,9-dihydroxy-3,6-dimethylidene-2-oxo-3a,4,5,6a,7,8,9a,9b-octahydroazuleno[4,5-b]furan-4-yl] (2S)-3-chloro-2-hydroxy-2-methylpropanoate",C[C@@](CCl)(C(=O)O[C@H]1CC(=C)[C@@H]2C[C@H]([C@@]([C@@H]2[C@@H]3[C@@H]1C(=C)C(=O)O3)(CCl)O)O)O,,,,,,
2179,442180,Berberastine,COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4C(C3)O)OCO5)OC,,,,,,
2180,442181,"[(3aR,4R,9S,11aR)-9-acetyloxy-6,10-dimethyl-3-methylidene-2-oxo-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-4-yl] 4-hydroxy-2-methylbut-2-enoate",CC1=CC[C@@H](C(=C[C@@H]2[C@@H]([C@@H](C1)OC(=O)C(=CCO)C)C(=C)C(=O)O2)C)OC(=O)C,,,,,,
2181,442182,"[(3aR,4S,11aR)-10-(hydroxymethyl)-6-methyl-3-methylidene-2-oxo-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-4-yl] (3R)-3,4-dihydroxy-2-methylidenebutanoate",CC1=CCCC(=C[C@@H]2[C@@H]([C@H](C1)OC(=O)C(=C)[C@H](CO)O)C(=C)C(=O)O2)CO,,,,,,
2182,442183,Conchosin A,C[C@]12[C@H]3[C@@H](CC[C@H]4[C@@]1([C@@H](CC2=O)OC4)O)C(=C)C(=O)O3,,,,,,
2183,442184,Calafatimine,CN1CCC2=CC(=C(C3=C2[C@H]1CC4=C(C(=C(C=C4)OC)OC5=CC=C(CC6=NCCC7=CC(=C(O3)C=C76)OC)C=C5)OC)OC)OC,,,,,,
2184,442185,"(1'R,2'S,3R,5'S,13'R)-14-hydroxy-8',10,15-trimethoxy-14'-methylspiro[12-oxa-4-azapentacyclo[9.7.2.04,19.07,20.013,18]icosa-1(19),7(20),8,10,13(18),14,16-heptaene-3,4'-6-oxa-14-azapentacyclo[9.5.1.01,5.02,13.07,17]heptadeca-7,9,11(17)-triene]-2-one",CN1CC[C@@]23[C@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@@H]3[C@]6(C4)C(=O)C7=C8N6CCC9=C8C(=C(C=C9)OC)OC1=C7C=CC(=C1O)OC,,,,,,
2185,442186,(+-)-Carnegine,C[C@H]1C2=CC(=C(C=C2CCN1C)OC)OC,,,,,,
2186,442187,Confertifolin,C[C@]12CCCC([C@@H]1CCC3=C2COC3=O)(C)C,,,,,,
2187,442188,Caseadine,COC1=C(C2=C(CCN3[C@H]2CC4=CC(=C(C=C4C3)OC)OC)C=C1)O,,,,,,
2188,442189,CID 442189,CC(=C)[C@@H]1[C@@H]2C[C@]3([C@@]4(CO4)[C@H]5[C@@H]([C@]3([C@H]1C(=O)O2)O)O5)C,,,,,,
2189,442190,Cassyfiline,COC1=C(C=C2C[C@H]3C4=C(CCN3)C(=C5C(=C4C2=C1)OCO5)OC)O,,,,,,
2190,442191,alpha-Cyclocostunolide,CC1=CCC[C@]2([C@H]1[C@@H]3[C@@H](CC2)C(=C)C(=O)O3)C,,,,,,
2191,442192,beta-Cyclocostunolide,C[C@]12CCCC(=C)[C@@H]1[C@@H]3[C@@H](CC2)C(=C)C(=O)O3,,,,,,
2192,442193,"[(3S,4R,8R,12R)-10-methyl-5-methylidene-6,14-dioxo-7,13-dioxatricyclo[10.2.1.04,8]pentadeca-1(15),9-dien-3-yl] 2-methylprop-2-enoate",CC1=C[C@@H]2[C@@H]([C@H](CC3=C[C@@H](C1)OC3=O)OC(=O)C(=C)C)C(=C)C(=O)O2,,,,,,
2193,442194,Cassythicine,CN1CCC2=CC3=C(C4=C2[C@@H]1CC5=CC(=C(C=C54)OC)O)OCO3,,,,,,
2194,442195,Cephaeline,CC[C@H]1CN2CCC3=CC(=C(C=C3[C@@H]2C[C@@H]1C[C@@H]4C5=CC(=C(C=C5CCN4)O)OC)OC)OC,,,,,,
2195,442196,8-Deoxylactucin,CC1=C2[C@@H]([C@@H]3[C@@H](CC1)C(=C)C(=O)O3)C(=CC2=O)CO,,,,,,
2196,442197,Corpaine,CN1CCC2=CC(=C(C=C2[C@@]13[C@H](C4=C(C3=O)C=CC5=C4OCO5)O)O)OC,,,,,,
2197,442198,CID 442198,CC=C(CO)C(=O)O[C@@H]1CC(=CC[C@H](C(=C[C@@H]2[C@@H]1C(=C)C(=O)O2)C)O)C,,,,,,
2198,442199,CID 442199,C[C@@]12CCC3=CC[C@H]4[C@@H](C[C@]3(O1)CO2)OC(=O)C4=C,,,,,,
2199,442200,Dihydromikanolide,C[C@@H]1[C@@H]2[C@H](C[C@]3([C@@H](O3)[C@H]4[C@H](O4)C5=C[C@H]2OC5=O)C)OC1=O,,,,,,
2200,442201,Cularicine,CN1CCC2=C3[C@@H]1CC4=CC5=C(C=C4OC3=C(C=C2)O)OCO5,,,,,,
2201,442202,Drimenin,C[C@]12CCCC([C@@H]1CC=C3[C@@H]2C(=O)OC3)(C)C,,,,,,
2202,442203,Cularidine,CN1CCC2=C3[C@@H]1CC4=CC(=C(C=C4OC3=C(C=C2)O)OC)OC,,,,,,
2203,442204,CID 442204,CC(=CCOC(=O)C)C(=O)O[C@@H]1C[C@@]2([C@H](O2)[C@@H]3[C@@H](O3)C(=C[C@@H]4[C@@H]1C(=C)C(=O)O4)CO)C,,,,,,
2204,442205,Elephantin,CC(=CC(=O)O[C@H]1CC2=C[C@@H](C[C@@]3([C@H](O3)[C@@H]4[C@@H]1C(=C)C(=O)O4)C)OC2=O)C,,,,,,
2205,442206,Elephantopin,CC(=C)C(=O)O[C@H]1CC2=C[C@@H](C[C@@]3([C@H](O3)[C@@H]4[C@@H]1C(=C)C(=O)O4)C)OC2=O,,,,,,
2206,442207,CID 442207,C[C@@H]1[C@](O1)(C)C(=O)O[C@H]2[C@@H]3[C@@H]([C@@H]4[C@](O4)(CCC=C([C@@H]2OC(=O)C)C(=O)OC)C)OC(=O)C3=C,,,,,,
2207,442208,CID 442208,CC1=C[C@@H]2[C@H]3[C@H](C[C@@]4(C(=O)C=C1O4)C)O[C@@]([C@]3(C(=O)O2)C)(C(C)C)O,,,,,,
2208,442209,Eremofrullanolide,C[C@H]1CCCC2=C[C@H]3[C@@H](C[C@]12C)C(=C)C(=O)O3,,,,,,
2209,442210,Eremophilenolide,C[C@H]1CCC[C@H]2[C@@]1(CC3=C(C(=O)O[C@H]3C2)C)C,,,,,,
2210,442211,Cularimine,COC1=C2C3=C(CCN[C@H]3CC4=CC(=C(C=C4O2)OC)OC)C=C1,,,,,,
2211,442212,CID 442212,CC1=C[C@@H]2[C@@H]([C@@H](C[C@@]3([C@H](O3)C[C@@H]1OC(=O)C)C)OC(=O)C(=C)C)C(=C)C(=O)O2,,,,,,
2212,442213,"[(1R,2R,4R,6R,8S,11R)-4,9-dimethyl-14-methylidene-2-(2-methylprop-2-enoyloxy)-13-oxo-5,12-dioxatricyclo[9.3.0.04,6]tetradec-9-en-8-yl] 2-methylprop-2-enoate",CC1=C[C@@H]2[C@@H]([C@@H](C[C@@]3([C@H](O3)C[C@@H]1OC(=O)C(=C)C)C)OC(=O)C(=C)C)C(=C)C(=O)O2,,,,,,
2213,442214,Daphnandrine,CN1CCC2=CC(=C(C3=C2[C@@H]1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)C[C@@H]6C7=CC(=C(C=C7CCN6)OC)O3)OC)O)OC,,,,,,
2214,442215,"[(3aR,4R,6R,6aR,7R,9aS,9bS)-6-(chloromethyl)-6,7,9a-trihydroxy-9-methyl-3-methylidene-2-oxo-3a,4,5,6a,7,9b-hexahydroazuleno[4,5-b]furan-4-yl] 2-methylbut-2-enoate",CC=C(C)C(=O)O[C@@H]1C[C@@]([C@@H]2[C@@H](C=C([C@@]2([C@@H]3[C@@H]1C(=C)C(=O)O3)O)C)O)(CCl)O,,,,,,
2215,442216,CID 442216,CC=C(C)C(=O)O[C@@H]1C[C@@]([C@@H]2[C@@H](C=C([C@@]2([C@@H]3[C@@H]1C(=C)C(=O)O3)O)C)OC(=O)C)(CCl)O,,,,,,
2216,442217,Emetamine,CC[C@H]1CN2CCC3=CC(=C(C=C3[C@@H]2C[C@@H]1CC4=NC=CC5=CC(=C(C=C54)OC)OC)OC)OC,,,,,,
2217,442218,Erysonine,COC1=C(C=C2CCN3CC=C4[C@]3(C2=C1)C[C@H](C=C4)O)O,,,,,,
2218,442219,Erysotrine,CO[C@@H]1C[C@@]23C(=CCN2CCC4=CC(=C(C=C34)OC)OC)C=C1,,,,,,
2219,442220,Erythratidine,CO[C@@H]1C[C@@]23C(=C[C@@H]1O)CCN2CCC4=CC(=C(C=C34)OC)OC,,,,,,
2220,442221,"[(1R,2S,6R,7R,9R,10R,11S,12R,14R)-9-(chloromethyl)-1,9,11-trihydroxy-14-methyl-5-methylidene-4-oxo-3,13-dioxatetracyclo[8.4.0.02,6.012,14]tetradecan-7-yl] 2-methylbut-2-enoate",CC=C(C)C(=O)O[C@@H]1C[C@@]([C@@H]2[C@@H]([C@@H]3[C@]([C@@]2([C@@H]4[C@@H]1C(=C)C(=O)O4)O)(O3)C)O)(CCl)O,,,,,,
2221,442222,Eschscholtzidine,CN1[C@H]2CC3=CC4=C(C=C3[C@@H]1CC5=CC(=C(C=C25)OC)OC)OCO4,,,,,,
2222,442223,CID 442223,CC=C(C)C(=O)O[C@@H]1C=C([C@H](C[C@@H](C(=C[C@@H]2[C@@H]1C(=C)C(=O)O2)C)OC(=O)C)O)C,,,,,,
2223,442224,CID 442224,CC=C(C)C(=O)O[C@@H]1C=C([C@H](C[C@@H](C(=C[C@@H]2[C@@H]1C(=C)C(=O)O2)CO)OC(=O)C)O)C,,,,,,
2224,442225,CID 442225,C[C@@H]1[C@](O1)(C)C(=O)O[C@@H]2C=C([C@H](C[C@@H](C(=C[C@@H]3[C@@H]2C(=C)C(=O)O3)C)OC(=O)C)O)C,,,,,,
2225,442226,CID 442226,CC1=CC[C@H](C(=C[C@@H]2[C@@H]([C@@H](C1)O)C(=C)C(=O)O2)C)OC(=O)C,,,,,,
2226,442227,"[(1S,2R,4S,10R,11R)-4-(hydroxymethyl)-8-methyl-12-methylidene-13-oxo-3,14-dioxatricyclo[9.3.0.02,4]tetradec-7-en-10-yl] 4-hydroxy-2-methylbut-2-enoate",CC1=CCC[C@@]2([C@H](O2)[C@@H]3[C@@H]([C@@H](C1)OC(=O)C(=CCO)C)C(=C)C(=O)O3)CO,,,,,,
2227,442228,"[(3aR,4R,6R,6aR,7R,9aS,9bS)-7,9a-dihydroxy-9-methyl-3-methylidene-2-oxospiro[3a,4,5,6a,7,9b-hexahydroazuleno[4,5-b]furan-6,2'-oxirane]-4-yl] 2-methylbut-2-enoate",CC=C(C)C(=O)O[C@@H]1C[C@]2(CO2)[C@@H]3[C@@H](C=C([C@@]3([C@@H]4[C@@H]1C(=C)C(=O)O4)O)C)O,,,,,,
2228,442229,"[(3aR,4R,6R,6aR,7R,9aS,9bS)-7-acetyloxy-9a-hydroxy-9-methyl-3-methylidene-2-oxospiro[3a,4,5,6a,7,9b-hexahydroazuleno[4,5-b]furan-6,2'-oxirane]-4-yl] 2-methylbut-2-enoate",CC=C(C)C(=O)O[C@@H]1C[C@]2(CO2)[C@@H]3[C@@H](C=C([C@@]3([C@@H]4[C@@H]1C(=C)C(=O)O4)O)C)OC(=O)C,,,,,,
2229,442230,CID 442230,CC=C(C)C(=O)O[C@H]1[C@@H]2[C@@H](C=C([C@H](CC=C(C1O)C)OC(=O)C)C)OC(=O)C2=C,,,,,,
2230,442231,CID 442231,C[C@@H]1[C@](O1)(C)C(=O)OC2C([C@@H]3[C@@H](C=C([C@H](CC=C2C)OC(=O)C)C)OC(=O)C3=C)O,,,,,,
2231,442232,"(3aR,4R,11aR)-4-hydroxy-6,10-dimethyl-3-methylidene-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-2-one",CC1=C[C@@H]2[C@@H]([C@@H](CC(=CCC1)C)O)C(=C)C(=O)O2,,,,,,
2232,442233,Fetidine,CN1CCC2=CC(=C(C3=C2[C@@H]1CC4=CC(=C(C=C43)OC)OC5=C(C=CC(=C5OC)OC)C[C@H]6C7=CC(=C(C=C7CCN6C)OC)OC)O)OC,,,,,,
2233,442234,CID 442234,CC1=C[C@@H]2[C@@H]([C@@H](CC(=CCC1)C)OC(=O)C(=CCO)CO)C(=C)C(=O)O2,,,,,,
2234,442235,CID 442235,CC=C(C)C(=O)O[C@@H]1C[C@]2(CO2)[C@@H]3[C@@H]([C@@H]4[C@]([C@@]3([C@@H]5[C@@H]1C(=C)C(=O)O5)O)(O4)C)O,,,,,,
2235,442236,Fumaricine,CN1CCC2=CC(=C(C=C2[C@@]13CC4=C([C@@H]3O)C5=C(C=C4)OCO5)OC)OC,,,,,,
2236,442237,Gigantine,C[C@H]1C2=CC(=C(C(=C2CCN1C)O)OC)OC,,,,,,
2237,442238,CID 442238,CC=C(C)C(=O)O[C@@H]1C[C@@]2(CO2)[C@@H]3[C@@H]([C@@H]4[C@]([C@@]3([C@@H]5[C@@H]1C(=C)C(=O)O5)O)(O4)C)O,,,,,,
2238,442239,CID 442239,CC=C(C)C(=O)O[C@@H]1CC(=C2C[C@@H]3[C@]([C@@H]2[C@@H]4[C@@H]1C(=C)C(=O)O4)(O3)C)CO,,,,,,
2239,442240,Farinosin,C[C@@]12C[C@@H]3[C@H](C[C@H]1C(=C)C(=O)C=C2)[C@@](C(=O)O3)(C)O,,,,,,
2240,442241,Fastigilin B,C[C@H]1[C@@H]2C=CC(=O)[C@]2([C@H]([C@@H]3[C@@H](C(=O)O[C@@H]3[C@@H]1O)C)OC(=O)C=C(C)C)C,,,,,,
2241,442242,Fastigilin C,C[C@H]1[C@@H]2C=CC(=O)[C@]2([C@H]([C@H]3[C@@H]([C@@H]1O)OC(=O)C3=C)OC(=O)C=C(C)C)C,,,,,,
2242,442243,Florilenalin,C[C@]1(C[C@@H]([C@H]2[C@H]1C[C@H]3[C@@H](CC2=C)OC(=O)C3=C)O)O,,,,,,
2243,442244,Geigerin,C[C@H]1C[C@@H]2[C@@H]([C@@H](C(=O)O2)C)[C@@H](C3=C(C(=O)C[C@H]13)C)O,,,,,,
2244,442245,Suavedol,CN1CCC2=CC(=C(C3=C2[C@H]1CC34C=CC(=O)C=C4)O)OC,,,,,,
2245,442246,Hasubanonine,CN1CC[C@@]23[C@@]1(CCC4=C2C(=C(C=C4)OC)OC)C(=C(C(=O)C3)OC)OC,,,,,,
2246,442247,(-)-alpha-Hydrastine,CN1CCC2=CC3=C(C=C2[C@@H]1[C@H]4C5=C(C(=C(C=C5)OC)OC)C(=O)O4)OCO3,,,,,,
2247,442248,Glaucolide A,CC(=C)C(=O)O[C@H]1C[C@@](C(=O)CC[C@@]2([C@H](O2)[C@@H]3C1=C(C(=O)O3)COC(=O)C)C)(C)OC(=O)C,,,,,,
2248,442249,Ipecoside,CC(=O)N1CCC2=CC(=C(C=C2[C@H]1C[C@H]3[C@H]([C@@H](OC=C3C(=O)OC)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)C=C)O)O,,,,,,
2249,442250,Glaucolide B,CC(=O)OCC1=C2[C@H](C[C@@](C(=O)CC[C@@]3([C@@H]([C@H]2OC1=O)O3)C)(C)OC(=O)C)OC(=O)C,,,,,,
2250,442251,"3,6,10-trimethyl-7,8,11,11a-tetrahydro-4H-cyclodeca[b]furan-2-one",CC1=CCC2=C(C(=O)OC2CC(=CCC1)C)C,,,,,,
2251,442252,CID 442252,CC(=C)C(=O)O[C@@H]1C=C(C2=CC(=O)[C@](O2)(C[C@H]3[C@H]1C(=C)C(=O)O3)C)CO,,,,,,
2252,442253,"[(1S,2S,6R,7R,9R,10S,11S,12R,14S)-11-hydroxy-14-methyl-5-methylidene-4-oxospiro[3,13-dioxatetracyclo[8.4.0.02,6.012,14]tetradecane-9,2'-oxirane]-7-yl] 4-acetyloxy-2-methylbut-2-enoate",CC(=CCOC(=O)C)C(=O)O[C@@H]1C[C@]2(CO2)[C@H]3[C@@H]([C@@H]4[C@@H]1C(=C)C(=O)O4)[C@]5([C@@H]([C@H]3O)O5)C,,,,,,
2253,442254,Granilin,C[C@@]12C[C@@H]3[C@H](C[C@H]1C(=C)[C@H](C[C@H]2O)O)C(=C)C(=O)O3,,,,,,
2254,442255,Asebogenin,COC1=CC(=C(C(=C1)O)C(=O)CCC2=CC=C(C=C2)O)O,,,,,,
2255,442256,Grosheimin,C[C@H]1[C@H]2[C@@H](CC1=O)C(=C)C[C@@H]([C@@H]3[C@@H]2OC(=O)C3=C)O,,,,,,
2256,442257,CID 442257,CC1=CC[C@@H](C(=C[C@@H]2[C@@H]([C@@H](C1)OC(=O)C(=CCO)CO)C(=C)C(=O)O2)C)OC(=O)C,,,,,,
2257,442258,7alpha-Hydroxydehydrocostus lactone,C=C1CC[C@@]2([C@@H]([C@@H]3[C@H]1CCC3=C)OC(=O)C2=C)O,,,,,,
2258,442259,"NCGC00386023-01_C19H22O8_2-Propenoic acid, 2-(hydroxymethyl)-, (1aR,5aR,8aR,9S,10aR,11R)-1a,2,5a,7,8,8a,9,10-octahydro-11-hydroxy-8-methylene-7-oxo-3H-4,10a-(methanooxymethano)oxireno[5,6]cyclodeca[1,2-b]furan-9-yl ester",C=C1[C@@H]2[C@H](C[C@]34[C@H](O3)CCC(=C[C@H]2OC1=O)CO[C@H]4O)OC(=O)C(=C)CO,,,,,,
2259,442260,Auriculoside,COC1=C(C=C(C=C1O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)[C@@H]3CCC4=C(O3)C=C(C=C4)O)O,,,,,,
2260,442261,Betagarin,COC1=CC=CC=C1[C@@H]2CC(=O)C3=C(C4=C(C=C3O2)OCO4)OC,,,,,,
2261,442262,Hymenoflorin,C[C@@H]1C[C@@H]2[C@H](C[C@]3([C@H]1C=CC3=O)C)C(C(=O)O2)(CO)O,,,,,,
2262,442263,"3-[(3aS,4R,5R,8aR)-4-hydroxy-5,7-dimethyl-3-methylidene-2-oxo-4,5,8,8a-tetrahydro-3aH-cyclohepta[b]furan-6-yl]propyl acetate",C[C@H]1[C@H]([C@H]2[C@@H](CC(=C1CCCOC(=O)C)C)OC(=O)C2=C)O,,,,,,
2263,442264,"[(3S,3aR,4S,6S,6aS,9aS,9bS)-3-acetyloxy-6-hydroxy-3,6,9-trimethyl-2-oxo-4,5,6a,7,9a,9b-hexahydro-3aH-azuleno[4,5-b]furan-4-yl] 2-methylbut-2-enoate",CC=C(C)C(=O)O[C@H]1C[C@]([C@H]2CC=C([C@H]2[C@H]3[C@@H]1[C@](C(=O)O3)(C)OC(=O)C)C)(C)O,,,,,,
2264,442265,"[(1R,3aS,5R,5aR,8aR,9R,9aR)-1,5,8a-trimethyl-2,8-dioxo-3a,4,5,5a,9,9a-hexahydro-1H-azuleno[6,5-b]furan-9-yl] acetate",C[C@@H]1C[C@H]2[C@@H]([C@H](C(=O)O2)C)[C@H]([C@]3([C@H]1C=CC3=O)C)OC(=O)C,,,,,,
2265,442266,Lactucin,CC1=C2[C@@H]([C@@H]3[C@@H]([C@H](C1)O)C(=C)C(=O)O3)C(=CC2=O)CO,,,,,,
2266,442267,"[(3S,3aR,4S,11aS)-4-acetyloxy-3,6,10-trimethyl-2-oxo-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-3-yl] 2-methylbut-2-enoate",CC=C(C)C(=O)O[C@]1([C@@H]2[C@H](CC(=CCCC(=C[C@@H]2OC1=O)C)C)OC(=O)C)C,,,,,,
2267,442268,"[(3aR,4R,11aS)-6,10-dimethyl-3-methylidene-2-oxo-3a,4,7,8,11,11a-hexahydrocyclodeca[b]furan-4-yl] acetate",CC1=C[C@H]([C@H]2[C@H](CC(=CCC1)C)OC(=O)C2=C)OC(=O)C,,,,,,
2268,442269,CID 442269,CC=C(COC(=O)C)C(=O)O[C@@H]1C[C@@]2(C=C[C@@](O2)(C(=C[C@@H]3[C@@H]1C(=C)C(=O)O3)C)O)C,,,,,,
2269,442270,Ligulatin B,C[C@H]1CC[C@@H]2[C@H]([C@]3([C@H]1CCC3=O)COC(=O)C)OC(=O)C2=C,,,,,,
2270,442271,"(1S,12S,13S)-5,10-dimethyl-8,14,16-trioxatetracyclo[10.2.2.01,13.07,11]hexadeca-4,7(11),9-trien-15-one",CC1=CCC[C@@]23[C@@H](O2)[C@H](C4=C(C1)OC=C4C)OC3=O,,,,,,
2271,442272,Linifolin A,C[C@@H]1C[C@H]2[C@H]([C@H]([C@]3([C@H]1C=CC3=O)C)OC(=O)C)C(=C)C(=O)O2,,,,,,
2272,442273,CID 442273,CC1=CCC[C@@]2(C(O2)[C@@H]3[C@@H]([C@@H](C1)OC(=O)C)C(=C)C(=O)O3)C,,,,,,
2273,442274,CID 442274,C[C@@H]1[C@](O1)(C)C(=O)O[C@H]2[C@@H]3[C@@H](C=C([C@H]4[C@H](O4)C=C([C@@H]2O)C(=O)OC)C)OC(=O)C3=C,,,,,,
2274,442275,CID 442275,CC1=C[C@@H]2[C@@H]([C@@H]([C@H](C(=C[C@@H]3[C@H]1O3)C(=O)OC)OC(=O)C)OC(=O)[C@@](C)([C@@H](C)OC(=O)C)O)C(=C)C(=O)O2,,,,,,
2275,442276,Hyenanchin,CC(=C)C1([C@@H]2[C@H]([C@]3([C@@]4(CO4)[C@H]5[C@@H]([C@]3([C@H]1C(=O)O2)O)O5)C)O)O,,,,,,
2276,442277,Broussin,COC1=CC=C(C=C1)[C@@H]2CCC3=C(O2)C=C(C=C3)O,,,,,,
2277,442278,Michelenolide,C[C@@]12CC[C@@H]3[C@@H]([C@@H]4[C@](O4)(CC[C@H]1O2)C)OC(=O)C3=C,,,,,,
2278,442279,Micheliolide,CC1=C2CC[C@@]([C@@H]2[C@@H]3[C@@H](CC1)C(=C)C(=O)O3)(C)O,,,,,,
2279,442280,CID 442280,C[C@@H]1C[C@@H]2[C@H](C[C@@]34[C@H]1[C@H](CC3=O)OC4)C(=C)C(=O)O2,,,,,,
2280,442281,Microlenin,C[C@@H]1C[C@@H]2[C@H]([C@@H]([C@]3([C@H]1C=CC3=O)C)O)[C@]4(CC5CC(=O)[C@]46[C@@H]5[C@@H](C[C@@H]7[C@H](C6)C(=C)C(=O)O7)C)C(=O)O2,,,,,,
2281,442282,Mikanolide,C[C@]12C[C@H]3[C@H]([C@H]4C=C([C@@H]5[C@H]([C@@H]1O2)O5)C(=O)O4)C(=C)C(=O)O3,,,,,,
2282,442283,CID 442283,CC=C(C)C(=O)O[C@H]1CC(=CC(=O)C=C([C@@H]([C@@H]2[C@@H]1C(=C)C(=O)O2)O)C)C,,,,,,
2283,442284,Multiradiatin,C[C@H]1[C@@H]2C=CC(=O)[C@]2([C@H]([C@H]3[C@@H](C1=O)OC(=O)C3=C)OC(=O)C=C(C)C)C,,,,,,
2284,442285,CID 442285,CC=C(C)C(=O)O[C@H]1CC(=CC[C@@H](C(=C[C@@H]2[C@@H]1C(=C)C(=O)O2)C)O)C,,,,,,
2285,442286,CID 442286,CC1=C[C@@H]2[C@@H]([C@@H](C[C@@]3([C@H](C[C@]1(O3)O)O)C)OC(=O)C(C)C)C(=C)C(=O)O2,,,,,,
2286,442287,"[(3aR,4R,11aR)-4-hydroxy-10-methyl-3-methylidene-2-oxo-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-6-yl]methyl acetate",CC1=C[C@@H]2[C@@H]([C@@H](CC(=CCC1)COC(=O)C)O)C(=C)C(=O)O2,,,,,,
2287,442288,Parthenin,C[C@H]1CC[C@@H]2[C@H]([C@]3([C@]1(C=CC3=O)O)C)OC(=O)C2=C,,,,,,
2288,442289,Broussonin C,CC(=CCC1=C(C=CC(=C1)CCCC2=C(C=C(C=C2)O)O)O)C,,,,,,
2289,442290,1-Peroxyferolide,CC(=O)O[C@@H]1CC(=C)[C@@H](CC[C@@]2([C@H](O2)[C@@H]3[C@@H]1C(=C)C(=O)O3)C)OO,,,,,,
2290,442291,Picrotin,C[C@@]12[C@H]3[C@H]4[C@H]([C@@H]([C@@]1(C[C@@H]5[C@]2(O5)C(=O)O3)O)C(=O)O4)C(C)(C)O,,,,,,
2291,442292,Picrotoxinin,CC(=C)[C@@H]1[C@@H]2[C@@H]3[C@@]4([C@]([C@H]1C(=O)O2)(C[C@@H]5[C@]4(O5)C(=O)O3)O)C,,,['Drugs that bind to but do not activate GABA-A RECEPTORS thereby blocking the actions of endogenous or exogenous GABA-A RECEPTOR AGONISTS. (See all compounds classified as GABA-A Receptor Antagonists.)'],,,
2292,442293,Pleniradin,CC1=C[C@@H]2[C@H](C[C@@H]3[C@@H]1[C@H](C[C@@]3(C)O)O)C(=C)C(=O)O2,,,,,,
2293,442294,Plenolin,C[C@@H]1C[C@@H]2[C@@H]([C@@H](C(=O)O2)C)[C@@H]([C@]3([C@H]1C=CC3=O)C)O,,,,,,
2294,442295,"[(3S,3aR,4S,6S,6aR,9aS,9bS)-3,6-diacetyloxy-3,6,9-trimethyl-2-oxo-4,5,6a,7,9a,9b-hexahydro-3aH-azuleno[4,5-b]furan-4-yl] 2-methylpropanoate",CC1=CC[C@@H]2[C@@H]1[C@H]3[C@@H]([C@H](C[C@]2(C)OC(=O)C)OC(=O)C(C)C)[C@](C(=O)O3)(C)OC(=O)C,,,,,,
2295,442296,CID 442296,CC=C(CO)C(=O)OCC(=CCO)C(=O)O[C@@H]1CC(=CC[C@@H](C(=C[C@@H]2[C@@H]1C(=C)C(=O)O2)C)OC(=O)C)C,,,,,,
2296,442297,CID 442297,CC=C(C)C(=O)O[C@H](CC(=CCO)C)[C@@H]1[C@H](OC(=O)C1=C)C=C(C)CO,,,,,,
2297,442298,"[(1S,3R,5R,10R,11R)-3,8-dimethyl-12-methylidene-13-oxo-4,14-dioxatricyclo[9.3.0.03,5]tetradec-8-en-10-yl] acetate",CC1=C[C@H]([C@H]2[C@H](C[C@@]3([C@H](O3)CC1)C)OC(=O)C2=C)OC(=O)C,,,,,,
2298,442299,"10,10-Dimethyloctahydro-6,8b-ethanocyclopenta(de)isochromene-1,4-dione",CC1(C[C@]23[C@@H]4CC[C@H]1[C@@H]2CC(=O)[C@H]3COC4=O)C,,,,,,
2299,442300,Isococculidine,CO[C@@H]1C[C@@]23[C@H](CCN2CCC4=C3C=C(C=C4)OC)C=C1,,,,,,
2300,442301,CID 442301,CC1=CCCC(=CC[C@H]2[C@H](C1)OC(=O)C2=C)C(=O)OC,,,,,,
2301,442302,CID 442302,CC=C(CO)C(=O)OCC(=CC)C(=O)O[C@@H]1C[C@]2(CO2)[C@@H]3[C@@H](C=C([C@@H]3[C@@H]4[C@@H]1C(=C)C(=O)O4)C)OC(=O)C,,,,,,
2302,442303,Stramonin B,C[C@H]1CC[C@@H]2[C@H]([C@]3([C@H]1C=CC3=O)C)OC(=O)[C@]24CO4,,,,,,
2303,442304,Laudanidine,CN1CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C=C3)OC)O)OC)OC,,,,,,
2304,442305,"(3aS,8S,11aR)-8-hydroxy-6,10-dimethyl-3-methylidene-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-2-one",CC1=C[C@H](CC(=C[C@@H]2[C@@H](CC1)C(=C)C(=O)O2)C)O,,,,,,
2305,442306,Tetraneurin E,CC(=O)O[C@H]1CC[C@@]2([C@@]1([C@H]3[C@@H](CC[C@@H]2CO)C(=C)C(=O)O3)C)O,,,,,,
2306,442307,CID 442307,CC[C@H](C)C(=O)O[C@H]1C[C@]([C@H]2C[C@H](C(=C2[C@H]3[C@]1([C@](C(=O)O3)(C)O)O)C)OC(=O)C(=CC)C)(C)OC(=O)C,,,,,,
2307,442308,"[(3aR,4S,11aR)-6,10-dimethyl-3-methylidene-2-oxo-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-4-yl] acetate",CC1=C[C@@H]2[C@@H]([C@H](CC(=CCC1)C)OC(=O)C)C(=C)C(=O)O2,,,,,,
2308,442309,Laurifine,COC1=CC2=C(CCNCCC3=CC(=C(C=C32)OC)OC)C=C1,,,,,,
2309,442310,CID 442310,CC1=C[C@@H]2[C@@H]([C@@H](CC(=CCC1)C)OC(=O)C)C(=C)C(=O)O2,,,,,,
2310,442311,epi-Tulipinolide diepoxide,CC(=O)O[C@@H]1C[C@@]2([C@H](O2)CC[C@@]3([C@H](O3)[C@@H]4[C@@H]1C(=C)C(=O)O4)C)C,,,,,,
2311,442312,Longifolonine,COC1=C(C=C2C(=C1)CCN=C2C(=O)C3=CC=C(C=C3)O)O,,,,,,
2312,442313,Lophocerine,CC(C)CC1C2=CC(=C(C=C2CCN1C)OC)O,,,,,,
2313,442314,CID 442314,C[C@@H]1[C@](O1)(C)C(=O)O[C@@H]2CC(=CC[C@@H](C(=C[C@H]3[C@@H]2C(=C)C(=O)O3)C)OC(=O)C)C,,,,,,
2314,442315,Lophophorine,C[C@H]1C2=C3C(=C(C=C2CCN1C)OC)OCO3,,,,,,
2315,442316,Vermeerin,C[C@@H]1C[C@H]2[C@H](C[C@]3([C@H]1CC(=O)OC3)C)C(=C)C(=O)O2,,,,,,
2316,442317,(+)-Luguine,C1[C@H](C2=C3C=CC4=C(C3=CN=C2C5=CC6=C(C=C51)OCO6)OCO4)O,,,,,,
2317,442318,Vernodalol,COC(=O)C(=C)[C@@H]1[C@H](C[C@@]2(COC(=O)C(=C)[C@@H]2[C@H]1O)C=C)OC(=O)C(=C)CO,,,,,,
2318,442319,Vernoflexin,CC(=CC(=O)O[C@H]1C[C@@H]2[C@H](C1=C)[C@@H]3[C@@H](CCC2=C)C(=C)C(=O)O3)C,,,,,,
2319,442320,Vernoflexuoside,C=C1CC[C@@H]2[C@@H]([C@@H]3[C@H]1C[C@@H](C3=C)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)OC(=O)C2=C,,,,,,
2320,442321,Macoline,CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC(=C(C=C4)O)OC5=CC=C(C[C@@H]6C7=C(O3)C(=C(C=C7CC[N+]6(C)C)OC)O)C=C5)OC,,,,,,
2321,442322,Vernolepin,C=C[C@]12C[C@@H]([C@@H]3[C@@H]([C@H]1C(=C)C(=O)OC2)OC(=O)C3=C)O,,,,,,
2322,442323,CID 442323,CC(=C)C(=O)O[C@H]1C[C@]23[C@H](O2)CCC(=C[C@@H]4[C@@H]1C(=C)C(=O)O4)CO[C@H]3O,,,,,,
2323,442324,Vernomenin,C=C[C@]12C[C@H]3[C@H]([C@@H]([C@H]1C(=C)C(=O)OC2)O)C(=C)C(=O)O3,,,,,,
2324,442325,CID 442325,CC(C)C(=O)O[C@H]1C[C@]23[C@H](O2)CCC(=C[C@@H]4[C@@H]1C(=C)C(=O)O4)CO[C@H]3O,,,,,,
2325,442326,CID 442326,CC1=C[C@@H]2[C@@H]([C@@H](C[C@@]3([C@H](O3)C[C@@H]1OC(=O)C)C)OC(=O)C(C)C)C(=C)C(=O)O2,,,,,,
2326,442327,Viscidulin B,C[C@H]1[C@@H]2[C@H](CC(=C)[C@@H]3CC4C([C@@H]3[C@H]2OC1=O)(O4)C)OC(=O)C,,,,,,
2327,442328,(+)-Mecambroline,CN1CCC2=CC3=C(C4=C2[C@@H]1CC5=C4C=C(C=C5)O)OCO3,,,,,,
2328,442329,"1(3H)-Isobenzofuranone, 6,7-dimethoxy-3-[(5R)-5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl]-, hydrochloride, (3S)-",C[NH+]1CCC2=CC3=C(C(=C2[C@@H]1[C@@H]4C5=C(C(=C(C=C5)OC)OC)C(=O)O4)OC)OCO3.[Cl-],,,"['Agents that suppress cough. They act centrally on the medullary cough center. EXPECTORANTS, also used in the treatment of cough, act locally. (See all compounds classified as Antitussive Agents.)']",,,
2329,442330,Narcotoline,CN1CCC2=CC3=C(C(=C2[C@@H]1[C@@H]4C5=C(C(=C(C=C5)OC)OC)C(=O)O4)O)OCO3,,,,,,
2330,442331,"(4S,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,6,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ol",CN1CC[C@]23[C@@H]4[C@H](CC=C2[C@@H]1CC5=C3C(=C(C=C5)OC)O4)O,,,,,,
2331,442332,Ochotensine,CN1CCC2=CC(=C(C=C2[C@@]13CC4=C(C3=C)C=CC5=C4OCO5)OC)O,,,,,,
2332,442333,Oxyacanthine,CN1CCC2=CC(=C(C3=C2[C@@H]1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)C[C@@H]6C7=CC(=C(C=C7CCN6C)OC)O3)O)OC)OC,,,,,,
2333,442334,"[1-[(3aR,7S,8aS)-7-methyl-3-methylidene-2-oxo-4,7,8,8a-tetrahydro-3aH-cyclohepta[b]furan-6-yl]-3-oxobutyl] acetate",C[C@H]1C[C@H]2[C@H](CC=C1C(CC(=O)C)OC(=O)C)C(=C)C(=O)O2,,,,,,
2334,442335,Xanthumin,C[C@H]1C[C@@H]2[C@H](CC=C1[C@@H](CC(=O)C)OC(=O)C)C(=C)C(=O)O2,,,,,,
2335,442336,(-)-Pellotine,C[C@@H]1C2=C(C(=C(C=C2CCN1C)OC)OC)O,,,,,,
2336,442337,Xerantholide,C[C@H]1C[C@H]2[C@H](CC3=C(C(=O)C[C@@H]13)C)C(=C)C(=O)O2,,,,,,
2337,442338,CID 442338,CC1=C[C@@H]2[C@@H]([C@@H](C[C@@]3([C@H](C[C@]1(O3)O)O)C)OC(=O)C(=C)C)C(=C)C(=O)O2,,,,,,
2338,442339,"1-[(2-Hydroxy-3,4-dimethoxyphenyl)methylidene]-6,7-dimethoxy-3,4-dihydroisoquinoline-2-carbaldehyde",COC1=C(C(=C(C=C1)C=C2C3=CC(=C(C=C3CCN2C=O)OC)OC)O)OC,,,,,,
2339,442340,Pukateine,CN1CCC2=CC3=C(C4=C2[C@H]1CC5=C4C(=CC=C5)O)OCO3,,,,,,
2340,442341,Pycnamine,CN1CCC2=CC(=C3C=C2[C@H]1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)C[C@@H]6C7=C(O3)C(=C(C=C7CCN6C)OC)OC)O)OC,,,"['Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)']",,,
2341,442342,Davidigenin,C1=CC(=CC=C1CCC(=O)C2=C(C=C(C=C2)O)O)O,,,,,,
2342,442343,Levomenol,CC1=CC[C@H](CC1)[C@](C)(CCC=C(C)C)O,"['Levomenol has been known to elicit a number of potentially beneficial pharmacological effects, including anti-irritant, anti-inflammatory, and anti-microbial actions. Bisabolol is also demonstrated to enhance the percutaneous absorption of certain molecules']","['Levomenol is an anti-inflammatory and natural moisturizing agent that has been found to diminish the signs of photodamage, reduce pruritus, and ameliorate skin texture and elasticity.']",,"['The purpose of the present investigations was to study the cutaneous absorption of sesquiterpenic alcohol, the major active principle of chamomile. For these investigations 14C-labelled levomenol ((-)-6-methyl-2-(4-methyl-3-cyclohexen-1-yl)-5-hepten-2-ol; (-)-alpha-bisabolol) was prepared by biochemical incorporation of [14C]-acetate into the molecule. 5 h after topical application of the radiolabelled substance onto nude mice half of the radioactivity was found in the skin. The other part was measured in tissue and organes. 90% of this radioactivity was analysed as intact levomenol.', 'To demonstrate the distribution of the substance in the skin a part of this tissue was cutted into horizontal slices by a cryotome. From the slices autoradiograms were produced. The densitometric measuration showed that there was a fast penetration of levomenol into the skin. 5 h after the topical application the substance was displaced from outermost to innermost areas. From these results a fast cutaneous absorption and a long therapeutical effect of the antiphlogistic and spasmolytic levomenol in the skin can be expected.']",,
2343,442344,"[(1R,2R,9S)-4,11,11-trimethyl-8-methylidene-3-oxo-2-bicyclo[7.2.0]undec-4-enyl] acetate",CC1=CCCC(=C)[C@H]2CC([C@@H]2[C@H](C1=O)OC(=O)C)(C)C,,,,,,
2344,442345,Rodiasine,CN1CCC2=CC(=C3C=C2[C@H]1CC4=CC(=C(C=C4)O)C5=C(C=CC(=C5)C[C@H]6C7=C(O3)C(=C(C=C7CCN6C)OC)OC)OC)OC,,,,,,
2345,442346,Canellal,C[C@H]1CC[C@]2([C@H](C1=C)CC=C([C@@]2(C=O)O)C=O)C,,,,,,
2346,442347,Carotol,CC1=CC[C@]2(CC[C@@H]([C@]2(CC1)O)C(C)C)C,,,,,,
2347,442348,"(1S,2R,5S)-2,6,6,8-tetramethyltricyclo[5.3.1.01,5]undec-8-ene",C[C@@H]1CC[C@@H]2[C@]13CC=C(C(C3)C2(C)C)C,,,,,,
2348,442349,Centarol,CC1=CC[C@@H]2[C@H]([C@H]1O)C(CCC[C@]2(C)O)(C)C,,,,,,
2349,442350,Rugosinone,COC1=C(C(=C(C=C1)C(=O)C2=NC=CC3=CC4=C(C=C32)OCO4)O)OC,,,,,,
2350,442351,alpha-Chamigrene,CC1=CC[C@@]2(CC1)C(=CCCC2(C)C)C,,,,,,
2351,442352,Diffutin,COC1=C(C=C(C=C1)[C@@H]2CCC3=C(O2)C=C(C=C3O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)OC,,,,,,
2352,442353,(-)-beta-Chamigrene,CC1=CC[C@@]2(CC1)C(=C)CCCC2(C)C,,,,,,
2353,442354,Cinnamodial,CC(=O)O[C@@H]1C=C([C@@]([C@@]2([C@@H]1C(CCC2)(C)C)C)(C=O)O)C=O,,,,,,
2354,442355,(-)-alpha-Copaene,CC1=CCC2C3C1[C@@]2(CCC3C(C)C)C,,,,,,
2355,442356,(-)-Salsoline,C[C@H]1C2=CC(=C(C=C2CCN1)O)OC,,,"['Toxic substances from microorganisms, plants or animals that interfere with the functions of the nervous system. Most venoms contain neurotoxic substances. Myotoxins are included in this concept. (See all compounds classified as Neurotoxins.)']",,,
2356,442357,Cuauhtemone,CC(=C1C[C@@H]2[C@](CC[C@H]([C@@]2(C)O)O)(CC1=O)C)C,,,,,,
2357,442358,"7,3'-Dihydroxy-4'-methoxy-8-methylflavan",CC1=C(C=CC2=C1O[C@@H](CC2)C3=CC(=C(C=C3)OC)O)O,,,,,,
2358,442359,alpha-Cubebene,C[C@@H]1CC[C@H]([C@H]2[C@]13[C@@H]2C(=CC3)C)C(C)C,,,,,,
2359,442360,(-)-alpha-Curcumene,CC1=CC=C(C=C1)[C@H](C)CCC=C(C)C,,,,,,
2360,442361,"7,4'-Dihydroxy-8-methylflavan",CC1=C(C=CC2=C1O[C@@H](CC2)C3=CC=C(C=C3)O)O,,,,,,
2361,442362,Cycloeudesmol,C[C@H]1CCC[C@]2([C@@]13C[C@@]3(CC2)C(C)(C)O)C,,,,,,
2362,442363,Daucol,CC(C)[C@H]1CC[C@]2([C@]13CC[C@](O3)([C@H](C2)O)C)C,,,,,,
2363,442364,Debneyol,C[C@@H]1CCCC2=CC[C@H](C[C@]12C)[C@@](C)(CO)O,,,,,,
2364,442365,Dehydromyodesmone,C[C@H]1CCC(=C1C(=O)C=C(C)C)C2=COC=C2,,,,,,
2365,442366,Thalmine,CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC(=C(C=C4)OC)OC5=CC=C(C[C@H]6C7=CC(=C(C(=C7CCN6C)O3)O)OC)C=C5)OC,,,,,,
2366,442367,Dehydrongaione,CC(=CC(=O)C[C@]1(CC[C@H](O1)C2=COC=C2)C)C,,,,,,
2367,442368,"3,7,11-Trimethyldodeca-1,3,6,10-tetraene",CC(=CCCC(=CCC=C(C)C=C)C)C,,,,,,
2368,442369,Tiliacorine,CN1CCC2=CC3=C4C=C2[C@@H]1CC5=CC(=C(C=C5)O)C6=C(C=CC(=C6)C[C@H]7C8=C(O4)C(=C(C=C8CCN7C)OC)O3)OC,,,,,,
2369,442370,"10-[[(3R,4S,5S,6R)-5-methoxy-4-[(2R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl]oxy]-10-oxodeca-2,4,6,8-tetraenoic acid",CC(=CCC1[C@@](O1)(C)[C@H]2[C@@H]([C@@H](CC[C@]23CO3)OC(=O)C=CC=CC=CC=CC(=O)O)OC)C,,,,,,
2370,442371,Glutinosone,C[C@H]1[C@@H]2C[C@@H](CCC2=CC(=O)[C@@H]1O)C(=C)C,,,,,,
2371,442372,"(3S,4R,5S)-4-hydroxy-5-methoxy-4-[(2S)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-one",CC(=CCC1[C@@](O1)(C)[C@]2([C@@H](C(=O)CC[C@]23CO3)OC)O)C,,,,,,
2372,442373,Helminthosporal,CC1=C(C2C(CCC1(C2C=O)C)C(C)C)C=O,,,,,,
2373,442374,CID 442374,CC1=C(C2C(CCC1(C2CO)C)C(C)C)C=O,,,,,,
2374,442375,CID 442375,CC1=C2CC(CC[C@@]2(C[C@@H](C1)O[C@H]3[C@@H]([C@H]([C@@H](O3)[C@H](CO)O[C@H]4[C@@H]([C@H]([C@@H](O4)[C@@H](CO)O)O)O)O)O)C)C(=C)CO[C@H]5[C@@H]([C@H]([C@@H](O5)[C@@H](CO)O[C@H]6[C@@H]([C@H]([C@@H](O6)[C@@H](CO)O)O)O)O)O,,,,,,
2375,442376,Hirsutic acid C,C[C@@]1(C[C@@H]2C[C@]34[C@H](O3)[C@@H](C(=C)[C@]4([C@@H]2C1)C)O)C(=O)O,,,,,,
2376,442377,10beta-Hydroxy-6beta-isobutyrylfuranoeremophilane,C[C@H]1CCC[C@]2([C@@]1([C@@H](C3=C(C2)OC=C3C)OC(=O)C(C)C)C)O,,,,,,
2377,442378,Hydroxyisopatchoulenone,C[C@H]1CC[C@H]([C@H](C2=C(C(=O)C[C@H]12)C)O)C(=C)C,,,,,,
2378,442379,Ipomoeamarone,CC(C)CC(=O)C[C@@]1(CC[C@@H](O1)C2=COC=C2)C,,,,,,
2379,442380,"4-[(1S,5R)-2,5,6,6-tetramethylcyclohex-2-en-1-yl]but-3-en-2-one",C[C@@H]1CC=C([C@@H](C1(C)C)C=CC(=O)C)C,,,,,,
2380,442381,Juvabione,C[C@H](CC(=O)CC(C)C)[C@@H]1CCC(=CC1)C(=O)OC,,,,,,
2381,442382,"[(3R,3aS,4S,6R,8S,8aS)-3,6-dihydroxy-6,8a-dimethyl-8-(2-methylbut-2-enoyloxy)-7-oxo-3-propan-2-yl-1,2,3a,4,5,8-hexahydroazulen-4-yl] 2-methylbut-2-enoate",CC=C(C)C(=O)O[C@H]1C[C@@](C(=O)[C@H]([C@@]2([C@@H]1[C@@](CC2)(C(C)C)O)C)OC(=O)C(=CC)C)(C)O,,,,,,
2382,442383,Lubimin,C[C@@H]1C[C@@H](C[C@@H]([C@]12CC[C@H](C2)C(=C)C)C=O)O,,,,,,
2383,442384,"(6S,8S)-2,2,6,8-tetramethyltricyclo[5.3.1.03,8]undecan-3-ol",C[C@H]1CCC2([C@@]3(C1CC(C2(C)C)CC3)C)O,,,,,,
2384,442385,"[(1R,2R,7S,8aR)-1,8a-dimethyl-6-oxo-7-prop-1-en-2-yl-1,2,3,4,7,8-hexahydronaphthalen-2-yl] 2-methylbut-2-enoate",CC=C(C)C(=O)O[C@@H]1CCC2=CC(=O)[C@@H](C[C@@]2([C@H]1C)C)C(=C)C,,,,,,
2385,442386,CID 442386,CC(=CC(=O)O)C=C[C@@]1([C@@]2(CC(=O)C[C@]1(OC2)C)C)O,,,,,,
2386,442387,Phytuberin,CC(=O)OC(C)(C)[C@@H]1CC[C@]2(CO[C@]3([C@]2(C1)OC=C3)C)C,,,,,,
2387,442388,Pinguisone,C[C@@H]1CC(=O)[C@@]2([C@]1(CC3=C([C@H]2C)C=CO3)C)C,,,,,,
2388,442389,"[4-Acetyloxy-3-(acetyloxymethylidene)-7,11-dimethyldodeca-1,6,8,10-tetraenyl] acetate",CC(=CC=CC(=CCC(C(=COC(=O)C)C=COC(=O)C)OC(=O)C)C)C,,,,,,
2389,442390,"(1R,3R,8R,12S,13R,17R,24R,25S,26R)-12-hydroxy-17-[(1R)-1-hydroxyethyl]-5,13,25-trimethylspiro[2,10,16,23-tetraoxatetracyclo[22.2.1.03,8.08,25]heptacosa-4,18,20-triene-26,2'-oxirane]-11,22-dione",C[C@@H]1CCO[C@H](C=CC=CC(=O)O[C@@H]2C[C@@H]3[C@@]4([C@]2([C@]5(CCC(=C[C@H]5O3)C)COC(=O)[C@H]1O)C)CO4)[C@@H](C)O,,,,,,
2390,442391,Rugosal,CC(C)[C@H]1CC[C@]2([C@@]13[C@H](C=C([C@H](C2)OO3)C=O)O)C,,,,,,
2391,442392,Sclerosporin,CC1=C[C@H]2[C@@H](CC1)C(=CC[C@@H]2C(C)C)C(=O)O,,,,,,
2392,442393,beta-Selinene,CC(=C)[C@@H]1CC[C@]2(CCCC(=C)[C@@H]2C1)C,,,,,,
2393,442394,CID 442394,CC1=CCC[C@@]2([C@@H](O2)[C@@H]([C@@H]([C@H](C1)OC(=O)C)C(C)C)OC(=O)C)C,,,,,,
2394,442395,CID 442395,CC(=CCC[C@@]1([C@@H]2[C@H]1C=C(CC2)CO)C)CO,,,,,,
2395,442396,"(S)-2,3-Dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-6,8-dimethyl-4-benzopyrone",CC1=C(C(=C2C(=C1O)C(=O)C[C@H](O2)C3=CC=C(C=C3)O)C)O,,,,,,
2396,442397,Fisetinidol,C1[C@@H]([C@H](OC2=C1C=CC(=C2)O)C3=CC(=C(C=C3)O)O)O,,,,,,
2397,442398,Fisetinidol-4beta-ol,C1=CC(=C(C=C1[C@@H]2[C@H]([C@H](C3=C(O2)C=C(C=C3)O)O)O)O)O,,,,,,
2398,442399,Solavetivone,C[C@@H]1CC(=O)C=C([C@]12CC[C@H](C2)C(=C)C)C,,,,,,
2399,442400,T-2 Toxin,CC1=C[C@@H]2[C@](C[C@@H]1OC(=O)CC(C)C)([C@]3([C@@H]([C@H]([C@H]([C@]34CO4)O2)O)OC(=O)C)C)COC(=O)C,,,,"['T2-Trichothecene is readily absorbed through skin & the gut in pigs & rats.', 'T-2 toxin is transmitted in the milk in lactating cattle & pigs.', 'Estimated that the  eggs from chickens treated orally with 1 mg T-2 toxin/kg body weight daily for 8 consecutive days, which is equivalent to 1.6 mg/kg dietary T-2, contain  0.9 ug of this material.', 'The radioactivity of orally admin (3)H-T2-trichothecene (1 mg/kg body wt) to mice & rats was recovered in feces (55%) & urine (15%) within 72 hr. It was distributed in the liver, kidneys & other organs, without specific accumulation.', '(3)H-T-2 Toxin given orally to mice and rats was distributed rapidly to tissues and eliminated in feces and urine. Maximal levels of radiolabel were found after 30 min in plasma of mice after oral administration ... and of guinea pigs after intramuscular injection ... . In chicks administered (3)H-T-2 toxin in the diet, maximal levels were reached by 4 hr in blood, plasma, abdominal fat, heart, kidneys, gizzard, liver and the remainder of the carcass and by 12 hr in muscle, skin, bile and gall bladder ... . The distribution of T-2 toxin in tissues of swine was similar to that in chickens ... .']","[""Two major metabolites were obtained from the urine of a lactating cow given 180 mg of T-2 toxin orally. They were 3'-hydroxy-HT 2 toxin & 3'-hydroxy T 2 toxin."", 'Human liver enzymes deacetylate T2-trichothecene to HT2-trichothecene in vitro.', 'The radioactivity of orally admin (3)H-T2-trichothecene (1 mg/kg body wt) to mice & rats was recovered in feces (55%) & urine (15%) within 72 hr. ... Analysis of the radioactivity recovered in feces of rats revealed that 2.7% of the dose was excreted as unchanged T2-trichothecene & 7.5% as 4-O-deacetylated T2-trichothecene (HT2-trichothecene)...the remaining fecal excretion products were not identified. In urine, HT2-trichothecene, representing 1.4% of the total dose & 8-hydroxydiacetoxyscirpenol (1.8%) were identified; 3 unidentified metabolites...were also isolated. The epoxide moeity...seems to be essential for its toxicological activity; the liver detoxifies T2-trichothecene, probably through epoxide hydrolase. In vitro, rat liver homogenate metabolizes T2-trichothecene to HT2-trichothecene, T2-trichothecene tetraol, 4-deacetylneosolaniol...& neosolaniol... The same metabolites were obtained from HT2-trichothecene, indicating that T2-trichothecene was preferentially hydrolyzed at the C-4 position to give NT2-trichothecene.', 'Trichothecenes are sesquiterpenoid toxins produced by Fusarium species. Since these mycotoxins are very stable, there is interest in microbial transformations that can remove toxins from contaminated grain or cereal products. Twenty-three yeast species assigned to the Trichomonascus clade (Saccharomycotina, Ascomycota), including four Trichomonascus species and 19 anamorphic species presently classified in Blastobotrys, were tested for their ability to convert the trichothecene T-2 toxin to less-toxic products. These species gave three types of biotransformations: acetylation to 3-acetyl T-2 toxin, glycosylation to T-2 toxin 3-glucoside, and removal of the isovaleryl group to form neosolaniol. Some species gave more than one type of biotransformation. Three Blastobotrys species converted T-2 toxin into T-2 toxin 3-glucoside, a compound that has been identified as a masked mycotoxin in Fusarium-infected grain. This is the first report of a microbial whole-cell method for producing trichothecene glycosides, and the potential large-scale availability of T-2 toxin 3-glucoside will facilitate toxicity testing and development of methods for detection of this compound in agricultural and other products.', 'For more Metabolism/Metabolites (Complete) data for T-2 TOXIN (6 total), please visit the HSDB record page.']","['The plasma half-life for T-2 toxin is less than 20 minutes.', ""T-2 toxin was converted to 3'-hydroxy-HT 2 when incubated with 9000 g supernatants of human or bovine liver homogenates for 75 min at 37 °C. The metabolism of T-2 toxin was more rapid in human (20 min half-life) than in bovine (40 min half-life). The metabolite was as toxic & produced emesis almost as rapidly as T-2 toxin.""]"
2400,442401,Tetradymol,C[C@H]1CCC[C@]2([C@@]1(CC3=C(C2)OC=C3C)C)O,,,,,,
2401,442402,Thujopsene,CC1=CC[C@@]2(CCCC([C@]23[C@H]1C3)(C)C)C,,,,,,
2402,442403,"12,13-Epoxytrichothec-9-en-4-ol acetate",CC1=C[C@@H]2[C@](CC1)([C@]3([C@@H](C[C@H]([C@]34CO4)O2)OC(=O)C)C)C,,,,,,
2403,442404,CID 442404,CC=CC(=O)O[C@@H]1C[C@@H]2[C@@]3([C@]1([C@]4(CC(=O)C(=C[C@H]4O2)C)C)C)CO3,,,,,,
2404,442405,alpha-Vetivone,C[C@@H]1CC(=O)C=C2[C@]1(CC(=C(C)C)CC2)C,,,,,,
2405,442406,beta-Vetivone,C[C@@H]1CC(=O)C=C([C@@]12CCC(=C(C)C)C2)C,,,,,,
2406,442407,CID 442407,C[C@@H]1CCOC(=O)C=CC=CC(=O)O[C@@H]2C[C@@H]3[C@@]4([C@]2([C@]5(CCC(=C[C@H]5O3)C)COC(=O)[C@H]1O)C)CO4,,,,,,
2407,442408,CID 442408,CC1=C[C@@H]2[C@]([C@@H](C1=O)O)([C@]3(C[C@H]([C@H]([C@]34CO4)O2)O)C)CO,,,,,,
2408,442409,CID 442409,CC1=CCC2C3C1[C@]2(CCC3C(C)C)C,,,,,,
2409,442410,Garbanzol,C1=CC(=CC=C1[C@@H]2[C@H](C(=O)C3=C(O2)C=C(C=C3)O)O)O,,,,,,
2410,442411,Glepidotin B,CC(=CCC1=C2C(=C(C=C1O)O)C(=O)[C@@H]([C@H](O2)C3=CC=CC=C3)O)C,,,,,,
2411,442412,Glycyphyllin,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=CC(=CC(=C2C(=O)CCC3=CC=C(C=C3)O)O)O)O)O)O,,,,,,
2412,442413,7-Hydroxyflavan,C1CC2=C(C=C(C=C2)O)O[C@@H]1C3=CC=CC=C3,,,,,,
2413,442414,Kazinol A,CC(=CCC1=CC(=C(C(=C1O)O)CC=C(C)C)[C@@H]2CCC3=C(O2)C=C(C=C3)O)C,,,,,,
2414,442415,6-Methoxyaromadendrin 3-O-acetate,CC(=O)O[C@@H]1[C@H](OC2=C(C1=O)C(=C(C(=C2)O)OC)O)C3=CC=C(C=C3)O,,,,,,
2415,442416,Agnuside,C1=CO[C@H]([C@H]2[C@@H]1[C@@H](C=C2COC(=O)C3=CC=C(C=C3)O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O,,,,,,
2416,442417,CID 442417,CC=C1[C@H]2[C@@]3(C=C[C@H]4[C@@H]3[C@@H](O2)O[C@@H]([C@H]4C(=O)OC)O)OC1=O,,,,,,
2417,442418,Antirrhinoside,C[C@@]12[C@H]3[C@@H](OC=C[C@]3([C@@H]([C@@H]1O2)O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O,,,,,,
2418,442419,6-Methoxytaxifolin,COC1=C(C2=C(C=C1O)O[C@@H]([C@H](C2=O)O)C3=CC(=C(C=C3)O)O)O,,,,,,
2419,442420,Boschnialactone,C[C@@H]1CC[C@H]2[C@@H]1COC(=O)C2,,,,,,
2420,442421,O-Methylodoratol,COC1=CC=C(C=C1)CC(C(=O)C2=C(C=C(C=C2)OC)OC)O,,,,,,
2421,442422,Dolichodial,C[C@H]1CC[C@@H]([C@@H]1C=O)C(=C)C=O,,,,,,
2422,442423,Gardenoside,COC(=O)C1=CO[C@H]([C@H]2[C@@H]1C=C[C@]2(CO)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
2423,442424,Genipin,COC(=O)C1=CO[C@H]([C@H]2[C@@H]1CC=C2CO)O,,,['Gastrointestinal agents that stimulate the flow of bile into the duodenum (cholagogues) or stimulate the production of bile by the liver (choleretic). (See all compounds classified as Cholagogues and Choleretics.)'],,,
2424,442425,Ipolamiide,C[C@@]1(CC[C@]2([C@@H]1[C@@H](OC=C2C(=O)OC)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O,,,,,,
2425,442426,(+)-Iridodial,C[C@H]1CC[C@@H]([C@@H]1C=O)[C@@H](C)C=O,,,,,,
2426,442427,Iridomyrmecin,C[C@H]1CC[C@H]2[C@@H]1COC(=O)[C@H]2C,,,,,,
2427,442428,Naringin,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=CC(=C4C(=O)C[C@H](OC4=C3)C5=CC=C(C=C5)O)O)CO)O)O)O)O)O,,,,,,
2428,442429,(+)-Neomatatabiol,C[C@H]1CC[C@H]2[C@@H]1[C@H](OC[C@H]2C)O,,,,,,
2429,442430,Nepetalactone trans-cis-form,C[C@H]1CC[C@H]2[C@H]1C(=O)OC=C2C,,,,,,
2430,442431,Narirutin,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=CC(=C4C(=O)C[C@H](OC4=C3)C5=CC=C(C=C5)O)O)O)O)O)O)O)O,,,,,,
2431,442432,Paederoside,CSC(=O)OCC1=C[C@H]2[C@H]3[C@@H]1[C@@H](OC=C3C(=O)O2)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O,,,,,,
2432,442433,Scandoside methyl ester,COC(=O)C1=CO[C@H]([C@H]2[C@@H]1[C@@H](C=C2CO)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
2433,442434,"[(1S,2S,4S,5R,6S,8S,10R)-8,10-diethoxy-6-hydroxy-2-(hydroxymethyl)-3,9-dioxatricyclo[4.4.0.02,4]decan-5-yl] 4-hydroxybenzoate",CCO[C@@H]1C[C@@]2([C@H]([C@@H](O1)OCC)[C@@]3([C@H]([C@H]2OC(=O)C4=CC=C(C=C4)O)O3)CO)O,,,,,,
2434,442435,Swertiamarin,C=C[C@H]1[C@@H](OC=C2[C@]1(CCOC2=O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
2435,442436,Valtrate,CC(C)CC(=O)O[C@H]1C=C2[C@@H]([C@@]13CO3)[C@@H](OC=C2COC(=O)C)OC(=O)CC(C)C,,,,,,
2436,442437,Neoastilbin,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2[C@@H](OC3=CC(=CC(=C3C2=O)O)O)C4=CC(=C(C=C4)O)O)O)O)O,,,,,,
2437,442438,(+)-Iridodial lactol,C[C@H]1CC[C@H]2[C@@H]1[C@@H](OC=C2C)O,,,,,,
2438,442439,"(S)-7-(((2-O-6-Deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl)oxy)-2,3-dihydro-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one",C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=CC(=C4C(=O)C[C@H](OC4=C3)C5=CC(=C(C=C5)OC)O)O)CO)O)O)O)O)O,,,,,,
2439,442440,2-Hydroxy-1-(2-hydroxy-4-methoxyphenyl)-3-(4-methoxyphenyl)propan-1-one,COC1=CC=C(C=C1)CC(C(=O)C2=C(C=C(C=C2)OC)O)O,,,,,,
2440,442441,"Cyclohex-2,5-dienecarbonyl-CoA; (Acyl-CoA); [M+H]+",CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)C4C=CCC=C4)O,,,,,,
2441,442442,c0214; (Acyl-CoA); [M+H]+,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)C4=CCC=CC4)O,,,,,,
2442,442443,Cyclohex-1-ene-1-carboxyl-CoA; (Acyl-CoA); [M+H]+,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)C4=CCCCC4)O,,,,,,
2443,442444,2-Hydroxycyclohexane-1-carboxyl-CoA; (Acyl-CoA); [M+H]+,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)C4CCCCC4O)O,,,,,,
2444,442445,2-oxocyclohexanecarbonyl-CoA; (Acyl-CoA); [M+H]+,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)C4CCCCC4=O)O,,,,,,
2445,442446,CID 442446,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)[C@@H](CC4=CC=CC=C4)CC(=O)O)O,,,,,,
2446,442447,"3-[2-[3-[[4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethylsulfanylcarbonyl]-4-phenylbut-3-enoic acid",CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)C(=CC4=CC=CC=C4)CC(=O)O)O,,,,,,
2447,442448,(Hydroxymethylphenyl)succinyl-CoA,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)[C@H](CC(=O)O)[C@H](C4=CC=CC=C4)O)O,,,,,,
2448,442449,Benzoylsuccinyl-CoA; (Acyl-CoA); [M+H]+,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)[C@H](CC(=O)O)C(=O)C4=CC=CC=C4)O,,,,,,
2449,442450,6-oxocyclohex-1-ene-1-carboxyl-CoA,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)C4=CCCCC4=O)O,,,,,,
2450,442451,CHC-CoA,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)C4CCCCC4)O,,,,,,
2451,442452,"2,6-Dihydroxycyclohexane-1-carboxyl-CoA",CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)C4C(CCCC4O)O)O,,,,,,
2452,442453,c0232; (Acyl-CoA); [M+H]+,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)C4C(CCCC4=O)O)O,,,,,,
2453,442454,Pinocembrin 7-rhamnosylglucoside,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=CC(=C4C(=O)C[C@H](OC4=C3)C5=CC=CC=C5)O)CO)O)O)O)O)O,,,,,,
2454,442455,Piperaduncin B,CC(C)([C@@H]1[C@H](C2=C(C=C(C(=C2O1)C(=O)CCC3=CC=CC=C3)O)OC)C4=C(C=CC(=C4)C(=O)OC)O)O,,,,,,
2455,442456,Poncirin,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=CC(=C4C(=O)C[C@H](OC4=C3)C5=CC=C(C=C5)OC)O)CO)O)O)O)O)O,,,,,,
2456,442457,5'-Prenylhomoeriodictyol,CC(=CCC1=C(C(=CC(=C1)[C@@H]2CC(=O)C3=C(C=C(C=C3O2)O)O)OC)O)C,,,,,,
2457,442458,Sanggenone C,CC1=C[C@@H]([C@@H]([C@H](C1)C2=C(C=C(C=C2)O)O)C(=O)C3=C(C=C(C=C3)O)O)C4=C(C5=C(C=C4O)OC6(C7=C(C=C(C=C7)O)OC6(C5=O)O)CC=C(C)C)O,,,,,,
2458,442459,"2-[(1R,5S,6R)-6-(2,4-dihydroxybenzoyl)-5-(2,4-dihydroxyphenyl)-3-methylcyclohex-2-en-1-yl]-1,3,8,10a-tetrahydroxy-5a-(3-methylbut-2-enyl)-[1]benzofuro[3,2-b]chromen-11-one",CC1=C[C@H]([C@@H]([C@H](C1)C2=C(C=C(C=C2)O)O)C(=O)C3=C(C=C(C=C3)O)O)C4=C(C5=C(C=C4O)OC6(C7=C(C=C(C=C7)O)OC6(C5=O)O)CC=C(C)C)O,,,,,,
2459,442460,"(1S,2R,4S)-(-)-Bornyl acetate",CC(=O)O[C@@H]1CC2CCC1(C2(C)C)C,,,,"['The percutaneous absorptions of camphene, isoborneol-acetate, limonene, menthol and alpha-pinene as constituents of a foam bath (Pinimenthol) were measured on animals using radioactively labelled ingredients. Pharmacokinetic measurements showed maximum blood levels for all tested ingredients 10 min after the onset of percutaneous absorption. None of the ingredients was preferentially absorbed. Blood levels of all ingredients after 10 min of percutaneous absorption were a direct function of the size of the skin area involved.']",['Isobornyl acetate readily hydrolyzes (within hours) to isobornyl alcohol during the first step of its biochemical pathway. The alcohol will become conjugated with glucoronic acid and be excreted in the urine (expected within hours to days).'],
2460,442461,(-)-3-Carene,CC1=CC[C@H]2[C@@H](C1)C2(C)C,,,,,,
2461,442462,"7-Oxabicyclo[4.1.0]heptan-2-one, 1-methyl-4-(1-methylethenyl)-, (1R,4R,6R)-",CC(=C)[C@@H]1C[C@@H]2[C@@](O2)(C(=O)C1)C,,,,,,
2462,442463,Chrysanthenone,CC1=CCC2C(=O)C1C2(C)C,,,,,,
2463,442464,"[(1S)-3-but-2-enyl-2-methyl-4-oxocyclopent-2-en-1-yl] (1R,3R)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropane-1-carboxylate",CC=CCC1=C([C@H](CC1=O)OC(=O)[C@@H]2[C@H](C2(C)C)C=C(C)C)C,,,,,,
2464,442465,CID 442465,CC=CCC1=C([C@H](CC1=O)OC(=O)[C@@H]2[C@H](C2(C)C)C=C(C)C(=O)OC)C,,,,,,
2465,442466,"(1S,10S,11R,13R,15R)-11-hydroxy-15-methyl-6-azatetracyclo[8.6.0.01,6.02,13]hexadec-2-en-14-one",C[C@@H]1C[C@@]23[C@@H]4CCCN2CCC=C3[C@H](C1=O)C[C@H]4O,,,,,,
2466,442467,"(1R,2R,10S,11R,13R,15R)-11-hydroxy-15-methyl-6-azatetracyclo[8.6.0.01,6.02,13]hexadecan-14-one",C[C@@H]1C[C@]23[C@@H]4CCCN2CCC[C@@H]3[C@@H](C[C@H]4C1=O)O,,,,,,
2467,442468,Annotine,CC12C[C@@]34[C@@H]5CCCN3CC=C[C@@]4([C@@H]1C[C@H]5OC2=O)O,,,,,,
2468,442469,"1,2-Dihydroxymint lactone",CC1=C2CC[C@@]([C@H]([C@@H]2OC1=O)O)(C)O,,,,,,
2469,442470,Carolinianine,CC1=C[C@@H]2[C@@H](CC[C@H]3N2[C@H](C1)C[C@H]4N3C(=O)CCC4)O,,,,,,
2470,442471,Evodone,C[C@H]1CC2=C(C(=CO2)C)C(=O)C1,,,,,,
2471,442472,Cernuine,C[C@H]1C[C@@H]2CCC[C@H]3N2[C@H](C1)C[C@H]4N3C(=O)CCC4,,,,,,
2472,442473,Fawcettidine,C[C@@H]1C[C@H]2CC(=O)[C@@H]3[C@]24CCCN(C4=C1)CCC3,,,,,,
2473,442474,(R)-Linalyl acetate,CC(=CCC[C@](C)(C=C)OC(=O)C)C,,,,,,
2474,442475,Fawcettimine,C[C@@H]1C[C@H]2CC(=O)[C@@H]3[C@]24CCCN([C@@]4(C1)O)CCC3,,,,,,
2475,442476,"1-[(1R,9R,10R,16R)-16-methyl-6,14-diazatetracyclo[7.5.3.01,10.02,7]heptadec-2(7)-en-6-yl]ethanone",C[C@@H]1C[C@@H]2CC3=C(CCCN3C(=O)C)[C@@]4(C1)[C@@H]2CCCN4,,,,,,
2476,442477,Inundatine,C[C@@H]1C[C@H]2CC(=O)[C@@]34C[C@H](CN5[C@]3(C1)[C@@H]2CC4C5)O,,,,,,
2477,442478,(+)-Menthofuran,C[C@@H]1CCC2=C(C1)OC=C2C,,,,,,
2478,442479,"1-[(4As,5R,7S,8aR)-5-[[(1S,5S,9S,11R,13S,17R)-11,14-dimethyl-6,14-diazatetracyclo[7.6.2.02,7.013,17]heptadec-6-en-5-yl]methyl]-7-methyl-3,4,4a,5,6,7,8,8a-octahydro-2H-quinolin-1-yl]ethanone",C[C@@H]1C[C@H]2CC3=N[C@@H](CCC3[C@@H]4C[C@H]2[C@H](C1)N(C4)C)C[C@H]5C[C@@H](C[C@@H]6[C@H]5CCCN6C(=O)C)C,,,,,,
2479,442480,Luciduline,C[C@@H]1C[C@H]2CC(=O)[C@@H]3C[C@H]2[C@H](C1)N(C3)C,,,,,,
2480,442481,Lycocernuine,C[C@@H]1C[C@@H]2C[C@@H]3CCCC(=O)N3[C@@H]4N2[C@H](C1)[C@@H](CC4)O,,,,,,
2481,442482,(R)-(-)-alpha-Phellandrene,CC1=CC[C@@H](C=C1)C(C)C,,,,,,
2482,442483,"(1R,9R,10R,16R)-16-methyl-6,14-diazatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene",C[C@@H]1C[C@@H]2CC3=C(C=CC=N3)[C@@]4(C1)[C@@H]2CCCN4,,,,,,
2483,442484,(+)-beta-Phellandrene,CC(C)[C@@H]1CCC(=C)C=C1,,,,,,
2484,442485,"[(1S,2S,10S,11R,13S,14R,15S)-2,14-Dihydroxy-15-methyl-6-azatetracyclo[8.6.0.01,6.02,13]hexadecan-11-yl] acetate",C[C@H]1C[C@@]23[C@@H]4CCCN2CCC[C@@]3([C@H]([C@@H]1O)C[C@H]4OC(=O)C)O,,,,,,
2485,442486,Lycoflexine,C[C@@H]1C[C@H]2CC(=O)[C@@]34[C@@]2(CCCN(C3)CCC4)C(=O)C1,,,,,,
2486,442487,Lyconnotine,CC(C[C@@]12[C@@H]3CCCN1CC=CC2=CC[C@H]3O)C(=O)OC,,,,,,
2487,442488,"(1R,2R,10S,13R,15R)-15-methyl-6-azatetracyclo[8.6.0.01,6.02,13]hexadecan-11-one",C[C@@H]1C[C@@H]2CC(=O)[C@H]3CCCN4[C@]3(C1)[C@@H]2CCC4,,,,,,
2488,442489,Magellanine,CC1=CC(=O)[C@]23C[C@@H]4CN(CC[C@@H]4[C@H]2[C@H](C[C@@H]3C1)O)C,,,,,,
2489,442490,Megastachine,C[C@@H]1C[C@H]2[C@H]3[C@@H]([C@@H]4[C@]25CCCN(C5=C1)CCC4)[C@@H](C(=O)O3)[C@@H](C)O,,,,,,
2490,442491,"(1R,9R,10R,16R)-14,16-Dimethyl-6,14-diazatetracyclo[7.5.3.01,10.02,7]heptadec-2(7)-en-5-one",C[C@@H]1C[C@@H]2CC3=C(CCC(=O)N3)[C@@]4(C1)[C@@H]2CCCN4C,,,,,,
2491,442492,"(1R,9R,10R,16R)-14,16-dimethyl-6,14-diazatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3-dien-5-one",C[C@@H]1C[C@@H]2CC3=C(C=CC(=O)N3)[C@@]4(C1)[C@@H]2CCCN4C,,,,,,
2492,442493,Oxolucidine B,C[C@@H]1C[C@H]2CC3=N[C@@H](CC[C@@]3([C@@H]4C[C@H]2[C@H](C1)N(C4)C)O)C[C@H]5C[C@@H](C[C@@H]6[C@H]5CCCN6C(=O)C)C,,,,,,
2493,442494,Phlegmarine,C[C@@H]1C[C@H]([C@H]2CCCN[C@@H]2C1)C[C@@H]3CCCCN3,,,,,,
2494,442495,Pulegone,C[C@@H]1CCC(=C(C)C)C(=O)C1,,,,,"['(R)-(+)-Pulegone, a monoterpene ketone, is a major component of pennyroyal oil. Ingestion of high doses of pennyroyal oil has caused severe toxicity and occasionally death. Studies have shown that metabolites of pulegone were responsible for the toxicity. Previous metabolism studies have used high, near lethal doses and isolation and analysis techniques that may cause degradation of some metabolites. To clarify these issues and further explore the metabolic pathways, a study of (14)C-labeled pulegone in F344 rats at doses from 0.8 to 80 mg/kg has been conducted. High-pressure liquid chromatography (HPLC) analysis of the collected urine showed the metabolism of pulegone to be extensive and complex. Fourteen metabolites were isolated by HPLC and characterized by NMR, UV, and mass spectroscopy. The results demonstrated that pulegone was metabolized by three major pathways: 1) hydroxylation to give monohydroxylated pulegones, followed by glucuronidation or further metabolism; 2) reduction of the carbon-carbon double bond to give diastereomeric menthone/isomenthone, followed by hydroxylation and glucuronidation; and 3) Michael addition of glutathione to pulegone, followed by further metabolism to give diastereomeric 8-(N-acetylcystein-S-yl)menthone/isomenthone. This 1,4-addition not only took place in vivo but also in vitro under catalysis of glutathione S-transferase or mild base. Several hydroxylated products of the two mercapturic acids were also observed. Contrary to the previous study, all but one of the major metabolites characterized in the present study are phase II metabolites, and most of the metabolites in free forms are structurally different from those previously identified phase I metabolites.', 'Pulegone, a monoterpene that protects source plants against predators, is a hepatotoxic constituent of the folklore abortifacient pennyroyal oil. In the rat, pulegone extensively depleted glutathione measured in both liver tissue and plasma, and its toxicity was markedly enhanced in animals treated with buthionine sulfoximine. The glutathione-depleting effect of pulegone was compromised following inhibition of cytochrome P-450 by piperonyl butoxide. In addition, /the authors/ found no evidence for conjugation of glutathione to unchanged pulegone in vitro. Administration of menthofuran, a known oxidative and hepatotoxic metabolite of pulegone, only marginally affected glutathione levels in plasma and liver, and toxicity was not augmented by buthionine sulfoximine. These results provide indirect evidence for cytochrome P-450-catalyzed bioactivation of pulegone via at least two independent pathways: 1) the formation and subsequent activation of menthofuran from pulegone; and 2) the formation of reactive intermediate(s) from pulegone, but not menthofuran, which can be detoxified through a mechanism requiring reduced glutathione.', '(R)-(+)-Pulegone, a monoterpene constituent of pennyroyal oil, is a hepatotoxin that has been used in folklore medicine as an abortifacient despite its potential lethal effects. Pulegone is metabolized by human liver cytochrome P-450s to menthofuran, a proximate hepatotoxic metabolite of pulegone. Expressed human liver cytochrome (CYP) P-450s (1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4) were tested for their ability to catalyze the oxidations of pulegone and menthofuran. Expressed CYP2E1, CYP1A2, and CYP2C19 oxidized pulegone to menthofuran, with respective Km and Vmax values of 29 uM and 8.4 nmol/min/nmol P-450 for CYP2E1, 94 uM and 2.4 nmol/min/nmol P-450 for CYP1A2, and 31 uM and 1.5 nmol/min/nmol P-450 for CYP2C19. The human liver P-450s involved in the metabolism of menthofuran are the same as pulegone except for the addition of CYP2A6. These P-450s were found to oxidize menthofuran to a newly identified metabolite, 2-hydroxymenthofuran, which is an intermediate in the formation of the known metabolites mintlactone and isomintlactone. Based on studies with (18)O2 and H2(18)O, 2-hydroxymenthofuran arises predominantly from a dihydrodiol formed from a furan epoxide. CYP2E1, CYP1A2, and CYP2C19 oxidized menthofuran with respective Km and Vmax values of 33 uM and 0.43 nmol/min/nmol P-450 for CYP2E1, 57 uM and 0.29 nmol/min/nmol P-450 for CYP1A2, and 62 uM and 0.26 nmol/min/nmol P-450 for CYP2C19.', 'The major in vivo metabolites of (S)-(-)-pulegone in humans using a metabolism of ingestion-correlated amounts (MICA) experiment were newly identified as 2-(2-hydroxy-1-methylethyl)-5-methylcyclohexanone (8-hydroxymenthone, M1), 3-hydroxy-3-methyl-6-(1-methylethyl)cyclohexanone (1-hydroxymenthone, M2), 3-methyl-6-(1-methylethyl)cyclohexanol (menthol), and E-2-(2-hydroxy-1-methylethylidene)-5-methylcyclohexanone (10-hydroxypulegone, M4) on the basis of mass spectrometric analysis in combination with syntheses and NMR experiments. Minor metabolites were be identified as 3-methyl-6-(1-methylethyl)-2-cyclohexenone (piperitone, M5) and alpha,alpha,4-trimethyl-1-cyclohexene-1-methanol (3-p-menthen-8-ol, M6). Menthofuran was not a major metabolite of pulegone and is most probably an artifact formed during workup from known (M4) and/or unknown precursors. The differences in toxicity between (S)-(-)- and (R)-(+)-pulegone can be explained by the strongly diminished ability for enzymatic reduction of the double bond in (R)-(+)-pulegone. This might lead to further oxidative metabolism of 10-hydroxypulegone (M4) and the formation of further currently undetected metabolites that might account for the observed hepatotoxic and pneumotoxic activity in humans.', 'For more Metabolism/Metabolites (Complete) data for Pulegone (25 total), please visit the HSDB record page.']",
2495,442496,Sauroxine,C[C@@H]1C[C@@H]2CC3=C(CCC(=O)N3)[C@@]4(C1)[C@H]2CCCN4C,,,,,,
2496,442497,Rotundifolone,CC(=C1CC[C@]2([C@@H](C1=O)O2)C)C,,,,,,
2497,442498,"(1R,9S,13Z)-1-Amino-13-ethylidene-11-methyl-6-azatricyclo[7.3.1.02,7]trideca-2(7),3,11-trien-5-one",CC=C1[C@H]2CC(=C[C@@]1(C3=C(C2)NC(=O)C=C3)N)C,,,,,,
2498,442499,Serratanidine,C[C@]1(C[C@@H]([C@]23CCCN4[C@@]2(CCC4)C(=O)C[C@@H]3[C@H]1O)O)O,,,,,,
2499,442500,Serratine,C[C@@]1(C[C@H]2CC(=O)[C@@]34[C@@]2(CCCN3CCC4)[C@H](C1)O)O,,,,,,
2500,442501,(+)-alpha-Terpineol,CC1=CC[C@@H](CC1)C(C)(C)O,,,,,,
2501,442502,Spirolucidine,C[C@@H]1C[C@H]2C[C@]3([C@@H]4C[C@H]2[C@H](C1)N(C4)C)C(=O)CC[C@@H](N3)C[C@H]5C[C@@H](C[C@H]6[C@@H]5CCCN6C(=O)C)C,,,,,,
2502,442503,Acanthicifoline,CC1C2=CN=CC(=C2CC(=O)N1)OC,,,,,,
2503,442504,(-)-Umbellulone,CC1=CC(=O)[C@@]2([C@H]1C2)C(C)C,,,,,,
2504,442505,"(4S,4aS)-1-amino-7-ethenyl-4,7-dimethyl-4,4a,5,6-tetrahydropyrrolo[1,2-c]pyrimidin-3-one",C[C@H]1[C@@H]2CCC(N2C(=NC1=O)N)(C)C=C,,,,,,
2505,442506,Bakankoside,C=C[C@@H]1[C@@H]2CCNC(=O)C2=CO[C@H]1O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
2506,442507,Boschniakine,C[C@@H]1CCC2=C1C=NC=C2C=O,,,,,,
2507,442508,Aucuparin,COC1=CC(=CC(=C1O)OC)C2=CC=CC=C2,,,,,,
2508,442509,3-Butylidene-7-hydroxy-2-benzofuran-1-one,CCCC=C1C2=C(C(=CC=C2)O)C(=O)O1,,,,,,
2509,442510,Cleomiscosin A,COC1=C(C=CC(=C1)[C@@H]2[C@H](OC3=C4C(=CC(=C3O2)OC)C=CC(=O)O4)CO)O,,,,,,
2510,442511,Euglobal-Ia1,CC(C)C[C@@H]1[C@H]2CC(C=C[C@]2(OC3=C(C(=C(C(=C13)O)C=O)O)C=O)C)C(C)C,,,,,,
2511,442512,Flossonol,C[C@@H]1C[C@@H](C2=C(C1=O)C=C(C(=C2)OC)C)O,,,,,,
2512,442513,Altholactone,C1=CC=C(C=C1)[C@@H]2[C@H]([C@H]3[C@@H](O2)C=CC(=O)O3)O,,,,,,
2513,442514,Hematoxylin,C1C2=CC(=C(C=C2[C@H]3[C@@]1(COC4=C3C=CC(=C4O)O)O)O)O,,,['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)'],,,
2514,442515,Cantleyine,C[C@H]1[C@H](CC2=C(C=NC=C12)C(=O)OC)O,,,,,,
2515,442516,Cassinine,CC[C@@H]1CCC(=O)O[C@@H]2[C@H]([C@@]34[C@@H]([C@@H]([C@H]([C@H]([C@@]3([C@H]([C@H]2OC(=O)C)OC(=O)C)COC(=O)C)OC(=O)C)OC(=O)C)[C@@](O4)(COC(=O)C5=C1N=CC=C5)C)OC(=O)C6=CC=CC=C6)C,,,,,,
2516,442517,Catheduline E2,C[C@@H]1C[C@@H]([C@@H]([C@@]2([C@]13C[C@@H]([C@H]([C@@H]2OC(=O)C4=CC=CC=C4)OC(=O)C5=CN=CC=C5)C(O3)(C)C)COC(=O)C6=CN=CC=C6)OC(=O)C)OC(=O)C,,,,,,
2517,442518,Celapanine,CC1CC[C@@H]([C@@]2([C@]13[C@@H]([C@@H]([C@H]([C@@H]2OC(=O)C4=CN=CC=C4)OC(=O)C)C(O3)(C)C)OC(=O)C5=COC=C5)C)OC(=O)C,,,,,,
2518,442519,(+)-8-Hydroxycalamenene,C[C@H]1CC[C@@H](C2=C1C(=CC(=C2)C)O)C(C)C,,,,,,
2519,442520,Strobopinin,CC1=C(C2=C(C=C1O)O[C@@H](CC2=O)C3=CC=CC=C3)O,,,,,,
2520,442521,"2-Benzoyl-3,5-dihydroxy-4-[[(1R,2S,5S)-2-hydroxy-2-methyl-5-isopropenylcyclopentyl]methyl]-6,6-bis(3-methyl-2-butenyl)-2,4-cyclohexadiene-1-one",CC(=CCC1(C(=O)C(=C(C(=C(C2=CC=CC=C2)O)C1=O)O)C[C@@H]3[C@H](CC[C@]3(C)O)C(=C)C)CC=C(C)C)C,,,,,,
2521,442522,Karwinaphthol B,C[C@H]1CC2=CC3=CC(=CC(=C3C(=C2[C@H](O1)C)O)OC)OC,,,,,,
2522,442523,Dendroban-12-one,CC(C)[C@H]1[C@H]2[C@@H]3CC[C@H]4[C@@]3([C@@H]([C@@H]1OC2=O)N(C4)C)C,,,,,,
2523,442524,Karwinskione,CC1CC2=C(C=C3C(=CC(=CC3=C2C4=C(C5=C(C6=C(CC(CC6=O)(C)O)C=C5C=C4)O)O)OC)OC)C(O1)C,,,,,,
2524,442525,Deoxynupharidine,C[C@H]1CC[C@H]2[C@@H](CC[C@H](N2C1)C3=COC=C3)C,,,,,,
2525,442526,2-[3-(Aminomethylidene)-4-hydroxy-2-oxooxan-4-yl]but-3-enal,C=CC(C=O)C1(CCOC(=O)C1=CN)O,,,,,,
2526,442527,"(2R)-4-methoxy-2-(2-phenylethenyl)-2,3-dihydropyran-6-one",COC1=CC(=O)O[C@H](C1)C=CC2=CC=CC=C2,,,,,,
2527,442528,CID 442528,CC(=CCCC(=CC[C@@]1(C(=O)C(=C(C(=C(C2=CC=CC=C2)O)C1=O)O)CC=C(C)C)CC=C(C)C)C)C,,,,,,
2528,442529,Fabianine,C[C@H]1CC[C@H](C2=C1C=CC(=N2)C)C(C)(C)O,,,,,,
2529,442530,Ochratoxin A,C[C@@H]1CC2=C(C=C(C(=C2C(=O)O1)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)Cl,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)', 'A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)']","['Since there are pathomorphological similarities between porcine mycotoxic nephropathy caused by ochratoxin A and Balkan endemic nephropathy (BEN), it has been suggested that the same aetiological agent has a role in BEN. Based on the results from several field and experimental studies carried out on pigs, an appropriate analytical method of monitoring possible human exposure to ochratoxin A was developed. The toxicokinetic properties of the toxin were species specific, although in all the animal species studied (with the exception of fish), as well as in humans, two binding proteins were found in the plasma. The monkey had the longest elimination half-life of the toxin, 510 hr, in contrast to the fish whose elimination half-life was only 0.68 hr. The fish kidney displayed a specific pattern of distribution. In the laying quail the most prominent observation was the accumulation of labelled ochratoxin A in egg yolk. Generally, (14C)ochratoxin A was eliminated rapidly from the quail body, but had a long retention time in the circulating blood in the mouse. Although the elimination of ochratoxin A from the body depending on its binding to plasma constituents, the existence of enterohepatic circulation might have been partially responsible for its prolonged retention and elimination from the body of mammals. The toxicokinetic profile of ochratoxin A did not contradict the mycotoxic hypothesis in the aetiology of BEN.', '... Ochratoxin A is  rapidly absorbed throughout the entire  gastrointestinal tract and distributes itself in the  body as a two compartment open model and  has a particular high affinity for serum albumin. Ochratoxin A  is hydrolyzed by the  intestinal microflora into nontoxic compounds   (7-carboxy-5-chloro-8-hydroxy-3,4-dihydro-3R-methylisocoumarin (Ochratoxin alpha) and phenylalanine).   It is excreted as either ochratoxin A, hydroxylated ochratoxin A or Ochratoxin alpha in both the urine  and feces. Ochratoxin A  appears to exert its toxic effect by promoting an increased level of  lipid peroxidation by  inhibition of an amino acylation reaction and possibly by conversion  into metabolites that are  capable of binding DNA. These in turn cause other secondary effects  associated with ochratoxin A. It  would appear that this compound presents a true potential  hazard for humans as its occurrence  is wide spread and it is highly carcinogenic.', 'Rats intubated daily with 500 ug ochratoxin A or fed 250 ug daily in barley. There was little accumulation of cmpd in liver or kidneys. Avg total amount excreted daily in urine & feces was just over 10% of administered dose. Small amount of hydrolysis product also excreted.', 'Rats given single ip injection of 1 mg ochratoxin A labelled with (14)C. Reached highest levels in serum (90%), liver (4.5%), & kidney (4.4%) 30 min later. Ochratoxin A was excreted primarily in urine as unchanged toxin or metabolites. Excretion in feces less significant.', 'For more Absorption, Distribution and Excretion (Complete) data for OCHRATOXIN A (24 total), please visit the HSDB record page.']","['... Ochratoxin A  is hydrolyzed by the  intestinal microflora into nontoxic compounds   (7-carboxy-5-chloro-8-hydroxy-3,4-dihydro-3R-methylisocoumarin (Ochratoxin alpha) and phenylalanine).   It is excreted as either ochratoxin A, hydroxylated ochratoxin A or Ochratoxin alpha in both the urine  and feces. ...', 'Hydroxyochratoxin A was isolated & identified from urine of rats after injection with ochratoxin A. By incubating ochratoxin A with rat liver microsomes & NADPH, 1 major (90%) & 2 minor metabolites, more polar than ochratoxin A, were formed.', 'Single oral or iv dose (2.5 mg/kg) ochratoxin A admin to healthy adult rats. Ochratoxin alpha only metabolite recovered from cecum & large intestine. Ochratoxin A excreted via urine & feces, both as free drug & ochratoxin alpha. Unidentified metabolites in urine.', 'Ochratoxin A is cleaved into phenylalanine and a less toxic iso-coumarin derivative (ochratoxin alpha) by the microbial flora of the colon ... and by carboxypeptidase A and alpha-chymotrypsin ... .', 'For more Metabolism/Metabolites (Complete) data for OCHRATOXIN A (9 total), please visit the HSDB record page.']","['Pregnant ICR mice were administered a single ip injection of 5 mg/kg ochratoxin A (OA) on day 11 or 13 of gestation. The half-life of OA in serum was calculated to be 28.7 hr on day 11 and 23.6 hr on day 13 of gestation.', 'In rats ... the plasma half-life of ochratoxin A is about 60 hr ... .', 'The apparent plasma elimination half-time of ochratoxin A after oral administration at 50 ug/kg bw varied from 0.68 hr in fish to 120 hr in rats and 510 hr in monkeys ... .', 'The fate of ochratoxin A has been studied in laboratory rodents and in breeding animals. In rats, orally administered ochratoxin A is readily absorbed, and considerable amounts of the toxin are detected in plasma, where maximal concentrations occur 2-4 hr after administration. Pharmacokinetic analysis of curves of plasma level versus time suggests its distribution in two distinct body compartments. The half-time of the toxin depends on both the dose and the animal species, varying from 0.7 hr in fish to 840 h in monkeys. In plasma, the toxin is bound to albumin, like many acidic compounds. This interaction is competitively inhibited by phenylbutazone, ethylbiscoumacetate and sulfamethoxy-pyridazine and is decreased in albumin-deficient rats.', 'The toxicokinetic properties of the toxin were species specific, although in all the animal species studied (with the exception of fish), as well as in humans, two binding proteins were found in the plasma. The monkey had the longest elimination half-life of the toxin, 510 hr, in contrast to the fish whose elimination half-life was only 0.68 hr. The fish kidney displayed a specific pattern of distribution. In the laying quail, the most prominent observation was the accumulation of labelled ochratoxin A in egg yolk. Generally, (14)C-ochratoxin A was eliminated rapidly from the quail body, but had a long retention time in the circulating blood in the mouse. Although the elimination of ochratoxin A from the body depending on its binding to plasma constituents, the existence of enterohepatic circulation might have been partially responsible for its prolonged retention and elimination from the body of mammals. The toxicokinetic profile of ochratoxin A did not contradict the mycotoxic hypothesis in the etiology of BEN.']"
2530,442531,Ohioensin-A,C1[C@H]2[C@@H]3[C@H](C4=C(C=CC(=C4)O)C5=C3C(=C(C=C5O)O)C1=O)OC6=CC=CC=C26,,,,,,
2531,442532,Gentianadine,C1COC(=O)C2=C1C=CN=C2,,,,,,
2532,442533,CID 442533,C[C@@H](CC1=CC2=CC(=O)C=C(C2=C(O1)O)O)O,,,,,,
2533,442534,Paeoniflorin,C[C@]12C[C@@]3([C@@H]4C[C@]1([C@@]4([C@H](O2)O3)COC(=O)C5=CC=CC=C5)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)O,,,"['Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)']",,,
2534,442535,Gentianamine,C=CC1=CN=CC2=C1C(COC2=O)CO,,,,,,
2535,442536,Gentioflavine,CC1C(=C2CCOC(=O)C2=CN1)C=O,,,,,,
2536,442537,CID 442537,CC1=C(OC(=C2C1=CC(=CC2=O)OC)O)C,,,,,,
2537,442538,Rhododendrin,C[C@H](CCC1=CC=C(C=C1)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O,,,,,,
2538,442539,"(1'S,2S,4R,5'R)-5,7-dihydroxy-6',6'-dimethyl-4-(2-methylpropyl)spiro[3,4-dihydrochromene-2,2'-bicyclo[3.1.1]heptane]-6,8-dicarbaldehyde",CC(C)C[C@@H]1C[C@]2(CC[C@@H]3C[C@H]2C3(C)C)OC4=C(C(=C(C(=C14)O)C=O)O)C=O,,,,,,
2539,442540,Taxifolin 3-O-acetate,CC(=O)O[C@@H]1[C@H](OC2=CC(=CC(=C2C1=O)O)O)C3=CC(=C(C=C3)O)O,,,,,,
2540,442541,Robustaol A,CC1=C(C(=C(C(=C1OC)C(=O)C(C)C)O)CC2=C(C(=C(C(=C2O)C(=O)CC(C)C)O)C=O)O)O,,,,,,
2541,442542,Tephrowatsin A,CC(=CCC1=C2C(=C(C=C1OC)OC)[C@@H](C[C@H](O2)C3=CC=CC=C3)O)C,,,,,,
2542,442543,Theasinensin A,C1[C@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3C4=C(C(=C(C=C4[C@@H]5[C@@H](CC6=C(C=C(C=C6O5)O)O)OC(=O)C7=CC(=C(C(=C7)O)O)O)O)O)O)O)O)O)OC(=O)C8=CC(=C(C(=C8)O)O)O,,,,,,
2543,442544,Tremulacin,C1CC(=O)C(C=C1)(C(=O)OCC2=CC=CC=C2O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)OC(=O)C4=CC=CC=C4)O,,,,,,
2544,442545,"2,4,8-Trihydroxy-1-tetralone",C1C(C2=C(C(=CC=C2)O)C(=O)C1O)O,,,,,,
2545,442546,"2',4',6'-Trihydroxy-3'-formyldihydrochalcone",C1=CC=C(C=C1)CCC(=O)C2=C(C=C(C(=C2O)C=O)O)O,,,,,,
2546,442547,Uncinatone,C[C@H]1CC2=C(C3=C(C(=C2O1)O)[C@]4(CCC(=C(C4=CC3=O)C)C)C)O,,,,,,
2547,442548,"1alpha,7alpha-Bis(3-methyl-2-butenyl)-3-(3,4-dihydroxybenzoyl)-4-hydroxy-5alpha-[(R)-2-(1-methylethenyl)-5-methyl-5-hexenyl]-8,8-dimethylbicyclo[3.3.1]non-3-ene-2,9-dione",CC(=CC[C@H]1C[C@]2(C(=O)C(=C(C3=CC(=C(C=C3)O)O)O)C(=O)[C@](C2=O)(C1(C)C)CC=C(C)C)C[C@@H](CCC(=C)C)C(=C)C)C,,,,,,
2548,442549,"(11S)-11-methyl-15,17-bis(oxidanyl)-12-oxabicyclo[12.4.0]octadeca-1(18),2,14,16-tetraene-7,13-dione",C[C@H]1CCCC(=O)CCCC=CC2=C(C(=CC(=C2)O)O)C(=O)O1,,,,,,
2549,442550,N-(p-Hydroxyphenethyl)actinidine,C[C@H]1CCC2=C1C=[N+](C=C2C)CCC3=CC=C(C=C3)O,,,,,,
2550,442551,Jasminine,C[C@H]1C2=CN=CC(=C2CC(=O)N1)C(=O)OC,,,,,,
2551,442552,beta-Skytanthine,C[C@H]1CC[C@H]2[C@H]1CN(C[C@H]2C)C,,,,,,
2552,442553,Tecomine,C[C@H]1CN(C[C@@H]2C1=CC(=O)[C@H]2C)C,,,,,,
2553,442554,Thiobinupharidine,C[C@@H]1CC[C@H](N2[C@H]1CC[C@@]3(C2)C[C@]4(CC[C@H]5[C@@H](CC[C@H](N5C4)C6=COC=C6)C)SC3)C7=COC=C7,,,,,,
2554,442555,Valerianine,C[C@H]1CCC2=C1C=NC=C2COC,,,,,,
2555,442556,Wilfordine,CC(=O)OC[C@]12[C@@H]([C@@H]([C@@H]3[C@H]([C@]14[C@@]([C@H]([C@@H]([C@@H]2OC(=O)C)OC(=O)C5=CC=CC=C5)OC(=O)C(CCC6=C(C=CC=N6)C(=O)OC[C@@]3(O4)C)(C)O)(C)O)OC(=O)C)OC(=O)C)OC(=O)C,,,,,,
2556,442557,"(2S)-N-[(3S,4S,7S)-7-[(2S)-butan-2-yl]-5,8-dioxo-3-propan-2-yl-2-oxa-6,9-diazabicyclo[10.2.2]hexadeca-1(14),10,12,15-tetraen-4-yl]-2-(dimethylamino)-4-methylpentanamide",CC[C@H](C)[C@H]1C(=O)NC=CC2=CC=C(C=C2)O[C@H]([C@@H](C(=O)N1)NC(=O)[C@H](CC(C)C)N(C)C)C(C)C,,,,,,
2557,442558,CID 442558,CC[C@H](C)[C@H]1C(=O)NC=CC2=CC=C(C=C2)O[C@@H]([C@@H](C(=O)N1)NC(=O)[C@H](CC3=CC=CC=C3)N(C)C)C4=CC=CC=C4,,,,,,
2558,442559,CID 442559,CN(C)[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@H]3[C@H](OC4=CC=C(C=C4)C=CNC(=O)[C@@H](NC3=O)CC5=CC=CC=C5)C6=CC=CC=C6,,,,,,
2559,442560,CID 442560,CC(C)[C@H]1[C@@H](C(=O)N[C@H](C(=O)NC=CC2=CC=C(O1)C=C2)CC3=CNC4=CC=CC=C43)NC(=O)[C@H](C(C)C)NC,,,,,,
2560,442561,CID 442561,CC[C@H](C)[C@H]1C(=O)NC=CC2=CC=C(C=C2)O[C@H]([C@@H](C(=O)N1)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)N(C)C)C(C)C,,,,,,
2561,442562,CID 442562,CC[C@H](C)[C@@H](C(=O)N1CC[C@H]2[C@H]1C(=O)N[C@H](C(=O)NC=CC3=CC=C(O2)C=C3)CC4=CC=CC=C4)NC(=O)[C@H](CC5=CC=CC=C5)N(C)C,,,,,,
2562,442563,CID 442563,CC[C@H](C)[C@@H](C(=O)N[C@H]1[C@H](OC2=CC=C(C=C2)C=CNC(=O)[C@@H](NC1=O)C(=O)C3=CC=CC=C3)C4=CC=CC=C4)N(C)C,,,,,,
2563,442564,CID 442564,CN(C)[C@@H](CC1=CC=CC=C1)C(=O)N[C@H]2[C@H](OC3=CC=C(C=C3)C=CNC(=O)[C@@H]4CCCN4C2=O)C5=CC=CC=C5,,,,,,
2564,442565,"(2S)-N-[(3S,4S,7S)-7-benzyl-5,8-dioxo-3-propan-2-yl-2-oxa-6,9-diazabicyclo[10.2.2]hexadeca-1(14),10,12,15-tetraen-4-yl]-1-methylpyrrolidine-2-carboxamide",CC(C)[C@H]1[C@@H](C(=O)N[C@H](C(=O)NC=CC2=CC=C(O1)C=C2)CC3=CC=CC=C3)NC(=O)[C@@H]4CCCN4C,,,,,,
2565,442566,CID 442566,CC(C)C[C@@H](C(=O)N[C@H]1[C@H](OC2=CC=C(C=C2)C=CNC(=O)[C@@H](NC1=O)CC3=CC=CC=C3)C4=CC=CC=C4)N(C)C,,,,,,
2566,442567,"(2S,3S)-2-(dimethylamino)-3-methyl-N-[(3S,4S,7S)-7-(2-methylpropyl)-5,8-dioxo-3-propan-2-yl-2-oxa-6,9-diazabicyclo[10.2.2]hexadeca-1(14),10,12,15-tetraen-4-yl]pentanamide",CC[C@H](C)[C@@H](C(=O)N[C@H]1[C@@H](OC2=CC=C(C=C2)C=CNC(=O)[C@@H](NC1=O)CC(C)C)C(C)C)N(C)C,,,,,,
2567,442568,Hymenocardine,CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]1C(=O)N[C@H](C(=O)NCC(=O)C2=CC=C(C=C2)OC1(C)C)CC3=CNC4=CC=CC=C43)N(C)C,,,,,,
2568,442569,"(2S,3R)-2-(dimethylamino)-3-methyl-N-[(3R,4S,7S)-7-(2-methylpropyl)-5,8-dioxo-3-phenyl-2-oxa-6,9-diazabicyclo[10.2.2]hexadeca-1(14),10,12,15-tetraen-4-yl]pentanamide",CC[C@@H](C)[C@@H](C(=O)N[C@H]1[C@H](OC2=CC=C(C=C2)C=CNC(=O)[C@@H](NC1=O)CC(C)C)C3=CC=CC=C3)N(C)C,,,,,,
2569,442570,CID 442570,CC(C)[C@@H](C(=O)N[C@H]1[C@H](OC2=CC=C(C=C2)C=CNC(=O)[C@@H](NC1=O)CC3=CC=CC=C3)C4=CC=CC=C4)N(C)C,,,,,,
2570,442571,CID 442571,CC(C)[C@@H](C(=O)N[C@H]1[C@H](OC2=CC=C(C=C2)C=CNC(=O)[C@@H](NC1=O)CC3=CNC4=CC=CC=C43)C5=CC=CC=C5)N(C)C,,,,,,
2571,442572,CID 442572,CC(C)[C@@H](C(=O)O[C@@H](C1=CC=CC=C1)[C@H](C(=O)NC=CC2=CC=C(C=C2)O)NC(=O)C(=C(C)C)NC(=O)[C@@H]([C@H](C3=CC=CC=C3)O)N(C)C)NC,,,,,,
2572,442573,"(6S,9S,12S)-6-benzyl-9-[(2S)-butan-2-yl]-12-(dimethylamino)-15-methoxy-4,7,10-triazabicyclo[12.3.1]octadeca-1(18),2,14,16-tetraene-5,8,11-trione",CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)NC=CC2=CC(=C(C=C2)OC)C[C@@H](C(=O)N1)N(C)C)CC3=CC=CC=C3,,,,,,
2573,442574,CID 442574,CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)NC=CC2=CC(=C(C=C2)OC)C[C@@H](C(=O)N1)NC)CC3=CC=CC=C3,,,,,,
2574,442575,CID 442575,CC[C@H](C)[C@H]1C(=O)NC=CC2=CC=C(C=C2)O[C@H]3CCN([C@@H]3C(=O)N1)C(=O)CN(C)C,,,,,,
2575,442576,Pandamine,CC[C@H](C)[C@@H](C(=O)N[C@H]1[C@@H](OC2=CC=C(C=C2)C(CNC(=O)[C@@H](NC1=O)CC3=CC=CC=C3)O)C(C)C)N(C)C,,,,,,
2576,442577,CID 442577,CCCCC1C(=O)N(CN1C)[C@H]2[C@H](OC3=CC=C(C=C3)C=CNC(=O)[C@@H](NC2=O)C(C)C)C4=CC=CC=C4,,,,,,
2577,442578,CID 442578,CC(C)[C@H]1[C@@H](C(=O)N[C@H](C(=O)NC=CC2=CC=C(O1)C=C2)CC3=CC=CC=C3)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC5=CC=CC=C5)NC,,,,,,
2578,442579,CID 442579,CC[C@H](C)[C@@H](C(=O)N1CC[C@H]2[C@H]1C(=O)N3CCC[C@H]3C(=O)NC=CC4=C(C=C(O2)C=C4)OC)NC(=O)[C@H]([C@@H](C)CC)N(C)C,,,,,,
2579,442580,CID 442580,CC[C@H](C)[C@@H](C(=O)N1CC[C@H]2[C@H]1C(=O)N3CCC[C@H]3C(=O)NC=CC4=C(C=C(O2)C=C4)O)NC(=O)[C@H]([C@@H](C)CC)N(C)C,,,,,,
2580,442581,CID 442581,C1=CC(=CC=C1C2=CC(=C3C(=CC(=CC3=O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)COC(=O)CC(=O)O)O)O)O)O2)O)O,,,,,,
2581,442582,CID 442582,COC1=C(C2=C(C(=C(OC2=CC1=O)C3=CC(=C(C=C3)O)O)OC)O)O,,,,,,
2582,442583,"5,6,7-Trimethoxyflavone",COC1=C(C(=C2C(=C1)OC(=CC2=O)C3=CC=CC=C3)OC)OC,,,,,,
2583,442584,Carlinoside,C1[C@@H]([C@@H]([C@H]([C@@H](O1)C2=C3C(=C(C(=C2O)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)C(=O)C=C(O3)C5=CC(=C(C=C5)O)O)O)O)O,,,,,,
2584,442585,CID 442585,C1=CC(=CC=C1C2=CC(=C3C(=CC(=O)C(=C3O2)C4=C5C(=C(C=C(O5)C6=CC=C(C=C6)O)O)C(=CC4=O)O)O)O)O,,,,,,
2585,442586,Dasytrichone,CC1=C(C2=C(C(C1=O)(C)C)OC(=CC2=O)C3=CC=CC=C3)O,,,,,,
2586,442587,CID 442587,C1=CC(=C(C=C1C2=C(C(=C3C=CC(=O)C(=C3O2)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O)O)O,,,,,,
2587,442588,CID 442588,COC1=C(C=CC(=C1)C2=CC(=C3C=CC(=O)C=C3O2)O)O,,,,,,
2588,442589,CID 442589,CC(=CCC1=C2C(=C(C(=C(O2)C3=CC=CC=C3)O)O)C(=O)C=C1O)C,,,,,,
2589,442590,CID 442590,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C3C(=C(C(=C(O3)C4=CC(=C(C=C4)O)O)O)O)C(=CC2=O)O)O)O)O,,,,,,
2590,442591,CID 442591,COC1=CC(=C2C(=C1)OC3=CC(=O)C(=CC3=C2O)O)O,,,,,,
2591,442592,CID 442592,CC(=CCC1=C(C2=C(C=C1)C(=C3C(=O)C=CC=C3O2)O)O)C,,,,,,
2592,442593,CID 442593,CC1(C=CC2=C(O1)C3=C(C=C2)C(=C4C(=O)C=CC=C4O3)O)C,,,,,,
2593,442594,CID 442594,C1=CC(=O)C2=C(C3=C(C=CC(=C3)O)OC2=C1)O,,,,,,
2594,442595,"4-[(2S,8R)-12-hydroxy-8,21,21-trimethyl-5-(3-methylbut-2-enyl)-8-(4-methylpent-3-enyl)-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.02,15.02,19.04,13.06,11]docosa-4(13),5,9,11,15-pentaen-19-yl]-2-methylbut-2-enoic acid",CC(=CCC[C@@]1(C=CC2=C(C3=C(C(=C2O1)CC=C(C)C)O[C@@]45C6CC(C=C4C3=O)C(=O)C5(OC6(C)C)CC=C(C)C(=O)O)O)C)C,,,,,,
2595,442596,CID 442596,COC1=C(C=CC2=C1OC3=CC(=O)C(=C(C3=C2O)O)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O,,,,,,
2596,442597,CID 442597,C1=CC(=CC=C1C2=C(C(=C3C(=CC(=O)C(=C3O)O)O2)O)O)O,,,,,,
2597,442598,CID 442598,COC1=C(C=C2C(=C1)OC3=CC(=O)C=C(C3=C2O)O)O,,,,,,
2598,442599,CID 442599,CC(=CCC1=C(C(=O)C=C2C1=C(C3=C(O2)C=C(C4=C3OC(CC4)(C)C)O)O)OC)C,,,,,,
2599,442600,CID 442600,CC1(C=CC2=C(O1)C=C3C(=C2O)C(=C4C=CC(=O)C(=C4O3)O)O)C,,,,,,
2600,442601,CID 442601,C1=CC2=C(C=C1O)C(=C3C(=O)C=C(C(=C3O2)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O,,,,,,
2601,442602,CID 442602,C1=C(C(=O)C=C2C1=C(C3=C(O2)C=C(C(=C3O)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O)O,,,,,,
2602,442603,CID 442603,C1=CC(=C(C=C1C2=CC(=C3C(=CC(=O)C(=C3O2)O)O)O)O)O,,,,,,
2603,442604,CID 442604,C1=C(C(=CC(=C1O)O)O)C2=CC(=C3C(=CC(=O)C=C3O2)O)O,,,,,,
2604,442605,CID 442605,COC1=CC(=O)C2=C(C3=C(C(=CC=C3)O)OC2=C1)O,,,,,,
2605,442606,CID 442606,C1=CC(=C2C(=C1)OC3=C(C(=O)C=CC3=C2O)O)O,,,,,,
2606,442607,"4-[(2S)-12-hydroxy-8,8,21,21-tetramethyl-5-(3-methylbut-2-enyl)-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.02,15.02,19.04,13.06,11]docosa-4(13),5,9,11,15-pentaen-19-yl]-2-methylbut-2-enal",CC(=CCC1=C2C(=C(C3=C1O[C@@]45C6CC(C=C4C3=O)C(=O)C5(OC6(C)C)CC=C(C)C=O)O)C=CC(O2)(C)C)C,,,,,,
2607,442608,CID 442608,COC1=CC(=O)C2=C(C3=C(C=CC(=C3OC2=C1)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O,,,,,,
2608,442609,CID 442609,C1=CC2=C(C(=C1)O)OC3=CC(=O)C=C(C3=C2O)O,,,,,,
2609,442610,CID 442610,C1=C2C(=CC(=C1O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)OC4=CC(=O)C=C(C4=C2O)O,,,,,,
2610,442611,Isoscoparin,COC1=C(C=CC(=C1)C2=CC(=O)C3=C(O2)C=C(C(=C3O)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O,,,,,,
2611,442612,CID 442612,C1=CC(=CC=C1C2=CC(=C3C(=CC(=O)C(=C3O2)O)O)O)O,,,,,,
2612,442613,CID 442613,CC1=C[C@@H]([C@H]([C@@H](C1)C2=C(C=C(C=C2)O)O)C(=O)C3=C(C(=C(C=C3)O)CC=C(C)C)O)C4=C5C(=C(C(=C(O5)C6=C(C=C(C=C6)O)O)CC=C(C)C)O)C(=O)C=C4O,,,,,,
2613,442614,(-)-Usnic acid,CC1=C(C(=C2C(=C1O)[C@]3(C(=CC(=C(C3=O)C(=O)C)O)O2)C)C(=O)C)O,,,,,,
2614,442615,Lucenin-2,C1=CC(=C(C=C1C2=CC(=O)C3=C(C(=C(C(=C3O2)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O)O)O,,,,,,
2615,442616,CID 442616,C1=CC(=C(C=C1C2=CC(=C3C(=CC(=CC3=O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)COC(=O)CC(=O)O)O)O)O)O2)O)O)O,,,,,,
2616,442617,6-Methoxyluteolin 7-rhamnoside,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(C(=C3C(=C2)OC(=CC3=O)C4=CC(=C(C=C4)O)O)O)OC)O)O)O,,,,,,
2617,442618,Neocarlinoside,C1[C@@H]([C@@H]([C@H]([C@H](O1)C2=C3C(=C(C(=C2O)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)C(=O)C=C(O3)C5=CC(=C(C=C5)O)O)O)O)O,,,,,,
2618,442619,Neoschaftoside,C1[C@@H]([C@@H]([C@H]([C@H](O1)C2=C3C(=C(C(=C2O)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)C(=O)C=C(O3)C5=CC=C(C=C5)O)O)O)O,,,,,,
2619,442620,CID 442620,COC1=CC(=O)C2=C(C(=C(OC2=C1)C3=CC(=C(C=C3O)OC)O)OC)O,,,,,,
2620,442621,Oxyayanin B,COC1=C(C=C(C=C1)C2=C(C(=O)C3=C(C(=C(C=C3O2)OC)O)O)OC)O,,,,,,
2621,442622,CID 442622,COC1=C(C2=C(C(=C(OC2=CC1=O)C3=CC(=C(C=C3)O)O)O)O)O,,,,,,
2622,442623,CID 442623,CC1=C(C2=C(C(=C(OC2=CC1=O)C3=CC(=C(C=C3)O)O)O)O)O,,,,,,
2623,442624,"3-phenyl-1-[5-[(2S)-piperidin-2-yl]-3,4-dihydro-2H-pyridin-1-yl]prop-2-en-1-one",C1CCN[C@@H](C1)C2=CN(CCC2)C(=O)C=CC3=CC=CC=C3,,,,,,
2624,442625,Ammodendrine,CC(=O)N1CCCC(=C1)[C@H]2CCCCN2,,,,,,
2625,442626,Astrocasine,CN1CCCC[C@@H]1[C@H]2CC[C@@H]3C4=CC=CC=C4C=CC(=O)N3C2,,,,,,
2626,442627,3-Phenyl-1-[(3R)-3-[(2R)-piperidin-2-yl]piperidin-1-yl]prop-2-en-1-one,C1CCN[C@H](C1)[C@@H]2CCCN(C2)C(=O)C=CC3=CC=CC=C3,,,,,,
2627,442628,Australine,C1CN2[C@@H]([C@H]([C@@H]([C@H]2[C@H]1O)O)O)CO,,,,,,
2628,442629,Buchananine,C1=CC(=CN=C1)C(=O)OC[C@@H]2[C@H]([C@@H]([C@H]([C@H](O2)O)O)O)O,,,,,,
2629,442630,Carpaine,C[C@H]1[C@@H]2CC[C@H](N1)CCCCCCCC(=O)O[C@H]3CC[C@@H](CCCCCCCC(=O)O2)N[C@H]3C,,,,,,
2630,442631,Codonopsine,C[C@@H]1[C@H]([C@@H]([C@H](N1C)C2=CC(=C(C=C2)OC)OC)O)O,,,,,,
2631,442632,gamma-Coniceine,CCCC1=NCCCC1,,,,,,
2632,442633,CID 442633,CCC=CC=CC=CC=C[C@@H]1CC[C@@H]([C@@H](N1C)C)O,,,,,,
2633,442634,Cucurbitine,C1CNC[C@]1(C(=O)O)N,,,,,,
2634,442635,Dioscorine,CC1=CC(=O)O[C@@]2(C1)C[C@H]3CC[C@@H]2CN3C,,,,,,
2635,442636,Funebrine,C[C@@H]1[C@H](OC(=O)[C@H]1N=CC2=CC=C(N2[C@H]3[C@@H]([C@H](OC3=O)C)C)CO)C,,,,,,
2636,442637,Gerrardine,CN1[C@H](CC[C@@H]1[C@H]2[C@H](CSS2)O)[C@H]3[C@H](CSS3)O,,,,,,
2637,442638,Girgensonine,C1CCN(CC1)C(C#N)C2=CC=C(C=C2)O,,,,,,
2638,442639,CID 442639,CC=CC[C@@H](C)C(=O)C1=C(NC(=C(C1=O)OC)OC)O,,,,,,
2639,442640,"(2R,3S)-3-hydroxy-1,1-dimethylpyrrolidin-1-ium-2-carboxylate",C[N+]1(CC[C@@H]([C@@H]1C(=O)[O-])O)C,,,,,,
2640,442641,"3-Hydroxy-1,1-dimethylpyrrolidin-1-ium-2-carboxylic acid",C[N+]1(CCC(C1C(=O)O)O)C,,,,,,
2641,442642,(-)-Hygroline,C[C@H](C[C@H]1CCCN1C)O,,,,,,
2642,442643,Isolobinine,CCC(C[C@H]1C=CC[C@H](N1C)CC(=O)C2=CC=CC=C2)O,,,,,,
2643,442644,Juliflorine,C[C@H]1[C@H](CC[C@H](N1)CCCCCCCCCCC2C=C(CN3C2CCC3)CCCCCCCCCC[C@@H]4CC[C@@H]([C@@H](N4)C)O)O,,,,,,
2644,442645,Lentiginosine,C1CCN2C[C@@H]([C@H]([C@@H]2C1)O)O,,,,,,
2645,442646,Lobelanidine,CN1[C@H](CCC[C@H]1C[C@@H](C2=CC=CC=C2)O)C[C@H](C3=CC=CC=C3)O,,,,,,
2646,442647,Lobelanine,CN1[C@H](CCC[C@H]1CC(=O)C2=CC=CC=C2)CC(=O)C3=CC=CC=C3,,,,,,
2647,442648,Mearsine,CC1CC2CC(=O)C1C(=N2)C,,,,,,
2648,442649,Myosmine,C1CC(=NC1)C2=CN=CC=C2,,,,,,
2649,442650,"6-Hepta-1,3,5-trienyl-2,3,4,5-tetrahydropyridine",CC=CC=CC=CC1=NCCCC1,,,,,,
2650,442651,"(6S,7R)-2-azaspiro[5.5]undecan-7-ol",C1CC[C@@]2(CCCNC2)[C@@H](C1)O,,,,,,
2651,442652,"(2R,6R)-2-methyl-6-prop-1-enylpiperidine",CC=C[C@H]1CCC[C@H](N1)C,,,,,,
2652,442653,"1-[1-Oxo-3-(3,4,5-trimethoxyphenyl)prop-2-enyl]-2,3-dihydropyridin-6-one",COC1=CC(=CC(=C1OC)OC)C=CC(=O)N2CCC=CC2=O,,,,,,
2653,442654,(+)-Prosopinine,CCC(=O)CCCCCCCCC[C@@H]1CC[C@@H]([C@H](N1)CO)O,,,,,,
2654,442655,Ruspolinone,COC1=C(C=C(C=C1)C(=O)CC2CCCN2)OC,,,,,,
2655,442656,(-)-Santiaguine,C1CCN[C@H](C1)C2=CN(CCC2)C(=O)C3C(C(C3C4=CC=CC=C4)C(=O)N5CCCC(=C5)[C@H]6CCCCN6)C7=CC=CC=C7,,,,,,
2656,442657,(-)-Sedamine,CN1CCCC[C@H]1C[C@@H](C2=CC=CC=C2)O,,,,,,
2657,442658,Schaftoside,C1[C@@H]([C@@H]([C@H]([C@@H](O1)C2=C3C(=C(C(=C2O)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)C(=O)C=C(O3)C5=CC=C(C=C5)O)O)O)O,,,,,,
2658,442659,Swertiajaponin,COC1=C(C(=C2C(=C1)OC(=CC2=O)C3=CC(=C(C=C3)O)O)O)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O,,,,,,
2659,442660,CID 442660,COC1=C(C=C(C=C1)C2=C(C(=C3C(=CC(=O)C=C3O2)O)O)O)O,,,,,,
2660,442661,CID 442661,COC1=CC=C(C=C1)C2=C(C(=C3C(=O)C=C(C(=C3O2)OC)OC)O)O,,,,,,
2661,442662,Thymonin,COC1=C(C=CC(=C1)C2=CC(=O)C3=C(C(=C(C(=C3O2)OC)OC)O)O)O,,,,,,
2662,442663,Velloquercetin,CC(=C)C1CC2=C(O1)C=C3C(=C2O)C(=O)C(=C(O3)C4=CC(=C(C=C4)O)O)O,,,,,,
2663,442664,Vicenin-2,C1=CC(=CC=C1C2=CC(=O)C3=C(C(=C(C(=C3O2)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O)O,,,,,,
2664,442665,Violanthin,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)C2=C3C(=C(C(=C2O)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)C(=O)C=C(O3)C5=CC=C(C=C5)O)O)O)O,,,,,,
2665,442666,(-)-Acanthocarpan,C1[C@@]2([C@H](C3=C(O1)C4=C(C=C3)OCO4)OC5=CC6=C(C=C52)OCO6)O,,,,,,
2666,442667,Anhydroglycinol,C1C2=C(C3=C(O1)C=C(C=C3)O)OC4=C2C=CC(=C4)O,,,,,,
2667,442668,Betavulgarin,COC1=C2C(=CC3=C1OCO3)OC=C(C2=O)C4=CC=CC=C4O,,,,,,
2668,442669,CID 442669,COC1=CC(=O)C(=CC1=O)C2=COC3=CC(=O)C=CC3=C2O,,,,,,
2669,442670,Cajanol,COC1=CC(=C2C(=C1)OCC(C2=O)C3=C(C=C(C=C3)O)OC)O,,,,,,
2670,442671,Afzelechin-(4alpha->8)-afzelechin,C1[C@@H]([C@H](OC2=C1C(=CC(=C2[C@H]3[C@@H]([C@H](OC4=CC(=CC(=C34)O)O)C5=CC=C(C=C5)O)O)O)O)C6=CC=C(C=C6)O)O,,,,,,
2671,442672,CID 442672,C1[C@@H]2[C@H]([C@H]3[C@H](C(O2)O)OC(=O)C4=CC(=C(C(=C4C5=C(C(=C(C=C5C(=O)O3)O)O)O)O)O)O)OC(=O)C6=CC(=O)C(=C7C6=C8C(=C(O7)O)C=C(C(=C8O)OC9=C(C(=C(C=C9C(=O)O1)O)O)O)O)O,,,,,,
2672,442673,Casuarinin,C1[C@H]([C@@H](OC(=O)C2=CC(=C(C(=C2C3=C(C(=C(C=C3C(=O)O1)O)O)O)O)O)O)[C@H]4[C@@H]5[C@H](C6=C(C(=C(C(=C6C(=O)O5)C7=C(C(=C(C=C7C(=O)O4)O)O)O)O)O)O)O)OC(=O)C8=CC(=C(C(=C8)O)O)O,,,,,,
2673,442674,CID 442674,C1[C@@H]2[C@@H]3[C@@H]([C@H]([C@@H](O2)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C6=C5[C@H]([C@@H](C(=O)O3)CC(=O)O)[C@@H](C(=O)O6)O)O)O)OC(=O)C7=CC(=C(C(=C7C8=C(C(=C(C=C8C(=O)O1)O)O)O)O)O)O,,,"['Compounds that bind to and inhibit that enzymatic activity of LIPOXYGENASES. Included under this category are inhibitors that are specific for lipoxygenase subtypes and act to reduce the production of LEUKOTRIENES. (See all compounds classified as Lipoxygenase Inhibitors.)', 'Compounds that inhibit the activity of DNA TOPOISOMERASE I. (See all compounds classified as Topoisomerase I Inhibitors.)']",,,
2674,442675,cinchonain Ib,C1[C@H]([C@H](OC2=C1C(=CC3=C2[C@H](CC(=O)O3)C4=CC(=C(C=C4)O)O)O)C5=CC(=C(C=C5)O)O)O,,,,,,
2675,442676,"(3R,5R)-4-[3,4-dihydroxy-5-(3,4,5-trihydroxybenzoyl)oxybenzoyl]oxy-1-hydroxy-3,5-bis[(3,4,5-trihydroxybenzoyl)oxy]cyclohexane-1-carboxylic acid",C1[C@H](C([C@@H](CC1(C(=O)O)O)OC(=O)C2=CC(=C(C(=C2)O)O)O)OC(=O)C3=CC(=C(C(=C3)OC(=O)C4=CC(=C(C(=C4)O)O)O)O)O)OC(=O)C5=CC(=C(C(=C5)O)O)O,,,,,,
2676,442677,"(2S,3S)-2-(3,4-dihydroxyphenyl)-8-[(2R,3R,4R)-2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-chroman-4-yl]chromane-3,5,7-triol",C1[C@@H]([C@@H](OC2=C1C(=CC(=C2[C@@H]3[C@H]([C@H](OC4=CC(=CC(=C34)O)O)C5=CC(=C(C=C5)O)O)O)O)O)C6=CC(=C(C=C6)O)O)O,,,,,,
2677,442678,Epigallocatechin-(4beta->8)-epicatechin-3-O-gallate ester,C1[C@H]([C@H](OC2=C1C(=CC(=C2[C@@H]3[C@H]([C@H](OC4=CC(=CC(=C34)O)O)C5=CC(=C(C(=C5)O)O)O)O)O)O)C6=CC(=C(C=C6)O)O)OC(=O)C7=CC(=C(C(=C7)O)O)O,,,,,,
2678,442679,Eugeniin,C1[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC(=O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C(=C5)O)O)O)OC(=O)C6=CC(=C(C(=C6C7=C(C(=C(C=C7C(=O)O1)O)O)O)O)O)O,,,,,,
2679,442680,ent-Fisetinidol-(4beta->8)-catechin-(6->4beta)-ent-fisetinidol,C1[C@@H]([C@H](OC2=C(C(=C(C(=C21)O)[C@@H]3[C@H]([C@H](OC4=C3C=CC(=C4)O)C5=CC(=C(C=C5)O)O)O)O)[C@@H]6[C@H]([C@@H](OC7=C6C=CC(=C7)O)C8=CC(=C(C=C8)O)O)O)C9=CC(=C(C=C9)O)O)O,,,,,,
2680,442681,Fucofuroeckol B,C1=C(C=C(C=C1O)OC2=C(C=C(C3=C2OC4=C(O3)C=C5C(=C4O)C6=C(C=C(C=C6O5)O)O)O)O)O,,,,,,
2681,442682,Gallocatechin-(4alpha->8)-epigallocatechin,C1[C@H]([C@H](OC2=C1C(=CC(=C2[C@H]3[C@@H]([C@H](OC4=CC(=CC(=C34)O)O)C5=CC(=C(C(=C5)O)O)O)O)O)O)C6=CC(=C(C(=C6)O)O)O)O,,,,,,
2682,442683,"[(1R,7R,8S,26R,28R,29R,38R)-1,13,14,15,18,19,20,34,35,39,39-undecahydroxy-2,5,10,23,31-pentaoxo-6,9,24,27,30,40-hexaoxaoctacyclo[34.3.1.04,38.07,26.08,29.011,16.017,22.032,37]tetraconta-3,11,13,15,17,19,21,32,34,36-decaen-28-yl] 3,4,5-trihydroxybenzoate",C1[C@@H]2[C@@H]3[C@@H]([C@H]([C@H](O2)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C6=C5[C@@H]7C(=CC(=O)[C@@](C7(O)O)(O6)O)C(=O)O3)O)O)OC(=O)C8=CC(=C(C(=C8C9=C(C(=C(C=C9C(=O)O1)O)O)O)O)O)O,,,,,,
2683,442684,Guibourtinidol-(4alpha->6)-catechin,C1[C@@H]([C@H](OC2=C1C(=C(C(=C2)O)[C@@H]3[C@@H]([C@H](OC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O)O)O)C6=CC(=C(C=C6)O)O)O,,,,,,
2684,442685,Isoterchebin,C1[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC(=O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C(=C5)O)O)O)OC(=O)C6=CC(=C(C7=C6[C@H]8C(=CC(=O)[C@](C8(O)O)(O7)O)C(=O)O1)O)O,,,,,,
2685,442686,Kandelin A-1,C1[C@@H]([C@H](OC2=C1C(=CC(=C2[C@@H]3[C@H]([C@H](OC4=C3C(=CC5=C4[C@H](CC(=O)O5)C6=CC(=C(C=C6)O)O)O)C7=CC(=C(C=C7)O)O)O)O)O)C8=CC(=C(C=C8)O)O)O,,,,,,
2686,442687,"ent-Apigeniflavan-(2alpha->7,4alpha->8)-epiafzelechin",C1[C@H]([C@H](OC2=C1C(=CC3=C2[C@H]4C[C@@](O3)(OC5=CC(=CC(=C45)O)O)C6=CC=C(C=C6)O)O)C7=CC=C(C=C7)O)O,,,,,,
2687,442688,Pedunculagin,C1[C@@H]2[C@H]([C@H]3[C@H](C(O2)O)OC(=O)C4=CC(=C(C(=C4C5=C(C(=C(C=C5C(=O)O3)O)O)O)O)O)O)OC(=O)C6=CC(=C(C(=C6C7=C(C(=C(C=C7C(=O)O1)O)O)O)O)O)O,,,,,,
2688,442689,Robinetinidol-(4alpha->8)-catechin-(6->4alpha)-robinetinidol,C1[C@@H]([C@H](OC2=C(C(=C(C(=C21)O)[C@H]3[C@@H]([C@H](OC4=C3C=CC(=C4)O)C5=CC(=C(C(=C5)O)O)O)O)O)[C@H]6[C@@H]([C@H](OC7=C6C=CC(=C7)O)C8=CC(=C(C(=C8)O)O)O)O)C9=CC(=C(C=C9)O)O)O,,,,,,
2689,442690,Tellimagrandin I,C1[C@@H]2[C@H]([C@@H]([C@H](C(O2)O)OC(=O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C(=C5C6=C(C(=C(C=C6C(=O)O1)O)O)O)O)O)O,,,,,,
2690,442691,CID 442691,C1=C2C(=C3C4=C(OC5=C6C4=C(C(=C3OC2=O)O)OC(=C6C7=C8C(=CC(=O)C(=C8O)O)C(=O)OC7=C5O)O)O)C(=C(C1=O)O)O,,,,,,
2691,442692,"1,2,3,4-Tetragalloyl-alpha-D-glucose",C1=C(C=C(C(=C1O)O)O)C(=O)O[C@@H]2[C@H](O[C@@H]([C@@H]([C@H]2OC(=O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C(=C5)O)O)O)CO,,,,,,
2692,442693,Agrostophyllin,COC1=CC2=C3C(=C1)C=CC4=CC(=C(C(=C43)CO2)OC)O,,,,,,
2693,442694,Batatasin I,COC1=CC(=C2C(=C1)C=CC3=CC(=C(C=C32)O)OC)OC,,,,,,
2694,442695,Blestriarene B,COC1=C2C(=C(C(=C1)O)C3=C4C=CC5=C(C4=C(C=C3O)OC)C=CC(=C5)O)CCC6=C2C=CC(=C6)O,,,,,,
2695,442696,Canaliculatol,C1=CC(=CC=C1[C@H]2[C@@H]3[C@H]([C@@H](C4=C(C=C(C=C4O)O)[C@H]5[C@@H](OC6=CC(=CC3=C56)O)C7=CC=C(C=C7)O)C8=CC=C(C=C8)O)C9=C2C(=CC(=C9)O)O)O,,,,,,
2696,442697,Coelogin,COC1=C(C(=C2COC3=CC(=CC4=C3C2=C1CC4)O)O)OC,,,,,,
2697,442698,Copalliferol B,C1=CC(=CC=C1[C@H]2[C@@H]3[C@@H](C4=C2C(=CC(=C4)O)O)C(=C([C@@H](C5=C3C=C(C=C5O)O)C6=CC=C(C=C6)O)C7=CC(=CC(=C7)O)O)C8=CC=C(C=C8)O)O,,,,,,
2698,442699,Demethylbatatasin IV,C1=CC=C(C(=C1)CCC2=CC(=CC(=C2)O)O)O,,,,,,
2699,442700,Dihydropinosylvin,C1=CC=C(C=C1)CCC2=CC(=CC(=C2)O)O,,,,,,
2700,442701,"4,4'-Dihydroxy-3,5-dimethoxydihydrostilbene",COC1=CC(=CC(=C1O)OC)CCC2=CC=C(C=C2)O,,,,,,
2701,442702,"7-Methoxy-9,10-dihydrophenanthrene-2,5-diol",COC1=CC2=C(C3=C(CC2)C=C(C=C3)O)C(=C1)O,,,,,,
2702,442703,Glepidotin C,CC(=C)C(CC1=C(C=C(C=C1O)CCC2=CC=CC=C2)O)O,,,,,,
2703,442704,CID 442704,C1=CC(=CC=C1C=CC2=CC(=O)[C@@H]3[C@@H]([C@H]([C@H]2C3=O)C4=CC(=CC(=C4)O)O)C5=CC=C(C=C5)O)O,,,,,,
2704,442705,Hircinol,COC1=CC(=CC2=C1C3=C(CC2)C=CC=C3O)O,,,,,,
2705,442706,Amabiline,C[C@@H]([C@@](C(C)C)(C(=O)OCC1=CCN2[C@H]1CCC2)O)O,,,,,,
2706,442707,6-Hydroxy-4-methoxy-3-(3-methyl-2-butenyl)-2-(2-phenylethenyl)benzoic acid,CC(=CCC1=C(C=C(C(=C1C=CC2=CC=CC=C2)C(=O)O)O)OC)C,,,,,,
2707,442708,Isobatatasin I,COC1=CC(=C2C(=C1)C=CC3=CC(=C(C=C32)OC)O)OC,,,,,,
2708,442709,"(2S,3R,4S,5S,6R)-2-[3-hydroxy-5-[2-(4-hydroxy-3-methoxyphenyl)ethenyl]phenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol",COC1=C(C=CC(=C1)C=CC2=CC(=CC(=C2)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O,,,,,,
2709,442710,Marchantin A,C1CC2=C(C(=CC=C2)O)OC3=CC=CC(=C3)CCC4=CC(=C(C(=C4)OC5=CC=C1C=C5)O)O,,,,,,
2710,442711,3'-O-Methylbatatasin III,COC1=CC=CC(=C1)CCC2=CC(=CC(=C2)OC)O,,,,,,
2711,442712,CID 442712,CC=C(C)C(=O)O[C@H]1CCN2[C@@H]1C(=CC2)CO,,,,,,
2712,442713,CID 442713,CC=C1CC(=C)[C@@](C(=O)OC[C@H]2[C@@H](CN3[C@H]2[C@@H](CC3)OC1=O)O)(C)O,,,,,,
2713,442714,Auriculine,CC(=CCC1=CC(=CC(=C1O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC=C(C)C)C(=O)OC[C@H]3CCN4[C@@H]3CCC4)C,,,,,,
2714,442715,4-Prenyldihydropinosylvin,CC(=CCC1=C(C=C(C=C1O)CCC2=CC=CC=C2)O)C,,,,,,
2715,442716,CID 442716,C[C@@H]1C=C(C(=O)O[C@@H]2CCN(CC=C(C2=O)COC(=O)[C@@]1(C)OC(=O)C)C)C=C,,,,,,
2716,442717,"4'-Prenyl-2,4,3',5'-tetrahydroxystilbene",CC(=CCC1=C(C=C(C=C1O)C=CC2=C(C=C(C=C2)O)O)O)C,,,,,,
2717,442718,"5-[2-(4-Hydroxyphenyl)ethenyl]-2-(3-methylbut-2-enyl)benzene-1,3-diol",CC(=CCC1=C(C=C(C=C1O)C=CC2=CC=C(C=C2)O)O)C,,,,,,
2718,442719,"[(1R,4R,6R,7R)-4-[(1R)-1-chloroethyl]-4-hydroxy-6,7,14-trimethyl-3,8,17-trioxo-2,9-dioxa-14-azabicyclo[9.5.1]heptadec-11-en-7-yl] acetate",C[C@@H]1C[C@@](C(=O)O[C@@H]2CCN(CC=C(C2=O)COC(=O)[C@]1(C)OC(=O)C)C)([C@@H](C)Cl)O,,,,,,
2719,442720,"Alkannin beta,beta-dimethylacrylate",CC(=CC[C@@H](C1=CC(=O)C2=C(C=CC(=C2C1=O)O)O)OC(=O)C=C(C)C)C,,,,,,
2720,442721,Ardisianone,CCCCCCCCCCCCCC(CC1=CC(=O)C=C(C1=O)OC)OC(=O)C,,,,,,
2721,442722,CID 442722,CC=C(C)C(=O)O[C@@H]1CCN2[C@@H]1C(=CC2)COC(=O)[C@@]([C@H](C)O)(C(C)(C)O)O,,,,,,
2722,442723,Aristolindiquinone,CC1=C2C(=C(C=C1)O)C(=C(C(=O)C2=O)C)O,,,,,,
2723,442724,"[(7S,8R)-7-hydroxy-5,6,7,8-tetrahydro-3H-pyrrolizin-1-yl]methyl (2R)-2,3-dihydroxy-2-[(1R)-1-methoxyethyl]-3-methylbutanoate",C[C@H]([C@](C(=O)OCC1=CCN2[C@H]1[C@H](CC2)O)(C(C)(C)O)O)OC,,,,,,
2724,442725,Aurantio-obtusin beta-D-glucoside,CC1=CC2=C(C(=C1O)OC)C(=O)C3=C(C(=C(C=C3C2=O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)OC)O,,,,,,
2725,442726,Isocromadurine,C[C@@H]1C(=O)OCC2=CCN3[C@H]2[C@@H](CC3)OC(=O)[C@@H]([C@@]1(C)O)C,,,,,,
2726,442727,Cascaroside A,C1=CC2=C(C(=C1)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)C(=O)C4=C([C@H]2[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)C=C(C=C4O)CO,,,,,,
2727,442728,Cassiamin C,CC1=CC2=C(C(=C1C3=C(C4=C(C=C3C)C(=O)C5=C(C4=O)C(=CC=C5)O)O)O)C(=O)C6=C(C2=O)C=CC=C6O,,,,,,
2728,442729,7-Chloroemodin,CC1=CC2=C(C(=C1)O)C(=O)C3=C(C(=C(C=C3C2=O)O)Cl)O,,,,,,
2729,442730,Chryso-obtusin glucoside,CC1=CC2=C(C(=C1O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)OC)C(=O)C4=C(C(=C(C=C4C2=O)OC)OC)OC,,,,,,
2730,442731,Pulmatin,CC1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=CC=C3O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O,,,,,,
2731,442732,Coleone A,CC1=C2C(=C(C3=C1[C@@](C(O3)O)(C)CC=C)O)C(=C(C(=O)C2=O)C(C)C)O,,,,,,
2732,442733,CID 442733,CC(=CCC[C@@]1(C=CC2=C(O1)C=CC3=C2C(=O)C(=O)C(=C4C(=C5C(=O)C6=C(C7=C(C=C6)O[C@](C=C7)(C)CCC=C(C)C)C(=O)C5=O)C(=C8C(=C4O)C=CC9=C8C=C[C@@](O9)(C)CCC=C(C)C)O)C3=O)C)C,,,,,,
2733,442734,"[(7S,8R)-7-(2-methylbut-2-enoyloxy)-5,6,7,8-tetrahydro-3H-pyrrolizin-1-yl]methyl (2S)-2,3-dihydroxy-2-[(1S)-1-hydroxyethyl]-3-methylbutanoate",CC=C(C)C(=O)O[C@H]1CCN2[C@@H]1C(=CC2)COC(=O)[C@]([C@H](C)O)(C(C)(C)O)O,,,,,,
2734,442735,Cornudentanone,CCCCCCCCCCCC(CC1=CC(=O)C=C(C1=O)OC)OC(=O)C,,,,,,
2735,442736,Heliotridine,C1CN2CC=C([C@@H]2[C@H]1O)CO,,,,,"['Heliotridine, the hydrolysis product from heliotrine and lasiocarpine, was excreted in the form of the  N-oxide in larger quantities after the administration of each of these alkaloids /to rats/.', 'The pa /pyrrolizidine alkaloids/, like many other foreign substances, undergo metab changes in animal body by more than one pathway. ... The known metabolites represent products of n-oxidation and dehydrogenation of pyrrolizidine moiety, of o-demethylation of methoxy groups when these are present in acidic moiety, and products of hydrolysis of ester linkages. ... The part of the administered dose that is excreted in the urine as the unchanged parent alkaloid depends mainly on its basic properties and water solubility. Lasiocarpine is excreted in trace quantities.../and/ heliotridine, 40%...', 'Evidence from animal studies suggests that the hepatotoxicity is due to the formation of toxic pyrrolic metabolites by the mixed function oxidases of liver cells.', 'Levels of pyrrolic metabolites were measured in the livers of rats given some pyrrolizidine alkaloids and semisynthetic derivatives. ... Heliotridine-based alkaloids gave more pyrrole than similar retronecine esters, heliotridine ditiglate gave less pyrrole than retronecine ditiglate because the former was more open to hydrolytic attack.']",
2736,442737,"[(7S,8R)-7-hydroxy-5,6,7,8-tetrahydro-3H-pyrrolizin-1-yl]methyl (2S)-2-hydroxy-2-[(1S)-1-methoxyethyl]-3-methylbutanoate",C[C@@H]([C@@](C(C)C)(C(=O)OCC1=CCN2[C@H]1[C@H](CC2)O)O)OC,,,,,,
2737,442738,"(1R,6R,7S,17R)-4-ethylidene-7-hydroxy-7-(hydroxymethyl)-6-methyl-14-oxido-2,9-dioxa-14-azoniatricyclo[9.5.1.014,17]heptadec-11-ene-3,8-dione",CC=C1C[C@H]([C@@](C(=O)OCC2=CC[N+]3([C@H]2[C@@H](CC3)OC1=O)[O-])(CO)O)C,,,,,,
2738,442739,Droserone,CC1=C(C2=C(C(=CC=C2)O)C(=O)C1=O)O,,,,,,
2739,442740,Isolycopsamine,C[C@H]([C@](C(C)C)(C(=O)O[C@@H]1CCN2[C@@H]1C(=CC2)CO)O)O,,,,,,
2740,442741,Jacobine,C[C@@H]1C[C@]2([C@@H](O2)C)C(=O)O[C@@H]3CCN4[C@@H]3C(=CC4)COC(=O)[C@]1(C)O,,,,"[""Excretion of pyrrolizidine alkaloids (pa's) in diet of rabbits was not affected by the addition of copper and zinc to the diet. Isolated pa's from Senecio jacobaea were found to be readily transferred across the mucosa of isolated everted sacs of jejunum and ileum in vitro against a concentration gradient. These results suggest that the effects of dietary Senecio jacobaea on alterations in mineral metabolism are not due to changes in GI mineral absorption. In addition, it appears that the resistance of rabbits to dietary Senecio jacobaea intoxication is not caused by low GI absorption of pyrrolizidine alkaloids, but rather by efficient urinary elimination.""]","['In general, the hepatotoxic pyrrolidine alkaloids are metabolized in rat liver to give hydrolysis products, n-oxides and dehydropyrrolizidine (pyrrolic) deriv. The latter group appears on current evidence to mediate most of toxic reactions of alkaloids. These pyrrolic deriv are produced by mixed-function oxidases of liver cells. Initial product formed from alkaloids that are esters of...retronecine (eg, jacobine...) is very probably the dehydroalkaloid. Dehydroalkaloids are highly reactive alkylating agents which react immediately with cell constituents to give soluble or bound secondary metabolites or which hydrolyze to dehydroaminoalcohol. /pyrrolizidine alkaloids/', 'The effect of prolonged phenobarbital (pb) administration on the toxicity of Senecio jacobaea (sj) was studied in sheep. Results suggested that mixed-function oxidase induction by pb does not increase the susceptibility of sheep to sj intoxication. Sheep possess a high activity of hepatic microsomal epoxide hydrolase which could account for their resistance to sj intoxication.', 'Comparison is made of the alkylating activities of a series of semi-synthetic pyrrole esters and pyrrole derivatives of pyrrolizidine alkaloids under pseudo-first-order reaction conditions. Data for alkylation by jacobine pyrrole (a reactive metabolite of jacobine) fit a simple first-order rate expression for product formation. The large increase in reaction rate for jacobine pyrrole is suggestive of an electronic field effect due to the epoxide ring in proximity to the C-7 ester moiety.']",
2741,442742,"[(7S,8R)-7-(2-methylbut-2-enoyloxy)-5,6,7,8-tetrahydro-3H-pyrrolizin-1-yl]methyl (2R)-2,3-dihydroxy-2-[(1S)-1-methoxyethyl]-3-methylbutanoate",CC=C(C)C(=O)O[C@H]1CCN2[C@@H]1C(=CC2)COC(=O)[C@@]([C@H](C)OC)(C(C)(C)O)O,,,,,,
2742,442743,CID 442743,CC=C(C)C(=O)O[C@@H]1CCN2[C@@H]1C(=CC2)COC(=O)[C@@]3([C@@H](C(=O)O[C@@H]3C)C)O,,,,,,
2743,442744,Frangulin B,CC1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=C(C=C3O)O[C@H]4[C@@H]([C@](CO4)(CO)O)O,,,,,,
2744,442745,Hibiscoquinone A,CC1=CC2=C(C(=C(C=C2C(C)C)O)C=O)C(=O)C1=O,,,,,,
2745,442746,Nemorensine,CC1C[C@@]2(CC(=O)O[C@@H]3CCN4[C@@H]3[C@H](CC4)COC(=O)[C@@]1(O2)C)C,,,,,,
2746,442747,Hypoxylone,C1=CC2=C(C=CC(=C2C(=C1)O)O)C3=CC(=O)C4=C(C3=O)C=CC=C4O,,,,,,
2747,442748,"(4R)-4-hydroxy-6-(hydroxymethyl)-1-methyl-2,3,4,8-tetrahydroazocin-5-one",CN1CC[C@H](C(=O)C(=CC1)CO)O,,,,,,
2748,442749,"(1R,4S,8R,9R,14S,20R)-4-hydroxy-8-methyl-4,9-di(propan-2-yl)-2,7,12-trioxa-17-azatricyclo[12.5.1.017,20]icosane-3,6,11-trione",C[C@@H]1[C@H](CC(=O)OC[C@H]2CCN3[C@H]2[C@@H](CC3)OC(=O)[C@](CC(=O)O1)(C(C)C)O)C(C)C,,,,,,
2749,442750,2-Isoprenylemodin,CC1=CC2=C(C(=C1)O)C(=O)C3=C(C(=C(C=C3C2=O)O)CC=C(C)C)O,,,,,,
2750,442751,Phalaenopsine T,COC(=O)C[C@](CC1=CC=CC=C1)(C(=O)OC[C@H]2CCN3[C@H]2CCC3)O,,,,,,
2751,442752,Kigelinone,C[C@@H](C1=CC2=C(O1)C(=O)C3=C(C2=O)C=CC=C3O)O,,,,,,
2752,442753,Knipholone,CC1=CC(=C2C(=C1C3=C(C(=C(C=C3O)OC)C(=O)C)O)C(=O)C4=C(C2=O)C(=CC=C4)O)O,,,,,,
2753,442754,9-Methoxy-alpha-lapachone,CC1(CCC2=C(O1)C(=O)C3=C(C2=O)C=CC=C3OC)C,,,,,,
2754,442755,"(1R,7S,17R)-4-ethylidene-7-hydroxy-7-(hydroxymethyl)-6-methylidene-2,9-dioxa-14-azatricyclo[9.5.1.014,17]heptadec-11-ene-3,8-dione",CC=C1CC(=C)[C@@](C(=O)OCC2=CCN3[C@H]2[C@@H](CC3)OC1=O)(CO)O,,,,,,
2755,442756,Morindone,CC1=C(C2=C(C=C1)C(=O)C3=C(C2=O)C=CC(=C3O)O)O,,,,,,
2756,442757,Nanaomycin A,C[C@H]1C2=C(C[C@@H](O1)CC(=O)O)C(=O)C3=C(C2=O)C(=CC=C3)O,,,,,,
2757,442758,Rinderine,C[C@H]([C@@](C(C)C)(C(=O)OCC1=CCN2[C@H]1[C@H](CC2)O)O)O,,,,,,
2758,442759,2-Hydroxychrysophanol,CC1=CC2=C(C(=C1O)O)C(=O)C3=C(C2=O)C=CC=C3O,,,,,,
2759,442760,CID 442760,CC=C1C[C@H]([C@@](C(=O)OC[C@H]2[C@@H](CN3[C@H]2[C@@H](CC3)OC1=O)O)(C)O)C,,,,,,
2760,442761,Obtusifolin 2-glucoside,CC1=CC2=C(C(=C1O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)OC)C(=O)C4=C(C2=O)C=CC=C4O,,,,,,
2761,442762,Physcion 8-gentiobioside,CC1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=C(C=C3O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O)O)O)OC,,,,,,
2762,442763,"2,3-Dimethyl-5-(3,7,11,14,19,23,27,31,35-nonamethylhexatriaconta-2,6,10,14,18,22,26,30,34-nonaenyl)cyclohexa-2,5-diene-1,4-dione",CC1=C(C(=O)C(=CC1=O)CC=C(C)CCC=C(C)CCC=C(C)CCC(=CCCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C)C,,,,,,
2763,442764,Senecivernine,C[C@@H]1[C@H]([C@@](C(=O)OCC2=CCN3[C@H]2[C@@H](CC3)OC(=O)C1=C)(C)O)C,,,,,,
2764,442765,Pseudopurpurin,C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=C(C(=C3O)C(=O)O)O)O,,,,,,
2765,442766,Purpurin 1-methyl ether,COC1=C(C=C(C2=C1C(=O)C3=CC=CC=C3C2=O)O)O,,,,,,
2766,442767,Ventinone A,CC1=C(C(=C2C(=C1O)C(=O)C3=C(C2=O)C(=CC(=C3)OC)O)O)C,,,,,,
2767,442768,Dalbergin,COC1=C(C=C2C(=CC(=O)OC2=C1)C3=CC=CC=C3)O,,,,,"['6-Hydroxy-7-methoxyl-4-phenylcoumarin has known human metabolites that include 7-methoxyl-4-phenylcoumarin, 6-O-glucuronide.']",
2768,442769,Dalpanin,CC(C)(C1CC2=CC(=C(C=C2O1)O)C3COC4=C(C(=CC(=C4C3=O)O)O)[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O,,,,,,
2769,442770,(+-)-5-Deoxykievitone,CC(=CCC1=C(C=CC2=C1OCC(C2=O)C3=C(C=C(C=C3)O)O)O)C,,,,,,
2770,442771,Ferreirin,COC1=CC(=C(C=C1)C2COC3=CC(=CC(=C3C2=O)O)O)O,,,,,,
2771,442772,CID 442772,C1=CC(=CC=C1C2=COC3=C(C(=CC(=O)C3=C2O)O)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O,,,,,,
2772,442773,Hildecarpin,COC1=C(C=C2C(=C1)[C@H]3[C@@](CO2)(C4=CC5=C(C=C4O3)OCO5)O)O,,,,,,
2773,442774,Hispaglabridin A,CC(=CCC1=C(C=CC(=C1O)[C@H]2CC3=C(C4=C(C=C3)OC(C=C4)(C)C)OC2)O)C,,,,,,
2774,442775,4-(Acetyloxy)-alpha-ethenyl-3-methoxybenzenemethanol acetate,CC(=O)OC1=C(C=C(C=C1)[C@H](C=C)OC(=O)C)OC,,,,,,
2775,442776,Caffeic Acid 3-beta-D-Glucoside,C1=CC(=C(C=C1C=CC(=O)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O,,,,,,
2776,442777,CID 442777,C1[C@@H](CC(C[C@H]1O)(C(=O)O)OC(=O)C=CC2=CC(=C(C=C2)O)O)O,,,,,,
2777,442778,"[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] 3-(3,4-dihydroxyphenyl)prop-2-enoate",C1=CC(=C(C=C1C=CC(=O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O,,,,,,
2778,442779,"5-Methoxy-6-prop-1-enyl-1,3-benzodioxole",CC=CC1=CC2=C(C=C1OC)OCO2,,,,,,
2779,442780,Centrolobine,COC1=CC=C(C=C1)[C@@H]2CCC[C@@H](O2)CCC3=CC=C(C=C3)O,,,,,,
2780,442781,"[(2S,3S,4S,5R,6R)-5-hydroxy-2-methyl-6-[[(2R,3S,4S,5R,6R)-3,4,5-trihydroxy-6-[2-(4-hydroxyphenyl)ethoxy]oxan-2-yl]methoxy]-4-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-3-yl] 3-phenylprop-2-enoate",C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OCCC3=CC=C(C=C3)O)O)O)O)O)O[C@H]4[C@@H]([C@H]([C@@H](CO4)O)O)O)OC(=O)C=CC5=CC=CC=C5,,,,,,
2781,442782,"(3R,5R)-1,3,5-trihydroxy-4-[3-(4-hydroxyphenyl)prop-2-enoyloxy]cyclohexane-1-carboxylic acid",C1[C@H](C([C@@H](CC1(C(=O)O)O)O)OC(=O)C=CC2=CC=C(C=C2)O)O,,,,,,
2782,442783,"1,4,6-Heptatrien-3-one, 5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)-",COC1=C(C=CC(=C1)C=CC(=CC(=O)C=CC2=CC(=C(C=C2)O)OC)O)O,,,,,,
2783,442784,"1-[3-(3,4-Dimethoxyphenyl)prop-2-enoyl]piperidin-2-one",COC1=C(C=C(C=C1)C=CC(=O)N2CCCCC2=O)OC,,,,,,
2784,442785,3-[3-[5-(2-Carboxyethenyl)-2-hydroxy-3-methoxyphenyl]-4-hydroxy-5-methoxyphenyl]prop-2-enoic acid,COC1=CC(=CC(=C1O)C2=C(C(=CC(=C2)C=CC(=O)O)OC)O)C=CC(=O)O,,,,,,
2785,442786,"[(2R,3R,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-2-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-4-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] 3-(3,4-dihydroxyphenyl)prop-2-enoate",C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H](O[C@@H]([C@H]2OC(=O)C=CC3=CC(=C(C=C3)O)O)CO[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)OCCC5=CC(=C(C=C5)O)O)O)O)O)O,,,,,,
2786,442787,"[(2R,3S,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-4,5-dihydroxy-2-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-3-yl] 3-(3,4-dihydroxyphenyl)prop-2-enoate",C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OCCC3=CC(=C(C=C3)O)O)O)O)OC(=O)C=CC4=CC(=C(C=C4)O)O)O)O)O,,,,,,
2787,442788,Homoferreirin,COC1=CC(=C(C=C1)C2COC3=CC(=CC(=C3C2=O)O)O)OC,,,,,,
2788,442789,Furcatin,C=CCC1=CC=C(C=C1)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO[C@H]3[C@@H]([C@](CO3)(CO)O)O)O)O)O,,,,,,
2789,442790,3-Hydroxy-1-(4-hydroxy-3-methoxyphenyl)dec-3-en-5-one,CCCCCC(=O)C=C(CCC1=CC(=C(C=C1)O)OC)O,,,,,,
2790,442791,CID 442791,COC1=C(C=CC(=C1)CCC=CC(=O)CCC2=CC(=C(C=C2)O)OC)O,,,,,,
2791,442792,4-Hydroxyhomopterocarpin,COC1=CC2=C(C=C1)[C@@H]3COC4=C([C@@H]3O2)C=CC(=C4O)OC,,,,,,
2792,442793,Gingerol,CCCCC[C@@H](CC(=O)CCC1=CC(=C(C=C1)O)OC)O,,,,,,
2793,442794,"[(2R,3R,4S,5S,6R)-4,5-dihydroxy-2-[(1R,2S)-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxan-3-yl] 3-(4-hydroxyphenyl)prop-2-enoate",C1CC[C@H]([C@H](C1)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)OC(=O)C=CC3=CC=C(C=C3)O,,,,,,
2794,442795,CID 442795,C1=CC(=C(C=C1C=CC(=O)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)OC[C@H](C4=CC(=C(C=C4)O)O)O)CO)O)O,,,,,,
2795,442796,CID 442796,C1OC2=C(O1)C(=O)C3=C(C(=COC3=C2)C4=CC=C(C=C4)O)O,,,,,,
2796,442797,CID 442797,COC1=CC=C(C=C1)C2=COC3=CC(=O)C(=C(C3=C2O)O)OC,,,,,,
2797,442798,"[(2R,3R,4R,5R,6R)-5-hydroxy-6-[2-(3-hydroxy-4-methoxyphenyl)ethoxy]-2-[[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-4-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] 3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate",C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H](O[C@@H]([C@H]2OC(=O)C=CC3=CC(=C(C=C3)O)OC)CO[C@H]4[C@@H]([C@H]([C@H]([C@H](O4)CO)O)O)O)OCCC5=CC(=C(C=C5)OC)O)O)O)O)O,,,,,,
2798,442799,Lusitanicoside,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=CC=C(C=C3)CC=C)O)O)O)O)O)O,,,,,,
2799,442800,"[(2R,3R,4R,5R,6R)-4-[(2S,3R,4R,5S,6S)-4-[(2S,3R,4R)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxy-6-methyloxan-2-yl]oxy-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-2-(hydroxymethyl)oxan-3-yl] 3-(3,4-dihydroxyphenyl)prop-2-enoate",C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H](O[C@@H]([C@H]2OC(=O)C=CC3=CC(=C(C=C3)O)O)CO)OCCC4=CC(=C(C=C4)O)O)O)O)O[C@H]5[C@@H]([C@](CO5)(CO)O)O)O,,,,,,
2800,442801,CID 442801,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC[C@H](C3=CC(=C(C=C3)O)O)O)CO)OC(=O)C=CC4=CC(=C(C=C4)O)O)O)O)O)O,,,,,,
2801,442802,"(2S)-2-[3-(3,4-dihydroxyphenyl)prop-2-enoyloxy]butanedioic acid",C1=CC(=C(C=C1C=CC(=O)O[C@@H](CC(=O)O)C(=O)O)O)O,,,,,,
2802,442803,"[(2R,3R,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-2-[[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-4-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] 3-(3,4-dihydroxyphenyl)prop-2-enoate",C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H](O[C@@H]([C@H]2OC(=O)C=CC3=CC(=C(C=C3)O)O)CO[C@H]4[C@@H]([C@H]([C@H]([C@H](O4)CO)O)O)O)OCCC5=CC(=C(C=C5)O)O)O)O)O)O,,,,,,
2803,442804,CID 442804,CC(=CCC1=C2C(=C(C3=C1OC(C=C3)(C)C)OC)C(=O)C(=C(O2)O)C4=CC=C(C=C4)OC)C,,,,,,
2804,442805,Lotisoflavan,COC1=CC2=C(CC(CO2)C3=C(C=C(C=C3)O)O)C(=C1)OC,,,,,,
2805,442806,CID 442806,CC(=CCC1=C(C2=C(C(=COC2=CC1=O)C3=C(C=C(C=C3)O)O)O)O)C,,,,,,
2806,442807,"(3R,5R)-1,3,4,5-tetrakis[3-(3,4-dihydroxyphenyl)prop-2-enoyloxy]cyclohexane-1-carboxylic acid",C1[C@H](C([C@@H](CC1(C(=O)O)OC(=O)C=CC2=CC(=C(C=C2)O)O)OC(=O)C=CC3=CC(=C(C=C3)O)O)OC(=O)C=CC4=CC(=C(C=C4)O)O)OC(=O)C=CC5=CC(=C(C=C5)O)O,,,,,,
2807,442808,Melannin,COC1=C(C=C2C(=CC(=O)OC2=C1)C3=CC=C(C=C3)O)O,,,,,,
2808,442809,(R)-4-Methoxydalbergione,COC1=CC(=O)C(=CC1=O)[C@H](C=C)C2=CC=CC=C2,,,,,,
2809,442810,Millettone,CC1(C=CC2=C(O1)C=CC3=C2O[C@@H]4COC5=CC6=C(C=C5[C@@H]4C3=O)OCO6)C,,,,,,
2810,442811,Mucronulatol,COC1=C(C(=C(C=C1)[C@@H]2CC3=C(C=C(C=C3)O)OC2)OC)O,,,,,,
2811,442812,(-)-Nissolin,COC1=C(C=CC2=C1O[C@@H]3[C@H]2COC4=C3C=CC(=C4)O)O,,,,,,
2812,442813,Ononin,COC1=CC=C(C=C1)C2=COC3=C(C2=O)C=CC(=C3)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O,,,,,,
2813,442814,Pachyrrhizone,COC1=C2C(=CC3=C1O[C@@H]4COC5=CC6=C(C=C5[C@@H]4C3=O)OCO6)C=CO2,,,,,,
2814,442815,2-(beta-D-Glucosyl)-sn-glycerol3-phosphate,C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)OC(CO)COP(=O)(O)O)O)O)O)O,,,,,,
2815,442816,CID 442816,CC(=CCC1=C(C(=C(C(=C1O)N)OC)CC=C(C)C)C2=COC3=CC(=O)C=C(C3=C2O)O)C,,,,,,
2816,442817,CID 442817,COC1=C(C=C(C=C1)C2=COC3=CC(=O)C=C(C3=C2O)O)O,,,,,,
2817,442818,CID 442818,C1=CC(=CC=C1C2=COC3=C(C(=O)C=CC3=C2O)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O,,,,,,
2818,442819,Rotenonone,CC(=C)[C@H]1CC2=C(O1)C=CC3=C2OC4=C(C3=O)C5=CC(=C(C=C5OC4=O)OC)OC,,,,,,
2819,442820,Sayanedine,COC1=CC2=C(C=C1)C(=O)C(=CO2)C3=CC(=C(C=C3)O)OC,,,,,,
2820,442821,"2-[(2,3,4-Trihydroxy-5-phosphonooxypent-1-enyl)amino]benzoic acid",C1=CC=C(C(=C1)C(=O)O)NC=C(C(C(COP(=O)(O)O)O)O)O,,,,,,
2821,442822,Sophoraisoflavanone A,CC(=CCC1=C(C=CC(=C1OC)C2COC3=CC(=CC(=C3C2=O)O)O)O)C,,,,,,
2822,442823,(-)-Sparticarpin,COC1=C(C=C2C(=C1)[C@H]3[C@@H](CO2)C4=C(O3)C=C(C=C4)O)OC,,,,,,
2823,442824,Sumatrol,CC(=C)[C@H]1CC2=C(O1)C=C(C3=C2O[C@@H]4COC5=CC(=C(C=C5[C@@H]4C3=O)OC)OC)O,,,,,,
2824,442825,CID 442825,COC1=CC=C(C=C1)C2=COC3=CC(=O)C(=CC3=C2O)O,,,,,,
2825,442826,alpha-Toxicarol,CC1(C=CC2=C(O1)C=C(C3=C2O[C@@H]4COC5=CC(=C(C=C5[C@@H]4C3=O)OC)OC)O)C,,,,,,
2826,442827,Trifolirhizin,C1[C@@H]2[C@H](C3=C(O1)C=C(C=C3)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)OC5=CC6=C(C=C25)OCO6,,,,,,
2827,442828,(-)-Variabilin,COC1=CC2=C(C=C1)[C@@H]3[C@](CO2)(C4=C(O3)C=C(C=C4)OC)O,,,,,,
2828,442829,CID 442829,COC1=CC(=O)C2=C3C(=C(OC2=C1)O)C4=CC(=C(C=C4O3)O)O,,,,,,
2829,442830,Acanthoside D,COC1=CC(=CC(=C1O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)OC)[C@H]3[C@@H]4CO[C@H]([C@@H]4CO3)C5=CC(=C(C(=C5)OC)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)OC,,,,,,
2830,442831,1-Acetoxypinoresinol,CC(=O)O[C@]12CO[C@@H]([C@H]1CO[C@@H]2C3=CC(=C(C=C3)O)OC)C4=CC(=C(C=C4)O)OC,,,,,,
2831,442832,"5-[[(3R,4R)-4-[(3,4,5-trimethoxyphenyl)methyl]oxolan-3-yl]methyl]-1,3-benzodioxole",COC1=CC(=CC(=C1OC)OC)C[C@H]2COC[C@@H]2CC3=CC4=C(C=C3)OCO4,,,,,,
2832,442833,"9-(1,3-benzodioxol-5-yl)-4-[(3R,4R,5R)-3-hydroxy-4,5-dimethoxy-tetrahydropyran-2-yl]oxy-6,7-dimethoxy-3H-benzo[f]isobenzofuran-1-one",CO[C@@H]1COC([C@@H]([C@H]1OC)O)OC2=C3COC(=O)C3=C(C4=CC(=C(C=C42)OC)OC)C5=CC6=C(C=C5)OCO6,,,,,,
2833,442834,Denudatin B,C[C@@H]1[C@H](OC2=CC(=O)C(=C[C@@]12OC)CC=C)C3=CC(=C(C=C3)OC)OC,,,,,,
2834,442835,Yatein,COC1=CC(=CC(=C1OC)OC)C[C@@H]2[C@H](COC2=O)CC3=CC4=C(C=C3)OCO4,,,,,,
2835,442836,Eucommin A,COC1=CC(=CC(=C1O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)OC)[C@@H]3[C@H]4CO[C@@H]([C@H]4CO3)C5=CC(=C(C=C5)O)OC,,,,,,
2836,442837,Eudesobovatol A,C[C@]12CCC[C@@]([C@@H]1C[C@@H](CC2)C(C)(C)O)(C)OC3=CC(=CC(=C3O)OC4=CC=C(C=C4)CC=C)CC=C,,,,,,
2837,442838,Fargesone A,C[C@@H]1[C@H](O[C@@H]2[C@]1(C(=CC(=O)[C@H]2CC=C)OC)OC)C3=CC4=C(C=C3)OCO4,,,,,,
2838,442839,O-Acetylcypholophine,CC1=C(N=C(N1)CCCCOC(=O)C)CCC2=CC(=C(C=C2)OC)OC,,,,,,
2839,442840,Acutumidine,COC1=CC(=O)[C@@]2([C@@H]1O)[C@H](C[C@@]34[C@@]2(CCN3)CC(=O)C(=C4OC)OC)Cl,,,,,,
2840,442841,Alchornine,CC(=C)C1CN2C(=O)CC(NC2=N1)(C)C,,,,,,
2841,442842,(4R)-3-benzylidene-4-(1-methylimidazol-4-yl)pyrrolidin-2-one,CN1C=C(N=C1)[C@H]2CNC(=O)C2=CC3=CC=CC=C3,,,,,,
2842,442843,"(7S)-6,7-Dihydro-2-hydroxy-1,3,10-trimethoxy-14-methyl-7,11a-(iminoethano)-11aH-dibenzo[a,c]cyclohepten-9(5H)-one",CN1CC[C@@]23C=C(C(=O)C=C2[C@H]1CCC4=CC(=C(C(=C34)OC)O)OC)OC,,,,,,
2843,442844,"2-[2-(3,4-Dimethoxyphenyl)ethenyl]-5-(4-methoxyphenyl)-1,3-oxazole",COC1=CC=C(C=C1)C2=CN=C(O2)C=CC3=CC(=C(C=C3)OC)OC,,,,,,
2844,442845,Balsoxine,COC1=C(C=C(C=C1)C2=CN=C(O2)C3=CC=CC=C3)OC,,,,,,
2845,442846,Cannabisativine,CCCCC[C@H]([C@H]([C@@H]1C=CC[C@@H]2N1CCCNCCCCNC(=O)C2)O)O,,,,,,
2846,442847,Celabenzine,C1CCN(CCCNC(=O)C[C@H](NC1)C2=CC=CC=C2)C(=O)C3=CC=CC=C3,,,,,,
2847,442848,CID 442848,CC=C(C)C(=O)N[C@@H](C1=CC=CC=C1)[C@H](C(=O)O[C@H]2C[C@]3([C@H](C4[C@@]([C@H](C[C@@H]5[C@]4(CO5)OC(=O)C)O)(C(=O)[C@@H](C(=C2C)C3(C)C)OC(=O)C)C)OC(=O)C6=CC=CC=C6)O)O,,,,,,
2848,442849,Cichorine,CC1=C(C=C2C(=C1OC)CNC2=O)O,,,,,,
2849,442850,Crinasiadine,C1OC2=C(O1)C=C3C(=C2)C4=CC=CC=C4NC3=O,,,,,,
2850,442851,Crinasiatine,C1C(OC2=C(O1)C=C3C4=CC=CC=C4NC(=O)C3=C2)CC5=CC=C(C=C5)O,,,,,,
2851,442852,CID 442852,COC1=C(C=C2C(=C1)[C@@H]3C[C@H]([C@H]4CCCCN4C3)OC(=O)C=CC5=CC2=C(C=C5)O)OC,,,,,,
2852,442853,Cynometrine,CN1C[C@H]([C@@H](C1=O)[C@@H](C2=CC=CC=C2)O)C3=CN(C=N3)C,,,,,,
2853,442854,(+)-Elaeocarpine,CC1=C2C(=CC=C1)O[C@@H]3CCN4CCC[C@@H]4[C@H]3C2=O,,,,,,
2854,442855,Elaeokanine C,CCCC(=O)[C@@H]1[C@H]2CCCN2CC[C@@H]1O,,,,,,
2855,442856,Exserohilone,CS[C@]12C[C@@H]3[C@@H](N1C(=O)[C@]4(C[C@@H]5[C@@H](N4C2=O)[C@@H](C=CC5=O)O)SC)[C@@H](C=CC3=O)O,,,,,,
2856,442857,CID 442857,CN1CCCC1C2=C3C(=C(C=C(O3)C4=CC=CC=C4)O)C(=O)C=C2O,,,,,,
2857,442858,Halfordinol,C1=CC(=CN=C1)C2=NC=C(O2)C3=CC=C(C=C3)O,,,,,,
2858,442859,CID 442859,C[C@@H]1CCC[C@H](N1C)C=C[C@@H]2[C@H]3CCCC[C@@H]3C[C@H]4[C@@H]2[C@@H](OC4=O)C,,,,,,
2859,442860,Homaline,CN1CCCN(C(=O)C[C@H]1C2=CC=CC=C2)CCCCN3CCCN([C@@H](CC3=O)C4=CC=CC=C4)C,,,,,,
2860,442861,Isoficine,CN1CCCC1C2=C(C3=C(C=C2O)OC(=CC3=O)C4=CC=CC=C4)O,,,,,,
2861,442862,CID 442862,CC1CC(NC1=O)C2=C3C(=C(C(=C(O3)C4=CC=C(C=C4)O)O)O)C(=O)C=C2O,,,,,,
2862,442863,"(1S,23R)-22-oxa-5,10,14-triazatetracyclo[16.9.2.01,23.021,28]nonacosa-2,16,18(29),19,21(28)-pentaene-4,15,25-trione",C1CCNC(=O)C=C[C@]23CCC(=O)C[C@H]2OC4=C3C=C(C=C4)C=CC(=O)NCCCNC1,,,,,,
2863,442864,Lythramine,CC(=O)O[C@H]1CCC2=CC(=C(C=C2)OC)C3=C(C=CC(=C3)CC[C@H]4C[C@H]5CCC[C@H](C1)N5CO4)O,,,,,,
2864,442865,CID 442865,C[C@@H]1[C@@H]2C[C@]([C@@H](C=CC=C(CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)C[C@@H]([C@]4([C@H]1O4)C)OC(=O)[C@@H](C)N(C)C(=O)C)C)C)OC)(NC(=O)O2)O,,,,,,
2865,442866,Mycosporine,COC1=C(C[C@](CC1=O)(CO)O)NC(CO)CO,,,,,,
2866,442867,Palustrine,CC[C@@H]([C@@H]1CC=C[C@H]2N1CCCNCCCCNC(=O)C2)O,,,,,,
2867,442868,Phyllospadine,CN1CCCC1C2=C3C(=C(C(=C2O)OC)O)C(=O)C=C(O3)C4=CC=C(C=C4)O,,,,,,
2868,442869,Pilosine,CN1C=NC=C1C[C@H]2COC(=O)[C@H]2[C@H](C3=CC=CC=C3)O,,,,,,
2869,442870,Pithecolobine,CCCCCCCCCC1CC(=O)NCCCNCCCCNCCCN1,,,,,,
2870,442871,"10-Methoxy-9-methyl-8-(3-methylbut-2-enoxy)-1,3,4,5-tetrahydro-2,5-benzoxazocin-6-one",CC1=C(C=C2C(=C1OC)COCCNC2=O)OCC=C(C)C,,,,,,
2871,442872,Securinine,C1CCN2[C@H](C1)[C@]34C[C@H]2C=CC3=CC(=O)O4,,,,,,
2872,442873,(+)-Galbacin,C[C@@H]1[C@H]([C@@H](O[C@H]1C2=CC3=C(C=C2)OCO3)C4=CC5=C(C=C4)OCO5)C,,,,,,
2873,442874,Sirodesmin H,C[C@@H]1C(C(=O)[C@]2(O1)C[C@@H]3[C@]([C@@H]2OC(=O)C)(C[C@@]45N3C(=O)[C@@](S4)(N(C5=O)C)CO)O)(C)C,,,,,,
2874,442875,(-)-Tylocrebrine,COC1=C(C2=C(C=C1)C3=C(C[C@@H]4CCCN4C3)C5=CC(=C(C=C52)OC)OC)OC,,,,,,
2875,442876,Grandisin,C[C@H]1[C@@H]([C@H](O[C@@H]1C2=CC(=C(C(=C2)OC)OC)OC)C3=CC(=C(C(=C3)OC)OC)OC)C,,,,,,
2876,442877,Withasomnine,C1CC2=C(C=NN2C1)C3=CC=CC=C3,,,,,,
2877,442878,Zinnimidine,CC1=C(C=C2C(=C1OC)CNC2=O)OCC=C(C)C,,,,,,
2878,442879,Hinokinin,C1[C@@H]([C@H](C(=O)O1)CC2=CC3=C(C=C2)OCO3)CC4=CC5=C(C=C4)OCO5,,,,,,
2879,442880,"4-[(3S)-3-(4-Hydroxyphenyl)penta-1,4-dienyl]phenol",C=C[C@@H](C=CC1=CC=C(C=C1)O)C2=CC=C(C=C2)O,,,,,,
2880,442881,Aniflorine,CN(C)C1=CC=CC=C1[C@@]2(CCN3C2=NC4=C(C3=O)C=CC=C4OC)O,,,,,,
2881,442882,Justicidin B,COC1=CC2=CC3=C(C(=C2C=C1OC)C4=CC5=C(C=C4)OCO5)C(=O)OC3,,,,,,
2882,442883,Anisessine,CCOC(=O)C1=CC=CC=C1NC2CCN3C2=NC4=CC=CC=C4C3=O,,,,,,
2883,442884,Anisotine,CNC1=C(C=C(C=C1)C2CCN3C2=NC4=CC=CC=C4C3=O)C(=O)OC,,,,,,
2884,442885,Kadsurin A,C[C@@H]1[C@H](O[C@]2([C@@]1(C=C(C(=O)C2)CC=C)OC)OC)C3=CC4=C(C=C3)OCO4,,,,,,
2885,442886,CID 442886,CC(C)[C@@H]1[C@H](C2=C3C(=C(C4=C(N3C)C(=CC=C4)OC5=C(C6=C(C=C5)C(=C7C(=CC(=CC7=O)OC)N6C)O)O)O)C(=O)C=C2O1)O,,,,,,
2886,442887,Atalaphylline,CC(=CCC1=C2C(=C(C(=C1O)CC=C(C)C)O)C(=O)C3=C(N2)C(=CC=C3)O)C,,,,,,
2887,442888,Balfourodine,CC(C)([C@H]1CC2=C(O1)N(C3=C(C2=O)C=CC=C3OC)C)O,,,,,,
2888,442889,"4-(6,7-dihydroxy-3,7-dimethyloct-2-enoxy)-1H-quinolin-2-one",CC(=CCOC1=CC(=O)NC2=CC=CC=C21)CCC(C(C)(C)O)O,,,,,,
2889,442890,"2-methoxy-4-[(2S,3S)-7-methoxy-3-methyl-5-prop-1-enyl-2,3-dihydro-1-benzofuran-2-yl]phenol",CC=CC1=CC2=C(C(=C1)OC)O[C@@H]([C@H]2C)C3=CC(=C(C=C3)O)OC,,,,,,
2890,442891,CID 442891,CC(C1=C(NC2=CC=CC=C2C1=O)O)C3(CCC(C(O3)(C)C)O)C,,,,,,
2891,442892,CID 442892,CC(=CCC1=C(C2=C(C3=C(C(=C(C=C3)O)OC)N(C2=CC1=O)C)O)O)C,,,,,,
2892,442893,Cusparine,COC1=CC(=NC2=CC=CC=C21)CCC3=CC4=C(C=C3)OCO4,,,,,,
2893,442894,Deoxypeganine,C1CC2=NC3=CC=CC=C3CN2C1,,,,,,
2894,442895,"2,4-Dimethyl-3,5-bis(2,4,5-trimethoxyphenyl)oxolane",C[C@H]1[C@@H]([C@@H](O[C@@H]1C2=CC(=C(C=C2OC)OC)OC)C)C3=CC(=C(C=C3OC)OC)OC,,,,,,
2895,442896,"(1S,2R)-5,7,8-trimethoxy-2,3-dimethyl-1-(2,4,5-trimethoxyphenyl)-1,2-dihydronaphthalene",C[C@@H]1[C@H](C2=C(C=C1C)C(=CC(=C2OC)OC)OC)C3=CC(=C(C=C3OC)OC)OC,,,,,,
2896,442897,Dubinidine,CC(CO)(C1CC2=C(C3=CC=CC=C3N=C2O1)OC)O,,,,,,
2897,442898,Echinorine,C[N+]1=CC=C(C2=CC=CC=C21)OC,,,,,,
2898,442899,Evoxanthidine,COC1=C2C(=CC3=C1OCO3)NC4=CC=CC=C4C2=O,,,,,,
2899,442900,Agrimol C,CCCC(=O)C1=C(C(=C(C(=C1O)CC2=C(C(=C(C(=C2O)C)OC)C(=O)CCC)O)O)CC3=C(C(=C(C(=C3O)C)OC)C(=O)CCC)O)O,,,,,,
2900,442901,Agrimophol,CCCC(=O)C1=C(C(=C(C(=C1O)C[C@]2(C(=C(C(=C(C2=O)C(=O)[C@H](C)CC)O)C)O)C)O)C)OC,,,,,,
2901,442902,CID 442902,CN1C2=CC=CC=C2C(=C3C1=C4C=COC4=CC3=O)O,,,,,,
2902,442903,"3-[2-(3,4-Dimethoxyphenyl)ethyl]-4-methoxyquinoline",COC1=C(C=C(C=C1)CCC2=C(C3=CC=CC=C3N=C2)OC)OC,,,,,,
2903,442904,"2',6'-Dimethoxy-4'-hydroxyacetophenone",CC(=O)C1=C(C=C(C=C1OC)O)OC,,,,,,
2904,442905,CID 442905,CC(=CCC1=C2C(=C(C(=C1O)C3CC(OC4=CC(=O)C5=C(C6=CC=CC=C6NC5=C34)O)(C)C)O)C(=O)C7=CC=CC=C7N2C)C,,,,,,
2905,442906,Glycoperine,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(C3=C(C=C2)C(=C4C=COC4=N3)OC)OC)O)O)O,,,,,,
2906,442907,Glycophymoline,COC1=NC(=NC2=CC=CC=C21)CC3=CC=CC=C3,,,,,,
2907,442908,Megaphone,C[C@H]([C@H](C1=CC(=C(C(=C1)OC)OC)OC)O)[C@]2(C[C@H](C=CC2=O)OC)CC=C,,,,,,
2908,442909,Haplodimerine,CC1([C@H]2[C@H]([C@@H]3[C@H]2OC4=NC5=C(C=CC(=C5OC)OC)C(=C34)OC)C6=C(O1)C7=CC=CC=C7NC6=O)C,,,,,,
2909,442910,Haplophyllidine,CC(=CC[C@@]1([C@@H](CCC2=C1N=C3C(=C2OC)C=CO3)O)OC)C,,,,,,
2910,442911,Humulon,CC(C)CC(=O)C1=C(C(=C([C@@](C1=O)(CC=C(C)C)O)O)CC=C(C)C)O,,,,,,
2911,442912,"(S)-[(2R,5R)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol",CC[C@H]1CN2CCC1C[C@@H]2[C@H](C3=C4C=C(C=CC4=NC=C3)OC)O,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)']",,,
2912,442913,Isodictamnine,CN1C2=CC=CC=C2C(=O)C3=C1OC=C3,,,,,,
2913,442914,"3-[[(3aS,7aR)-2-hydroxy-3a,4,5,6,7,7a-hexahydro-3H-furo[3,2-b]pyridin-2-yl]methyl]quinazolin-4-one",C1C[C@@H]2[C@H](CC(O2)(CN3C=NC4=CC=CC=C4C3=O)O)NC1,,,,,,
2914,442915,Japonine,CN1C2=C(C=C(C=C2)OC)C(=O)C(=C1C3=CC=CC=C3)OC,,,,,,
2915,442916,4-Hydroxy-3-(3-methyl-2-butenyl)acetophenone,CC(=CCC1=C(C=CC(=C1)C(=O)C)O)C,,,,,,
2916,442917,Lemobiline,CC1C2=C(N(C3=CC=CC=C3C2=O)C)OC1(C)C,,,,,,
2917,442918,Neoisostegane,COC1=C(C=C2C(=C1)C[C@H]3COC(=O)[C@@H]3CC4=C(C(=C(C=C42)OC)OC)OC)OC,,,,,,
2918,442919,"2-Methyl-1-(2,4,6-trihydroxyphenyl)butan-1-one",CCC(C)C(=O)C1=C(C=C(C=C1O)O)O,,,,,,
2919,442920,Lunacridine,CC(C)[C@@H](CC1=C(C2=C(C(=CC=C2)OC)N(C1=O)C)OC)O,,,,,,
2920,442921,Lunacrine,CC(C)[C@H]1CC2=C(O1)N(C3=C(C2=O)C=CC=C3OC)C,,,,,,
2921,442922,Lunamarine,CN1C(=CC(=O)C2=C1C=C(C=C2)OC)C3=CC4=C(C=C3)OCO4,,,,,,
2922,442923,Paeonolide,CC(=O)C1=C(C=C(C=C1)OC)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO[C@H]3[C@@H]([C@H]([C@H](CO3)O)O)O)O)O)O,,,,,,
2923,442924,Paeonoside,CC(=O)C1=C(C=C(C=C1)OC)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O,,,,,,
2924,442925,Maculosine,CC(C)(C(COC1=C2C=COC2=NC3=CC4=C(C=C31)OCO4)O)O,,,,,,
2925,442926,Tricyclodehydroisohumulone,CC(C)CC(=O)C1=C([C@]23C[C@@H](C([C@H]2CC(=O)[C@@]3(C1=O)O)(C)C)C(=C)C)O,,,,,,
2926,442927,Melochinone,CC1=C(C(=O)C2=C(N1)C=CC3=C2CCCC=C3C4=CC=CC=C4)OC,,,,,,
2927,442928,Otobain,C[C@H]1CC2=C([C@H]([C@@H]1C)C3=CC4=C(C=C3)OCO4)C5=C(C=C2)OCO5,,,,,,
2928,442929,"(3R)-1,2,3,9-tetrahydropyrrolo[2,1-b]quinazolin-3-ol",C1CN2CC3=CC=CC=C3N=C2[C@@H]1O,,,,,,
2929,442930,Pteleatine,CC(C)([C@H]1CC2=C(C3=C(C(=CC=C3)O)[N+](=C2O1)C)OC)O,,,,,,
2930,442931,"Furo(2,3-b)quinolinium, 2,3-dihydro-6-hydroxy-2-(1-hydroxy-1-methylethyl)-4-methoxy-9-methyl-, (R)-",CC(C)([C@H]1CC2=C(C3=C(C=CC(=C3)O)[N+](=C2O1)C)OC)O,,,,,,
2931,442932,Phrymarolin I,CC(=O)O[C@]12CO[C@@H]([C@H]1CO[C@H]2OC3=C(C=C4C(=C3)OCO4)OC)C5=CC6=C(C=C5OC)OCO6,,,,,,
2932,442933,Swietenidin B,COC1=C(C(=O)NC2=CC=CC=C21)OC,,,,,,
2933,442934,Vasicinol,C1CN2CC3=C(C=CC(=C3)O)N=C2[C@H]1O,,,,,,
2934,442935,Vasicinone,C1CN2C(=NC3=CC=CC=C3C2=O)[C@H]1O,,,,,,
2935,442936,Albine,C=CC[C@@H]1[C@H]2C[C@H](CN1)CN3[C@@H]2CC(=O)C=C3,,,,,,
2936,442937,"(6R,6aR,13S,13aS)-1,3,4,6,6a,7,8,9,10,12,13,13a-dodecahydro-2H-6,13-methanodipyrido[1,2-a:3',2'-e]azocine",C1CCN2C[C@@H]3C[C@@H]([C@H]2C1)C=C4[C@H]3NCCC4,,,,,,
2937,442938,Anagyrine,C1CCN2C[C@@H]3C[C@@H]([C@H]2C1)CN4C3=CC=CC4=O,,,,,,
2938,442939,"4-(Prop-2-en-1-yl)decahydro-8H-1,5-methanopyrido[1,2-a][1,5]diazocin-8-one",C=CC[C@H]1[C@H]2C[C@H](CN1)[C@H]3CCCC(=O)N3C2,,,,,,
2939,442940,(+)-Aphylline,C1CCN2C[C@H]3C[C@H]([C@@H]2C1)C(=O)N4[C@@H]3CCCC4,,,,,,
2940,442941,Argentine,C1[C@H]2CN(C[C@H]1C3=CC=CC(=O)N3C2)C(=O)N4C[C@@H]5C[C@@H](C4)C6=CC=CC(=O)N6C5,,,,,,
2941,442942,Argyrolobine,C1CCN2C[C@H]3C[C@H]([C@@H]2C1)C(=O)N4C3=CCCC4O,,,,,,
2942,442943,"(1S,9R,10R,12S)-12-Hydroxy-7,15-diazatetracyclo[7.7.1.02,7.010,15]heptadeca-2,4-dien-6-one",C1CN2C[C@@H]3C[C@@H]([C@H]2C[C@H]1O)CN4C3=CC=CC4=O,,,,,,
2943,442944,Cadiamine,C1CC(NC(=O)C1)C2CC(C3CC(CCN3C2)O)CO,,,,,,
2944,442945,2-Oxospartein-13-yl 1H-pyrrole-2-carboxylate,C1C[C@@H]2[C@@H]3C[C@@H](CN2C(=O)C1)[C@@H]4C[C@H](CCN4C3)OC(=O)C5=CC=CN5,,,,,,
2945,442946,Camoensine,C1C[C@@H]2[C@H]3C[C@H](CN2C1)C4=CC=CC(=O)N4C3,,,,,,
2946,442947,"N-methyl-N-(2,2,2-trifluoroethyl)amine hydrochloride",CN1C[C@@H]2C[C@@H](C1)C3=CC=CC(=O)N3C2,,,,,,
2947,442948,Cinegalline,COC1=C(C=C(C=C1O)C(=O)O[C@H]2CCN3C[C@H]4C[C@H]([C@@H]3C2)CN5[C@@H]4CCCC5=O)O,,,,,,
2948,442949,"(1S,5S)-1,2,3,4,5,6-hexahydro-8H-1,5-methanopyrido[1,2-a][1,5]diazocin-8-one",C1[C@H]2CNC[C@H]1C3=CC=CC(=O)N3C2,,,,,,
2949,442950,"5,6-Didehydrospartein-2-one",C1CCN2C[C@H]3C[C@H]([C@@H]2C1)CN4C3=CCCC4=O,,,,,,
2950,442951,Ascosalitoxin,CCC(C)C(=O)C(C)C1=CC(=C(C(=C1C=O)O)C)O,,,,,,
2951,442952,Dimethamine,CN1C[C@H]2C[C@H](C1)C3=C(CCC(=O)N3C2)C4=CC=C5[C@H]6C[C@@H](CN(C6)C)CN5C4=O,,,,,,
2952,442953,Homoormosanine,C1CCN2C[C@@]34C[C@H]([C@H]2C1)C[C@H]5[C@H]3N(CCC5)CN6[C@@H]4CCCC6,,,,,,
2953,442954,"4-Pentadec-8-enylbenzene-1,3-diol",CCCCCCC=CCCCCCCCC1=C(C=C(C=C1)O)O,,,,,,
2954,442955,Leontiformine,C1CCN2C[C@@H](CC[C@@H]2C1)[C@H]3CCCCN3C=O,,,,,,
2955,442956,"(1R,2R,9S,10S)-7,15-Diazatetracyclo[7.7.1.02,7.010,15]heptadecan-6-one",C1CCN2C[C@H]3C[C@H]([C@@H]2C1)CN4[C@@H]3CCCC4=O,,,,,,
2956,442957,"2,3-Didehydrospartein-4-one",C1CCN2C[C@H]3C[C@H]([C@@H]2C1)CN4[C@@H]3CC(=O)C=C4,,,,,,
2957,442958,4-Hydroxyspartein-2-one,C1CCN2C[C@H]3C[C@H]([C@@H]2C1)CN4[C@@H]3C[C@@H](CC4=O)O,,,,,,
2958,442959,(-)-Ormosanine,C1CCN[C@H](C1)[C@]23C[C@@H](C[C@H]4[C@H]2NCCC4)[C@H]5CCCCN5C3,,,,,,
2959,442960,Panamine,C1CCN2C[C@@]34C[C@H]([C@H]2C1)C[C@H]5[C@H]3N(CCC5)[C@@H]6CCC[C@@H]4N6,,,,,,
2960,442961,Piptanthine,C1CCN[C@@H](C1)[C@@]23C[C@H](C[C@@H]4[C@@H]2NCCC4)[C@H]5CCCCN5C3,,,,,,
2961,442962,Spartein-5-ol,C1CCN2C[C@H]3C[C@H]([C@@H]2C1)CN4[C@@H]3[C@H](CCC4)O,,,,,,
2962,442963,"(1R)-3-(3-Butenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-8H-pyrido[1,2-a][1,4]diazocin-8-one",C=CCCN1C[C@@H]2C[C@@H](C1)C3=CC=CC(=O)N3C2,,,,,,
2963,442964,"(1R,2R,9S,10S)-7,15-Diazatetracyclo[7.7.1.02,7.010,15]heptadecane;sulfuric acid;pentahydrate",C1CCN2C[C@@H]3C[C@@H]([C@H]2C1)CN4[C@H]3CCCC4.O.O.O.O.O.OS(=O)(=O)O,,,,,,
2964,442965,Sparteine-sulfate,C1CCN2C[C@@H]3C[C@@H]([C@H]2C1)CN4[C@H]3CCCC4,,,,,,
2965,442966,Templetine,C1CCN[C@@H](C1)[C@@]23C[C@H](C[C@@H]4[C@H]2NCCC4)[C@H]5CCCCN5C3,,,,,,
2966,442967,CID 442967,C1CCN2C[C@@H]3C[C@@H]([C@@H]2C1)CN4C3=CC=CC4=O,,,,,,
2967,442968,Tinctorine,CN1C[C@@H]2C[C@@H]([C@H]1CC=C)CN3C2=CC=CC3=O,,,,,,
2968,442969,Tsukushinamine A,C=CC[C@@H]1[C@]23C=CCC(=O)N2C[C@H]4C[C@@H]3CN1C4,,,,,,
2969,442970,Buxamine E,C[C@@H]([C@H]1CC[C@@]2([C@@]1(CC=C3[C@H]2CC[C@@H]4C(=C3)CC[C@@H](C4(C)C)N(C)C)C)C)N,,,,,,
2970,442971,alpha-Chaconine,C[C@H]1CC[C@@H]2[C@H]([C@H]3[C@@H](N2C1)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC=C6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O[C@H]8[C@@H]([C@@H]([C@H]([C@@H](O8)C)O)O)O)O)O[C@H]9[C@@H]([C@@H]([C@H]([C@@H](O9)C)O)O)O)C)C)C,,,,,,
2971,442972,Cyclopamine,C[C@H]1C[C@@H]2[C@H]([C@H]([C@]3(O2)CC[C@H]4[C@@H]5CC=C6C[C@H](CC[C@@]6([C@H]5CC4=C3C)C)O)C)NC1,,,,,"['Conversion to teratogen of cyclopamine by rumen microorganisms is not essential. Indeed, ruminant sheep and non-ruminant rabbits were about equally susceptible to cyclopamine on a body weight basis.']",
2972,442973,Cyclovirobuxine C,C[C@@H]([C@H]1[C@@H](C[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)NC)C)C)O)N(C)C,,,,,,
2973,442974,5-(12-Heptadecenyl)-resorcinol,CCCCC=CCCCCCCCCCCCC1=CC(=CC(=C1)O)O,,,,,,
2974,442975,Demissine,C[C@H]1CC[C@H]2[C@H]([C@H]3[C@@H](N2C1)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC[C@@H]6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@H]([C@H](O7)CO)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O[C@H]9[C@@H]([C@H]([C@@H](CO9)O)O)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)O)O)C)C)C,,,,,,
2975,442976,Germine,C[C@H]1CC[C@H]2[C@@]([C@@H]3[C@@H](CN2C1)[C@@H]4C[C@@]56[C@H]([C@@]4([C@H]([C@@H]3O)O)O)[C@@H](C[C@H]7[C@@]5(CC[C@@H]([C@]7(O6)O)O)C)O)(C)O,,,,,,
2976,442977,Imperialine,C[C@H]1CC[C@H]2[C@@]([C@@H]3CC[C@@H]4[C@H]([C@@H]3CN2C1)C[C@H]5[C@H]4CC(=O)[C@@H]6[C@@]5(CC[C@@H](C6)O)C)(C)O,,,,,,
2977,442978,Irehine,C[C@@H]([C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C)N(C)C,,,,,,
2978,442979,Kurchessine,C[C@@H]([C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)N(C)C)C)C)N(C)C,,,,,,
2979,442980,Paravallarine,C[C@H]1[C@H]2CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC=C5[C@@]4(CC[C@@H](C5)NC)C)C(=O)O1,,,,,,
2980,442981,CID 442981,CC[C@@H](C)C(=O)O[C@H]1[C@@H]([C@H]2[C@@H](CN3C[C@H](CC[C@H]3[C@@]2(C)O)C)[C@H]4[C@@]1([C@@H]5[C@@H]([C@@H]([C@H]6[C@]7([C@]5(C4)O[C@@]6([C@H](CC7)OC(=O)[C@](C)([C@@H](C)O)O)O)C)OC(=O)C)OC(=O)C)O)O,,,,,,
2981,442982,Protoverine,C[C@H]1CC[C@H]2[C@@]([C@@H]3[C@@H](CN2C1)[C@@H]4C[C@@]56[C@H]([C@@]4([C@H]([C@@H]3O)O)O)[C@@H]([C@@H]([C@H]7[C@@]5(CC[C@@H]([C@]7(O6)O)O)C)O)O)(C)O,,,,,,
2982,442983,Solacapine,C[C@@H]1C[C@@H]([C@H](NC1)[C@@H](C)[C@H]2[C@@H](C[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC[C@@H]5[C@@]4(CC[C@@H](C5)N)C)C)O)O,,,,,,
2983,442984,CID 442984,C[C@H]1CC[C@H]2[C@H]([C@H]3[C@@H](N2C1)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC=C6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@H]([C@H](O7)CO)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O[C@H]9[C@@H]([C@@H]([C@H]([C@@H](O9)C)O)O)O)C)C)C,,,,,,
2984,442985,Purapuridine,C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC=C6[C@@]5(CC[C@@H](C6)O)C)C)C)NC1,,,,"['LABELED SOLASODINE WAS INJECTED INTO 2 NORMAL MEN AND INTO SYRIAN HAMSTERS. IN BOTH MEN, BLOOD (3)H WAS LARGELY ASSOCIATED WITH ERYTHROCYTES WHICH AFTER 8 DAYS STILL ACCOUNTED FOR 3.3% OF THE DOSE; PLASMA CONTAINED 1.6%, URINE 7% AND FECES 20% OF THE DOSE. EXCRETION OF (3)H BY HAMSTERS HAD DECLINED TO A VERY LOW LEVEL AFTER 8 DAYS WHEN 22-30% OF THE DOSE HAD BEEN EXCRETED. UNCHANGED SOLASODINE WAS STILL DETECTABLE IN LIVER 22 DAYS AFTER ADMIN.']",,
2985,442986,Veracevine,C[C@H]1CC[C@H]2[C@@]([C@]3([C@H](C[C@]4([C@@H]5CC[C@H]6[C@]7([C@]5(C[C@]4([C@@H]3CN2C1)O)O[C@@]6([C@H](CC7)O)O)C)O)O)O)(C)O,,,,,,
2986,442987,Zygadenine,C[C@H]1CC[C@H]2[C@@]([C@@H]3[C@@H](CN2C1)[C@@H]4C[C@@]56[C@H]([C@@]4([C@H]([C@@H]3O)O)O)CC[C@H]7[C@@]5(CC[C@@H]([C@]7(O6)O)O)C)(C)O,,,,,,
2987,442988,Theogallin,C1[C@H]([C@H]([C@@H](C[C@@]1(C(=O)O)O)OC(=O)C2=CC(=C(C(=C2)O)O)O)O)O,,,,,,
2988,442989,Trichocarpin,C1=CC=C(C=C1)COC(=O)C2=C(C=CC(=C2)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
2989,442990,Turgorin,C1=C(C=C(C(=C1O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COS(=O)(=O)[O-])O)O)O)O)C(=O)O,,,,,,
2990,442991,"3,5-dihydroxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(sulfooxymethyl)oxan-2-yl]oxybenzoic acid",C1=C(C=C(C(=C1O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COS(=O)(=O)O)O)O)O)O)C(=O)O,,,,,,
2991,442992,"2-[7-(Hydroxymethyl)-3,11-dimethyldodeca-2,6,10-trienyl]benzene-1,4-diol",CC(=CCCC(=CCCC(=CCC1=C(C=CC(=C1)O)O)C)CO)C,,,,,,
2992,442993,"[(3S,6S)-6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2R)-3-hydroxy-2-phenylpropanoate",CN1C2C[C@@H](CC1[C@H](C2)O)OC(=O)[C@@H](CO)C3=CC=CC=C3,,,"['Substances that eliminate free radicals. Among other effects, they protect PANCREATIC ISLETS against damage by CYTOKINES and prevent myocardial and pulmonary REPERFUSION INJURY. (See all compounds classified as Free Radical Scavengers.)', 'Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)', 'Drugs that selectively bind to and activate alpha adrenergic receptors. (See all compounds classified as Adrenergic alpha-Agonists.)', 'Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)']",,,
2993,442994,alpha-Methylenebenzeneacetic acid,CN1C2CC(CC1[C@@H]3[C@H]2O3)OC(=O)C(=C)C4=CC=CC=C4,,,,,,
2994,442995,Belladonnine,CN1C2CCC1CC(C2)OC(=O)[C@H]3CC[C@@](C4=CC=CC=C34)(C5=CC=CC=C5)C(=O)OC6CC7CCC(C6)N7C,,,,,,
2995,442996,Bellendine,CC1=COC2=C(C1=O)C3CCC(C2)N3C,,,,,,
2996,442997,Benzoyl ecgonine,CN1C2CCC1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)O,,,,,,
2997,442998,Brugine,CN1C2CCC1CC(C2)OC(=O)[C@@H]3CCSS3,,,,,,
2998,442999,Calystegin A3,C1CC2([C@@H]([C@@H](CC1N2)O)O)O,,,,,,
2999,443000,Calystegin B2,C1CC2([C@@H]([C@@H]([C@H](C1N2)O)O)O)O,,,,,,
3000,443001,CID 443001,CN1C2CCC1[C@H]([C@H](C2)OC(=O)C=CC3=CC=CC=C3)C(=O)OC,,,,,,
3001,443002,Convoline,COC1=C(C=C(C=C1)C(=O)OC2CC3CCC(C2)N3O)OC,,,,,,
3002,443003,Ecgonine,CN1C2CCC1[C@H]([C@H](C2)O)C(=O)O,,,['Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. (See all compounds classified as Narcotics.)'],,,
3003,443004,Knightinol,CC(=O)O[C@@H]1CC2CCC([C@@H]1C(C3=CC=CC=C3)O)N2C,,,,,,
3004,443005,(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) (2R)-2-hydroxy-3-phenylpropanoate,CN1C2CCC1CC(C2)OC(=O)[C@@H](CC3=CC=CC=C3)O,,,,,,
3005,443006,"[(6S,7R)-6,7-dihydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 2-methylbut-2-enoate",CC=C(C)C(=O)OC1CC2[C@@H]([C@@H](C(C1)N2C)O)O,,,,,,
3006,443007,Phyllalbine,CN1C2CCC1CC(C2)OC(=O)C3=CC(=C(C=C3)O)OC,,,,,,
3007,443008,Physoperuvine,CN1C2CCCC1(CC2)O,,,,,,
3008,443009,"(4S)-6-Methyl-2-oxa-6-azatricyclo[3.3.1.03,7]nonan-4-ol",CN1C2CC3CC1C([C@H]2O)O3,,,,,,
3009,443010,"Cyclohepta(6)pyran-5,8-imin-4(5H)-one, 2,3,6,7,8,9-hexahydro-10-methyl-2-phenyl-,(2alpha,5beta,8beta)-(+)-",CN1C2CCC1C3=C(C2)O[C@@H](CC3=O)C4=CC=CC=C4,,,,,,
3010,443011,Tigloidin,CC=C(C)C(=O)OC1CC2CCC(C1)N2C,,,,,,
3011,443012,Valeroidine,CC(C)CC(=O)O[C@@H]1CC2C[C@H](C(C1)N2C)O,,,,,,
3012,443013,Lignans,COC1=CC(=CC(=C1OC)OC)[C@H]2[C@H]3C(COC3=O)[C@H](C4=CC5=C(C=C24)OCO5)O,,,,,,
3013,443014,Podophyllotoxone,COC1=CC(=CC(=C1OC)OC)[C@H]2[C@@H]3[C@H](COC3=O)C(=O)C4=CC5=C(C=C24)OCO5,,,,,,
3014,443015,Podorhizol beta-D-glucoside,COC1=CC(=CC(=C1OC)OC)[C@H]([C@@H]2[C@H](COC2=O)CC3=CC4=C(C=C3)OCO4)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O,,,,,,
3015,443016,Prostalidin A,COC1=C2C(=CC3=C(C4=C(C=C31)C(=O)OC4)C5=CC6=C(C=C5O)OCO6)OCO2,,,,,,
3016,443017,2-[2-Hydroxy-5-(3-hydroxyprop-1-enyl)phenyl]-4-prop-2-enylphenol,C=CCC1=CC(=C(C=C1)O)C2=C(C=CC(=C2)C=CCO)O,,,,,,
3017,443018,Saucernetin,C[C@H]1[C@@H]([C@@H](O[C@H]1C2=CC(=C(C=C2)OC)OC)C3=CC(=C(C=C3)OC)OC)C,,,,,,
3018,443019,Sesamolinol,COC1=C(C=CC(=C1)O[C@@H]2[C@H]3CO[C@@H]([C@H]3CO2)C4=CC5=C(C=C4)OCO5)O,,,,,,
3019,443020,Simplexoside,COC1=C(C=CC(=C1)[C@@H]2[C@H]3CO[C@@H]([C@H]3CO2)C4=CC5=C(C=C4)OCO5)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O,,,,,,
3020,443021,(-)-Steganacin,CC(=O)O[C@@H]1[C@H]2COC(=O)[C@@H]2CC3=CC(=C(C(=C3C4=CC5=C(C=C14)OCO5)OC)OC)OC,,,,,,
3021,443022,Styraxin,COC1=C(C=CC(=C1)[C@H]2[C@H]3[C@@H](CO2)[C@@H](OC3=O)C4=CC5=C(C=C4)OCO5)O,,,,,,
3022,443023,(+)-Syringaresinol,COC1=CC(=CC(=C1O)OC)[C@@H]2[C@H]3CO[C@@H]([C@H]3CO2)C4=CC(=C(C(=C4)OC)O)OC,,,,,,
3023,443024,Acanthoside B,COC1=CC(=CC(=C1O)OC)[C@@H]2[C@H]3CO[C@@H]([C@H]3CO2)C4=CC(=C(C(=C4)OC)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)OC,,,,,,
3024,443025,"(3S,4R)-4-[(3,4-dimethoxyphenyl)methyl]-3-hydroxy-3-[(4-hydroxy-3-methoxyphenyl)methyl]oxolan-2-one",COC1=C(C=C(C=C1)C[C@@H]2COC(=O)[C@@]2(CC3=CC(=C(C=C3)O)OC)O)OC,,,,,,
3025,443026,Veraguensin,C[C@H]1[C@@H]([C@H](O[C@H]1C2=CC(=C(C=C2)OC)OC)C3=CC(=C(C=C3)OC)OC)C,,,,,,
3026,443027,Schizandrin C,C[C@@H]1CC2=CC3=C(C(=C2C4=C(C5=C(C=C4C[C@@H]1C)OCO5)OC)OC)OCO3,,,,,,
3027,443028,Yangambin,COC1=CC(=CC(=C1OC)OC)[C@@H]2[C@H]3CO[C@@H]([C@H]3CO2)C4=CC(=C(C(=C4)OC)OC)OC,,,,,,
3028,443029,Azafenidin,C#CCOC1=C(C=C(C(=C1)N2C(=O)N3CCCCC3=N2)Cl)Cl,,,,,,
3029,443030,Cabucine,C[C@H]1[C@H]2CN3CCC4=C([C@@H]3C[C@@H]2C(=CO1)C(=O)OC)NC5=C4C=C(C=C5)OC,,,,,,
3030,443031,Bispyribac,COC1=CC(=NC(=N1)OC2=C(C(=CC=C2)OC3=NC(=CC(=N3)OC)OC)C(=O)O)OC,,,"['Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)']","['A series of rat metabolism studies with [14CPy]-bispyribac-sodium and [14C-Bn]-bispyribac-sodium indicated that pretreatment, dose level, sex and position of the radiolabel made little effect on the absorption, distribution, elimination and metabolism. It was readily absorbed by male and female rats following intravenous or oral dosing. The total recovery of the administered radioactivity was 95.8-101.6% for all treatment groups. Most of the dose (>43%) of the administered dose was excreted in feces within 48 hours and essentially complete within 5 days. Less than 2% of the administered dose remained in the carcass and tissues and <0.1% of the dose was recovered in air.', 'Five Fischer 344 rats/sex/group were dosed orally with either 10 or 100 mg/kg of (14)C (Py) KIH-2023 (specific activity: 1.46 GBq/mmol, radiochemical purity: 97.7%, lot no. CP-1221) following overnight fasting. Bispyribac (KIH-2023, purity: 95.2%, lot no. G35-04) was used in the preparation of the dosing solutions. Bile was collected hourly through the first 6 hrs post-dose and at the 6-12 and 12-24 hr intervals. Urine and feces were collected at 0-6, 6-12 and 12-24 hr intervals post-dose. The percentage of the administered dose recovered in the bile over the first 24 hrs after dosing was approximately 36 to 37% for the males and 24 to 27% for the females at the two dose levels. In that first 24 hrs, 2.4% or less of the dose was recovered in the feces. However, at 24 hrs, 22.5 to 30.0% of the radiolabel at the low dose and 40 to 44% at the high dose was still associated with the tissues of the gastrointestinal tract and may not have been absorbed. Only two of the five major radiolabeled moieties in the bile were identified, demethylated Bispyribac and Bispyribac. These two moieties constituted 52.0 to 60.1% of the recovered radiolabel in the bile. Overall, the data indicate that the hepato-biliary pathway is a significant route for the uptake and excretion of the test material.', 'One Fischer 344 rat/sex/group was dosed by either oral gavage or intravenous injection with 100 mg/kg of (14)C Bispyribac (KIH-2023, specific activity: 1.50 GBq/mmol, radiochemical purity: 98.2%) (label on the 2nd carbon of the pyrimidine ring). Technical grade Bispyribac (KIH-2023, purity: 95.2%) was used to supplement the dosing preparations. Carbon dioxide was collected up to 24 hrs post-dose. Urine and feces were collected at the 0-12, 12-24, 24-48 and 48-72 hr intervals. In phase B, two rats/sex were dosed by oral gavage with 100 mg/kg of the test material. At 15 and 30 minutes and 1, 2, 4, 8, 24, and 48 hrs post-dose, blood was collected by retroorbital bleeding from one male and one female. In phase C, two rats/sex were dosed by oral gavage with 100 mg/kg of the test material. One animal/sex was euthanized by exsanguination at 2 and 72 hrs post-dose. Blood was collected along with specified tissues. In phase E, one male was treated by oral gavage with 100 mg/kg of the test material. Urine and feces were collected over 0-24 and 24-48 hr intervals post-dose for metabolite analysis. When the test material was dosed orally, a greater percentage of the dose was recovered in the feces. Intravenous injection resulted in a lower percentage of radiolabel recovered in the feces with a corresponding increase in recovery from the urine. The presence of the radiolabel in the feces after intravenous dosing indicated that biliary excretion had occurred. Recovery of radiolabeled carbon dioxide was negligible. Peak blood levels were evident at 2 hrs post-dose. The highest levels of radiolabel recovered in the 2 hr samples were in the contents of the gastrointestinal tract. Otherwise, the level of radiolabeling in the tissues had largely dissipated by 72 hrs. The predominant radioalabeled moiety in both the urine and feces was the parent compound. It constituted 86% of the recovered label. ...', 'Groups of Fischer 344 rats were dosed orally by gavage or by intravenous injection with bis-(pyrimidine-2-(14)C) Bispyribac (KIH-2023, radiochemical purity: 98.3%, specific activity: 87.0 :Ci/mg) ((14)C (Py) Bispyribac) or U-(benzene-(14)C) Bispyribac (radiochemical purity: >99%, specific activity: 50 :Ci/mg) (14)C (Bn) Bispyribac). In Groups 1A, B, C and D, 5 animals/sex/group were dosed orally with 30 mg/kg of either (14)C (Py) Bispyribac (A and C) or (14)C (Bn) Bispyribac (B and D). For Groups 2 A and B, 5 animals/sex/group were dosed daily by oral gavage with 30 mg/kg of Bispyribac, technical grade (purity: 97.2%) for 14 days, followed a dose of 30 mg/kg of either (14)C (Py) Bispyribac (A) or (14)C (Bn) Bispyribac (B). For Groups 3A, B, C and D, 5 animals/sex/group were dosed orally by gavage with 600 mg/kg of either (14)C (Py) Bispyribac (A and C) or (14C) (Bn) Bispyribac (B and D). For Groups 4A, B, C and D, five animals/sex/group received intravenous injections of 30 mg/kg of either (14)C (Py) Bispyribac (A and C) or (14)C (Bn) Bispyribac (B and D). For all groups designated A or B, urine and feces samples were collected at 0-12 hr, 12-24 hr, 24-48 hr, 48-72 hr, 72-96 hr and 96-120 hours post-dose. At that time the animals were euthanized, a blood sample collected and the animals dissected for specified tissues. For all groups designated C or D, blood was collected from the tail vein at 0.25, 0.5, 1, 2, 4, 8, 24, 48, 72 and 96 hours post-dose. At 120 hrs, the animals were euthanized and a blood sample collected. The feces were the primary route of excretion for both of the radiolabeled compounds. At the lower dose, the males excreted from 11 to 13% and 80 to 85% of the administered dose in the urine and feces, respectively. At the higher dose, excretion in the urine ranged from 25 to 28% of the administered dose. In the feces, 70% of the dose was excreted. For the females, the percentage of administered dose excreted by either route did not vary at both dose levels. The percent of administered dose excreted in the urine ranged from 28 to 37%. For the feces, the range was from 48 to 60% (note: two of the radiolabel recovery values from the feces, for Groups 1A and 2A, were close to or in excess of 100% of the administered dose and appeared to be at variance from all of the other data collected). At the lower dosing level via the oral route, peak plasma levels were achieved within 30 minutes of dosing for both radiolabeled compounds. At 600 mg/kg, the plasma levels remained at a peak concentration for up to 4 hrs post-dose. ... The liver, intestinal tract and plasma were the primary sites of recovery of radiolabel at 120 hrs post-dose. Analysis of the radiolabeled material revealed the unmetabolized test compound was the primary moiety excreted.  This moiety constituted 68.5 to 82.9% of the administered dose recovered from both the feces and urine (note: the value for the 3B females of 99.8% was well in excess of all of the other recoveries).  The quantity of administered dose, sex of the treated animal or the route of treatment did not greatly alter the percent of unmetabolized test material recovered. ...', 'Absorption, distribution and metabolism of Bispyribac-sodium (sodium 2,6-bis(4,6-dimethoxypyrimidin-2-yloxy)benzoate) or (KIH-2023) in rats orally dosed with 14C-KIH-2023 were investigated. More than 90% of the dosed radioactivity was detected in the excreta within 96 hr after dosing. Level of the radioactivity in the blood of male and female rats reached maxima at 2 and 1 hr after dosing, respectively, and then decreased rapidly to about a half level of maxima (C1/2). The radioactivity of tissues was lower at 96 hr after dosing than that at C1/2-time. Most of the radioactivity in the urine, feces, liver and plasma was detected as unchanged KIH-2023. The major radioactive compounds excreted into the bile were KIH-2023 and its glucuronide. Repeated oral administration of KIH-2023 for 15 days gave similar results from the single oral one in the excretion, tissue distribution and metabolism of 14C-KIH-2023.']","['Parent and 5 metabolites were identified in the excreta of male and female /rats/ following /IV or orally/ administered [14Cpy]-bispyribac-sodium and parent and 3 metabolites identified with [14C-Bn]-bispyribac-sodium administration. The parent compound, bispyribac-sodium, was the major component identified in the feces (37-69% of the dose) and urine (5-41%of the dose), in both sexes. Metabolites identified in the excreta constituted 8.3-14.6% and unknown metabolites constituted 0.7-5.2% of the dose.', 'One Fischer 344 rat/sex/group was dosed by either oral gavage or intravenous injection with 100 mg/kg of (14)C Bispyribac (KIH-2023, specific activity: 1.50 GBq/mmol, radiochemical purity: 98.2%) (label on the 2nd carbon of the pyrimidine ring). Technical grade Bispyribac (KIH-2023, purity: 95.2%) was used to supplement the dosing preparations. ... Demethylation of the parent compound was the predominant metabolic process identified.', 'Groups of Fischer 344 rats were dosed orally by gavage or by intravenous injection with bis-(pyrimidine-2-(14)C) Bispyribac (KIH-2023, radiochemical purity: 98.3%, specific activity: 87.0 :Ci/mg) ((14)C (Py) Bispyribac) or U-(benzene-(14)C) Bispyribac (radiochemical purity: >99%, specific activity: 50 :Ci/mg) (14)C (Bn) Bispyribac). In Groups 1A, B, C and D, 5 animals/sex/group were dosed orally with 30 mg/kg of either (14)C (Py) Bispyribac (A and C) or (14)C (Bn) Bispyribac (B and D). For Groups 2 A and B, 5 animals/sex/group were dosed daily by oral gavage with 30 mg/kg of Bispyribac, technical grade (purity: 97.2%) for 14 days, followed a dose of 30 mg/kg of either (14)C (Py) Bispyribac (A) or (14)C (Bn) Bispyribac (B). For Groups 3A, B, C and D, 5 animals/sex/group were dosed orally by gavage with 600 mg/kg of either (14)C (Py) Bispyribac (A and C) or (14C) (Bn) Bispyribac (B and D). For Groups 4A, B, C and D, five animals/sex/group received intravenous injections of 30 mg/kg of either (14)C (Py) Bispyribac (A and C) or (14)C (Bn) Bispyribac (B and D). ... The test material was metabolized by cleavage of the ether linkage between the benzene and pyrimidine rings and removal of the methyl groups from the pyrimidine moieties. The position of the radiolabel did not alter the metabolic profile. ...']","['Groups of Fischer 344 rats were dosed orally by gavage or by intravenous injection with bis-(pyrimidine-2-(14)C) Bispyribac (KIH-2023, radiochemical purity: 98.3%, specific activity: 87.0 :Ci/mg) ((14)C (Py) Bispyribac) or U-(benzene-(14)C) Bispyribac (radiochemical purity: >99%, specific activity: 50 :Ci/mg) (14)C (Bn) Bispyribac). In Groups 1A, B, C and D, 5 animals/sex/group were dosed orally with 30 mg/kg of either (14)C (Py) Bispyribac (A and C) or (14)C (Bn) Bispyribac (B and D). For Groups 2 A and B, 5 animals/sex/group were dosed daily by oral gavage with 30 mg/kg of Bispyribac, technical grade (purity: 97.2%) for 14 days, followed a dose of 30 mg/kg of either (14)C (Py) Bispyribac (A) or (14)C (Bn) Bispyribac (B). For Groups 3A, B, C and D, 5 animals/sex/group were dosed orally by gavage with 600 mg/kg of either (14)C (Py) Bispyribac (A and C) or (14C) (Bn) Bispyribac (B and D). For Groups 4A, B, C and D, five animals/sex/group received intravenous injections of 30 mg/kg of either (14)C (Py) Bispyribac (A and C) or (14)C (Bn) Bispyribac (B and D). ... The pharmacokinetic parameters (calculated for only the 30 mg/kg doses) were as follows: males, t1/2-28.4 to 37.9 hours, tmax-0.29 to 0.31 hours, females, t1/2-28.0 to 37.1 hrs, tmax-0.32 to 0.36 hrs.']"
3031,443032,Ptca,CN(C)C1CSSSSSC1,,,,,,
3032,443033,Flumetover,CCN(C)C(=O)C1=C(C=C(C=C1)C(F)(F)F)C2=CC(=C(C=C2)OC)OC,,,,,,
3033,443034,"(E)-3-(3,4-Dihydroxyphenyl)acrylaldehyde",C1=CC(=C(C=C1C=CC=O)O)O,,,,,,
3034,443035,Itopa,CC1=NSC(=C1Cl)N(C)C(=O)CC2=CC=C(C=C2)OC3=CC=C(C=C3)C(F)(F)F,,,,,,
3035,443036,Thenylchlor,CC1=C(C(=CC=C1)C)N(CC2=C(C=CS2)OC)C(=O)CCl,,,,,,
3036,443037,Chlorpromazine N-oxide,C[N+](C)(CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl)[O-],,,,,,
3037,443038,1-(4-Chlorophenyl)-4-oxo-5-propoxy-cinnoline-3-carboxylic acid,CCCOC1=CC=CC2=C1C(=O)C(=NN2C3=CC=C(C=C3)Cl)C(=O)O,,,,,,
3038,443039,Isoimide,C1CCC2=C(C1)C(=NC3=CC=C(C=C3)Br)OC2=O,,,,,,
3039,443040,"N-(4-Bromophenyl)-3,4,5,6-tetrahydrophthalimide",C1CCC2=C(C1)C(=O)N(C2=O)C3=CC=C(C=C3)Br,,,,,,
3040,443041,Thiadiazolidinone,C1CCN2C(=O)SC(=NC3=CC=C(C=C3)Br)N2C1,,,,,,
3041,443042,4-(Methylamino)butanal,CNCCCC=O,,,,,,
3042,443043,Triazolidinonethione,C1CCN2C(=S)N(C(=O)N2C1)C3=CC=C(C=C3)Br,,,,,,
3043,443044,3-Hydroxyoxepan-2-one,C1CCOC(=O)C(C1)O,,,,,,
3044,443045,Thiadiazolidinethione,C1CCN2C(=S)SC(=NC3=CC=C(C=C3)Br)N2C1,,,,,,
3045,443046,"[Cyano-(3-phenoxyphenyl)methyl] 3-(2-chloro-3,3,3-trifluoroprop-1-enyl)-2,2-dimethylcyclopropane-1-carboxylate",CC1(C(C1C(=O)OC(C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C=C(C(F)(F)F)Cl)C,,,"['Chemicals that kill or inhibit the growth of fungi in agricultural applications, on wood, plastics, or other materials, in swimming pools, etc. (See all compounds classified as Fungicides, Industrial.)', 'Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']",,,
3046,443047,"[cyano-(3-phenoxyphenyl)methyl] (1S,3S)-3-(2,2-dibromoethenyl)-2,2-dimethylcyclopropane-1-carboxylate",CC1([C@@H]([C@@H]1C(=O)OC(C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C=C(Br)Br)C,,,,,,
3047,443048,Flumiclorac-pentyl,CCCCCOC(=O)COC1=C(C=C(C(=C1)N2C(=O)C3=C(C2=O)CCCC3)F)Cl,,,,,,
3048,443049,O-ethyl O-(5-methyl-4-nitrophenyl) N-(1-methylpropyl)phosphoramidothioate,CCC(C)NP(=S)(OCC)OC1=CC(=C(C=C1)[N+](=O)[O-])C,,,,,,
3049,443050,"1H-Isoindole-1,3(2H)-dione, 2-(4-((4-chlorophenyl)methoxy)phenyl)-4,5,6,7-tetrahydro-",C1CCC2=C(C1)C(=O)N(C2=O)C3=CC=C(C=C3)OCC4=CC=C(C=C4)Cl,,,,,,
3050,443051,2'-Deoxy-5-hydroxymethylcytidine-5'-diphosphate,C1[C@@H]([C@H](O[C@H]1N2C=C(C(=NC2=O)N)CO)COP(=O)(O)OP(=O)(O)O)O,,,,,,
3051,443052,2'-Deoxy-5-hydroxymethylcytidine-5'-triphosphate,C1[C@@H]([C@H](O[C@H]1N2C=C(C(=NC2=O)N)CO)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O,,,,,,
3052,443053,CID 443053,CC=C(C)C(=O)O[C@H]1C[C@H]([C@]2(CO[C@@H]3[C@@H]2[C@]14CO[C@@]([C@H]4[C@]5([C@@H]3O[C@]6([C@@]5([C@@H]7C[C@H]6[C@]8(C=CO[C@H]8O7)O)O)C)C)(C(=O)OC)O)C(=O)OC)OC(=O)C,,,,,,
3053,443054,Brassicanal A,CSC1=C(C2=CC=CC=C2N1)C=O,,,,,,
3054,443055,24-epi-Brassinolide,C[C@@H]([C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2COC(=O)[C@@H]4[C@@]3(C[C@H]([C@H](C4)O)O)C)C)[C@H]([C@@H]([C@H](C)C(C)C)O)O,,,"['Any of the hormones produced naturally in plants and active in controlling growth and other functions. There are three primary classes: auxins, cytokinins, and gibberellins. (See all compounds classified as Plant Growth Regulators.)']",,,
3055,443056,25-Hydroxy-24-epi-brassinolide,C[C@@H]([C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2COC(=O)[C@@H]4[C@@]3(C[C@H]([C@H](C4)O)O)C)C)[C@H]([C@@H]([C@H](C)C(C)(C)O)O)O,,,,,,
3056,443057,26-Hydroxy-24-epi-brassinolide,C[C@@H]([C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2COC(=O)[C@@H]4[C@@]3(C[C@H]([C@H](C4)O)O)C)C)[C@H]([C@@H]([C@H](C)C(C)CO)O)O,,,,,,
3057,443058,"9,10-Dihydrokadsurenone",CCCC1=C[C@@]2([C@@H]([C@H](OC2=CC1=O)C3=CC(=C(C=C3)OC)OC)C)OC,,,,,,
3058,443059,Spinosyn A,CC[C@H]1CCC[C@@H]([C@H](C(=O)C2=C[C@H]3[C@@H]4C[C@@H](C[C@H]4C=C[C@H]3[C@@H]2CC(=O)O1)O[C@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)C)OC)OC)OC)C)O[C@H]6CC[C@@H]([C@H](O6)C)N(C)C,,,,"['... Dairy cows were dosed for 28 days with spinosad at rates equivalent to 0, 1, 3, and 10 ug/g  in the diet. Chicken hens were dosed for 42 days with spinosad at rates equivalent to 0, 0.1,  0.3, 1, and 5 ug/g in the diet. Milk, eggs, and tissue samples were analyzed by high-performance  liquid chromatography and/or immunoassay methods. Spinosad residues occurred in all of the  sample types but were lowest in eggs, skim milk, and lean meat and were highest in the fat. /Spinosad/', 'Spinosad is rapidly absorbed and extensively metabolized. There were no major differences in   the bioavailability, routes or rates of excretion, or metabolism of Spinosyn A and Spinosyn D   following oral administration in rats. In addition, the routes and rates of excretion were not   affected by repeated administration.']",,
3059,443060,Spinosyn B,CC[C@H]1CCC[C@@H]([C@H](C(=O)C2=C[C@H]3[C@@H]4C[C@@H](C[C@H]4C=C[C@H]3[C@@H]2CC(=O)O1)O[C@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)C)OC)OC)OC)C)O[C@H]6CC[C@@H]([C@H](O6)C)NC,,,,,,
3060,443061,"5-[(1R)-1-hydroxy-2,6,6-trimethyl-4-oxocyclohex-2-en-1-yl]-3-methylpenta-2,4-dienoic acid",CC1=CC(=O)CC([C@@]1(C=CC(=CC(=O)O)C)O)(C)C,,,,,,
3061,443062,"S-[2-[3-[[4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] 4-hydroxybutanethioate",CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)CCCO)O,,,,,,
3062,443063,"Methyl 2-nitro-5-(2,4,6-trichlorophenoxy)benzoate",COC(=O)C1=C(C=CC(=C1)OC2=C(C=C(C=C2Cl)Cl)Cl)[N+](=O)[O-],,,,,,
3063,443064,"Ethyl 5-(2,4-dichlorophenoxy)-2-nitrobenzoate",CCOC(=O)C1=C(C=CC(=C1)OC2=C(C=C(C=C2)Cl)Cl)[N+](=O)[O-],,,,,,
3064,443065,2-Tetrahydrothiopheneacetic acid,C1CC(SC1)CC(=O)O,,,,,,
3065,443066,Tetrahydrothiophene-2-carboxylic acid,C1CC(SC1)C(=O)O,,,,,,
3066,443067,(1S)-1-(ethylcarbamoyl)ethyl N-phenylcarbamate,CCNC(=O)[C@H](C)OC(=O)NC1=CC=CC=C1,,,,,,
3067,443068,2-N-Dodecyltetrahydrothiophene,CCCCCCCCCCCCC1CCCS1,,,,,,
3068,443069,Hymexazol O-glucoside,CC1=CC(=NO1)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O,,,,,,
3069,443070,Hymexazol N-glucoside,CC1=CC(=O)N(O1)[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O,,,,,,
3070,443071,5-Methyl-3-isoxazolyl sulfate,CC1=CC(=NO1)OS(=O)(=O)O,,,,,,
3071,443072,3-beta-D-glucopyranuronosyloxy-5-methylisoxazole,CC1=CC(=NO1)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O)O)O,,,,,,
3072,443073,"2,3-Dihydroxybutanamide",CC(C(C(=O)N)O)O,,,,,,
3073,443074,3-Hydroxybutanamide,CC(CC(=O)N)O,,,,,,
3074,443075,5-N-Methyloxaluric acid,CNC(=O)NC(=O)C(=O)O,,,,,,
3075,443076,2-Methoxy-estradiol-17beta 3-glucuronide,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=C(C=C34)OC)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)C(=O)O)O)O)O,,,,,['2-Methoxy-estradiol-17beta 3-glucuronide is a known human metabolite of 2-O-methoxyestradiol.'],
3076,443077,2-Methoxyestrone 3-glucuronide,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=CC(=C(C=C34)OC)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)C(=O)O)O)O)O,,,,,,
3077,443078,Etiocholanolone glucuronide,C[C@]12CC[C@H](C[C@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)C(=O)O)O)O)O,,,,,['Etiocholanolone glucuronide is a known human metabolite of Etiocholanolone.'],
3078,443079,CID 443079,COC1=CC(=CC2=C1O[C@@H]([C@H](O2)C3=CC(=C(C=C3)O)OC)CO)C4=CC(=C5C(=CC(=O)C=C5O4)O)O,,,,,,
3079,443080,1-(2-Methoxyphenyl)-3-naphthalen-2-ylurea,COC1=CC=CC=C1NC(=O)NC2=CC3=CC=CC=C3C=C2,,,,,,
3080,443081,"(6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-((6,7-dihydro-5H-cyclopenta[b]pyridinium-1-yl)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate",CON=C(C1=CSC(=N1)N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CC=CC5=C4CCC5)C(=O)[O-],,,,,,
3081,443082,"(6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(6,7-dihydro-5H-cyclopenta[b]pyridin-1-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",CON=C(C1=CSC(=N1)N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CC=CC5=C4CCC5)C(=O)O,,,,,,
3082,443083,CID 443083,CON=C(C1=NSC(=N1)N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=C5C=CC=NN5C=C4)C(=O)[O-].[Cl-],,,,,,
3083,443084,CID 443084,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)[O-])C.[K+],,,,,,
3084,443085,"(6R,7R)-3-[[3-amino-2-(2-hydroxyethyl)pyrazol-1-ium-1-yl]methyl]-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate",CON=C(C1=CSC(=N1)N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CC=C(N4CCO)N)C(=O)[O-],,,,,,
3085,443086,"(6R,7R)-3-[[3-amino-2-(2-hydroxyethyl)pyrazol-1-ium-1-yl]methyl]-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",CON=C(C1=CSC(=N1)N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CC=C(N4CCO)N)C(=O)O,,,,,,
3086,443087,cyclo[Leu-D-Phe-Pro-Val-Orn-Leu-D-Phe-Pro-Val-Orn].HCl,CC(C)C[C@H]1C(=O)N[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N3CCC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCN)C(C)C)CC4=CC=CC=C4)CC(C)C)CCCN)C(C)C)CC5=CC=CC=C5.Cl,,,,,,
3087,443088,Imazalil nitrate,C=CCOC(CN1C=CN=C1)C2=C(C=C(C=C2)Cl)Cl.[N+](=O)(O)[O-],,,,,,
3088,443089,CID 443089,C[C@H]1C[C@@H]([C@@H]([C@H](C=C([C@H]([C@@H](C=CC=C(C(=O)NC2=CC(=O)C=C([C@H]1OC)C2=O)C)OC)OC(=O)N)C)C)OC)OC,,,,,,
3089,443090,17beta-Estradiol 17-glucosiduronate,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)[O-])O)O)O)CCC5=C3C=CC(=C5)O,,,,,,
3090,443091,CID 443091,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O[C@H]4[C@@H]([C@H](C([C@H](O4)C(=O)O)O)O)O)CCC5=C3C=CC(=C5)O,,,,,,
3091,443092,CID 443092,CC[C@@H]1[C@H](C2=CC3=C(C(=C([N-]3)C=C4[C@H]([C@@H](C(=N4)C5=C6C(=C(C(=CC1=N2)[N-]6)C)C(=O)[C@@H]5C(=O)OC)CCC(=O)OCC=C(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C)C)C(=O)C)C.[Mg+2],,,,,,
3092,443093,CID 443093,CC=C1[C@H](C2=NC1=CC3=C(C4=C([N-]3)C(=C5[C@H]([C@@H](C(=N5)C=C6C(=C(C(=C2)[N-]6)C(=O)C)C)C)CCC(=O)OCC=C(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C4=O)C(=O)OC)C)C.[Mg+2],,,,,,
3093,443094,CID 443094,CC=C1[C@H](C2=NC1=CC3=C(C4=C(N3)C(=C5[C@H]([C@@H](C(=N5)C=C6C(=C(C(=C2)N6)C(=O)C)C)C)CCC(=O)OCC=C(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C4=O)C(=O)OC)C)C,,,,,,
3094,443095,"(2S,3S,4S,5R,6S)-6-[4-[(5S,5aR,8aR,9R)-5-[(7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl)oxy]-8-oxo-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-9-yl]-2,6-dimethoxyphenoxy]-3,4,5-trihydroxyoxane-2-carboxylate",CC1OCC2C(O1)C(C(C(O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)C(=O)[O-])O)O)O)OC)O)O,,,,,,
3095,443096,CID 443096,CC1OCC2C(O1)C(C(C(O2)O[C@H]3[C@H]4COC(=O)[C@@H]4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)C(=O)O)O)O)O)OC)O)O,,,,,,
3096,443097,6alpha-Glucuronosylhyodeoxycholate,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C[C@@H]([C@H]4[C@@]3(CC[C@H](C4)O)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)C(=O)[O-])O)O)O)C,,,,,,
3097,443098,CID 443098,C[C@H](CCC(=O)O)[C@@H]1CCC2[C@@]1(CC[C@@H]3[C@@H]2C[C@H]([C@@H]4[C@]3(CC[C@H](C4)O)C)O[C@@H]5[C@@H]([C@@H]([C@@H]([C@H](O5)C(=O)O)O)O)O)C,,,,,,
3098,443099,"(1S,6R)-6-hydroxy-5-methylidene-1-(1,2,3-trihydroxy-2-methylpropyl)-2-oxa-7,9-diazabicyclo[4.2.2]decane-8,10-dione",CC(CO)(C([C@@]12C(=O)N[C@@](C(=C)CCO1)(C(=O)N2)O)O)O,,,,,,
3099,443100,Lenapenem hydrochloride hydrate,C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)[C@@H](CCNC)O)C(=O)O)[C@@H](C)O.O.Cl,,,,,,
3100,443101,Acriflavine,C[N+]1=C2C=C(C=CC2=CC3=C1C=C(C=C3)N)N.C1=CC(=CC2=NC3=C(C=CC(=C3)N)C=C21)N.[Cl-],,,"['Agents that are capable of inserting themselves between the successive bases in DNA, thus kinking, uncoiling or otherwise deforming it and therefore preventing its proper functioning. They are used in the study of DNA. (See all compounds classified as Intercalating Agents.)', 'Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from DISINFECTANTS, which are used on inanimate objects. (See all compounds classified as Anti-Infective Agents, Local.)', 'Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
3101,443102,CID 443102,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4C5[C@H]([C@H](OC5OC4=C1)SCC(C(=O)NCC(=O)O)NC(=O)CCC(C(=O)O)N)O,,,,,,
3102,443103,Estriol 3-glucuronide,C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@H]([C@@H]2O)O)CCC4=C3C=CC(=C4)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)C(=O)O)O)O)O,,,,,,
3103,443104,17beta-Estradiol 3-sulfate-17-(beta-D-glucuronide),C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)[O-])O)O)O)CCC5=C3C=CC(=C5)OS(=O)(=O)O,,,,,,
3104,443105,CID 443105,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O[C@H]4[C@@H]([C@H](C([C@H](O4)C(=O)O)O)O)O)CCC5=C3C=CC(=C5)OS(=O)(=O)O,,,,,,
3105,443106,3-Chlorosalicylanilide,C1=CC=C(C=C1)NC(=O)C2=C(C(=CC=C2)Cl)O,,,,,,
3106,443107,N-Acetyl-leu-leu-leu-leu-tyr-amide,CC(C)CC(C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CC1=CC=C(C=C1)O)C(=O)N)NC(=O)C,,,,,,
3107,443108,N-Acetyl-leu-leu-leu-tyr-amide,CC(C)CC(C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CC1=CC=C(C=C1)O)C(=O)N)NC(=O)C,,,,,,
3108,443109,N-Acetyl-leu-leu-tyr-amide,CC(C)CC(C(=O)NC(CC(C)C)C(=O)NC(CC1=CC=C(C=C1)O)C(=O)N)NC(=O)C,,,,,,
3109,443110,N-Formyl-norleucyl-leucyl-phenylalanyl-methylester,CCCCC(C(=O)NC(CC(C)C)C(=O)NC(CC1=CC=CC=C1)C(=O)OC)NC=O,,,,,,
3110,443111,"(10R,11R,21S)-21-hydroxy-11,19-dimethyl-10-propan-2-yl-9,26-dioxa-3,15,28-triazatricyclo[23.2.1.03,7]octacosa-1(27),6,12,17,19,25(28)-hexaene-2,8,14,23-tetrone",C[C@@H]1C=CC(=O)NCC=CC(=C[C@H](CC(=O)CC2=NC(=CO2)C(=O)N3CCC=C3C(=O)O[C@@H]1C(C)C)O)C,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
3111,443112,CID 443112,C[C@H]1C=C[C@H]([C@H](CCCC[C@H](OC(=O)[C@H](C2([C@@H]([C@H]([C@@H]([C@H]1O2)C)O)OC)O)C)C3=CC=CC=C3)OC)OC,,,,,,
3112,443113,Sulfoglycolithocholate,C[C@H](CCC(=O)NCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)OS(=O)(=O)[O-])C)C,,,,,,
3113,443114,CID 443114,C[C@H](CCC(=O)NCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3C2CC[C@H]4[C@@]3(CC[C@H](C4)OS(=O)(=O)O)C)C,,,,,,
3114,443115,S-Octylglutathione,CCCCCCCCSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N,,,,,['Octyl-glutathione is a known human metabolite of 1-iodooctane.'],
3115,443116,S-Decylglutathione,CCCCCCCCCCSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N,,,,,,
3116,443117,CID 443117,CCCCC[C@@H](C=C[C@H]1C(CC(=O)C1CCCCCCC(=O)O)SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)O,,,,,,
3117,443118,Acetylleucyl-leucyl-norleucinal,CCCC[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)C,,,['Exogenous and endogenous compounds which inhibit CYSTEINE ENDOPEPTIDASES. (See all compounds classified as Cysteine Proteinase Inhibitors.)'],,,
3118,443119,Chymostatin,CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C=O)NC(=O)[C@H](C2CCN=C(N2)N)NC(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O,,,['Exogenous or endogenous compounds which inhibit SERINE ENDOPEPTIDASES. (See all compounds classified as Serine Proteinase Inhibitors.)'],,,
3119,443120,S-(p-Azidophenacyl)glutathione,C1=CC(=CC=C1C(=O)CSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)N=[N+]=[N-],,,,,,
3120,443121,CID 443121,C1=CC(=CC=C1C(=O)CSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)N[N+]#N,,,,,,
3121,443122,D-Ornithine hydrochloride,C(C[C@H](C(=O)O)N)CN.Cl,,,,,,
3122,443123,"6-(3,3-DMA)chrysin",CC(=CCC1=C(C2=C(C=C1O)OC(=CC2=O)C3=CC=CC=C3)O)C,,,,,,
3123,443124,CID 443124,CC(=CCC1=C2C(=C(C=C(O2)C3=CC=CC=C3)O)C(=O)C=C1O)C,,,,,,
3124,443125,2-Pyridyl hydroxymethane sulfonic acid,C1=CC=NC(=C1)OCS(=O)(=O)O,,,,,,
3125,443126,Leucyl-leucyl-norleucine,CCCCC(C(=O)O)NC(=O)C(CC(C)C)NC(=O)[C@H](CC(C)C)N,,,,,,
3126,443127,methyl (2R)-2-[[(2S)-2-[[(2R)-2-acetamidopropanoyl]amino]propanoyl]amino]propanoate,C[C@H](C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)OC)NC(=O)C,,,,,,
3127,443128,N-Acetyl-leu-leu-tyr,CC(C)CC(C(=O)NC(CC(C)C)C(=O)NC(CC1=CC=C(C=C1)O)C(=O)O)NC(=O)C,,,,,,
3128,443129,N-Acetyl-leucyl-leucine,CC(C)CC(C(=O)NC(CC(C)C)C(=O)O)NC(=O)C,,,,,,
3129,443130,Mersalyl acid,COC(CNC(=O)C1=CC=CC=C1OCC(=O)O)C[Hg].O,"['Elevated blood pressure, edema.']","['Mersalyl acid is an organomercuric compound. It is used as a diuretic. Mercury is a heavy, silvery d-block metal and one of six elements that are liquid at or near room temperature and pressure. It is a naturally occuring substance, and combines with other elements such as chlorine, sulfur, or oxygen to form inorganic mercury compounds (salts). Mercury also combines with carbon to make organic mercury compounds.']",['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],"['Organic mercury is metabolized into inorganic mercury, which is eventually excreted in the urine and feces.', 'The hepatobiliary excretion of mersayl was studied in the isolated perfused rat liver and in isolated rat liver plasma membrane vesicles. In the isolated perfused liver, mersalyl was found to be immediately absorbed by the perfusion medium and concentratively excreted into bile. Uptake is characterized by saturation kinetics (S)0.5 = 20 microM, Vmax = 117 nmoles/min/g liver, cooperatively of mersalyl binding sites, stimulation by extracellular sodium and temperature dependence. Uptake of mersalyl into basolateral membrane vesicles also demonstrates characteristics of a carrier-mediated transport, dependence on extravesicular sodium, cooperativity of mersalyl binding sites, temperature dependence and trans-stimulation by intravesicular non-radioactive mersalyl. Uptake was found to be inhibited by alpha-naphthylacetic acid and mercapto group reagents, suggesting involvement of mercapto groups on the carrier and a binding site for carboxylic anions. Data from the isolated perfused liver and from isolated basolateral vesicles suggest that mersalyl uptake into the liver is carrier mediated. Uptake mechanism and driving forces appear analogous to those for the uptake of chemically related compounds such as taurocholic acid. It is, therefore, speculated that mersalyl may be transported by carrier molecules which accept various chemically unrelated compounds.']","['Organic mercury is absorbed primarily in the gastrointestinal tract, followed by distribution throughout the body via the bloodstream. Organic mercury forms a complex with free cysteine and the cysteine and sulfhydryl groups on proteins such as hemoglobin (Hgb). These complexes function to mimic methionine and, as a result, are transported throughout the body. This includes travel across the blood-brain barrier and across the placenta.']",
3130,443131,"(1R,2S,4R)-(+)-Bornyl acetate",CC(=O)O[C@H]1CC2CCC1(C2(C)C)C,,,,"['The percutaneous absorptions of camphene, isoborneol-acetate, limonene, menthol and alpha-pinene as constituents of a foam bath (Pinimenthol) were measured on animals using radioactively labelled ingredients. Pharmacokinetic measurements showed maximum blood levels for all tested ingredients 10 min after the onset of percutaneous absorption. None of the ingredients was preferentially absorbed. Blood levels of all ingredients after 10 min of percutaneous absorption were a direct function of the size of the skin area involved.']",['Isobornyl acetate readily hydrolyzes (within hours) to isobornyl alcohol during the first step of its biochemical pathway. The alcohol will become conjugated with glucoronic acid and be excreted in the urine (expected within hours to days).'],
3131,443132,CID 443132,C(C(C(=O)[O-])O)(C(=O)O)O.C(C(C(=O)[O-])O)(C(=O)O)O.O.O.O.[K+].[K+].[SbH3].[SbH3],,,,,,
3132,443133,"estra-1,3,5(10)-triene-3,16alpha,17beta-triol 17-D-glucuronide",C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@H]([C@@H]2O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)[O-])O)O)O)O)CCC5=C3C=CC(=C5)O,,,,,,
3133,443134,CID 443134,C[C@]12CCC3[C@H]([C@@H]1C[C@H]([C@@H]2O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)O)CCC5=C3C=CC(=C5)O,,,,,,
3134,443135,(S)-1-Phenylethanol,C[C@@H](C1=CC=CC=C1)O,,,,,,
3135,443136,"4-[(1S,5S)-2,5,6,6-tetramethylcyclohex-2-en-1-yl]but-3-en-2-one",C[C@H]1CC=C([C@@H](C1(C)C)C=CC(=O)C)C,,,,,,
3136,443137,"[(1R,2S,3S,4R,5S,6S)-3-amino-2,4,5-trihydroxy-6-phosphonooxycyclohexyl]-(diaminomethylidene)azanium",[C@@H]1([C@@H]([C@H]([C@@H]([C@H]([C@@H]1O)O)OP(=O)(O)O)[NH+]=C(N)N)O)N,,,,,,
3137,443138,CID 443138,[C@H]1([C@@H]([C@@H](C(C([C@H]1OP(=O)(O)O)O)O)N)O)N=C(N)N,,,,,,
3138,443139,"5,6-Dichloro-1,3-cyclohexadiene",C1=CC(C(C=C1)Cl)Cl,,,,,,
3139,443140,"3-Chloro-2-hydroxypenta-2,4-dienoic acid",C=CC(=C(C(=O)O)O)Cl,,,,,,
3140,443141,"2-Hydroxyhexa-2,4-dienoic acid",CC=CC=C(C(=O)O)O,,,,,,
3141,443142,4-Amino-4-deoxychorismic acid,C=C(C(=O)O)O[C@@H]1C=C(C=C[C@H]1N)C(=O)O,,,,,,
3142,443143,(-)-Anaferine,C1CCN[C@H](C1)CC(=O)C[C@H]2CCCCN2,,,,,,
3143,443144,(-)-Hygrine,CC(=O)C[C@@H]1CCCN1C,,,,,,
3144,443145,Perhydroazepino-N-carbonyl-L-Leu-D-Trp-D-Trp,CC(C)C[C@@H](C(=O)N[C@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@H](CC3=CNC4=CC=CC=C43)C(=O)O)NC(=O)N5CCCCCC5,,,,,,
3145,443146,CPT-11 carboxylate form,CCC1=C2CN3C(=CC(=C(C3=O)CO)[C@@](CC)(C(=O)[O-])O)C2=NC4=C1C=C(C=C4)OC(=O)N5CCC(CC5)N6CCCCC6,,,,,,
3146,443147,"(2S)-2-[12-ethyl-8-(hydroxymethyl)-9-oxo-2-(4-piperidin-1-ylpiperidine-1-carbonyl)oxy-11H-indolizino[1,2-b]quinolin-7-yl]-2-hydroxybutanoic acid",CCC1=C2CN3C(=CC(=C(C3=O)CO)[C@@](CC)(C(=O)O)O)C2=NC4=C1C=C(C=C4)OC(=O)N5CCC(CC5)N6CCCCC6,,,,,,
3147,443148,SN-38 carboxylate form,CCC1=C2CN3C(=CC(=C(C3=O)CO)[C@@](CC)(C(=O)[O-])O)C2=NC4=C1C=C(C=C4)O,,,,,,
3148,443149,"(2S)-2-[12-ethyl-2-hydroxy-8-(hydroxymethyl)-9-oxo-11H-indolizino[1,2-b]quinolin-7-yl]-2-hydroxybutanoic acid",CCC1=C2CN3C(=CC(=C(C3=O)CO)[C@@](CC)(C(=O)O)O)C2=NC4=C1C=C(C=C4)O,,,,,,
3149,443150,N-Ethylmaleimide-S-glutathione,C1=CC(=O)N(C1=O)CCSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N,,,,,,
3150,443151,Temocaprilat,C1[C@H](SC[C@@H](C(=O)N1CC(=O)O)N[C@@H](CCC2=CC=CC=C2)C(=O)O)C3=CC=CS3,,,,,,
3151,443152,SN38 glucuronide carboxylate form,CCC1=C2CN3C(=CC(=C(C3=O)CO)[C@@](CC)(C(=O)[O-])O)C2=NC4=C1C=C(C=C4)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)C(=O)O)O)O)O,,,,,,
3152,443153,"7-[(1S)-1-Carboxy-1-hydroxypropyl]-12-ethyl-9,11-dihydro-8-(hydroxymethyl)-9-oxoindolizino[1,2-b]quinolin-2-yl beta-D-glucopyranosiduronic acid",CCC1=C2CN3C(=CC(=C(C3=O)CO)[C@@](CC)(C(=O)O)O)C2=NC4=C1C=C(C=C4)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)C(=O)O)O)O)O,,,,,,
3153,443154,SN38 glucuronide,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O)O)O,,,,,,
3154,443155,"(R)-[(2S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-quinolin-4-ylmethanol",C=C[C@H]1CN2CCC1C[C@H]2[C@@H](C3=CC=NC4=CC=CC=C34)O,,,,,,
3155,443156,(+)-3-Carene,CC1=CC[C@@H]2[C@H](C1)C2(C)C,,,,,['(+)-3-carene has known human metabolites that include 3-Caren-10-ol and Carene epoxide.'],
3156,443157,(S)-(-)-Citronellal,C[C@@H](CCC=C(C)C)CC=O,,,,,,
3157,443158,(-)-Linalool,CC(=CCC[C@](C)(C=C)O)C,,,,,,
3158,443159,(+)-Menthone,C[C@H]1CC[C@@H](C(=O)C1)C(C)C,,,,,"['...KETONES (EG CARVONE & MENTHONE) ARE REDUCED TO SECONDARY ALCOHOLS WHICH ARE THEN EXCRETED AS GLUCURONIDES. MENTHONE, ASYMMETRIC REDUCTION /TO/ NEO-MENTHOL, GLUCURONIDE CONJUGATION /TO/ MENTHYL GLUCURONIDE.']",
3159,443160,(+)-alpha-Phellandrene,CC1=CC[C@H](C=C1)C(C)C,,,,,,
3160,443161,(-)-beta-Phellandrene,CC(C)[C@H]1CCC(=C)C=C1,,,,,,
3161,443162,(-)-alpha-Terpineol,CC1=CC[C@H](CC1)C(C)(C)O,,,,"['AFTER LETHAL IV PINE OIL 0.1 ML/KG TO HORSE, BLOOD & TISSUE LEVELS OF ALPHA-TERPINEOL 150-300 PPM WERE OBSERVED. AFTER SMALLER PINE OIL DOSES (0.033 ML/KG) BLOOD LEVELS BECAME UNDETECTABLE AFTER 2 HR, & NO TISSUE LEVELS DETECTED (TIME NOT SPECIFIED).']",,
3162,443163,(-)-Dihydrocarveol,C[C@@H]1CC[C@H](C[C@H]1O)C(=C)C,,,,,,
3163,443164,"(1R,2S,4R)-Neo-dihydrocarveol",C[C@@H]1CC[C@H](C[C@@H]1O)C(=C)C,,,,,,
3164,443165,"(1S,2S,4R)-Iso-dihydrocarveol",C[C@H]1CC[C@H](C[C@@H]1O)C(=C)C,,,,,,
3165,443166,(+)-Neoisodihydrocarveol,C[C@H]1CC[C@H](C[C@H]1O)C(=C)C,,,,,,
3166,443167,(+)-Isodihydrocarvone,C[C@H]1CC[C@H](CC1=O)C(=C)C,,,,,,
3167,443168,"(4R,7R)-4-isopropenyl-7-methyloxepan-2-one",C[C@@H]1CC[C@H](CC(=O)O1)C(=C)C,,,,,,
3168,443169,"(3S,6S)-6-isopropenyl-3-methyloxepan-2-one",C[C@H]1CC[C@H](COC1=O)C(=C)C,,,,,,
3169,443170,(3S)-6-hydroxy-3-prop-1-en-2-ylheptanoate,CC(CC[C@@H](CC(=O)[O-])C(=C)C)O,,,,,,
3170,443171,(3R)-6-Hydroxy-3-isopropenyl-heptanoate,CC(CC[C@H](CC(=O)O)C(=C)C)O,,,,,,
3171,443172,(3S)-3-Isopropenyl-6-oxoheptanoate,CC(=C)[C@@H](CCC(=O)C)CC(=O)[O-],,,,,,
3172,443173,(3S)-3-isopropenyl-6-oxoheptanoic acid,CC(=C)[C@@H](CCC(=O)C)CC(=O)O,,,,,,
3173,443174,"(5S)-5-(hydroxymethyl)-2,6-dimethylhept-6-enoate",CC(CC[C@H](CO)C(=C)C)C(=O)[O-],,,,,,
3174,443175,(5R)-6-Hydroxy-5-isopropenyl-2-methylhexanoate,CC(CC[C@H](CO)C(=C)C)C(=O)O,,,,,,
3175,443176,(3R)-3-Isopropenyl-6-oxoheptanoyl-CoA; (Acyl-CoA); [M+H]+,CC(=C)[C@H](CCC(=O)C)CC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
3176,443177,(+)-cis-Carveol,CC1=CC[C@@H](C[C@@H]1O)C(=C)C,,,,,,
3177,443178,(+)-trans-Carveol,CC1=CC[C@@H](C[C@H]1O)C(=C)C,,,,,,
3178,443179,(-)-Neoisodihydrocarveol,C[C@@H]1CC[C@@H](C[C@@H]1O)C(=C)C,,,,,,
3179,443180,(-)-Isodihydrocarveol,C[C@@H]1CC[C@@H](C[C@H]1O)C(=C)C,,,,,,
3180,443181,cis-Dihydrocarvone,C[C@@H]1CC[C@@H](CC1=O)C(=C)C,,,,,,
3181,443182,"(4S,7R)-4-isopropenyl-7-methyloxepan-2-one",C[C@@H]1CC[C@@H](CC(=O)O1)C(=C)C,,,,,,
3182,443183,"(1S,4S)-Dihydrocarvone",C[C@H]1CC[C@@H](CC1=O)C(=C)C,,,,,,
3183,443184,"(1S,2R,4S)-Neo-dihydrocarveol",C[C@H]1CC[C@@H](C[C@H]1O)C(=C)C,,,,,,
3184,443185,(3R)-6-hydroxy-3-prop-1-en-2-ylheptanoate,CC(CC[C@H](CC(=O)[O-])C(=C)C)O,,,,,,
3185,443186,(3S)-6-Hydroxy-3-isopropenyl-heptanoate,CC(CC[C@@H](CC(=O)O)C(=C)C)O,,,,,,
3186,443187,"(3S,6R)-6-isopropenyl-3-methyloxepan-2-one",C[C@H]1CC[C@@H](COC1=O)C(=C)C,,,,,,
3187,443188,(3R)-3-Isopropenyl-6-oxoheptanoate,CC(=C)[C@H](CCC(=O)C)CC(=O)[O-],,,,,,
3188,443189,(3R)-3-isopropenyl-6-oxoheptanoic acid,CC(=C)[C@H](CCC(=O)C)CC(=O)O,,,,,,
3189,443190,"(5R)-5-(hydroxymethyl)-2,6-dimethylhept-6-enoate",CC(CC[C@@H](CO)C(=C)C)C(=O)[O-],,,,,,
3190,443191,(5S)-6-Hydroxy-5-isopropenyl-2-methylhexanoate,CC(CC[C@@H](CO)C(=C)C)C(=O)O,,,,,,
3191,443192,"S-[2-[3-[[4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] (3S)-6-oxo-3-prop-1-en-2-ylheptanethioate",CC(=C)[C@@H](CCC(=O)C)CC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
3192,443193,2-Hydroxy-2H-benzo[h]chromene-2-carboxylate,C1=CC=C2C(=C1)C=CC3=C2OC(C=C3)(C(=O)O)O,,,,,,
3193,443194,4-(1-Hydroxy-2-naphthyl)-2-oxobut-3-enoic acid,C1=CC=C2C(=C1)C=CC(=C2O)C=CC(=O)C(=O)O,,,,,,
3194,443195,1-Hydroxy-2-naphthaldehyde,C1=CC=C2C(=C1)C=CC(=C2O)C=O,,,,,,
3195,443196,"(9R,10S)-9,10-epoxy-9,10-dihydrophenanthrene",C1=CC=C2C(=C1)[C@H]3[C@H](O3)C4=CC=CC=C42,,,,,,
3196,443197,"(1aS,9aR)-1a,9a-dihydrophenanthro[1,2-b]oxirene",C1=CC=C2C(=C1)C=CC3=C2C=C[C@@H]4[C@H]3O4,,,,,,
3197,443198,Methyl-D-erythritol Phosphate,C[C@](CO)([C@@H](COP(=O)(O)O)O)O,,,,,,
3198,443199,4-CDP-2-C-methyl-D-erythritol,C[C@](CO)([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=CC(=NC2=O)N)O)O)O)O,,,,,,
3199,443200,4-CDP-2-C-methyl-D-erythritol 2-phosphate,C[C@](CO)([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=CC(=NC2=O)N)O)O)O)OP(=O)(O)O,,,,,,
3200,443201,1-deoxy-D-xylulose 5-phosphate,CC(=O)[C@H]([C@@H](COP(=O)(O)O)O)O,,,,,,
3201,443202,CID 443202,CC1(C(C(C(C(O1)O[C@]23C=CC=C2C#CC4=CC#C[C@H]3OC5=C(C=C(C=C5Cl)[C@H](CC(=O)OC[C@@H]4OC(=C6C=C(C=C7C6=NC(=O)C(=C)O7)OC)O)N)O)O)O)N(C)C)C,,,,,,
3202,443203,CID 443203,CC1(C(C(C(C(O1)O[C@]23C=CC=C2C#CC4=CC#C[C@H]3OC5=C(C=C(C=C5)[C@H](CC(=O)OC[C@@H]4OC(=C6C=C(C=C7C6=NC(=O)C(=C)O7)OC)O)N)Cl)O)O)N(C)C)C,,,,,,
3203,443204,CID 443204,CC1(C(C(C(C(O1)O[C@]23C=CC=C2C4=C5[C@H]3OC6=C(C=C(C=C6Cl)[C@H](CC(=O)OC[C@@H](C(=C4)C=C5)OC(=C7C=C(C=C8C7=NC(=O)C(=C)O8)OC)O)N)O)O)O)N(C)C)C,,,,,,
3204,443205,CID 443205,CC1(C(C(C(C(O1)O[C@]23C=CC=C2C4=C5[C@H]3OC6=C(C=C(C=C6)[C@H](CC(=O)OC[C@@H](C(=C4)C=C5)OC(=C7C=C(C=C8C7=NC(=O)C(=C)O8)OC)O)N)Cl)O)O)N(C)C)C,,,,,,
3205,443206,"7-(Oxiran-2-yl)-2-oxatricyclo[8.3.0.01,3]trideca-6,10,12-trien-4,8-diyne",C1C(O1)C2=CC#CC3C4(O3)C=CC=C4C#C2,,,,,,
3206,443207,CID 443207,C1=C[C@@]23[C@@H](O2)C#CC=C(C#CC3=C1)[C@H](CO)O,,,,,,
3207,443208,"dTDP-4-dimethylamino-4,6-dideoxy-5-C-methyl-L-mannose",CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)O[C@@H]3[C@@H]([C@@H]([C@@H](C(O3)(C)C)N(C)C)O)O)O,,,,,,
3208,443209,CID 443209,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=C4C=C(C=C5C4=NC(=O)C(=C)O5)OC)O)O,,,,,,
3209,443210,2'Deoxy-thymidine-5'-diphospho-alpha-D-glucose,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O,,,,,,
3210,443211,dTDP-4-dehydro-beta-L-rhamnose,C[C@H]1C(=O)[C@H]([C@H]([C@H](O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)O)O,,,,,,
3211,443212,"4,4-Dimethyl-5alpha-cholesta-8,14,24-trien-3beta-ol",C[C@H](CCC=C(C)C)[C@H]1CC=C2[C@@]1(CCC3=C2CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)C,,,,,,
3212,443213,"cis-3-(1-Carboxy-ethyl)-3,5-cyclo-hexadiene-1,2-diol",CC(C1=CC=C[C@@H]([C@@H]1O)O)C(=O)O,,,,,,
3213,443214,Trimethyl(2-oxopent-3-enyl)azanium,CC=CC(=O)C[N+](C)(C)C,,,,,,
3214,443215,dTDP-4-oxo-5-C-methyl-L-rhamnose,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)O[C@@H]3[C@@H]([C@@H](C(=O)C(O3)(C)C)O)O)O,,,,,,
3215,443216,"dTDP-4-amino-4,6-dideoxy-5-C-methyl-L-mannose",CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)O[C@@H]3[C@@H]([C@@H]([C@@H](C(O3)(C)C)N)O)O)O,,,,,,
3216,443217,3-Hydroxy-L-tyrosyl-AMP,C1=CC(=C(C=C1C[C@@H](C(=O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=CN=C43)N)O)O)N)O)O,,,,,,
3217,443218,"3,5-Dihydroxyanthranilic acid",C1=C(C=C(C(=C1C(=O)O)N)O)O,,,,,,
3218,443219,5-Methoxy-3-hydroxyanthranilate,COC1=CC(=C(C(=C1)O)N)C(=O)O,,,,,,
3219,443220,N-Pyruvoyl-5-methoxy-3-hydroxyanthranilate,CC(=O)C(=O)NC1=C(C=C(C=C1O)OC)C(=O)O,,,,,,
3220,443221,CID 443221,CCNC1COC(CC1OC)OC2C(C(C(OC2O[C@H]3C#CC=CC#C[C@@]4(CC(=O)C(=C3C4=CCSSSC)NC(=O)OC)O)C)NOC5CC(C(C(O5)C)SC(=O)C6=C(C(=C(C(=C6OC)OC)OC7C(C(C(C(O7)C)O)OC)O)I)C)O)O,,,,,,
3221,443222,CID 443222,C[C@H]1C(=C([C@@H]2C#CC=CC#CC3[C@]14[C@]2(O4)C5=CC(=C6C(=C5N3)C(=O)C7=C(C=CC(=C7C6=O)O)O)O)OC)C(=O)O,,,,,,
3222,443223,"D-Glycero-D-manno-heptose 1,7-bisphosphate",C([C@H]([C@@H]1[C@H]([C@@H]([C@@H](C(O1)OP(=O)(O)O)O)O)O)O)OP(=O)(O)O,,,,,,
3223,443224,"7-Hydroxy-6-methylhepta-3,5-dien-2-one",CC(=CC=CC(=O)C)CO,,,,,,
3224,443225,"N-(2,6-dimethylphenyl)-4-[[2-(ethylamino)acetyl]amino]benzamide",CCNCC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC=C2C)C,,,,,,
3225,443226,"4-[(2-aminoacetyl)amino]-N-(2,6-dimethylphenyl)benzamide",CC1=C(C(=CC=C1)C)NC(=O)C2=CC=C(C=C2)NC(=O)CN,,,,,,
3226,443227,"4-(acetylamino)-N-(2,6-dimethylphenyl)benzamide",CC1=C(C(=CC=C1)C)NC(=O)C2=CC=C(C=C2)NC(=O)C,,,,,,
3227,443228,2-(2-Naphthoxy)propionic acid methyl ester,CC(C(=O)OC)OC1=CC2=CC=CC=C2C=C1,,,,,,
3228,443229,Carfentrazone,CC1=NN(C(=O)N1C(F)F)C2=C(C=C(C(=C2)CC(C(=O)O)Cl)Cl)F,,,,,,
3229,443230,(R)-2-Hydroxypropyl-CoM,C[C@H](CSCCS(=O)(=O)O)O,,,,,,
3230,443231,2-Oxopropyl-CoM,CC(=O)CSCCS(=O)(=O)O,,,,,,
3231,443232,2-{[(2S)-2-hydroxypropyl]sulfanyl}ethanesulfonic acid,C[C@@H](CSCCS(=O)(=O)O)O,,,,,,
3232,443233,(S)-3-sulfolactic acid,C([C@H](C(=O)O)O)S(=O)(=O)O,,,,,,
3233,443234,5'-Dehydroadenosine,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)C=O)O)O)N,,,,,,
3234,443235,"(2R,4R,5R)-2-(6-amino-1,4-dihydropurin-9-yl)-4-hydroxy-5-(hydroxymethyl)oxolan-3-one",C1=NC2C(=C(N1)N)N=CN2[C@H]3C(=O)[C@@H]([C@H](O3)CO)O,,,,,,
3235,443236,"(2R)-2-acetamido-3-[[(2R)-2-acetamido-3-[[(2R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-[(2R,3R,5S,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyoxan-3-yl]amino]-3-oxopropyl]disulfanyl]-N-[(2R,3S,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-[(2R,3R,5S,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyoxan-3-yl]propanamide",CC(=O)N[C@@H](CSSC[C@@H](C(=O)NC1[C@H]([C@@H]([C@H](O[C@@H]1OC2[C@@H]([C@H](C([C@H]([C@H]2O)O)O)O)O)CO)O)O)NC(=O)C)C(=O)N[C@H]3[C@H]([C@@H]([C@H](O[C@@H]3OC4[C@@H]([C@H](C([C@H]([C@H]4O)O)O)O)O)CO)O)O,,,,,,
3236,443237,"4alpha-Methyl-5alpha-ergosta-8,14,24(28)-trien-3beta-ol",C[C@H]1[C@@H]2CCC3=C([C@]2(CC[C@@H]1O)C)CC[C@]4(C3=CC[C@@H]4[C@H](C)CCC(=C)C(C)C)C,,,,,,
3237,443238,"(3S,4S,5R,10R,13R,14R,17R)-3-hydroxy-4,10,13-trimethyl-17-[(2R)-6-methylheptan-2-yl]-1,2,3,5,6,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthrene-4-carbaldehyde",C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CCC3C2=CC[C@@H]4[C@@]3(CC[C@@H]([C@@]4(C)C=O)O)C)C,,,,,,
3238,443239,DL-threo-beta-Hydroxyaspartic acid,[C@H]([C@@H](C(=O)O)O)(C(=O)O)N,,,,,,
3239,443240,CID 443240,C[C@@H](C=C[C@@H](C)C(=C)C)C1CC[C@@]2([C@@]1(CCC34C2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)O)C)C,,,,,,
3240,443241,2-(2-Methoxy-2-oxoethyl)but-2-enedioic acid,COC(=O)CC(=CC(=O)O)C(=O)O,,,,,,
3241,443242,2-(alpha-D-mannosyl)-3-phosphoglyceric acid,C([C@@H]1[C@H]([C@@H]([C@@H]([C@H](O1)OC(COP(=O)(O)O)C(=O)O)O)O)O)O,,,,,,
3242,443243,Uridine-5'-diphosphosulfoquinovose,C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CS(=O)(=O)[O-])O)O)O)O)O,,,,,,
3243,443244,UDP-6-sulfoquinovose,C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CS(=O)(=O)O)O)O)O)O)O,,,,,,
3244,443245,"(3S,4S,10S,13R)-4,10,13-trimethyl-17-[(2R)-6-methyl-5-methylideneheptan-2-yl]-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol",C[C@@H]1[C@H](CC[C@]2(C1CC=C3C2CC[C@]4(C3CCC4[C@H](C)CCC(=C)C(C)C)C)C)O,,,,,,
3245,443246,"(3S,4S,10S,13R)-4,10,13-trimethyl-17-[(2R)-5-propan-2-ylhept-5-en-2-yl]-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol",CC=C(CC[C@@H](C)C1CCC2[C@@]1(CCC3C2=CCC4[C@@]3(CC[C@@H]([C@H]4C)O)C)C)C(C)C,,,,,,
3246,443247,"(1r,2R,3S,4s,5R,6S)-2,3,4,5,6-pentakis(phosphonooxy)cyclohexyl trihydrogen diphosphate",[C@H]1([C@H](C([C@H]([C@@H](C1OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O,,,,,,
3247,443248,6-O-(beta-D-Xylopyranosyl)-beta-D-glucopyranose,C1[C@H]([C@@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)O)O)O)O)O)O)O,,,,,,
3248,443249,(2R)-O-phospho-3-sulfolactic acid,C([C@@H](C(=O)O)OP(=O)(O)O)S(=O)(=O)O,,,,,,
3249,443250,(R)-2-Hydroxy-3-sulfopropanoic acid,C([C@@H](C(=O)O)O)S(=O)(=O)O,,,,,,
3250,443251,"cobalt(3+);3-[(7S,8S,12S,13S)-7,12,18-tris(2-carboxyethyl)-3,8,13,17-tetrakis(carboxymethyl)-8,13-dimethyl-2,3,7,12-tetrahydroporphyrin-22,24-diid-2-yl]propanoic acid",C[C@@]1([C@@H](C2=CC3=NC(=CC4=C(C(=C([N-]4)C=C5[C@@]([C@@H](C(=N5)C=C1[N-]2)CCC(=O)O)(C)CC(=O)O)CC(=O)O)CCC(=O)O)C(C3CC(=O)O)CCC(=O)O)CCC(=O)O)CC(=O)O.[Co+3],,,,,,
3251,443252,"3-[(7S,8S,12S,13S)-7,12,18-tris(2-carboxyethyl)-3,8,13,17-tetrakis(carboxymethyl)-8,13-dimethyl-2,3,7,12,22,24-hexahydroporphyrin-2-yl]propanoic acid",C[C@@]1([C@@H](C2=CC3=NC(=CC4=C(C(=C(N4)C=C5[C@@]([C@@H](C(=N5)C=C1N2)CCC(=O)O)(C)CC(=O)O)CC(=O)O)CCC(=O)O)C(C3CC(=O)O)CCC(=O)O)CCC(=O)O)CC(=O)O,,,,,,
3252,443253,"cobalt(3+);3-[(7S,8S,12S,13S)-7,12,18-tris(2-carboxyethyl)-3,8,13,17-tetrakis(carboxymethyl)-8,13,15-trimethyl-2,3,7,12-tetrahydroporphyrin-22,24-diid-2-yl]propanoic acid",CC1=C2[C@@]([C@@H](C(=N2)C=C3[C@@]([C@@H](C(=CC4=NC(=CC5=C(C(=C1[N-]5)CC(=O)O)CCC(=O)O)C(C4CC(=O)O)CCC(=O)O)[N-]3)CCC(=O)O)(C)CC(=O)O)CCC(=O)O)(C)CC(=O)O.[Co+3],,,,,,
3253,443254,"3-[(7S,8S,12S,13S)-7,12,18-tris(2-carboxyethyl)-3,8,13,17-tetrakis(carboxymethyl)-8,13,15-trimethyl-2,3,7,12,22,24-hexahydroporphyrin-2-yl]propanoic acid",CC1=C2[C@@]([C@@H](C(=N2)C=C3[C@@]([C@@H](C(=CC4=NC(=CC5=C(C(=C1N5)CC(=O)O)CCC(=O)O)C(C4CC(=O)O)CCC(=O)O)N3)CCC(=O)O)(C)CC(=O)O)CCC(=O)O)(C)CC(=O)O,,,,,,
3254,443255,CID 443255,CC1C23C4=NC(=CC5=C(C(C(=N5)C=C6[C@H]([C@](C(=CC(=N2)[C@H]([C@@]3(CC(=O)O1)C)CCC(=O)O)[N-]6)(C)CC(=O)O)CCC(=O)O)CC(=O)O)CCC(=O)O)[C@](C4CC(=O)O)(C)CCC(=O)O.[Co+2],,,,,,
3255,443256,CID 443256,CC1C23C4=NC(=CC5=C(C(C(=CC6=NC(=CC(=N2)[C@H]([C@@]3(CC(=O)O1)C)CCC(=O)O)[C@@]([C@@H]6CCC(=O)O)(C)CC(=O)O)N5)CC(=O)O)CCC(=O)O)[C@](C4CC(=O)O)(C)CCC(=O)O,,,,,,
3256,443257,CID 443257,CC1C23C4=NC(=CC5=N[C@@](CC6=C([C@](C(=CC(=N2)[C@H]([C@@]3(CC(=O)O1)C)CCC(=O)O)[N-]6)(C)CC(=O)O)CCC(=O)O)(C(=C5CCC(=O)O)CC(=O)O)C)[C@](C4CC(=O)O)(C)CCC(=O)O.[Co+2],,,,,,
3257,443258,CID 443258,CC1C23C4=NC(=CC5=N[C@@](CC6=C([C@](C(=N6)C=C(N2)[C@H]([C@@]3(CC(=O)O1)C)CCC(=O)O)(C)CC(=O)O)CCC(=O)O)(C(=C5CCC(=O)O)CC(=O)O)C)[C@](C4CC(=O)O)(C)CCC(=O)O,,,,,,
3258,443259,CID 443259,C[C@@]12CC3=C([C@](C(=N3)C=C4[C@H]([C@]([C@@]([N-]4)(C5=C([C@@](C(=N5)CC(=N1)C(=C2CC(=O)O)CCC(=O)O)(C)CCC(=O)O)CC(=O)O)C)(C)CC(=O)O)CCC(=O)O)(C)CC(=O)O)CCC(=O)O.[Co+2],,,,,,
3259,443260,CID 443260,C[C@@]12CC3=C([C@](C(=N3)C=C4[C@H]([C@]([C@@]([N-]4)([C@H]5[C@@H]([C@@](C(=N5)CC(=N1)C(=C2CC(=O)O)CCC(=O)O)(C)CCC(=O)O)CC(=O)O)C)(C)CC(=O)O)CCC(=O)O)(C)CC(=O)O)CCC(=O)O.[Co+2],,,,,,
3260,443261,"3-[(1R,2S,3S,7S,11S,17R,18R,19R)-8,13,17-tris(2-carboxyethyl)-2,7,12,18-tetrakis(carboxymethyl)-1,2,7,11,17-pentamethyl-3,10,15,18,19,21-hexahydrocorrin-3-yl]propanoic acid",C[C@@]12CC3=C([C@](C(=N3)C=C4[C@H]([C@]([C@@](N4)([C@H]5[C@@H]([C@@](C(=N5)CC(=N1)C(=C2CC(=O)O)CCC(=O)O)(C)CCC(=O)O)CC(=O)O)C)(C)CC(=O)O)CCC(=O)O)(C)CC(=O)O)CCC(=O)O,,,,,,
3261,443262,Mannosylglycerate,C([C@@H]1[C@H]([C@@H]([C@@H]([C@H](O1)OC(CO)C(=O)O)O)O)O)O,,,,,,
3262,443263,CID 443263,CC1C2=N[C@@](CC3=C([C@](C(=N3)C(=C4[C@H]([C@]([C@@]([N-]4)([C@H]5[C@@H]([C@@](C1=N5)(C)CCC(=O)O)CC(=O)O)C)(C)CC(=O)O)CCC(=O)O)C)(C)CC(=O)O)CCC(=O)O)(C(=C2CCC(=O)O)C)C.[Co+2],,,,,,
3263,443264,"3-[(1R,2S,3S,7S,11S,17R,18R,19R)-8,13,17-tris(2-carboxyethyl)-2,7,18-tris(carboxymethyl)-1,2,5,7,11,12,15,17-octamethyl-3,10,15,18,19,22-hexahydrocorrin-3-yl]propanoic acid",CC1C2=N[C@@](CC3=C([C@](C(=C(C4=N[C@@]([C@H]5[C@@H]([C@@](C1=N5)(C)CCC(=O)O)CC(=O)O)([C@@]([C@@H]4CCC(=O)O)(C)CC(=O)O)C)C)N3)(C)CC(=O)O)CCC(=O)O)(C(=C2CCC(=O)O)C)C,,,,,,
3264,443265,2-O-(beta-D-glucosyl)glycerol,C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)OC(CO)CO)O)O)O)O,,,,,,
3265,443266,"1D-myo-Inositol 1,4,5,6-tetrakisphosphate",[C@H]1([C@@H]([C@H]([C@@H]([C@H]([C@@H]1OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)O)O,,,,,,
3266,443267,"1-Carbazol-9-yl-3-(3,5-dimethylpyrazol-1-yl)-propan-2-ol",CC1=CC(=NN1CC(CN2C3=CC=CC=C3C4=CC=CC=C42)O)C,,,,,,
3267,443268,"2-(4-Chloro-3,5-dimethylphenoxy)-N-(2-phenyl-2H-benzotriazol-5-yl)-acetamide",CC1=CC(=CC(=C1Cl)C)OCC(=O)NC2=CC3=NN(N=C3C=C2)C4=CC=CC=C4,,,,,,
3268,443269,CID 443269,CC1=CC2=NC(=NC(=C2C=C1)C)NC(=NC(=O)CC3=CC=C(C=C3)Cl)N,,,,,,
3269,443270,"1-Benzyl-7,8-dimethoxy-3-phenyl-3H-pyrazolo[3,4-c]isoquinoline",COC1=C(C=C2C(=C1)C=NC3=C2C(=NN3C4=CC=CC=C4)CC5=CC=CC=C5)OC,,,,,,
3270,443271,N-(3-Benzooxazol-2-yl-4-hydroxy-phenyl)-2-p-tolyloxyacetamide,CC1=CC=C(C=C1)OCC(=O)NC2=CC(=C(C=C2)O)C3=NC4=CC=CC=C4O3,,,,,,
3271,443272,"8-Allyl-2-phenyl-8H-1,3a,8-triaza-cyclopenta[a]indene",C=CCN1C2=CC=CC=C2N3C1=NC(=C3)C4=CC=CC=C4,,,,,,
3272,443273,"3-(4-Chlorobenzyl)-5-(2-methoxyphenyl)-1,2,4-oxadiazole",COC1=CC=CC=C1C2=NC(=NO2)CC3=CC=C(C=C3)Cl,,,,,,
3273,443274,"2-Phenethylsulfanyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-ylamine",C1CCC2=C(C1)C3=C(N=C(N=C3S2)SCCC4=CC=CC=C4)N,,,,,,
3274,443275,"(5,12,13-Triaza-indeno[1,2-b]anthracen-13-yl)-acetic acid ethylester",CCOC(=O)CN1C2=CC=CC=C2C3=NC4=CC5=CC=CC=C5C=C4N=C31,,,,,,
3275,443276,"2,2'-(1-phenyl-1H-1,2,4-triazole-3,5-diyl)diphenol",C1=CC=C(C=C1)N2C(=NC(=N2)C3=CC=CC=C3O)C4=CC=CC=C4O,,,,,,
3276,443277,"2-(2-Chlorophenyl)-5-(5-methyl-2-thienyl)-1,3,4-oxadiazole",CC1=CC=C(S1)C2=NN=C(O2)C3=CC=CC=C3Cl,,,,,,
3277,443278,Pifithrin-Beta,CC1=CC=C(C=C1)C2=CN3C4=C(CCCC4)SC3=N2,,,,,,
3278,443279,"6,8-Di-DMA-chrysin",CC(=CCC1=C(C(=C2C(=C1O)C(=O)C=C(O2)C3=CC=CC=C3)CC=C(C)C)O)C,,,,,,
3279,443280,"6-(3,7-Dimethylocta-2,6-dienyl)-5,7-dihydroxy-2-phenylchromen-4-one",CC(=CCCC(=CCC1=C(C2=C(C=C1O)OC(=CC2=O)C3=CC=CC=C3)O)C)C,,,,,,
3280,443281,CID 443281,CC(=CCCC(=CCC1=C2C(=C(C=C(O2)C3=CC=CC=C3)O)C(=O)C=C1O)C)C,,,,,,
3281,443282,CID 443282,CC(=CCC1=C(C2=C(C(=C(OC2=CC1=O)C3=CC=CC=C3)O)O)O)C,,,,,,
3282,443283,CID 443283,CC(=CCC1=C2C(=C(C(=C(O2)C3=CC=CC=C3)OC)O)C(=O)C=C1O)C,,,,,,
3283,443284,CID 443284,CC(C)(C=C)C1=C2C(=C(C(=C(O2)C3=CC=CC=C3)OC)O)C(=O)C=C1O,,,,,,
3284,443285,CID 443285,CC(C)(C=C)C1=C2C(=C(C(=C(O2)C3=CC=C(C=C3)OC)O)O)C(=O)C=C1O,,,,,,
3285,443286,CID 443286,CC(C)(C=C)C1=C2C(=C(C(=C(O2)C3=CC=CC=C3)O)O)C(=O)C=C1O,,,,,,
3286,443287,2-Chlorophenylhydrazine hydrochloride,C1=CC=C(C(=C1)NN)Cl.Cl,,,,,,
3287,443288,4-Glutathionyl cyclophosphamide,C1COP(=O)(NC1SCC(C(=O)NCC(=O)O)NC(=O)CCC(C(=O)O)N)N(CCCl)CCCl,,,,,,
3288,443289,Cyclo(D-trp-D-asp-pro-D-val-leu),CC(C)C[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(=O)N1)C(C)C)CC(=O)O)CC3=CNC4=CC=CC=C43,,,"['Compounds and drugs that bind to and inhibit or block the activation of ENDOTHELIN RECECPTORS. (See all compounds classified as Endothelin Receptor Antagonists.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']",,,
3289,443290,"3-[(5S,6R)-5,6-dihydroxycyclohexa-1,3-dienyl]propanoic acid",C1=C[C@@H]([C@@H](C(=C1)CCC(=O)O)O)O,,,,,,
3290,443291,cyclo[D-Asp-Pro-D-Gly(thien-2-yl)-Leu-D-Trp],CC(C)C[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(=O)N1)C3=CC=CS3)CC(=O)O)CC4=CNC5=CC=CC=C54,,,,,,
3291,443292,"6-Hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl)benzothiazole",CC1=C(C2=C(C(=C1O)C)SC(=N2)NC)CC3=CN=CC=C3,,,,,,
3292,443293,E3040 sulfate,CC1=C(C2=C(C(=C1OS(=O)(=O)O)C)SC(=N2)NC)CC3=CN=CC=C3,,,,,,
3293,443294,E3040 glucuronide,CC1=C(C2=C(C(=C1O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)C(=O)O)O)O)O)C)SC(=N2)NC)CC4=CN=CC=C4,,,,,,
3294,443295,N-Formyl-methionyl-leucyl-phenylalanine,CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCSC)NC=O,,,,,,
3295,443296,Grepafloxacin glucuronide,CC1CN(CCN1)C2=C(C(=C3C(=C2)N(C=C(C3=O)C(=O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)C5CC5)C)F,,,,,,
3296,443297,Hydroxylamine hydrochloride,NO.Cl,,,,,,
3297,443298,CID 443298,COC(=O)C1=CC=CC=C1C2=C3C=CC(=NC(=O)C4=C(C(=C(C=C4)N[N+]#N)[125I])O)C=C3OC5=C2C=CC(=C5)N,,,,,,
3298,443299,CID 443299,CC[C@H]1CN2CCC1C[C@H]2[C@@H](C3=C4C=CC=C(C4=NC=C3)NC(=O)C5=CC(=C(C=C5[O-])N[N+]#N)[125I])O,,,,,,
3299,443300,CID 443300,CC[C@H]1CN2CCC1C[C@H]2[C@@H](C3=C4C=CC=C(C4=NC=C3)NC(=O)C5=CC(=C(C=C5O)N[N+]#N)[125I])O,,,,,,
3300,443301,N2-(L-Phenylalanyl)-N1-(naphthalenyl)-L-arigninamide,C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC2=CC3=CC=CC=C3C=C2)N,,,,,,
3301,443302,Monochloro-monoglutathionyl melphalan,C1=CC(=CC=C1CC(C(=O)O)N)N(CCSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)CCCl,,,,,,
3302,443303,N-tert-Butyloxycarbonyl-deacetyl-leupeptin,CC(C)C[C@@H](C(=O)NC(CC(C)C)C(=O)NC(CCCN=C(N)N)C=O)NC(=O)OC(C)(C)C,,,,,,
3303,443304,NAc-DNP-Cys,CC(=O)N[C@@H](CSC1=C(C=C(C=C1)[N+](=O)[O-])[N+](=O)[O-])C(=O)O,,,,,,
3304,443305,NAc-FnorLRF-amide,CCCCC(C(=O)NC(CCCN=C(N)N)C(=O)NC(CC1=CC=CC=C1)C(=O)N)NC(=O)C(CC2=CC=CC=C2)NC(=O)C,,,,,,
3305,443306,N-Acetyl-leu-leu-leu-leu-leu-tyr-amide,CC(C)CC(C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CC1=CC=C(C=C1)O)C(=O)N)NC(=O)C,,,,,,
3306,443307,Nafenopin glucuronide,CC(C)(C(=O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)C(=O)O)O)O)O)OC2=CC=C(C=C2)C3CCCC4=CC=CC=C34,,,,,,
3307,443308,CID 443308,C[C@H](C(=O)N[C@@H](CC(C)C)[C@H](CC(=O)O)O)NC(=O)C[C@@H]([C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)C(C)C)O,,,,,,
3308,443309,Pristinamycin IB,CCC1C(=O)N2CCCC2C(=O)N(C(C(=O)N3CCC(=O)CC3C(=O)NC(C(=O)OC(C(C(=O)N1)NC(=O)C4=C(C=CC=N4)O)C)C5=CC=CC=C5)CC6=CC=C(C=C6)NC)C,,,,,,
3309,443310,Pristinamycin IC,CC1C(C(=O)NC(C(=O)N2CCCC2C(=O)N(C(C(=O)N3CCC(=O)CC3C(=O)NC(C(=O)O1)C4=CC=CC=C4)CC5=CC=C(C=C5)N(C)C)C)C)NC(=O)C6=C(C=CC=N6)O,,,,,,
3310,443311,Puromycin dihydrochloride,CN(C)C1=NC=NC2=C1N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)NC(=O)[C@H](CC4=CC=C(C=C4)OC)N)O.Cl.Cl,,,"['Antimetabolites that are useful in cancer chemotherapy. (See all compounds classified as Antimetabolites, Antineoplastic.)', 'Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)', 'Agents destructive to the protozoal organisms belonging to the suborder TRYPANOSOMATINA. (See all compounds classified as Trypanocidal Agents.)']",,,
3311,443312,CID 443312,COC1=CC(=CC(=C1O)OC)C2=C(C(=C3C(=CC(=O)C=C3O2)O)O)O,,,,,,
3312,443313,Tetramethylchloromethylrosamine,CN(C)C1=CC2=C(C=C1)C(=C3C=CC(=[N+](C)C)C=C3O2)C4=CC=C(C=C4)CCl,,,,,,
3313,443314,Tween 20,CCCCCCCCCCCC(=O)OCCOCC(C1C(C(CO1)OCCO)OCCO)OCCO,,,"['Usually inert substances added to a prescription in order to provide suitable consistency to the dosage form. These include binders, matrix, base or diluent in pills, tablets, creams, salves, etc. (See all compounds classified as Excipients.)', 'Agents that modify interfacial tension of water; usually substances that have one lipophilic and one hydrophilic group in the molecule; includes soaps, detergents, emulsifiers, dispersing and wetting agents, and several groups of antiseptics. (See all compounds classified as Surface-Active Agents.)']","['/Investigators/ found that the labeled lauric acid moiety of Polysorbate 20 was rapidly absorbed and oxidized by rats. After 24 hours, some 75 percent of the lauric acid was oxidized and expired as CO2. 4 percent was not absorbed from the alimentary tract.', ""The polyoxyethylene sorbitan moiety left after hydrolysis of the ester is poorly absorbed from the rat's gastrointestinal tract. In one study with a radioactive carbon label in the polyoxyethylene portion of Polysorbate 20, 90 percent was excreted in the feces and 8 percent in the urine. No radioactivity was found in the liver, carcass, or expired C02."", 'After intravenous injection of Polysorbate 20 into rats, the distribution of the labeled lauric acid moiety was: expired CO2, 68 percent; carcass, 22 percent; urine, 5 percent; feces and gastrointestinal contents, 2.5 percent; and liver 0.7 percent. The distribution of the labeled polyoxyethylene moiety was: urine, 83 percent; feces, 11 percent; carcass, 2 percent; liver, 0.15 percent; and expired CO2 nil.', '/Investigators/ fed Polysorbate 20 to rats and followed the distribution of labeled lauric acid to various tissues. The approximate distribution of radioactivity 24 hours after oral administration was: expired C02, 80 percent; carcass, 12 percent; unabsorbed from the gastrointestinal tract, 4 percent; urine, 2.5 percent; and liver, 1.2 percent.', 'For more Absorption, Distribution and Excretion (Complete) data for Polysorbate 20 (7 total), please visit the HSDB record page.']","['The metabolism of Polysorbates in rats has been studied in detail with 14C-label tracer techniques. When administered orally, the ester link of the Polysorbate molecule is hydrolyzed by pancreatic lipase, and the fatty acid moiety is released to be absorbed and metabolized as any other dietary fatty acid.', 'After intravenous injection into rats, the ester bond is hydrolyzed by blood lipases. When Polysorbate 20 was injected into rats, the labeled lauric acid moiety was metabolized and appeared mostly as expired CO2. The polyoxyethylene moiety was not catabolized, since no radioactivity was recovered as CO2 when this portion of the molecule was labeled. Most of the labeled polyoxyethylene appeared in the urine, but some was present in the feces, indicating biliary excretion.']",
3314,443315,"2-[2-[3,4-Bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy]ethyl octadec-9-enoate",CCCCCCCCC=CCCCCCCCC(=O)OCCOCC(C1C(C(CO1)OCCO)OCCO)OCCO,,,,,,
3315,443316,"15,16-Dihydrobiliverdin",CC1=C(C(=O)N[C@@H]1CC2=C(C(=C(N2)C=C3C(=C(C(=CC4=NC(=O)C(=C4C=C)C)N3)C)CCC(=O)O)CCC(=O)O)C)C=C,,,,,,
3316,443317,CID 443317,C1=NC(=O)C2=C(N1)N(C=N2)[C@H]3C(=O)[C@@H]([C@H](O3)CO)O,,,,,,
3317,443318,CID 443318,CC=C1CN2[C@H]3C[C@H]1C([C@@H]2CC4=C3NC5=CC=CC=C45)(C=O)C(=O)OC,,,,,,
3318,443319,CID 443319,CC=C1CN2[C@H]3C[C@H]1[C@@H]([C@@H]2CC4=C3NC5=CC=CC=C45)C=O,,,,,,
3319,443320,"(1S,12S,14S)-15-ethylidene-3,17-diazapentacyclo[12.3.1.02,10.04,9.012,17]octadeca-2(10),4,6,8-tetraene-13-carbaldehyde",CC=C1CN2[C@H]3C[C@H]1C([C@@H]2CC4=C3NC5=CC=CC=C45)C=O,,,,,,
3320,443321,"[(1S,12S,14S)-15-ethylidene-3,17-diazapentacyclo[12.3.1.02,10.04,9.012,17]octadeca-2(10),4,6,8-tetraen-13-yl]methanol",CC=C1CN2[C@H]3C[C@H]1C([C@@H]2CC4=C3NC5=CC=CC=C45)CO,,,,,,
3321,443322,7-Deoxyloganic acid,C[C@H]1CC[C@H]2[C@@H]1[C@@H](OC=C2C(=O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
3322,443323,"3alpha,12alpha-Dihydroxy-5beta-chol-6-en-24-oic acid",C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2C=C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C,,,,,,
3323,443324,Anhydrovinblastine,CCC1=C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC,,,,,,
3324,443325,19-Hydroxytabersonine,CC([C@]12CC(=C3[C@@]4([C@H]1N(CC4)CC=C2)C5=CC=CC=C5N3)C(=O)OC)O,,,,,,
3325,443326,16-Hydroxytabersonine,CC[C@]12CC(=C3[C@@]4([C@H]1N(CC4)CC=C2)C5=C(N3)C=C(C=C5)O)C(=O)OC,,,,,,
3326,443327,Lamiide,C[C@@]1([C@H](C[C@]2([C@@H]1[C@@H](OC=C2C(=O)OC)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O)O,,,,,,
3327,443328,Lamioside,CC1=CO[C@H]([C@H]2[C@@]1([C@@H](C[C@]2(C)OC(=O)C)O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
3328,443329,Deoxyloganin tetraacetate,C[C@H]1CC[C@H]2[C@@H]1[C@@H](OC=C2C(=O)OC)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)COC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C,,,,,,
3329,443330,Deoxyloganic acid tetraacetate,C[C@H]1CC[C@H]2[C@@H]1[C@@H](OC=C2C(=O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)COC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C,,,,,,
3330,443331,8-Epideoxyloganin,C[C@@H]1CC[C@H]2[C@@H]1[C@@H](OC=C2C(=O)OC)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
3331,443332,8-Epideoxyloganic acid,C[C@@H]1CC[C@H]2[C@@H]1[C@@H](OC=C2C(=O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
3332,443333,8-Epideoxyloganin tetraacetate,C[C@@H]1CC[C@H]2[C@@H]1[C@@H](OC=C2C(=O)OC)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)COC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C,,,,,,
3333,443334,8-Epiiridodial,C[C@@H]1CC[C@H]2[C@@H]1[C@@H](OC=C2C)O,,,,,,
3334,443335,Iridotrial glucoside,C[C@H]1CC[C@H]2[C@@H]1[C@@H](OC=C2C=O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
3335,443336,Asperuloside tetraacetate,CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H]3[C@@H]4[C@H](C=C3COC(=O)C)OC(=O)C4=CO2)OC(=O)C)OC(=O)C)OC(=O)C,,,,,,
3336,443337,8-Epiiridodial glucoside,C[C@@H]1CC[C@H]2[C@@H]1[C@@H](OC=C2C)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
3337,443338,Iridodial glucoside tetraacetate,C[C@H]1CC[C@H]2[C@@H]1[C@@H](OC=C2C)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)COC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C,,,,,,
3338,443339,8-Epiiridodial glucoside tetraacetate,C[C@@H]1CC[C@H]2[C@@H]1[C@@H](OC=C2C)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)COC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C,,,,,,
3339,443340,10-Hydroxyloganin,COC(=O)C1=CO[C@H]([C@H]2[C@@H]1C[C@@H]([C@@H]2CO)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
3340,443341,10-Hydroxymorroniside,COC(=O)C1=CO[C@H]([C@H]2[C@@H]1CC(O[C@H]2CO)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
3341,443342,7-Epiloganic acid,C[C@H]1[C@@H](C[C@H]2[C@@H]1[C@@H](OC=C2C(=O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O,,,,,,
3342,443343,7-Epiloganin tetraacetate,C[C@H]1[C@@H](C[C@H]2[C@@H]1[C@@H](OC=C2C(=O)OC)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)COC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C)O,,,,,,
3343,443344,Loganin pentaacetate,C[C@H]1[C@H](C[C@H]2[C@@H]1[C@@H](OC=C2C(=O)OC)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)COC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C,,,,,,
3344,443345,10-Deoxygeniposide tetraacetate,CC1=CC[C@H]2[C@@H]1[C@@H](OC=C2C(=O)OC)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)COC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C,,,,,,
3345,443346,7-Deoxygardoside metyl ester tetraacetate,CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H]3[C@H](CCC3=C)C(=CO2)C(=O)OC)OC(=O)C)OC(=O)C)OC(=O)C,,,,,,
3346,443347,11-Hydroxyiridodial glucoside pentaacetate,C[C@H]1CC[C@H]2[C@@H]1[C@@H](OC=C2COC(=O)C)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)COC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C,,,,,,
3347,443348,8-epi-11-Hydroxyiridodial glucoside pentaacetate,C[C@@H]1CC[C@H]2[C@@H]1[C@@H](OC=C2COC(=O)C)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)COC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C,,,,,,
3348,443349,7-Dehydrologanin tetraacetate,C[C@@H]1[C@@H]2[C@H](CC1=O)C(=CO[C@H]2O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)COC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C)C(=O)OC,,,,,,
3349,443350,Deutzioside pentaacetate,CC1=CO[C@H]([C@H]2[C@@H]1[C@@H]([C@H]3[C@@H]2O3)OC(=O)C)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)COC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C,,,,,,
3350,443351,Iridodial glucoside,C[C@H]1CC[C@H]2[C@@H]1[C@@H](OC=C2C)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
3351,443352,Deutzioside,CC1=CO[C@H]([C@H]2[C@@H]1[C@@H]([C@H]3[C@@H]2O3)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O,,,,,,
3352,443353,10-Deoxygeniposidic acid,CC1=CC[C@H]2[C@@H]1[C@@H](OC=C2C(=O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
3353,443354,Geniposidic acid,C1C=C([C@@H]2[C@H]1C(=CO[C@H]2O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)C(=O)O)CO,,,,,,
3354,443355,Secogalioside,COC(=O)C1=CO[C@H]([C@H]2[C@@H]1C[C@H]3O[C@@H]2[C@@H](O3)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O,,,,,,
3355,443356,16-Methoxytabersonine,CC[C@]12CC(=C3[C@@]4([C@H]1N(CC4)CC=C2)C5=C(N3)C=C(C=C5)OC)C(=O)OC,,,,,,
3356,443357,"Methyl (1R,12S,20R)-12-ethyl-14-oxa-8,17-diazahexacyclo[10.7.1.01,9.02,7.013,15.017,20]icosa-2,4,6,9-tetraene-10-carboxylate",CC[C@]12CC(=C3[C@@]4([C@H]1N(CC4)CC5C2O5)C6=CC=CC=C6N3)C(=O)OC,,,,,,
3357,443358,Horhammericine,CC([C@]12CC(=C3[C@@]4([C@H]1N(CC4)CC5C2O5)C6=CC=CC=C6N3)C(=O)OC)O,,,,,,
3358,443359,CID 443359,COC(=O)C(=CO)[C@@H](C[C@H]1C2=C(CCN1)C3=CC=CC=C3N2)[C@@H](C=C)C=O,,,,,,
3359,443360,"methyl 2-[(2S,3R,12bS)-3-ethenyl-2,3,6,7,12,12b-hexahydro-1H-indolo[2,3-a]quinolizin-5-ium-2-yl]-3-hydroxyprop-2-enoate",COC(=O)C(=CO)[C@H]1C[C@H]2C3=C(CC[N+]2=C[C@@H]1C=C)C4=CC=CC=C4N3,,,,,,
3360,443361,Cathenamine,C[C@H]1C2=CN3CCC4=C([C@@H]3C[C@@H]2C(=CO1)C(=O)OC)NC5=CC=CC=C45,,,,,,
3361,443362,19-epi-Cathenamine,C[C@@H]1C2=CN3CCC4=C([C@@H]3C[C@@H]2C(=CO1)C(=O)OC)NC5=CC=CC=C45,,,,,,
3362,443363,MET-enkephalin,CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)N,['Metenkefalin is indicated in Bosnia for the treatment of relapsing-remitting multiple sclerosis.'],,"['Substances used for their pharmacological actions on any aspect of neurotransmitter systems. Neurotransmitter agents include agonists, antagonists, degradation inhibitors, uptake inhibitors, depleters, precursors, and modulators of receptor function. (See all compounds classified as Neurotransmitter Agents.)']","['Metenkefalin reaches a C<sub>max</sub> of 1266.14pg/mL, with a T<sub>max</sub> of 0.16h, and an AUC of 360.64pg\\*h/mL.']",,['The half life of metenkefalin is 4.2-39 minutes.']
3363,443364,"(7S)-7-[[(2S)-4-hydroxy-2-(2-methylpropyl)-1-oxo-3,3a-dihydro-2H-imidazo[1,2-a]indol-4-yl]methyl]-6,7-dihydroquinazolino[3,2-a][1,4]benzodiazepine-5,13-dione",CC(C)C[C@H]1C(=O)N2C(N1)C(C3=CC=CC=C32)(C[C@H]4C5=NC6=CC=CC=C6C(=O)N5C7=CC=CC=C7C(=O)N4)O,,,,,,
3364,443365,"(4R)-4-[(11R)-11-methoxy-8-methyltetradeca-1,5,7,13-tetraenyl]-2-[(1R,2S)-2-methylcyclopropyl]-4,5-dihydro-1,3-thiazole",C[C@H]1C[C@H]1C2=N[C@@H](CS2)C=CCCC=CC=C(C)CC[C@H](CC=C)OC,,,,,,
3365,443366,"(3R,4S)-3-(6-chloro-3-pyridyl)-7-azabicyclo[2.2.1]heptane",C1CC2C[C@@H]([C@H]1N2)C3=CN=C(C=C3)Cl,,,"['Drugs that bind to and activate nicotinic cholinergic receptors (RECEPTORS, NICOTINIC). Nicotinic agonists act at postganglionic nicotinic receptors, at neuroeffector junctions in the peripheral nervous system, and at nicotinic receptors in the central nervous system. Agents that function as neuromuscular depolarizing blocking agents are included here because they activate nicotinic receptors, although they are used clinically to block nicotinic transmission. (See all compounds classified as Nicotinic Agonists.)', 'A subclass of analgesic agents that typically do not bind to OPIOID RECEPTORS and are not addictive. Many non-narcotic analgesics are offered as NONPRESCRIPTION DRUGS. (See all compounds classified as Analgesics, Non-Narcotic.)']",,,
3366,443367,CID 443367,CC=C1CN2CC[C@@H]1[C@](C3=C(CC2)C4=CC=CC=C4N3)(CO)C(=O)OC,,,,,,
3367,443368,"(11S,13S)-3-Amino-5,12,13,14-tetrahydroxy-14-(hydroxymethyl)-8,10-dioxa-2-aza-4-azoniatetracyclo[7.3.1.17,11.01,6]tetradec-3-en-9-olate",C(C1([C@@H]2C(C34[C@@H](C(O2)(OC1C3C([NH+]=C(N4)N)O)[O-])O)O)O)O,,,,,,
3368,443369,CID 443369,C(C1(C2C3C(N=C(NC34[C@@H](C(O2)(OC1C4O)O)O)N)O)O)O,,,"['Drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They act on any part of the nervous system and on every type of nerve fiber. In contact with a nerve trunk, these anesthetics can cause both sensory and motor paralysis in the innervated area. Their action is completely reversible. (From Gilman AG, et. al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed) Nearly all local anesthetics act by reducing the tendency of voltage-dependent sodium channels to activate. (See all compounds classified as Anesthetics, Local.)', 'Substances which, when ingested, inhaled, or absorbed, or when applied to, injected into, or developed within the body in relatively small amounts may, by their chemical action, cause damage to structure or disturbance of function. (From Dorland, 27th ed) (See all compounds classified as Poisons.)', 'A class of drugs that act by inhibition of sodium influx through cell membranes. Blockade of sodium channels slows the rate and amplitude of initial rapid depolarization, reduces cell excitability, and reduces conduction velocity. (See all compounds classified as Sodium Channel Blockers.)']","['Twenty-three specimens of a tree-frog Polypedates sp. were collected from two locations (Mymensingh and Barisal) of Bangladesh in 1999, and assayed for their toxicity scores and toxin principle. Among the tissues, only the skin of the Mymensingh specimens was found to be toxic in mouse test, with the toxicity scores of 31-923 ug/g. The toxin isolated from the skin was analyzed by high-performance liquid chromatography, electrospray ionization-time of flight mass spectrometry and proton nuclear magnetic resonance, and characterized as tetrodotoxin, a toxin principle.', 'Tetrodotoxin (TTX) and its analogs (TTXs), widely distributed among marine as well as terrestrial animals, induce dangerous intoxications. These highly potential toxins are also known as the causative agent of puffer fish poisoning. ... TTX, anhydrotetrodotoxin, 11-deoxytetrodotoxin and trideoxytetrodotoxin were determined in separated tissues of Bangladeshi marine puffers, Takifugu oblongus. TTX was predominant in skin, muscle and liver, whereas trideoxytetrodotoxin preponderated in the ovary. The toxicity of the various tissues was determined by a mouse bioassay.', 'To investigate the relationship between the toxicity of puffer fish and the distribution of tetrodotoxin-producing bacteria in puffer fish Fugu rubripes collected from the Bohai Sea of China, bacteria were isolated from each organ (ovaries, livers, intestines and gallbladders) and screened for tetrodotoxin (TTX) production. 20 out of 36 isolated strains were found to produce TTX in vitro. In the organs of ovaries and livers whose toxicity is more potent than other organs, the number and toxicity of TTX-producing strains was greater than that of others. Most TTX-producing bacterial strains were identified as Bacillus spp. (19 strains) and Actinomycete spp. (1 strain) based on the morphological observation, physiological and biochemical characteristics and G+C content of DNA. The purified toxin was identified to be TTX by high performance liquid chromatography assay, thin-layer chromatography assay and electrospray ionization mass spectrometry analysis. Our results suggested that TTX-producing bacteria are closely related to the toxification of the puffer fish. More research is needed to elucidate the mechanism of TTX synthesis and the role of TTX in bacteria.', 'The liver homogenate of puffer fish was fractionated into blood cell, nuclear, mitochondrial, microsomal and cytosol fractions by the differential centrifugation method. ... Analyses by HPLC and LC-FABMS demonstrated that tetrodotoxin is the major toxic principle in each fraction. These results reveal that tetrodotoxin is widely distributed in organelles in liver cells, though predominantly in the cytosol fraction.', 'For more Absorption, Distribution and Excretion (Complete) data for Tetrodotoxin (9 total), please visit the HSDB record page.']","['The metabolic source of tetrodotoxin is uncertain. No algal source has been identified, and until recently tetrodotoxin was assumed to be a metabolic product of the host. However, recent reports of the production of tetrodotoxin/anhydrotetrodotoxin by several bacterial species, including strains of the family Vibrionaceae, Pseudomonas sp., and Photobacterium phosphoreum, point toward a bacterial origin of this family of toxins.', 'To investigate the genes related to the biosynthesis or accumulation of tetrodotoxin (TTX) in pufferfish, mRNA expression patterns in the liver from pufferfish, akamefugu Takifugu chrysops and kusafugu Takifugu niphobles, were compared by mRNA arbitrarily primed reverse transcription-polymerase chain reaction (RAP RT-PCR) with fish bearing different concentrations of TTX and its derivatives. RAP RT-PCR provided a 383 bp cDNA fragment and its transcripts were higher in toxic than non-toxic pufferfish liver. Its deduced amino acid sequence was similar to those of fibrinogen-like proteins reported for other vertebrates. Northern blot analysis and rapid amplification of cDNA ends (RACE) revealed that the cDNA fragment of 383 bp was composed of at least three fibrinogen-like protein (flp) genes, flp-1, flp-2 and flp-3. Relative mRNA levels of flp-1, flp-2 and flp-3 showed a linear correlation with toxicity of the liver for two pufferfish species.']",
3369,443370,Quinoline-3-carboxamides,C1=CC(=CC=C1N2C=C(C(=O)C3=C2C=C(C=C3)C4=CC=NC=C4)C(=O)N)F,,,,,,
3370,443371,(S)-Practolol,CC(C)NC[C@@H](COC1=CC=C(C=C1)NC(=O)C)O,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Drugs that bind to and block the activation of ADRENERGIC BETA-1 RECEPTORS. (See all compounds classified as Adrenergic beta-1 Receptor Antagonists.)']",,,
3371,443372,Levisoprenaline,CC(C)NC[C@@H](C1=CC(=C(C=C1)O)O)O,,,,,,
3372,443373,1-Fluoro-4-[2-(4-methylsulfonylphenyl)cyclopenten-1-yl]benzene,CS(=O)(=O)C1=CC=C(C=C1)C2=C(CCC2)C3=CC=C(C=C3)F,,,,,,
3373,443374,2-(1-ethylpyrrolidin-2-yl)-5-(5-ethylsulfonyl-2-methoxyphenyl)-1H-pyrrole,CCN1CCCC1C2=CC=C(N2)C3=C(C=CC(=C3)S(=O)(=O)CC)OC,,,,,,
3374,443375,Devazepide,CN1C2=CC=CC=C2C(=N[C@@H](C1=O)NC(=O)C3=CC4=CC=CC=C4N3)C5=CC=CC=C5,,,"['Chemical substances which inhibit the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites. (See all compounds classified as Hormone Antagonists.)']",,,
3375,443376,Teprotide,CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@@H]7CCC(=O)N7,,,"['Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (See all compounds classified as Angiotensin-Converting Enzyme Inhibitors.)']",,,
3376,443377,"(2S)-N-[3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-2-[[4-(2,5-dioxopyrrolidin-1-yl)-2-sulfanylbutanoyl]amino]-4-methylpentanamide",CC(C)C[C@@H](C(=O)NC(C(=O)NC)C(C)(C)C)NC(=O)C(CCN1C(=O)CCC1=O)S,,,,,,
3377,443378,5-Chloro-3-(4-methylsulfonylphenyl)-2-pyridin-3-ylpyridine,CS(=O)(=O)C1=CC=C(C=C1)C2=C(N=CC(=C2)Cl)C3=CN=CC=C3,,,,,,
3378,443379,CX6Kcq2zkm,C[C@H](C(=O)N1CCC[C@H]1C(=O)O)N[C@@H](CCC2=CC=CC=C2)C(=O)O,,,,,,
3379,443380,Candoxatrilat,COCCOC[C@H](CC1(CCCC1)C(=O)NC2CCC(CC2)C(=O)O)C(=O)O,,,['Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). (See all compounds classified as Protease Inhibitors.)'],,,
3380,443381,Cycloguanil pamoate,CC1(N=C(N=C(N1C2=CC=C(C=C2)Cl)N)N)C.CC1(N=C(N=C(N1C2=CC=C(C=C2)Cl)N)N)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O,,,,,,
3381,443382,Chloramphenicol palmitate,CCCCCCCCCCCCCCCC(=O)OC[C@H]([C@@H](C1=CC=C(C=C1)[N+](=O)[O-])O)NC(=O)C(Cl)Cl,,,,,,
3382,443383,CID 443383,C1=CC(=CC=C1[C@H]([C@H](COC(=O)CCC(=O)[O-])NC(=O)C(Cl)Cl)O)[N+](=O)[O-].[Na+],,,,,,
3383,443384,"4-[(2S,3R)-2-[(2,2-dichloroacetyl)amino]-3-hydroxy-3-(4-nitrophenyl)propoxy]-4-oxobutanoic acid",C1=CC(=CC=C1[C@H]([C@H](COC(=O)CCC(=O)O)NC(=O)C(Cl)Cl)O)[N+](=O)[O-],,,,,,
3384,443385,Clindamycin phosphate,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)OP(=O)(O)O)O)O)[C@H](C)Cl,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
3385,443386,CID 443386,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)N3C(=O)[C@H](NC3(C)C)C4=CC=CC=C4)C(=O)[O-])C.[K+],,,,,,
3386,443387,Hetacillin,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)N3C(=O)[C@H](NC3(C)C)C4=CC=CC=C4)C(=O)O)C,['Hetacillin is a beta-lactam antibiotic prodrug used to treat bacterial infections. In the body it gets converted to ampicillin.'],"['Hetacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name ""penicillin"" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Hetacillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Hetacillin results from the inhibition of cell wall synthesis and is mediated through Hetacillin binding to penicillin binding proteins (PBPs).']",,,['Hydrolyzed to active ampicillin via esterases'],
3387,443388,CID 443388,C#CCN(CC1=CC2=C(C=C1)NC(=NC2=O)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,,,,,,
3388,443389,SB 221284,CSC1=C(C=C2C(=C1)CCN2C(=O)NC3=CN=CC=C3)C(F)(F)F,,,,,,
3389,443390,N-(3-(3-Pyridinyl)-5-fluorophenyl)-5-methoxy-6-(trifluoromethyl)indoline-1-carboxamide,COC1=C(C=C2C(=C1)CCN2C(=O)NC3=CC(=CC(=C3)C4=CN=CC=C4)F)C(F)(F)F,,,,,,
3390,443391,"5-methyl-N-[6-(2-methylpyridin-3-yl)oxypyridin-3-yl]-6-(trifluoromethyl)-2,3-dihydroindole-1-carboxamide",CC1=CC2=C(C=C1C(F)(F)F)N(CC2)C(=O)NC3=CN=C(C=C3)OC4=C(N=CC=C4)C,,,,,,
3391,443392,Penicillin T,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=C(C=C3)N)C(=O)O)C,,,,,,
3392,443393,CID 443393,C[C@H]([C@H]1[C@H]2CC(=C(N2C1=O)C(=O)O)SC=CNC(=O)C)OS(=O)(=O)O,,,,,,
3393,443394,3-(Diethylamino)propyl 3-hydroxy-2-phenylpropanoate,CCN(CC)CCCOC(=O)C(CO)C1=CC=CC=C1,,,,,,
3394,443395,Tridihexethyl bromide,CC[N+](CC)(CC)CCC(C1CCCCC1)(C2=CC=CC=C2)O.[Br-],,,,,,
3395,443396,Propantheline chloride,CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13)C(C)C.[Cl-],,,,,,
3396,443397,N-[(1-methyl-4H-pyridin-2-yl)methylidene]hydroxylamine,CN1C=CCC=C1C=NO,,,,,,
3397,443398,R-Soterenol,CC(C)NC[C@@H](C1=CC(=C(C=C1)O)NS(=O)(=O)C)O,,,,,,
3398,443399,4-[(1R)-1-hydroxy-2-[[(2S)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]-2-(hydroxymethyl)phenol,C[C@@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=CC(=C(C=C2)O)CO)O,,,,,,
3399,443400,"Dichloroisoproterenol, (R)-",CC(C)NC[C@@H](C1=CC(=C(C=C1)Cl)Cl)O,,,,,,
3400,443401,"methyl (1R,12R,19R)-12-(1-hydroxyethyl)-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,9-tetraene-10-carboxylate",CC([C@@]12CCCN3[C@@H]1[C@@]4(CC3)C5=CC=CC=C5NC4=C(C2)C(=O)OC)O,,,,,,
3401,443402,Echitovenine,CC([C@@]12CCCN3[C@@H]1[C@@]4(CC3)C5=CC=CC=C5NC4=C(C2)C(=O)OC)OC(=O)C,,,,,,
3402,443403,"(4S,4aR,7S,7aR,12bS)-1,2,3,4,4a,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol",C1CN[C@H]2CC3=C4[C@@]15[C@H]2C=C[C@@H]([C@@H]5OC4=C(C=C3)O)O,,,,,,
3403,443404,(-)-Metazocine,C[C@H]1[C@H]2CC3=C([C@@]1(CCN2C)C)C=C(C=C3)O,,,,,,
3404,443405,"Phenazocine, (-)-",C[C@H]1[C@H]2CC3=C([C@@]1(CCN2CCC4=CC=CC=C4)C)C=C(C=C3)O,,,"['Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. (See all compounds classified as Narcotics.)', 'Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)']",,,
3405,443406,(-)-Bremazocine,CC[C@@]12CCN([C@@H](C1(C)C)CC3=C2C=C(C=C3)O)CC4(CC4)O,,,['Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)'],,,
3406,443407,CID 443407,CCC[C@@](C)([C@H]1C[C@@]23C=C[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)C)OC)O,,,"['Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. (See all compounds classified as Hypnotics and Sedatives.)', 'Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. (See all compounds classified as Narcotics.)', 'Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)']","['Eleven juvenile African elephants were given etorphine hydrochloride (2.19 +/- 0.11 micrograms/kg of body weight; mean +/- SD) as a single IM injection; 3 elephants were given additional etorphine (0.42 +/- 0.09 micrograms/kg) IV. After immobilization, each elephant was maintained in lateral recumbency by administration of a 0.5% halothane/oxygen mixture or by administration of multiple IV injections of etorphine. At postinjection hours 0.25 and 0.5 and at 30-minute intervals thereafter, blood samples were collected via an auricular artery, and serum concentrations of etorphine were determined by use of radioimmunoassay. The highest mean serum concentration of etorphine in 6 elephants given a single IM injection and subsequently maintained on halothane and oxygen was 1.62 +/- 0.97 ng/mL at postinjection hours 0.5; thereafter, the mean serum concentration decreased steadily. In 4 elephants maintained in lateral recumbency with multiple IV administrations of etorphine, a correlation was not found between the time to develop initial signs of arousal and serum concentrations of etorphine before arousal. After administration of the initial immobilizing dose of etorphine, the interval between successive IV administrations of etorphine decreased. /Etorphine hydrochloride/', 'In a forensic case involving Immobilon /commerical formulation/, the etorphine concentrations measured in postmortem femoral vein and heart blood specimens were 14.5 and 23.5 ug/L, respectively. No etorphine was detected in the urine.']",,
3407,443408,Diprenorphine,CC(C)([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O,"['Diprenorphine is indicated to reverse the effects of powerful opioids including etorphine and carfentanil, often used for tranquilizing large animals. This drug is not approved for use in humans.']",,['Agents inhibiting the effect of narcotics on the central nervous system. (See all compounds classified as Narcotic Antagonists.)'],,,
3408,443409,CID 443409,CC[C@@]12CCN([C@@H](C1C)C(=O)C3=C2C=C(C=C3)O)CC4CC4,,,"['Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)']",,,
3409,443410,CID 443410,CN=C(NCCCC1=CN=CN1)S,,,,,,
3410,443411,CID 443411,CC1=C(N=CN1)CCCCNC(=NC)S,,,,,,
3411,443412,CID 443412,CN=C(NCCOCC1=CN=CN1)S,,,,,,
3412,443413,"[(1R,10S,12R,16S,18R)-13-ethylidene-8,15-diazahexacyclo[14.2.1.01,9.02,7.010,15.012,17]nonadeca-2,4,6,8-tetraen-18-yl] acetate",CC=C1CN2[C@H]3C[C@@H]1C4[C@@H]2C[C@]5([C@@H]4OC(=O)C)C3=NC6=CC=CC=C56,,,,,,
3413,443414,"[(1R,9R,10S,12R,14R,16S,18R)-13-ethylidene-14-hydroxy-8,15-diazahexacyclo[14.2.1.01,9.02,7.010,15.012,17]nonadeca-2,4,6-trien-18-yl] acetate",CC=C1[C@@H]2C[C@H]3[C@H]4[C@@]5(C[C@@H](C2[C@H]5OC(=O)C)N3[C@@H]1O)C6=CC=CC=C6N4,,,,,,
3414,443415,17-O-Acetylnorajmaline,CC[C@H]1[C@@H]2C[C@H]3[C@H]4[C@@]5(C[C@@H](C2[C@H]5OC(=O)C)N3[C@@H]1O)C6=CC=CC=C6N4,,,,,,
3415,443416,"(1R,9R,10S,12R,13S,14R,16S,18R)-13-ethyl-8,15-diazahexacyclo[14.2.1.01,9.02,7.010,15.012,17]nonadeca-2,4,6-triene-14,18-diol",CC[C@H]1[C@@H]2C[C@H]3[C@H]4[C@@]5(C[C@@H](C2[C@H]5O)N3[C@@H]1O)C6=CC=CC=C6N4,,,,,,
3416,443417,Lochnerinine,CC[C@]12CC(=C3[C@@]4([C@H]1N(CC4)CC5C2O5)C6=C(N3)C=C(C=C6)OC)C(=O)OC,,,,,,
3417,443418,Demethylalangiside,C=C[C@@H]1[C@@H]2C[C@@H]3C4=CC(=C(C=C4CCN3C(=O)C2=CO[C@H]1O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O)O,,,,,,
3418,443419,Demethylisoalangiside,C=C[C@@H]1[C@@H]2C[C@H]3C4=CC(=C(C=C4CCN3C(=O)C2=CO[C@H]1O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O)O,,,,,,
3419,443420,Isoalangiside,COC1=C(C=C2[C@@H]3C[C@H]4[C@H]([C@@H](OC=C4C(=O)N3CCC2=C1)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)C=C)O,,,,,,
3420,443421,Protoemetine,CC[C@H]1CN2CCC3=CC(=C(C=C3[C@@H]2C[C@@H]1CC=O)OC)OC,,,,,,
3421,443422,(R)-Canadine,COC1=C(C2=C(C[C@@H]3C4=CC5=C(C=C4CCN3C2)OCO5)C=C1)OC,,,"['A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)']",,,
3422,443423,(+/-)-Cromakalim,CC1(C(C(C2=C(O1)C=CC(=C2)C#N)N3CCCC3=O)O)C,,,"['Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)', 'Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)']",,,
3423,443424,L-alpha-formylglycine,C(=O)[C@@H](C(=O)O)N,,,,,,
3424,443425,13(1)-Hydroxy-Mg-protoporphyrin IX 13-monomethyl ester,CC1=C(C2=CC3=NC(=CC4=C(C(=C([N-]4)C=C5C(=C(C(=N5)C=C1[N-]2)C)CCC(=O)O)C(CC(=O)OC)O)C)C(=C3C)C=C)C=C.[Mg+2],,,,,,
3425,443426,"3-[8,13-Bis(ethenyl)-18-(1-hydroxy-3-methoxy-3-oxopropyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid",CC1=C(C2=CC3=NC(=CC4=NC(=CC5=C(C(=C(N5)C=C1N2)C=C)C)C(=C4CCC(=O)O)C)C(=C3C)C(CC(=O)OC)O)C=C,,,,,,
3426,443427,13(1)-Oxo-Mg-protoporphyrin IX 13-monomethyl ester,CC1=C(C2=CC3=NC(=CC4=C(C(=C([N-]4)C=C5C(=C(C(=N5)C=C1[N-]2)C)CCC(=O)O)C(=O)CC(=O)OC)C)C(=C3C)C=C)C=C.[Mg+2],,,,,,
3427,443428,"3-[8,13-bis(ethenyl)-18-(1-hydroxy-3-methoxy-3-oxopropylidene)-3,7,12,17-tetramethyl-24H-porphyrin-2-yl]propanoic acid",CC1=C(C2=NC1=CC3=NC(=CC4=NC(=CC5=C(C(=C(CC(=O)OC)O)C(=C2)N5)C)C(=C4C)C=C)C(=C3C)C=C)CCC(=O)O,,,,,,
3428,443429,"Mg-2,4-Divinylpheoporphyrin",CC1=C(C2=CC3=NC(=CC4=C(C5=C([N-]4)C(=C6C(=C(C(=N6)C=C1[N-]2)C)CCC(=O)O)[C@H](C5=O)C(=O)OC)C)C(=C3C)C=C)C=C.[Mg+2],,,,,,
3429,443430,[8-vinyl]-Protopheide a,CC1=C(C2=CC3=NC(=CC4=C(C5=C([C@@H](C(=C6C(=C(C(=N6)C=C1N2)C)CCC(=O)O)C5=N4)C(=O)OC)O)C)C(=C3C)C=C)C=C,,,,,,
3430,443431,Divinyl chlorophyllide a,C[C@H]1[C@@H](C2=C3[C@H](C(=O)C4=C3[N-]C(=C4C)C=C5C(=C(C(=N5)C=C6C(=C(C(=CC1=N2)[N-]6)C)C=C)C)C=C)C(=O)OC)CCC(=O)O.[Mg+2],,,,,,
3431,443432,"3-[(3R,21S,22S)-11,16-bis(ethenyl)-4-hydroxy-3-methoxycarbonyl-12,17,21,26-tetramethyl-7,23,24,25-tetrazahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1,4,6,8(26),9,11,13(25),14,16,18(24),19-undecaen-22-yl]propanoic acid",C[C@H]1[C@@H](C2=C3[C@H](C(=C4C3=NC(=C4C)C=C5C(=C(C(=N5)C=C6C(=C(C(=N6)C=C1N2)C)C=C)C)C=C)O)C(=O)OC)CCC(=O)O,,,,,,
3432,443433,N-Butyrylhomoserine lactone,CCCC(=O)NC1CCOC1=O,,,,,,
3433,443434,"4,5-Dihydroxypentane-2,3-dione",CC(=O)C(=O)C(CO)O,,,,,,
3434,443435,N-(3-(S)-Hydroxybutyryl)homoserine lactone,C[C@@H](CC(=O)NC1CCOC1=O)O,,,,,,
3435,443436,2-(Butylamido)-4-hydroxybutanoic acid,CCCC(=O)NC(CCO)C(=O)O,,,,,,
3436,443437,N-Heptanoylhomoserine lactone,CCCCCCC(=O)N[C@H]1CCOC1=O,,,,,,
3437,443438,3-hydroxy-N-[(3S)-2-oxooxolan-3-yl]tetradec-7-enamide,CCCCCCC=CCCCC(CC(=O)N[C@H]1CCOC1=O)O,,,,,,
3438,443439,Cyclo(deltaAla-L-Val),CC(C)[C@H]1C(=O)NC(=C)C(=O)N1,,,,,,
3439,443440,Cyclo(L-Phe-L-Pro),C1C[C@H]2C(=O)N[C@H](C(=O)N2C1)CC3=CC=CC=C3,,,,,,
3440,443441,2-heptyl-3-hydroxyquinolin-4(1H)-one,CCCCCCCC1=NC2=CC=CC=C2C(=O)C1O,,,,,,
3441,443442,CID 443442,C[C@H]1[C@@H](C2=C3[C@H](C(=O)C4=C3[N-]C(=C4C)C=C5C(=C(C(=N5)C=C6C(=C(C(=CC1=N2)[N-]6)C)C=C)C)C=C)C(=O)OC)CCC(=O)OCC=C(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C.[Mg+2],,,,,,
3442,443443,CID 443443,C[C@H]1[C@H](C2=C3[C@H](C(=C4C3=NC(=C4C)C=C5C(=C(C(=N5)C=C6C(=C(C(=N6)C=C1N2)C)C=C)C)C=C)O)C(=O)OC)CCC(=O)OCC=C(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C,,,,,,
3443,443444,CID 443444,CC[C@@H]1[C@H](C2=CC3=C(C(=C([N-]3)C=C4[C@H]([C@@H](C(=N4)C5=C6C(=C(C(=CC1=N2)[N-]6)C)C(=O)[C@@H]5C(=O)OC)CCC(=O)OCC=C(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C)C)C(=O)C)C.[Zn+2],,,,,,
3444,443445,ZINC gluconate,C([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O.C([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O.[Zn+2],"['Zinc gluconate is mainly indicated in conditions like zinc deficiency, and can also be administered in adjunctive therapy as an alternative drug of choice in diarrhea.']","['Zinc is an important mineral found in almost every cell in the human body. It promotes the activity of about 100 enzymes. Zinc deficiency is often associated with an increased risk of infection. When they are used to treat the common cold, zinc supplements may interfere with rhinovirus cleavage or adhesion and may play a role in protecting plasma membranes from microbial toxins and complement.']",,"['Please refer to DrugBank entry [DB01593]', 'Feces and urine', 'Stored primarily in skeletal muscle and bone.', 'Please refer to DrugBank entry [DB01593]']",['Please refer to DrugBank entry [DB01593]'],['280 days']
3445,443446,Gibberellin A14 aldehyde,C[C@@]12CC[C@@H]([C@@]([C@H]1[C@@H]([C@]34[C@H]2CC[C@H](C3)C(=C)C4)C=O)(C)C(=O)O)O,,,,,,
3446,443447,Gibberellin A51-catabolite,C[C@]1(CC(=O)C=C2[C@@H]1[C@@H]([C@]34[C@H]2CC[C@H](C3)C(=C)C4)C(=O)O)C(=O)O,,,,,,
3447,443448,Gibberellin A29-catabolite,C[C@]1(CC(=O)C=C2[C@@H]1[C@@H]([C@]34[C@H]2CC[C@](C3)(C(=C)C4)O)C(=O)O)C(=O)O,,,,,,
3448,443449,"Gibbane-1,10-dicarboxylic acid, 2,3-epoxy-4a,7-dihydroxy-1-methyl-8-methylene-, 1,4a-lactone, (1alpha,2beta,3beta,4aalpha,4bbeta,10beta)-",CC12[C@H]3[C@@H]([C@@]45CC(=C)[C@@](C4)(CC[C@H]5[C@@]3(C[C@H]6[C@@H]1O6)OC2=O)O)C(=O)O,,,,,,
3449,443450,Gibberellin A12,C[C@@]12CCC[C@@]([C@H]1[C@@H]([C@]34[C@H]2CC[C@H](C3)C(=C)C4)C(=O)O)(C)C(=O)O,,,,,,
3450,443451,Gibberellin A14,C[C@@]12CC[C@@H]([C@@]([C@H]1[C@@H]([C@]34[C@H]2CC[C@H](C3)C(=C)C4)C(=O)O)(C)C(=O)O)O,,,,,,
3451,443452,"(1R,2S,3S,4S,5S,8R,9R,12R)-5-Hydroxy-8-(hydroxymethyl)-4-methyl-13-methylidenetetracyclo[10.2.1.01,9.03,8]pentadecane-2,4-dicarboxylic acid",C[C@]1([C@H](CC[C@@]2([C@@H]1[C@@H]([C@]34[C@H]2CC[C@H](C3)C(=C)C4)C(=O)O)CO)O)C(=O)O,,,,,,
3452,443453,"(1R,4aR,4bR,7R,9aR,10S,10aS)-4a-(hydroxymethyl)-1-methyl-8-methylenedodecahydro-1H-7,9a-methanobenzo[a]azulene-1,10-dicarboxylic acid",C[C@]1(CCC[C@@]2([C@@H]1[C@@H]([C@]34[C@H]2CC[C@H](C3)C(=C)C4)C(=O)O)CO)C(=O)O,,,,,,
3453,443454,Gibberellin A24,C[C@]1(CCC[C@@]2([C@@H]1[C@@H]([C@]34[C@H]2CC[C@H](C3)C(=C)C4)C(=O)O)C=O)C(=O)O,,,,,,
3454,443455,Gibberellin A36,C[C@]1([C@H](CC[C@@]2([C@@H]1[C@@H]([C@]34[C@H]2CC[C@H](C3)C(=C)C4)C(=O)O)C=O)O)C(=O)O,,,,,,
3455,443456,"(1R,2R,5R,8R,9S,10R)-11-methyl-6-methylidene-16-oxo-15-oxapentacyclo[9.3.2.15,8.01,10.02,8]heptadecane-9-carboxylic acid",CC12CCC[C@@]3([C@@H]1[C@@H]([C@]45[C@H]3CC[C@H](C4)C(=C)C5)C(=O)O)OC2=O,,,,,,
3456,443457,CID 443457,CC12[C@H](CC[C@@]3([C@@H]1[C@@H]([C@]45[C@H]3CC[C@H](C4)C(=C)C5)C(=O)O)OC2=O)O,,,,,,
3457,443458,CID 443458,CC12C[C@H](C[C@@]3([C@@H]1[C@@H]([C@]45[C@H]3CC[C@H](C4)C(=C)C5)C(=O)O)OC2=O)O,,,,,,
3458,443459,"2,3-Didehydrogibberellin A9",CC12C=CC[C@@]3([C@@H]1[C@@H]([C@]45[C@H]3CC[C@H](C4)C(=C)C5)C(=O)O)OC2=O,,,,,,
3459,443460,"(1R,2R,5R,8R,9S,10R,12S)-12-Hydroxy-11-methyl-6-methylidene-16-oxo-15-oxapentacyclo[9.3.2.15,8.01,10.02,8]heptadec-13-ene-9-carboxylic acid",CC12[C@H](C=C[C@@]3([C@@H]1[C@@H]([C@]45[C@H]3CC[C@H](C4)C(=C)C5)C(=O)O)OC2=O)O,,,,,,
3460,443461,"(1R,2R,5R,8R,9S,10R,12R,13S)-12,13-dihydroxy-11-methyl-6-methylidene-16-oxo-15-oxapentacyclo[9.3.2.15,8.01,10.02,8]heptadecane-9-carboxylic acid",CC12[C@H]3[C@@H]([C@@]45C[C@@H](CC[C@H]4[C@@]3(C[C@@H]([C@@H]1O)O)OC2=O)C(=C)C5)C(=O)O,,,,,,
3461,443462,Gibberellin A34-catabolite,C[C@@]1([C@H]2[C@@H]([C@@]34C[C@@H](CC[C@H]3C2=CC(=O)[C@@H]1O)C(=C)C4)C(=O)O)C(=O)O,,,,,,
3462,443463,Gibberellin A8-catabolite,C[C@@]1([C@H]2[C@@H]([C@@]34CC(=C)[C@@](C3)(CC[C@H]4C2=CC(=O)[C@@H]1O)O)C(=O)O)C(=O)O,,,,,,
3463,443464,CID 443464,CC12C=CC[C@@]3([C@@H]1[C@@H]([C@]45[C@H]3CC[C@](C4)(C(=C)C5)O)C(=O)O)OC2=O,,,,,,
3464,443465,ent-Kaur-16-en-19-ol,C[C@]1(CCC[C@@]2([C@@H]1CC[C@]34[C@H]2CC[C@H](C3)C(=C)C4)C)CO,,,,,,
3465,443466,ent-Kaurenal,C[C@]1(CCC[C@@]2([C@@H]1CC[C@]34[C@H]2CC[C@H](C3)C(=C)C4)C)C=O,,,,,,
3466,443467,ent-7alpha-Hydroxykaur-16-en-19-oic acid,C[C@@]12CCC[C@@]([C@H]1C[C@@H]([C@]34[C@H]2CC[C@H](C3)C(=C)C4)O)(C)C(=O)O,,,,,,
3467,443468,"6beta,7beta-Dihydroxykaurenoic acid",C[C@@]12CCC[C@@]([C@H]1[C@@H]([C@@H]([C@]34[C@H]2CC[C@H](C3)C(=C)C4)O)O)(C)C(=O)O,,,,,,
3468,443469,Sandaracopimaradiene,C[C@@]1(CC[C@H]2C(=C1)CC[C@@H]3[C@@]2(CCCC3(C)C)C)C=C,,,,,,
3469,443470,"Abieta-7,13-diene",CC(C)C1=CC2=CC[C@@H]3[C@@]([C@H]2CC1)(CCCC3(C)C)C,,,,,,
3470,443471,Levopimaradiene,CC(C)C1=CC[C@H]2C(=C1)CC[C@@H]3[C@@]2(CCCC3(C)C)C,,,,,,
3471,443472,Neoabietadiene,CC(=C1CC[C@H]2C(=C1)CC[C@@H]3[C@@]2(CCCC3(C)C)C)C,,,,,,
3472,443473,Palustradiene,CC(C)C1=CC2=C(CC1)[C@]3(CCCC([C@@H]3CC2)(C)C)C,,,,,,
3473,443474,Abietyl alcohol,CC(C)C1=CC2=CC[C@H]3[C@](CCC[C@@]3([C@H]2CC1)C)(C)CO,,,,,,
3474,443475,Levopimaradienol,CC(C)C1=CC[C@H]2C(=C1)CC[C@@H]3[C@@]2(CCC[C@@]3(C)CO)C,,,,,,
3475,443476,Neoabietinol,CC(=C1CC[C@H]2C(=C1)CC[C@@H]3[C@@]2(CCC[C@@]3(C)CO)C)C,,,,,,
3476,443477,Neoabietal,CC(=C1CC[C@H]2C(=C1)CC[C@@H]3[C@@]2(CCC[C@@]3(C)C=O)C)C,,,,,,
3477,443478,Levopimaradienal,CC(C)C1=CC[C@H]2C(=C1)CC[C@@H]3[C@@]2(CCC[C@@]3(C)C=O)C,,,,,,
3478,443479,Abietal,CC(C)C1=CC2=CC[C@H]3[C@](CCC[C@@]3([C@H]2CC1)C)(C)C=O,,,,,,
3479,443480,Aphidicolan-16beta-ol,C[C@]12CCCC([C@@H]1CC[C@@H]3[C@@]24CC[C@@]([C@@H](C3)C4)(C)O)(C)C,,,,,,
3480,443481,CID 443481,C[C@]12CCCC([C@@H]1CC[C@@H]3[C@@]24CCC(=C)[C@@H](C3)C4)(C)C,,,,,,
3481,443482,Aphidicol-15-ene,CC1=CC[C@]23C[C@@H]1C[C@@H]2CC[C@@H]4[C@@]3(CCCC4(C)C)C,,,,,,
3482,443483,(+)-Cembrene,CC1=CCCC(=CCC=C(C=CC(CC1)C(C)C)C)C,,,,,,
3483,443484,"Taxa-4,11-diene",CC1=C2CC[C@@]3(CCC=C([C@H]3C[C@@H](C2(C)C)CC1)C)C,,,,,,
3484,443485,"Taxa-4(20),11-dien-5alpha-ol",CC1=C2CC[C@@]3(CC[C@@H](C(=C)[C@H]3C[C@@H](C2(C)C)CC1)O)C,,,,,,
3485,443486,"Taxa-4(20),11(12)-dien-5alpha-yl acetate",CC1=C2CC[C@@]3(CC[C@@H](C(=C)[C@H]3C[C@@H](C2(C)C)CC1)OC(=O)C)C,,,,,,
3486,443487,"Taxa-4(20),11(12)-dien-5alpha,13alpha-diol",CC1=C2CC[C@@]3(CC[C@@H](C(=C)[C@H]3C[C@@H](C2(C)C)C[C@@H]1O)O)C,,,,,,
3487,443488,"10beta-Hydroxytaxa-4(20),11-dien-5alpha-yl acetate",CC1=C2[C@H](C[C@@]3(CC[C@@H](C(=C)[C@H]3C[C@@H](C2(C)C)CC1)OC(=O)C)C)O,,,,,,
3488,443489,10-Deacetyl-2-debenzoylbaccatin III,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1O)O)O)(CO4)OC(=O)C)O)C)O,,,,,,
3489,443490,"[5-[(1S,4aS,8aS)-5,5,8a-trimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]-3-methylpent-2-enyl] phosphono hydrogen phosphate",CC(=CCOP(=O)(O)OP(=O)(O)O)CC[C@H]1C(=C)CC[C@@H]2[C@@]1(CCCC2(C)C)C,,,,,,
3490,443491,"[5-[(1R,4aS,8aS)-5,5,8a-trimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]-3-methylpent-2-enyl] phosphono hydrogen phosphate",CC(=CCOP(=O)(O)OP(=O)(O)O)CC[C@@H]1C(=C)CC[C@@H]2[C@@]1(CCCC2(C)C)C,,,,,,
3491,443492,"2-(3,7,11,15,19-Pentamethylicosa-6,10,14,18-tetraenoxy)phenazine",CC(CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)CCOC1=CC2=NC3=CC=CC=C3N=C2C=C1,,,,,,
3492,443493,CID 443493,CC(CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)CCOC1=CC2=C(C=C1)NC3=CC=CC=C3N2,,,,,,
3493,443494,Gibberellin A53 aldehyde,C[C@@]12CCC[C@@]([C@H]1[C@@H]([C@]34[C@H]2CC[C@](C3)(C(=C)C4)O)C=O)(C)C(=O)O,,,,,,
3494,443495,Sodium arsenite,[O-][As]=O.[Na+],,,['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],"['Arsenite crosses the placenta.', 'RATE OF ABSORPTION OF INORG ARSENICALS FROM DIGESTIVE TRACT DEPENDS UPON THEIR SOLUBILITY. SODIUM ARSENITE IS READILY SOL, RAPIDLY ABSORBED.', 'AT 20 HR AFTER IV INJECTION OF 4 MG (76)ARSENIC AS SODIUM ARSENITE TO ONE PATIENT WITH TERMINAL CANCER, HIGHEST LEVELS OF ARSENIC WERE FOUND IN LIVER & KIDNEYS & RELATIVELY SMALLER LEVELS IN VARIOUS OTHER TISSUES. EXCRETION OF (76)ARSENIC IN THE FIRST 24 HOURS AFTER AN IV INJECTION OF LABELLED SODIUM ARSENITE TO 2 PATIENTS WITH TERMINAL CANCER WAS 16.7% OF THE INJECTED DOSE; EXCRETION WAS MAINLY VIA THE URINE.', 'FOLLOWING IV ADMINISTRATION OF (76)ARSENIC AS SODIUM ARSENITE TO FIVE RATS AND FOUR RABBITS, THE URINARY EXCRETION OF (76)ARSENIC IN THE FIRST 48 HOURS WAS LESS THAN 10% OF THE DOSE IN RATS AND 30% IN RABBITS. FOLLOWING IP INJECTION IN MICE, 75% OF THE DOSE WAS EXCRETED WITHIN THE FIRST 24 HOURS. IN ALL SPECIES TESTED, LESS THAN 10% OF THE TOTAL ... WAS EXCRETED IN THE FECES. UNLIKE RABBITS, RATS RETAIN MOST OF THE INJECTED DOSE IN THE BLOOD FOR A PROLONGED PERIOD. TISSUE DISTRIBUTION STUDIES REVEALED HIGHEST LEVELS OF (76)ARSENIC IN THE BLOOD AND SPLEEN OF RATS, IN THE LIVER, KIDNEYS AND LUNGS OF RABBITS AND IN THE LIVER, KIDNEYS AND SPLEEN OF MICE.', 'For more Absorption, Distribution and Excretion (Complete) data for SODIUM ARSENITE (9 total), please visit the HSDB record page.']","['The urinary metabolites of sodium arsenite have been investigated in rabbits given sodium arsenite and water-soluble dimercaptans. Rabbits injected sc with NaAsO2 (1 mg arsenic/kg) were given im 1 hr later, either saline, 2,3-dimercapto-1-propanesulfonic acid, mesodimercaptosuccinic acid, or N-(2,3-dimercaptopropyl)phthalamidic acid at 0.2 mmol/kg. Arsenic metabolites in urine collected from treated rabbits were isolated by combined anion-cation-exchange chromatography. Column fractions were acid-digested and analyzed for arsenic by direct hydride-flame atomic absorption spectrophotometry. The relative amounts of inorganic arsenic, methylarsonate, and dimethylarsinate found in 0 to 24 hr urine of rabbits given only sodium arsenite agreed closely with those reported for human subjects given arsenite po. This finding suggests that the rabbit biotransforms arsenite in a manner very similar to humans. The urinary excretion of total arsenic between 0 and 24 hr was elevated after dimercaptan administration. but urinary excretion of total arsenic between 0 and 48 hr was unaffected. This result indicates that the action of these dimercaptans occurs early after treatment. In addition, the dimercaptans influenced differently the amounts of the arsenic metabolites excreted in the urine between 0 and 24 hr. 2,3-Dimercapto-1-propanesulfonic acid, mesodimercaptosuccinic acid, or 2,3-dimercapto-1-propanesulfonic acid increased arsenite excretion but decreased dimethylarsinate excretion. 2,3-dimercapto-1-propanesulfonic acid or N-(2,3-dimercaptopropyl)phthalamidic acid treatment increased methylarsonate excretion but mesodimercaptosuccinic acid did not. Arsenate excretion increased after 2,3-dimercapto-1-propanesulfonic acid or mesodimercaptosuccinic acid, treatment but was not affected by N-(2,3-dimercaptopropyl)phthalamidic acid treatment. These results suggest that the dimercaptans, in addition to increasing arsenic excretion, also influence the biotransformation of arsenite to less toxic species. The different effects on the urinary excretion of arsenic metabolites suggest that these dimercaptan metal binding agents have mechanisms of action in addition to simple chelation of inorganic arsenic.', 'The fungi Candida hemicola biotransforms sodium arsenite to trimethyl arsine.', 'Cows and dogs were fed sodium arsenite and sodium arsenate daily for five days. Urine was collected and analyzed for methylarsenate and inorganic arsenate. In the cow, the levels rose to 0.1 to 0.5 and 1.0 to 4.0 ppm, respectively. When cows were returned to normal diets, all values returned to control levels (0.02 to 0.10 ppm and 0.1 to 0.2 ppm). In dogs, arsenite feeding produced identical peak values 5.0 to 7.0 ppm for both methylarsenate and inorganic arsenate. Feeding of sodium arsenate to dogs produced a rise to 10 ppm methylarsenate and 5.0 ppm inorganic arsenate. Six days after withdrawal from the arsenic-containing diet, all values reached control levels ... .', 'Mice were administered im 1.3 mg As(III)/kg after exposure to a toxic concentration of sodium arsenite (250 mg As(III)/l) for 2, 6 and 8 days. Whereas mice not exposed to the treated drinking water excreted one-half the im administered As(III), those mice previously exposed to the treated water excreted 80% of the applied As(III) as As(V) in 2 days; more than 95%, after 4 days; and after 8 days only traces of As(III) were present ... .', 'Cultured BALB/3T3-Cl-A31-1-1 mouse embryo cells were used to study the cytotoxicity, neoplastic transformation, and metabolic reduction or oxidation of trivalent arsenic, in the form of sodium arsenite (arsenic(3+)), and pentavalent arsenic, in the form of sodium arsenate (arsenic(5+)). Uptake of arsenic(3+) and arsenic(5+) by the cells was highest during the first hour and was dose dependent; cells treated with equimolar concn of the agents demonstrated four fold greater uptake for arsenic(3+) than for arsenic(5+). Arsenic(3+) was more cytotoxic than arsenic(5+), although no differences were apparent between the two products with respect to total arsenic in the cells. The relative transformation activity for arsenic(3+) compared to arsenic(5+) was equal to about 4:1. Arsenic(5+) showed a high rate of intracellular metabolic reduction; arsenic(5+) exposure yielded more than 70 percent arsenic(3+) in cytosol, as compared to 100 percent for arsenic(3+) exposure. Ion exchange chromatography did not detect any methylated metabolites. In cell free medium incubations, up to 30 percent of arsenic(3+) was oxidized to arsenic(5+), as compared to only 4 percent oxidation in the presence of cells. Unchanged arsenic(5+) was recovered following its incubation in cell free medium, while the presence of cells resulted in the generation of up to 5 percent arsenic(3+), in a dose dependent manner. The reduction of arsenic(5+) to arsenic(3+) by the cells was inhibited up to 25 percent by depletion of glutathione with diethylmaleate. The authors conclude that arsenic(3+) is responsible for the cytotoxic and transforming action of inorganic arsenic.']",
3495,443496,dTDP-4-dehydro-6-deoxy-D-galactose,C[C@@H]1C(=O)[C@@H]([C@H](C(O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)O)O,,,,,,
3496,443497,"[(3S,5R,6R)-3,5-dihydroxy-6-methyl-4-oxooxan-2-yl] [hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl] hydrogen phosphate",C[C@@H]1[C@H](C(=O)[C@H](C(O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)O)O,,,,,,
3497,443498,"dTDP-3-dehydro-4,6-dideoxy-D-glucose",C[C@@H]1CC(=O)[C@H](C(O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)O,,,,,,
3498,443499,"dTDP-3-amino-3,4,6-trideoxy-D-glucose",C[C@@H]1C[C@@H]([C@H](C(O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)O)N,,,,,,
3499,443500,"[(3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl] [hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl] hydrogen phosphate",C[C@@H]1C[C@@H]([C@H](C(O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)O)N(C)C,,,,,,
3500,443501,"[hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl] [(3R,4R,5S,6R)-3,4,5-trihydroxy-6-methyloxan-2-yl] hydrogen phosphate",C[C@@H]1[C@H]([C@H]([C@H](C(O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)O)O)O,,,,,,
3501,443502,D-Mycinose,C[C@@H]1[C@H]([C@H]([C@H](C(O1)O)OC)OC)O,,,,,,
3502,443503,"[(4R,6S)-4-hydroxy-4,6-dimethyl-5-oxooxan-2-yl] [hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl] hydrogen phosphate",C[C@H]1C(=O)[C@](CC(O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)(C)O,,,,,,
3503,443504,"(4R,5S,6S)-4-Methoxy-4,6-dimethyltetrahydro-2H-pyran-2,5-diol",C[C@H]1[C@@H]([C@](CC(O1)O)(C)OC)O,,,,,,
3504,443505,"[(4R,5R,6S)-4-(dimethylamino)-5-hydroxy-6-methyloxan-2-yl] [hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl] hydrogen phosphate",C[C@H]1[C@@H]([C@@H](CC(O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)N(C)C)O,,,,,,
3505,443506,"[(4S,5R,6S)-4,5-dihydroxy-6-methyloxan-2-yl] [hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl] hydrogen phosphate",C[C@H]1[C@@H]([C@H](CC(O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)O)O,,,,,,
3506,443507,"[hydroxy-[(4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxyphosphoryl] [(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl hydrogen phosphate",C[C@H]1[C@@H]([C@H](CC(O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)OC)O,,,,,,
3507,443508,"dTDP-4-dehydro-2,6-dideoxy-D-glucose",C[C@@H]1C(=O)[C@@H](CC(O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)O,,,,,,
3508,443509,"[(4R,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl] [hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl] hydrogen phosphate",C[C@@H]1[C@H]([C@@H](CC(O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)O)O,,,,,,
3509,443510,"[(3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl] [hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl] hydrogen phosphate",C[C@@H]1[C@H]([C@@H]([C@H](C(O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)O)N)O,,,,,,
3510,443511,"[(3R,4S,6R)-3,4-dihydroxy-6-methyl-5-oxooxan-2-yl] [hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl] hydrogen phosphate",C[C@@H]1C(=O)[C@H]([C@H](C(O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)O)O,,,,,,
3511,443512,"[hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl] [(4S,6S)-4-hydroxy-6-methyl-5-oxooxan-2-yl] hydrogen phosphate",C[C@H]1C(=O)[C@H](CC(O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)O,,,,,,
3512,443513,"[hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl] [(4S,6R)-4-hydroxy-6-methyl-5-oxooxan-2-yl] hydrogen phosphate",C[C@@H]1C(=O)[C@H](CC(O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)O,,,,,,
3513,443514,Perillyl-CoA; (Acyl-CoA); [M+H]+,CC(=C)C1CCC(=CC1)C(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=CN=C43)N)O)OP(=O)(O)O)O,,,,,,
3514,443515,"[hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl] [(6R)-4-hydroxy-6-methyl-5-oxo-2H-pyran-2-yl] hydrogen phosphate",C[C@@H]1C(=O)C(=CC(O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)O,,,,,,
3515,443516,"[hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl] [(6S)-4-hydroxy-6-methyl-5-oxo-2H-pyran-2-yl] hydrogen phosphate",C[C@H]1C(=O)C(=CC(O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)O,,,,,,
3516,443517,"[hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl] [(5S,6S)-5-hydroxy-6-methyl-4-oxooxan-2-yl] hydrogen phosphate",C[C@H]1[C@@H](C(=O)CC(O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)O,,,,,,
3517,443518,"[(3R,4S,5S,6R)-4-(dimethylamino)-3,5-dihydroxy-6-methyloxan-2-yl] [hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl] hydrogen phosphate",C[C@@H]1[C@H]([C@@H]([C@H](C(O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)O)N(C)C)O,,,,,,
3518,443519,c0893; (Acyl-CoA); [M+H]+,CC(=C)C1CCC(C(C1)O)C(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=CN=C43)N)O)OP(=O)(O)O)O,,,,,,
3519,443520,4-Isopropenyl-2-ketocyclohexane-1-carbonyl-CoA,CC(=C)C1CCC(C(=O)C1)C(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=CN=C43)N)O)OP(=O)(O)O)O,,,,,,
3520,443521,3-Isopropenylpimelyl-CoA,CC(=C)C(CCCC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O)CC(=O)O,,,,,,
3521,443522,"(1S,4R)-1-Hydroxy-2-oxolimonene",CC(=C)[C@@H]1CC[C@](C(=O)C1)(C)O,,,,,,
3522,443523,"2-Methyl-5-isopropylhexa-2,5-dienoic acid",CC(C)C(=C)CC=C(C)C(=O)O,,,,,,
3523,443524,CID 443524,CC(C)C(=C)CC=C(C)C(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
3524,443525,"S-[2-[3-[[4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] 3-hydroxy-2,6-dimethyl-5-methylideneheptanethioate",CC(C)C(=C)CC(C(C)C(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O)O,,,,,,
3525,443526,"2,6-Dimethyl-5-methylene-3-oxo-heptanoyl-CoA",CC(C)C(=C)CC(=O)C(C)C(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
3526,443527,"S-[2-[3-[[4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] 4-methyl-3-methylidenepentanethioate",CC(C)C(=C)CC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
3527,443528,3-Isopropylbut-3-enoic acid,CC(C)C(=C)CC(=O)O,,,,,,
3528,443529,(+)-cis-Isopulegone,C[C@@H]1CC[C@@H](C(=O)C1)C(=C)C,,,,,,
3529,443530,CID 443530,C[C@H]1C=CC=C([C@@]2(CC(=O)C(=C[C@H]2C(=O)O[C@H]3C[C@@H](CC=C([C@H]1O)C)O[C@]4(C3)C[C@@H]([C@@H]([C@H](O4)C(C)C)C)O)C)O)C,,,,,,
3530,443531,CID 443531,C[C@H]1C=CC=C2CO[C@H]3[C@@]2([C@@H](C=C(C3=O)C)C(=O)O[C@H]4C[C@@H](CC=C([C@H]1O)C)O[C@]5(C4)C[C@@H]([C@@H]([C@H](O5)C(C)C)C)O)O,,,,,,
3531,443532,CID 443532,C[C@H]1C=CC=C2CO[C@H]3[C@@]2([C@@H](C=C([C@H]3O)C)C(=O)O[C@H]4C[C@@H](CC=C([C@H]1O)C)O[C@]5(C4)C[C@@H]([C@@H]([C@H](O5)C(C)C)C)O)O,,,,,,
3532,443533,CID 443533,C[C@H]1C=CC=C2CO[C@H]3[C@@]2([C@@H](C=C([C@H]3OC)C)C(=O)O[C@H]4C[C@@H](CC=C([C@H]1O)C)O[C@]5(C4)C[C@@H]([C@@H]([C@H](O5)C(C)C)C)O)O,,,,,,
3533,443534,CID 443534,C[C@H]1C=CC=C2CO[C@H]3[C@@]2([C@@H](C=C([C@H]3O)C)C(=O)O[C@H]4C[C@@H](CC=C([C@H]1O[C@H]5C[C@@H]([C@H]([C@@H](O5)C)O)OC)C)O[C@]6(C4)C[C@@H]([C@@H]([C@H](O6)C(C)C)C)O)O,,,,,,
3534,443535,CID 443535,C[C@H]1C=CC=C2CO[C@H]3[C@@]2([C@@H](C=C([C@H]3OC)C)C(=O)O[C@H]4C[C@@H](CC=C([C@H]1O[C@H]5C[C@@H]([C@H]([C@@H](O5)C)O)OC)C)O[C@]6(C4)C[C@@H]([C@@H]([C@H](O6)C(C)C)C)O)O,,,,,,
3535,443536,CID 443536,C[C@H]1C=CC=C2CO[C@H]3[C@@]2([C@@H](C=C([C@H]3O)C)C(=O)O[C@H]4C[C@@H](CC=C([C@H]1O[C@H]5C[C@@H]([C@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O)OC)OC)C)O[C@]7(C4)C[C@@H]([C@@H]([C@H](O7)C(C)C)C)O)O,,,,,,
3536,443537,CID 443537,C[C@H]1C=CC=C2CO[C@H]3[C@@]2([C@@H](C=C([C@H]3OC)C)C(=O)O[C@H]4C[C@@H](CC=C([C@H]1O[C@H]5C[C@@H]([C@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O)OC)OC)C)O[C@]7(C4)C[C@@H]([C@@H]([C@H](O7)C(C)C)C)O)O,,,,,,
3537,443538,CID 443538,C[C@H]1C=CC=C([C@@]2(CC(=O)C(=C[C@H]2C(=O)O[C@H]3C[C@@H](CC=C([C@H]1O)C)O[C@]4(C3)C=C[C@@H]([C@H](O4)C(C)C)C)C)O)C,,,,,,
3538,443539,CID 443539,C[C@H]1C=CC=C2CO[C@H]3[C@@]2([C@@H](C=C(C3=O)C)C(=O)O[C@H]4C[C@@H](CC=C([C@H]1O)C)O[C@]5(C4)C=C[C@@H]([C@H](O5)C(C)C)C)O,,,,,,
3539,443540,CID 443540,C[C@H]1C=CC=C2CO[C@H]3[C@@]2([C@@H](C=C([C@H]3O)C)C(=O)O[C@H]4C[C@@H](CC=C([C@H]1O)C)O[C@]5(C4)C=C[C@@H]([C@H](O5)C(C)C)C)O,,,,,,
3540,443541,CID 443541,C[C@H]1C=CC=C2CO[C@H]3[C@@]2([C@@H](C=C([C@H]3OC)C)C(=O)O[C@H]4C[C@@H](CC=C([C@H]1O)C)O[C@]5(C4)C=C[C@@H]([C@H](O5)C(C)C)C)O,,,,,,
3541,443542,CID 443542,C[C@H]1C=CC=C2CO[C@H]3[C@@]2([C@@H](C=C([C@H]3O)C)C(=O)O[C@H]4C[C@@H](CC=C([C@H]1O[C@H]5C[C@@H]([C@H]([C@@H](O5)C)O)OC)C)O[C@]6(C4)C=C[C@@H]([C@H](O6)C(C)C)C)O,,,,,,
3542,443543,CID 443543,C[C@H]1C=CC=C2CO[C@H]3[C@@]2([C@@H](C=C([C@H]3OC)C)C(=O)O[C@H]4C[C@@H](CC=C([C@H]1O[C@H]5C[C@@H]([C@H]([C@@H](O5)C)O)OC)C)O[C@]6(C4)C=C[C@@H]([C@H](O6)C(C)C)C)O,,,,,,
3543,443544,"(1'R,2R,3S,4'S,6S,8'R,12'S,13'S,20'R,21'R,24'S)-21',24'-dihydroxy-12'-[(2R,4S,5S,6S)-5-[(2S,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-3,11',13',22'-tetramethyl-2-propan-2-ylspiro[2,3-dihydropyran-6,6'-3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene]-2'-one",C[C@H]1C=CC=C2CO[C@H]3[C@@]2([C@@H](C=C([C@H]3O)C)C(=O)O[C@H]4C[C@@H](CC=C([C@H]1O[C@H]5C[C@@H]([C@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O)OC)OC)C)O[C@]7(C4)C=C[C@@H]([C@H](O7)C(C)C)C)O,,,,,,
3544,443545,CID 443545,C[C@H]1C=CC=C2CO[C@H]3[C@@]2([C@@H](C=C([C@H]3OC)C)C(=O)O[C@H]4C[C@@H](CC=C([C@H]1O[C@H]5C[C@@H]([C@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O)OC)OC)C)O[C@]7(C4)C=C[C@@H]([C@H](O7)C(C)C)C)O,,,,,,
3545,443546,CID 443546,CCC(C)[C@@H]1[C@H]([C@H](C[C@@]2(O1)C[C@@H]3C[C@H](O2)CC=C([C@H]([C@H](C=CC=C([C@@]4(CC(=O)C(=C[C@H]4C(=O)O3)C)O)C)C)O)C)O)C,,,,,,
3546,443547,CID 443547,CCC(C)[C@@H]1[C@H]([C@H](C[C@@]2(O1)C[C@@H]3C[C@H](O2)CC=C([C@H]([C@H](C=CC=C4CO[C@H]5[C@@]4([C@@H](C=C(C5=O)C)C(=O)O3)O)C)O)C)O)C,,,,,,
3547,443548,CID 443548,CCC(C)[C@@H]1[C@H]([C@H](C[C@@]2(O1)C[C@@H]3C[C@H](O2)CC=C([C@H]([C@H](C=CC=C4CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O)C)O)C,,,,,,
3548,443549,CID 443549,CCC(C)[C@@H]1[C@H]([C@H](C[C@@]2(O1)C[C@@H]3C[C@H](O2)CC=C([C@H]([C@H](C=CC=C4CO[C@H]5[C@@]4([C@@H](C=C([C@H]5OC)C)C(=O)O3)O)C)O)C)O)C,,,,,,
3549,443550,CID 443550,CCC(C)[C@@H]1[C@H]([C@H](C[C@@]2(O1)C[C@@H]3C[C@H](O2)CC=C([C@H]([C@H](C=CC=C4CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O)OC)C)O)C,,,,,,
3550,443551,CID 443551,CCC(C)[C@@H]1[C@H]([C@H](C[C@@]2(O1)C[C@@H]3C[C@H](O2)CC=C([C@H]([C@H](C=CC=C4CO[C@H]5[C@@]4([C@@H](C=C([C@H]5OC)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O)OC)C)O)C,,,,,,
3551,443552,CID 443552,CCC(C)[C@@H]1[C@H]([C@H](C[C@@]2(O1)C[C@@H]3C[C@H](O2)CC=C([C@H]([C@H](C=CC=C4CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)C)O)C,,,,,,
3552,443553,CID 443553,CCC(C)[C@@H]1[C@H]([C@H](C[C@@]2(O1)C[C@@H]3C[C@H](O2)CC=C([C@H]([C@H](C=CC=C4CO[C@H]5[C@@]4([C@@H](C=C([C@H]5OC)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)C)O)C,,,,,,
3553,443554,CID 443554,CCC(C)[C@@H]1[C@H](C=C[C@@]2(O1)C[C@@H]3C[C@H](O2)CC=C([C@H]([C@H](C=CC=C([C@@]4(CC(=O)C(=C[C@H]4C(=O)O3)C)O)C)C)O)C)C,,,,,,
3554,443555,CID 443555,CCC(C)[C@@H]1[C@H](C=C[C@@]2(O1)C[C@@H]3C[C@H](O2)CC=C([C@H]([C@H](C=CC=C4CO[C@H]5[C@@]4([C@@H](C=C(C5=O)C)C(=O)O3)O)C)O)C)C,,,,,,
3555,443556,CID 443556,CCC(C)[C@@H]1[C@H](C=C[C@@]2(O1)C[C@@H]3C[C@H](O2)CC=C([C@H]([C@H](C=CC=C4CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O)C)C,,,,,,
3556,443557,CID 443557,CCC(C)[C@@H]1[C@H](C=C[C@@]2(O1)C[C@@H]3C[C@H](O2)CC=C([C@H]([C@H](C=CC=C4CO[C@H]5[C@@]4([C@@H](C=C([C@H]5OC)C)C(=O)O3)O)C)O)C)C,,,,,,
3557,443558,CID 443558,CCC(C)[C@@H]1[C@H](C=C[C@@]2(O1)C[C@@H]3C[C@H](O2)CC=C([C@H]([C@H](C=CC=C4CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O)OC)C)C,,,,,,
3558,443559,CID 443559,CCC(C)[C@@H]1[C@H](C=C[C@@]2(O1)C[C@@H]3C[C@H](O2)CC=C([C@H]([C@H](C=CC=C4CO[C@H]5[C@@]4([C@@H](C=C([C@H]5OC)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O)OC)C)C,,,,,,
3559,443560,"(1'R,2R,3S,4'S,6S,8'R,12'S,13'S,20'R,21'R,24'S)-2-butan-2-yl-24'-hydroxy-12'-[(2R,4S,5S,6S)-5-[(2S,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-21'-methoxy-3,11',13',22'-tetramethylspiro[2,3-dihydropyran-6,6'-3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene]-2'-one",CCC(C)[C@@H]1[C@H](C=C[C@@]2(O1)C[C@@H]3C[C@H](O2)CC=C([C@H]([C@H](C=CC=C4CO[C@H]5[C@@]4([C@@H](C=C([C@H]5OC)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)C)C,,,,,,
3560,443561,Megalomicin B,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)OC(=O)C)(C)O)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O[C@H]4C[C@H]([C@H]([C@@H](O4)C)O)N(C)C)C)C)O)(C)O,,,,,,
3561,443562,Megalomicin C1,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)OC(=O)C)(C)OC(=O)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O[C@H]4C[C@H]([C@H]([C@@H](O4)C)O)N(C)C)C)C)O)(C)O,,,,,,
3562,443563,Megalomicin C2,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)OC(=O)CC)(C)OC(=O)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O[C@H]4C[C@H]([C@H]([C@@H](O4)C)O)N(C)C)C)C)O)(C)O,,,,,,
3563,443564,Oleandolide,C[C@H]1C[C@@]2(CO2)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]([C@H]1O)C)O)C)C)C)O)C,,,,,,
3564,443565,L-Olivosyl-oleandolide,C[C@H]1C[C@@]2(CO2)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]([C@H]1O)C)O[C@H]3C[C@@H]([C@H]([C@@H](O3)C)O)O)C)C)C)O)C,,,,,,
3565,443566,L-Oleandrosyl-oleandolide,C[C@H]1C[C@@]2(CO2)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]([C@H]1O)C)O[C@H]3C[C@@H]([C@H]([C@@H](O3)C)O)OC)C)C)C)O)C,,,,,,
3566,443567,"(3R,4S,5S,7R,11R,12S)-4-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-12-[(1R)-1-hydroxyethyl]-3,5,7,11-tetramethyl-1-oxacyclododec-9-ene-2,8-dione",C[C@H]1C[C@H](C(=O)C=C[C@H]([C@H](OC(=O)[C@@H]([C@H]1O[C@H]2[C@@H]([C@H](C[C@H](O2)C)N(C)C)O)C)[C@@H](C)O)C)C,,,,,,
3567,443568,"(3R,4S,5S,7R,11S,12R)-4-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-12-ethyl-11-hydroxy-3,5,7,11-tetramethyl-1-oxacyclododec-9-ene-2,8-dione",CC[C@@H]1[C@@](C=CC(=O)[C@@H](C[C@@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2[C@@H]([C@H](C[C@H](O2)C)N(C)C)O)C)C)(C)O,,,,,,
3568,443569,CID 443569,CC[C@@H]1[C@@H](C=CC(=O)[C@@H](C[C@@H]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O)C)C)C,,,,,,
3569,443570,CID 443570,CC[C@@H]1[C@@H](C=CC(=O)[C@@H](C[C@H]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]2[C@@H]([C@H](C[C@H](O2)C)N(C)C)O)C)C)C,,,,,,
3570,443571,"(3R,5R,6S,7S,9R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-13-hydroxy-3,5,7,9,13-pentamethyl-1-oxacyclotetradec-11-ene-2,4,10-trione",CC[C@@H]1[C@@](C=CC(=O)[C@@H](C[C@@H]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]2[C@@H]([C@H](C[C@H](O2)C)N(C)C)O)C)C)(C)O,,,,,,
3571,443572,CID 443572,CC[C@H]1C[C@H](C(=O)C=CC(=C[C@@H]([C@@H](OC(=O)C[C@H]([C@@H]([C@H]1O)C)O)CC)C)C)C,,,,,,
3572,443573,CID 443573,CC[C@H]1C[C@H](C(=O)C=CC(=C[C@@H]([C@@H](OC(=O)C[C@H]([C@@H]([C@H]1O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O)N(C)C)O)C)O)CC)C)C)C,,,,,,
3573,443574,CID 443574,CC[C@H]1[C@H](C=C(C=CC(=O)[C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)O)C)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O)N(C)C)O)CC=O)C)C)CO,,,,,,
3574,443575,CID 443575,CC[C@H]1[C@H](C=C(C=CC(=O)[C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)O)C)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O)N(C)C)O)CC=O)C)C)CO[C@H]3[C@@H]([C@@H]([C@@H]([C@H](O3)C)O)O)O,,,,,,
3575,443576,Liposidomycin B,CC(C)CCCCCCCCC(CC(=O)OC1CN(C(C(=O)N(C1C(=O)O)C)C([C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=O)NC3=O)O)O)O[C@H]4[C@@H]([C@@H]([C@H](O4)CN)O)OS(=O)(=O)O)C)OC(=O)CC(C)CC(=O)O,,,,,,
3576,443577,CID 443577,CC(C(C(=O)NC=C1C[C@H]([C@@H](O1)N2C=CC(=O)NC2=O)O)NC(=O)C(CCSC)NC(=O)NC(CC3=CC(=CC=C3)O)C(=O)O)N(C)C(=O)C(CC4=CC(=CC=C4)O)N,,,,,,
3577,443578,"(1S,2R,5R,7R,8R,9S,11R,13S,14R)-8-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-9-methoxy-1,5,7,9,11,13-hexamethyl-15-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone",CC[C@@H]1[C@@]2([C@@H]([C@@H](C(=O)[C@@H](C[C@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,,,,,,
3578,443579,"(1S,2R,18R,19R,22S,25R,28R,40R)-2-[(2R,4S,5R,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-48-[(2S,3R,4S,5S,6R)-3-[(2R,4S,5R,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-18,32,35,37-tetrahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8,10,12(48),14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carboxylic acid",C[C@H]1[C@@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H]7C(=O)N[C@H](C8=C(C(=CC(=C8)O)O)C9=C(C=CC(=C9)[C@H](C(=O)N7)NC(=O)[C@@H]5NC(=O)[C@@H](NC(=O)[C@@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC(=O)[C@@H](CC(C)C)NC)CC(=O)N)O)C(=O)O)O[C@H]1C[C@]([C@H]([C@@H](O1)C)O)(C)N)Cl)CO)O)O)(C)N)O,,,,,,
3579,443580,3-[4-[(3-Carboxyphenyl)carbamoyl]thiazolidin-2-yl]sulfanyl-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,CC1C2C(C(=O)N2C(=C1SC3NC(CS3)C(=O)NC4=CC=CC(=C4)C(=O)O)C(=O)O)C(C)O,,,,,,
3580,443581,"3-[[4-[1-(2-Amino-2-oxoethyl)pyridin-1-ium-4-yl]-1,3-thiazol-2-yl]sulfanyl]-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid",CC1C2C(C(=O)N2C(=C1SC3=NC(=CS3)C4=CC=[N+](C=C4)CC(=O)N)C(=O)O)C(C)O,,,,,,
3581,443582,2-(Biaryl)carbapenems,CC(C1C2CC(=C(N2C1=O)C(=O)O)C3=CC=C(C=C3)C4=CC=CC=C4)O,,,,,,
3582,443583,"(1S,2R,5R,7R,8R,9S,11R,13R,14R)-8-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-1,5,7,9,11,13-hexamethyl-9-(3-quinolin-3-ylprop-2-enoxy)-3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone",CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OCC=CC4=CC5=CC=CC=C5N=C4)C)C)NC(=O)O2)C,,,,,,
3583,443584,Phosphophosphinate,C[C@@H](CP(=O)([C@@H](C)N)OP(=O)(O)O)C(=O)O,,,,,,
3584,443585,"2,6-Diamino-7-hydroxy-azelaic acid",C(CC(C(CC(=O)O)O)N)CC(C(=O)O)N,,,,,,
3585,443586,"(S)-3,5-Dihydroxyphenylglycine",C1=C(C=C(C=C1O)O)[C@@H](C(=O)O)N,,,,,,
3586,443587,(2S)-2-amino-8-(oxiran-2-yl)-8-oxooctanoic acid,C1C(O1)C(=O)CCCCC[C@@H](C(=O)O)N,,,,,,
3587,443588,"(4R)-2-[(4R)-2-(2-hydroxyphenyl)-4,5-dihydro-1,3-thiazol-4-yl]-3-methyl-1,3-thiazolidine-4-carboxylic acid",CN1[C@@H](CSC1[C@H]2CSC(=N2)C3=CC=CC=C3O)C(=O)O,,,"['Organic chemicals that form two or more coordination links with an iron ion. Once coordination has occurred, the complex formed is called a chelate. The iron-binding porphyrin group of hemoglobin is an example of a metal chelate found in biological systems. (See all compounds classified as Iron Chelating Agents.)', 'Low-molecular-weight compounds produced by microorganisms that aid in the transport and sequestration of ferric iron. (The Encyclopedia of Molecular Biology, 1994) (See all compounds classified as Siderophores.)', 'Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)']",,,
3588,443589,Yersiniabactin,C[C@@]1(CSC(=N1)C(C)(C)[C@@H]([C@@H]2CSC(N2)[C@H]3CSC(=N3)C4=CC=CC=C4O)O)C(=O)O,,,"['Low-molecular-weight compounds produced by microorganisms that aid in the transport and sequestration of ferric iron. (The Encyclopedia of Molecular Biology, 1994) (See all compounds classified as Siderophores.)']",,,
3589,443590,Telomestatin,CC1=C2C3=NC(=C(O3)C)C4=NC(=CO4)C5=NC(=CO5)C6=NC(=CO6)C7=NC(=CO7)C8=NC(=CO8)C9=NC(CS9)C(=N2)O1,,,,,,
3590,443591,Fengycin,CCCCCCCCCCCCCC(CC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](CCCN)C(=O)N[C@@H]1CC2=CC=C(C=C2)OC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]3CCCN3C(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)[C@H](C)O)CCC(=O)O)C)CCC(=O)N)CC4=CC=C(C=C4)O)[C@H](C)CC)O,,,,,,
3591,443592,Surfactin,CC(C)CCCCCCCCC[C@@H]1CC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)O1)CC(C)C)CC(C)C)CC(=O)O)C(C)C)CC(C)C)CC(C)C)CCC(=O)O,,,"['Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. (See all compounds classified as Antibiotics, Antineoplastic.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)']",,,
3592,443593,"[(1S,2R,3S,5S,6S,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] 2-methylpropanoate",C[C@@H]1[C@@H]2C[C@]([C@@H](C=CC=C(CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)C[C@@H]([C@]4([C@H]1O4)C)OC(=O)C(C)C)C)C)OC)(NC(=O)O2)O,,,['Agents that interact with TUBULIN to inhibit or promote polymerization of MICROTUBULES. (See all compounds classified as Tubulin Modulators.)'],,,
3593,443594,CID 443594,C[C@H]1C[C@H]([C@@](O[C@@H]1[C@H]2C[C@@H]([C@@]3(O2)[C@@H]([C@H](C[C@@H](O3)[C@@]4(CC[C@@]5(O4)C[C@@H]([C@H]([C@H](O5)[C@@H](C)C=C(C)C(=O)[C@H](C)C[C@H](C)C(=O)O)C)O)C)O[C@@H]6CC[C@@H]([C@@H](O6)C)OC)C)C)(CO)O)C,,,,,,
3594,443595,CID 443595,CC1=CC2=CC3=C(C(=O)C2=C(O1)O)OC4(C5C3O5)C(C6=C(C7=C(C(=C6O4)O)C(=O)C(=CC7=O)OC)O)O,,,,,,
3595,443596,CID 443596,CC1C(C(C(C(O1)O[C@H]2[C@@H](C=C3C2=CC#C[C@@H]4[C@@](O4)(C#C3)[C@H]5COC(=O)O5)OC(=O)C6=C(C=CC7=C6C=C(C=C7C)OC)O)NC)O)O,,,,,,
3596,443597,Everninomycin,C[C@@H]1[C@H]([C@@H](C[C@@H](O1)O[C@@H]2[C@H](OC3(C[C@H]2O)O[C@@H]4[C@H](O[C@H]([C@H]([C@]4(O3)C)O)O[C@H]5[C@H]([C@@H](O[C@@H]([C@@H]5OC)C)OC6[C@H](O[C@H](C([C@H]6O)OC)O[C@H]7[C@@H]([C@H]8[C@H](CO7)O[C@@]9(O8)[C@H]1[C@H]([C@@H](CO9)OC(=O)C2=C(C=C(C=C2C)O)O)OCO1)O)COC)O)C)C)O[C@@H]1C[C@]([C@H]([C@@H](O1)C)OC)(C)[N+](=O)[O-])OC(=O)C1=C(C(=C(C(=C1OC)Cl)O)Cl)C,,,,,,
3597,443598,CID 443598,CC=C1C2=NC(=CS2)C(=O)N[C@@H](C3=NC(=CS3)C(=O)N[C@H](C4=NC(=CS4)C5=C(C=CC(=N5)C6=NC(=CS6)C7=NC(=CS7)C(=O)NC(=CC)C(=O)NC[C@H](C)O)C8=NC(=CS8)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)[C@@H](C)O)C(C)C,,,,,,
3598,443599,CID 443599,CC=C1C2=NC(=CS2)C(=O)N[C@@H](C3=NC(=CS3)C(=O)N[C@H](C4=NC(=CS4)C5=C(C=CC(=N5)C6=NC(=CS6)C7=NC(=CS7)C(=O)NC(=CC)C(=O)NC[C@H](C)O)C8=NC(=CS8)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)C(C)C)C(C)C,,,,,,
3599,443600,Actinonin,CCCCC[C@H](CC(=O)NO)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1CO,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
3600,443601,"(2S)-2-[[(5R,8S)-8-[[(2S,3R)-1-(2-amino-3-hydroxy-propanoyl)-3-hydroxy-pyrrolidine-2-carbonyl]amino]-14,16-dihydroxy-13-methyl-7,11-dioxo-10-oxa-3-thia-6-azabicyclo[10.4.0]hexadeca-1(16),12,14-triene-5-carbonyl]amino]propanoic acid",CC1=C2C(=C(C=C1O)O)CSC[C@H](NC(=O)[C@H](COC2=O)NC(=O)[C@@H]3[C@@H](CCN3C(=O)C(CO)N)O)C(=O)N[C@@H](C)C(=O)O,,,['Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)'],,,
3601,443602,Naphthyl dipeptide,CN([C@@H](CCCN)C(=O)NC1=CC2=CC=CC=C2C=C1)C(=O)[C@H](CC3=CC=CC=C3)N,,,,,,
3602,443603,CID 443603,CC(C)CC=CC(=O)N[C@@H]1[C@H]([C@H]([C@H](O[C@@H]1O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)NC(=O)C)CC([C@@H]3[C@H]([C@H]([C@@H](O3)N4C=CC(=O)NC4=O)O)O)O)O)O,,,,,,
3603,443604,CID 443604,CCN(CC)CCSCC(=O)O[C@@H]1C[C@@]([C@H]([C@@H]([C@@]23CCC([C@@]1([C@@H]2C(=O)CC3)C)C)C)O)(C)C=C,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],"['It is readily absorbed from the gut and can be found in the blood within 30 minutes after dosing.', 'Tiamulin is well absorbed orally by swine. Approximately 85% of a dose is absorbed and peak levels occur between 2-4 hours after a single oral dose. Tiamulin is apparently well distributed, with highest levels found in the lungs.', 'In pigs (2 animals per sex and group), following oral administration of 5 mg (14)C-tiamulin base/kg bw/day for 10 consecutive days, approximately 35% of the dose was eliminated in urine and 65% in feces. The total residue concentrations in liver, kidney, muscle and fat were 21,880, 600, 720 and 720 ug equivalents/kg, respectively, 10 days after dosing and 480, 220, 430, 910 ug equivalents/kg after 25 days.']","['In laying hens, broilers and turkeys (6 animals per group) orally dosed with 10 mg (3)H-tiamulin hydrogen fumarate/kg bw/day for 5 consecutive days, over 15 metabolites were detected in tissue extracts but most of the residue was accounted for by 4 metabolites. No individual metabolite represented more than 30% of the total residue in poultry tissues.', 'In the liver of pigs orally treated with tiamulin, the percentage of the metabolites that can be hydrolyzed to 8-alpha-hydroxymutilin (ie marker residue) to total residues was 3.5, 3.6 and 5.7% at 4, 24 and 96 hours after treatment, respectively.', 'In pigs (4 animals per sex and group) given ad libitum access to feed containing tiamulin at a concentration of 39 mg/kg for 10 consecutive days, the average concentrations of metabolites in liver that could be hydrolyzed to form 8-alpha-hydroxymutilin, as detected by gas chromatography with electrochemical detection, were 447 and 247 ug equivalent/kg at 2 and 12 hours after dosing, respectively. In animals does for 18 consecutive days, the average concentrations of 8-alpha-hydroxymutilin in liver were 184, 256, 214 and 175 ug equivalents/kg at 12, 16, 20 and 24 hours after dosing, respectively.', 'In pigs orally dosed with (3)H-tiamulin, 6-desmethyltiamulin accounted for less than 1% of the total residue in bile and urine samples and had 67% of the antimicrobiological activity of tiamulin when tested by agar plate diffusion. Four other metabolites were found to have antimicrobiological activities relative to tiamulin of between 0.7 and 3.3% and all other metabolites had relative activities of less than 0.3%.', 'Tiamulin is extensively metabolized to over 20 metabolites, some having antibacterial activity. Approximately 30% of these metabolites are excreted in the urine with the remainder excreted in the feces.']",
3604,443605,CID 443605,C[C@H]1[C@@H]([C@](C[C@H]([C@]2([C@H]3[C@@]1(CCC2C)CCC3=O)C)OC(=O)CSC(C)(C)CNC(=O)C(C(C)C)N)(C)C=C)O,['* Pigs:'],,,,,
3605,443606,"alpha-D-Glucopyranose, 2-deoxy-2-(dimethylamino)",CN(C)[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1O)CO)O)O,,,,,,
3606,443607,"2-Propenoic acid, 3-hydroxy-, (2Z)-",C(=CO)C(=O)O,,,,,,
3607,443608,CID 443608,C[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)OC(C)C(C=CC=CC=CC(=O)C(C)C(C(C)C2CC=CC=CC=CC(C(=O)C(=CC=CC(=CC(C(=CCC(=O)O2)C)O)C)C)O)O)O)OC)O)OC,,,,,,
3608,443609,CID 443609,CC=C1CN2[C@H]3C[C@H]1[C@@H]([C@@H]2CC4=C3NC5=C4C=CC(=C5)OC)C=O,,,,,,
3609,443610,CID 443610,CC=C1CN2[C@H]3C[C@@H]1C4[C@@H]2C[C@]5([C@@H]4OC(=O)C)C3=NC6=C5C=CC(=C6)OC,,,,,,
3610,443611,CID 443611,CC=C1CN2[C@H]3C[C@@H]1C4[C@@H]2C[C@]5([C@@H]4O)C3N(C6=CC=CC=C56)C,,,,,,
3611,443612,Deoxyanisatin,C[C@@H]1C[C@H]([C@]2([C@@]13C[C@H]([C@]([C@@]24COC4=O)(C)O)OC(=O)C3)O)O,,,,,,
3612,443613,Palustric acid,CC(C)C1=CC2=C(CC1)[C@]3(CCC[C@@]([C@@H]3CC2)(C)C(=O)O)C,,,,,,
3613,443614,Soyasaponin II,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@H](CO[C@H]2O[C@@H]3[C@H]([C@@H]([C@H](O[C@H]3O[C@H]4CC[C@]5([C@H]([C@@]4(C)CO)CC[C@@]6([C@@H]5CC=C7[C@]6(CC[C@@]8([C@H]7CC(C[C@H]8O)(C)C)C)C)C)C)C(=O)O)O)O)O)O)O)O)O,,,,,,
3614,443615,beta-Fabatriose,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@H]([C@H](O[C@H]2O[C@@H]3[C@H]([C@@H]([C@H](O[C@H]3O)C(=O)O)O)O)CO)O)O)O)O)O,,,,,,
3615,443616,CID 443616,C1=CC(=CC=C1C=CC(=O)CC2=CC(=O)C=C(O2)O)O,,,,,,
3616,443617,S-(2-acetamidoethyl) 5-(4-hydroxyphenyl)-3-oxopent-4-enethioate,CC(=O)NCCSC(=O)CC(=O)C=CC1=CC=C(C=C1)O,,,,,,
3617,443618,CID 443618,CC1=C(OC(=CC1=O)C=CC2=CC=C(C=C2)O)O,,,,,,
3618,443619,Cerberoside,C[C@H]1[C@@H]([C@H]([C@@H]([C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3CC[C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)C)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O)O)O)OC)O,,,,,,
3619,443620,N-Methylantranyl-Coenzyme A,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)C4=CC=CC=C4NC)O,,,,,,
3620,443621,CID 443621,C1=CC(=CC=C1C=CC(=O)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=CC4=C(C=C(C=C4[O+]=C3C5=CC(=C(C=C5)O)O)O)O)O)O)O)O,,,,,,
3621,443622,"[(2R,3S,4S,5R,6S)-6-[2-(3,4-dihydroxyphenyl)-5-hydroxy-7-oxochromen-3-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl 3-(4-hydroxyphenyl)prop-2-enoate",C1=CC(=CC=C1C=CC(=O)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=CC(=O)C=C(C4=C3)O)C5=CC(=C(C=C5)O)O)O)O)O)O,,,,,,
3622,443623,Cyanidin 3-O-(6-O-cis-p-coumaroyl)glucoside 5-O-glucoside,C1=CC(=CC=C1C=CC(=O)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C([O+]=C4C=C(C=C(C4=C3)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O)C6=CC(=C(C=C6)O)O)O)O)O)O,,,,,,
3623,443624,CID 443624,C[C@H]1[C@H](CC=CC=CC=C[C@@H](CC(=O)NC2=CC(=O)C=C(C2=O)CCC=C([C@@H]1O)C)OC)OC(=O)[C@H](C)NC(=O)C3CCCCC3,,,,,,
3624,443625,omega-Cycloheptylundecanoic acid,C1CCCC(CC1)CCCCCCCCCCC(=O)O,,,,,,
3625,443626,CID 443626,C(C(C(C(CC(=O)C(=O)O)(N)O)O)O)OP(=O)(O)O,,,,,,
3626,443627,AminoDHS,C1[C@H]([C@@H](C(=O)C=C1C(=O)O)O)N,,,,,,
3627,443628,AminoDHQ,C1[C@H]([C@@H](C(=O)C[C@]1(C(=O)O)O)O)N,,,,,,
3628,443629,Validamycin A,C1[C@@H]([C@H]([C@@H]([C@H]([C@H]1N[C@H]2C=C([C@H]([C@@H]([C@H]2O)O)O)CO)O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)CO,,,,,"['In animals, cleavage to glucose and an amine residue.']",['Less than or equal to 5 hr']
3629,443630,Valiolone,C1C(=O)[C@@H]([C@H]([C@@H]([C@]1(CO)O)O)O)O,,,,,,
3630,443631,4-Hydroxy-3-nitrosobenzamide,C1=CC(=C(C=C1C(=O)N)N=O)O,,,,,,
3631,443632,Esmeraldic acid,CC1C2=C3C(=CC=C2)NC4=C(C=CC=C4N3C5=C1C6=NC7=C(C=CC=C7N=C6C(=C5)C(=O)O)C(C)O)C(=O)O,,,,,,
3632,443633,Saphenic acid,CC(C1=C2C(=CC=C1)N=C3C(=N2)C=CC=C3C(=O)O)O,,,,,,
3633,443634,Saphenic acid methyl ester,CC(C1=C2C(=CC=C1)N=C3C(=N2)C=CC=C3C(=O)OC)O,,,,,,
3634,443635,6-Acetylphenazine-1-carboxylic acid,CC(=O)C1=C2C(=CC=C1)N=C3C(=N2)C=CC=C3C(=O)O,,,,,,
3635,443636,5-Deoxy-5-aminoshikimic acid,C1[C@H]([C@@H]([C@@H](C=C1C(=O)O)O)O)N,,,,,,
3636,443637,"3',4',5,7-Tetrahydroxyflavan",C1CC2=C(C=C(C=C2OC1C3=CC(=C(C=C3)O)O)O)O,,,,,,
3637,443638,Apiforol,C1[C@H](OC2=CC(=CC(=C2C1O)O)O)C3=CC=C(C=C3)O,,,,,,
3638,443639,(-)-Epiafzelechin,C1[C@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC=C(C=C3)O)O,,,,,,
3639,443640,CID 443640,C1=CC(=C(C=C1C=CC(=O)OC[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)OC3=CC(=[OH+])C4=CC(=C(OC4=C3)C5=CC(=C(C(=C5)O[C@@H]6[C@@H]([C@@H]([C@@H]([C@H](O6)C(=O)O)O)O)O)O)O)O[C@@H]7[C@@H]([C@@H]([C@H]([C@@H](O7)CO)O)O)O[C@@H]8[C@@H]([C@@H]([C@H]([C@@H](O8)CO)O)O)OC(=O)C=CC9=CC(=C(C=C9)O)O)O)O)O)O)O,,,,,,
3640,443641,CID 443641,C1=CC(=C(C=C1C=CC(=O)OC[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)OC3=CC(=O)C4=CC(=C(OC4=C3)C5=CC(=C(C(=C5)O[C@@H]6[C@@H]([C@@H]([C@@H]([C@H](O6)C(=O)O)O)O)O)O)O)O[C@@H]7[C@@H]([C@@H]([C@H]([C@@H](O7)CO)O)O)O[C@@H]8[C@@H]([C@@H]([C@H]([C@@H](O8)CO)O)O)OC(=O)C=CC9=CC(=C(C=C9)O)O)O)O)O)O)O,,,,,,
3641,443642,CID 443642,C1=CC(=C(C=C1C=CC(=O)OC[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)OC3=CC(=[OH+])C4=CC(=C(OC4=C3)C5=CC(=C(C(=C5)O[C@@H]6[C@@H]([C@@H]([C@@H]([C@H](O6)C(=O)O)O)O)O)O)O)O[C@@H]7[C@@H]([C@@H]([C@H]([C@@H](O7)COC(=O)CC(=O)O)O)O)O[C@@H]8[C@@H]([C@@H]([C@H]([C@@H](O8)CO)O)O)OC(=O)C=CC9=CC(=C(C=C9)O)O)O)O)O)O)O,,,,,,
3642,443643,CID 443643,C1=CC(=C(C=C1C=CC(=O)OC[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)OC3=CC(=O)C4=CC(=C(OC4=C3)C5=CC(=C(C(=C5)O[C@@H]6[C@@H]([C@@H]([C@@H]([C@H](O6)C(=O)O)O)O)O)O)O)O[C@@H]7[C@@H]([C@@H]([C@H]([C@@H](O7)COC(=O)CC(=O)O)O)O)O[C@@H]8[C@@H]([C@@H]([C@H]([C@@H](O8)CO)O)O)OC(=O)C=CC9=CC(=C(C=C9)O)O)O)O)O)O)O,,,,,,
3643,443644,CID 443644,C1=CC(=C(C=C1C=CC(=O)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=CC(=[OH+])C4=CC(=C(OC4=C3)C5=CC(=C(C(=C5)O)O)O)O[C@H]6[C@@H]([C@H]([C@H]([C@H](O6)COC(=O)CC(=O)OC(C(C(=O)O)O)C(=O)O)O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)OC(=O)C=CC8=CC(=C(C=C8)O)O)O)O)O)O)O,,,,,,
3644,443645,"2-[3-[[(2R,3R,4S,5R,6S)-5-[(2S,3R,4S,5S,6R)-3-[3-(3,4-dihydroxyphenyl)prop-2-enoyloxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[7-[(2S,3R,4S,5S,6R)-6-[3-(3,4-dihydroxyphenyl)prop-2-enoyloxymethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-5-oxo-2-(3,4,5-trihydroxyphenyl)chromen-3-yl]oxy-3,4-dihydroxyoxan-2-yl]methoxy]-3-oxopropanoyl]oxy-3-hydroxybutanedioic acid",C1=CC(=C(C=C1C=CC(=O)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=CC(=O)C4=CC(=C(OC4=C3)C5=CC(=C(C(=C5)O)O)O)O[C@H]6[C@@H]([C@H]([C@H]([C@H](O6)COC(=O)CC(=O)OC(C(C(=O)O)O)C(=O)O)O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)OC(=O)C=CC8=CC(=C(C=C8)O)O)O)O)O)O)O,,,,,,
3645,443646,CID 443646,C1=CC(=C(C=C1O)O)C2=COC3=CC(=O)C=C(C3=C2O)O,,,,,,
3646,443647,CID 443647,COC1=CC(=C(C=C1)C2=COC3=CC(=O)C=C(C3=C2O)O)O,,,,,,
3647,443648,Pelargonidin 3-glucoside,C1=CC(=CC=C1C2=[O+]C3=CC(=CC(=C3C=C2O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O)O,,,,,,
3648,443649,pelargonidin-3-O-beta-D-glucoside,C1=CC(=CC=C1C2=C(C=C3C(=CC(=O)C=C3O2)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O,,,,,,
3649,443650,Delphinidin 3-glucoside,C1=C(C=C(C(=C1O)O)O)C2=[O+]C3=CC(=CC(=C3C=C2O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O,,,,,,
3650,443651,Petunidin 3-glucoside,COC1=CC(=CC(=C1O)O)C2=[O+]C3=CC(=CC(=C3C=C2O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O,,,,,,
3651,443652,Oenin,COC1=CC(=CC(=C1O)OC)C2=[O+]C3=CC(=CC(=C3C=C2O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O,,,,,,
3652,443653,malvidin 3-O-beta-D-glucoside betaine,COC1=CC(=CC(=C1O)OC)C2=C(C=C3C(=CC(=O)C=C3O2)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O,,,,,,
3653,443654,Peonidin-3-glucoside,COC1=C(C=CC(=C1)C2=[O+]C3=CC(=CC(=C3C=C2O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O)O,,,,,,
3654,443655,peonidin 3-O-beta-D-glucoside betaine,COC1=C(C=CC(=C1)C2=C(C=C3C(=CC(=O)C=C3O2)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O,,,,,,
3655,443656,Vetispiradiene,C[C@@H]1CCC=C([C@]12CC[C@@H](C2)C(=C)C)C,,,,,,
3656,443657,O-Phosphono-L-allothreonine,C[C@@H]([C@@H](C(=O)O)N)OP(=O)(O)O,,,,,,
3657,443658,"2-[(3S,4S,5S,6S)-4,6-dimethoxy-3,5,11-trimethyltrideca-7,9,11-trienyl]-8-hydroxy-5,7-dimethoxy-3-methylchromen-4-one",CC=C(C)C=CC=C[C@@H]([C@@H](C)[C@H]([C@@H](C)CCC1=C(C(=O)C2=C(O1)C(=C(C=C2OC)OC)O)C)OC)OC,,,,,,
3658,443659,CID 443659,CC=C(C)C=CC=C[C@@H]([C@@H](C)[C@H]([C@@H](C)CCC1=C(C(=C2C(=CC(=O)C=C2O1)O)O)C)OC)OC,,,,,,
3659,443660,CID 443660,CC=C(C)C=CC=C[C@@H]([C@@H](C)[C@H]([C@@H](C)CCC1=C(C(=C2C(=CC(=O)C=C2OC)O1)O)C)OC)OC,,,,,,
3660,443661,"[(6S,7S,12R)-12-[(2S,6R,7R,9R)-7,9-dihydroxy-4,6-dimethyldec-4-en-2-yl]-7,9-dimethyl-2-oxo-1-oxacyclododec-9-en-6-yl] (12S,13S,15S)-12,13,15-trihydroxy-4,6,10-trimethylhexadeca-2,4,6,8,10-pentaenoate",C[C@H]1CC(=CC[C@@H](OC(=O)CCC[C@@H]1OC(=O)C=CC(=CC(=CC=CC(=C[C@@H]([C@H](C[C@H](C)O)O)O)C)C)C)[C@@H](C)CC(=C[C@@H](C)[C@@H](C[C@@H](C)O)O)C)C,,,,,,
3661,443662,"[(2S,3S,4R,6S)-6-[(2R,3S,4R,5R,6S)-4-(dimethylamino)-5-hydroxy-6-[[(4R,5S,6S,7R,9R,16R)-4-hydroxy-5-methoxy-9,16-dimethyl-2,10-dioxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-6-yl]oxy]-2-methyloxan-3-yl]oxy-4-hydroxy-2,4-dimethyloxan-3-yl] 2-methylpropanoate",C[C@@H]1CC=CC=CC(=O)[C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)O)OC)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)OC(=O)C(C)C)(C)O)N(C)C)O)CC=O)C,,,,,,
3662,443663,"(1S,3R,4R,7R,9R,11R,15S,16R,17R,18S,19E,21E,25E,27E,29E,31E,33R,35S,36R,37S)-33-(((2R,3S,4S,5S,6R)-4-Amino-3,5-dihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-1,3,4,7,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid",C[C@H]1C=CC=CCCC=CC=CC=CC=C[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H]([C@@H](CC[C@H](C[C@H](C[C@H](CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)N)O,,,,,,
3663,443664,"(1S,3R,4R,7R,9R,11R,15S,16S,17R,18S,33R,35S,36R,37S)-33-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-17-[(4R,5R,6S)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-1,3,4,7,9,11,37-heptahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid",C[C@H]1C=CC=CCCC=CC=CC=CC=C[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H]([C@@H](CC[C@H](C[C@H](C[C@H](CC(=O)O[C@H]([C@@H]([C@@H]1OC3C[C@H]([C@H]([C@@H](O3)C)O)O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@H]4[C@H]([C@H]([C@@H]([C@H](O4)C)O)N)O,,,,,,
3664,443665,CID 443665,C[C@H](CO)NC(=O)C(=CC=CCC(C=CC(=C[C@@H](C)[C@H](C(=CC(C)C)C)O)C)O)C,,,,,,
3665,443666,CID 443666,CCC(C)C=C(C)[C@@H]([C@H](C)C=C(C)C=CC=CC=CC=C(C)C(=O)N[C@H](C)CO)O,,,,,,
3666,443667,CID 443667,CCC=C(C)[C@@H]([C@H](C)C=C(C)C=CC=CC=CC=C(C)C(=O)N[C@H](C)CO)O,,,,,,
3667,443668,CID 443668,CC=C(C)[C@@H]([C@H](C)C=C(C)C=CC=CC=CC=C(C)C(=O)N[C@@H](C)CO)O,,,,,,
3668,443669,Powellin,COC1=C2CN3CC[C@@]4([C@H]3C[C@H](C=C4)O)C2=CC5=C1OCO5,,,,,,
3669,443670,Hamayne,C1[C@H](C=C[C@]23[C@H]1N(C[C@@H]2O)CC4=CC5=C(C=C34)OCO5)O,,,,,,
3670,443671,3-O-Acetylhamayne,CC(=O)O[C@@H]1C[C@H]2[C@@]3(C=C1)[C@H](CN2CC4=CC5=C(C=C34)OCO5)O,,,,,,
3671,443672,1-O-Acetyllycorine,CC(=O)O[C@@H]1[C@H](C=C2CCN3[C@H]2[C@@H]1C4=CC5=C(C=C4C3)OCO5)O,,,,,,
3672,443673,1-Epideacetylbowdensine,COC1=C2CN3CC[C@@]4([C@H]3CC[C@@H]([C@@H]4O)O)C2=CC5=C1OCO5,,,,,,
3673,443674,"2,3,3a,4,5,7,12b,12c-Octahydro-1H,10H-[1,3]dioxolo[4,5-j]pyrrolo[3,2,1-de]phenanthridine-1,2-diol",C1CN2CC3=CC4=C(C=C3C5C2C1C[C@H]([C@H]5O)O)OCO4,,,,,,
3674,443675,"1,2-O-Diacetylzephyranthine",CC(=O)O[C@@H]1CC2CCN3C2C([C@@H]1OC(=O)C)C4=CC5=C(C=C4C3)OCO5,,,,,,
3675,443676,CID 443676,CN1C[C@@H]([C@]23C=C[C@H](C[C@H]2OC4=C(C=CC(=C34)C1)OC)O)O,,,,,,
3676,443677,"(8aR)-3-Methoxy-5,6,9,10,11,12-hexahydro-4abetaH-benzofuro[3a,3,2-ef][2]benzazepin-6alpha-ol",COC1=C2C3=C(CNCC[C@@]34C=C[C@H](C[C@H]4O2)O)C=C1,,,,,,
3677,443678,Haemanthidine,CO[C@H]1C[C@H]2[C@@]3(C=C1)[C@H](CN2C(C4=CC5=C(C=C34)OCO5)O)O,,,,,,
3678,443679,CID 443679,C[C@H]1C=CC=C(C(=O)N=C2C=C(C3=C(C(=O)C(C(C3=C2O)O)C)C(=O)C(=CC([C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)O)C)O)C)C)O)C,,,,,,
3679,443680,CID 443680,C[C@H]1C=C([C@H](CC(=O)NC2=CC(=CC(=C2)CC(=CC=C[C@H](C(=O)C[C@@H]1O)OC)C)O)O)C,,,,,,
3680,443681,"(1S,13R,16S,18S)-18-methoxy-15-methyl-5,7,12-trioxa-15-azapentacyclo[11.7.0.01,16.02,10.04,8]icosa-2,4(8),9,19-tetraene-11,11-diol",CN1C[C@H]2[C@]3([C@@H]1C[C@@H](C=C3)OC)C4=CC5=C(C=C4C(O2)(O)O)OCO5,,,,,,
3681,443682,Sekisanin,CN1C[C@]2([C@]3([C@@H]1C[C@@H](C=C3)OC)C4=CC5=C(C=C4CO2)OCO5)O,,,,,,
3682,443683,(-)-8-Demethylmaritidine,COC1=C(C=C2CN3CC[C@]4([C@@H]3C[C@@H](C=C4)O)C2=C1)O,,,,,,
3683,443684,Trisphaeridine,C1OC2=C(O1)C=C3C4=CC=CC=C4N=CC3=C2,,,,,,
3684,443685,Obliquine,CN1[C@H]2C[C@@H](C=C[C@@]23[C@@H](C1=O)N(CC4=CC5=C(C=C34)OCO5)CCC6=CC=C(C=C6)O)OC,,,,,,
3685,443686,Narcissidine,CO[C@@H]1[C@H]([C@@H]2[C@H]3C(=CCN3CC4=CC(=C(C=C24)OC)OC)[C@H]1O)O,,,,,,
3686,443687,Nangustine,C1C=C2[C@H]3CN([C@H]2[C@@H]([C@H]1O)O)CC4=CC5=C(C=C34)OCO5,,,,,,
3687,443688,Pancracine,C1[C@@H]([C@H](C=C2[C@H]1N3C[C@H]2C4=CC5=C(C=C4C3)OCO5)O)O,,,,,,
3688,443689,Pseudolycorine,COC1=C(C=C2[C@@H]3[C@@H]([C@H](C=C4[C@H]3N(CC4)CC2=C1)O)O)O,,,,,,
3689,443690,Vasconine,COC1=C(C=C2C3=CC=CC4=C3[N+](=CC2=C1)CC4)OC,,,,,,
3690,443691,ent-6beta-Hydroxybuphanisine,CO[C@H]1C[C@H]2[C@]3(CCN2[C@H](C4=CC5=C(C=C43)OCO5)O)C=C1,,,,,,
3691,443692,ent-6alpha-Hydroxybuphanisine,CO[C@H]1C[C@H]2[C@]3(CCN2[C@@H](C4=CC5=C(C=C43)OCO5)O)C=C1,,,,,,
3692,443693,Vittatine,C1CN2CC3=CC4=C(C=C3[C@@]15[C@@H]2C[C@@H](C=C5)O)OCO4,,,,,,
3693,443694,CID 443694,C1[C@@H](C=C[C@]23[C@H]1N(CC2O)CC4=CC5=C(C=C34)OCO5)O,,,,,,
3694,443695,Zephyramine,COC1=C(C=C2C(=C1)CN3CC[C@@]24C3CC[C@H]5[C@@H]4O5)OC,,,,,,
3695,443696,(+/-)-Bocconarborine A,CN1[C@H](C2=CC3=C(C=C2C4=C1C5=CC6=C(C=C5C=C4)OCO6)OCO3)CC(=O)C[C@@H]7C8=C(C=CC(=C8OC)OC)C9=C(N7C)C1=CC2=C(C=C1C=C9)OCO2,,,,,,
3696,443697,(+/-)-Bocconarborine B,CN1[C@H](C2=CC3=C(C=C2C4=C1C5=CC6=C(C=C5C=C4)OCO6)OCO3)CC(=O)C[C@H]7C8=C(C=CC(=C8OC)OC)C9=C(N7C)C1=CC2=C(C=C1C=C9)OCO2,,,,,,
3697,443698,"6-(2-Hydroxyethyl)-5,6-dihydrosanguinarine",CN1C(C2=C(C=CC3=C2OCO3)C4=C1C5=CC6=C(C=C5C=C4)OCO6)CCO,,,,,,
3698,443699,"3-Methoxy-8,9-methylenedioxy-3,4-dihydrophenanthridine",COC1CC2=C(C=C1)C3=CC4=C(C=C3C=N2)OCO4,,,,,,
3699,443700,(+/-)-6-Acetonyldihydrochelerythrine,CC(=O)CC1C2=C(C=CC(=C2OC)OC)C3=C(N1C)C4=CC5=C(C=C4C=C3)OCO5,,,,,,
3700,443701,"(4R,5S,6S,7S,9R,16R)-7-ethyl-4,6-dihydroxy-5-methoxy-9,16-dimethyl-1-oxacyclohexadeca-11,13-diene-2,10-dione",CC[C@H]1C[C@H](C(=O)C=CC=CC[C@H](OC(=O)C[C@H]([C@@H]([C@H]1O)OC)O)C)C,,,,,,
3701,443702,CID 443702,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)C=CC4=CC(=C(C(=C4)OC)O)O)O,,,,,,
3702,443703,"4,5-Dihydroxy-3-methoxycinnamaldehyde",COC1=CC(=CC(=C1O)O)C=CC=O,,,,,,
3703,443704,"5-(3-Hydroxyprop-1-enyl)-3-methoxybenzene-1,2-diol",COC1=CC(=CC(=C1O)O)C=CCO,,,,,,
3704,443705,CID 443705,C1[C@H]([C@H]([C@@H](CC1(C(=O)O)O)OC(=O)C=CC2=CC=C(C=C2)O)O)O,,,,,,
3705,443706,CID 443706,C1[C@H]([C@H]([C@@H](CC1(C(=O)O)O)OC(=O)C=CC2=CC(=C(C=C2)O)O)O)O,,,,,,
3706,443707,"[(3S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-oxooxan-2-yl] [[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] hydrogen phosphate",C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC3[C@@H](C(=O)[C@@H]([C@H](O3)CO)O)O)O)O,,,,,,
3707,443708,"[(3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl] [[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] hydrogen phosphate",C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)N)O)O)O,,,,,,
3708,443709,3-amino-3-deoxy-D-glucopyranose,C([C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)N)O)O,,,,,,
3709,443710,Kanosamine 6-phosphate,C([C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)N)O)OP(=O)(O)O,,,,,,
3710,443711,Aminofructose 6-phosphate,C([C@@H]1[C@H]([C@@H](C(O1)(CO)O)N)O)OP(=O)(O)O,,,,,,
3711,443712,1-Deoxy-1-iminoerythritol 4-phosphate,C(C(C(C=N)O)O)OP(=O)(O)O,,,,,,
3712,443713,"[4-[(1-Hydroxy-2-oxoazepan-3-yl)amino]-4-oxobutan-2-yl] 6-[hydroxy(octadec-2-enoyl)amino]-2-[[2-(2-hydroxyphenyl)-4,5-dihydro-1,3-oxazole-4-carbonyl]amino]hexanoate",CCCCCCCCCCCCCCCC=CC(=O)N(CCCCC(C(=O)OC(C)CC(=O)NC1CCCCN(C1=O)O)NC(=O)C2COC(=N2)C3=CC=CC=C3O)O,,,"['Low-molecular-weight compounds produced by microorganisms that aid in the transport and sequestration of ferric iron. (The Encyclopedia of Molecular Biology, 1994) (See all compounds classified as Siderophores.)', 'Organic chemicals that form two or more coordination links with an iron ion. Once coordination has occurred, the complex formed is called a chelate. The iron-binding porphyrin group of hemoglobin is an example of a metal chelate found in biological systems. (See all compounds classified as Iron Chelating Agents.)']",,,
3713,443714,Iron cyanide (Fe(CN)2),[C-]#N.[C-]#N.[Fe+2],,,,,,
3714,443715,"N,N'-[1-(Aminomethyl)-1,5-pentanediyl]bis(2,3-dihydroxybenzamide)",C1=CC(=C(C(=C1)O)O)C(=O)NCCCCC(CN)NC(=O)C2=C(C(=CC=C2)O)O,,,,,,
3715,443716,Hydroxysanguinarine,CN1C2=C(C=CC3=CC4=C(C=C32)OCO4)C5=C(C1=O)C6=C(C=C5)OCO6,,,,,,
3716,443717,"N-Methyl-2,3,7,8-tetramethoxy-5,6-dihydrobenzophenathridine-6-ethanoic acid",CN1[C@H](C2=C(C=CC(=C2OC)OC)C3=C1C4=CC(=C(C=C4C=C3)OC)OC)CC(=O)O,,,,,,
3717,443718,"N-methyl-2,3,7,8-tetramethoxybenzophenanthridine-6(5H)-one",CN1C2=C(C=CC3=CC(=C(C=C32)OC)OC)C4=C(C1=O)C(=C(C=C4)OC)OC,,,,,,
3718,443719,Norchelerythrine,COC1=C(C2=CN=C3C(=C2C=C1)C=CC4=CC5=C(C=C43)OCO5)OC,,,"['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)']",,,
3719,443720,Chelilutine,C[N+]1=C2C(=C3C(=CC(=C(C3=C1)OC)OC)OC)C=CC4=CC5=C(C=C42)OCO5,,,,,,
3720,443721,Epinorgalanthamine,COC1=C2C3=C(CNCC[C@]34C=C[C@H](C[C@@H]4O2)O)C=C1,,,,,,
3721,443722,Sanguinine,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)O)O,,,,,"['O-Desmethylgalantamine has known human metabolites that include (2S,3S,4S,5R)-3,4,5-trihydroxy-6-[[(1S,12S,14R)-14-hydroxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-9-yl]oxy]oxane-2-carboxylic acid and [(1S,12S,14R)-14-hydroxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-9-yl] hydrogen sulfate.']",
3722,443723,Lycoramine,CN1CC[C@@]23CC[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O,,,,,,
3723,443724,Epinorlycoramine,COC1=C2C3=C(CNCC[C@]34CC[C@H](C[C@@H]4O2)O)C=C1,,,,,,
3724,443725,Assoanine,COC1=C(C=C2C(=C1)CN3CCC4=C3C2=CC=C4)OC,,,,,,
3725,443726,2-O-Acetylpseudolycorine,CC(=O)O[C@H]1C=C2CCN3[C@H]2[C@@H]([C@@H]1O)C4=CC(=C(C=C4C3)OC)O,,,,,,
3726,443727,Papyramine,CO[C@H]1CC2[C@]3(CCN2C(C4=CC(=C(C=C43)OC)OC)O)C=C1,,,,,,
3727,443728,9-O-Demethyl-2alpha-hydroxyhomolycorine,CN1CCC2=C[C@@H]([C@@H]3[C@H]([C@@H]21)C4=CC(=C(C=C4C(=O)O3)OC)O)O,,,,,,
3728,443729,"[(5S,5aS,11bS,11cS)-5-acetyloxy-9-methoxy-1-methyl-7-oxo-2,3,5,5a,11b,11c-hexahydroisochromeno[3,4-g]indol-10-yl] 3-hydroxybutanoate",CC(CC(=O)OC1=C(C=C2C(=C1)[C@@H]3[C@@H]([C@H](C=C4[C@H]3N(CC4)C)OC(=O)C)OC2=O)OC)O,,,,,,
3729,443730,O-Methyllycorenine,CN1CCC2=CC[C@@H]3[C@H]([C@@H]21)C4=CC(=C(C=C4[C@H](O3)OC)OC)OC,,,,,,
3730,443731,(+/-)-gamma-Lycorane,C1C[C@@H]2CCN3[C@@H]2C(C1)C4=CC5=C(C=C4C3)OCO5,,,,,,
3731,443732,3-Buten-1-amine,C=CCCN,,,,,,
3732,443733,"Methyl 5-(but-3-en-1-yl)amino-1,3,4-oxadiazole-2-carboxylate",COC(=O)C1=NN=C(O1)NCCC=C,,,,,,
3733,443734,CID 443734,C[C@H]1C=CC=C(C(=O)NC2=CC(=O)C3=C(C2=O)C=C(C(=C3C(=O)C(=CC([C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)O)C)O)CO)C)O)C)C,,,,,,
3734,443735,CID 443735,C[C@H]1C=CC=C(C(=O)NC2=CC(=O)C3=C(C(=C(C(=C3C2=O)O)C)O)C(=O)C(=CC([C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)O)C)O)CO)C)C,,,,,,
3735,443736,"5-Hydroxy-2-oxo-4-ureido-2,5-dihydro-1H-imidazole-5-carboxylate",C1(=NC(=O)NC1(C(=O)O)O)NC(=O)N,,,,,,
3736,443737,2-Iodo-6-methoxyphenol,COC1=C(C(=CC=C1)I)O,,,,,,
3737,443738,2-Bromo-5-hydroxy-N-[2-(4-hydroxyphenyl)ethyl]-4-methoxy-N-methylbenzamide,CN(CCC1=CC=C(C=C1)O)C(=O)C2=CC(=C(C=C2Br)OC)O,,,,,,
3738,443739,Norsanguinine,C1CNCC2=C3[C@@]14C=C[C@@H](C[C@@H]4OC3=C(C=C2)O)O,,,,,,
3739,443740,(+)-Plicamine,CN1[C@H]2C[C@H](C=C[C@@]23[C@@H](C1=O)N(C(=O)C4=CC5=C(C=C34)OCO5)CCC6=CC=C(C=C6)O)OC,,,,,,
3740,443741,7-Deoxypancratistatin,C1OC2=C(O1)C=C3C(=C2)[C@@H]4[C@H]([C@@H]([C@@H]([C@H]([C@@H]4O)O)O)O)NC3=O,,,,,,
3741,443742,"(+)-2,7-Dideoxypancratistatin",C1[C@@H]([C@H]2[C@H]([C@@H]([C@@H]1O)O)NC(=O)C3=CC4=C(C=C23)OCO4)O,,,,,,
3742,443743,Arnottin II,COC1=C(C2=C(C=C1)[C@@]3(C=CC4=CC5=C(C=C4C3=O)OCO5)OC2=O)OC,,,,,,
3743,443744,(+)-Sceletium A4,CN1CC[C@]2([C@@H]1C3=C(CC2)N=CC=C3)C4=CC(=C(C=C4)OC)OC,,,,,,
3744,443745,(-)-Tortuosamine,CNCC[C@@]1(CCC2=C(C1)C=CC=N2)C3=CC(=C(C=C3)OC)OC,,,,,,
3745,443746,"2,3,4-Trioxycyclopentanone",CC1(O[C@H]2[C@@H](CC(=O)[C@H]2O1)O[Si](C)(C)C(C)(C)C)C,,,,,,
3746,443747,"methyl {2-[(1R)-1-(3,4-dimethoxyphenyl)-4-oxocyclohex-2-en-1-yl]ethyl}methylcarbamate",CN(CC[C@@]1(CCC(=O)C=C1)C2=CC(=C(C=C2)OC)OC)C(=O)OC,,,,,,
3747,443748,"1,2-Dimethoxy-4-(2-prop-2-enoxyethenyl)benzene",COC1=C(C=C(C=C1)C=COCC=C)OC,,,,,,
3748,443749,"6-(2-Methoxyethenyl)-1,3-benzodioxole-5-carboxylic acid",COC=CC1=CC2=C(C=C1C(=O)O)OCO2,,,,,,
3749,443750,"(5Z,8Z,11Z,14Z)-N-(3,4-dihydroxyphenethyl)icosa-5,8,11,14-tetraenamide",CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCC1=CC(=C(C=C1)O)O,,,,,,
3750,443751,"N-[2-(3,4-dihydroxyphenyl)ethyl]-9-octadecenamide",CCCCCCCCC=CCCCCCCCC(=O)NCCC1=CC(=C(C=C1)O)O,,,,,,
3751,443752,Iron(II) gluconate hydrate,C([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O.C([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O.O.[Fe+2],,,,,,
3752,443753,Calcium pantothenate,CC(C)(CO)[C@H](C(=O)NCCC(=O)[O-])O.CC(C)(CO)[C@H](C(=O)NCCC(=O)[O-])O.[Ca+2],,,"['A group of water-soluble vitamins, some of which are COENZYMES. (See all compounds classified as Vitamin B Complex.)']",,,
3753,443754,Trimagnesium;dioxido(oxo)silane,[O-][Si](=O)[O-].[O-][Si](=O)[O-].[O-][Si](=O)[O-].[O-][Si](=O)[O-].[Mg+2].[Mg+2].[Mg+2],,,,,,
3754,443755,Sodium saccharin hydrate,C1=CC=C2C(=C1)C(=O)[N-]S2(=O)=O.O.[Na+],,,,,,
3755,443756,"(1R,2R,5S,8S,9S,10S,11S)-5-hydroxy-11-methyl-6-methylidene-12-oxo-13-oxapentacyclo[9.3.3.15,8.01,10.02,8]octadecane-9-carboxylic acid",C[C@]12CCC[C@@]3([C@@H]1[C@@H]([C@]45[C@H]3CC[C@](C4)(C(=C)C5)O)C(=O)O)COC2=O,,,,,,
3756,443757,Esmeraldin B,CC1C2=C3C(=CC=C2)NC4=C(C=CC=C4N3C5=C1C6=NC7=C(C=CC=C7N=C6C(=C5)C(=O)O)C(C)OC(=O)C8=C(C=CC=C8O)C)C(=O)O,,,,,,
3757,443758,(+)-Epitaxifolin,C1=CC(=C(C=C1[C@H]2[C@H](C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,,,,,,
3758,443759,"[(4R,6R)-4-amino-6-methyl-5-oxooxan-2-yl] [hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl] hydrogen phosphate",C[C@@H]1C(=O)[C@@H](CC(O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)N,,,,,,
3759,443760,"[(4S,6R)-4-amino-4,6-dimethyl-5-oxooxan-2-yl] [hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl] hydrogen phosphate",C[C@@H]1C(=O)[C@@](CC(O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)(C)N,,,,,,
3760,443761,"[(4S,6S)-4-amino-4,6-dimethyl-5-oxooxan-2-yl] [hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl] hydrogen phosphate",C[C@H]1C(=O)[C@@](CC(O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)(C)N,,,,,,
3761,443762,"[(4S,5R,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl] [hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl] hydrogen phosphate",C[C@H]1[C@@H]([C@@](CC(O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)(C)N)O,,,,,,
3762,443763,"[(4S,5S,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl] [hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl] hydrogen phosphate",C[C@H]1[C@H]([C@@](CC(O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)(C)N)O,,,,,,
3763,443764,"3,5-Dihydroxyphenylacetyl-CoA; (Acyl-CoA); [M+H]+",CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)CC4=CC(=CC(=C4)O)O)O,,,,,,
3764,443765,"3,5-Dihydroxyphenylglyoxylate",C1=C(C=C(C=C1O)O)C(=O)C(=O)O,,,,,,
3765,443766,Norreticuline,COC1=C(C=C(C=C1)CC2C3=CC(=C(C=C3CCN2)OC)O)O,,,,,,
3766,443767,"2,3,9,10-Tetrahydroxyberbine",C1CN2CC3=C(CC2C4=CC(=C(C=C41)O)O)C=CC(=C3O)O,,,,,,
3767,443768,"2,3,9,10-Tetrahydroxyberberine",C1C[N+]2=C(C=C3C=CC(=C(C3=C2)O)O)C4=CC(=C(C=C41)O)O,,,,,,
3768,443769,CID 443769,CC[C@@H](C)C[C@@H](C)C=C(C)C=CC=CC(=O)C1=C(NC=C(C1=O)C2=CC=C(C=C2)O)O,,,,,,
3769,443770,CID 443770,CC[C@@H](C)C[C@@H](C)C=C(C)C=CC=CC(=O)C1=C(N(C=C(C1=O)C2(CCC(CC2)O)O)O)O,,,,,,
3770,443771,CID 443771,CC[C@@H](C)C[C@@H](C)C=C(C)C=CC=CC(=O)C1=C(NC(C1=O)C(C2=CC=C(C=C2)O)O)O,,,,,,
3771,443772,CID 443772,CC[C@@H](C)C[C@@H](C)C=C(C)C=CC=CC(=O)C1=C(NC(C1=O)CC2=CC=C(C=C2)O)O,,,,,,
3772,443773,Dioncophylline A,C[C@@H]1CC2=C([C@H](N1)C)C(=C(C=C2)C3=C4C=CC=C(C4=C(C=C3C)OC)OC)O,,,,,,
3773,443774,Dioncophylline C,C[C@@H]1CC2=C(C=CC(=C2[C@H](N1)C)O)C3=C4C=CC=C(C4=C(C=C3C)OC)O,,,,,,
3774,443775,Dioncophyllinol B,C[C@@H]1[C@@H](C2=C([C@H](N1)C)C(=C(C=C2)C3=C(C4=C(C=C3)C=C(C=C4OC)C)O)O)O,,,,,,
3775,443776,Ancistrobrevine A,C[C@H]1CC2=CC(=C(C(=C2[C@H](N1C)C)OC)C3=C4C=C(C=C(C4=C(C=C3)OC)OC)C)OC,,,,,,
3776,443777,Isoshinanolone,C[C@@H]1CC(=O)C2=C([C@@H]1O)C=CC=C2O,,,,,,
3777,443778,"1,8-Dihydroxy-3-methylnaphthalene",CC1=CC2=C(C(=CC=C2)O)C(=C1)O,,,,,,
3778,443779,CID 443779,CC1=CC2=CC(=O)C=C(C2=C(N1)C)O,,,,,,
3779,443780,CID 443780,CC1=CC2=CC=CC(=O)C2=C(N1)C,,,,,,
3780,443781,Deoxyribose triphosphate,C1[C@@H]([C@H](O[C@H]1O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O,,,,,,
3781,443782,CID 443782,CC(=O)C1=C(C2=C(C3=C(CC2=CC1=CC(=O)CC(=O)O)C=C(C=C3O)O)O)O,,,,,,
3782,443783,Tetracenomycin E,CC1=C(C(=CC2=CC3=C(C(=C12)O)C(=O)C4=C(C3=O)C=C(C=C4O)OC)OC)C(=O)O,,,,,,
3783,443784,Tetracenomycin M,CC1(CC(CC2=CC3=C(C(=C21)O)C(=O)C4=C(C3=O)C=C(C=C4O)O)O)O,,,,,,
3784,443785,tetracenomycin F1 methyl ester,CC1=C(C(=CC2=CC3=C(C(=C12)O)C(=O)C4=C(C3)C=C(C=C4O)O)O)C(=O)OC,,,,,,
3785,443786,Decarboxytetracenomycin F1,CC1=CC(=CC2=CC3=C(C(=C12)O)C(=O)C4=C(C3)C=C(C=C4O)O)O,,,,,,
3786,443787,Tetracenomycin D3 methylester,CC1=C(C(=CC2=CC3=C(C(=C12)O)C(=O)C4=C(C3=O)C=C(C=C4O)O)O)C(=O)OC,,,,,,
3787,443788,Tetracenomycin D1,CC1=CC(=CC2=CC3=C(C(=C12)O)C(=O)C4=C(C3=O)C=C(C=C4O)O)O,,,,,,
3788,443789,Tetracenomycin B1,CC1=CC(=CC2=CC3=C(C(=C12)O)C(=O)C4=C(C3=O)C=C(C=C4O)OC)O,,,,,,
3789,443790,Tetracenomycin B2,CC1=C(C(=CC2=CC3=C(C(=C12)O)C(=O)C4=C(C3=O)C=C(C=C4O)OC)O)C(=O)OC,,,,,,
3790,443791,"methyl (6aR,10aS)-3,6a,10,10a,12-pentahydroxy-8-methoxy-1-methyl-6,7,11-trioxo-10H-tetracene-2-carboxylate",CC1=C(C(=CC2=CC3=C(C(=C12)O)C(=O)[C@@]4(C(C=C(C(=O)[C@@]4(C3=O)O)OC)O)O)O)C(=O)OC,,,,,,
3791,443792,"methyl (6aR,10aR)-6a,12-dihydroxy-3,8,10a-trimethoxy-1-methyl-6,7,10,11-tetraoxo-6,6a,7,10,10a,11-hexahydrotetracene-2-carboxylate",CC1=C(C(=CC2=CC3=C(C(=C12)O)C(=O)[C@@]4(C(=O)C=C(C(=O)[C@@]4(C3=O)O)OC)OC)OC)C(=O)OC,,,,,,
3792,443793,"methyl (6aR,7S,10aR)-6a,7,12-trihydroxy-8,10a-dimethoxy-1-methyl-6,10,11-trioxo-3-[(2R,3S,4S,5R,6R)-3,4,5-trimethoxy-6-methyloxan-2-yl]oxy-7H-tetracene-2-carboxylate",C[C@@H]1[C@H]([C@@H]([C@@H]([C@H](O1)OC2=CC3=CC4=C(C(=C3C(=C2C(=O)OC)C)O)C(=O)[C@@]5(C(=O)C=C([C@H]([C@@]5(C4=O)O)O)OC)OC)OC)OC)OC,,,,,,
3793,443794,4-Demethylpremithramycinone,CC(=O)C1=C([C@@]2([C@@H](CC3=CC4=CC(=CC(=C4C(=C3C2=O)O)O)O)[C@@H](C1=O)O)O)O,,,,,,
3794,443795,Premithramycinone,CC(=O)C1=C([C@@]2([C@@H](CC3=CC4=CC(=CC(=C4C(=C3C2=O)O)O)O)[C@@H](C1=O)OC)O)O,,,,,,
3795,443796,Premithramycin A1,C[C@@H]1[C@H]([C@@H](C[C@@H](O1)O[C@@]23[C@@H](CC4=CC5=CC(=CC(=C5C(=C4C2=O)O)O)O)[C@@H](C(=O)C(=C3O)C(=O)C)OC)O)O,,,,,,
3796,443797,Premithramycin A2',C[C@@H]1[C@@H]([C@@H](C[C@@H](O1)O[C@@H]2C[C@@H](O[C@@H]([C@H]2O)C)O[C@@]34[C@@H](CC5=CC6=CC(=CC(=C6C(=C5C3=O)O)O)O)[C@@H](C(=O)C(=C4O)C(=O)C)OC)O)O,,,,,,
3797,443798,Premithramycin A3',C[C@@H]1[C@H]([C@@H](C[C@@H](O1)O[C@@]23[C@@H](CC4=CC5=CC(=CC(=C5C(=C4C2=O)O)O)O)[C@@H](C(=O)C(=C3O)C(=O)C)OC)O[C@H]6C[C@H]([C@H]([C@H](O6)C)O)O[C@H]7C[C@]([C@@H]([C@H](O7)C)O)(C)O)O,,,,,,
3798,443799,Premithramycin A3,C[C@@H]1[C@H]([C@@H](C[C@@H](O1)O[C@@]23[C@@H](CC4=C(C2=O)C(=C5C(=C4)C=C(C(=C5O)C)O)O)[C@@H](C(=O)C(=C3O)C(=O)C)OC)O[C@H]6C[C@H]([C@H]([C@H](O6)C)O)O[C@H]7C[C@]([C@@H]([C@H](O7)C)O)(C)O)O,,,,,,
3799,443800,Premithramycin B,C[C@@H]1[C@H]([C@@H](C[C@@H](O1)O[C@@H]2C[C@@H](O[C@@H]([C@H]2O)C)OC3=CC4=CC5=C(C(=C4C(=C3C)O)O)C(=O)[C@]6([C@@H](C5)[C@@H](C(=O)C(=C6O)C(=O)C)OC)O[C@H]7C[C@H]([C@@H]([C@H](O7)C)O)O[C@H]8C[C@H]([C@H]([C@H](O8)C)O)O[C@H]9C[C@]([C@@H]([C@H](O9)C)O)(C)O)O)O,,,,,,
3800,443801,Dehydrorabelomycin,CC1=CC2=CC(=C3C(=C2C(=C1)O)C(=O)C4=C(C3=O)C(=CC=C4)O)O,,,,,,
3801,443802,CID 443802,CC1=CC(=O)C2=C3C(=C(C2=C1)O)C(=C4C(=O)C=CC=C4C3=O)O,,,,,,
3802,443803,Stealthin C,CC1=CC2=C(C(=C1)O)C3=C(C2N)C(=O)C4=C(C3=O)C=CC=C4O,,,,,,
3803,443804,CID 443804,CC1=CC2=C(C(=C1)O)C3=C(C4=CC=CC(=O)C4=C(C3=C2[N+]#N)O)[O-],,,,,,
3804,443805,CID 443805,CC1=CC2=C(C(=C1)O)C3=C(C4=CC=CC(=O)C4=C(C3=C2[N+]#N)O)O,,,,,,
3805,443806,"(1S,3aS)-1-[(2S)-butan-2-yl]-7-hydroxy-1,3a,5-trimethyl-2,8,13-trioxo-1,2,8,13-tetrahydro-3aH-benzo[b][1,3]oxazolo[3,2-f]phenanthridin-12-yl 2,6-dideoxy-alpha-L-ribo-hexopyranoside",CC[C@H](C)[C@]1(C(=O)O[C@@]2(N1C3=C(C4=C2C=C(C=C4O)C)C(=O)C5=C(C3=O)C(=CC=C5)O[C@H]6C[C@H]([C@H]([C@@H](O6)C)O)O)C)C,,,,,,
3806,443807,8-O-Methyltetrangulol,CC1=CC2=C(C(=C1)O)C3=C(C=C2)C(=O)C4=C(C3=O)C=CC=C4OC,,,,,,
3807,443808,19-Hydroxytetrangulol,C1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C4=C(C=C(C=C4C=C3)CO)O,,,,,,
3808,443809,"(5R,6R)-1,5,6-trihydroxy-3-(hydroxymethyl)-8-methoxy-5,6-dihydrobenzo[a]anthracene-7,12-dione",COC1=CC=CC2=C1C(=O)C3=C(C2=O)C4=C(C=C(C=C4O)CO)[C@H]([C@@H]3O)O,,,,,,
3809,443810,Rabelomycin,C[C@]1(CC2=CC(=C3C(=C2C(=O)C1)C(=O)C4=C(C3=O)C(=CC=C4)O)O)O,,,,,,
3810,443811,"(3R)-9-[(2R,4R,5S,6R)-4,5-dihydroxy-6-methyl-tetrahydropyran-2-yl]-3,6,8-trihydroxy-3-methyl-2,4-dihydrobenzo[a]anthracene-1,7,12-trione",C[C@@H]1[C@H]([C@@H](C[C@@H](O1)C2=C(C3=C(C=C2)C(=O)C4=C5C(=CC(=C4C3=O)O)C[C@@](CC5=O)(C)O)O)O)O,,,,,,
3811,443812,Urdamycinone B,C[C@@H]1[C@H]([C@@H](C[C@@H](O1)C2=C(C3=C(C=C2)C(=O)C4=C(C3=O)C=CC5=C4C(=O)C[C@](C5)(C)O)O)O)O,,,,,,
3812,443813,"(3R)-3,8-dihydroxy-9-[(2R,4R,5R,6R)-5-hydroxy-4-[(2S,5S,6S)-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6-methyl-tetrahydropyran-2-yl]-3-methyl-2,4-dihydrobenzo[a]anthracene-1,7,12-trione",C[C@H]1[C@H](CC[C@@H](O1)O[C@@H]2C[C@@H](O[C@@H]([C@H]2O)C)C3=C(C4=C(C=C3)C(=O)C5=C(C4=O)C=CC6=C5C(=O)C[C@](C6)(C)O)O)O,,,,,,
3813,443814,"(3R)-9-[(2R,4R,5S,6R)-4,5-dihydroxy-6-methyl-tetrahydropyran-2-yl]-3,5,8-trihydroxy-3-methyl-2,4-dihydrobenzo[a]anthracene-1,7,12-trione",C[C@@H]1[C@H]([C@@H](C[C@@H](O1)C2=C(C3=C(C=C2)C(=O)C4=C5C(=C(C=C4C3=O)O)C[C@@](CC5=O)(C)O)O)O)O,,,,,,
3814,443815,"(3R,4aR,12bS)-9-[(2R,4R,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]-3,4a,8-trihydroxy-12b-[(2S,5S,6S)-5-hydroxy-6-methyloxan-2-yl]oxy-3-methyl-2,4-dihydrobenzo[a]anthracene-1,7,12-trione",C[C@H]1[C@H](CC[C@@H](O1)O[C@]23C(=O)C[C@](C[C@]2(C=CC4=C3C(=O)C5=C(C4=O)C(=C(C=C5)[C@H]6C[C@H]([C@@H]([C@H](O6)C)O)O)O)O)(C)O)O,,,,,,
3815,443816,"(3R)-9-[(2R,4R,5R,6R)-4-[(2S,5S,6S)-5-[(2S,4R,5S,6R)-4,5-dihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6-methyl-tetrahydropyran-2-yl]oxy-5-hydroxy-6-methyl-tetrahydropyran-2-yl]-3,5,8-trihydroxy-3-methyl-2,4-dihydrobenzo[a]anthracene-1,7,12-trione",C[C@H]1[C@H](CC[C@@H](O1)O[C@@H]2C[C@@H](O[C@@H]([C@H]2O)C)C3=C(C4=C(C=C3)C(=O)C5=C6C(=C(C=C5C4=O)O)C[C@@](CC6=O)(C)O)O)O[C@H]7C[C@H]([C@@H]([C@H](O7)C)O)O,,,,,,
3816,443817,Urdamycinone F,C[C@@H]1[C@H]([C@@H](C[C@@H](O1)C2=C(C3=C(C=C2)C(=O)C4=C(C3=O)[C@@H](C[C@]5([C@@]4(C(=O)C[C@](C5)(C)O)O)O)O)O)O)O,,,,,,
3817,443818,Urdamycin F,C[C@H]1[C@H](CC[C@@H](O1)O[C@]23C(=O)C[C@](C[C@]2(C[C@H](C4=C3C(=O)C5=C(C4=O)C(=C(C=C5)[C@H]6C[C@H]([C@@H]([C@H](O6)C)O)O[C@H]7CC[C@@H]([C@@H](O7)C)O[C@H]8C[C@H]([C@@H]([C@H](O8)C)O)O)O)O)O)(C)O)O,,,,,,
3818,443819,Urdamycin A,C[C@H]1[C@H](CC[C@@H](O1)O[C@]23C(=O)C[C@](C[C@]2(C=CC4=C3C(=O)C5=C(C4=O)C(=C(C=C5)[C@H]6C[C@H]([C@@H]([C@H](O6)C)O)O[C@H]7CC[C@@H]([C@@H](O7)C)O[C@H]8C[C@H]([C@@H]([C@H](O8)C)O)O)O)O)(C)O)O,,,,,,
3819,443820,Nogalonic acid methyl ester,CC(=O)CC(=O)C1=C(C2=C(C=C1CC(=O)OC)C(=O)C3=C(C2=O)C(=CC=C3)O)O,,,,,,
3820,443821,Nogalonic acid,CC(=O)CC(=O)C1=C(C2=C(C=C1CC(=O)O)C(=O)C3=C(C2=O)C(=CC=C3)O)O,,,,,,
3821,443822,Auraviketone,C[C@]1(CC(=O)C2=C(C3=C(C=C2C1C(=O)OC)C(=O)C4=C(C3=O)C(=CC=C4)O)O)O,,,,,,
3822,443823,Dihydro-nogalonic acid methyl ester,CC(CC(=O)C1=C(C2=C(C=C1CC(=O)OC)C(=O)C3=C(C2=O)C(=CC=C3)O)O)O,,,,,,
3823,443824,"methyl (2R)-2,4,5,7-tetrahydroxy-2-methyl-6,11-dioxo-3,4-dihydro-1H-tetracene-1-carboxylate",C[C@]1(CC(C2=C(C3=C(C=C2C1C(=O)OC)C(=O)C4=C(C3=O)C(=CC=C4)O)O)O)O,,,,,,
3824,443825,"2-[4,5-dihydroxy-3-(1-hydroxy-3-oxopent-1-enyl)-10-oxo-9H-anthracen-2-yl]acetic acid",CCC(=O)C=C(C1=C(C=C2CC3=C(C(=CC=C3)O)C(=O)C2=C1O)CC(=O)O)O,,,,,,
3825,443826,"Methyl 2-[4,5-dihydroxy-3-(1-hydroxy-3-oxopent-1-enyl)-9,10-dioxoanthracen-2-yl]acetate",CCC(=O)C=C(C1=C(C2=C(C=C1CC(=O)OC)C(=O)C3=C(C2=O)C(=CC=C3)O)O)O,,,,,,
3826,443827,Aklaviketone,CC[C@]1(CC(=O)C2=C(C3=C(C=C2[C@H]1C(=O)OC)C(=O)C4=C(C3=O)C(=CC=C4)O)O)O,,,,,,
3827,443828,Rhodomycin D,CC[C@]1(C[C@@H](C2=C([C@H]1C(=O)OC)C(=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4O)O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O)N)O,,,,,,
3828,443829,13-Deoxycarminomycin,CC[C@]1(C[C@@H](C2=C(C1)C(=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4O)O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O)N)O,,,,,,
3829,443830,13-Dihydrocarminomycin,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)O)O)(C(C)O)O)N)O,,,,,,
3830,443831,Carminomycin,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)O)O)(C(=O)C)O)N)O,,,"['Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)', 'Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. (See all compounds classified as Antibiotics, Antineoplastic.)']",,,
3831,443832,Daunorubicinol,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)([C@H](C)O)O)N)O,,,,,,
3832,443833,CID 443833,CC1=C2C(=CC3=CC=CC(=O)C3=C2O)C[C@H](O1)CC(=O)O,,,,,,
3833,443834,5-Deoxodihydrokalafungin,C[C@@H]1C2=C(C[C@H](O1)CC(=O)O)CC3=C(C2=O)C(=CC=C3)O,,,,,,
3834,443835,Dihydrokalafungin,C[C@@H]1C2=C(C[C@H](O1)CC(=O)O)C(=O)C3=C(C2=O)C(=CC=C3)O,,,,,,
3835,443836,Kalamycin,C[C@@H]1C2=C([C@@H]3[C@H](O1)CC(=O)O3)C(=O)C4=C(C2=O)C(=CC=C4)O,,,,,,
3836,443837,2-Decarboxytetrangomycin,CC1(CC2=C(C(=O)C1C(=O)O)C3=C(C=C2)C(=O)C4=C(C3=O)C=CC=C4O)O,,,,,,
3837,443838,"Benzo[b]phenanthridine-7,12-dione, 1,8-dihydroxy-3-methyl-",CC1=CC2=CN=C3C(=C2C(=C1)O)C(=O)C4=C(C3=O)C(=CC=C4)O,,,,,,
3838,443839,"[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl] [hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl] hydrogen phosphate",C[C@H]1[C@H]([C@H](C[C@@H](O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)N)O,,,,,,
3839,443840,"[(2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyloxan-2-yl] [hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl] hydrogen phosphate",C[C@@H]1[C@H]([C@@](C[C@@H](O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)(C)O)O,,,,,,
3840,443841,"Thymidine 5'-diphosphoric acid beta-(2,6-dideoxy-beta-D-glucopyranosyl) ester",C[C@@H]1[C@H]([C@@H](C[C@@H](O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)O)O,,,,,,
3841,443842,"[(2S,4R,5R,6R)-4,5-dihydroxy-6-methyloxan-2-yl] [hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl] hydrogen phosphate",C[C@@H]1[C@@H]([C@@H](C[C@@H](O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)O)O,,,,,,
3842,443843,"[hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl] [(2S,5S,6S)-5-hydroxy-6-methyloxan-2-yl] hydrogen phosphate",C[C@H]1[C@H](CC[C@@H](O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)C)O)O,,,,,,
3843,443844,"8-azabicyclo[3.2.1]octane-2-carboxylic acid, 3-hydroxy-8-methyl-, methyl ester, (1R,2R,3S,5S)-",CN1C2CCC1[C@H]([C@H](C2)O)C(=O)OC,,,,,,
3844,443845,Pseudoecgonine,CN1C2CCC1[C@@H]([C@H](C2)O)C(=O)O,,,,,,
3845,443846,Pseudoecgonyl-CoA,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)[C@@H]4[C@H](CC5CCC4N5C)O)O,,,,,,
3846,443847,Fridamycin E,C[C@@](CC1=C(C2=C(C=C1)C(=O)C3=C(C2=O)C=CC=C3O)O)(CC(=O)O)O,,,,,,
3847,443848,Anatalline,C1CNC(CC1C2=CN=CC=C2)C3=CN=CC=C3,,,,,,
3848,443849,5-Aminopentanal,C(CCN)CC=O,,,,,,
3849,443850,3-Dimethylallyl-4-hydroxyphenylpyruvate,CC(=CCC1=C(C=CC(=C1)CC(=O)C(=O)O)O)C,,,,,,
3850,443851,3-Dimethylallyl-4-hydroxymandelic acid,CC(=CCC1=C(C=CC(=C1)C(C(=O)O)O)O)C,,,,,,
3851,443852,4-Hydroxy-3-(3-methylbut-2-en-1-yl)benzoic acid,CC(=CCC1=C(C=CC(=C1)C(=O)O)O)C,,,,,,
3852,443853,3-Dimethylallyl-4-hydroxybenzaldehyde,CC(=CCC1=C(C=CC(=C1)C=O)O)C,,,,,,
3853,443854,CID 443854,CC1=C2C(=C(C(=C(O2)O)N)O)C=CC1=O,,,,,,
3854,443855,CID 443855,C1=CC2=C(C(=C(OC2=CC1=O)O)N)O,,,,,,
3855,443856,CID 443856,C1=CC(=O)C(=C2C1=C(C(=C(O2)O)N)O)Cl,,,,,,
3856,443857,CID 443857,CC(=CCC1=C(C=CC(=C1)C(=O)NC2=C(OC3=C(C2=O)C=CC(=C3Cl)O[C@H]4[C@@H]([C@@H]([C@H](C(O4)(C)C)O)O)O)O)O)C,,,,,,
3857,443858,CID 443858,CC(=CCC1=C(C=CC(=C1)C(=O)NC2=C(OC3=C(C2=O)C=CC(=C3Cl)O[C@H]4[C@@H]([C@@H]([C@H](C(O4)(C)C)OC)O)O)O)O)C,,,,,,
3858,443859,CID 443859,CC1=C(C=CC2=C1OC(=C(C2=O)NC(=O)C3=CC(=C(C=C3)O)CC=C(C)C)O)O[C@H]4[C@@H]([C@@H]([C@H](C(O4)(C)C)O)O)O,,,,,,
3859,443860,CID 443860,CC1=C(C=CC2=C1OC(=C(C2=O)NC(=O)C3=CC(=C(C=C3)O)CC=C(C)C)O)O[C@H]4[C@@H]([C@@H]([C@H](C(O4)(C)C)OC)O)O,,,,,,
3860,443861,"3-methyl-1H-pyrrole-2,4-dicarboxylic acid",CC1=C(NC=C1C(=O)O)C(=O)O,,,,,,
3861,443862,CID 443862,CC1=C2C(=C(C(=C(O2)O)NC(=O)C3=C(C(=CN3)C(=O)O)C)O)C=CC1=O,,,,,,
3862,443863,CID 443863,CC1=C2C(=C(C(=C(O2)O)NC(=O)C3=CNC(=C3C)C(=O)NC4=C(OC5=C(C(=O)C=CC5=C4O)C)O)O)C=CC1=O,,,,,,
3863,443864,"2-N,4-N-bis[7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyloxan-2-yl]oxy-2-hydroxy-8-methyl-4-oxochromen-3-yl]-3-methyl-1H-pyrrole-2,4-dicarboxamide",CC1=C(C=CC2=C1OC(=C(C2=O)NC(=O)C3=CNC(=C3C)C(=O)NC4=C(OC5=C(C4=O)C=CC(=C5C)O[C@H]6[C@@H]([C@@H]([C@H](C(O6)(C)C)OC)O)O)O)O)O[C@H]7[C@@H]([C@@H]([C@H](C(O7)(C)C)OC)O)O,,,,,,
3864,443865,"[hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl] [(3R,4R,5R)-3,4,5-trihydroxy-6,6-dimethyloxan-2-yl] hydrogen phosphate",CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC3[C@@H]([C@@H]([C@H](C(O3)(C)C)O)O)O)O,,,,,,
3865,443866,Pemirolast potassium,CC1=CC=CN2C1=NC=C(C2=O)C3=NN=N[N-]3.[K+],,,"['Drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists. Classical antihistaminics block the histamine H1 receptors only. (See all compounds classified as Histamine Antagonists.)']",,,
3866,443867,Butenafine hydrochloride,CC(C)(C)C1=CC=C(C=C1)CN(C)CC2=CC=CC3=CC=CC=C32.Cl,,,"['Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)']",,,
3867,443868,Barnidipine hydrochloride,CC1=C([C@@H](C(=C(N1)C)C(=O)O[C@H]2CCN(C2)CC3=CC=CC=C3)C4=CC(=CC=C4)[N+](=O)[O-])C(=O)OC.Cl,,,['A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)'],,,
3868,443869,Barnidipine,CC1=C([C@@H](C(=C(N1)C)C(=O)O[C@H]2CCN(C2)CC3=CC=CC=C3)C4=CC(=CC=C4)[N+](=O)[O-])C(=O)OC,['Indicated for the treatment of mild to moderate essential hypertension and management of chronic stable angina.'],"['Barnidipine reduces peripheral resistance and lowers blood pressure. The chronic use of the drug is not reported to lead to an increase in basic heart frequency. The antihypertensive effects of barnidipine are reported to remain during the entire 24-hour dose interval. Barnidipine does not exert any negative effect on serum lipids profile, glucose level or blood electrolytes.']",['A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)'],"['Following a single, modified-release dose of 10mg barnidipine, the peak plasma concentration was approximately 0.48 µg/L and the area under the curve (AUC) was 2.85 µg/Lxh. The peak plasma concentrations are reached within 5 to 6 hours after oral administration of 20mg barnidipine. While the plasma concentrations of the drug may vary between individuals, the absolute bioavailability of the barnidipine is approximately 1.1% due to extensive first-pass hepatic metabolism. After repeated administration of 20mg barnidipine to healthy individuals, the concomitant intake of food did not have a statistically significant effect on the AUC, Cmax or half-life of the drug.', 'Barnidipine and its metabolites are metabolized into feces (60%), urine (40%) and breath (1%). Following a single dose administration of barnidipine ranging from 5 to 20mg in healthy volunteers, urinary excretion of unchanged drug was negligible (≤0.003% of an administered dose).', 'After administration of single oral doses of radiolabelled barnidipine in rats, levels of radioactivity were found to be higher in the kidney, liver and gastrointestinal tract than in plasma, whereas the brain showed the lowest level of radioactivity. The drug was also detectable in the breast milk.']","['Barnidipine is expected to undergo hepatic metabolism. The primary metabolism of barnidipine involves the oxidation of the 1,4-dihydropyridine ring and hydrolysis of the methyl ester. Secondary metabolism involves N-debenzylization of the side chain, hydrolysis of the N-benzylpyrrolidine ester, and reduction of the nitro group. Both the primary and secondary metabolic pathways are mediated by the CYP3A isoenzyme family and the metabolites formed are pharmacologically inactive.', 'Barnidipine has known human metabolites that include 3-O-(1-Benzylpyrrolidin-3-yl) 5-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate, 3-O-methyl 5-O-pyrrolidin-3-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, and 5-methoxycarbonyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylic acid.']","['In a two-compartment analytical model, the median terminal elimination half life of barnidipine was 20 hours after repeated administration.']"
3869,443870,Luvatren,CC1=CC=C(C=C1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)O.Cl,,,,,,
3870,443871,"(2R)-3-phenyl-2-[[(1S,3S)-3-propan-2-ylcyclohexanecarbonyl]amino]propanoic acid",CC(C)[C@H]1CCC[C@@H](C1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)O,,,,,,
3871,443872,Eplerenone,C[C@]12CCC(=O)C=C1C[C@H]([C@@H]3[C@]24[C@H](O4)C[C@]5([C@H]3CC[C@@]56CCC(=O)O6)C)C(=O)OC,['For improvement of survival of stable patients with left ventricular systolic dysfunction (ejection fraction <40%) and clinical evidence of congestive heart failure after an acute myocardial infarction.'],"['Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of eplerenone. Eplerenone selectively binds to recombinant human mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone and androgen receptors.']","['Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Drugs that bind to and block the activation of MINERALOCORTICOID RECEPTORS by MINERALOCORTICOIDS such as ALDOSTERONE. (See all compounds classified as Mineralocorticoid Receptor Antagonists.)']","['The absolute bioavailability of eplerenone is unknown.', '43 to 90 L', 'Apparent plasma cl=10 L/hr', 'Apparent plasma clearance: approximately 10 L/hr. Less than 5% is recovered as unchanged drug in the urine and feces. Renal: 67%. Fecal: 32%.', 'Mean peak plasma concentrations of eplerenone are reached approximately 1.5 hours following oral administration. The absolute bioavailability of eplerenone is unknown. Both peak plasma levels (Cmax) and area under the curve (AUC) are dose proportional for doses of 25 to 100 mg and less than proportional at doses above 100 mg. The plasma protein binding of eplerenone is about 50% and it is primarily bound to alpha 1-acid glycoproteins. The apparent volume of distribution at steady state ranged from 43 to 90 L. Eplerenone does not preferentially bind to red blood cells.', 'Eplerenone is distributed into milk in rats; ... .', '... Preclinical data show that eplerenone and/or metabolites are present in rat breast milk (0.85:1 [milk:plasma] AUC ratio) obtained after a single oral dose. Peak concentrations in plasma and milk were obtained from 0.5 to 1 hour after dosing.']","['Eplerenone is metabolized primarily by CYP3A4, however, no active metabolites have been identified in human plasma.', 'Eplerenone metabolism is primarily mediated via CYP3A4. No active metabolites have been identified in human plasma.', 'Eplerenone has known human metabolites that include 21-hydroxyeplerenone and 6beta-hydroxyeplerenone.']","['4-6 hours', 'Elimination: 4 to 6 hours.']"
3872,443873,Temocapril hydrochloride,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CS[C@@H](CN(C2=O)CC(=O)O)C3=CC=CS3.Cl,,,"['A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (See all compounds classified as Angiotensin-Converting Enzyme Inhibitors.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']",,,
3873,443874,Temocapril,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CS[C@@H](CN(C2=O)CC(=O)O)C3=CC=CS3,"['Temocapril is an ACE inhibitor primarily indicated in the treatment of hypertension and congestive heart failure, diabetic nephropathy, and improvement of prognosis for coronary artery diseases (including acute myocardial infarction).']","[""Temocapril is a prodrug of its active metabolite (and diacid form) temocaprilat which contains a thiazepine ring. Temocaprilat has slightly higher potency than enalaprilat in ACE inhibition isolated from rabbit lung. ACE inhibitors exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.). When compared with other Angiotensin-converting Enzyme Inhibitors, temocapril's advantages include a rapid onset of action and what research suggests is tighter vascular ACE binding than enalaprilat.""]","['A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (See all compounds classified as Angiotensin-Converting Enzyme Inhibitors.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']","['Temocapril is rapidly absorbed in the gastrointestinal tract and converted into the  diacid (active) metabolite, which inhibits ACE in plasma.', 'Temocapril is eliminated primarily through the liver and kidneys.', '19.4% urinary recovery.']",,['13.1 hours in patients with normal liver function.']
3874,443875,"(1R,3S)-5-[2-[(1R,3aS,7aR)-1-[(2R)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol",C[C@H](C=CC(C1CC1)O)[C@H]2CC[C@@H]3[C@@]2(CCCC3=CC=C4C[C@H](C[C@@H](C4=C)O)O)C,,,,,,
3875,443876,CID 443876,C[C@H]1C=CC=C2CO[C@H]3[C@@]2([C@@H](C=C([C@H]3O)C)C(=O)O[C@H]4C[C@@H](CC=C([C@H]1O[C@H]5C[C@@H]([C@H]([C@@H](O5)C)O[C@H]6CC([C@H]([C@@H](O6)C)O)OC)OC)C)O[C@]7(C4)C=C[C@@H]([C@H](O7)C8CCCCC8)C)O,,,,,,
3876,443877,"(1R)-6-fluoranyl-1-methyl-7-[4-[(5-methyl-2-oxidanylidene-1,3-dioxol-4-yl)methyl]piperazin-1-yl]-4-oxidanylidene-1H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid",C[C@@H]1N2C3=CC(=C(C=C3C(=O)C(=C2S1)C(=O)O)F)N4CCN(CC4)CC5=C(OC(=O)O5)C,,,,,,
3877,443878,Tolterodine tartrate,CC1=CC(=C(C=C1)O)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,,,"['Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS. (See all compounds classified as Urological Agents.)', 'Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)']",,,
3878,443879,Tolterodine,CC1=CC(=C(C=C1)O)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2,"['For the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).']","['Tolterodine is a competitive muscarinic receptor antagonist. Both urinary bladder contraction and salivation are mediated via cholinergic muscarinic receptors. After oral administration, tolterodine is metabolized in the liver, resulting in the formation of the 5-hydroxymethyl derivative, a major pharmacologically active metabolite. The 5-hydroxymethyl metabolite, which exhibits an antimuscarinic activity similar to that of tolterodine, contributes significantly to the therapeutic effect. Both tolterodine and the 5-hydroxymethyl metabolite exhibit a high specificity for muscarinic receptors, since both show negligible activity or affinity for other neurotransmitter receptors and other potential cellular targets, such as calcium channels. Tolterodine has a pronounced effect on bladder function. The main effects of tolterodine are an increase in residual urine, reflecting an incomplete emptying of the bladder, and a decrease in detrusor pressure, consistent with an antimuscarinic action on the lower urinary tract.']","['Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS. (See all compounds classified as Urological Agents.)', 'Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)']","['Following administration of a 5-mg oral dose of 14C-tolterodine solution to healthy volunteers, 77% of radioactivity was recovered in urine and 17% was recovered in feces in 7 days.', '113 ± 26.7 L']",['Tolterodine has known human metabolites that include 5-Hydroxymethyl tolterodine and N-Dealkylated tolterodine.'],['1.9-3.7 hours']
3879,443880,Betamethasone 17-propionate 21-methoxide,CCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)C(=O)COC,,,,,,
3880,443881,Gestonorone caproate,CCCCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@H]34)C)C(=O)C,,,,,,
3881,443882,CID 443882,CC1=C(C2=NC1=CC3=NC(=CC4=C5C=CC(=C(O)OC)[C@H]([C@]5(C(=CC6=NC(=C2)C(=C6C)CCC(=O)OC)N4)C)C(=O)OC)C(=C3C=C)C)CCC(=O)O,,,,,,
3882,443883,"Ergometrine Maleate,(S)",C[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C.C(=CC(=O)O)C(=O)O,,,,,,
3883,443884,Ergometrine,C[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C,['Used to treat postpartum haemorrhage and postabortion haemorrhage in patients with uterine atony.'],['Ergonovine belongs to the group of medicines known as ergot alkaloids. These medicines are usually given to stop excessive bleeding that sometimes occurs after abortion or a baby is delivered. They work by causing the muscle of the uterus to contract.'],"['Drugs that stimulate contraction of the myometrium. They are used to induce LABOR, OBSTETRIC at term, to prevent or control postpartum or postabortion hemorrhage, and to assess fetal status in high risk pregnancies. They may also be used alone or with other drugs to induce abortions (ABORTIFACIENTS). Oxytocics used clinically include the neurohypophyseal hormone OXYTOCIN and certain prostaglandins and ergot alkaloids. (From AMA Drug Evaluations, 1994, p1157) (See all compounds classified as Oxytocics.)']","['Absorption is rapid and complete after oral or intramuscular administration.', 'Thought to be eliminated by non-renal mechanisms (i.e. hepatic metabolism, excretion in feces)', 'Ergonovine maleate and methylergonovine maleate are rapidly absorbed after oral or im administration.', 'Uterine contractions are usually initiated within 5-15 minutes following oral administration, within 2-5 minutes after im injection, and immediately following iv injection of ergonovine or methylergonovine. Uterine contractions persist for 3 hours or longer after oral or im administration and for 45 minutes after iv injection of either drug.', 'Little is known about the elimination of ergonovine or methylergonovine. It has been suggested that the drugs are principally eliminated by nonrenal mechanisms (i.e., metabolism in the liver, excretion in feces).', 'The aim of this investigation was to assess the pharmacokinetics and bioavailability of ergometrine in six human male subjects after an oral dose of 0.200 mg and after an intravenous dose of 0.075 mg of ergometrine maleate. A large variation in bioavailability of between 34% and 117% in the six volunteers was observed. The lag time was also subject dependent and ranged between 0.0073 hr (0.4 min) and 0.47 hr (28 min). After intravenous administration, the pharmacokinetic profile can be described by a two-compartment model. The distribution half-life t1/2 alpha is 0.18 +/- 0.20 hr, the elimination half-life t1/2 beta is 2.06 +/- 0.90 hr, the total body clearance (CL) amounts to 35.9 +/- 13.4 L hr-1 and the steady-state volume (Vss) of distribution is 73.4 +/- 22.01. After oral administration, the pharmacokinetic profile can be described by a one-compartment model. The absorption half-life t1/2 abs is 0.19 +/- 0.22 hr, and the elimination half-life t1/2 beta 1.90 +/- 0.16 hr. This study with oral ergometrine shows such a large interindividual variability in bioavailability that the oral route of administration does not seem not to be the most reliable means of accurate dosing in preventing post-partum hemorrhage.']",['Hepatic.'],"['t<sub>1/2 &alpha;</sub>=10 minutes; t<sub>1/2 &beta;</sub>=2 hours', 'The aim of this investigation was to assess the pharmacokinetics and bioavailability of ergometrine in six human male subjects after an oral dose of 0.200 mg and after an intravenous dose of 0.075 mg of ergometrine maleat. ...  After intravenous administration, the pharmacokinetic profile can be described by a two-compartment model. The distribution half-life t1/2 alpha is 0.18 +/- 0.20 hr, the elimination half-life t1/2 beta is 2.06 +/- 0.90 hr ...  After oral administration, the pharmacokinetic profile can be described by a one-compartment model. The absorption half-life t1/2 abs is 0.19 +/- 0.22 hr, and the elimination half-life t1/2 beta 1.90 +/- 0.16 hr. ...', 'Plasma concentrations of methylergonovine appear to decline in a biphasic manner. ... Following iv administration of ergonovine to adults, the half-life of the drug in the initial phase (t1/2 alpha) reportedly is about 10 minutes and the half-life in the terminal phase (t1/2 beta) is about 2 hours.']"
3884,443885,"N,N-dimethyl-3-phenyl-3-(pyridin-2-yl)propan-1-amine maleate",CN(C)CCC(C1=CC=CC=C1)C2=CC=CC=N2.C(=CC(=O)O)C(=O)O,,,,,,
3885,443886,CID 443886,CC(C(=O)N[C@H]1[C@@H]2N(C1=O)[C@H](C(S2)(C)C)C(=O)[O-])OC3=CC=CC=C3.[K+],,,,,,
3886,443887,"(1S,6R,8S,11S,12S,15S)-5,15-dihydroxy-2,16-dimethyl-7-oxapentacyclo[9.7.0.02,8.06,8.012,16]octadec-4-ene-4-carbonitrile",CC12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CC[C@]45C3(CC(=C([C@H]4O5)O)C#N)C,,,,,,
3887,443888,CID 443888,CCCC[C@H](C)C[C@@H](C=C[C@@H]1[C@H]2C[C@@H](C[C@H]2C[C@H]1O)CCOCC(=O)OC)O,,,,,,
3888,443889,2-[(2R)-2-hydroxy-2-(4-hydroxyphenyl)ethyl]-1-[2-[[5-(methylaminomethyl)furan-2-yl]methylsulfanyl]ethyl]-3-methylsulfonylguanidine,CNCC1=CC=C(O1)CSCCNC(=NC[C@@H](C2=CC=C(C=C2)O)O)NS(=O)(=O)C,,,,,,
3889,443890,But-2-enedioic acid;iron,C(=CC(=O)O)C(=O)O.[Fe],,,,,,
3890,443891,(R)-(+)-Toborinone,COC1=C(C=C(C=C1)CNC[C@H](COC2=CC3=C(C=C2)NC(=O)C=C3)O)OC,,,,,,
3891,443892,CID 443892,CC1=C(C=CC2=C1OC(=C(C2=O)NC(=O)C3=CC(=C(C=C3)O)CC=C(C)C)[O-])O[C@H]4[C@@H]([C@@H]([C@H](C(O4)(C)C)OC)OC(=O)N)O.[Na+],,,,,,
3892,443893,CID 443893,C1C(N(C2=C(N1)NC(=NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-].[Ca+2],,,,,,
3893,443894,(R)-(+)-Tolvaptan,CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCC[C@H](C4=C3C=CC(=C4)Cl)O)C,"['Treatment of symptomatic and resistant to fluid restriction euvolemic or hypervolemic hyponatremia associated with congestive heart failure, SIADH, and cirrhosis.']","['Urine volume and fluid intake increase in a dose dependent manner which results in overall negative fluid balance in patients taking tolvaptan. Increases in serum sodium and osmolality can be observed 4-8 hours post-administration and is maintained for 24 hours. The magnitude of serum sodium and osmolality change increases with escalating doses. Furthermore, a decrease in urine osmolality and increase in free water clearance can be observed 4 hours after post-administration of tolvaptan. The affinity for V2 receptors is 29x greater than that of V1a receptors and does not have any appreciable affinity for V2 receptors.']",,"['Tmax, Healthy subjects: 2 - 4 hours; Cmax, Healthy subjects, 30 mg: 374 ng/mL; Cmax, Healthy subjects, 90 mg: 418 ng/mL; Cmax, heart failure patients, 30 mg: 460 ng/mL; Cmax, heart failure patients, 90 mg: 723 ng/mL; AUC(0-24 hours), 60 mg: 3.71 μg·h/mL; AUC(∞), 60 mg: 4.55 μg·h/mL; The pharmacokinetic properties of tolvaptan are stereospecific, with a steady-state ratio of the S-(-) to the R-(+) enantiomer of about 3. The absolute bioavailability of tolvaptan is unknown. At least 40% of the dose is absorbed as tolvaptan or metabolites. Food does not impact the bioavailability of tolvaptan.', 'Fecal- very little renal elimination (<1% is excreted unchanged in the urine)', 'Healthy subjects: 3L/kg; slightly higher in heart failure patients.', '4 mL/min/kg (post-oral dosing).']",['Metabolism exclusively by CYP3A4 enzyme in the liver. Metabolites are inactive.'],"['Terminal half life, oral dose = 12 hours.']"
3894,443895,CID 443895,C=CC[N@@+]12CC[C@@]34[C@@H]1C[C@@H](C(=CCO)C2)C5=CN6C7C(=CN(C53)C8=CC=CC=C48)[C@H]9C[C@H]1[C@@]7(CC[N@+]1(CC9=CCO)CC=C)C1=CC=CC=C16.[Cl-].[Cl-],,,,,,
3895,443896,CID 443896,C1=C[C@@H]([C@@H](C(=C1)C=CC(=O)O)O)O,,,,,,
3896,443897,CID 443897,C(=CC(=O)C=CC(=O)O)C=C(C(=O)O)O,,,,,,
3897,443898,CID 443898,COC1=CC=C(C=C1)C2=COC3=CC(=CC(=O)C3=C2O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)COC(=O)CC(=O)O)O)O)O,,,,,,
3898,443899,CID 443899,C1=CC(=CC=C1C2=C(C(=C3C(=CC(=O)C=C3O2)O)O)O[C@H]4[C@@H]([C@H]([C@H]([C@H](O4)CO)O)O)O)O,,,,,,
3899,443900,CID 443900,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=CC(=O)C4=C(C=C(OC4=C3)C5=CC=C(C=C5)O)O)CO)O)O)O)O)O,,,,,,
3900,443901,Isoswertisin 2''-rhamnoside,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2C3=C(C=C(C4=C3OC(=CC4=O)C5=CC=C(C=C5)O)O)OC)CO)O)O)O)O)O,,,,,,
3901,443902,"2-Hydroxy-2,3-dihydrogenistein",C1=CC(=CC=C1C2C(OC3=CC(=CC(=C3C2=O)O)O)O)O,,,,,,
3902,443903,CID 443903,C1=CC(=C(C=C1C2=CC(=C3C(=CC(=CC3=O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)C(=O)O)O)O)O)O2)O)O)O,,,,,,
3903,443904,CID 443904,COC1=CC(=CC(=C1O)O)C2=C(C(=C3C(=CC(=O)C=C3O2)O)O)O,,,,,,
3904,443905,CID 443905,C1=CC(=CC=C1C2=C(C(=C3C(=CC(=O)C=C3O2)O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)O,,,,,,
3905,443906,CID 443906,C1=CC(=CC=C1C=CC(=O)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)O[C@@H]3[C@H]([C@@H]([C@H](O[C@H]3O[C@@H]4[C@H]([C@@H]([C@H](O[C@H]4OC5=C(OC6=CC(=O)C=C(C6=C5O)O)C7=CC=C(C=C7)O)CO)O)O)CO)O)O)O)O)O)O,,,,,,
3906,443907,CID 443907,C1[C@@H]([C@H]([C@@H]([C@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C(OC4=CC(=O)C=C(C4=C3O)O)C5=CC(=C(C=C5)O)O)CO)O)O)O)O)O,,,,,,
3907,443908,CID 443908,C1=CC(=C(C=C1C2=C(C(=C3C(=CC(=O)C=C3O2)O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)COC(=O)CC(=O)O)O)O)O)O)O,,,,,,
3908,443909,CID 443909,C1=CC(=CC=C1C2=C(C=C3C(=CC(=CC3=[O+]2)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)COC(=O)C=CC6=CC(=C(C=C6)O)O)O)O)O)O,,,,,,
3909,443910,"[(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[2-(4-hydroxyphenyl)-7-oxo-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-3-yl]oxyoxan-2-yl]methyl 3-(3,4-dihydroxyphenyl)prop-2-enoate",C1=CC(=CC=C1C2=C(C=C3C(=CC(=O)C=C3O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O2)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)COC(=O)C=CC6=CC(=C(C=C6)O)O)O)O)O)O,,,,,,
3910,443911,CID 443911,C1=CC(=CC=C1C2=C(C=C3C(=CC(=CC3=[O+]2)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)COC(=O)CC(=O)O)O)O)O)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)COC(=O)C=CC6=CC(=C(C=C6)O)O)O)O)O)O,,,,,,
3911,443912,"3-[[(2R,3S,4S,5R,6S)-6-[3-[(2S,3R,4S,5S,6R)-6-[3-(3,4-dihydroxyphenyl)prop-2-enoyloxymethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-2-(4-hydroxyphenyl)-7-oxochromen-5-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methoxy]-3-oxopropanoic acid",C1=CC(=CC=C1C2=C(C=C3C(=CC(=O)C=C3O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)COC(=O)CC(=O)O)O)O)O)O2)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)COC(=O)C=CC6=CC(=C(C=C6)O)O)O)O)O)O,,,,,,
3912,443913,Pelargonidin 3-O-(6-O-malonyl-beta-D-glucoside),C1=CC(=CC=C1C2=[O+]C3=CC(=CC(=C3C=C2O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)COC(=O)CC(=O)O)O)O)O)O)O)O,,,,,,
3913,443914,"3-oxo-3-[[(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[5-hydroxy-2-(4-hydroxyphenyl)-7-oxochromen-3-yl]oxyoxan-2-yl]methoxy]propanoic acid",C1=CC(=CC=C1C2=C(C=C3C(=CC(=O)C=C3O2)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)COC(=O)CC(=O)O)O)O)O)O,,,,,,
3914,443915,Cyanidin 3-O-(6-O-malonyl-beta-D-glucoside),C1=CC(=C(C=C1C2=[O+]C3=CC(=CC(=C3C=C2O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)COC(=O)CC(=O)O)O)O)O)O)O)O)O,,,,,,
3915,443916,"3-[[(2R,3S,4S,5R,6S)-6-[2-(3,4-dihydroxyphenyl)-5-hydroxy-7-oxochromen-3-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methoxy]-3-oxopropanoic acid",C1=CC(=C(C=C1C2=C(C=C3C(=CC(=O)C=C3O2)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)COC(=O)CC(=O)O)O)O)O)O)O,,,,,,
3916,443917,Pelargonidin 3-O-rutinoside,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=CC4=C(C=C(C=C4[O+]=C3C5=CC=C(C=C5)O)O)O)O)O)O)O)O)O,,,,,,
3917,443918,pelargonidin 3-O-rutinoside betaine,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=CC(=O)C=C(C4=C3)O)C5=CC=C(C=C5)O)O)O)O)O)O)O,,,,,,
3918,443919,Pelargonidin 3-O-rutinoside 5-O-beta-D-glucoside,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C([O+]=C4C=C(C=C(C4=C3)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O)C6=CC=C(C=C6)O)O)O)O)O)O)O,,,,,,
3919,443920,CID 443920,C[C@H]1[C@@H]([C@H]([C@H]([C@H](O1)OC[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)OC3=C(OC4=CC(=O)C=C(C4=C3)O[C@@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)CO)O)O)O)C6=CC=C(C=C6)O)O)O)O)O)O)O,,,,,,
3920,443921,Cyanidin 3-O-rutinoside 5-O-beta-D-glucoside,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C([O+]=C4C=C(C=C(C4=C3)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O)C6=CC(=C(C=C6)O)O)O)O)O)O)O)O,,,,,,
3921,443922,CID 443922,C[C@H]1[C@@H]([C@H]([C@H]([C@H](O1)OC[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)OC3=C(OC4=CC(=O)C=C(C4=C3)O[C@@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)CO)O)O)O)C6=CC(=C(C=C6)O)O)O)O)O)O)O)O,,,,,,
3922,443923,CID 443923,C1=CC(=CC=C1C2=C(C=C3C(=CC(=CC3=[O+]2)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)COC(=O)CC(=O)O)O)OC(=O)CC(=O)O)O)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)COC(=O)C=CC6=CC(=C(C=C6)O)O)O)O)O)O,,,,,,
3923,443924,CID 443924,C1=CC(=CC=C1C2=C(C=C3C(=CC(=O)C=C3O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)COC(=O)CC(=O)O)O)OC(=O)CC(=O)O)O)O2)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)COC(=O)C=CC6=CC(=C(C=C6)O)O)O)O)O)O,,,,,,
3924,443925,CID 443925,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@]2(CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)C=CC6=CC(=C(C=C6)O)OC)C)C)C,,,,,,
3925,443926,CID 443926,C[N+]1=CC=CC(=C1)OC(=O)NCCCCCCN(C)C(=O)OC2=C[N+](=CC=C2)C.[Br-].[Br-],,,,,,
3926,443927,CID 443927,C[N+]1=CC=CC(=C1)OC(=O)NCCCCCCN(C)C(=O)OC2=C[N+](=CC=C2)C,,,,,,
3927,443928,Paramethasone acetate,C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@H]3[C@H](C[C@@]2([C@]1(C(=O)COC(=O)C)O)C)O)C)F,,,,,,
3928,443929,CID 443929,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)COC(=O)CCC(=O)[O-])O)CCC4=CC(=O)C=C[C@]34C)O.[Na+],,,,,,
3929,443930,CID 443930,C[C@]12CC(C3[C@H]([C@@H]1CC[C@@]2(C(=O)COC(=O)CCC(=O)O)O)CCC4=CC(=O)C=C[C@]34C)O,,,,,,
3930,443931,CID 443931,C1=CC(=C(C=C1C2=C(C(=C3C(=CC(=O)C=C3O2)O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)O)O,,,,,,
3931,443932,"3-[(3S,5R,8R,9R,10S,12R,13S,14S,17R)-12,14-dihydroxy-3-[(2R,4S,5S,6R)-4-hydroxy-5-[(2S,4S,5S,6R)-4-hydroxy-5-[(2S,4S,5S,6R)-4-hydroxy-6-methyl-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one",C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@H]3C[C@H]([C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C)O)O[C@H]7C[C@@H]([C@@H]([C@H](O7)C)O[C@H]8C[C@@H]([C@@H]([C@H](O8)C)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O)O,,,,,,
3932,443933,Siccanin (TN),CC1=CC(=C2[C@H]3C4C(CCC5C4(CCCC5(C)C)CO3)(OC2=C1)C)O,,,,,,
3933,443934,CID 443934,CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CC#N)SC1)C(=O)[O-].[Na+],,,,,,
3934,443935,Epitiostanol,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CC[C@@H]4[C@@]3(C[C@@H]5[C@H](C4)S5)C,,,,,,
3935,443936,Difluprednate,CCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2C[C@@H](C4=CC(=O)C=C[C@@]43C)F)F)O)C)C(=O)COC(=O)C,['For the treatment of inflammation and pain associated with ocular surgery.'],['Difluprednate is a corticosteroid used as an anti-inflammatory steroidal drug used primarily in ocular surgery.'],"['A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. (See all compounds classified as Glucocorticoids.)']","['Difluprednate penetrates the corneal epithelium rapidly and effectively. Low systemic absorption.', '78.5% of radioactivity was excreted aftert 24 hours, and 99.5% by 7 days after a single dose of labeled difluprednate instilled in the right eyes of pigmented rabbits.']","['Difluprednate is rapidly deacetylated in the aqueous humor to difluoroprednisolone butyrate (DFB), the drug’s active metabolite. Endogenous tissue esterases then metabolize DFB to the inert metabolite hydroxyfluoroprednisolone butyrate (HFB), which limits systemic exposure to the active compound.']",
3936,443937,"1-Azabicyclo[2.2.2]octan-3-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate;butanedioic acid",C1CN2CCC1C(C2)OC(=O)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5.C(CC(=O)O)C(=O)O,,,,,,
3937,443938,"1-azabicyclo[2.2.2]octan-3-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate",C1CN2CCC1C(C2)OC(=O)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5,,,,,,
3938,443939,Doxorubicin Hydrochloride,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,"['Myocet liposomal, in combination with cyclophosphamide, is indicated for the first-line treatment of metastatic breast cancer in adult women.']",,"['Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. (See all compounds classified as Antibiotics, Antineoplastic.)', 'Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)']",,,
3939,443940,"(2R,3S)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid",C1=CC(=C(C=C1[C@@H]([C@H](C(=O)O)N)O)O)O,,,,,,
3940,443941,CID 443941,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)C(=O)OC4=CC5=C(CCC5)C=C4)C(=O)[O-])C.[Na+],,,,,,
3941,443942,Dimefline hydrochloride,CC1=C(OC2=C(C1=O)C=CC(=C2CN(C)C)OC)C3=CC=CC=C3.Cl,,,,,,
3942,443943,Halcinonide,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@]2([C@H](C[C@]4([C@H]3C[C@@H]5[C@]4(OC(O5)(C)C)C(=O)CCl)C)O)F,['Indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.'],,['Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)'],,,
3943,443944,Metrizamide,CC(=O)NC1=C(C(=C(C(=C1I)C(=O)N[C@@H]2[C@H]([C@@H]([C@H](OC2O)CO)O)O)I)N(C)C(=O)C)I,,,['Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)'],,,
3944,443945,Dibenzepin hydrochloride,CN1C2=CC=CC=C2C(=O)N(C3=CC=CC=C31)CCN(C)C.Cl,,,"['Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However, the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system. (See all compounds classified as Antidepressive Agents, Tricyclic.)']",,,
3945,443946,Metildigoxin,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)OC,,,"['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)']",,,
3946,443947,Oxendolone,CC[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]2([C@H]1O)C,,,,,,
3947,443948,"[(4R,5S,6S,7R,9R,10R,16R)-6-[(2S,3R,4R,5S,6R)-4-(dimethylamino)-3-hydroxy-5-[(2S,4R,5S,6S)-4-hydroxy-4,6-dimethyl-5-propanoyloxyoxan-2-yl]oxy-6-methyloxan-2-yl]oxy-10-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-4-yl] propanoate",CCC(=O)O[C@@H]1CC(=O)O[C@@H](CC=CC=C[C@@H]([C@@H](C[C@@H]([C@@H]([C@H]1OC)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)OC(=O)CC)(C)O)N(C)C)O)CC=O)C)O)C,,,,,,
3948,443949,Tiaramide hydrochloride,C1CN(CCN1CCO)C(=O)CN2C3=C(C=CC(=C3)Cl)SC2=O.Cl,,,"['Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)', 'Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)']",,,
3949,443950,Tramazoline hydrochloride,C1CCC2=C(C1)C=CC=C2NC3=NCCN3.Cl,,,['Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)'],,,
3950,443951,Terguride,CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)C,,,['Drugs that bind to and activate dopamine receptors. (See all compounds classified as Dopamine Agonists.)'],,,
3951,443952,CID 443952,COCCOC1=CN=C(N=C1)[N-]S(=O)(=O)C2=CC=CC=C2.[Na+],,,,,,
3952,443953,Erythromycin ethylsuccinate,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)CCC(=O)OCC)(C)O)C)C)O)(C)O,,,"['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)', 'Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. (See all compounds classified as Gastrointestinal Agents.)']","['ERYTHROMYCIN ETHYLSUCCINATE IS PARTIALLY DISSOCIATED IN INTESTINE; BOTH ERYTHROMYCIN & UNDISSOCIATED ESTER ARE ABSORBED &, IN THE BLOOD, THE ESTER IS HYDROLYZED TO RELEASE FREE ERYTHROMYCIN.', 'ERYTHROMYCIN ETHYLSUCCINATE...IS ADEQUATELY ABSORBED FOLLOWING ORAL ADMINISTRATION, PARTICULARLY WHEN THE STOMACH IS EMPTY. PEAK CONCENTRATIONS IN PLASMA ARE 1.5 UG/ML (0.5 UG/ML OF BASE) 1 TO 2 HR AFTER ADMINISTRATION OF A 500 MG TABLET.', 'IN PATIENTS, MEAN BILE LEVELS OF ERYTHROMYCIN WERE APPROXIMATELY 10 TIMES HIGHER THAN CORRESPONDING SERUM CONCN 1 HR AFTER IV (ERYTHROMYCIN LACTOBIONATE) & IM (ERYTHROMYCIN SUCCINATE) INJECTION.', 'IN HEALTHY ADULT SUBJECTS & IN ADULT PATIENTS WITH BRONCHIAL INFECTIONS, PHARMACOKINETICS OF VARIOUS FORMULATIONS OF ERYTHROMYCIN WERE STUDIED. ERYTHROMYCIN ETHYLSUCCINATE WAS BETTER THAN ERYTHROMYCIN STEARATE FOR ORAL TREATMENT IN THAT IT WAS RAPIDLY & CONSISTENTLY ABSORBED.']",,
3953,443954,CID 443954,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H](C2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)C)O,,,,,,
3954,443955,Vinpocetine,CC[C@@]12CCCN3[C@@H]1C4=C(CC3)C5=CC=CC=C5N4C(=C2)C(=O)OCC,,,"['Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases. (See all compounds classified as Phosphodiesterase Inhibitors.)', 'Drugs used to specifically facilitate learning or memory, particularly to prevent the cognitive deficits associated with dementias. These drugs act by a variety of mechanisms. (See all compounds classified as Nootropic Agents.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)', 'Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids. (See all compounds classified as Neuroprotective Agents.)']",,,
3955,443956,Formoterol hemifumarate,CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O.CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O.C(=CC(=O)O)C(=O)O,,,"['Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)', 'Compounds bind to and activate ADRENERGIC BETA-2 RECEPTORS. (See all compounds classified as Adrenergic beta-2 Receptor Agonists.)']",,,
3956,443957,"5-[(3S,8R,9S,10R,13R,14S,17R)-14-hydroxy-10,13-dimethyl-3-[(3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-1,2,3,6,7,8,9,11,12,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]pyran-2-one",C[C@H]1[C@@H]([C@H]([C@H](C(O1)O[C@H]2CC[C@@]3([C@H]4CC[C@@]5([C@H](CC[C@@]5([C@@H]4CCC3=C2)O)C6=COC(=O)C=C6)C)C)O)O)O,,,,,,
3957,443958,Amcinonide,CC(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@]4([C@H]3CCC5=CC(=O)C=C[C@@]54C)F)O)C)OC6(O2)CCCC6,['For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.'],"['Amcinonide is a topical corticosteroid. The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. Amcinonide reduces or inhibits the actions of chemicals in the body that cause inflammation, redness, and swelling. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. When in an ointment form, amcinonide also helps the skin maintain moisture.']","['A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. (See all compounds classified as Glucocorticoids.)']","['Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption.', 'Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys.  Some of the topical corticosteroids and their metabolites are also excreted into the bile.']","['Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys.']",
3958,443959,"(1S,2R)-3,4,6-trichlorocyclohexa-3,5-diene-1,2-diol",C1=C([C@H]([C@H](C(=C1Cl)Cl)O)O)Cl,,,,,,
3959,443960,"2,3,5-Trichlorohexa-2,4-dienedioic acid",C(=C(C(=O)O)Cl)C(=C(C(=O)O)Cl)Cl,,,,,,
3960,443961,CID 443961,C1=C(C(=O)OC1=C(C(=O)O)Cl)Cl,,,,,,
3961,443962,CID 443962,C(=C(C(=O)O)Cl)C(=O)C(C(=O)O)Cl,,,,,,
3962,443963,2-Chloro-3-oxohexanedioic acid,C(CC(=O)O)C(=O)C(C(=O)O)Cl,,,,,,
3963,443964,"(1R,2R)-3-chlorocyclohexa-3,5-diene-1,2-diol",C1=C[C@H]([C@H](C(=C1)Cl)O)O,,,,,,
3964,443965,Piperazine phosphate hydrate,C1CNCCN1.O.OP(=O)(O)O,,,,,,
3965,443966,"(6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(6,7-dihydro-5H-cyclopenta[b]pyridin-1-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate;sulfuric acid",CON=C(C1=CSC(=N1)N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CC=CC5=C4CCC5)C(=O)[O-].OS(=O)(=O)O,,,,,,
3966,443967,Betamethasone acetate,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)C)O)C)O)F)C,,,"['Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)', 'A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. (See all compounds classified as Glucocorticoids.)']",,,
3967,443968,Tocopherol calcium succinate,CC1=C(C(=C(C2=C1O[C@](CC2)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C)OC(=O)CCC(=O)[O-])C.CC1=C(C(=C(C2=C1O[C@](CC2)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C)OC(=O)CCC(=O)[O-])C.[Ca+2],,,"['Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)', 'Organic substances that are required in small amounts for maintenance and growth, but which cannot be manufactured by the human body. (See all compounds classified as Vitamins.)']",,,
3968,443969,"[(1R)-1,2-Diphenylethyl]-dimethylazanium;chloride",C[NH+](C)[C@H](CC1=CC=CC=C1)C2=CC=CC=C2.[Cl-],,,,,,
3969,443970,Lefetamine,CN(C)[C@H](CC1=CC=CC=C1)C2=CC=CC=C2,,,,,,
3970,443971,Aminohippurate sodium,C1=CC(=CC=C1C(=O)NCC(=O)[O-])N.[Na+],,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']",,,
3971,443972,Deprodone propionate,CCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)C(=O)C,,,,,,
3972,443973,CID 443973,CC(C(C1=CC=C(C=C1)O)O)[NH+]2CCC(CC2)CC3=CC=CC=C3.[C@@H]([C@H](C(=O)[O-])O)(C(=O)O)O,,,,,,
3973,443974,But-2-enedioic acid;10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
3974,443975,CID 443975,CCCC[N+]1([C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@@H](CO)C4=CC=CC=C4)C.[Br-],,,,,,
3975,443976,"[(1S,2S,4R,5S)-9-butyl-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] (2R)-3-hydroxy-2-phenylpropanoate",CCCC[N+]1([C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@@H](CO)C4=CC=CC=C4)C,,,,,,
3976,443977,Cycotiamine hydrochloride,CC1=NC=C(C(=N1)N)CN(C=O)C(=C2CCOC(=O)S2)C.Cl,,,,,,
3977,443978,CID 443978,CCC[C@H](C=C(C)C=CC=CC(=O)N1CCCC1=O)O,,,,,,
3978,443979,Anabiol,CCC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@]4([C@H]([C@@H]3CCC2=C1)CC[C@@H]4OC(=O)CC)C,,,,,,
3979,443980,Flumethasone pivalate,C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)C(C)(C)C)O)C)O)F)C)F,,,"['A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. (See all compounds classified as Glucocorticoids.)']",,,
3980,443981,"(1R,3S)-5-[2-[(1R,3aS,7aR)-1-[(2R,5S)-5-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol",C[C@H](CC[C@@H](C(C)C)O)[C@H]1CC[C@@H]2[C@@]1(CCCC2=CC=C3C[C@H](C[C@@H](C3=C)O)O)C,,,,,,
3981,443982,CID 443982,CO[C@@]1([C@@H]2N(C1=O)C(=C(CO2)CSC3=NN=NN3CCO)C(=O)[O-])NC(=O)CSC(F)F.[Na+],,,,,,
3982,443983,Noleptan,CN(CC1=C(C=CC=C1Cl)NC(=O)C2=CC=CC=C2)CC(=O)[NH+]3CCOCC3.[Cl-],,,"['Agents that suppress cough. They act centrally on the medullary cough center. EXPECTORANTS, also used in the treatment of cough, act locally. (See all compounds classified as Antitussive Agents.)']",,,
3983,443984,Sulbenicillin sodium,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)S(=O)(=O)[O-])C(=O)[O-])C.[Na+].[Na+],,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
3984,443985,CID 443985,CCCCOC1=CC=C(C=C1)C[N+]2([C@@H]3CC[C@@H]2CC(C3)OC(=O)[C@@H](CO)C4=CC=CC=C4)C.[Br-],,,,,,
3985,443986,CID 443986,CCCCOC1=CC=C(C=C1)C[N+]2([C@@H]3CC[C@@H]2CC(C3)OC(=O)[C@@H](CO)C4=CC=CC=C4)C,,,,,,
3986,443987,Disodium bis[mu-tartrato(4-)]diantimonate(2-),C12C3C(=O)O[Sb-]4(O3)OC(C5C(=O)O[Sb-](O1)(O5)OC2=O)C(=O)O4.[Na+].[Na+],,,,,,
3987,443988,"(1R,9S,10S)-4,17-dimethyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene;phosphoric acid",CC1=CC2=C(C[C@H]3[C@@H]4[C@@]2(CCCC4)CCN3C)C=C1.OP(=O)(O)O,,,,,,
3988,443989,CID 443989,CC1=CC2=C(CC3C4[C@@]2(CCCC4)CCN3C)C=C1,,,,,,
3989,443990,"(1R,3S)-5-[2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylenecyclohexane-1,3-diol",C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CCCC2=CC=C3C[C@H](C[C@@H](C3=C)O)O)C,,,['Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)'],,,
3990,443991,"(6R,7R)-7-[(2-amino-2-cyclohexa-2,5-dien-1-ylacetyl)amino]-3-methoxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",COC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)C(C3C=CCC=C3)N)SC1)C(=O)O,,,,,,
3991,443992,N2-Acetyl-L-aminoadipate,CC(=O)N[C@@H](CCCC(=O)O)C(=O)O,,,,,,
3992,443993,N-acetyl-L-2-aminoadipic acid 6-phosphate,CC(=O)N[C@@H](CCCC(=O)OP(=O)(O)O)C(=O)O,,,,,,
3993,443994,N-acetyl-6-oxo-L-norleucine,CC(=O)N[C@@H](CCCC=O)C(=O)O,,,,,,
3994,443995,CID 443995,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H](C)C(=O)N2[C@@H](CN(C2=O)C)C(=O)O.Cl,,,,,,
3995,443996,Ajicef,C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)NC(=O)C4=C(NC=N4)C(=O)O)C(=O)[O-])C[N+]5=CC=C(C=C5)CCS(=O)(=O)[O-].[Na+],,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
3996,443997,Iofetamine hydrochloride I 123,CC(C)NC(C)CC1=CC=C(C=C1)[123I].Cl,,,"['Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161) (See all compounds classified as Radiopharmaceuticals.)']",,,
3997,443998,[(2S)-1-Methoxy-1-oxo-3-sulfanylpropan-2-yl]azanium;chloride,COC(=O)[C@@H](CS)[NH3+].[Cl-],,,,,,
3998,443999,methyl (2S)-2-amino-3-sulfanylpropanoate,COC(=O)[C@@H](CS)N,,,,,,
3999,444000,Estramustine phosphate sodium,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OP(=O)([O-])[O-])CCC4=C3C=CC(=C4)OC(=O)N(CCCl)CCCl.[Na+].[Na+],,,"['Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) (See all compounds classified as Antineoplastic Agents, Hormonal.)', 'A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026) (See all compounds classified as Antineoplastic Agents, Alkylating.)']",,,
4000,444001,CID 444001,C[C@@]1([C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C(N)O)C(=O)[C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)[NH+](C)C)O)O.[Cl-],,,,,,
4001,444002,CID 444002,C[C@H]1CC=CC=C[C@H]([C@@H](C[C@H]([C@H]([C@@H]([C@@H](CC(=O)O1)OC(=O)C)OC)O[C@@H]2[C@@H]([C@@H]([C@H]([C@@H](O2)C)O[C@@H]3C[C@@]([C@@H]([C@@H](O3)C)OC(=O)CC(C)C)(C)O)N(C)C)OC(=O)C)CC=O)C)OC(=O)C,,,,,,
4002,444003,CID 444003,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)[O-])C.O.O.[Na+],,,,,,
4003,444004,CID 444004,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@H]([C@H]([C@H](COP(=O)(O)[O-])O)O)O.O.O.[Na+],,,,,,
4004,444005,Sarpogrelate hydrochloride,CN(C)CC(COC1=CC=CC=C1CCC2=CC(=CC=C2)OC)OC(=O)CCC(=O)O.Cl,,,"['Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. (See all compounds classified as Fibrinolytic Agents.)', 'Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS. (See all compounds classified as Serotonin Antagonists.)', 'Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)']",,,
4005,444006,"2,2-dimethylpropanoyloxymethyl (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[2-(4-methyl-1,3-thiazol-5-yl)ethenyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate",CC1=C(SC=N1)C=CC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)OCOC(=O)C(C)(C)C,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
4006,444007,(3S)-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-3-(1H-indol-3-yl)-2-[3-(2-methylpropoxycarbonylamino)propanoylamino]propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-oxobutanoic acid,CC(C)COC(=O)NCCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N,,,,,,
4007,444008,Tibolone,C[C@@H]1CC2=C(CCC(=O)C2)[C@@H]3[C@@H]1[C@@H]4CC[C@]([C@]4(CC3)C)(C#C)O,['For the relief of post-menopausal symptoms and for the prevention of osteoporosis.'],"['Tibolone prevents bone loss and treating post-menopausal symptoms without stimulating the endometrial tissues, which may lead to malignancy. Typical, drugs that treat post-menopausal symptoms such as estrogen, have a proliferative effect on the endometrium, increasing the risk of endometrial carcinoma. The effects on the bone, brain and vaginal tissues can be explained by the estrogenic activity of tibolone.  It is important to note that activity is not expressed in the endometrium. Tibolone behaves differently from estrogen plus progesterone combinations on the breast. Therefore, tibolone can be characterized as a selective estrogen activity regulator.  Tibolone has been demonstrated to be an effective agent in treating symptoms associated with menopause. A 16 week trial in 1189 women examined the effect of tibolone 2.5 mg once daily on climacteric symptoms. Women treated with tibolone showed improvement from baseline in typical menopausal symptoms including hot flashes, sweating, insomnia, and anxiety.']","['Substances that possess antiestrogenic actions but can also produce estrogenic effects as well. They act as complete or partial agonist or as antagonist. They can be either steroidal or nonsteroidal in structure. (See all compounds classified as Estrogen Receptor Modulators.)', 'Compounds which inhibit or antagonize the biosynthesis or actions of androgens. (See all compounds classified as Androgen Antagonists.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'These compounds stimulate anabolism and inhibit catabolism. They stimulate the development of muscle mass, strength, and power. (See all compounds classified as Anabolic Agents.)', 'Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) (See all compounds classified as Antineoplastic Agents, Hormonal.)']","['Tibolone is extensively and rapidly absorbed after oral administration. The parent drug undergoes extensive metabolism, with. Greater than 80% of a radioactive dose excreted from the body as metabolites, which suggests very low plasma concentrations of tibolone. Plasma concentrations of the metabolites appear within 30 minutes and peak within 1–1.5 hours.2,7 The plasma concentrations of the hydroxymetabolites are higher than those of the ∆4-isomer. Food does not appear to have an effect on the absorption of this drug.', 'Excreted in the urine and feces in the form of sulfated metabolites,.  The predominant route of elimination of tibolone is via the feces, although some excretion occurs via the urine.', 'Elimination of tibolone is not dependent renal function.']","['Tibolone is metabolized mainly in the liver.   The cytochrome P450 isoenzyme system is involved in minor hydroxylation of tibolone.  Tibolone is rapidly converted into three major metabolites: 3 alpha- and 3 beta-hydroxy-tibolone, which have oestrogenic effects, and the Delta(4)-isomer, which has both progestogenic and androgenic effects. The 3-hydroxy metabolites are present in the circulation, predominantly in their inactive sulfated form.']",['The elimination half-life is approximately 45 h.']
4008,444009,CID 444009,[NH+](O)(O)[O-].[N+](=O)(O)[O-].[N+](=O)(O)[O-].[BiH3],,,,,,
4009,444010,CID 444010,N(O)(O)[O-],,,,,,
4010,444011,CID 444011,C[C@H]1CC=CC=C[C@H]([C@@H](C[C@H]([C@H]([C@@H]([C@@H](CC(=O)O1)O)OC)O[C@@H]2[C@@H]([C@@H]([C@H]([C@@H](O2)C)O[C@@H]3C[C@@]([C@@H]([C@@H](O3)C)O)(C)O)N(C)C)O)CC=O)C)O,,,,,,
4011,444012,CID 444012,C1=CC(=C(C=C1N)[O-])C(=O)[O-].C1=CC(=C(C=C1N)[O-])C(=O)[O-].O.[OH-].[Al+3].[Ca+2],,,,,,
4012,444013,Gadoversetamide,COCCNC(=O)CN(CCN(CCN(CC(=O)NCCOC)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Gd+3],"['Gadoversetamide is an MRI contrast agent used for MRI diagnostic procedures to provide increased enhancement and visualization of lesions of the brain, spine and liver, including tumors.']",,['Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)'],"['The mean cumulative urinary excretion of gadoversetamide at 72 hours was approximately 93.5% for renal impaired patients and 95.8% for subjects with normal renal function', '162 ± 25 mL/kg [normal subjects]', '72 +/- 16.3 mL/hr/kg [healthy]', 'Gadoversetamide (0.1 mmol/kg) is eliminated primarily in the urine with 95.5 + or -  17.4% (mean + or - SD) of the administered dose eliminated by 24 hours. Animal data demonstrated that insignificant levels of 153Gd-labeled gadoversetamide are eliminated via the feces. In experimentally induced anephria in the rat, hepatobiliary excretion did not significantly compensate for the absence of urinary elimination. The renal and plasma clearance rates of gadoversetamide in normal subjects are similar (69 + or - 15.4 and 72 + or - 16.3 mL/hr/kg, respectively) indicating that the drug is cleared through the kidneys via glomerular filtration. Within the studied dose range (0.1 to 0.7 mmol/kg), the kinetics of gadoversetamide appear to be linear.', 'The volume of distribution at steady state of gadoversetamide in normal subjects is 162 + or -  25 mL/kg, roughly equivalent to that of extracellular water.', 'Radiolabeled gadoversetamide ((153)Gd) was excreted in the milk of lactating rats receiving a single intravenous dose of 0.1 mmol/kg.', 'Optimark injection does not cross the intact blood brain barrier, and, therefore, does not accumulate in the normal brain or in lesions that may have a normal blood-brain barrier (eg, cysts, mature post-operative scars, etc.). However, disruption of the blood-brain barrier or abnormal vascularity allows accumulation of Optimark injection in the extravascular spaces of lesions such as neoplasms, abscesses, and subacute infarcts. The pharmacokinetic parameters of Optimark injection in various lesions are not known.', 'For more Absorption, Distribution and Excretion (Complete) data for GADOVERSETAMIDE (6 total), please visit the HSDB record page.']","['None detected', 'Gadoversetamide is not metabolized.']","['Distribution 13.3 &plusmn; 6.8 (mean) minutes, elimination 103.6 &plusmn; 19.5 (mean) minutes.', 'The pharmacokinetics of intravenously administered gadoversetamide in normal subjects conforms to a two-compartment open-model with mean distribution and elimination half-lives (reported as mean + or - SD) of about 13.3 + or - 6.8 and 103.6 + or - 19.5 minutes.']"
4013,444014,"[(1R,5R)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;bromide",C[N+]1([C@@H]2CC[C@@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[Br-],,,,,,
4014,444015,"[(1R,5R)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate",C[N+]1([C@@H]2CC[C@@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C,,,,,,
4015,444016,4-{4-[(R)-(4-chlorophenyl)(pyridin-2-yl)methoxy]piperidin-1-yl}butanoic acid benzenesulfonate,C1CN(CCC1O[C@H](C2=CC=C(C=C2)Cl)C3=CC=CC=N3)CCCC(=O)O.C1=CC=C(C=C1)S(=O)(=O)O,,,,,,
4016,444017,4-[4-[(R)-(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid,C1CN(CCC1O[C@H](C2=CC=C(C=C2)Cl)C3=CC=CC=N3)CCCC(=O)O,,,,,,
4017,444018,trialuminum;(2R)-2-acetamido-5-amino-5-oxopentanoate;tetrahydroxide,CC(=O)N[C@H](CCC(=O)N)C(=O)[O-].CC(=O)N[C@H](CCC(=O)N)C(=O)[O-].CC(=O)N[C@H](CCC(=O)N)C(=O)[O-].CC(=O)N[C@H](CCC(=O)N)C(=O)[O-].CC(=O)N[C@H](CCC(=O)N)C(=O)[O-].[OH-].[OH-].[OH-].[OH-].[Al+3].[Al+3].[Al+3],,,,,,
4018,444019,N-Acetyl-D-glutamine,CC(=O)N[C@H](CCC(=O)N)C(=O)O,,,,,,
4019,444020,Voglibose,C1[C@@H]([C@@H]([C@H]([C@@H]([C@]1(CO)O)O)O)O)NC(CO)CO,['For the treatment of diabetes. It is specifically used for lowering post-prandial blood glucose levels thereby reducing the risk of macrovascular complications.'],"['Voglibose, an alpha-glucosidase inhibitor, is a synthetic compound with potent and enduring therapeutic efficacies against disorders of sensory, motor and autonomic nerve systems due to diabetes mellitus. The drug was approved in Japan in 1994 for the treatment of diabetes, and it is under further investigation by Takeda for the treatment of impaired glucose tolerance. Alpha-glucosidase inhibitors are oral anti-diabetic drugs used for diabetes mellitus type 2 that work by preventing the digestion of complex carbohydrates (such as starch). Complex carbohydrates are normally converted into simple sugars (monosaccharides) which can be absorbed through the intestine. Hence, alpha-glucosidase inhibitors reduce the impact of complex carbohydrates on blood sugar.']","['Substances which lower blood glucose levels. (See all compounds classified as Hypoglycemic Agents.)', 'Compounds that inhibit or block the activity of GLYCOSIDE HYDROLASES such as ALPHA-AMYLASES and ALPHA-GLUCOSIDASES. (See all compounds classified as Glycoside Hydrolase Inhibitors.)']",['Slowly and poorly absorbed. The reported pharmacokinetic parameters of voglibose with metformin are Cmax corresponds to 1.38 mcg/ml while AUC is 8.17 mcg.h/ml and tmax is of 2.5 hours.'],['Little metabolism occurs and no metabolites have as yet been identified.'],['The half-life of voglibose is very similar to the one found for metformin and it is reported to be of 4.08 hours.']
4020,444021,Sultamicillin tosylate,CC1=CC=C(C=C1)S(=O)(=O)O.CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)OCOC(=O)[C@H]4C(S(=O)(=O)[C@H]5N4C(=O)C5)(C)C)C,,,,,,
4021,444022,Sultamicillin,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)OCOC(=O)[C@H]4C(S(=O)(=O)[C@H]5N4C(=O)C5)(C)C)C,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
4022,444023,"2,2-dimethylpropanoyloxymethyl (6R,7R)-7-[2-(2-amino-1,3-thiazol-4-yl)pent-2-enoylamino]-3-(carbamoyloxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate;hydrochloride",CCC=C(C1=CSC(=N1)N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)COC(=O)N)C(=O)OCOC(=O)C(C)(C)C.Cl,,,,,,
4023,444024,CID 444024,C1=CC(=CC=C1CN2C=CN=C2)C=CC(=O)[O-].[Na+],,,,,,
4024,444025,Loteprednol etabonate,CCOC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)C(=O)OCCl,['A number of prescription loteprednol etabonate ophthalmic products are specifically indicated for the treatment of post-operative inflammation and pain following ocular surgery.'],"['Loteprednol etabonate (LE) belongs to a unique class of corticosteroids with potent anti-inflammatory effects designed to be active at the site of action. Animal studies have shown that LE has a binding affinity to steroid receptors that is 4.3 times greater than dexamethasone. This particular class of steroids consists of bioactive molecules whose in-vivo transformation to non-toxic substances can be predicted from their chemistry and knowledge of enzymatic pathways in the body. Cortienic acid is an inactive metabolite of hydrocortisone and analogs of cortienic acid are also devoid of corticosteroid activity. Specifically, LE is an ester derivative of one of these analogs, cortienic acid etabonate. In particular, LE possesses a metabolically labile 17 beta-chloromethyl ester function which was designed in order to be hydrolyzed to an inactive carboxylic acid moiety. This inactive metabolite is more hydrophilic and is thus readily eliminated from the body. LE also exhibits good ocular permeation properties and good skin permeation properties.']","['Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)']","['Loteprednol etabonate (LE) demonstrates good ocular permeation properties as it is lipid soluble, allowing the agent to penetrate into cells with relative ease.  Results from the ocular administration of loteprednol in normal, healthy volunteers have shown that there are low or undetectable concentrations of either unchanged material or its metabolite. Following twice-daily unilateral topical ocular dosing of LE for 14 days in healthy subjects, the plasma concentrations of loteprednol etabonate were below the limit of quantitation (1 ng/mL) at all time points. These finds suggest that limited, if any, systemic absorption of LE occurs.', 'Following systemic administration to rats, loteprednol etabonate is eliminated primarily via the biliary/faecal route, with most of the dose eliminated in the form of the metabolite, PJ-90.', 'The only data available regarding the volume of distribution of loteprednol etabonate (LE) is the volume of distribution the agent demonstrated when administered to dogs - a value of 3.7 L/kg. It has been shown, however, that the topical ocular administration of LE distributes preferentially into the cellular components of blood.', 'Loteprednol etabonate was slowly hydrolyzed in liver at clearance rates of  0.21 +/- 0.04 and 2.41 +/- 0.13 ml/h/kg in the liver and plasma, respectively.']","['Loteprednol etabonate (LE) is readily and extensively metabolized to two inactive metabolites, PJ-90 (Δ1-cortienic acid) and PJ-91 (Δ1-cortienic acid etabonate).  Metabolism occurs locally in ocular tissues, and to the extent that loteprednol etabonate reaches the systemic circulation, likely the liver and other tissues into which it distributes.  In particular, studies have demonstrated that LE (chloromethyl 17alpha-ethoxycarbonyloxy-11beta-hydroxy-3-oxoandrosta-1,4-diene) is rapidly hydrolyzed at the location of its 17beta-chloromethyl ester function by paraoxonase 1 in human plasma at the site of administration at the level of the affected eye tissue to the 17beta-carboxylate PJ-91 metabolite and PJ-90 metabolite. Both metabolites are considered inactive.']",['The terminal half-life of loteprednol etabonate as determined when administered intravenously at a dose of 5 mg/kg in the dog animal model is 2.8 hours.']
4025,444026,CID 444026,CC1=C(OC(=O)O1)COC(=O)[C@H]2C(S[C@H]3[NH+]2C(=O)[C@H]3NC(=O)[C@@H](C4=CC=CC=C4)N)(C)C.[Cl-],,,,,,
4026,444027,"(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl (2S,5R,6R)-6-[(2-amino-2-phenylacetyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate",CC1=C(OC(=O)O1)COC(=O)[C@H]2C(S[C@H]3N2C(=O)[C@H]3NC(=O)C(C4=CC=CC=C4)N)(C)C,,,,,,
4027,444028,Colforsin daropate hydrochloride,CC(=O)O[C@H]1[C@H]([C@@H]2[C@]([C@H](CCC2(C)C)O)([C@@]3([C@@]1(O[C@@](CC3=O)(C)C=C)C)O)C)OC(=O)CCN(C)C.Cl,,,"['Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)', 'Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)', 'Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)']",,,
4028,444029,Colforsin daropate,CC(=O)O[C@H]1[C@H]([C@@H]2[C@]([C@H](CCC2(C)C)O)([C@@]3([C@@]1(O[C@@](CC3=O)(C)C=C)C)O)C)OC(=O)CCN(C)C,,,,,,
4029,444030,Darifenacin hydrobromide,C1CN(C[C@@H]1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5.Br,['Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with overactive bladder syndrome.'],,"['Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)', 'Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS. (See all compounds classified as Urological Agents.)']",,,
4030,444031,Darifenacin,C1CN(C[C@@H]1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5,"['For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.']","['Darifenacin is a competitive muscarinic receptor antagonist. <i>In vitro</i> studies using human recombinant muscarinic receptor subtypes show that darifenacin has greater affinity for the M3 receptor than for the other known muscarinic receptors (9 and 12-fold greater affinity for M3 compared to M1 and M5, respectively, and 59-fold greater affinity for M3 compared to both M2 and M4). Muscarinic receptors play an important role in several major cholinergically mediated functions, including contractions of the urinary bladder smooth muscle and stimulation of salivary secretion. Adverse drug effects such as dry mouth, constipation and abnormal vision may be mediated through effects on M3 receptors in these organs.']","['Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)', 'Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS. (See all compounds classified as Urological Agents.)']","['The mean oral bioavailability at steady state is estimated to be 15% and 19% for 7.5 mg and 15 mg tablets, respectively.', '163 L', '40 L/h [extensive metabolizers]']",['Hepatic. Primarily mediated by the cytochrome P450 enzymes CYP2D6 and CYP3A4.'],['The elimination half-life of darifenacin following chronic dosing is approximately 13-19 hours.']
4031,444032,Difeterol hydrochloride,CC(C(C1=CC=CC=C1)O)N(C)CCOC(C2=CC=CC=C2)C3=CC=CC=C3.Cl,,,,,,
4032,444033,"2-[(1S,2S,4R,8S,9S,11S,12S,13R)-6-cyclohexyl-11-hydroxy-9,13-dimethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icosa-14,17-dien-8-yl]-2-oxoethyl 2-methylpropanoate",CC(C)C(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@H]4[C@H]3CCC5=CC(=O)C=C[C@]45C)O)C)OC(O2)C6CCCCC6,,,,,,
4033,444034,Dihydroergocristine mesylate,CC(C)[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O,,,"['Drugs that bind to but do not activate ADRENERGIC RECEPTORS. Adrenergic antagonists block the actions of the endogenous adrenergic transmitters EPINEPHRINE and NOREPINEPHRINE. (See all compounds classified as Adrenergic Antagonists.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)']",,,
4034,444035,Migrenin (TN),CC1=CC(=O)N(N1C)C2=CC=CC=C2.CN1C=NC2=C1C(=O)N(C(=O)N2C)C.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,,,,,,
4035,444036,Fluticasone propionate,CCC(=O)O[C@@]1([C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2C[C@@H](C4=CC(=O)C=C[C@@]43C)F)F)O)C)C)C(=O)SCF,['Fluticasone propionate is indicated as an inhaler for the treatment and management of asthma by prophylaxisas well as inflammatory and pruritic dermatoses. Fluticasone propionate nasal spray is indicated for managing allergic and nonallergic rhinitis.'],"['Systemically, fluticasone propionate activates glucocorticoid receptors, and inhibits lung eosinophilia in rats. Fluticasone propionate as a topical formulation is also associated with vasoconstriction in the skin.']","['Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)', 'Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)', 'Drugs used to treat or prevent skin disorders or for the routine care of skin. (See all compounds classified as Dermatologic Agents.)', 'Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)']","['Intranasal bioavailability of fluticasone propionate is <2%, and oral bioavailability is <1%. Intranasal exposure results in the majority of the dose being swallowed. Topical absorption of fluticasone propionate is very low but can change depending on a number of factors including integrity of the skin and the presence of inflammation or disease. A study of 24 healthy Caucasian males showed an inhaled bioavailability of 9.0%.', 'Fluticasone propionate is mainly eliminated in the feces with <5% eliminated in the urine.', 'The volume of distribution of intravenous fluticasone propionate is 4.2L/kg. A study of 24 healthy Caucasian males showed a volume of distribution at steady state of 577L following intravenous administration.', '1093mL/min for fluticasone propionate. A study of 24 healthy Caucasian males showed a clearance of 63.9L/h following intravenous administration.']","['Fluticasone propionate is cleared from hepatic metabolism by cytochrome P450 3A4. Fluticasone propionate is hydrolysed at the FIVE-S-fluoromethyl carbothioate group, forming an inactive metabolite.']",['7.8 hours for intravenous fluticasone propionate. A study of 24 healthy Caucasian males shows a half life of 14.0 hours following intravenous administration and 10.8 hours following inhalation.']
4036,444037,Roxithromycin,CC[C@@H]1[C@@]([C@@H]([C@H](C(=NOCOCCOC)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
4037,444038,"(5R)-5-(3-ethoxy-4-pentoxyphenyl)-1,3-thiazolidine-2,4-dione",CCCCCOC1=C(C=C(C=C1)[C@@H]2C(=O)NC(=O)S2)OCC,,,,,,
4038,444039,1-[4-Cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenylpiperidine-4-carboxylic acid monohydrochloride,CC1CN(CCC1(C2=CC=CC=C2)C(=O)O)C3CCC(CC3)(C#N)C4=CC=C(C=C4)F.Cl,,,,,,
4039,444040,Benexate hydrochloride,C1CC(CCC1CN=C(N)N)C(=O)OC2=CC=CC=C2C(=O)OCC3=CC=CC=C3.Cl,,,,,,
4040,444041,beta-CYCLODEXTRIN,C([C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5O)O)O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6O)O)O[C@@H]7[C@H](O[C@@H]([C@@H]([C@H]7O)O)O[C@@H]8[C@H](O[C@H](O2)[C@@H]([C@H]8O)O)CO)CO)CO)CO)CO)CO)O)O)O,,,"['Substances used in the processing or storage of foods or animal feed including ANTIOXIDANTS; FOOD PRESERVATIVES; FOOD COLORING AGENTS; FLAVORING AGENTS; ANTI-INFECTIVE AGENTS; EXCIPIENTS and other similarly used substances. Many of the same substances are used as PHARMACEUTIC AIDS. (See all compounds classified as Food Additives.)', 'Compounds that bind to and reduce the biological availability of a chemical or pharmaceutical agent. (See all compounds classified as Sequestering Agents.)']",,,
4041,444042,CID 444042,CCCCCCCCCCCCCCCCCC(=O)NCCCC[C@H](C(=O)O)NC(=O)CC[C@H](C(=O)N)NC(=O)[C@@H](C)NC(=O)[C@@H](C)O[C@@H]1[C@H]([C@@H](O[C@@H]([C@H]1O)CO)O)NC(=O)C,,,,,,
4042,444043,Magnesium;trihydroxide,[OH-].[OH-].[OH-].[Mg+2],,,,,,
4043,444044,"3-[18-(2-Carboxyethyl)-7,12-diethyl-3,8,13,17-tetramethylporphyrin-21,23-diid-2-yl]propanoic acid;iron(2+)",CCC1=C(C2=CC3=NC(=CC4=C(C(=C([N-]4)C=C5C(=C(C(=N5)C=C1[N-]2)C)CC)C)CCC(=O)O)C(=C3C)CCC(=O)O)C.[Fe+2],,,,,,
4044,444045,dThd-P-dCyd-P-dCyd,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)OP(=O)(O)OC[C@@H]3[C@H](C[C@@H](O3)N4C=CC(=NC4=O)N)OP(=O)(O)OC[C@@H]5[C@H](C[C@@H](O5)N6C=CC(=NC6=O)N)O,,,,,,
4045,444046,"[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-(hydroxymethyl)oxolan-3-yl] [(2R,3S,5R)-5-(6-amino-2-oxo-1H-pyrimidin-3-ium-3-yl)-3-[hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl]oxyoxolan-2-yl]methyl hydrogen phosphate",CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=O)(O)O[C@H]4C[C@@H](O[C@@H]4CO)N5C=C(C(=NC5=O)N)C)[N+]6=CC=C(NC6=O)N)O,,,,,,
4046,444047,"[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-(hydroxymethyl)oxolan-3-yl] [(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3-[hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl]oxyoxolan-2-yl]methyl hydrogen phosphate",CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=O)(O)O[C@H]4C[C@@H](O[C@@H]4CO)N5C=C(C(=NC5=O)N)C)N6C=CC(=NC6=O)N)O,,,,,,
4047,444048,CID 444048,C[C@@]1(C(C2=C3[C@@H](CN(C3=CC(=C2N1)O)C(=O)C4=CC5=CC(=C(C(=C5N4)OC)OC)OC)CN)O)C(=O)OC,,,,,,
4048,444049,CID 444049,C[N+]1=C(SC2=CC=CC=C21)CC3=CC=[N+](C4=CC=CC=C34)CCC[N+](C)(C)CCC[N+](C)(C)CCC[N+]5=CC=C(C6=CC=CC=C65)CC7=[N+](C8=CC=CC=C8S7)C,,,,,,
4049,444050,Magnesium;tetrahydroxide;dihydrate,O.O.[OH-].[OH-].[OH-].[OH-].[Mg+2],,,,,,
4050,444051,L-Gamma-Glutamyl-S-Benzyl-N-[(S)-Carboxy(Phenyl)methyl]-L-Cysteinamide,C1=CC=C(C=C1)CSC[C@@H](C(=O)N[C@H](C2=CC=CC=C2)C(=O)O)NC(=O)CC[C@@H](C(=O)O)N,,,,,,
4051,444052,"(8S)-8-Acetyl-10alpha-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-1-methoxynaphthacene-5,6,8alpha,11,12-pentol",C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C(C4=C(C5=C(C(=CC=C5)OC)C(=C4C(=C23)O)O)O)O)(C(=O)C)O)N)O,,,,,,
4052,444053,Uridylyl-2'-5'-phospho-adenosine,C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O,,,,,,
4053,444054,CID 444054,C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O[C@@H]4[C@@H]([C@H](O[C@H]4N)CO)O)O)O)NC(=NC2=O)N,,,,,,
4054,444055,"2-[2,3-dichloro-4-[(2S)-2-(sulfanylmethyl)butanoyl]phenoxy]acetic acid",CC[C@H](CS)C(=O)C1=C(C(=C(C=C1)OCC(=O)O)Cl)Cl,,,,,,
4055,444056,4-[6-[6-(4-methylpyrazin-1-yl)-1H-benzimidazol-2-yl]-1H-benzimidazol-2-yl]phenol,CN1C=CN(C=C1)C2=CC3=C(C=C2)N=C(N3)C4=CC5=C(C=C4)N=C(N5)C6=CC=C(C=C6)O,,,,,,
4056,444057,L-Gamma-Glutamyl-S-Nonyl-L-Cysteinylglycine,CCCCCCCCCSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N,,,,,,
4057,444058,"2-(4-ethoxyphenyl)-6-[6-(4-methyl-2,3-dihydropyrazin-1-yl)-1H-benzimidazol-2-yl]-1H-benzimidazole",CCOC1=CC=C(C=C1)C2=NC3=C(N2)C=C(C=C3)C4=NC5=C(N4)C=C(C=C5)N6CCN(C=C6)C,,,,,,
4058,444059,Methylamine monomethylamine,CN.CN,,,,,,
4059,444060,2-Hydroxy-5-[2-[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinyl]benzoic acid,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)NNC3=CC(=C(C=C3)O)C(=O)O,,,,,,
4060,444061,"2,6-Dideoxy-beta-D-glucose",C[C@@H]1[C@H]([C@@H](C[C@@H](O1)O)O)O,,,,,,
4061,444062,"(1S,3S,4R)-3,4-dihydroxy-1-methoxy-1-[(2R,3S)-3,4,5,7,10-pentahydroxy-6-methyl-1,2,3,4-tetrahydroanthracen-2-yl]pentan-2-one",CC1=C(C2=C(C3=C(C[C@H]([C@@H](C3O)O)[C@@H](C(=O)[C@H]([C@@H](C)O)O)OC)C=C2C=C1O)O)O,,,,,,
4062,444063,"2,6-Dideoxy-beta-D-galactose",C[C@@H]1[C@@H]([C@@H](C[C@@H](O1)O)O)O,,,,,,
4063,444064,"2,6-Dideoxy-3 C-Methyl-D-Ribopyranoside",C[C@@H]1[C@H]([C@@](C[C@@H](O1)O)(C)O)O,,,,,,
4064,444065,CID 444065,C[C@H](C(=O)N[C@H](CCC(=O)N[C@@H](CCC[C@H](C(=O)O)N)C(=O)N[C@@H](C)C(=O)O)C(=O)O)NC(=O)[C@@H](C)O[C@@H]1[C@H]([C@H](O[C@@H]([C@H]1O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)NC(=O)C)CO)O)NC(=O)C,,,,,,
4065,444066,"(Z)-1,2-Ethenediamine",C(=C\N)\N,,,,,,
4066,444067,Magnesium;hexahydroxide,[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2],,,,,,
4067,444068,"(2S,4S)-4-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2-(1,2-dihydroxyethyl)-7-methoxy-3,4-dihydro-1H-tetracene-2,5,6,11,12-pentol",C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C(C4=C(C5=C(C(=CC=C5)OC)C(=C4C(=C23)O)O)O)O)(C(CO)O)O)N)O,,,,,,
4068,444069,"(2S,4S)-4-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2-(1-hydroxyethyl)-7-methoxy-3,4-dihydro-1H-tetracene-2,5,6,11,12-pentol",C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C(C4=C(C5=C(C(=CC=C5)OC)C(=C4C(=C23)O)O)O)O)(C(C)O)O)N)O,,,,,,
4069,444070,CID 444070,C1[C@@H]([C@H](O[C@H]1N2C=NC3=C2NC(=NC3=O)N)COP(=O)(O)O[C@H]4C[C@@H](O[C@@H]4COP(=O)(O)O[C@H]5C[C@@H](O[C@@H]5COP(=O)(O)O[C@H]6C[C@@H](O[C@@H]6CO)N7C=CC(=NC7=O)N)N8C=NC9=C8NC(=NC9=O)N)N1C=CC(=NC1=O)N)O,,,,,,
4070,444071,CID 444071,CC1=C(C2=CC3=NC(=CC4=C(C(=C([N-]4)C=C5C(=C(C(=N5)C=C1[N-]2)C)[C@H](C)S)C)[C@H](CS)S)C(=C3CCC(=O)O)C)CCC(=O)O.[Fe+2],,,,,,
4071,444072,CID 444072,CC1=C(C2=CC3=NC(=CC4=NC(=CC5=C(C(=C(N5)C=C1N2)[C@H](C)S)C)C(=C4CCC(=O)O)C)C(=C3C)CCC(=O)O)[C@H](CS)S,,,,,,
4072,444073,Heptaaquacalcium(2+),O.O.O.O.O.O.O.[Ca+2],,,,,,
4073,444074,Azanide;rhodium,[NH2-].[NH2-].[NH2-].[NH2-].[NH2-].[NH2-].[Rh],,,,,,
4074,444075,"1,5-Di(4-Amidinophenoxy)-3-Oxa-Pentane",C1=CC(=CC=C1C(=N)N)OCCOCCOC2=CC=C(C=C2)C(=N)N,,,,,,
4075,444076,"1,1,5,5-Tetrafluorophosphopentylphosphonic acid adenylate ester",C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(C(CCCC(F)(F)P(=O)(O)O)(F)F)O)O)O)N,,,,,,
4076,444077,"2,6-Diamino-3,5-dihydroxy-4-methylbenzamide",CC1=C(C(=C(C(=C1O)N)C(=O)N)N)O,,,,,,
4077,444078,Threoninamide,C[C@H]([C@@H](C(=O)N)N)O,,,,,,
4078,444079,(2R)-2-amino-3-methylbutanamide,CC(C)[C@H](C(=O)N)N,,,,,,
4079,444080,N-Methyl-L-valine,CC(C)[C@@H](C(=O)O)NC,,,,,,
4080,444081,CID 444081,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)OP(=O)(O)OC[C@@H]3[C@H](C[C@@H](O3)[N+]4=CC=C(NC4=O)N)OP(=O)(O)OC[C@@H]5[C@H](C[C@@H](O5)N6C=NC7=C6NC(=NC7=O)N)OP(=O)(O)OC[C@@H]8[C@H](C[C@@H](O8)N9C=NC1=C(N=CN=C19)N)O,,,,,,
4081,444082,CID 444082,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)OP(=O)(O)OC[C@@H]3[C@H](C[C@@H](O3)N4C=CC(=NC4=O)N)OP(=O)(O)OC[C@@H]5[C@H](C[C@@H](O5)N6C=NC7=C6NC(=NC7=O)N)OP(=O)(O)OC[C@@H]8[C@H](C[C@@H](O8)N9C=NC1=C(N=CN=C19)N)O,,,,,,
4082,444083,"methyl (1R,10S,12S,13R,21R,22S,23R,24R)-23-(dimethylamino)-4,6,8,12,17,22,24-heptahydroxy-1,12-dimethyl-10-[(2R,3R,4R,5S,6S)-3,4,5-trimethoxy-4,6-dimethyloxan-2-yl]oxy-20,25-dioxahexacyclo[19.3.1.02,19.05,18.07,16.09,14]pentacosa-2(19),3,5,7,9(14),15,17-heptaene-13-carboxylate",C[C@H]1[C@@H]([C@@]([C@H]([C@@H](O1)O[C@H]2C[C@]([C@@H](C3=C2C(=C4C(=C3)C(=C5C(=C4O)C(=CC6=C5O[C@H]7[C@H]([C@@H]([C@H]([C@@]6(O7)C)O)N(C)C)O)O)O)O)C(=O)OC)(C)O)OC)(C)OC)OC,,,,,,
4083,444084,2H-indene,C1C=C2C=CC=CC2=C1,,,,,,
4084,444085,Unk-D-Ser-Ala-Cys-Val-OH,C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@@H](CO)NC(=O)C1=NC2=CC=CC=C2N=C1,,,,,,
4085,444086,dCyd-P-dCyd-P-dCyd-P-dCyd,C1[C@@H]([C@H](O[C@H]1N2C=CC(=NC2=O)N)COP(=O)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=O)(O)O[C@H]4C[C@@H](O[C@@H]4COP(=O)(O)O[C@H]5C[C@@H](O[C@@H]5CO)N6C=CC(=NC6=O)N)N7C=CC(=NC7=O)N)N8C=CC(=NC8=O)N)O,,,,,,
4086,444087,3'-O-[3'-O-[3'-O-(5'-Thymidylyl)-2'-deoxy-5'-cytidylyl]-2'-deoxy-5'-cytidylyl]-2'-deoxycytidine,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=O)(O)O[C@H]4C[C@@H](O[C@@H]4COP(=O)(O)O[C@H]5C[C@@H](O[C@@H]5CO)N6C=CC(=NC6=O)N)N7C=CC(=NC7=O)N)N8C=CC(=NC8=O)N)O,,,,,,
4087,444088,"(1S,2S)-1-[[(2R)-2-[[(2S)-2-[[(2R)-3-hydroxy-2-[(3-hydroxyquinoline-2-carbonyl)amino]propanoyl]amino]propanoyl]amino]-3,3-bis(sulfanyl)propanoyl]-methylamino]-2-methylcyclopropane-1-carboxylic acid",C[C@H]1C[C@]1(C(=O)O)N(C)C(=O)[C@H](C(S)S)NC(=O)[C@H](C)NC(=O)[C@@H](CO)NC(=O)C2=NC3=CC=CC=C3C=C2O,,,,,,
4088,444089,CID 444089,C[C@H]1C[C@]1(C(=O)O)N(C)C(=O)[C@H](CS)NC(=O)[C@@H](C)NC(=O)[C@@H](CO)NC(=O)C2=NC3=CC=CC=C3C=C2O,,,,,,
4089,444090,(2R)-butane-2-thiol,CC[C@@H](C)S,,,,,,
4090,444091,"(2S,4S)-4-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2-[(1S)-1-hydroxyethyl]-3,4-dihydro-1H-tetracene-2,5,6,11,12-pentol",C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C(C4=C(C5=CC=CC=C5C(=C4C(=C23)O)O)O)O)([C@H](C)O)O)N)O,,,,,,
4091,444092,CID 444092,CC1=C(C(=C2C(=C3[C@@H]([C@H](CN3C2=C1O)[NH3+])N)COC(=O)N)O)N,,,,,,
4092,444093,CID 444093,CC1=C(C(=C2C(=C3[C@@H]([C@H](CN3C2=C1O)N)N)COC(=O)N)O)N,,,,,,
4093,444094,"4,5,6,7-Tetrabromo-3H-isobenzofuran-1-one",C1C2=C(C(=C(C(=C2Br)Br)Br)Br)C(=O)O1,,,,,,
4094,444095,"3-[18-(2-carboxyethyl)-3,7,12,17-tetramethyl-8,13-bis[(1S)-1-sulfanylethyl]porphyrin-21,23-diid-2-yl]propanoic acid;iron(2+)",CC1=C(C2=CC3=NC(=CC4=C(C(=C([N-]4)C=C5C(=C(C(=N5)C=C1[N-]2)C)[C@H](C)S)C)[C@H](C)S)C(=C3CCC(=O)O)C)CCC(=O)O.[Fe+2],,,,,,
4095,444096,"3-[18-(2-carboxyethyl)-3,7,12,17-tetramethyl-8,13-bis[(1S)-1-sulfanylethyl]-22,23-dihydroporphyrin-2-yl]propanoic acid",CC1=C(C2=CC3=NC(=CC4=NC(=CC5=C(C(=C(N5)C=C1N2)[C@H](C)S)C)C(=C4CCC(=O)O)C)C(=C3C)CCC(=O)O)[C@H](C)S,,,,,,
4096,444097,Protoporphyrin IX containing fe,CC1=C(C2=CC3=NC(=CC4=C(C(=C([N-]4)C=C5C(=C(C(=N5)C=C1[N-]2)C=C)C)C=C)C)C(=C3CCC(=O)O)C)CCC(=O)O.[Fe+2],,,,,,
4097,444098,CID 444098,CC1=C(C2=CC3=NC(=CC4=C(C(=C([N-]4)C=C5C(=C(C(=N5)C=C1[N-]2)C)C=C)C)C=C)C(=C3CCC(=O)O)C)CCC(=O)O.[Fe+2],,,,,,
4098,444099,"(2R,3R)-2-hydroxy-3-propan-2-ylbutanedioic acid",CC(C)[C@H]([C@H](C(=O)O)O)C(=O)O,,,,,,
4099,444100,(4S)-4-[[(2S)-2-acetamido-3-phenylpropanoyl]amino]-5-(dipentylamino)-5-oxopentanoic acid,CCCCCN(CCCCC)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C,,,,,,
4100,444101,(4S)-4-[[(2S)-2-acetamido-3-[4-[difluoro(phosphono)methyl]phenyl]propanoyl]amino]-5-(dipentylamino)-5-oxopentanoic acid,CCCCCN(CCCCC)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)C(F)(F)P(=O)(O)O)NC(=O)C,,,,,,
4101,444102,CID 444102,CCCCCN(CCCCC)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC1=CC(=C(C=C1)OP(=O)(O)O)[C@H](O)S)NC(=O)C,,,,,,
4102,444103,(4S)-4-[[(2S)-2-acetamido-3-[3-[(S)-hydroxy(sulfanyl)methyl]-4-phosphonooxyphenyl]propanoyl]amino]-5-(dipentylamino)-5-oxopentanoic acid,CCCCCN(CCCCC)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC1=CC(=C(C=C1)OP(=O)(O)O)[C@@H](O)S)NC(=O)C,,,,,,
4103,444104,Glutathionesulfonic acid,C(CC(=O)N[C@@H](CS(=O)(=O)O)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,,,,,,
4104,444105,CID 444105,C1C[C@H](N(C1)C(=O)[C@@H](CC2=CC=CC=C2)N)C(=O)N[C@@H](CCCN=C(N)N)C(CN)(O)O,,,,,,
4105,444106,"3-(4-Carbamimidoylphenyl)-2,2-dihydroxypropanoic acid",C1=CC(=CC=C1CC(C(=O)O)(O)O)C(=N)N,,,,,,
4106,444107,Phenyl[1-(n-succinylamino)pentyl]phosphonate,CCCC[C@H](NC(=O)CCC(=O)O)P(=O)(O)OC1=CC=CC=C1,,,,,,
4107,444108,"(6E,10E)-2,6,10-trimethyldodeca-2,6,10-triene",C/C=C(\C)/CC/C=C(\C)/CCC=C(C)C,,,,,,
4108,444109,Pro-leu,CC(C)C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1,,,,,,
4109,444110,CID 444110,CCCCCN(CCCCC)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC1=CC(=C(C=C1)OP(=O)(O)O)C(O)O)NC(=O)C,,,,,,
4110,444111,(4S)-4-[[(2S)-2-acetamido-3-(3-formyl-4-phosphonooxyphenyl)propanoyl]amino]-5-(dipentylamino)-5-oxopentanoic acid,CCCCCN(CCCCC)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC1=CC(=C(C=C1)OP(=O)(O)O)C=O)NC(=O)C,,,,,,
4111,444112,N-Acetyl-O-phosphono-Tyr-Glu Dipentylamide,CCCCCN(CCCCC)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)OP(=O)(O)O)NC(=O)C,,,,,,
4112,444113,(4S)-4-[[(2S)-2-acetamido-3-(4-phosphonooxyphenyl)propanoyl]amino]-5-[3-cyclopentylpropyl(methyl)amino]-5-oxopentanoic acid,CC(=O)N[C@@H](CC1=CC=C(C=C1)OP(=O)(O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N(C)CCCC2CCCC2,,,,,,
4113,444114,(4S)-4-[[(2S)-2-acetamido-3-(4-phosphonooxyphenyl)propanoyl]amino]-5-[(3R)-3-butylpiperidin-1-yl]-5-oxopentanoic acid,CCCC[C@@H]1CCCN(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)OP(=O)(O)O)NC(=O)C,,,,,,
4114,444115,H-Thr-Pro-Tyr-Asp-Ile-Asn-Gln-Met-Leu-OH,CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H]([C@@H](C)O)N,,,,,,
4115,444116,H-Val-Pro-Leu-Arg-Pro-Met-Thr-Tyr-OH,C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]3CCCN3C(=O)[C@H](C(C)C)N)O,,,,,,
4116,444117,H-Lys-Pro-Ile-Val-Gln-Tyr-Asp-Asn-Phe-OH,CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CCCCN)N,,,,,,
4117,444118,Serinol phosphate,C([C@H](COP(=O)(O)O)N)O,,,,,,
4118,444119,"1-[(2R,4S,5R)-5-[[[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxymethyl]-3,4-dihydroxyoxolan-2-yl]pyridin-1-ium-3-carboxylic acid",C1=CC(=C[N+](=C1)[C@H]2C([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)OP(=O)(O)O)O)O)O)C(=O)O,,,,,,
4119,444120,"1-[(8R,9S,10R,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2,5,6,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone",CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4[C@@]3(CCC(=C4)O)C)C,,,,,,
4120,444121,CID 444121,C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)S)O)O)NC(=NC2=O)N,,,,,,
4121,444122,"(2S,3abeta,7abeta)-N-[(S)-1-(Hydroxymethyl)-4-guanidinobutyl]-1-[N-[(R)-1-oxo-2-hydroxy-3-(4-hydroxyphenyl)propyl]-L-leucyl]-6beta-hydroxyoctahydro-1H-indole-2alpha-carboxamide",CC(C)C[C@@H](C(=O)N1[C@H]2C[C@@H](CC[C@H]2C[C@H]1C(=O)N[C@@H](CCCN=C(N)N)CO)O)NC(=O)[C@@H](CC3=CC=C(C=C3)O)O,,,,,,
4122,444123,cis-Diamino platinum,[NH2-].[NH2-].[Pt+2],,,,,,
4123,444124,"3-[18-(2-Carboxyethyl)-8,13-diethyl-3,7,12,17-tetramethylporphyrin-21,23-diid-2-yl]propanoic acid;iron(2+)",CCC1=C(C2=CC3=NC(=CC4=C(C(=C([N-]4)C=C5C(=C(C(=N5)C=C1[N-]2)C)CCC(=O)O)CCC(=O)O)C)C(=C3CC)C)C.[Fe+2],,,,,,
4124,444125,"3-[18-(2-carboxyethyl)-3,8,13,17-tetramethyl-7,12-bis[(1S)-1-sulfanylethyl]porphyrin-21,23-diid-2-yl]propanoic acid;iron(2+)",CC1=C(C2=CC3=NC(=CC4=C(C(=C([N-]4)C=C5C(=C(C(=N5)C=C1[N-]2)[C@H](C)S)C)[C@H](C)S)C)C(=C3CCC(=O)O)C)CCC(=O)O.[Fe+2],,,,,,
4125,444126,"3-[18-(2-carboxyethyl)-3,7,12,17-tetramethyl-8,13-bis[(1R)-1-sulfanylethyl]-22,23-dihydroporphyrin-2-yl]propanoic acid",CC1=C(C2=CC3=NC(=CC4=NC(=CC5=C(C(=C(N5)C=C1N2)[C@@H](C)S)C)C(=C4CCC(=O)O)C)C(=C3C)CCC(=O)O)[C@@H](C)S,,,,,,
4126,444127,Uridine-diphosphate-2(N-acetylglucosaminyl-3-fluoro-2-phosphonooxy)propionic acid,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=O)NC3=O)O)O)CO)O)O[C@](CF)(C(=O)O)OP(=O)(O)O,,,,,,
4127,444128,Glu-Asp-Leu,CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)N,,,,,,
4128,444129,"[(2S,4R,5R)-5-amino-4-hydroxyoxolan-2-yl]methyl dihydrogen phosphate;hydron",[H+].[H+].[H+].C1[C@H](O[C@H]([C@@H]1O)N)COP(=O)(O)O,,,,,,
4129,444130,"[(2S,4R,5R)-5-amino-4-hydroxyoxolan-2-yl]methyl dihydrogen phosphate",C1[C@H](O[C@H]([C@@H]1O)N)COP(=O)(O)O,,,,,,
4130,444131,H-Pro-Pro-Gly-Pro-Pro-Gly-Pro-Pro-Gly-al,C1C[C@H](NC1)C(=O)N2CCC[C@H]2C(=O)NCC(=O)N3CCC[C@H]3C(=O)N4CCC[C@H]4C(=O)NCC(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)NCC=O,,,,,,
4131,444132,H-Pro-Pro-Gly-Pro-Pro-Gly-al,C1C[C@H](NC1)C(=O)N2CCC[C@H]2C(=O)NCC(=O)N3CCC[C@H]3C(=O)N4CCC[C@H]4C(=O)NCC=O,,,,,,
4132,444133,CID 444133,CN(C)C(=O)[C-]1[CH-][CH-][CH-][CH-]1.[CH-]1[CH-][CH-][C-]([CH-]1)C(=O)O.[Fe],,,,,,
4133,444134,CID 444134,CN(C)[C-]([C-]1C[CH-][CH-]C1)[O-],,,,,,
4134,444135,CID 444135,C1[CH-][CH-]C[C-]1[C-](O)[O-],,,,,,
4135,444136,"[(2R,3S,5R)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)-2-[(3-oxo-1,2,3lambda5-dioxaphosphiran-3-yl)oxymethyl]oxolan-3-yl] dihydrogen phosphate",CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP3(=O)OO3)OP(=O)(O)O,,,,,,
4136,444137,"(4R)-2-(2-ethoxyethyl)-4-(ethylamino)-1,1-dioxo-3,4,5,6-tetrahydrothieno[3,2-e]thiazine-6-sulfonamide",CCN[C@H]1CN(S(=O)(=O)C2=C1CC(S2)S(=O)(=O)N)CCOCC,,,,,,
4137,444138,"(3S,6S)-6-amino-N-[(3S)-7-amino-1-(cyclohexylamino)-2,2-dihydroxy-1-oxoheptan-3-yl]-6-benzyl-5-oxo-2,3,7,8-tetrahydro-1H-pyrazolo[1,2-a]pyridazine-3-carboxamide",C1CCC(CC1)NC(=O)C([C@H](CCCCN)NC(=O)[C@@H]2CCN3N2C(=O)[C@@](CC3)(CC4=CC=CC=C4)N)(O)O,,,,,,
4138,444139,"4,6-Dideoxy-4-amino-alpha-D-glucose",C[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O)O)O)N,,,,,,
4139,444140,"azane;(1S,2R,3R,4R)-4-(hydroxymethyl)cyclohexane-1,2,3-triol",C1C[C@@H]([C@H]([C@@H]([C@H]1CO)O)O)O.N,,,,,,
4140,444141,CID 444141,C1C[C@@H]([C@H](C([C@H]1CO)O)O)O,,,,,,
4141,444142,"(2R,3R,7S,8R)-8-acetamido-7-(diaminomethylideneamino)-2-[(1R)-1,2-dihydroxyethyl]-1,4-dioxaspiro[2.5]oct-5-ene-5-carboxylic acid",CC(=O)N[C@@H]1[C@H](C=C(O[C@@]12[C@H](O2)[C@@H](CO)O)C(=O)O)N=C(N)N,,,,,,
4142,444143,CID 444143,C[C@H]1CC(=C([C@H](/C=C\C=C(\C(=O)NC2=CC(=C(C(=C2O)C=C(C[C@@H]([C@@H]1O)OC)C)OC)O)/C)OC)OC(=O)N)C,,,,,,
4143,444144,"[4-(4-Acetylamino-phenyl)-3,5-dioxo-4-aza-tricyclo[5.2.2.0 2,6]undec-1-ylcarbamoyloxy]-acetic acid",CC(=O)NC1=CC=C(C=C1)N2C(=O)[C@H]3[C@@H](C2=O)C4(CCC3CC4)NC(=O)OCC(=O)O,,,,,,
4144,444145,"(8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-2H-imidazo[4,5-d][1,3]diazepin-8-ol",C1[C@@H]([C@H](O[C@H]1N2CN=C3C2=NC=NC[C@H]3O)CO)O,,,,,,
4145,444146,"(2R,3R,4S,5R)-2-[(6S)-6-hydroxy-6,8-dihydropurin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol",C1N=C2[C@@H](N=CN=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
4146,444147,"5-Acetylamino-4-amino-6-(phenethyl-propyl-carbamoyl)-5,6-dihydro-4h-pyran-2-carboxylic acid",CCCN(CCC1=CC=CC=C1)C(=O)[C@H]2[C@@H]([C@H](C=C(O2)C(=O)O)N)NC(=O)C,,,,,,
4147,444148,CID 444148,C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(N)O)O)O)NC(=NC2=O)N,,,,,,
4148,444149,"2-[(4S)-4-[[5-(dimethylamino)naphthalen-1-yl]sulfonylamino]-5-oxo-5-[(2R)-2-[3-oxo-3-(1,3-thiazol-2-yl)propyl]piperidin-1-yl]pentyl]guanidine",CN(C)C1=CC=CC2=C1C=CC=C2S(=O)(=O)N[C@@H](CCCN=C(N)N)C(=O)N3CCCC[C@@H]3CCC(=O)C4=NC=CS4,,,,,,
4149,444150,Indole-3-glycerol phosphate,C1=CC=C2C(=C1)C(=CN2)[C@@H]([C@@H](COP(=O)(O)O)O)O,,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']",,,
4150,444151,"7-(diethylamino)-N-[2-(2,5-dioxopyrrolidin-1-yl)ethyl]-2-oxochromene-3-carboxamide",CCN(CC)C1=CC2=C(C=C1)C=C(C(=O)O2)C(=O)NCCN3C(=O)CCC3=O,,,,,,
4151,444152,Ethyl coenzyme A,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)[C@H](C(=O)NCCC(=O)NC)O,,,,,,
4152,444153,"(1S,7S)-7-amino-7-benzyl-N-((S)-6-guanidino-1,2-dioxo-1-(phenethylamino)hexan-3-yl)-8-oxo-hexahydro-1H-pyrazolo[1,2-a]pyridazine-1-carboxamide",C1CN2CC[C@](C(=O)N2[C@@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)C(=O)NCCC3=CC=CC=C3)(CC4=CC=CC=C4)N,,,,,,
4153,444154,"[(4S)-5-[[(2S)-5-amino-1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-1,5-dioxopentan-2-yl]amino]-4-[[(2S)-2-[[2-[[(2R)-2-[[(2S,3R)-2-azaniumyl-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-5-oxopentyl]-(diaminomethylidene)azanium",C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC[NH+]=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)[NH3+])O,,,,,,
4154,444155,"(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-oxopentanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid",C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N)O,,,,,,
4155,444156,CID 444156,C1C=CC(=C(C(=C1)CC2=CC=C(C=C2)C(=[NH2+])N)O)CC3=CC=C(C=C3)C(=[NH2+])N,,,,,,
4156,444157,CID 444157,C1C=CC(=C(C(=C1)CC2=CC=C(C=C2)C(=N)N)O)CC3=CC=C(C=C3)C(=N)N,,,,,,
4157,444158,"[(4S)-4-[[2-[[(2S)-2-azaniumyl-4-carboxybutanoyl]amino]acetyl]amino]-5,5-dihydroxypentyl]-(diaminomethylidene)azanium",C(C[C@@H](C(O)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)[NH3+])C[NH+]=C(N)N,,,,,,
4158,444159,"(4S)-4-amino-5-[[2-[[(2S)-5-(diaminomethylideneamino)-1,1-dihydroxypentan-2-yl]amino]-2-oxoethyl]amino]-5-oxopentanoic acid",C(C[C@@H](C(O)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)N)CN=C(N)N,,,,,,
4159,444160,"[(1S,3R,4S,6S,7S)-1,7-dihydroxy-6-phosphonooxy-2,5-dioxabicyclo[2.2.1]heptan-3-yl]methyl dihydrogen phosphate",C([C@@H]1[C@@H]2[C@@H]([C@](O1)([C@@H](O2)OP(=O)(O)O)O)O)OP(=O)(O)O,,,,,,
4160,444161,"(3S,6S)-6-amino-6-benzyl-N-[(2S)-5-(diaminomethylideneamino)-1,1-dihydroxy-1-(1,3-thiazol-2-yl)pentan-2-yl]-5-oxo-2,3,7,8-tetrahydro-1H-pyrazolo[1,2-a]pyridazine-3-carboxamide",C1CN2CC[C@](C(=O)N2[C@@H]1C(=O)N[C@@H](CCCN=C(N)N)C(C3=NC=CS3)(O)O)(CC4=CC=CC=C4)N,,,,,,
4161,444162,2-Acetamido-2-deoxy-d-glucopyranosylamine,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](OC1N)CO)O)O,,,,,,
4162,444163,(S)-Tetrahydro-2H-pyran-2-ol,C1CCO[C@@H](C1)O,,,,,,
4163,444164,CID 444164,C1[C@@H]([C@H](O[C@H]1N2C=CC(=NC2=O)N)COP(=O)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=O)(O)O[C@H]4C[C@@H](O[C@@H]4COP(=O)(O)O[C@H]5C[C@@H](O[C@@H]5COP(=O)(O)O[C@H]6C[C@@H](O[C@@H]6CO)N7C=NC8=C(N=CN=C87)N)N9C=CC(=NC9=O)N)N1C=NC2=C1NC(=NC2=O)N)N1C=CC(=NC1=O)N)O,,,,,,
4164,444165,CID 444165,[SH3+].[SH3+].[SH3+].[SH3+].[Fe].[Fe].[Fe].[Fe],,,,,,
4165,444166,Sulfanium;iron;iron(2+);sulfanide,[SH3+].[SH-].[SH-].[SH-].[Fe].[Fe].[Fe+2],,,,,,
4166,444167,4-Hydroxy-3-nitrophenylacetyl-epsilon-aminocaproic acid,C1=CC(=C(C=C1CC(=O)NCCCCCC(=O)O)[N+](=O)[O-])O,,,,,,
4167,444168,N-ethyl-2-(4-hydroxy-3-iodo-5-nitrophenyl)acetamide,CCNC(=O)CC1=CC(=C(C(=C1)I)O)[N+](=O)[O-],,,,,,
4168,444169,Iron;iron(2+);sulfanide,[SH-].[SH-].[Fe].[Fe+2],,,,,,
4169,444170,Fenugreekine,C1=CC(=NC(=C1)C(=O)N)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O,,,,,,
4170,444171,3'-Oxo-3'-deoxy-4'-O-carba-4'-de(hydroxymethyl)adenosine,C1CC(=O)[C@H]([C@@H]1N2C=NC3=C(N=CN=C32)N)O,,,,,,
4171,444172,Ac-Thr-Val-Ala-Ser-Ser-NH2,C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N)NC(=O)C)O,,,,,,
4172,444173,beta-D-Arabinopyranose,C1[C@H]([C@H]([C@@H]([C@@H](O1)O)O)O)O,,,,,,
4173,444174,Hydroxy diiron-oxo moiety,O.O.[Fe].[Fe],,,,,,
4174,444175,"(2R,3R,4R,5S,6R)-5-[(1R,2R)-2,3-dihydroxy-1-(2-hydroxyethoxy)propoxy]-6-(hydroxymethyl)oxane-2,3,4-triol;hydrate",C(CO[C@@H]([C@@H](CO)O)O[C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O)O)CO)O.O,,,,,,
4175,444176,"(2R,3R,4R,5S,6R)-5-[(1R,2R)-2,3-dihydroxy-1-(2-hydroxyethoxy)propoxy]-6-(hydroxymethyl)oxane-2,3,4-triol",C(CO[C@@H]([C@@H](CO)O)O[C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O)O)CO)O,,,,,,
4176,444177,Benzyl-carbamic acid [8-deethyl-ascomycin-8-YL]ethyl ester,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CCOC(=O)NCC4=CC=CC=C4)O)C)/C(=C/[C@@H]5CC[C@H]([C@@H](C5)OC)O)/C)O)C)OC)OC,,,,,,
4177,444178,"(7S,8S)-7,8-diaminononanoic acid",C[C@@H]([C@H](CCCCCC(=O)O)N)N,,,,,,
4178,444179,CID 444179,N.N.[Pt+2],,,,,,
4179,444180,CID 444180,CC(C)C[C@H]([C@@H](NO)O)C(=O)N[C@@H](CC(=O)N)C(=O)NCC1=CC(=CC=C1)N,,,,,,
4180,444181,CID 444181,CC(C)C[C@H](C(NO)O)C(=O)N[C@@H](CC(=O)O)C(=O)NCC1=CC=CC=C1,,,,,,
4181,444182,Sn-glycero-3-phosphoserine,C([C@H](COP(=O)(O)OC[C@@H](C(=O)O)N)O)O,,,,,,
4182,444183,L-alpha-Glycerophosphorylethanolamine,C(COP(=O)(O)OC[C@@H](CO)O)N,,,,,,
4183,444184,"Benzyl [(1r)-1-({(1s,2s,3s)-1-Benzyl-2-Hydroxy-4-({(1s)-1-[(2-Hydroxy-4-Methoxybenzyl)carbamoyl]-2-Methylpropyl}amino)-3-[(4-Methoxybenzyl)amino]-4-Oxobutyl}carbamoyl)-2,2-Dimethylpropyl]carbamate",CC(C)[C@@H](C(=O)NCC1=C(C=C(C=C1)OC)O)NC(=O)[C@@H]([C@@H]([C@H](CC2=CC=CC=C2)NC(=O)[C@H](C(C)(C)C)NC(=O)OCC3=CC=CC=C3)O)NCC4=CC=C(C=C4)OC,,,,,,
4184,444185,beta-D-Glucopyranose spirohydantoin,C([C@@H]1[C@H]([C@@H]([C@H]([C@]2(O1)C(=O)NC(=O)N2)O)O)O)O,,,,,,
4185,444186,CID 444186,CCCC[C@@H](C(=O)N)NC(=O)[C@@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC[NH+]=C(N)N)[NH3+],,,,,,
4186,444187,CID 444187,CCCC[C@@H](C(=O)N)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C(CC(C)C)NC(=O)C(C(C)C)NC(=O)[C@H](CCCN=C(N)N)N,,,,,,
4187,444188,"[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4S)-5-(7,8-dimethyl-2,4-dioxo-1H-benzo[g]pteridin-10-ium-10-yl)-2,3,4-trihydroxypentyl] hydrogen phosphate",CC1=CC2=C(C=C1C)[N+](=C3C(=N2)C(=O)NC(=O)N3)C[C@@H]([C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,,,,,,
4188,444189,"1-alpha-Pyrophosphoryl-2-alpha,3-alpha-dihydroxy-4-beta-cyclopentane-methanol-5-phosphate",C1[C@@H]([C@H]([C@H]([C@H]1OP(=O)(O)OP(=O)(O)O)O)O)COP(=O)(O)O,,,,,,
4189,444190,CID 444190,O.[OH-].[MgH+],,,,,,
4190,444191,H-Leu-Pro-Pro-Leu-Asp-Ile-Thr-Pro-Tyr-al,CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=C(C=C2)O)C=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]3CCCN3C(=O)[C@@H]4CCCN4C(=O)[C@H](CC(C)C)N,,,,,,
4191,444192,N-[[1-[N-Acetamidyl]-[1-cyclohexylmethyl-2-hydroxy-4-isopropyl]-but-4-YL]-carbonyl]-glutaminyl-arginyl-amide,CC(C)[C@H](C[C@@H]([C@H](CC1CCCCC1)NC(=O)C)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N,,,,,,
4192,444193,"[(2R)-1-[[(1S,2R,18R,19R,22S,25R,28R,40S)-22-(2-amino-2-oxoethyl)-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5S,6S)-4-azaniumyl-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-40-carboxy-5,15-dichloro-2,18,32,35,37-pentahydroxy-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34(39),35,37,46,49-pentadecaen-19-yl]amino]-4-methyl-1-oxopentan-2-yl]-methylazanium",C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)[NH2+]C)O)Cl)CO)O)O)(C)[NH3+])O,,,,,,
4193,444194,CID 444194,C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OC[C@@H]4C(=C([C@H]5[C@@H](O4)N=C6C(=N5)C(=O)N=C(N6)N)[S-])[S-])O)O)NC(=NC2=O)N,,,,,,
4194,444195,CID 444195,C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OCC4C(=C([C@H]5[C@@H](O4)N=C6C(=N5)C(=O)N=C(N6)N)S)S)O)O)NC(=NC2=O)N,,,,,,
4195,444196,"Methyl N-{(4s,5s)-5-[(L-Alanyl-L-Alanyl)amino]-4-Hydroxy-6-Phenylhexanoyl}-L-Valyl-L-Valinate",C[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)OC)O)N,,,,,,
4196,444197,Thr-Pro-Gly-Val-Tyr,C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N)O,,,,,,
4197,444198,2-Morpholin-4-ylethenesulfonic acid,C1COCCN1C=CS(=O)(=O)O,,,,,,
4198,444199,[4-(Aminomethyl)-5-hydroxy-6-methylpyridin-3-yl]methyl phosphono hydrogen phosphate,CC1=NC=C(C(=C1O)CN)COP(=O)(O)OP(=O)(O)O,,,,,,
4199,444200,Alpha-D-Fucose,C[C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)O)O)O)O,,,,,,
4200,444201,H-D-Phe-Pro-Arg-Me,CC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](CC2=CC=CC=C2)N,,,,,,
4201,444202,Oxidanium;actinium;azanide;[hydroxy(oxonio)phosphoryl]oxidanium;neptunium;nobelium;(1-pentylpyridin-1-ium-3-yl)methanamine;phosphoric acid;hydrate,[CH2-]CCCC[N+]1=CC=CC(=C1)CN.[NH2-].[NH2-].[NH2-].[NH2-].[NH2-].[OH3+].O.[OH2+]P(=O)([OH2+])O.OP(=O)(O)O.[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Np].[No].[No].[No].[No].[No].[No].[No],,,,,,
4202,444203,(1-Pentylpyridin-1-ium-3-yl)methanamine,CCCCC[N+]1=CC=CC(=C1)CN,,,,,,
4203,444204,H-Ala-Pro-Thr-Met-Pro-Pro-Pro-Leu-Pro-Pro-OH,C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)O)NC(=O)[C@@H]6CCCN6C(=O)[C@H](C)N)O,,,,,,
4204,444205,"2-(Acetylamino)-1,5-Anhydro-2-Deoxy-D-Glucitol",CC(=O)N[C@H]1CO[C@@H]([C@H]([C@@H]1O)O)CO,,,,,,
4205,444206,Met-Leu,CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCSC)N,,,,,,
4206,444207,"3-[18-(2-Carboxyethyl)-8-ethenyl-13-ethyl-3,7,12,17-tetramethylporphyrin-21,23-diid-2-yl]propanoic acid;iron(2+)",CCC1=C(C2=CC3=NC(=CC4=C(C(=C([N-]4)C=C5C(=C(C(=N5)C=C1[N-]2)C)CCC(=O)O)CCC(=O)O)C)C(=C3C=C)C)C.[Fe+2],,,,,,
4207,444208,"3-[(1Z,4Z,9Z,15Z)-18-(2-carboxyethyl)-13-ethyl-3,7,12,17-tetramethyl-8-vinyl-21,23-dihydroporphyrin-2-yl]propanoic acid",CCC1=C(C2=CC3=C(C(=C(N3)C=C4C(=C(C(=N4)C=C5C(=C(C(=N5)C=C1N2)C)CCC(=O)O)CCC(=O)O)C)C)C=C)C,,,,,,
4208,444209,"3,4,5-Trimethyl-1,3-thiazole",CC1=C(SC=[N+]1C)C,,,,,,
4209,444210,hexadecanethioic S-acid,CCCCCCCCCCCCCCCC(=O)S,,,,,,
4210,444211,"2,3-Dihydroacridin-9-amine",C1CC=C2C(=C1)C(=C3C=CC=CC3=N2)N,,,,,,
4211,444212,trans-Aconitic acid,C(/C(=C\C(=O)O)/C(=O)O)C(=O)O,,,,,,
4212,444213,H-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr(SO3H)-Ala-OH,CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)OS(=O)(=O)O)C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)N,,,,,,
4213,444214,"(2S)-1-[(2R)-2-(methylamino)-3-phenylpropanoyl]-N-[(2S)-4,4,5,5,5-pentafluoro-3,3-dihydroxy-1-(1H-indol-3-yl)pentan-2-yl]pyrrolidine-2-carboxamide",CN[C@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(C(C(F)(F)F)(F)F)(O)O,,,,,,
4214,444215,5-beta-D-Ribofuranosylnicotinamide adenine dinucleotide,C1=C(C=NC=C1C(=O)N)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O,,,,,,
4215,444216,Actinium;azanide;hydron;neptunium;nobelium;(6-pentylpyridin-2-yl)methanamine;phosphonooxidanium;trihydrate,[H+].[H+].CCCCCC1=NC(=CC=C1)CN.[NH2-].[NH2-].[NH2-].[NH2-].[NH2-].O.O.O.[OH2+]P(=O)(O)O.[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Np].[No].[No].[No].[No].[No].[No].[No],,,,,,
4216,444217,(6-Pentylpyridin-2-yl)methanamine,CCCCCC1=NC(=CC=C1)CN,,,,,,
4217,444218,"Actinium;azanide;hydron;[hydroxy(methanidyl)phosphoryl]oxidanium;neptunium;nobelium;(2-pentyl-1,3-thiazol-4-yl)methanamine;trihydrate",[H+].[H+].CCCCCC1=NC(=CS1)CN.[CH2-]P(=O)([OH2+])O.[NH2-].[NH2-].[NH2-].[NH2-].[NH2-].O.O.O.[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Np].[No].[No].[No].[No].[No].[No].[No],,,,,,
4218,444219,"(2-Pentyl-1,3-thiazol-4-yl)methanamine",CCCCCC1=NC(=CS1)CN,,,,,,
4219,444220,"Actinium;azanide;hydron;[hydroxy(methanidyl)phosphoryl]oxidanium;neptunium;nobelium;(2-pentyl-1,3-thiazol-4-yl)methanamine;trihydrate",[H+].[H+].[CH2-]CCCCC1=NC(=CS1)CN.[CH2-]P(=O)([OH2+])O.[NH2-].[NH2-].[NH2-].[NH2-].[NH2-].O.O.O.[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Np].[No].[No].[No].[No].[No].[No].[No],,,,,,
4220,444221,Actinium;azanide;neptunium;nobelium;(1-pentylpyridin-1-ium-3-yl)methanamine;phosphonooxidanium;phosphoric acid;dihydrate,[CH2-]CCCC[N+]1=CC=CC(=C1)CN.[NH2-].[NH2-].[NH2-].[NH2-].[NH2-].O.O.[OH2+]P(=O)(O)O.OP(=O)(O)O.[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Np].[No].[No].[No].[No].[No].[No].[No],,,,,,
4221,444222,Histidyl-adenosine monophosphate,C1=C(NC=N1)C[C@@H](C(=O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=CN=C43)N)O)O)N,,,,,,
4222,444223,H-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr(SO3H)-Unk,CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)OS(=O)(=O)O)C(=O)N[C@@H](CC(C)C)C3OO3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC(=O)O)N,,,,,,
4223,444224,1-Ethoxycarbonyl-d-phe-pro-2(4-aminobutyl)hydrazine,CCOC(=O)N[C@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)NNCCCCN,,,,,,
4224,444225,"N-[(2R)-2-amino-4,5-dihydroxy-6-(hydroxymethyl)-2H-pyran-3-yl]acetamide",CC(=O)NC1=C(C(=C(O[C@H]1N)CO)O)O,,,,,,
4225,444226,"4-[[(2S)-2-[[(2R,3R)-3-carboxy-2-hydroxy-3-sulfanylpropanoyl]amino]-4-methylpentanoyl]amino]butyl-(diaminomethylidene)azanium",CC(C)C[C@@H](C(=O)NCCCC[NH+]=C(N)N)NC(=O)[C@H]([C@H](C(=O)O)S)O,,,,,,
4226,444227,"(2R,3R)-4-[[(2S)-1-[4-(diaminomethylideneamino)butylamino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-4-oxo-2-sulfanylbutanoic acid",CC(C)C[C@@H](C(=O)NCCCCN=C(N)N)NC(=O)[C@H]([C@H](C(=O)O)S)O,,,,,,
4227,444228,3-Aminopyridinium,C1=CC(=C[NH+]=C1)N,,,,,,
4228,444229,4-Aminopyridinium,C1=C[NH+]=CC=C1N,,,,,,
4229,444230,3-ethenyl-1H-imidazol-3-ium,C=C[N+]1=CNC=C1,,,,,,
4230,444231,"1H-imidazo[1,2-a]pyridin-4-ium",C1=CC=[N+]2C=CNC2=C1,,,,,,
4231,444232,2-Aminopyridinium,C1=CC=[NH+]C(=C1)N,,,,,,
4232,444233,"2-(1,5-Dideoxyribose)-4-amido-thiazole",C[C@@H]1[C@H]([C@H]([C@@H](O1)C2=NC(=CS2)C(=O)N)O)O,,,,,,
4233,444234,Imidazolium,C1=C[NH+]=CN1,,,,,,
4234,444235,1-Methylimidazolium,C[N+]1=CNC=C1,,,,,,
4235,444236,CID 444236,C[C@@H](C(NO)O)NC(=O)[C@H](CC(C)C)N,,,,,,
4236,444237,Sucrose octasulfate,C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)COS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O)COS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O,,,['Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)'],,,
4237,444238,2-[N'-(4-Amino-butyl)-hydrazinocarbonyl]-pyrrolidine-1-carboxylic acid benzyl ester,C1C[C@H](N(C1)C(=O)OCC2=CC=CC=C2)C(=O)NNCCCCN,,,,,,
4238,444239,CID 444239,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)OP(=O)(O)OC[C@@H]3[C@H](C[C@@H](O3)N4C=NC5=C(N=CN=C54)N)OP(=O)(O)OC[C@@H]6[C@H](C[C@@H](O6)N7C=NC8=C7NC(=NC8=O)N)OP(=O)(O)OC[C@@H]9[C@H](C[C@@H](O9)N1C=NC2=C1NC(=NC2=O)N)O,,,,,,
4239,444240,D-Leucyl-N-(4-Fluorobenzyl)-L-Phenylalaninamide,CC(C)C[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC2=CC=C(C=C2)F)N,,,,,,
4240,444241,"Androsta-3-ene-3,17beta-diol",C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4[C@@]3(CCC(=C4)O)C,,,,,,
4241,444242,CID 444242,C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)C)O,,,,,,
4242,444243,"[(2R,3S,4S)-5-(7,8-dimethyl-2,4-dioxo-1H-benzo[g]pteridin-10-ium-10-yl)-2,3,4-trihydroxypentyl] dihydrogen phosphate",CC1=CC2=C(C=C1C)[N+](=C3C(=N2)C(=O)NC(=O)N3)C[C@@H]([C@@H]([C@@H](COP(=O)(O)O)O)O)O,,,,,,
4243,444244,"(2S,3R,4S,5R,6R)-2-[[(1S,3S,4S,5S,8R)-3-[(2S,3R,4S,5S,6R)-2-[[(1S,3S,4S,5S,8R)-3-[(2S,3R,4S,5S,6R)-3,5-dihydroxy-2-[[(1S,4R,5S,8R)-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol",C1[C@H]([C@H]2[C@@H]([C@@H](O1)CO2)O[C@H]3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)O[C@H]4[C@H]([C@H]5[C@@H]([C@@H](O4)CO5)O[C@H]6[C@@H]([C@H]([C@H]([C@H](O6)CO)O)O[C@H]7[C@H]([C@H]8[C@@H]([C@@H](O7)CO8)O[C@H]9[C@@H]([C@H]([C@H]([C@H](O9)CO)O)O)O)O)O)O)O)O,,,,,,
4244,444245,H-Gly-Gly-Arg-Lys-Lys-Tyr-Lys-Leu-OH,CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)CN,,,,,,
4245,444246,H-Gly-Gly-Lys-Lys-Lys-Tyr-Gln-Leu-OH,CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)CN,,,,,,
4246,444247,H-Gly-Gly-Lys-Lys-Lys-Tyr-Lys-Leu-OH,CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)CN,,,,,,
4247,444248,H-Gly-Gly-Lys-Lys-Lys-Tyr-Arg-Leu-OH,CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)CN,,,,,,
4248,444249,[(4S)-4-[[(2S)-6-azaniumyl-2-[[(2S)-6-azaniumyl-2-[[2-[(2-azaniumylacetyl)amino]acetyl]amino]hexanoyl]amino]hexanoyl]amino]-5-[[(2S)-1-[[(2S)-6-azaniumyl-1-[[(1S)-1-carboxy-3-methylbutyl]amino]-1-oxohexan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-oxopentyl]-(diaminomethylidene)azanium,CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCCC[NH3+])NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCC[NH+]=C(N)N)NC(=O)[C@H](CCCC[NH3+])NC(=O)[C@H](CCCC[NH3+])NC(=O)CNC(=O)C[NH3+],,,,,,
4249,444250,CID 444250,CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)CNC(=O)CN,,,,,,
4250,444251,"1-[(2S,4S)-2,5,6,11,12-pentahydroxy-4-[(2R,4S,5S,6S)-5-hydroxy-6-methyl-4-(2-methylpropylamino)oxan-2-yl]oxy-7-methoxy-3,4-dihydro-1H-tetracen-2-yl]ethanone",C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C(C4=C(C5=C(C(=CC=C5)OC)C(=C4C(=C23)O)O)O)O)(C(=O)C)O)NCC(C)C)O,,,,,,
4251,444252,Man(a1-2)Man(a1-3)Man(b1-4)GlcNAc(b1-4)GlcNAc(b)-NH2,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1N)CO)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)CO)O)O[C@@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O[C@@H]5[C@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O)O)NC(=O)C)O,,,,,,
4252,444253,Man(a1-2)Man(a1-2)Man(a1-3)[Man(a1-3)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc(b)-NH2,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1N)CO)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)CO[C@@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)O[C@@H]5[C@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O)O)O[C@@H]6[C@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O[C@@H]7[C@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O[C@@H]8[C@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O)O)NC(=O)C)O,,,,,,
4253,444254,Precose,C[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@H](O[C@@H]([C@@H]([C@H]2O)O)O[C@@H]3[C@H](O[C@H]([C@@H]([C@H]3O)O)O)CO)CO)O)O)N[C@H]4C=C([C@H]([C@@H]([C@H]4O)O)O)CO,,,['Compounds that inhibit or block the activity of GLYCOSIDE HYDROLASES such as ALPHA-AMYLASES and ALPHA-GLUCOSIDASES. (See all compounds classified as Glycoside Hydrolase Inhibitors.)'],"['In a study of 6 healthy men, less than 2% of an oral dose of acarbose was absorbed as active drug, while approximately 35% of total radioactivity from a 14C-labeled oral dose was absorbed. An average of 51% of an oral dose was excreted in the feces as unabsorbed drug-related radioactivity within 96 hours of ingestion. Because acarbose acts locally within the gastrointestinal tract, this low systemic bioavailability of parent compound is therapeutically desired.', 'Following oral dosing of healthy volunteers with 14C-labeled acarbose, peak plasma concentrations of radioactivity were attained 14-24 hours after dosing, while peak plasma concentrations of active drug were attained at approximately 1 hour. The delayed absorption of acarbose-related radioactivity reflects the absorption of metabolites that may be formed by either intestinal bacteria or intestinal enzymatic hydrolysis.', 'Acarbose is metabolized exclusively within the gastrointestinal tract, principally by intestinal bacteria, but also by digestive enzymes. A fraction of these metabolites (approximately 34% of the dose) was absorbed and subsequently excreted in the urine.', 'The fraction of acarbose that is absorbed as intact drug is almost completely excreted by the kidneys. When acarbose was given intravenously, 89% of the dose was recovered in the urine as active drug within 48 hours. In contrast, less than 2% of an oral dose was recovered in the urine as active (i.e., parent compound and active metabolite) drug. This is consistent with the low bioavailability of the parent drug.', 'For more Absorption, Distribution and Excretion (Complete) data for Acarbose (6 total), please visit the HSDB record page.']","['Acarbose is metabolized exclusively within the gastrointestinal tract, principally by intestinal bacteria, but also by digestive enzymes.  ... At least 13 metabolites have been separated chromatographically from urine specimens. The major metabolites have been identified as 4-methylpyrogallol derivatives (i.e., sulfate, methyl, and glucuronide conjugates). One metabolite (formed by cleavage of a glucose molecule from acarbose) also has alpha-glucosidase inhibitory activity. This metabolite, together with the parent compound, recovered from the urine, accounts for less than 2% of the total administered dose.']",['The plasma elimination half-life of acarbose activity is approximately 2 hours in healthy volunteers.']
4254,444255,"[[(2R,3S,4R,5R)-5-(6-amino-7H-purin-9-ium-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate",C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)[N+]4=CNC5=C(N=CN=C54)N)O)O)O)O)C(=O)N,,,,,,
4255,444256,4-[4-[(2-Oxoindol-3-yl)methyl]phenyl]piperazine-1-carbaldehyde,C1CN(CCN1C=O)C2=CC=C(C=C2)CC3=C4C=CC=CC4=NC3=O,,,,,,
4256,444257,"[1-[(2R,3R,4S,5R)-5-[[[[(2R,3R,4R,5R)-5-[6-(dioxaziridin-3-yl)purin-9-yl]-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxymethyl]-3,4-dihydroxyoxolan-2-yl]pyridin-1-ium-3-carbonyl]oxidanium",C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C4N=CN=C5N6OO6)OP(=O)(O)O)O)O)O)C(=O)[OH2+],,,,,,
4257,444258,"1-[(2R,3R,4S,5R)-5-[[[[(2R,3R,4R,5R)-5-[6-(dioxaziridin-3-yl)purin-9-yl]-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxymethyl]-3,4-dihydroxyoxolan-2-yl]pyridin-1-ium-3-carboxylic acid",C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C4N=CN=C5N6OO6)OP(=O)(O)O)O)O)O)C(=O)O,,,,,,
4258,444259,3-[5-[[3-(2-carboxyethyl)-4-(carboxymethyl)-5-(sulfanylmethyl)-1H-pyrrol-2-yl]methyl]-4-(carboxymethyl)-1H-pyrrol-3-yl]propanoic acid,C1=C(C(=C(N1)CC2=C(C(=C(N2)CS)CC(=O)O)CCC(=O)O)CC(=O)O)CCC(=O)O,,,,,,
4259,444260,Formycin-5'-monophosphate,C1=NC2=C(NN=C2C(=N1)N)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O,,,,,,
4260,444261,Phospho-5'-pyridoxyl tyrosine,CC1=NC=C(C(=C1O)CN[C@@H](CC2=CC=C(C=C2)O)C(=O)O)COP(=O)(O)O,,,,,,
4261,444262,3alpha-Hydroxy-7-oxo-5beta-cholanic acid,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C(=O)C[C@H]4[C@@]3(CC[C@H](C4)O)C)C,,,['Gastrointestinal agents that stimulate the flow of bile into the duodenum (cholagogues) or stimulate the production of bile by the liver (choleretic). (See all compounds classified as Cholagogues and Choleretics.)'],,,
4262,444263,CID 444263,C1=CC(=CC=C1[C@@H](C(C(=O)O)(O)O)O)C(=N)N,,,,,,
4263,444264,CID 444264,CC1=CC2=C(C=C1CN)N(C3=C(N2CC4=CC=C(C=C4)O)C(=O)NC(=O)N3)C[C@@H]([C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]5[C@H]([C@H]([C@@H](O5)N6C=NC7=C(N=CN=C76)N)O)O)O)O)O,,,,,,
4264,444265,CID 444265,CC1=CC2=C(C=C1CN)[N+](=C3C(=N2)C(=O)NC(=O)N3)C[C@@H]([C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,,,,,,
4265,444266,Maleic acid,C(=C\C(=O)O)\C(=O)O,,,['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],,,
4266,444267,"calcium;(1R,2R)-1-hydroxypropane-1,2,3-tricarboxylic acid",C([C@H]([C@H](C(=O)O)O)C(=O)O)C(=O)O.[Ca+2],,,,,,
4267,444268,CID 444268,C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C4NC=NC5=O)OP(=O)(O)O)O)O)O)C(=O)N,,,,,,
4268,444269,CID 444269,C([C@@H]([C@H](C(=O)O)[O-])C(=O)O)C(=O)O.[MgH+],,,,,,
4269,444270,"trihydroxy-[(1R)-4-methoxy-1-[[(2S)-1-[(2R)-2-(morpholine-4-carbonylamino)-3,3-diphenylpropanoyl]pyrrolidine-2-carbonyl]amino]butyl]boranuide",[B-]([C@H](CCCOC)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](C(C2=CC=CC=C2)C3=CC=CC=C3)NC(=O)N4CCOCC4)(O)(O)O,,,,,,
4270,444271,CID 444271,CC[C@H]/1[C@@H](/C/2=C\C3=C(C(=C([N-]3)/C=C/4\[C@H]([C@@H](/C(=C/5\[C@@H](C(C6=C5[N-]C(=C6C)/C=C1/[N-]2)O)C(=O)OC)/[N-]4)CCC(=O)OCCC(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C)C)C(=O)C)C.[Mg+2],,,,,,
4271,444272,CID 444272,CC[C@@H]\1[C@H](/C/2=C/C3=C(C(=C(N3)/C=C\4/[C@H]([C@@H](/C(=C/5\[C@H](C(C6=C5NC(=C6C)/C=C1\N2)O)C(=O)OC)/N4)CCC(=O)OCCC(C)CCC[C@@H](C)CCC[C@@H](C)CCCC(C)C)C)C)C(=O)C)C,,,,,,
4272,444273,CID 444273,CC[C@@H]1[C@H](/C/2=C/C3=C(C(=C(N3)/C=C\4/[C@H]([C@@H](C(N4)C5=C6C(=C([C@@H]5C(=O)OC)O)C(C(N6)CC1N2)C)CCC(=O)OCCC(C)CCC[C@@H](C)CCC[C@@H](C)CCCC(C)C)C)C)C(=O)C)C,,,,,,
4273,444274,"2-[(E)-3,7,11,15,19,23,27,31,35,39-decamethyltetracont-2-enyl]-5,6-dimethoxy-3-methylbenzene-1,4-diol",CC1=C(C(=C(C(=C1O)OC)OC)O)C/C=C(\C)/CCCC(C)CCCC(C)CCCC(C)CCCC(C)CCCC(C)CCCC(C)CCCC(C)CCCC(C)CCCC(C)C,,,,,,
4274,444275,CID 444275,CC[C@@H]1[C@H](C2=CC3=C(C(=C([N-]3)C=C4[C@H]([C@@H](C(=C5[C@H](C(C6=C5[N-]C(=C6C)C=C1[N-]2)O)C(=O)OC)[N-]4)CCC(=O)OCC=C(C)C)C)C)C(=O)C)C.[Mg+2],,,,,,
4275,444276,CID 444276,CC[C@@H]\1[C@H](/C/2=C/C3=C(C(=C(N3)/C=C\4/[C@H]([C@@H](/C(=C/5\[C@H](C(C6=C5NC(=C6C)/C=C1\N2)O)C(=O)OC)/N4)CCC(=O)OCC=C(C)C)C)C)C(=O)C)C,,,,,,
4276,444277,CID 444277,CC[C@@H]1[C@H](/C/2=C/C3=C(C(=C(N3)/C=C\4/[C@H]([C@@H](C(N4)C5=C6C(=C([C@@H]5C(=O)OC)O)C(C(N6)CC1N2)C)CCC(=O)OCCC(C)CC)C)C)C(=O)C)C,,,,,,
4277,444278,"2,3-dimethoxy-5-methyl-6-[(E)-3,7,11,15,19-pentamethylicos-6-enyl]benzene-1,4-diol",CC1=C(C(=C(C(=C1O)OC)OC)O)CCC(C)CC/C=C(\C)/CCCC(C)CCCC(C)CCCC(C)C,,,,,,
4278,444279,Dodecyldimethylhydroxyammonium,CCCCCCCCCCCC[N+](C)(C)O,,,,,,
4279,444280,benzyl N-[(2S)-3-(4-hydroxyphenyl)-1-oxo-1-[(3-oxo-4-sulfanylbutan-2-yl)amino]propan-2-yl]carbamate,CC(C(=O)CS)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)OCC2=CC=CC=C2,,,,,,
4280,444281,"[(2R,3S,5R)-5-[(6S)-2,4-dioxo-6-sulfanyl-1,3-diazinan-1-yl]-3-hydroxyoxolan-2-yl]methyl dihydrogen phosphate",C1[C@@H]([C@H](O[C@H]1N2[C@H](CC(=O)NC2=O)S)COP(=O)(O)O)O,,,,,,
4281,444282,"[(1R)-1-[[(2S)-1-[(2R)-3,3-diphenyl-2-(phenylmethoxycarbonylamino)propanoyl]pyrrolidine-2-carbonyl]amino]-2-methylpropyl]boronic acid",B([C@H](C(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](C(C2=CC=CC=C2)C3=CC=CC=C3)NC(=O)OCC4=CC=CC=C4)(O)O,,,,,,
4282,444283,5-[hydroxy-(4-nitrophenoxy)phosphoryl]pentanoic Acid,C1=CC(=CC=C1[N+](=O)[O-])OP(=O)(CCCCC(=O)O)O,,,,,,
4283,444284,"[[(2R,3S,4R,5R)-5-(6-amino-7,8-dihydropurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(3R)-3-hydroxy-2,2-dimethyl-4-[[3-(methylamino)-3-oxopropyl]amino]-4-oxobutyl] hydrogen phosphate",CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2CNC3=C(N=CN=C32)N)O)OP(=O)(O)O)[C@H](C(=O)NCCC(=O)NC)O,,,,,,
4284,444285,Azane;cobalt,N.N.N.N.N.N.[Co],,,,,,
4285,444286,2-[(3-Hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethyl)-amino]-2-methyl-succinic acid,CC1=NC=C(C(=C1O)CN[C@@](C)(CC(=O)O)C(=O)O)COP(=O)(O)O,,,,,,
4286,444287,[(4S)-4-azaniumyl-5-oxopentyl]-(diaminomethylidene)azanium,C(C[C@@H](C=O)[NH3+])C[NH+]=C(N)N,,,,,,
4287,444288,Argininal,C(C[C@@H](C=O)N)CN=C(N)N,,,,,,
4288,444289,"2,7-Dibenzyl-1,1-dioxo-3,6-bis-phenoxymethyl-[1,2,7]thiadiazepane-4,5-diol",C1=CC=C(C=C1)CN2[C@@H]([C@@H]([C@H]([C@H](N(S2(=O)=O)CC3=CC=CC=C3)COC4=CC=CC=C4)O)O)COC5=CC=CC=C5,,,,,,
4289,444290,"(4R,5S,6S,7R)-1,3-dibenzyl-5,6-dihydroxy-4,7-bis(phenoxymethyl)-1,3-diazepan-2-one",C1=CC=C(C=C1)CN2[C@@H]([C@@H]([C@H]([C@H](N(C2=O)CC3=CC=CC=C3)COC4=CC=CC=C4)O)O)COC5=CC=CC=C5,,,,,,
4290,444291,CID 444291,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(S)S)O,,,,,,
4291,444292,2-[(3-Hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethylene)-amino]-succinic acid,CC1=NC=C(C(=C1O)CN[C@@H](CC(=O)O)C(=O)O)COP(=O)(O)O,,,,,,
4292,444293,"4-[(1,3-Dicarboxy-propylamino)-methyl]-3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridinium",CC1=NC=C(C(=C1O)CN[C@@H](CCC(=O)O)C(=O)O)COP(=O)(O)O,,,,,,
4293,444294,(-)-Camphor,C[C@]12CC[C@H](C1(C)C)CC2=O,['Indicated for the temporary symptomatic relief of minor aches and pains of muscles and joints in topical analgesics.'],"['Camphor exerts an analgesic action when applied topically by producing a warm sensation. It excites and desensitizes sensory nerves by activating heat-sensitive TRP vanilloid subtype 1 (TRPV1) and TRPV3 receptors. (S)-camphor is reported to exert a weaker action on TRPV1 channels, which is thought to be a result of tachyphylaxis, which is the reduction of the response to multiple stimulations.']",,"['Absorption of camphor in the mucous membranes and the gastrointestinal tract is rapid, and peak concentration following oral ingestion occurs within 5 to 90 minutes.', 'Camphor undergoes renal excretion.', 'Volume of distribution of camphor is 2 to 4 L/kg. Camphor and its metabolites are relatively fat-soluble thus may accumulate in adipose and other tissues. Camphor ingested by mothers was present in amnionic fluid, cord and fetal blood and fetal brain, liver and kidneys.', 'No pharmacokinetic data available.']","['(S)-camphor undergoes rapid oxidation to 5-exo-hydroxyfenchone, which is predominantly mediated by human liver microsomal cytochrome (P450). CYP2A6 is the major enzyme involved in the hydroxylation of (-)-camphor by human liver microsomes.']","['Following oral ingestion of 200 mg camphor, the half life was 167 minutes.']"
4294,444295,"dioxidanium;actinium;[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [hydroxy-[hydroxy(phosphonooxy)phosphoryl]oxyphosphoryl] hydrogen phosphate;azanide;hydrate",C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N.[NH2-].[NH2-].[NH2-].[NH2-].[NH2-].[OH3+].[OH3+].O.[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Ac],,,,,,
4295,444296,"(4S)-4-[[(2S)-6-amino-2-[[(2S)-2-[[(2S,3S)-2-amino-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]amino]-5-[(2S)-2-[[(2S)-1-[[(2S)-1-[[2-[[(1S)-1-carboxy-2-methylpropyl]amino]-2-oxoethyl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-5-oxopentanoic acid",CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CN=CN2)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)O)N,,,,,,
4296,444297,"actinium;[[[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]-[hydroxy(oxonio)phosphoryl]oxidanium;azanide;trihydrate",C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)[OH+]P(=O)([OH2+])O)O)O)N.[NH2-].[NH2-].[NH2-].[NH2-].[NH2-].O.O.O.[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Ac],,,,,,
4297,444298,H-Gly-Ser-Ser-Ser-Thr-al,C[C@H]([C@@H](C=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)CN)O,,,,,,
4298,444299,CID 444299,CCCCCCCCCCCCCC=C[C@@H]([C@@H](CO)N)O,,,,,,
4299,444300,n-Hydroxyamidocarboxymethyldethia coenzyme *a,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)[C@H](C(=O)NCCC(=O)NCCCC(=O)NO)O,,,,,,
4300,444301,"[(2S,3S,4R)-5-(7,8-dimethyl-2,4-dioxo-1H-benzo[g]pteridin-10-ium-10-yl)-2,3,4-trihydroxypentyl] dihydrogen phosphate",CC1=CC2=C(C=C1C)[N+](=C3C(=N2)C(=O)NC(=O)N3)C[C@H]([C@@H]([C@H](COP(=O)(O)O)O)O)O,,,,,,
4301,444302,"4-Carboxy-5-(1-pentyl)hexylsulfanyl-1,2,3-triazole",CCCCCC(CCCCC)SC1=NNN=C1C(=O)O,,,,,,
4302,444303,CID 444303,CCCCCCCCCCC1=C(NC(=O)C1=O)O,,,,,,
4303,444304,"3-[2-[[3-(2-carboxyethyl)-5-[(4-ethyl-3-methyl-5-oxopyrrol-2-yl)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-4-methyl-5-[[(3R,4R)-4-methyl-5-oxo-3-[(1R)-1-sulfanylethyl]pyrrolidin-2-yl]methyl]-1H-pyrrol-3-yl]propanoic acid",CCC1=C(C(=NC1=O)CC2=C(C(=C(N2)CC3=C(C(=C(N3)CC4[C@@H]([C@H](C(=O)N4)C)[C@@H](C)S)C)CCC(=O)O)CCC(=O)O)C)C,,,,,,
4304,444305,L-Tartaric acid,[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,"['Tartaric Acid is primarily indicated in conditions like Antiscorbutic, Antiseptic.']","['Tartaric acid is used to generate carbon dioxide through interaction with sodium bicarbonate following oral administration. Carbon dioxide extends the stomach and provides a negative contrast medium during double contrast radiography. In high doses, this agent acts as a muscle toxin by inhibiting the production of malic acid, which could cause paralysis and maybe death.']",,"['Oral or parenteral doses of monosodium 14C-L(+)-tartrate (400 mg/kg) are rapidly excreted by rats and a proportion completely metabolized to CO2. The oral dose was well-absorbed.', 'Only about 15-20% of consumed tartaric acid is secreted in the urine unchanged.']","['Most tartarate that is consumed by humans is metabolized by bacteria in the gastrointestinal tract , primarily in the large instestine.']",
4305,444306,3-(4-Iodo-phenyl)-2-mercapto-propionic acid,C1=CC(=CC=C1C[C@@H](C(=O)O)S)I,,,,,,
4306,444307,"1-[(2S,4S)-4-[(2R,4S,5S,6S)-5-amino-4-hydroxy-6-methyloxan-2-yl]oxy-2,5,6,11,12-pentahydroxy-7-methoxy-3,4-dihydro-1H-tetracen-2-yl]ethanone",C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C(C4=C(C5=C(C(=CC=C5)OC)C(=C4C(=C23)O)O)O)O)(C(=O)C)O)O)N,,,,,,
4307,444308,Molybdenum;tetrahydrate,O.O.O.O.[Mo],,,,,,
4308,444309,CID 444309,CC(C)(COP(=O)(O)OP(=O)(C)OC[C@H]1C[C@H]([C@@H]([C@@H]1OC(O)(O)O)O)N2C=NC3=C(C=CN=C32)N)[C@H](C(=O)NCCC(=O)NCCC[N+](=O)[O-])O,,,,,,
4309,444310,"[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2S,3S,4R)-5-(7,8-dimethyl-2,4-dioxo-1H-benzo[g]pteridin-10-ium-10-yl)-2,3,4-trihydroxypentyl] hydrogen phosphate",CC1=CC2=C(C=C1C)[N+](=C3C(=N2)C(=O)NC(=O)N3)C[C@H]([C@@H]([C@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,,,,,,
4310,444311,CID 444311,C1[C@@H]([C@H](O[C@H]1N2C=NC3=C2NC(=NC3=O)N)COP(=O)(O)O[C@H]4C[C@@H](O[C@@H]4COP(=O)(O)O[C@H]5C[C@@H](O[C@@H]5COP(=O)(O)O[C@H]6C[C@@H](O[C@@H]6CO)N7C=CC(=NC7=O)N)N8C=CC(=NC8=O)N)N9C=NC1=C9NC(=NC1=O)N)O,,,,,,
4311,444312,"[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]-[(1R,2S)-1-hydroxy-3-[[(2R,3S,4S)-3-hydroxy-5-[[(2S,3R)-3-hydroxy-1-oxo-1-[2-[4-[4-[3-[[(1S)-1-phenylethyl]amino]propylcarbamoyl]-1,3-thiazol-2-yl]-1,3-thiazol-2-yl]ethylamino]butan-2-yl]amino]-4-methyl-5-oxopentan-2-yl]amino]-1-(1H-imidazol-5-yl)-3-oxopropan-2-yl]azanide;cobalt(3+);hydrogen peroxide",CC1=C(N=C(N=C1N)[C@H](CC(=O)N)NC[C@@H](C(=O)N)N)C(=O)[N-][C@@H]([C@H](C2=CN=CN2)O)C(=O)N[C@H](C)[C@H]([C@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCCC3=NC(=CS3)C4=NC(=CS4)C(=O)NCCCN[C@@H](C)C5=CC=CC=C5)O.OO.[Co+3],,,,,,
4312,444313,CID 444313,CC1=C(N=C(N=C1N)[C@H](CC(=O)N)NC[C@@H](C(=O)N)N)C(=O)N[C@@H]([C@H](C2=CN=CN2)O)C(=O)N[C@@H](C)[C@H]([C@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCCC3=NC(=CS3)C4=NC(=CS4)C(=O)NCCCN[C@H](C)C5=CC=CC=C5)O,,,,,,
4313,444314,alpha-L-gulose,C([C@H]1[C@H]([C@@H]([C@@H]([C@@H](O1)O)O)O)O)O,,,,,,
4314,444315,3-O-formamido-alpha-D-mannopyranoside,C([C@@H]1[C@H]([C@@H]([C@@H]([C@H](O1)O)O)OC(=O)N)O)O,,,,,,
4315,444316,CID 444316,CC1=C(N=C(N=C1N)[C@H](CC(=O)N)NC[C@@H](C(=O)N)N)C(=O)N[C@@H]([C@H](C2=C[NH+]=CN2)O)C(=O)N[C@@H](C)[C@H]([C@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCCC3=NC(=CS3)C4=NC(=CS4)C(=O)NCCCN[C@H](C)C5=CC=CC=C5)O,,,,,,
4316,444317,(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoic acid,CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)N[C@@H](C(C)C)C(=O)O)N,,,,,,
4317,444318,Mercuracyclopropane,C1C[Hg]1,,,,,,
4318,444319,"N-(4-{[(2,4-Diaminopteridin-1-Ium-6-Yl)methyl](Methyl)amino}benzoyl)-L-Glutamic Acid",CN(CC1=C[NH+]=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,,,,,,
4319,444320,"2',5'-Dideoxyuridine",C[C@@H]1[C@H](C[C@@H](O1)N2C=CC(=O)NC2=O)O,,,,,,
4320,444321,CID 444321,CC1=C(C2=CC3=C(C(=C([N-]3)C=C4C(=C(C)S)C(=C([N-]4)C=C5C(=C(C)S)C(=C([N-]5)C=C1[N-]2)C)C)C)CCC(=O)O)CCC(=O)O.[Fe],,,,,,
4321,444322,CID 444322,CC\1=C(/C/2=C/C3=C(C(=C(N3)/C=C\4/C(=C(C)S)C(=C(N4)/C=C\5/C(=C(C)S)C(=C(N5)/C=C1\N2)C)C)C)CCC(=O)O)CCC(=O)O,,,,,,
4322,444323,CID 444323,CC1=C2C=C3C(=O)[C@](C(=CC4=C([C@](C(=CC5=C(C(=CC=C(O)O)C(=CC(=C1CCC(=O)O)[N-]2)[N-]5)C)[N-]4)(C)CC(=O)O)O)[N-]3)(C)CC(=O)O.[Fe],,,,,,
4323,444324,CID 444324,CC1=C2C=C3C(=O)[C@](/C(=C/C4=C([C@](C(=CC5=C(C(=CC=C(O)O)/C(=C/C(=C1CCC(=O)O)N2)/N5)C)N4)(C)CC(=O)O)O)/N3)(C)CC(=O)O,,,,,,
4324,444325,CID 444325,CC1=CC2=C(C=C1C)[N+](=C3C(=N2)C(=O)NC(=O)N3)C[C@@H]([C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4C(=C([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,,,,,,
4325,444326,CID 444326,CC1=C2C=C3C(=O)[C@](/C(=C/C4=C([C@](/C(=C/C5=C(C(=CC=C(O)O)/C(=C/C(=C1CCC(=O)O)N2)/N5)C)/N4)(C)CC(=O)O)O)/N3)(C)CC(=O)O,,,,,,
4326,444327,CID 444327,C[C@@]1([C@@H](C2C=C3C(=C(C(=CC4=C(C(=C([N-]4)C=C5[C@@]([C@@H](C(=CC1[N-]2)[N-]5)CCC(=O)O)(C)CC(=O)O)CC(=O)O)CCC(=O)O)[N-]3)CCC(=O)O)CC(=O)O)CCC(=O)O)CC(=O)O.[Fe],,,,,,
4327,444328,"3-[(2S,3S,5Z,7S,8S,9Z,15Z,19Z)-7,13,17-tris(2-carboxyethyl)-3,8,12,18-tetrakis(carboxymethyl)-3,8-dimethyl-1,2,4,7,21,22,23,24-octahydroporphyrin-2-yl]propanoic acid",C[C@@]1([C@@H](C2/C=C\3/C(=C(/C(=C/C4=C(C(=C(N4)/C=C\5/[C@@]([C@@H](/C(=C/C1N2)/N5)CCC(=O)O)(C)CC(=O)O)CC(=O)O)CCC(=O)O)/N3)CCC(=O)O)CC(=O)O)CCC(=O)O)CC(=O)O,,,,,,
4328,444329,CID 444329,CC1=C2/C=C\3/C(=O)[C@](/C(=C/C4=C([C@](/C(=C/C5=C(C(=CC=C(O)O)/C(=C/C(=C1CCC(=O)O)N2)/N5)C)/N4)(C)CC(=O)O)O)/N3)(C)CC(=O)O,,,,,,
4329,444330,CID 444330,C([C@@H]1C(=C([C@H]2[C@@H](O1)NC3=NC(NC(=O)C3N2)N)[S-])[S-])OP(=O)(O)[O-].C([C@H]1C(=C([C@H]2[C@@H](O1)NC3=C(N2)C(=O)N=C(N3)N)[S-])[S-])OP(=O)(O)[O-].[OH-].[OH-].[Mg+2].[W],,,,,,
4330,444331,CID 444331,C([C@@H]1C(=C([C@H]2[C@@H](O1)NC3=C(N2)C(=O)N=C(N3)N)S)S)OP(=O)(O)O,,,,,,
4331,444332,CID 444332,C([C@@H]1C(=C([C@H]2[C@@H](O1)NC3=NC(NC(=O)C3N2)N)S)S)OP(=O)(O)O,,,,,,
4332,444333,Sodium;hydroxide;dihydrate,O.O.[OH-].[Na+],,,,,,
4333,444334,Copper;hydrate,O.[Cu],,,,,,
4334,444335,CID 444335,CN1C=[N+](C2=C1C(=O)N=C(N2)N)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)O)O)O,,,,,,
4335,444336,CID 444336,CC1=C(C(CCC1)(C)C)/C=C/C(C)C/C=C/C(C)C=CN,,,,,,
4336,444337,CID 444337,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C5NC(=NC6=O)N)O)O)O)N,,,,,,
4337,444338,"3-Hydroxy-1,2,3lambda5-dioxaphosphirane 3-oxide",OP1(=O)OO1,,,,,,
4338,444339,"ethyl (3S,4S)-8-amino-3-hydroxy-4-[[(2S)-3-methyl-2-[[(2S)-3-methyl-2-(3-methylbutanoylamino)butanoyl]amino]butanoyl]amino]octanoate",CCOC(=O)C[C@@H]([C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C)O,,,,,,
4339,444340,3-Hydroxy-6-methyl-4-(3-methyl-2-(3-methyl-2-(3-methyl-butyrylamino)-butyrylamino)-butyrylamino)-heptanoic acid ethyl ester,CCOC(=O)C[C@@H]([C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C)O,,,,,,
4340,444341,"(4S)-2,2-difluoro-3,3-dihydroxy-N,6-dimethyl-4-[[(2S)-3-methyl-2-[[(2S)-3-methyl-2-(3-methylbutanoylamino)butanoyl]amino]butanoyl]amino]heptanamide",CC(C)C[C@@H](C(C(C(=O)NC)(F)F)(O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C,,,,,,
4341,444342,"(2R,3S,4S)-3,4-dihydro-2H-pyran-2,3,4,5-tetrol",C1=C([C@H]([C@@H]([C@@H](O1)O)O)O)O,,,,,,
4342,444343,"(3R,4S)-2,2-difluoro-3-hydroxy-N,6-dimethyl-4-[[(2S)-3-methyl-2-[[(2S)-3-methyl-2-(3-methylbutanoylamino)butanoyl]amino]butanoyl]amino]heptanamide",CC(C)C[C@@H]([C@H](C(C(=O)NC)(F)F)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C,,,,,,
4343,444344,Alpha-L-Xylopyranose,C1[C@@H]([C@H]([C@@H]([C@@H](O1)O)O)O)O,,,,,,
4344,444345,"(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,17,19,21,23,25,27-decaen-16-one",C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)C=NC6=O)NC)OC,,,,,,
4345,444346,Aeruginosin 98-b,CC[C@@H](C)[C@H](C(=O)N1[C@H]2C[C@@H](CC[C@H]2C[C@H]1C(=O)NCCCCN=C(N)N)OS(=O)(=O)O)NC(=O)[C@@H](CC3=CC=C(C=C3)O)O,,,,,,
4346,444347,CID 444347,CC1=C(C(CCC1)(C)C)/C=C/C(=C/CCC(=CCO)C)/C,,,,,,
4347,444348,(2R)-2-phosphonooxypropanoic acid,C[C@H](C(=O)O)OP(=O)(O)O,,,,,,
4348,444349,"2-[[(4S)-4-[(3S,5R,7R,8R,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonic acid",C[C@@H](CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](CC3[C@H]2[C@@H](C[C@@H]4[C@@]3(CC[C@@H](C4)O)C)O)O)C,,,,,,
4349,444350,N-[(4s)-4-Ammonio-4-Carboxybutanoyl]-S-(4-Bromobenzyl)-L-Cysteinylglycine,C1=CC(=CC=C1CSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)[NH3+])Br,,,,,,
4350,444351,CID 444351,C1=CC(=CC=C1CSC[C@@H](C(=O)NCC(=O)O)NC(=O)CCC(C(=O)O)N)Br,,,,,,
4351,444352,"(2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-1-oxo-3-[(1R)-2,4,6-trinitrocyclohexa-2,4-dien-1-yl]sulfanylpropan-2-yl]amino]-5-oxopentanoic acid",C1=C(C=C([C@@H](C1[N+](=O)[O-])SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)[N+](=O)[O-])[N+](=O)[O-],,,,,,
4352,444353,"(2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-1-oxo-3-[(1S)-2,4,6-trinitrocyclohexa-2,4-dien-1-yl]sulfanylpropan-2-yl]amino]-5-oxopentanoic acid",C1=C(C=C([C@H](C1[N+](=O)[O-])SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)[N+](=O)[O-])[N+](=O)[O-],,,,,,
4353,444354,"3-[18-(2-carboxyethyl)-7-ethenyl-17-formyl-12-[(1S,8E)-1-hydroxy-5,9,13-trimethyltetradeca-8,12-dienyl]-3,8,13-trimethylporphyrin-22,24-diid-2-yl]propanoic acid;iron(2+)",CC1=C(C2=CC3=NC(=CC4=C(C(=C([N-]4)C=C5C(=C(C(=N5)C=C1[N-]2)[C@H](CCCC(C)CC/C=C(\C)/CCC=C(C)C)O)C)C=O)CCC(=O)O)C(=C3C)CCC(=O)O)C=C.[Fe+2],,,,,,
4354,444355,"3-[18-(2-carboxyethyl)-7-ethenyl-17-(hydroxymethylidene)-12-[(1S,8E)-1-hydroxy-5,9,13-trimethyltetradeca-8,12-dienyl]-3,8,13-trimethyl-22H-porphyrin-2-yl]propanoic acid",CC1=C(C2=CC3=NC(=CC4=C(C(=CO)C(=N4)C=C5C(=C(C(=N5)C=C1N2)[C@H](CCCC(C)CC/C=C(\C)/CCC=C(C)C)O)C)CCC(=O)O)C(=C3C)CCC(=O)O)C=C,,,,,,
4355,444356,CID 444356,CCNC(=O)[C@@H](C)NC(=O)[C@@H](C)NC(=O)[C@H](C)N.C[C@H]([C@@H](C=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CO)N)O,,,,,,
4356,444357,CID 444357,CCNC(=O)C(C)NC(=O)[C@@H](C)NC(=O)[C@H](C)N,,,,,,
4357,444358,H-Ser-Ser-Ser-Thr-al,C[C@H]([C@@H](C=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CO)N)O,,,,,,
4358,444359,CID 444359,CC1=CC=C(C=C1)S(=O)(=O)N[C@@H](CCCCN)C(=O)CN,,,,,,
4359,444360,2-Amino-5-guanidino-pentanoic acid,C(C[C@@H](C(=O)O)[NH3+])C[NH+]=C(N)N,,,,,,
4360,444361,"Hydroxylamine, N-hydroxy-",N(O)O,,,,,,
4361,444362,"[4-(Aminomethyl)-1,2-dimethyl-3-oxo-2,4-dihydropyridin-5-yl]methyl dihydrogen phosphate",CC1C(=O)C(C(=CN1C)COP(=O)(O)O)CN,,,,,,
4362,444363,"2-[4-(2-Hydroxyethyl)-2,3-dihydropyrazin-1-yl]ethanesulfonic acid",C1CN(C=CN1CCO)CCS(=O)(=O)O,,,,,,
4363,444364,CID 444364,CC1=C(C(CCC1)(C)C)C=CC(=C/C=C/C(=CCN)C)C,,,,,,
4364,444365,Trioxido(Oxo)tungsten,O.O.O.O.[W],,,,,,
4365,444366,(2S)-3-(4-hydroxyphenyl)-2-[[(2S)-4-methyl-2-(sulfanylmethyl)pentanoyl]amino]propanoic acid,CC(C)C[C@H](CS)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O,,,,,,
4366,444367,"WURCS=2.0/1,1,0/[a2122h-1a_1-5_1*N_2*NCC/3=O]/1",CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1N)CO)O)O,,,,,,
4367,444368,benzyl N-[(2S)-1-[[2-hydroxy-3-[[(2S)-4-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]-2-sulfanylpropyl]amino]-4-methyl-1-oxopentan-2-yl]carbamate,CC(C)C[C@@H](C(=O)NCC(CNC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1)(O)S)NC(=O)OCC2=CC=CC=C2,,,,,,
4368,444369,N-[(2S)-1-[[(2S)-2-hydroxy-3-[(4-phenoxyphenyl)sulfonylamino]-2-sulfanylpropyl]amino]-4-methyl-1-oxopentan-2-yl]pyridine-4-carboxamide,CC(C)C[C@@H](C(=O)NC[C@](CNS(=O)(=O)C1=CC=C(C=C1)OC2=CC=CC=C2)(O)S)NC(=O)C3=CC=NC=C3,,,,,,
4369,444370,"benzyl N-[(2S)-1-[(3S,4R)-3-hydroxy-4-[[(2S)-4-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]-3-sulfanylpyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]carbamate",CC(C)C[C@@H](C(=O)N[C@@H]1CN(C[C@]1(O)S)C(=O)[C@H](CC(C)C)NC(=O)OCC2=CC=CC=C2)NC(=O)OCC3=CC=CC=C3,,,,,,
4370,444371,"pyridin-4-ylmethyl N-[(2S)-1-[[(3R,4S)-4-hydroxy-1-[(2S)-4-methyl-2-(phenylmethoxycarbonylamino)pentyl]-4-sulfanylpyrrolidin-3-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate",CC(C)C[C@@H](CN1C[C@H]([C@@](C1)(O)S)NC(=O)[C@H](CC(C)C)NC(=O)OCC2=CC=NC=C2)NC(=O)OCC3=CC=CC=C3,,,,,,
4371,444372,"Azane;butane-1,4-diamine;platinum",C(CCN)CN.N.N.N.N.[Pt].[Pt],,,,,,
4372,444373,N-(3-Carboxypropanoyl)-L-Valyl-N-[(1r)-5-Amino-1-Phosphonopentyl]-L-Prolinamide,CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)P(=O)(O)O)NC(=O)CCC(=O)O,,,,,,
4373,444374,[(1R)-1-[[(2S)-1-[(2R)-2-amino-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-2-(3-cyanophenyl)ethyl]-trihydroxyboranuide,[B-]([C@H](CC1=CC(=CC=C1)C#N)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](CC3=CC=CC=C3)N)(O)(O)O,,,,,,
4374,444375,"[(4S)-4-[[(2S)-1-[(2R)-2-azaniumyl-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-5,5-dihydroxyhexyl]-(diaminomethylidene)azanium",CC([C@H](CCC[NH+]=C(N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](CC2=CC=CC=C2)[NH3+])(O)O,,,,,,
4375,444376,CID 444376,CC(C(CCCN=C(N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](CC2=CC=CC=C2)N)(O)O,,,,,,
4376,444377,CID 444377,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)S)O)O)N,,,,,,
4377,444378,CID 444378,CN1C=[N+](C2=C1C(=O)N=C(N2)N)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O,,,,,,
4378,444379,Mu-Oxo-Diiron,O.[Fe].[Fe],,,,,,
4379,444380,"(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-sulfooxyphenyl)propanoyl]amino]-4-methylpentanoic acid",CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)OS(=O)(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)N,,,,,,
4380,444381,CID 444381,CC(=CC(=O)C[C@@H]([C@@H]1[C@@H](C[C@]2([C@@]1([C@@H](C[C@H]3C2=CC[C@H]4[C@]3(CC[C@H]([C@@]4(C)C(=O)O[C@@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)CO)O)O)O)OC(=O)C)C)O)C)C=O)O)C(=O)O)C,,,,,,
4381,444382,"(3R,4S,5R,9R,10R,13S,14S,16S,17S)-3-acetyloxy-17-[(1S)-1-carboxy-5-methyl-3-oxohex-4-enyl]-16-hydroxy-4,10,13,14-tetramethyl-2,3,5,6,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene-4-carboxylic acid",CC(=CC(=O)C[C@@H]([C@@H]1[C@H](C[C@]2([C@]1(CC[C@H]3C2=CC[C@@H]4[C@@]3(CC[C@H]([C@@]4(C)C(=O)O)OC(=O)C)C)C)C)O)C(=O)O)C,,,,,,
4382,444383,H-Pro-Pro-Pro-Pro-Pro-Pro-Pro-Pro-Pro-Pro-OH,C1C[C@H](NC1)C(=O)N2CCC[C@H]2C(=O)N3CCC[C@H]3C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N7CCC[C@H]7C(=O)N8CCC[C@H]8C(=O)N9CCC[C@H]9C(=O)N1CCC[C@H]1C(=O)O,,,,,,
4383,444384,2-(2-{[1-(2-{2-[2-Amino-3-(3H-imidazol-4-yl)-propionylamino]-propionylamino}-acetyl)-pyrrolidine-2-carbonyl]-amino}-3-methyl-pentanoylamino)-propionic acid,CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC2=CN=CN2)N,,,,,,
4384,444385,H-His-Val-Gly-Pro-Ile-Ala-OH,CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CN=CN2)N,,,,,,
4385,444386,[(1S)-1-carboxy-4-[[(2R)-1-(carboxymethylamino)-3-[(2R)-2-hydroxypropanoyl]sulfanyl-1-oxopropan-2-yl]amino]-4-oxobutyl]azanium,C[C@H](C(=O)SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)[NH3+])O,,,,,,
4386,444387,CID 444387,CC1=CC2=C(C=C1C)[N+](=C3C(=N2)C(=O)NC(=O)N3)C[C@@H](C([C@@H](COP(=O)(O)O)O)O)O,,,,,,
4387,444388,"(7S,8R,9S,10R)-10-amino-7,8,9,10-tetrahydrobenzo[a]pyrene-7,8,9-triol",C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4[C@H]([C@@H]([C@@H]([C@H]5O)O)O)N)C=C2,,,,,,
4388,444389,"N,O6-Disulfo-Glucosamine",C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O)NS(=O)(=O)O)O)O)OS(=O)(=O)O,,,,,,
4389,444390,2-O-Sulfo-Alpha-L-Idopyranuronic Acid,[C@@H]1([C@@H]([C@@H](O[C@H]([C@@H]1OS(=O)(=O)O)O)C(=O)O)O)O,,,,,,
4390,444391,"(7R)-10beta-Amino-7,8,9,10-tetrahydrobenzo[a]pyrene-7beta,8alpha,9alpha-triol",C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4[C@@H]([C@H]([C@H]([C@@H]5O)O)O)N)C=C2,,,,,,
4391,444392,Sulfanium;iron;iron(2+);sulfanide,[SH3+].[SH-].[SH-].[SH-].[Fe].[Fe].[Fe+2],,,,,,
4392,444393,"(4S,5R,6R,7R)-7-(hydroxymethyl)-1,2,3,3a,4,5,6,7-octahydrotriazolo[1,5-a]pyridine-4,5,6-triol",C1C2[C@@H]([C@H]([C@@H]([C@H](N2NN1)CO)O)O)O,,,,,,
4393,444394,"(1S,2S,5S)2-(4-Glutaridylbenzyl)-5-phenyl-1-cyclohexanol",C1C[C@@H]([C@H](C[C@H]1C2=CC=CC=C2)O)C3=CC=C(C=C3)C(=O)NCCCC(=O)O,,,,,,
4394,444395,"(7R,8S,9R,10R)-10-amino-7,8,9,10-tetrahydrobenzo[a]pyrene-7,8,9-triol",C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4[C@H]([C@H]([C@H]([C@@H]5O)O)O)N)C=C2,,,,,,
4395,444396,"(2s)-2-[(4-{[(2,4-Diamino-7,8-dihydropteridin-6-yl)methyl](methyl)amino}phenyl)formamido]pentanedioic acid",CN(CC1=NC2=C(N=C(N=C2NC1)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,,,,,,
4396,444397,"(2R,3R)-heptane-1,2,3-triol",CCCC[C@H]([C@@H](CO)O)O,,,,,,
4397,444398,"[(4S)-5-amino-4-[[(2S,3R)-3-[[(Z)-2-[[(4R)-4-amino-5-hydroxypentanoyl]-methylamino]but-2-enoyl]amino]-3-carboxy-2-methylpropanoyl]amino]-5-oxopentyl]-(diaminomethylidene)azanium",C/C=C(/C(=O)N[C@H]([C@H](C)C(=O)N[C@@H](CCC[NH+]=C(N)N)C(=O)N)C(=O)O)\N(C)C(=O)CC[C@H](CO)N,,,,,,
4398,444399,"(2R,3S)-4-[[(2S)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-[[(Z)-2-[[(4R)-4-amino-5-hydroxypentanoyl]-methylamino]but-2-enoyl]amino]-3-methyl-4-oxobutanoic acid",C/C=C(/C(=O)N[C@H]([C@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N)C(=O)O)\N(C)C(=O)CC[C@H](CO)N,,,,,,
4399,444400,"(2S,3S,4E,6E,8R,9R)-3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienamide",C[C@H](/C=C(\C)/C=C/[C@@H]([C@H](C)C(=O)N)N)[C@@H](CC1=CC=CC=C1)OC,,,,,,
4400,444401,CID 444401,C1C[C@H]2C(=O)N[C@H](C(C(=O)N=CC=CC=CC=CC(=O)N[C@@H](C(=O)N2C1)CCC3=CC=CC=C3)(O)O)CCCN=C(N)N,,,,,,
4401,444402,CID 444402,CCCCCCCCCCCCCCCCCCOC[C@H](COP(=O)(O)OCCSC)NC(C)O,,,,,,
4402,444403,benzyl N-[(2S)-1-[2-[hydroxy-[2-[(2S)-4-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]hydrazinyl]-sulfanylmethyl]hydrazinyl]-4-methyl-1-oxopentan-2-yl]carbamate,CC(C)C[C@@H](C(=O)NNC(NNC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1)(O)S)NC(=O)OCC2=CC=CC=C2,,,,,,
4403,444404,"benzyl N-[(2S)-1-[2-[(R)-hydroxy-[2-[(1S)-3-methyl-1-(phenylmethoxycarbonylamino)butyl]-1,3-thiazol-4-yl]-sulfanylmethyl]hydrazinyl]-4-methyl-1-oxopentan-2-yl]carbamate",CC(C)C[C@@H](C1=NC(=CS1)[C@@](NNC(=O)[C@H](CC(C)C)NC(=O)OCC2=CC=CC=C2)(O)S)NC(=O)OCC3=CC=CC=C3,,,,,,
4404,444405,benzyl N-[(2S)-1-[2-[(R)-hydroxy-[2-(3-phenylmethoxybenzoyl)hydrazinyl]-sulfanylmethyl]hydrazinyl]-4-methyl-1-oxopentan-2-yl]carbamate,CC(C)C[C@@H](C(=O)NN[C@](NNC(=O)C1=CC(=CC=C1)OCC2=CC=CC=C2)(O)S)NC(=O)OCC3=CC=CC=C3,,,,,,
4405,444406,methyl (3S)-3-(3-carbamimidoylphenyl)-5-(4-carbamimidoylphenyl)pentanoate,COC(=O)C[C@H](CCC1=CC=C(C=C1)C(=N)N)C2=CC(=CC=C2)C(=N)N,,,,,,
4406,444407,[(4S)-4-[[(2S)-1-[(2S)-1-[(2S)-2-[[(2S)-1-[(2S)-1-[(2S)-1-[(2S)-2-azaniumyl-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-5-[[(2S)-1-[[(1S)-1-carboxy-4-(diaminomethylideneazaniumyl)butyl]amino]-5-(diaminomethylideneazaniumyl)-1-oxopentan-2-yl]amino]-5-oxopentyl]-(diaminomethylidene)azanium,CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N3CCC[C@H]3C(=O)N[C@@H](C(C)C)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@@H](CCC[NH+]=C(N)N)C(=O)N[C@@H](CCC[NH+]=C(N)N)C(=O)N[C@@H](CCC[NH+]=C(N)N)C(=O)O)[NH3+],,,,,,
4407,444408,Ras inhibitory peptide,CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N3CCC[C@H]3C(=O)N[C@@H](C(C)C)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N,,,,,,
4408,444409,CID 444409,C[C@@]1(C=C([C@@]2([C@]3([C@H](CCC([C@@H]3[C@@H]([C@@H]([C@]2(O1)C)OC(=O)CCCCN4CCN(CC4)C)O)(C)C)O)C)O)O)C=C,,,,,,
4409,444410,"1-O-[(1-O-Methyl-2-O,3-O,6-O-tri(sulfo)-4-deoxy-alpha-D-glucopyranose)-4-yl]-4-O-[4-O-[4-O-(2-O,6-O-disulfo-3-O,4-O-dimethyl-alpha-D-glucopyranosyl)-2-O,3-O-dimethyl-beta-D-glucopyranuronosyl]-2-O,3-O,6-O-tri(sulfo)-alpha-D-glucopyranosyl]-2-O-sulfo-3-O-methyl-alpha-L-idopyranuronic acid",CO[C@@H]1[C@H](O[C@@H]([C@@H]([C@H]1OC)OS(=O)(=O)O)O[C@H]2[C@@H]([C@H]([C@@H](O[C@@H]2C(=O)O)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3OS(=O)(=O)O)OS(=O)(=O)O)O[C@H]4[C@@H]([C@H]([C@@H](O[C@H]4C(=O)O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5OS(=O)(=O)O)OS(=O)(=O)O)OC)COS(=O)(=O)O)OS(=O)(=O)O)OC)COS(=O)(=O)O)OC)OC)COS(=O)(=O)O,,,,,,
4410,444411,CID 444411,C1[C@@H]([C@H](O[C@H]1N2[C@@H]([C@H](C(=O)NC2=O)F)S)COP(=O)(O)O)O,,,,,,
4411,444412,CID 444412,CN1[C@H](CNC2=C1C(=O)N=C(N2)N)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,,,,,,
4412,444413,Lys-Cys-Lys,C(CCN)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)O)N,,,,,,
4413,444414,Iron monohydroxide,O.[Fe],,,,,,
4414,444415,CID 444415,CC1=C(C2=CC3=NC(=CC4=C(C(=C([N-]4)C=C5C(=C(C(=N5)C=C1[N-]2)C=C)C)C#C)C)C(=C3CCC(=O)O)C)CCC(=O)O.[Fe+2],,,,,,
4415,444416,CID 444416,CC1=C(C2=CC3=NC(=CC4=NC(=CC5=C(C(=C(N5)C=C1N2)C#C)C)C(=C4CCC(=O)O)C)C(=C3C)CCC(=O)O)C=C,,,,,,
4416,444417,"(2S)-1-[(2S)-3-methyl-2-[[4-(morpholine-4-carbonyl)benzoyl]amino]butanoyl]-N-[(3S)-5,5,6,6,6-pentafluoro-4,4-dihydroxy-2-methylhexan-3-yl]pyrrolidine-2-carboxamide",CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(C(C(F)(F)F)(F)F)(O)O)NC(=O)C2=CC=C(C=C2)C(=O)N3CCOCC3,,,,,,
4417,444418,(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoic acid,C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)NCC(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N5CCC[C@H]5C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)O)N,,,,,,
4418,444419,H-Lys-1Nal-Lys-OH,C1=CC=C2C(=C1)C=CC=C2C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCCN)N,,,,,,
4419,444420,Tetrasulfanium;iron;hydrate,O.[SH3+].[SH3+].[SH3+].[SH3+].[Fe].[Fe].[Fe].[Fe],,,,,,
4420,444421,"2-[3-[(4-azanyl-2-methyl-pyrimidin-5-yl)methyl]-4-methyl-2H-1,3-thiazol-5-yl]ethyl phosphono hydrogen phosphate",CC1=C(SCN1CC2=CN=C(N=C2N)C)CCOP(=O)(O)OP(=O)(O)O,,,,,,
4421,444422,H-Gly-Ile-Leu-al.H-Val-Phe-Thr-Unk,CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C=O)NC(=O)CN.C[C@H]([C@@H](C(=O)N[C@H](C)C(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](C(C)C)N)O,,,,,,
4422,444423,"(2S,3S)-2-[(2-aminoacetyl)amino]-3-methyl-N-[(2S)-4-methyl-1-oxopentan-2-yl]pentanamide",CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C=O)NC(=O)CN,,,,,,
4423,444424,CID 444424,C[C@H]([C@@H](C(=O)N[C@H](C)C(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)[C@H](C(C)C)N)O,,,,,,
4424,444425,Cbz-Ala-Val-Phe-ol,C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)CO)NC(=O)OCC2=CC=CC=C2,,,,,,
4425,444426,"(2S,3R)-3-acetyloxy-2-[(2S)-4-prop-2-enoxycarbonyl-2,5-dihydro-1,3-thiazol-2-yl]butanoic acid",C[C@H]([C@H]([C@H]1N=C(CS1)C(=O)OCC=C)C(=O)O)OC(=O)C,,,,,,
4426,444427,"[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-[(4S)-3-carbamoyl-4-(2-hydroxypropyl)-3,4-dihydro-2H-pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate",CC(C[C@H]1C=CN(CC1C(=O)N)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O)O,,,,,,
4427,444428,"[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-[(4R)-3-carbamoyl-4-[(2S)-3-hydroxypentan-2-yl]-4H-pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate",CCC([C@@H](C)[C@H]1C=CN(C=C1C(=O)N)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O)O,,,,,,
4428,444429,"[(2R,3S)-5-(7,8-dimethyl-2,4-dioxo-1H-benzo[g]pteridin-10-ium-10-yl)-2,3,4-trihydroxypentyl] dihydrogen phosphate",CC1=CC2=C(C=C1C)[N+](=C3C(=N2)C(=O)NC(=O)N3)CC([C@@H]([C@@H](COP(=O)(O)O)O)O)O,,,,,,
4429,444430,"(2S)-6-amino-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-4-phenylbutanoyl]amino]hexanoic acid",C1=CC=C(C=C1)CC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCCN)N,,,,,,
4430,444431,CID 444431,C.C([C@H]1C(=C([C@H]2[C@@H](O1)NC3=NC(NC(=O)C3N2)N)[S-])[S-])OP(=O)(O)[O-].C([C@@H]1C(=C([C@H]2[C@@H](O1)N=C3C(=N2)C(=O)N=C(N3)N)[S-])[S-])OP(=O)(O)[O-].O.[Mg+2].[W],,,,,,
4431,444432,CID 444432,C([C@@H]1C(=C([C@H]2[C@@H](O1)N=C3C(=N2)C(=O)N=C(N3)N)S)S)OP(=O)(O)O,,,,,,
4432,444433,"(2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2,6-diaminohexanoyl]amino]pentanoyl]amino]hexanoic Acid",C(CCN)C[C@@H](C(=O)N[C@@H](CCCN)C(=O)N[C@@H](CCCCN)C(=O)O)N,,,,,,
4433,444434,4beta-Carboxycyclohexane-1alpha-methaneaminium,C1CC(CCC1C[NH3+])C(=O)O,,,,,,
4434,444435,CID 444435,C1CC=C([C@@H](C1)[C@H]2C=CN(C=C2C(=O)N)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,,,,,,
4435,444436,CID 444436,C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=CC(=O)NC2=O)O)O.C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)CO)OP(=O)O)O)NC(=NC2=O)N,,,,,,
4436,444437,5'-Deoxyuridine,C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=CC(=O)NC2=O)O)O,,,,,,
4437,444438,CID 444438,C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)CO)OP(=O)O)O)NC(=NC2=O)N,,,,,,
4438,444439,(S)-5-Oxopyrrolidine-2-carboxamide,C1CC(=O)N[C@@H]1C(=O)N,,,,,,
4439,444440,"6-Methyl-5-(4,5,6-trihydroxy-3-hydroxymethyl-cyclohex-2-enylamino)-tetrahydro-pyran-2,3,4-triol",C[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O)O)O)N[C@H]2C=C([C@H]([C@@H]([C@H]2O)O)O)CO,,,,,,
4440,444441,Lys-Met-Lys,CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCCN)N,,,,,,
4441,444442,"3-[2-[[3-(2-carboxyethyl)-5-[(4-ethyl-3-methyl-5-oxopyrrol-2-yl)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-4-methyl-5-[[3-methyl-2-oxo-4-[(1R)-1-sulfanylethyl]-1,3-dihydropyrrol-5-yl]methyl]-1H-pyrrol-3-yl]propanoic acid",CCC1=C(C(=NC1=O)CC2=C(C(=C(N2)CC3=C(C(=C(N3)CC4=C(C(C(=O)N4)C)[C@@H](C)S)C)CCC(=O)O)CCC(=O)O)C)C,,,,,,
4442,444443,CID 444443,CCCCCONCC(=O)N,,,,,,
4443,444444,CID 444444,CC(C)C[C@@H](C(NO)O)N(CC1=CC=CC=C1)P(=O)(C)C2=CC=CC=C2,,,,,,
4444,444445,"(2S)-6-amino-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]hexanoic acid",C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCCN)N,,,,,,
4445,444446,"(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylpentanoyl]amino]hexanoic acid",CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCCN)N,,,,,,
4446,444447,"(2S)-6-amino-2-[[(2S)-3-cyclohexyl-2-[[(2S)-2,6-diaminohexanoyl]amino]propanoyl]amino]hexanoic acid",C1CCC(CC1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCCN)N,,,,,,
4447,444448,"(2S)-6-amino-2-[[2-[[(2S)-2,6-diaminohexanoyl]amino]acetyl]amino]hexanoic Acid",C(CCN)C[C@@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)N,,,,,,
4448,444449,"(E,2S,3R)-3-hydroxy-4-oxo-2-sulfanyldodec-10-enamide",C/C=C/CCCCCC(=O)[C@H]([C@@H](C(=O)N)S)O,,,,,,
4449,444450,Purine Riboside-5'-Monophosphate,C1=C2C(=NC=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O,,,,,,
4450,444451,Selenazole-4-carboxyamide-adenine dinucleotide,C1=C(N=C([Se]1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O)C(=O)N,,,,,,
4451,444452,H-Lys-Phe-Lys-al,C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCCN)C=O)NC(=O)[C@H](CCCCN)N,,,,,,
4452,444453,1-Methyl-6-amino-3H-purine-1-ium,C[N+]1=C(C2=C(N=CN2)N=C1)N,,,,,,
4453,444454,"(2S)-6-amino-2-[[(2S)-1-[(2S)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]hexanoic Acid",C1C[C@H](N(C1)C(=O)[C@H](CCCCN)N)C(=O)N[C@@H](CCCCN)C(=O)O,,,,,,
4454,444455,4-S-Glutathionyl-5-pentyl-tetrahydro-furan-2-OL,CCCCC[C@@H]1[C@H](C[C@@H](O1)O)SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N,,,,,,
4455,444456,1-Deoxy-1-methoxycarbamido-beta-D-gluco-2-heptulopyranosonamide,COC(=O)N[C@]1([C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)C(=O)N,,,,,,
4456,444457,"(2S)-6-amino-2-[[(2S)-4-amino-2-[[(2S)-2,6-diaminohexanoyl]amino]butanoyl]amino]hexanoic acid",C(CCN)C[C@@H](C(=O)N[C@@H](CCN)C(=O)N[C@@H](CCCCN)C(=O)O)N,,,,,,
4457,444458,(R)-4-Aminopentanoic acid,C[C@H](CCC(=O)O)N,,,,,,
4458,444459,CID 444459,C([C@H]1C(=C([C@H]2[C@@H](O1)N=C3C(=N2)C(=O)N=C(N3)N)[S-])[S-])OP(=O)(O)[O-].C(=C/1\C(=C([C@H]2C(=NC3=NC(NC(=O)C3=N2)N)O1)[S-])[S-])\OP(=O)(O)[O-].[Mg+2].[W],,,,,,
4459,444460,CID 444460,C(=C/1\C(=C([C@H]2C(=NC3=NC(NC(=O)C3=N2)N)O1)S)S)\OP(=O)(O)O,,,,,,
4460,444461,"L-Gamma-Glutamyl-S-[(9s,10s)-10-Hydroxy-9,10-Dihydrophenanthren-9-Yl]-L-Cysteinylglycine",C1=CC=C2C(=C1)[C@@H]([C@H](C3=CC=CC=C32)SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)O,,,,,,
4461,444462,N-[(4r)-4-Ammonio-4-Carboxybutanoyl]-L-Cysteinylglycine,C(CC(=O)N[C@@H](CS)C(=O)NCC(=O)O)[C@@H](C(=O)O)[NH3+],,,,,,
4462,444463,Lys-Asp-Lys,C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N,,,,,,
4463,444464,"(2S)-6-amino-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-hydroxypropanoyl]amino]hexanoic acid",C(CCN)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N,,,,,,
4464,444465,"(2S)-6-amino-2-[[(2S,3R)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-hydroxybutanoyl]amino]hexanoic acid",C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCCN)N)O,,,,,,
4465,444466,CID 444466,C(C(NO)O)OP(=O)(O)O,,,,,,
4466,444467,CID 444467,CC(=CC[C@@H]1[C@@](O1)(C)[C@]2([C@@H](C(=O)CC[C@@]2(CN)O)OC)O)C,,,,,,
4467,444468,CID 444468,[H+].CC1=C(C2=CC3=NC(=CC4=C(C(=C([N-]4)C=C5C(=C(C(=N5)C=C1[N-]2)C=C)C)C=C)C)C(=C3CCC(=O)O)C)CCC(=O)O.[Fe+2],,,,,,
4468,444469,"[[[(4s,5s)-4-[[(3s,6s,8ar)-6-Azanyl-5-Oxo-6-(Phenylmethyl)-1,2,3,7,8,8a-Hexahydroindolizin-3-Yl]carbonylamino]-5-(1,3-Benzothiazol-2-Yl)-5-Hydroxy-Pentyl]amino]-Azanyl-Methylidene]azanium",C1C[C@H](N2[C@H]1CC[C@@](C2=O)(CC3=CC=CC=C3)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)C4=NC5=CC=CC=C5S4,,,,,,
4469,444470,"(2S)-6-amino-2-[[(2S)-3-amino-2-[[(2S)-2,6-diaminohexanoyl]amino]propanoyl]amino]hexanoic acid",C(CCN)C[C@@H](C(=O)N[C@@H](CN)C(=O)N[C@@H](CCCCN)C(=O)O)N,,,,,,
4470,444471,"(2S)-6-amino-2-[[(2S)-4-amino-2-[[(2S)-2,6-diaminohexanoyl]amino]-4-oxobutanoyl]amino]hexanoic acid",C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N,,,,,,
4471,444472,"(2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2,6-diaminohexanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid",C(CCN)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N,,,,,,
4472,444473,"1,4-Butanediamine, N,N'-dibutyl-",CCCCNCCCCNCCCC,,,,,,
4473,444474,(2S)-2-amino-N-[(2S)-1-amino-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]butanamide,CC[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N)N,,,,,,
4474,444475,CID 444475,C[C@H]([C@H](C1=CN=C2C(=N1)C(=O)N=C(N2)N)O)O,,,,,,
4475,444476,CID 444476,CC(=CC[C@@H]1C(O1)(C)[C@H]2[C@@H]([C@@H](CC[C@@]2(CN)O)OC(=O)NC(=O)CCl)OC)C,,,,,,
4476,444477,Lysyl-norvalyl-lysine,CCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCCN)N,,,,,,
4477,444478,"1-[2-(8-Carbamoylmethyl-6,9-dioxo-2-oxa-7,10-diaza-bicyclo[11.2.2] heptadeca-1(16),13(17),14-trien-11-YL)-2-hydroxy-ethyl]-pyrrolidine-2-carboxylic acid [1-(1-carbamoyl-2-methyl-propylcarbamoyl)-2-methyl-butyl]-amide",CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N)NC(=O)[C@@H]1CCCN1C[C@@H]([C@@H]2CC3=CC=C(C=C3)OCCCC(=O)N[C@H](C(=O)N2)CC(=O)N)O,,,,,,
4478,444479,"(2S)-N-[(2S,3R)-4-[[(8S,11S)-8-[(2S)-butan-2-yl]-7,10-dioxo-2-oxa-6,9-diazabicyclo[11.2.2]heptadeca-1(15),5,13,16-tetraen-11-yl]amino]-3-hydroxy-1-(4-hydroxyphenyl)butan-2-yl]-3-methyl-2-(2-oxopyrrolidin-1-yl)butanamide",CC[C@H](C)[C@H]1C(=O)N=CCCOC2=CC=C(C[C@@H](C(=O)N1)NC[C@H]([C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](C(C)C)N4CCCC4=O)O)C=C2,,,,,,
4479,444480,"1-[2-(8-Carbamoylmethyl-6,9-dioxo-2-oxa-7,10-diaza-bicyclo[11.2.2]heptadeca-1(16),13(17),14-trien-11-YL)-2-hydroxy-ethyl]-piperidine-2-carboxylic acid tert-butylamide",CC(C)(C)NC(=O)[C@@H]1CCCCN1C[C@H]([C@@H]2CC3=CC=C(C=C3)OCCCC(=O)N[C@H](C(=O)N2)CC(=O)N)O,,,,,,
4480,444481,"[1-Benzyl-3-(8-Sec-Butyl-7,10-Dioxo-2-Oxa-6,9-Diaza-Bicyclo[11.2.2] Heptadeca-1(16),13(17),14-Trien-11-Ylamino)-2-Hydroxy-Propyl]-Carbamic Acid Tert-Butyl Ester",CC[C@H](C)[C@H]1C(=O)NCCCOC2=CC=C(C[C@@H](C(=O)N1)NC[C@H]([C@H](CC3=CC=CC=C3)NC(=O)OC(C)(C)C)O)C=C2,,,,,,
4481,444482,CID 444482,CC(C)CCNC[C@H]([C@@H]1CC2=CC=C(C=C2)OCCCC(=O)N[C@H](C(=O)N1)C(C)C)O,,,,,,
4482,444483,CID 444483,CC(C)CCNC[C@H]([C@@H]1CC2=CC=C(C=C2)OCCCC(=O)N[C@H](C(=O)N1)CC(=O)N)O,,,,,,
4483,444484,"N-[3-(8-Sec-butyl-7,10-dioxo-2-oxa-6,9-diaza-bicyclo[11.2.2] heptadeca-1(16),13(17),14-trien-11-yamino)-2-hydroxy-1-(4-hydroxy-benzyl)-propyl]-3-methyl-2-propionylamino-butyramide",CC[C@H](C)[C@H]1C(=O)NCCCOC2=CC=C(C[C@@H](C(=O)N1)NC[C@H]([C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](C(C)C)NC(=O)CC)O)C=C2,,,,,,
4484,444485,Dephospho coenzyme a,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O)[C@H](C(=O)NCCC(=O)NCCS)O,,,,,,
4485,444486,"2,6-Dipyridin-2-ylpyridine;platinum",C1=CC=NC(=C1)C2=NC(=CC=C2)C3=CC=CC=N3.[Pt],,,,,,
4486,444487,"(2S)-6-amino-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]hexanoyl]amino]hexanoic acid",CCCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCCN)N,,,,,,
4487,444488,"3-[18-(2-carboxyethyl)-3,8,13,17-tetramethyl-7-[(1S)-1-sulfanylethyl]-12-[(1R)-1-sulfanylethyl]porphyrin-21,23-diid-2-yl]propanoic acid;iron(2+)",CC1=C(C2=CC3=NC(=CC4=C(C(=C([N-]4)C=C5C(=C(C(=N5)C=C1[N-]2)[C@H](C)S)C)[C@@H](C)S)C)C(=C3CCC(=O)O)C)CCC(=O)O.[Fe+2],,,,,,
4488,444489,"3-[18-(2-carboxyethyl)-3,7,12,17-tetramethyl-13-[(1S)-1-sulfanylethyl]-8-[(1R)-1-sulfanylethyl]-22,23-dihydroporphyrin-2-yl]propanoic acid",CC1=C(C2=CC3=NC(=CC4=NC(=CC5=C(C(=C(N5)C=C1N2)[C@@H](C)S)C)C(=C4CCC(=O)O)C)C(=C3C)CCC(=O)O)[C@H](C)S,,,,,,
4489,444490,Adenosine-5'-[phenylalaninol-phosphate],C1=CC=C(C=C1)C[C@@H](COP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=CN=C43)N)O)O)N,,,,,,
4490,444491,"3-[18-(2-Carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid;hydrogen peroxide;fluoride",CC1=C(C2=CC3=NC(=CC4=NC(=CC5=C(C(=C(N5)C=C1N2)C=C)C)C(=C4CCC(=O)O)C)C(=C3C)CCC(=O)O)C=C.OO.[F-],,,,,,
4491,444492,"3-[18-(2-Carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid;fluoride",CC1=C(C2=CC3=NC(=CC4=NC(=CC5=C(C(=C(N5)C=C1N2)C=C)C)C(=C4CCC(=O)O)C)C(=C3C)CCC(=O)O)C=C.[F-],,,,,,
4492,444493,Acetyl coenzyme A,CC(=O)SCCNC(=O)CCNC(=O)[C@@H](C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
4493,444494,H-Gly-Tyr-NH2.H-Tyr-NH2,C1=CC(=CC=C1C[C@@H](C(=O)N)N)O.C1=CC(=CC=C1C[C@@H](C(=O)N)NC(=O)CN)O,,,,,,
4494,444495,CID 444495,C[C@@H]1[C@H](C(=CC2=C(C(=C(N2)CC3=C(C(=C(N3)C[C@@H]4C(=C(C(=O)N4)C=C)C)C)CCC(=O)O)CCC(=O)O)C)NC1=O)[C@@H](C)S,,,,,,
4495,444496,CID 444496,CC1=C(C(=O)N[C@@H]1CC2=C(C(=C(N2)C=C3C(=C(C(N3)C[C@H]4C(=C(C(=O)N4)C)[C@H](C)S)C)CCC(=O)O)CCC(=O)O)C)[C@@H](C)S,,,,,,
4496,444497,Magnesium hydroxide hydrate,O.[OH-].[OH-].[Mg+2],,,,,,
4497,444498,CID 444498,C1=C(C2=C(N1)C(=O)N=C(N2)N)[C@H]3[C@@H]([C@@H]([C@H](N3)CO)O)O,,,,,,
4498,444499,CID 444499,C1=C(C2=C(N1)C(=O)N=CN2)[C@H]3[C@@H]([C@@H]([C@H](N3)CO)O)O,,,,,,
4499,444500,[(2S)-1-[[(2S)-1-[[(2S)-6-azaniumyl-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]azanium,CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCC[NH3+])C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)O)[NH3+],,,,,,
4500,444501,CID 444501,CC(C)[C@@H](C(=O)NC(C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)NC(CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)O)N,,,,,,
4501,444502,"[[(2R,3S,4R,5R)-5-(6-amino-7,8-dihydropurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4S)-5-(7,8-dimethyl-2,4-dioxo-1H-benzo[g]pteridin-10-ium-10-yl)-2,3,4-trihydroxypentyl] hydrogen phosphate",CC1=CC2=C(C=C1C)[N+](=C3C(=N2)C(=O)NC(=O)N3)C[C@@H]([C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5CNC6=C(N=CN=C65)N)O)O)O)O)O,,,,,,
4502,444503,"2',3'-Dideoxy-3'-fluoro-urididine-5'-diphosphate",C1[C@@H]([C@H](O[C@H]1N2C=CC(=O)NC2=O)COP(=O)(O)OP(=O)(O)O)F,,,,,,
4503,444504,CID 444504,C.C[AsH]O,,,,,,
4504,444505,CID 444505,C[AsH]O,,,,,,
4505,444506,H-Lys-Leu-Lys-OH,CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCCN)N,,,,,,
4506,444507,"1-(4-Carboxy-2-guanidinopentyl)-5,5'-DI(hydroxymethyl)pyrrolidin-2-one",C1CC(N(C1=O)C2=C(C=C(C=C2)C(=O)O)N=C(N)N)(CO)CO,,,,,,
4507,444508,"1-[4-Carboxy-2-(3-pentylamino)phenyl]-5,5'-DI(hydroxymethyl)pyrrolidin-2-one",CCC(CC)NC1=C(C=CC(=C1)C(=O)O)N2C(=O)CCC2(CO)CO,,,,,,
4508,444509,(2S)-2-amino-3-(1H-imidazol-5-yl)-N-[(2S)-1-oxopropan-2-yl]propanamide,C[C@@H](C=O)NC(=O)[C@H](CC1=CN=CN1)N,,,,,,
4509,444510,"(2S)-2-[[2-[(5S)-5-(benzylsulfonylamino)-6-oxo-2,5-dihydropyridin-1-yl]acetyl]amino]-5-(diaminomethylideneamino)pentanoic acid",C1C=C[C@@H](C(=O)N1CC(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NS(=O)(=O)CC2=CC=CC=C2,,,,,,
4510,444511,"1-N-(2-aminoethyl)-3-N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-4,6-dinitrobenzene-1,3-diamine",CC1(CC(CC(N1O)(C)C)NC2=C(C=C(C(=C2)NCCN)[N+](=O)[O-])[N+](=O)[O-])C,,,,,,
4511,444512,(2S)-2-benzyl-3-hydroxypropanoic acid,C1=CC=C(C=C1)C[C@@H](CO)C(=O)O,,,,,,
4512,444513,2-[(3S)-3-(benzylsulfonylamino)-2-oxopiperidin-1-yl]-N-[(2S)-1-[(3R)-1-carbamimidoylpiperidin-3-yl]-3-hydroxypropan-2-yl]acetamide,C1C[C@@H](CN(C1)C(=N)N)C[C@@H](CO)NC(=O)CN2CCC[C@@H](C2=O)NS(=O)(=O)CC3=CC=CC=C3,,,,,,
4513,444514,Triacetylchitotriose,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O)CO)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)NC(=O)C)O)NC(=O)C)O,,,,,,
4514,444515,"N-[(2S,3R,4R,5S,6R)-2-[(2R,3S,4R,5R,6S)-5-acetamido-6-[(2R,3S,4R,5R,6R)-5-formamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide;methane",C.CC1=CC(=O)OC2=C1C=CC(=C2)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)NC(=O)C)O)NC(=O)C)O)NC=O,,,,,,
4515,444516,"N-[(2S,3R,4R,5S,6R)-2-[(2R,3S,4R,5R,6S)-5-acetamido-6-[(2R,3S,4R,5R,6R)-5-formamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide",CC1=CC(=O)OC2=C1C=CC(=C2)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)NC(=O)C)O)NC(=O)C)O)NC=O,,,,,,
4516,444517,CID 444517,CC1=C(C2=CC3=NC(=CC4=C(C(=C([N-]4)C=C5C(=C(C(=N5)C=C1[N-]2)C=C)C)C=C)C)C(=C3CCC(=O)O)C)CCC(=O)O.[C-]#[O+].[Fe+3],,,,,,
4517,444518,3-[5-[[5-[[5-[[4-(2-carboxyethyl)-3-methyl-5-oxopyrrol-2-yl]methyl]-4-ethyl-3-methyl-1H-pyrrol-2-yl]methyl]-4-ethyl-3-methyl-1H-pyrrol-2-yl]methyl]-4-methyl-2-oxopyrrol-3-yl]propanoic acid,CCC1=C(NC(=C1C)CC2=C(C(=C(N2)CC3=NC(=O)C(=C3C)CCC(=O)O)C)CC)CC4=NC(=O)C(=C4C)CCC(=O)O,,,,,,
4518,444519,Ac-Asn-Trp-Glu-Thr-Phe-OH,C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CC(=O)N)NC(=O)C)O,,,,,,
4519,444520,"2,3-Dimethoxy-5-methyl-6-(3,7,11-trimethyltridecyl)benzene-1,4-diol",CCC(C)CCCC(C)CCCC(C)CCC1=C(C(=C(C(=C1O)OC)OC)O)C,,,,,,
4520,444521,CID 444521,CCCCC=CCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCN)O[C@@H]1[C@H](O1)CCCCCCCCCC=CCCCC,,,,,,
4521,444522,Heme BC,CCC1=C(C2=NC1=CC3=C(C(=C([N-]3)C=C4C(=C(C(=N4)C=C5C(=C(C(=C2)[N-]5)C)CCC(=O)O)CCC(=O)O)C)C=C)C)C.[Fe+2],,,,,,
4522,444523,Val-Arg,CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N,,,,,,
4523,444524,"WURCS=2.0/1,1,0/[a1122h-1b_1-5_1*N_2*NCC/3=O]/1",CC(=O)N[C@H]1[C@H]([C@@H]([C@H](O[C@H]1N)CO)O)O,,,,,,
4524,444525,6-Deoxy-beta-D-altropyranose,C[C@@H]1[C@H]([C@H]([C@@H]([C@@H](O1)O)O)O)O,,,,,,
4525,444526,"(2S)-2-[[(2S)-2-[[(2S)-2-[(6S)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-2-[[(1S)-1-carboxy-2-phenylethyl]carbamoylamino]acetyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoic acid",CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H]([C@@H]2CCN=C(N2)N)NC(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O,,,,,,
4526,444527,"2-(acetylamino)-1,5-anhydro-2-deoxy-D-mannitol",CC(=O)N[C@@H]1CO[C@@H]([C@H]([C@@H]1O)O)CO,,,,,,
4527,444528,{1-[(3-Hydroxy-methyl-5-phosphonooxy-methyl-pyridin-4-ylmethyl)-amino]-ethyl}-phosphonic acid,CC1=NC=C(C(=C1O)CN[C@@H](C)P(=O)(O)O)COP(=O)(O)O,,,,,,
4528,444529,CID 444529,CN(C)C1=CC=CC2=C1C=CC(=C2)S(=O)(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CCC[NH+]=C(N)N)C(CN)(O)O,,,,,,
4529,444530,CID 444530,CN(C)C1=CC=CC2=C1C=CC(=C2)S(=O)(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(CN)(O)O,,,,,,
4530,444531,"[(4S)-4-[[(2S,3aS,7aS)-1-[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,4R)-1-[(2S)-1-[(2S)-2-[[(2R)-2-azaniumyl-5-(diaminomethylideneazaniumyl)pentanoyl]amino]-5-(diaminomethylideneazaniumyl)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-2-(2,3-dihydro-1H-inden-2-yl)acetyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-4-carboxybutyl]-(diaminomethylidene)azanium",C1CC[C@H]2[C@@H](C1)C[C@H](N2C(=O)[C@@H](C3CC4=CC=CC=C4C3)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CC=CS5)NC(=O)CNC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H]7CCCN7C(=O)[C@H](CCC[NH+]=C(N)N)NC(=O)[C@@H](CCC[NH+]=C(N)N)[NH3+])O)C(=O)N[C@@H](CCC[NH+]=C(N)N)C(=O)O,,,,,,
4531,444532,"(2S)-2-[[(2S,3aS,7aS)-1-[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,4R)-1-[(2S)-1-[(2S)-2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-2-(2,3-dihydro-1H-inden-2-yl)acetyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid",C1CC[C@H]2[C@@H](C1)C[C@H](N2C(=O)[C@@H](C3CC4=CC=CC=C4C3)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CC=CS5)NC(=O)CNC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H]7CCCN7C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)N)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O,,,,,,
4532,444533,"tert-butyl N-[(2S,3S,5S)-5-benzyl-3-hydroxy-6-[[(1S)-1-(1H-imidazol-2-yl)propyl]amino]-6-oxo-1-phenylhexan-2-yl]carbamate",CC[C@@H](C1=NC=CN1)NC(=O)[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OC(C)(C)C)O,,,,,,
4533,444534,"dioxidanium;actinium;azanide;neptunium;nobelium;(1-pentyl-3,4-dihydro-2H-pyridin-5-yl)methanamine;phosphonooxidanium;hydrate",[CH2-]CCCCN1CCCC(=C1)CN.[NH2-].[NH2-].[NH2-].[NH2-].[NH2-].[OH3+].[OH3+].O.[OH2+]P(=O)(O)O.[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Np].[No].[No].[No].[No].[No].[No].[No].[No],,,,,,
4534,444535,"(1-pentyl-3,4-dihydro-2H-pyridin-5-yl)methanamine",CCCCCN1CCCC(=C1)CN,,,,,,
4535,444536,"tert-butyl N-[(2S,3S,5S)-5-benzyl-3-hydroxy-6-[[(1S)-1-(1H-imidazol-2-yl)-2-methylpropyl]amino]-6-oxo-1-phenylhexan-2-yl]carbamate",CC(C)[C@@H](C1=NC=CN1)NC(=O)[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OC(C)(C)C)O,,,,,,
4536,444537,CID 444537,CC1=C(/C/2=C/C3=C(C(=C(N3)/C=C\4/C(=C(C)S)C(=C(N4)/C=C\5/C(=C(C)S)C(=C(N5)C=C1N2)C)C)C)CCC(=O)O)CCC(=O)O,,,,,,
4537,444538,"3,3-Dihydroxy-1-propenylbenzene",C1=CC=C(C=C1)/C=C/C(O)O,,,,,,
4538,444539,Cinnamic acid,C1=CC=C(C=C1)/C=C/C(=O)O,,,,,,
4539,444540,H-Ala-Gln-Thr-Ser-Val-OH,C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)N)O,,,,,,
4540,444541,Dihydroxydimethylarsenic(V),C[AsH](C)(O)O,,,,,,
4541,444542,CID 444542,CC1=C2CC3=C(C(=C([N-]3)C=C4C(=C(C(=CC5=C(C(=C([N-]5)CC(=C1CCC(=O)O)[N-]2)CCC(=O)O)C)[N-]4)C=C)C)C=C)C.[Fe],,,,,,
4542,444543,"3-[(10Z,14Z)-18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethyl-5,20,21,22,23,24-hexahydroporphyrin-2-yl]propanoic acid",CC1=C2CC3=C(C(=C(N3)/C=C\4/C(=C(/C(=C/C5=C(C(=C(N5)CC(=C1CCC(=O)O)N2)CCC(=O)O)C)/N4)C=C)C)C=C)C,,,,,,
4543,444544,CID 444544,CC1=C(C2=CC3=C(C(=C([N-]3)C=C4C(=C(C(=CC5=C(C(=C([N-]5)C[C@@H]1[N-]2)C)CCC(=O)O)[N-]4)CCC(=O)O)C)C=C)C)C=C.[Fe],,,,,,
4544,444545,CID 444545,CC1=C(/C/2=C/C3=C(C(=C(N3)C=C4C(=C(/C(=C/C5=C(C(=C(N5)C[C@@H]1N2)C)CCC(=O)O)/N4)CCC(=O)O)C)C=C)C)C=C,,,,,,
4545,444546,CID 444546,CC1=C(C2=CC3=C(C(=C([N-]3)C=C4C(=C(C(=CC5=C(C(=C([N-]5)CC1[N-]2)C)CCC(=O)O)[N-]4)CCC(=O)O)C)C=C)C)C=O.[Fe],,,,,,
4546,444547,CID 444547,CC1=C(C2=CC3=C(C(=C(N3)C=C4C(=C(/C(=C/C5=C(C(=C(N5)CC1N2)C)CCC(=O)O)/N4)CCC(=O)O)C)C=C)C)C=O,,,,,,
4547,444548,CID 444548,CC1=C([C@@H]2CC3=C(C(=C([N-]3)C=C4C(=C(C(=CC5=C(C(=C([N-]5)C=C1[N-]2)C=C)C)[N-]4)C=C)C)C)CCC(=O)O)CCC(=O)O.[Fe],,,,,,
4548,444549,CID 444549,CC\1=C([C@@H]2CC3=C(C(=C(N3)/C=C\4/C(=C(/C(=C/C5=C(C(=C(N5)/C=C1\N2)C=C)C)/N4)C=C)C)C)CCC(=O)O)CCC(=O)O,,,,,,
4549,444550,[3-Hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethyl]-serine,CC1=NC=C(C(=C1O)CN[C@@H](CO)C(=O)O)COP(=O)(O)O,,,,,,
4550,444551,Imidazol-3-ide;2-pyridin-2-ylpyridine;ruthenium(1+),C1=CC=NC(=C1)C2=CC=CC=N2.C1=CC=NC(=C1)C2=CC=CC=N2.C1=CN=C[N-]1.[Ru+],,,,,,
4551,444552,4-Deoxy-2-O-Sulfo-Alpha-L-Threo-Hex-4-Enopyranuronic Acid,C1=C(O[C@H]([C@@H]([C@H]1O)OS(=O)(=O)O)O)C(=O)O,,,,,,
4552,444553,Ac-Ser-Tyr-Val-Lys-Ala-OH,C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CO)NC(=O)C,,,,,,
4553,444554,"(2S,3R,4S,5S,6R)-6-methyl-5-[[(5R,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohexa-1,3-dien-1-yl]amino]oxane-2,3,4-triol",C[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O)O)O)NC2=CC(=C([C@@H]([C@H]2O)O)O)CO,,,,,,
4554,444555,"(2R,3R,4S,5S)-6-methyl-5-[[(5R,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohexa-1,3-dien-1-yl]amino]oxane-2,3,4-triol",CC1[C@H]([C@@H]([C@H]([C@@H](O1)O)O)O)NC2=CC(=C([C@@H]([C@H]2O)O)O)CO,,,,,,
4555,444556,(2R)-N-[(2S)-2-hydroxy-3-(pyridin-2-ylsulfonylamino)-2-sulfanylpropyl]-4-methyl-2-(3-phenylphenyl)pentanamide,CC(C)C[C@H](C1=CC=CC(=C1)C2=CC=CC=C2)C(=O)NC[C@](CNS(=O)(=O)C3=CC=CC=N3)(O)S,,,,,,
4556,444557,CID 444557,C[C@@H]1C[C@@H]2[C@H](O2)/C=C\C=C\C(=O)C=C3C(=C(O1)O)C(=CC(=C3Cl)O)O,,,,,,
4557,444558,CID 444558,C[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(C)(O)O)NC(=O)OCC3=CC=CC=C3,,,,,,
4558,444559,CID 444559,C1=CC(=CC2C1[Hg]2)S(=O)(=O)O,,,,,,
4559,444560,4-(2-Oxo-2-hydroxyethyl)-N-Ac-L-Phe-L-Glu-L-Glu-L-Ile-OH,CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)CC(=O)O)NC(=O)C,,,,,,
4560,444561,H-Asp-Phe-Glu-Glu-Ile-OH,CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(=O)O)N,,,,,,
4561,444562,"5-Oxo-6-phenylmethanesulfonylamino-hexahydro-thiazolo[3,2-A]pyridine-3-carboxylic acid (3-guanidino-propyl)-amide",C1C[C@H]2N([C@@H](CS2)C(=O)NCCCN=C(N)N)C(=O)[C@@H]1NS(=O)(=O)CC3=CC=CC=C3,,,,,,
4562,444563,"[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2S,3R,4R)-5-(7,8-dimethyl-2,4-dioxo-1H-benzo[g]pteridin-10-ium-10-yl)-2,3,4-trihydroxypentyl] hydrogen phosphate",CC1=CC2=C(C=C1C)[N+](=C3C(=N2)C(=O)NC(=O)N3)C[C@H]([C@H]([C@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,,,,,,
4563,444564,"[(2R,3S,4R,5R)-5-(6-amino-7,8-dihydropurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate",C1NC2=C(N=CN=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)O)O)O)N,,,,,,
4564,444565,CID 444565,CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@@H]2CCCN2C(=O)CNC(=O)[C@H](CCCN=C(N)N)N,,,,,,
4565,444566,4-Amino-4-hydroxybutanamide,C(CC(=O)N)C(N)O,,,,,,
4566,444567,N-Methyl-N-(Methylbenzyl)formamide,C[C@@H](C1=CC=CC=C1)N(C)C=O,,,,,,
4567,444568,"(2S)-3-(2-amino-1,3-thiazol-4-yl)-2-methylpropanamide",C[C@@H](CC1=CSC(=N1)N)C(=O)N,,,,,,
4568,444569,(S)-2-Amino-3-cyclohexylpropan-1-ol,C1CCC(CC1)C[C@@H](CO)N,,,,,,
4569,444570,"1,5,5-Trimethylpyrrolidin-2-one",CC1(CCC(=O)N1C)C,,,,,,
4570,444571,CID 444571,C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)OP(=O)(O)O)NC(=NC2=O)N,,,,,,
4571,444572,"(3R)-N-hydroxy-2-(3-hydroxypropyl)-N'-[1-(2-methoxyethyl)-7-oxo-3,4-dihydro-2H-azepin-6-yl]-3-(2-methylpropyl)butanediamide",CC(C)C[C@H](C(CCCO)C(=O)NO)C(=O)NC1=CCCCN(C1=O)CCOC,,,,,,
4572,444573,CID 444573,C[C@@]1(C2=C[C@H]3[C@@H](C(=O)C(=C(N)O)[C@@H]([C@]3(C(C2=C(C4=C(C=CC(=C41)Cl)O)O)O)O)O)N(C)C)O,,,,,,
4573,444574,CID 444574,CC1=C(C2=CC3=C(C(=C([N-]3)C=C4C(=C(C(=CC5=C(C(=C([N-]5)CC1[N-]2)C)CCC(=O)O)[N-]4)CCC(=O)O)C)C(=O)C)C)C(=O)C.[Fe],,,,,,
4574,444575,CID 444575,CC1=C(/C/2=C/C3=C(C(=C(N3)C=C4C(=C(/C(=C/C5=C(C(=C(N5)CC1N2)C)CCC(=O)O)/N4)CCC(=O)O)C)C(=O)C)C)C(=O)C,,,,,,
4575,444576,CID 444576,C1[C@@H]([C@H](O[C@H]1N2[C@H](CC(=O)NC2=O)S)COP(=O)(O)O)O.F,,,,,,
4576,444577,"(2R)-2-[[4-[(6aS)-3-amino-1-oxo-2,3,4,6,6a,7,9,10a-octahydroimidazo[1,5-f]pteridin-8-yl]benzoyl]amino]pentanedioic acid",C1[C@@H]2CN(CN2C3C(=N1)NC(NC3=O)N)C4=CC=C(C=C4)C(=O)N[C@H](CCC(=O)O)C(=O)O,,,,,,
4577,444578,"L-Glutamic acid, 2-methyl-",C[C@](CCC(=O)O)(C(=O)O)N,,,,,,
4578,444579,CID 444579,C/C(=C\C(=O)C(=O)O)/N,,,,,,
4579,444581,1-(2-Amidinophenyl)-3-(phenoxyphenyl)urea,C1=CC=C(C=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC=C(C=C3)C(=N)N,,,,,,
4580,444582,CID 444582,C[C@@]1([C@H]2C[C@H]3C(=C(C(=C(N)O)C(=O)[C@]3(C(C2=C(C4=C(C=CC(=C41)Cl)O)O)O)O)O)N(C)C)O,,,,,,
4581,444583,N(1)Ala(Unk)-D-Val-OH.H-Aad(1)-OH,CC(C)[C@H](C(=O)O)NC(=O)[C@H](C[S-])NC(=O)CCC[C@@H](C(=O)O)N,,,,,,
4582,444584,CID 444584,CC(C)C(C(=O)O)NC(=O)[C@H](CS)NC(=O)CCC[C@@H](C(=O)O)N,,,,,,
4583,444585,H-Lys-Lys-Lys-Arg-Lys-Val-al,CC(C)[C@@H](C=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)N,,,,,,
4584,444586,CID 444586,C[C@H](C=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)N,,,,,,
4585,444587,N-{(2r)-2-[2-(Hydroxyamino)-2-Oxoethyl]-4-Methylpentanoyl}-3-Methyl-L-Valyl-N-(2-Aminoethyl)-L-Alaninamide,C[C@@H](C(=O)NCCN)NC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)CC(=O)NO,,,,,,
4586,444588,CID 444588,C[C@H]1C[C@H]([C@@H]2[C@@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@H]([C@@H](CC(=O)[C@H](CC(=C1)C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,,,,,,
4587,444589,[[O-Phosphono-N-acetyl-tyrosinyl]-glutamyl-3[cyclohexylmethyl]alaninyl]-amine,CC(=O)N[C@@H](CC1=CC=C(C=C1)OP(=O)(O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](CCC2CCCCC2)C(=O)N,,,,,,
4588,444590,"{3-[3-(3,4-Dimethoxy-phenyl)-1-(1-{1-[2-(3,4,5-trimethoxy-phenyl)-butyryl]-piperidin-2yl}-vinyloxy)-propyl]-phenoxy}-acetic acid",CC[C@@H](C1=CC(=C(C(=C1)OC)OC)OC)C(=O)N2CCCC[C@H]2C(=O)O[C@H](CCC3=CC(=C(C=C3)OC)OC)C4=CC(=CC=C4)OCC(=O)O,,,,,,
4589,444591,(Z)-2-hydroxypent-2-enedioic acid,C(/C=C(/C(=O)O)\O)C(=O)O,,,,,,
4590,444592,CID 444592,CC1=C2/C=C\3/C(=O)[C@](C(=CC4=C([C@](C(=CC5=C(C(=CC=C(O)O)/C(=C/C(=C1CCC(=O)O)N2)/N5)C)N4)(C)CC(=O)O)O)N3)(C)CC(=O)O,,,,,,
4591,444593,CID 444593,C(CO)C(=O)[C@H](C(=O)O)N/C=C\C=O,,,,,,
4592,444594,(2E)-3-[(4-hydroxy-2-oxobutyl)amino]prop-2-enal,C(CO)C(=O)CN/C=C/C=O,,,,,,
4593,444595,[[2-(4-Iodophenyl)acetyl]amino]methylphosphonic acid,C1=CC(=CC=C1CC(=O)NCP(=O)(O)O)I,,,,,,
4594,444596,Retinylamine,CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/CN)/C)/C,,,,,,
4595,444597,"[(2R)-3-[(3S,7R)-3,7-dimethylnonoxy]-2-[(3S,7R,11S)-3,7,11,15-tetramethylhexadecoxy]propyl] [(2S)-2-hydroxy-3-phosphonooxypropyl] hydrogen phosphate",CC[C@@H](C)CCC[C@H](C)CCOC[C@H](COP(=O)(O)OC[C@H](COP(=O)(O)O)O)OCC[C@@H](C)CCC[C@H](C)CCC[C@@H](C)CCCC(C)C,,,,,,
4596,444598,Cyclo[L-Val-L-Asn-L-Val-L-Pro-1-deoxo-Gly-N-acetyl-L-Cys*-3-[4-(phosphonooxy)phenyl]-L-Ala-],CC(C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)NCCSC[C@@H](C(=O)N[C@H](C(=O)N1)CC3=CC=C(C=C3)OP(=O)(O)O)NC(=O)C)C(C)C)CC(=O)N,,,,,,
4597,444599,Hydroxyaminovaline,CC(C)[C@H](C(=O)NO)N,,,,,,
4598,444600,(1r)-1-Benzyl-1-Methyl-1-(2-{[4-(1-Methylethyl)phenyl]amino}-2-Oxoethyl)-2-{(2s)-4-Methyl-2-[(Trifluoroacetyl)amino]pentanoyl}diazanium,CC(C)C[C@@H](C(=O)N[N@+](C)(CC1=CC=CC=C1)CC(=O)NC2=CC=C(C=C2)C(C)C)NC(=O)C(F)(F)F,,,,,,
4599,444601,Lys-Pro-Phe-pTyr-Val-Asn-Val-Glu-Phe,CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)OP(=O)(O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCCN)N,,,,,,
4600,444602,"S-(R*,R*)]-4-[Aminoiminomethyl)amino]-N-[[1-[3-hydroxy-2-[(2-naphthalenylsulfonyl)amino]-1-oxopropyl]-2-pyrrolidinyl] methyl]butanamide",C1C[C@H](N(C1)C(=O)[C@H](CO)NS(=O)(=O)C2=CC3=CC=CC=C3C=C2)CNC(=O)CCCN=C(N)N,,,,,,
4601,444603,"[S-(R*,R*)]-1-(Aminoiminomethyl)-N-[[1-[N-[(2-naphthalenylsulfonyl)-L-seryl]-3-pyrrolidinyl]methyl]-3-piperidenecarboxamide",C1C[C@@H](CN(C1)C(=N)N)C(=O)NC[C@@H]2CCCN2C(=O)[C@H](CO)NS(=O)(=O)C3=CC4=CC=CC=C4C=C3,,,,,,
4602,444604,naphth-2-oyl-Val-Pro-Asn(Mes)-SH,CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)NS(=O)(=O)C)C(=O)S)NC(=O)C2=CC3=CC=CC=C3C=C2,,,,,,
4603,444605,CID 444605,[CH3-].CC1=CC2=C(C=C1C)N(C=N2)[C@H]3[C@@H]([C@H]([C@@H](O3)CO)OP(=O)(O)O[C@H](C)CNC(=O)CC[C@]4([C@@H]([C@@H]5[C@@]6([C@]([C@@H](C([N-]6)/C(=C\7/[C@@]([C@@H](/C(=C\C8C([C@@H](/C(=C(/C4[N-]5)\C)/[N-]8)CCC(=O)N)(C)C)/[N-]7)CCC(=O)N)(C)CC(=O)N)/C)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)C)O.[Co],,,,,,
4604,444606,CID 444606,CC1=CC2=C(C=C1C)N(C=N2)[C@H]3[C@@H]([C@H]([C@@H](O3)CO)OP(=O)(O)O[C@H](C)CNC(=O)CC[C@]4([C@@H]([C@@H]5[C@@]6([C@]([C@@H](C(N6)/C(=C/7\[C@@]([C@@H](/C(=C/C8C([C@@H](/C(=C(\C4N5)/C)/N8)CCC(=O)N)(C)C)/N7)CCC(=O)N)(C)CC(=O)N)/C)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)C)O,,,,,,
4605,444607,"Thiophene-2,5-disulfonic acid 2-amide-5-(4-methyl-benzylamide)",CC1=CC=C(C=C1)CNS(=O)(=O)C2=CC=C(S2)S(=O)(=O)N,,,,,,
4606,444608,"2-(3-Methoxyphenyl)-1,1-dioxo-5,6-dihydrothieno[3,2-e]thiazine-6-sulfonamide",COC1=CC=CC(=C1)N2C=CC3=C(S2(=O)=O)SC(C3)S(=O)(=O)N,,,,,,
4607,444609,"(4R)-2-(3-methoxyphenyl)-4-(methylamino)-1,1-dioxo-3,4,5,6-tetrahydrothieno[3,2-e]thiazine-6-sulfonamide",CN[C@H]1CN(S(=O)(=O)C2=C1CC(S2)S(=O)(=O)N)C3=CC(=CC=C3)OC,,,,,,
4608,444610,"2-(3-Methoxyphenyl)-1,1-dioxo-3,4,5,6-tetrahydrothieno[3,2-e]thiazine-6-sulfonamide",COC1=CC=CC(=C1)N2CCC3=C(S2(=O)=O)SC(C3)S(=O)(=O)N,,,,,,
4609,444611,"(4R)-4-(ethylamino)-2-(2-methoxyethyl)-1,1-dioxo-3,4,5,6-tetrahydrothieno[3,2-e]thiazine-6-sulfonamide",CCN[C@H]1CN(S(=O)(=O)C2=C1CC(S2)S(=O)(=O)N)CCOC,,,,,,
4610,444612,"3,4-Dihydro-4-hydroxy-2-(4-methoxyphenyl)-2h-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide",COC1=CC=C(C=C1)N2C[C@@H](C3=C(S2(=O)=O)SC(=C3)S(=O)(=O)N)O,,,,,,
4611,444613,"(4R)-4-hydroxy-1,1-dioxo-2-(thiophen-2-ylmethyl)-3,4,5,6-tetrahydrothieno[3,2-e]thiazine-6-sulfonamide",C1[C@@H](C2=C(SC(C2)S(=O)(=O)N)S(=O)(=O)N1CC3=CC=CS3)O,,,,,,
4612,444614,"(4S)-2-(3-methoxyphenyl)-4-(methylamino)-1,1-dioxo-3,4,5,6-tetrahydrothieno[3,2-e]thiazine-6-sulfonamide",CN[C@@H]1CN(S(=O)(=O)C2=C1CC(S2)S(=O)(=O)N)C3=CC(=CC=C3)OC,,,,,,
4613,444615,Vanadium;tetrahydrate,O.O.O.O.[V],,,,,,
4614,444616,CID 444616,CC(=CC[C@@H]1[C@@](O1)(C)[C@H]2[C@@H]([C@@H](CC[C@@]2(CN)O)OC(=O)C=C/C=C/C=C/C=C/C(=O)O)OC)C,,,,,,
4615,444617,"N6-(2,5-Dimethoxy-benzyl)-N6-methyl-pyrido[2,3-D]pyrimidine-2,4,6-triamine",CN(CC1=C(C=CC(=C1)OC)OC)C2=CC3=C(N=C(N=C3N=C2)N)N,,,,,,
4616,444618,Cbz-Leu-Leu-Leu-SH,CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)S)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1,,,,,,
4617,444619,"hydron;(2R,4R,5S,6R)-6-methyloxane-2,4,5-triol",[H+].[H+].C[C@@H]1[C@H]([C@@H](C[C@@H](O1)O)O)O,,,,,,
4618,444620,"(2R,4R,6R)-6-methyloxane-2,4,5-triol",C[C@@H]1C([C@@H](C[C@@H](O1)O)O)O,,,,,,
4619,444621,"(2R,4S,5R,6R)-4,6-dimethyloxane-2,4,5-triol;hydron",[H+].C[C@@H]1[C@H]([C@@](C[C@@H](O1)O)(C)O)O,,,,,,
4620,444622,CID 444622,CC1=C(C2=C(C3=C(CC([C@@H](C3O)O)[C@@H](C(=O)[C@H]([C@H](C)O)O)OC)C=C2C=C1O)O)O,,,,,,
4621,444623,CID 444623,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=O)(O)O)N4C=NC5=C4NC(=NC5=O)N)OP(=O)(O)OC[C@@H]6[C@H](C[C@@H](O6)N7C=CC(=NC7=O)N)OP(=O)(O)OC[C@@H]8[C@H](C[C@@H](O8)N9C=NC1=C9NC(=NC1=O)N)OP(=O)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1NC(=NC2=O)N)O,,,,,,
4622,444624,"[[(2R,3S,4S,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(3R)-3-hydroxy-2,2-dimethyl-4-oxo-4-[[3-oxo-3-(2-sulfanylethylamino)propyl]amino]butyl] hydrogen phosphate",CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)[C@H](C(=O)NCCC(=O)NCCS)O,,,,,,
4623,444625,VSV8 peptide,CC(C)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)N,,,,,,
4624,444626,Cbz-Leu-Leu-MeOMe,CC(C)C[C@@H](C(=O)COC)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1,,,,,,
4625,444627,dAdo-P-dCyd-P-dCyd-P-dCyd,C1[C@@H]([C@H](O[C@H]1N2C=CC(=NC2=O)N)COP(=O)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=O)(O)O[C@H]4C[C@@H](O[C@@H]4COP(=O)(O)O[C@H]5C[C@@H](O[C@@H]5CO)N6C=NC7=C(N=CN=C76)N)N8C=CC(=NC8=O)N)N9C=CC(=NC9=O)N)O,,,,,,
4626,444628,dAdo-P-dCyd-P-dCyd-P-dCyd-P-dThd,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=O)(O)O[C@H]4C[C@@H](O[C@@H]4COP(=O)(O)O[C@H]5C[C@@H](O[C@@H]5COP(=O)(O)O[C@H]6C[C@@H](O[C@@H]6CO)N7C=NC8=C(N=CN=C87)N)N9C=CC(=NC9=O)N)N1C=CC(=NC1=O)N)N1C=CC(=NC1=O)N)O,,,,,,
4627,444629,CID 444629,CC1(CN(C(N(C1)S(=O)(=O)C2=CC=C(C=C2)OC)C(NO)O)S(=O)(=O)C3=CC=C(C=C3)OC)C,,,,,,
4628,444630,CID 444630,C(C[C@@H](C(CN)(O)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)N)CN=C(N)N,,,,,,
4629,444631,CID 444631,[BeH2].[F-].[F-].[F-],,,,,,
4630,444632,CID 444632,C1=C(N=C2C(=N1)NC(=NC2=O)N)[C@H]([C@@H](CO)O)O,,,,,,
4631,444633,CID 444633,C1[C@@H]([C@H](O[C@H]1N2C=CC(=NC2=O)N)COP(=O)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=O)(O)O[C@H]4C[C@@H](O[C@@H]4COP(=O)(O)O)N5C=NC6=C5NC(=NC6=O)N)N7C=NC8=C(N=CN=C87)N)O,,,,,,
4632,444634,"(3S)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nonan-1-ol",CC1=C(C(CCC1)(C)C)CCC(C)CCC[C@H](C)CCO,,,,,,
4633,444635,O3-Sulfonylgalactose,C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O)O)OS(=O)(=O)O)O)O,,,,,,
4634,444636,"(2E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,6,8-trien-1-amine",CC1=C(C(CCC1)(C)C)/C=C/C(=C/CC/C(=C/CN)/C)/C,,,,,,
4635,444637,"3,7,11,15-Tetramethyl-hexadecan-1-OL",C[C@@H](CCC[C@@H](C)CCCC(C)C)CCC[C@H](C)CCO,,,,,,
4636,444638,"(2R)-2-[(1R,2S)-2-hydroxycyclopentyl]pent-4-enoic acid",C=CC[C@H]([C@H]1CCC[C@@H]1O)C(=O)O,,,,,,
4637,444639,"(7R,8S)-8-amino-7-(carboxyamino)nonanoic acid;trifluoroalumane",C[C@@H]([C@@H](CCCCCC(=O)O)NC(=O)O)N.F[Al](F)F,,,,,,
4638,444640,7-(Carboxyamino)-8-amino-nonanoic acid,C[C@@H]([C@@H](CCCCCC(=O)O)NC(=O)O)N,,,,,,
4639,444641,Met-Ala-Ser,C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCSC)N,,,,,,
4640,444642,Hydroxy-nickel,O.[Ni],,,,,,
4641,444643,"1,4,5,6-Tetrahydronicotinamide Adenine Dinucleotide Phosphate",C1C=C[C@@H](CN1[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)OP(=O)(O)O)O)O)O)C(=O)N,,,,,,
4642,444644,CID 444644,[OH-].[CaH+],,,,,,
4643,444645,CID 444645,[H-].[CaH+],,,,,,
4644,444646,Copper;hydrate,O.[Cu].[Cu],,,,,,
4645,444647,Copper;hydrate,O.[Cu].[Cu],,,,,,
4646,444648,"(5R)-5-[(1S,2R)-1-formyl-2-hydroxypropyl]-3-[(2-{[(E)-iminomethyl]amino}ethyl)sulfanyl]-4,5-dihydro-1H-pyrrole-2-carbox ylic acid",C[C@H]([C@H]([C@H]1CC(=C(N1)C(=O)O)SCCN=CN)C(=O)O)O,,,,,,
4647,444649,(R)-3-Butylthiolane 1-oxide,CCCC[C@@H]1CCS(=O)C1,,,,,,
4648,444650,(3r)-3-Ethyl-N-[(4-Methylphenyl)sulfonyl]-L-Aspartic Acid,CC[C@H]([C@@H](C(=O)O)NS(=O)(=O)C1=CC=C(C=C1)C)C(=O)O,,,,,,
4649,444651,CID 444651,[H+].[B-]([C@H](CCCC[NH3+])NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C)NC(=O)OC(C)(C)C)(O)(O)OCCCO,,,,,,
4650,444652,CID 444652,[B-]([C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C)NC(=O)OC(C)(C)C)(O)(O)OCCCO,,,,,,
4651,444653,[(1R)-5-azaniumyl-1-[[(2S)-3-methyl-2-[[(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]amino]butanoyl]amino]pentyl]-trihydroxyboranuide,[B-]([C@H](CCCC[NH3+])NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)OC(C)(C)C)(O)(O)O,,,,,,
4652,444654,[(1R)-5-amino-1-[[(2S)-3-methyl-2-[[(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]amino]butanoyl]amino]pentyl]-trihydroxyboranuide,[B-]([C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)OC(C)(C)C)(O)(O)O,,,,,,
4653,444655,Benzamidinium chloride,C1=CC=C(C=C1)C(=[NH2+])N,,,,,,
4654,444656,CID 444656,[B-]([C@H](CCCC[NH3+])NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C)NC(=O)OC(C)(C)C)(O)(O)OC,,,,,,
4655,444657,CID 444657,[B-]([C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C)NC(=O)OC(C)(C)C)(O)(O)OC,,,,,,
4656,444658,"7,8-dimethyl-10-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]-1H-benzo[g]pteridin-10-ium-2,4-dione",CC1=CC2=C(C=C1C)[N+](=C3C(=N2)C(=O)NC(=O)N3)C[C@@H]([C@@H]([C@@H](CO)O)O)O,,,,,,
4657,444659,CID 444659,CC(=O)CC(=O)SCCNC(=O)CCNC(=O)[C@H](C(C)(C)COP(=O)(O)OP(=O)(O)O)O.[NH2-].[NH2-].[NH2-].[NH2-].[NH2-].[OH3+].O.OP(=O)(O)O.[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Ac].[Ac],,,,,,
4658,444660,"S-[2-[3-[[(2R)-2-hydroxy-4-[hydroxy(phosphonooxy)phosphoryl]oxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] 3-oxobutanethioate",CC(=O)CC(=O)SCCNC(=O)CCNC(=O)[C@@H](C(C)(C)COP(=O)(O)OP(=O)(O)O)O,,,,,,
4659,444661,CID 444661,O.[CaH2],,,,,,
4660,444662,CID 444662,C1=CC=C(C=C1)NC(N)[S-],,,,,,
4661,444663,CID 444663,C1=CC=C(C=C1)NC(N)S,,,,,,
4662,444664,"2-(1-Carboxy-2-hydroxy-2-methyl-propyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid",CC1([C@@H](N[C@H](S1)[C@H](C(=O)O)C(C)(C)O)C(=O)O)C,,,,,,
4663,444665,CID 444665,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@H]2OC(=O)CCC(=O)O)CCC4=CC(CC[C@H]34)O,,,,,,
4664,444666,formic acid;[(E)-pent-2-en-3-yl]mercury,CC/C(=C\C)/[Hg].C(=O)O,,,,,,
4665,444667,[(E)-pent-2-en-3-yl]mercury,CC/C(=C\C)/[Hg],,,,,,
4666,444668,3-[2-[[3-(2-carboxyethyl)-5-[(3-ethyl-4-methyl-5-oxopyrrol-2-yl)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(4-ethyl-3-methyl-5-oxopyrrol-2-yl)methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid,CCC1=C(C(=NC1=O)CC2=C(C(=C(N2)CC3=C(C(=C(N3)CC4=NC(=O)C(=C4CC)C)C)CCC(=O)O)CCC(=O)O)C)C,,,,,,
4667,444669,(E)-2-Hexadecenethioic acid S-(2-acetylaminoethyl) ester,CCCCCCCCCCCCC/C=C/C(=O)SCCNC(=O)C,,,,,,
4668,444670,2-Deoxy-2-fluoro xylopyranose,C1[C@H]([C@@H]([C@H]([C@H](O1)O)F)O)O,,,,,,
4669,444671,H-Phe-Tyr-Arg-Ala-Leu-Met-OH,C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)N,,,,,,
4670,444672,"[4R-(4alpha,5alpha,6alpha,7alpha)]-3,3'-{{Tetrahydro-5,6-dihydroxy-2-oxo-4,7-bis(phenylmethyl)-1H-1,3-diazepine-1,3(2H)-diyl]bis(methylene)]bis[N-1H-benzimidazol-2-ylbenzamide]",C1=CC=C(C=C1)C[C@@H]2[C@@H]([C@H]([C@H](N(C(=O)N2CC3=CC(=CC=C3)C(=O)NC4=NC5=CC=CC=C5N4)CC6=CC(=CC=C6)C(=O)NC7=NC8=CC=CC=C8N7)CC9=CC=CC=C9)O)O,,,,,,
4671,444673,(E)-3-prop-2-enylsulfinylprop-1-ene-1-thiol,C=CCS(=O)C/C=C/S,,,,,,
4672,444674,Phosphodifluoromethylphosphonic acid-adenylate ester,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(C(F)(F)P(=O)(O)O)O)O)O)N,,,,,,
4673,444675,[1-Myristoyl-glycerol-3-YL]phosphonylcholine,CCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OCC[N+](C)(C)C)O,,,,,,
4674,444676,Magnesium;trihydroxide;hydrate,O.[OH-].[OH-].[OH-].[Mg+2],,,,,,
4675,444677,CID 444677,C1C=CN=C[C@H]([C@@H]1OC(=O)C2=CC(=C(C(=C2)O)C(=O)C3=C(C=CC=C3O)C(=O)O)O)NC(=O)C4=CC=C(C=C4)O,,,,,,
4676,444678,(2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-[2-(4-fluoro-N-propan-2-ylanilino)-2-oxoethyl]sulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid,CC(C)N(C1=CC=C(C=C1)F)C(=O)CSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N,,,,,,
4677,444679,Ergosterol,C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3C2=CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,,['Precursor forms of vitamins. (See all compounds classified as Provitamins.)'],"['Vitamin D is excreted into breast milk in limited amounts. A direct relationship exists between maternal serum levels of vitamin D & the concn in breast milk. Chronic maternal ingestion of large doses may lead to greater than normal vitamin D activity in the milk & resulting hypercalcemia in the infant. /Vitamin D/', 'The results of experiments on rats given the ergosterol-containing diet for a long time indicate that ergosterol was incorporated in liver tissues in trace amounts which are not comparable with ergosterol concentrations exerting an effect in model experiments. Ergosterol was not detected in the liver after 3-day experiments. At the same time it was established that the proportion of unchanged ergosterol in rat feces was about 16% of the amount administered per os. The products of a possible ergosterol transformation (dehydroneoergosterol-24-methyl-1,3,5 (10), 6,8 (9), 22-hexaen-3 beta-ol; 24-methylcholesta-7,24 (28)-dien-3 beta-ol; 4-cholesta-7,22,25 (?)-trien-3 beta-ol; 4-methylcholesta-7,22 (?)-dien-3 beta-ol, and so forth were identified in feces.']","[""... The metabolism of ergosterol by cytochrome P450scc /is demonstrated/ in either a reconstituted system or isolated adrenal mitochondria. The major reaction product was identified as 17alpha,24-dihydroxyergosterol. Purified P450scc also generated hydroxyergosterol as a minor product, which is probably an intermediate in the synthesis of 17alpha,24-dihydroxyergosterol. In contrast to cholesterol and 7-dehydrocholesterol, cleavage of the ergosterol side chain was not observed. NMR analysis clearly located one hydroxyl group to C24, with evidence that the second hydroxyl group is at C17. 17alpha,24-Dihydroxyergosterol inhibited cell proliferation of HaCaT keratinocytes and melanoma cells. Thus, in comparison with cholesterol and 7-dehydrocholesterol, the 24-methyl group and the C22-C23 double bond of ergosterol prevent side chain cleavage by P450scc and change the enzyme's hydroxylase activity from C22 and C20, to C24 and C17, generating bioactive product."", 'In order to investigate the effect of the different stereochemistry of C-24 on the microbial C-26 oxidation of sterol side-chain the genetically modified Mycobacterium sp. BCS 396 strain was used to transform erogsterol. Ergosterol was converted to 3-oxo-4,22-ergostadien-26-oic acid methyl ester, 3-oxo-1,4,22-ergostatrien-26-oic acid methyl ester, and 3-oxo-1,4,22-ergostatrien-26-oic acid, the structures of which have been determined by IR, 1H NMR, 13C NMR, and mass spectroscopy. The X-ray structure of 3-oxo-4,22-ergostadien-26-oic acid methyl ester revealed that oxidation at C-26 of the ergostane side-chain generates a chiral center with S-configuration at C-25 as a result of chiral induction of the C-24 center.', 'The results of experiments on rats given the ergosterol-containing diet for a long time indicate that ergosterol was incorporated in liver tissues in trace amounts which are not comparable with ergosterol concentrations exerting an effect in model experiments. Ergosterol was not detected in the liver after 3-day experiments. At the same time it was established that the proportion of unchanged ergosterol in rat feces was about 16% of the amount administered per os. The products of a possible ergosterol transformation (dehydroneoergosterol-24-methyl-1,3,5 (10), 6,8 (9), 22-hexaen-3 beta-ol; 24-methylcholesta-7,24 (28)-dien-3 beta-ol; 4-cholesta-7,22,25 (?)-trien-3 beta-ol; 4-methylcholesta-7,22 (?)-dien-3 beta-ol, and so forth were identified in feces.', 'Metabolism of orally administered ergosterol (Erg) ... in rats and ... vitamin D biological activity were investigated. Most of orally administered Erg ... /was/ excreted in feces and the remaining sterols were absorbed through intestine. The absorbed sterols were not transported in skin as the intact forms but metabolized into brassicasterol and cholesterol, respectively, within 25 hr. Neither increment of intestinal calcium absorption nor plasma calcium concentrations were observed by oral administration of Erg  ... to vitamin D-deficient rats...', 'The chick-oviduct assay was used to investigate the effects of dietary ergosterol on the response to oral progestogens and estrogens. Progestogens alone had no effect on the oviduct but the hypertrophy due to estrogen was greatly enhanced by simultaneous treatment with progestogen at all dose levels tested.  Ergosterol had no effect on any of the responses of the oviduct studied.']",
4678,444680,Methyl cyclo[(2s)-2-[[(1r)-1-(n-(l-n-(3-methylbutanoyl)valyl-l-aspartyl)amino)-3-methylbutyl]hydroxyphosphinyloxy]-3-(3-aminomethyl)phenylpropanoate,CC(C)C[C@@H]1NC(=O)[C@H](CC(=O)NCC2=CC=CC(=C2)C[C@H](OP1(=O)O)C(=O)OC)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C,,,,,,
4679,444681,2-[(1R)-1-(N-(3-Methylbutanoyl)-L-valyl-L-asparaginyl)-amino)-3-methylbutyl]hydroxyphosphinyloxy]-3-phenylpropanoic acid methylester,CC(C)C[C@H](NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C)P(=O)(O)O[C@@H](CC1=CC=CC=C1)C(=O)OC,,,,,,
4680,444682,H-Asp-Tyr-Gln-Arg-Leu-Asn-OH,CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC(=O)O)N,,,,,,
4681,444683,(S)-(+)-2-butanol,CC[C@H](C)O,,,,,,
4682,444684,CID 444684,CC(N(CCC[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N=CC(=O)N1)CCCN(C(C)O)O)C=CCN(C(C)O)O)O)O,,,,,,
4683,444685,2'-Deoxymaltose,C1[C@H]([C@@H]([C@H](O[C@H]1O)CO)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O,,,,,,
4684,444686,"(2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-[[(2S)-4-(ethylamino)-6-(propan-2-ylamino)-1,3,5-triazinan-2-yl]sulfanyl]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid",CCNC1N[C@@H](NC(N1)NC(C)C)SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N,,,,,,
4685,444687,Calcium;tetrahydroxide;dihydrate,O.O.[OH-].[OH-].[OH-].[OH-].[Ca+2],,,,,,
4686,444688,Calcium;pentahydroxide,[OH-].[OH-].[OH-].[OH-].[OH-].[Ca+2],,,,,,
4687,444689,"(2S,3R,6S)-3-amino-6-(aminomethyl)oxan-2-ol",C1C[C@H]([C@H](O[C@@H]1CN)O)N,,,,,,
4688,444690,beta-Garosamine,C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O)O,,,,,,
4689,444691,Glc6P(?1-1b)Glc,C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)OC2[C@@H]([C@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O)O)O)O)O)O,,,,,,
4690,444692,Tungsten;dihydrate,O.O.[W],,,,,,
4691,444693,Ethanolaminium(1+),C(CO)[NH3+],,,,,,
4692,444694,CID 444694,C[C@H](C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC5=CC=CC=C5)N,,,,,,
4693,444695,4-Carbamoyl-4-{[6-(difluoro-phosphono-methyl)-naphthalene-2-carbonyl]-amino}-butyric acid,C1=CC2=C(C=CC(=C2)C(F)(F)P(=O)(O)O)C=C1C(=O)N[C@@H](CCC(=O)O)C(=O)N,,,,,,
4694,444696,cyclo[Ala-Asp-Glu-Tyr(Unk)-Leu-Unk-Asp],C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N=C(CSCC(=O)N[C@H](C(=O)N1)CC(=O)O)C(=O)N)CC(C)C)CC2=CC=C(C=C2)OC(C(=O)O)(C(=O)O)F)CCC(=O)O)CC(=O)O,,,,,,
4695,444697,"(2S)-2-amino-5-[[(4R,23R)-23-[[(4S)-4-amino-4-carboxybutanoyl]amino]-5,8,19,22-tetraoxo-1,2-dithia-6,9,13,18,21-pentazacyclotetracosa-9,12,17,20-tetraen-4-yl]amino]-5-oxopentanoic acid",C1CC=NC(=O)C=NC(=O)[C@H](CSSC[C@@H](C(=O)NCC(=O)N=CCC=NC1)NC(=O)CC[C@@H](C(=O)O)N)NC(=O)CC[C@@H](C(=O)O)N,,,,,,
4696,444698,"2-(Biphenyl-4-sulfonyl)-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid",C1[C@@H](N(CC2=CC=CC=C21)S(=O)(=O)C3=CC=C(C=C3)C4=CC=CC=C4)C(=O)O,,,,,,
4697,444699,CID 444699,C1=C(C2=C(N1)C(=O)N=C(N2)N)[C@H]3[C@@H]([C@@H]([C@H](N3)COP(=O)(O)O)O)O,,,,,,
4698,444700,Aspartyl-adenosine-5'-monophosphate,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OC(=O)[C@H](CC(=O)O)N)O)O)N,,,,,,
4699,444701,CID 444701,CC1=CC2(C(C=C1C)(N(C3=NC(=O)NC(=O)C3(N2)O)C[C@@H]([C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O)O)O,,,,,,
4700,444702,[(3S)-dioxetan-3-yl]methanol,C1[C@@H](OO1)CO,,,,,,
4701,444703,"(R)-(+)9B-(3-Methyl)phenyl-2,3-dihydrothiazolo[2,3-A]isoindol-5(9BH)-one",CC1=CC(=CC=C1)[C@@]23C4=CC=CC=C4C(=O)N2CCS3,,,,,,
4702,444704,"(R)-(+) 5(9BH)-Oxo-9B-phenyl-2,3-dihydrothiazolo[2,3-A]isoindol-3-carboxylic acid methyl ester",COC(=O)[C@@H]1CS[C@]2(N1C(=O)C3=CC=CC=C32)C4=CC=CC=C4,,,,,,
4703,444705,Trazeolide,C[C@H]1[C@@H](C2=C(C1(C)C)C=C(C(=C2)C(=O)CCC(=O)O)C)C(C)C,,,,,,
4704,444706,"6-(cyclohexylsulfanyl)-1-(ethoxymethyl)-5-(1-methylethyl)pyrimidine-2,4(1H,3H)-dione",CCOCN1C(=C(C(=O)NC1=O)C(C)C)SC2CCCCC2,,,,,,
4705,444707,"1,7,8,9,10,10-Hexachloro-4-methyl-4-azatricyclo[5.2.1.0(2,6)]dec-8-ene-3,5-dione",CN1C(=O)[C@H]2[C@@H](C1=O)[C@]3(C(=C([C@@]2(C3(Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
4706,444708,"3-[18-(2-carboxyethyl)-8,13-diethyl-3,7,12,17,22-pentamethyl-23H-porphyrin-2-yl]propanoic acid",CCC1=C(C2=CC3=C(C(=C(N3C)C=C4C(=C(C(=N4)C=C5C(=C(C(=N5)C=C1N2)C)CCC(=O)O)CCC(=O)O)C)C)CC)C,,,,,,
4707,444709,[amino-(2-methyl-3H-benzimidazol-5-yl)methylidene]azanium,CC1=NC2=C(N1)C=C(C=C2)C(=[NH2+])N,,,,,,
4708,444710,2-methyl-3H-benzimidazole-5-carboximidamide,CC1=NC2=C(N1)C=C(C=C2)C(=N)N,,,,,,
4709,444711,CID 444711,[HH].[HH].[HH].CC1=NC2=C(N1)C=C(C=C2)C(=N)N,,,,,,
4710,444712,CID 444712,C1=CC=C2C(=C1)NC(N2)CC3=NC4=C(N3)C=C(C=C4)C(=[NH2+])N,,,,,,
4711,444713,CID 444713,C1=CC=C2C(=C1)NC(N2)CC3=NC4=C(N3)C=C(C=C4)C(=N)N,,,,,,
4712,444714,CID 444714,C1=CC2=C(C=C1C(=[NH2+])N)NC(=N2)CC3NC4=CC(=C(N)N)C=CC4=[NH+]3,,,,,,
4713,444715,CID 444715,C1=CC2=C(C=C1C(=N)N)NC(=N2)CC3NC4=CC(=C(N)N)C=CC4=N3,,,,,,
4714,444716,CID 444716,C1=CC2=[NH+]C(NC2=CC1=C(N)N)C(C3NC4=CC(=C(N)N)C=CC4=[NH+]3)(O)O,,,,,,
4715,444717,CID 444717,C1=CC2=NC(NC2=CC1=C(N)N)C(C3NC4=CC(=C(N)N)C=CC4=N3)(O)O,,,,,,
4716,444718,L-(-)-3-Phenyllactic acid,C1=CC=C(C=C1)C[C@@H](C(=O)O)O,,,,,,
4717,444719,Methionine phosphonate,CSCC[C@H](N)P(=O)(O)O,,,,,,
4718,444720,(1-Amino-pentyl)-phosphonic acid,CCCC[C@H](N)P(=O)(O)O,,,,,,
4719,444721,4-(2-Hydroxyphenylthio)-1-butenylphosphonic acid,C1=CC=C(C(=C1)O)SCC/C=C/P(=O)(O)O,,,,,,
4720,444722,CID 444722,C1=CC2=C(C=C1C(=[NH2+])N)NC(=[NH+]2)/C(=C\3/NC4=CC(=C(N)N)C=CC4=N3)/O,,,,,,
4721,444723,CID 444723,C1=CC2=C(C=C1C(=N)N)NC(=N2)/C(=C\3/NC4=CC(=C(N)N)C=CC4=N3)/O,,,,,,
4722,444724,"3-[18-(2-carboxyethyl)-3,7,12,17-tetramethyl-8,13-bis[(1R)-1-sulfanylethyl]porphyrin-21,23-diid-2-yl]propanoic acid;iron(2+)",CC1=C(C2=CC3=NC(=CC4=C(C(=C([N-]4)C=C5C(=C(C(=N5)C=C1[N-]2)C)[C@@H](C)S)C)[C@@H](C)S)C(=C3CCC(=O)O)C)CCC(=O)O.[Fe+2],,,,,,
4723,444725,CID 444725,C1=CC(=CC=C1[C@H](CC2=CC3=C(C=C2)NC(=NC3=O)N)C(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O,,,,,,
4724,444726,"5-(hydroxyamino)-6-[[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]amino]-1H-pyrimidine-2,4-dione",C([C@@H]([C@@H]([C@@H](CO)O)O)O)NC1=C(C(=O)NC(=O)N1)NO,,,,,,
4725,444727,1-3 Sugar ring OF pentamannosyl 6-phosphate,C([C@@H]1[C@H]([C@@H]([C@@H]([C@H](O1)O)O)O[C@@H]2[C@H]([C@H]([C@@H]([C@H](O2)CO)O)O[C@@H]3[C@H]([C@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)O)O)O)O,,,,,,
4726,444728,1-Benzothiophen-2-yl(trihydroxy)boranuide,[B-](C1=CC2=CC=CC=C2S1)(O)(O)O,,,,,,
4727,444729,CID 444729,C1=CC(=CC=C1[C@@H](CC2=CC3=C(C=C2)NC(=NC3=O)N)C(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O,,,,,,
4728,444730,CID 444730,CC(C)[C@@H](C(=O)OC)NC(=O)CNC(=O)[C@H](C[S-])NCC1=CC=C(C=C1)C2=CC=CC=C2,,,,,,
4729,444731,CID 444731,CC(C)[C@@H](C(=O)OC)NC(=O)CNC(=O)C(CS)NCC1=CC=C(C=C1)C2=CC=CC=C2,,,,,,
4730,444732,trichostatin A,C[C@H](/C=C(\C)/C=C/C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C,,,"['Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)', 'Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)', 'Compounds that inhibit HISTONE DEACETYLASES. This class of drugs may influence gene expression by increasing the level of acetylated HISTONES in specific CHROMATIN domains. (See all compounds classified as Histone Deacetylase Inhibitors.)']",,,
4731,444733,"[[(2R,3R)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxy-2,3-dihydrofuran-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate",C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H](C(=C(O3)N4C=NC5=C(N=CN=C54)N)OP(=O)(O)O)O)O)O)C(=O)N,,,,,,
4732,444734,"(2S)-3-[(7S)-7,15-dimethylhexadecoxy]-2-octoxypropan-1-ol",CCCCCCCCO[C@@H](CO)COCCCCCC[C@@H](C)CCCCCCCC(C)C,,,,,,
4733,444735,CID 444735,CC(=CCCC=CCCC=CCCC=C(C)CCC=CCCC=C(C)C)C,,,,,,
4734,444736,CID 444736,CC1=C(C(CCC1)(C)C)/C=C/C(=C/CCC(=CCN)C)/C,,,,,,
4735,444737,CID 444737,C12=C(NC(=NC1=O)N)N=C(N2)I,,,,,,
4736,444738,CID 444738,[CH-]=O.[C-]#[O+].[C-]#[O+].[C-]#[O+].[C-]#[O+].O.O.[SH-].[SH-].[Fe].[Fe+2],,,,,,
4737,444739,CID 444739,[CH2-]O.[C-]#[O+].[C-]#[O+].[C-]#[O+].[C-]#[O+].[C-]#[O+].O.[SH-].[SH-].[Fe].[Fe+3],,,,,,
4738,444740,"[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dihydrogen phosphate;vanadium;trihydrate",C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)OP(=O)(O)O)O)O)O)O.O.O.O.[V],,,,,,
4739,444741,CID 444741,CC12C[C@@](O1)(C(C=N2)COP(=O)(O)O)CN,,,,,,
4740,444742,3-deoxy-D-xylHexNAc4S(b1-4)GlcA(b1-3)GalNAc4S(b1-4)GlcA(b1-3)GalNAc4S(b1-4)b-GlcA,CC(=O)N[C@@H]1C[C@H]([C@H](O[C@H]1O[C@H]2[C@@H]([C@H]([C@@H](O[C@@H]2C(=O)O)O[C@@H]3[C@H]([C@@H](O[C@@H]([C@@H]3OS(=O)(=O)O)CO)O[C@H]4[C@@H]([C@H]([C@@H](O[C@@H]4C(=O)O)O[C@@H]5[C@H]([C@@H](O[C@@H]([C@@H]5OS(=O)(=O)O)CO)O[C@H]6[C@@H]([C@H]([C@@H](O[C@@H]6C(=O)O)O)O)O)NC(=O)C)O)O)NC(=O)C)O)O)CO)OS(=O)(=O)O,,,,,,
4741,444743,"(5S)-2-[2-(4-bromophenyl)sulfonylethyl]-N-[(4-carbamimidoylcyclohexyl)methyl]-1,3-dioxo-5,8-dihydro-[1,2,4]triazolo[1,2-a]pyridazine-5-carboxamide",C1CC(CCC1CNC(=O)[C@@H]2C=CCN3N2C(=O)N(C3=O)CCS(=O)(=O)C4=CC=C(C=C4)Br)C(=N)N,,,,,,
4742,444744,CID 444744,C[C@H]1CN2C(=O)N(C(=O)N2C(=C1)C(=O)NC[C@H]3CCC(=CC3)C(=N)N)CC(C4=CC=CC=C4)C5=CC=CC=C5,,,,,,
4743,444745,"2-(2,2-Diphenyl-ethyl)-7-methyl-1,3-dioxo-2,3,5,8-tetrahydro-1h-[1,2,4] triazolo[1,2-a]pyridazine-5-carboxylic acid [4-(2-amino-3h-imidazol-4-yl)-cyclohexyl]-amide",CC1=C[C@H](N2C(=O)N(C(=O)N2C1)CC(C3=CC=CC=C3)C4=CC=CC=C4)C(=O)NC5CCC(CC5)C6=CN=C(N6)N,,,,,,
4744,444746,"1H-Indole-2-carboxamide, 5-chloro-N-((1S)-1-((4-fluorophenyl)methyl)-2-(4-hydroxy-1-piperidinyl)-2-oxoethyl)-",C1CN(CCC1O)C(=O)[C@H](CC2=CC=C(C=C2)F)NC(=O)C3=CC4=C(N3)C=CC(=C4)Cl,,,['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],,,
4745,444747,CID 444747,C1CC2C=C3C=CC(=CC4=CC=C([N-]4)C=C5CCC(=CC1[N-]2)[N-]5)[N-]3.[Mg+2],,,,,,
4746,444748,CID 444748,C1CC2/C=C\3/C=C/C(=C/C4=CC=C(N4)/C=C\5/CC/C(=C/C1N2)/N5)/N3,,,,,,
4747,444749,CID 444749,C.C,,,,,,
4748,444750,"3-[18-(2-Carboxyethyl)-7-ethenyl-12-ethyl-3,8,13,17-tetramethylporphyrin-21,23-diid-2-yl]propanoic acid;iron(2+)",CCC1=C(C2=CC3=NC(=CC4=C(C(=C([N-]4)C=C5C(=C(C(=N5)C=C1[N-]2)C)C=C)C)CCC(=O)O)C(=C3C)CCC(=O)O)C.[Fe+2],,,,,,
4749,444751,"[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-4-carboxy-1-[[(2S)-4-carboxy-1-[[(2S,3S)-1-[(2S)-2-[[(2S)-4-carboxy-1-[[(2S)-4-carboxy-1-[[(2S)-1-[[(1S)-1-carboxy-3-methylbutyl]amino]-1-oxo-3-(4-sulfooxyphenyl)propan-2-yl]amino]-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]azanium",CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)OS(=O)(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)[NH3+],,,,,,
4750,444752,CID 444752,CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)OS(=O)(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)C(CC(=O)O)N,,,,,,
4751,444753,Benzo[B]thiophene-2-carboxamidine,C1=CC=C2C(=C1)C=C(S2)C(=[NH2+])N,,,,,,
4752,444754,Benzothiphene-2-carboximidamide,C1=CC=C2C(=C1)C=C(S2)C(=N)N,,,,,,
4753,444755,"3-[18-(2-carboxyethyl)-3,8,13,17-tetramethyl-7-[(1R)-1-sulfanylethyl]-12-[(1S)-1-sulfanylethyl]porphyrin-21,23-diid-2-yl]propanoic acid;iron(2+)",CC1=C(C2=CC3=NC(=CC4=C(C(=C([N-]4)C=C5C(=C(C(=N5)C=C1[N-]2)[C@@H](C)S)C)[C@H](C)S)C)C(=C3CCC(=O)O)C)CCC(=O)O.[Fe+2],,,,,,
4754,444756,n-[2(s)-Cyclopentyl-1(r)-hydroxy-3(r)methyl]-5-[(2(s)-tertiary-butylamino-carbonyl)-4-(n1-(2)-(n-methylpiperazinyl)-3-chloro-pyrazinyl-5-carbonyl)-piperazino]-4(s)-hydroxy-2(r)-phenylmethyl-pentanamide,C[C@H]1CC[C@H]([C@H]1NC(=O)[C@H](CC2=CC=CC=C2)C[C@@H](CN3CCN(C[C@H]3C(=O)NC(C)(C)C)C(=O)C4=CN=C(C(=N4)Cl)N5CCN(CC5)C)O)O,,,,,,
4755,444757,"(2S)-4-(1-benzofuran-2-ylmethyl)-1-[(2S,4S)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butylpiperazine-2-carboxamide",CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CC6=CC=CC=C6O5,,,,,,
4756,444758,(2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-[(2R)-1-hydroxy-3-(4-nitrophenoxy)propan-2-yl]sulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid,C1=CC(=CC=C1[N+](=O)[O-])OC[C@@H](CO)SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N,,,,,,
4757,444759,4-(2-Aminoethoxy)-2-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylamino]butanoic acid,CC1=NC=C(C(=C1O)CNC(CCOCCN)C(=O)O)COP(=O)(O)O,,,,,,
4758,444760,CID 444760,C(COP(=O)(O)O)NC(=O)CN,,,,,,
4759,444761,"D-Gluco-2,5-anhydro-1-deoxy-1-phosphonohexitol-6-phosphate",C([C@@H]1[C@H]([C@@H]([C@@H](O1)CP(=O)(O)O)O)O)OP(=O)(O)O,,,,,,
4760,444762,"(2R,3R)-2,3,4-trihydroxy-3,6-dihydro-2H-pyran-6-carboxylic acid",C1=C([C@H]([C@@H](OC1C(=O)O)O)O)O,,,,,,
4761,444763,6-(Oxalyl-amino)-1H-indole-5-carboxylic acid,C1=CNC2=CC(=C(C=C21)C(=O)O)NC(=O)C(=O)O,,,,,,
4762,444764,2-(Oxaloamino)benzoic acid,C1=CC=C(C(=C1)C(=O)O)NC(=O)C(=O)O,,,,,,
4763,444765,"2-(Oxalyl-amino)-4,7-dihydro-5H-thieno[2,3-C]pyran-3-carboxylic acid",C1COCC2=C1C(=C(S2)NC(=O)C(=O)O)C(=O)O,,,,,,
4764,444766,"2-(Oxalyl-amino)-4,5,6,7-tetrahydro-thieno[2,3-C]pyridine-3-carboxylic acid",C1CNCC2=C1C(=C(S2)NC(=O)C(=O)O)C(=O)O,,,,,,
4765,444767,CID 444767,CN1CC[C@@H]([C@@H](C1)O)C2=C3C(=C(C=C(O3)C4=CC=CC=C4Cl)O)C(=O)C=C2O,,,,,,
4766,444768,"(4S)-4-(2-chlorophenyl)-1-ethyl-6-methyl-5-propan-2-yloxycarbonyl-4H-pyridine-2,3-dicarboxylic acid",CCN1C(=C([C@H](C(=C1C(=O)O)C(=O)O)C2=CC=CC=C2Cl)C(=O)OC(C)C)C,,,,,,
4767,444769,CID 444769,CC(=CCCC=CCCC=CCC/C=C(/C)\CCC=CCCC=C(C)C)C,,,,,,
4768,444770,CID 444770,CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=CCN)C)/C,,,,,,
4769,444771,"[(2Z,4E,6E,8E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6,8-nonatetraene-1-yl]amine",CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C\CN)/C)/C,,,,,,
4770,444772,4-(2-Hydroxyphenylthio)butylphosphonic acid,C1=CC=C(C(=C1)O)SCCCCP(=O)(O)O,,,,,,
4771,444773,N-(5'-Phosphopyridoxyl)-L-alanine,CC1=NC=C(C(=C1O)CN[C@@H](C)C(=O)O)COP(=O)(O)O,,,,,,
4772,444774,[4-[(2-Hydroxy-5-fluorophenyl)thio]butyl]phosphonic acid,C1=CC(=C(C=C1F)SCCCCP(=O)(O)O)O,,,,,,
4773,444775,CID 444775,CCC1=C(C2=CC3=C(C(=C(N3[CH2-])C=C4C(=C(C(=N4)C=C5C(=C(C(=CC1=N2)[N-]5)C)CCC(=O)O)CCC(=O)O)C)C)CC)C.[Cu],,,,,,
4774,444776,CID 444776,C[C@@H]1CC[C@@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@@H](C(=O)[C@H]([C@@H](/C(=C/[C@H](C(=O)C[C@@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,,,,,,
4775,444777,"(3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-[[(2S)-1-[[(2S)-3-carboxy-1-[(3R,4R)-4-hydroxy-3-methyl-1-oxonia-2-azabicyclo[1.1.0]butan-2-yl]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-oxobutanoic acid",C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N1[C@@]2([O+]1[C@H]2O)C)N,,,,,,
4776,444778,"(3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(3S,4R)-3-amino-4-methyloxolan-2-yl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-[[(2S)-1-[[(2S)-1-carboxy-3-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-oxobutanoic acid",C[C@H]1COC([C@H]1N)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C=O,,,,,,
4777,444779,"(3-Oxo-1,2,3lambda5-dioxaphosphiran-3-yl) dihydrogen phosphate",OP(=O)(O)OP1(=O)OO1,,,,,,
4778,444780,"(4S)-4-[[(2S,3S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3R)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-3-hydroxybutanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-5-[[(2S)-1-[[(2R,3R,4R)-2-(carboxymethyl)-4-hydroxy-1-oxoniabicyclo[1.1.0]butan-3-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-oxopentanoic acid",CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@]23[C@H]([O+]2[C@H]3O)CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)O)N,,,,,,
4779,444781,"(4S)-4-[[(2S,3S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3R)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-3-hydroxybutanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-5-[[(2S)-1-[[(2R,3R)-2-(2-carboxyethyl)-3-hydroxyoxiran-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-oxopentanoic acid",CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@]2([C@@H](O2)O)CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)O)N,,,,,,
4780,444782,"2-[2-(4-ethylpiperidin-1-yl)ethyl]-10-methoxy-7H-pyrido[4,3-c]carbazol-2-ium",CCC1CCN(CC1)CC[N+]2=CC3=C(C=CC4=C3C5=C(N4)C=CC(=C5)OC)C=C2,,,,,,
4781,444783,(2E)-2-hydroxy-3-(4-hydroxyphenyl)prop-2-enoic acid,C1=CC(=CC=C1/C=C(\C(=O)O)/O)O,,,,,,
4782,444784,(2S)-2-[[2-[(3S)-3-(benzylsulfonylamino)-2-oxopiperidin-1-yl]acetyl]amino]-3-[(3S)-1-carbamimidoylpiperidin-3-yl]propanoic acid,C1C[C@H](CN(C1)C(=N)N)C[C@@H](C(=O)O)NC(=O)CN2CCC[C@@H](C2=O)NS(=O)(=O)CC3=CC=CC=C3,,,,,,
4783,444785,H-Pro-Phe-Ser-Lys-Glu-Glu-Cys-OH,C1C[C@H](NC1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O,,,,,,
4784,444786,Ac-Gln-Val-Pro-Phe-Ser-Lys-Glu-Glu-Cys-OH,CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)C,,,,,,
4785,444787,Calcium;dihydrate,O.O.[Ca+2],,,,,,
4786,444788,Calcium;hydrate,O.[Ca+2],,,,,,
4787,444789,3-(1h-Indol-3-yl)-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-propionic acid,C1CN(CCC1C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N[C@@H](CC4=CNC5=CC=CC=C54)C(=O)O,,,,,,
4788,444790,"[(1R,3S,4R,5S,8S)-3-hydroxy-8-[(2S,3R,4R,5S,6R)-3-hydroxy-4-[[(1R,3R,4R,5S,8S)-8-[(2S,3R,4R,5S,6R)-3-hydroxy-4-[[(1R,3R,4R,5S,8S)-8-[(2S,3R,5R,6R)-3-hydroxy-6-(hydroxymethyl)-5-sulfooxyoxan-2-yl]oxy-4-sulfooxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-6-(hydroxymethyl)-5-sulfooxyoxan-2-yl]oxy-4-sulfooxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-6-(hydroxymethyl)-5-sulfooxyoxan-2-yl]oxy-2,6-dioxabicyclo[3.2.1]octan-4-yl] hydrogen sulfate",C1[C@H]([C@@H](O[C@@H]([C@@H]1OS(=O)(=O)O)CO)O[C@H]2[C@H]3CO[C@@H]2[C@H]([C@H](O3)O[C@@H]4[C@H]([C@@H](O[C@@H]([C@@H]4OS(=O)(=O)O)CO)O[C@H]5[C@H]6CO[C@@H]5[C@H]([C@H](O6)O[C@@H]7[C@H]([C@@H](O[C@@H]([C@@H]7OS(=O)(=O)O)CO)O[C@H]8[C@H]9CO[C@@H]8[C@H]([C@H](O9)O)OS(=O)(=O)O)O)OS(=O)(=O)O)O)OS(=O)(=O)O)O,,,,,,
4789,444791,alpha-D-glucopyranuronic acid,[C@@H]1([C@@H]([C@H](O[C@@H]([C@@H]1O)O)C(=O)O)O)O,,,,,,
4790,444792,6-Deoxy-2-O-methyl-alpha-L-galactopyranose,C[C@H]1[C@H]([C@H]([C@@H]([C@@H](O1)O)OC)O)O,,,,,,
4791,444793,CID 444793,CC1(C(=O)N=C2C(=N1)NC(=NC2=O)N)C,,,,,,
4792,444794,CID 444794,CC1C2=C(C[C@@]1(C)C/C=C/C(=C/C(=O)O)/C)C(CCC2)(C)C,,,,,,
4793,444795,Tretinoin,CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C,"[""For the the induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant); For the topical treatment of acne vulgaris, flat warts and other skin conditions (psoriasis, ichthyosis congenita, icthyosis vulgaris, lamellar icthyosis, keratosis palmaris et plantaris, epidermolytic hyperkeratosis, senile comedones, senile keratosis, keratosis follicularis (Darier's disease), and basal cell carcinomas.); For palliative therapy to improve fine wrinkling, mottled hyperpigmentation, roughness associated with photodamage.  Tretinoin is also indicated in combination with [benzoyl peroxide] for the treatment of acne vulgaris in patients aged nine years and older.""]","['Tretinoin, also known as all-<i>trans</i>-retinoic acid (ATRA), is a naturally occurring derivative of vitamin A (retinol). Retinoids such as tretinoin are important regulators of cell reproduction, proliferation, and differentiation and are used to treat acne and photodamaged skin and to manage keratinization disorders such as ichthyosis and keratosis follicularis. Tretinoin also represents the class of anticancer drugs called differentiating agents and is used in the treatment of acute promyelocytic leukemia (APL).']","['Agents that soften, separate, and cause desquamation of the cornified epithelium or horny layer of skin. They are used to expose mycelia of infecting fungi or to treat corns, warts, and certain other skin diseases. (See all compounds classified as Keratolytic Agents.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)']","['Tretinoin applied topically is typically between 1-31% absorbed.  When formulated with [benzoyl peroxide], the extent of absorption was examined after 14 days of once-daily application of 1.9 g of the combination product. On Day 14, at steady-state, the mean C<sub>max</sub> for tretinoin and the metabolites 4-keto 13-cis RA and 13-cis RA were 0.15-0.19, 0.27-0.34, and 0.13-0.28 ng/mL, depending on the patient age group. The corresponding ranges for the mean AUC<sub>0-24</sub> were 0.63-2.06, 2.39-2.89, and 0.96-1.99 ng\\*h/mL.', '/MILK/ It is not known whether topically applied tretinoin is excreted in human milk.', 'Studies with radiolabeled drug have demonstrated that after the oral administration of 2.75 and 50 mg doses of tretinoin, greater than 90% of the radioactivity was recovered in the urine and feces. Based upon data from 3 subjects, approximately 63% of radioactivity was recovered in the urine within 72 hours and 31% appeared in the feces within 6 days.', 'A single 45 mg/sq m (approximately 80 mg) oral dose to APL /acute promyelocytic leukemia/  patients resulted in a mean +/- SD peak tretinoin concentration of 347 +/- 266 ng/mL. Time to reach peak concentration was between 1 and 2 hours.', 'The apparent volume of distribution of tretinoin has not been determined. Tretinoin is greater than 95% bound in plasma, predominately to albumin. Plasma protein binding remains constant over the concentration range of 10 to 500 ng/mL.', 'For more Absorption, Distribution and Excretion (Complete) data for all-trans-Retinoic acid (12 total), please visit the HSDB record page.']","['Hepatic', 'Evidence suggests that tretinoin induces its own metabolism. In patients with APL receiving 45 mg/sq m tretinoin daily, urinary excretion of 4-oxo trans retinoic acid glucuronide increased approximately tenfold over the course of 2-6 weeks of continuous therapy, suggesting that increased metabolism of tretinoin may be the primary mechanism leading to the decreased plasma drug concentrations observed during continued administration. Possible mechanisms for the increased clearance of tretinoin with continuous daily dosing of the drug include induction of CYP enzymes or oxidative cofactors and increased expression of cellular retinoic acid binding proteins. Increasing the dosage of tretinoin to compensate for the apparent autoinduction has not been shown to increase therapeutic response. Reduced plasma retinoid concentrations have been associated with relapse and clinical resistance, and some investigators suggest that the clinical failure of tretinoin may be related to a lack of sustained effective concentrations of the drug during prolonged treatment.', 'Tretinoin metabolites have been identified in plasma and urine. Cytochrome P450 enzymes have been implicated in the oxidative metabolism of tretinoin. Metabolites include 13- cis retinoic acid, 4-oxo trans retinoic acid, 4-oxo cis retinoic acid, and 4-oxo trans retinoic acid glucuronide. In APL /acute promyelocytic leukemia/ patients, daily administration of a 45 mg/SQ m dose of tretinoin resulted in an approximately tenfold increase in the urinary excretion of 4-oxo trans retinoic acid glucuronide after 2 to 6 weeks of continuous dosing, when compared to baseline values.', 'Ethanol fed rats showed enhanced microsomal retinoic acid metabolism (50%) accompanied by increased microsomal cytochrome P450 content (34%). The increased hepatic microsomal cytochrome P450 dependent metabolism of retinoic acid after chronic ethanol consumption may contribute to the accelerated catabolism of retinoic acid in vivo.', ""Following ip administration of high doses of 15-(14)C- and 10,11-(3)H-labeled retinoic acid to rats, 3 major metabolites were isolated from feces in microgram amounts by column, thin-layer and high-pressure liquid chromatography. Mass spectrometry provided identification as all-trans-4-oxoretinoic acid, all-trans-5'-hydroxy-retinoic acid and 7-trans-9-cis-11-trans-13-trans-5'-hydroxyretinoic acid."", 'For more Metabolism/Metabolites (Complete) data for all-trans-Retinoic acid (8 total), please visit the HSDB record page.', 'Tretinoin has known human metabolites that include 18-Hydroxyretinoic acid, 4-Hydroxyretinoic acid, 5,6-Epoxy-retinoic acid, and All-trans-retinoyl glucuronide.']","['0.5-2 hours', 'In patients with APL /acute promyelocytic leukemia/ receiving tretinoin orally, a terminal elimination half-life of 0.5-2 hours has been reported following initial dosing.']"
4794,444796,pTpTpT,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=O)(O)O[C@H]4C[C@@H](O[C@@H]4COP(=O)(O)O)N5C=C(C(=O)NC5=O)C)N6C=C(C(=O)NC6=O)C)O,,,,,,
4795,444797,(R)-2-benzylsuccinic acid,C1=CC=C(C=C1)C[C@H](CC(=O)O)C(=O)O,,,,,,
4796,444798,CID 444798,[C-]#N.[C-]#N.[C-]#[O+].[Fe+2],,,,,,
4797,444799,CID 444799,CC\1=C(/C/2=C/C3=C(C(=C(N3)/C=C\4/C(=C(C)S)C(=C(N4)C=C5C(=C(C)S)C(=C(N5)/C=C1\N2)C)C)C)CCC(=O)O)CCC(=O)O,,,,,,
4798,444800,"2,3-Dimethylimidazolium Ion",CC1=[N+](C=CN1)C,,,,,,
4799,444801,CID 444801,CN.CN.CN,,,,,,
4800,444802,CID 444802,CC1=CC2=C(C=C1C)N(C=N2)[C@H]3[C@@H]([C@H]([C@@H](O3)CO)OP(=O)(O)O[C@H](C)CNC(=O)CC[C@]4([C@@H]([C@@H]5[C@@]6([C@]([C@@H](C([N-]6)/C(=C\7/[C@@]([C@@H](/C(=C\C8C([C@@H](/C(=C(/C4[N-]5)\C)/[N-]8)CCC(=O)N)(C)C)/[N-]7)CCC(=O)N)(C)CC(=O)N)/C)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)C)O.[C-]#N.[Co],,,,,,
4801,444803,"(2S)-2-[[4-[[(6R)-2-amino-4-oxo-2,3,4a,5,6,7-hexahydro-1H-pyrido[2,3-d]pyrimidin-6-yl]methylamino]benzoyl]amino]pentanedioic acid",C1[C@@H](CN=C2C1C(=O)NC(N2)N)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,,,,,,
4802,444804,Ac-Thr-Ser-Ser-Pro-Ser-Ala-Asp-al,C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C=O)NC(=O)C)O,,,,,,
4803,444805,CID 444805,C[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)[C@@H]3CCCN3C(=O)[C@@H](C)NC(=O)[C@H](CC4=CC=CC=C4)N,,,,,,
4804,444806,CID 444806,CC1=CS[C@@H](N=C1C(=O)O)[C@@H](C(=O)O)NC(=O)C(C2CSC(=N2)N)NOC,,,,,,
4805,444807,CID 444807,CC1=C(N[C@H](SC1)[C@@H](C(=O)O)NC(=O)CC2CCCS2)C(=O)O,,,,,,
4806,444808,2-Iodobenzylthio Group,C1=CC=C(C(=C1)CS)I,,,,,,
4807,444809,1-Thio-beta-D-glucopyranose,C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)S)O)O)O)O,,,,,,
4808,444810,(R)-chloroquine,CCN(CC)CCC[C@@H](C)NC1=C2C=CC(=CC2=NC=C1)Cl,,,,,"['(r)-chloroquine has known human metabolites that include (r)-chloroquine, N-desethyl.']",
4809,444811,H-Pro-Pro-Pro-Pro-Pro-Pro-Pro-Pro-Tyr(3-I)-OH,C1C[C@H](NC1)C(=O)N2CCC[C@H]2C(=O)N3CCC[C@H]3C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N7CCC[C@H]7C(=O)N8CCC[C@H]8C(=O)N[C@@H](CC9=CC(=C(C=C9)O)I)C(=O)O,,,,,,
4810,444812,6-Deoxy-beta-L-altropyranose,C[C@H]1[C@@H]([C@@H]([C@H]([C@H](O1)O)O)O)O,,,,,,
4811,444813,"5-[4-[[2-[(3aR,4S,7aS,7bS)-4-hydroxy-1a,7a-dimethyl-3,3a,5,6,7,7b-hexahydro-2H-oxireno[2,3-f]quinolin-4-ium-4-yl]acetyl]amino]anilino]-5-oxopentanoic acid",C[C@]12CCC[N@@+]([C@@H]1CCC3([C@H]2O3)C)(CC(=O)NC4=CC=C(C=C4)NC(=O)CCCC(=O)O)O,,,,,,
4812,444814,[(4R)-4-[[2-[[(2S)-2-[[(2R)-2-azaniumyl-3-sulfanylpropanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-4-carboxybutyl]-(diaminomethylidene)azanium,CC(C)C[C@@H](C(=O)NCC(=O)N[C@H](CCC[NH+]=C(N)N)C(=O)O)NC(=O)[C@H](CS)[NH3+],,,,,,
4813,444815,(2R)-2-[[2-[[(2S)-2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoic acid,CC(C)C[C@@H](C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CS)N,,,,,,
4814,444816,H-Gly-Ala-Thr-Pro-Gln-Asp-Leu-Asn-Thr-Nle-al,CCCC[C@@H](C=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)CN,,,,,,
4815,444817,H-Leu-Lys-Gly-Pro-Leu-OH,CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)O)N,,,,,,
4816,444818,6-o-Phosphoryl inosine monophosphate,C1=NC2=C(C(=N1)OP(=O)(O)O)N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O,,,,,,
4817,444819,CID 444819,C(C(=O)O)N(CO)O,,,,,,
4818,444820,H-Leu-Pro-Pro-Leu-Asp-Ile-Thr-Pro-Tyr-OH,CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]3CCCN3C(=O)[C@@H]4CCCN4C(=O)[C@H](CC(C)C)N,,,,,,
4819,444821,N-(3-Carboxypropanoyl)-L-Valyl-N-{(1r)-1-[(S)-Hydroxy(Oxido)phosphanyl]-2-Phenylethyl}-L-Prolinamide,CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)P(=O)(O)O)NC(=O)CCC(=O)O,,,,,,
4820,444822,"(2S)-2-(4-hydroxycyclohexa-2,4-dien-1-yl)-3,4-dihydro-2H-chromene-4,5,7-triol",C1C=C(C=CC1[C@@H]2CC(C3=C(C=C(C=C3O2)O)O)O)O,,,,,,
4821,444823,[(1R)-1-carboxy-3-(phenylmethoxycarbonylamino)propyl]-[(2S)-4-methyl-1-[[(2S)-1-(2-morpholin-4-ylethylamino)-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopentan-2-yl]azanium,CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCCN2CCOCC2)[NH2+][C@H](CCNC(=O)OCC3=CC=CC=C3)C(=O)O,,,,,,
4822,444824,N-[(1s)-3-{[(Benzyloxy)carbonyl]amino}-1-Carboxypropyl]-L-Leucyl-N-(2-Morpholin-4-Ylethyl)-L-Phenylalaninamide,CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCCN2CCOCC2)N[C@H](CCNC(=O)OCC3=CC=CC=C3)C(=O)O,,,,,,
4823,444825,CID 444825,C1=NC2=C(N1[C@H]3[C@H]4[C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)O)OP(=O)(O4)O)NC(=NC2=O)N,,,,,,
4824,444826,CID 444826,CCCC=CC=O.CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)[C@H](C(=O)NCCC(=O)NCCS)O,,,,,,
4825,444827,CID 444827,C#CCN(CC1=CC2=C(C=C1)NC(=NC2=O)N)C3=CC=C(C=C3)C(=O)N[C@H](CCC(=O)O)C(=O)O,,,,,,
4826,444828,"(4S,6S)-4-(ethylamino)-6-methyl-7,7-dioxo-3,4,5,6-tetrahydro-2H-thieno[2,3-b]thiopyran-2-sulfonamide",CCN[C@H]1C[C@@H](S(=O)(=O)C2=C1CC(S2)S(=O)(=O)N)C,,,,,,
4827,444829,"(4S,6S)-4-amino-6-methyl-7,7-dioxo-3,4,5,6-tetrahydro-2H-thieno[2,3-b]thiopyran-2-sulfonamide",C[C@H]1C[C@@H](C2=C(S1(=O)=O)SC(C2)S(=O)(=O)N)N,,,,,,
4828,444830,"(4S,6S)-6-methyl-4-(methylamino)-7,7-dioxo-3,4,5,6-tetrahydro-2H-thieno[2,3-b]thiopyran-2-sulfonamide",C[C@H]1C[C@@H](C2=C(S1(=O)=O)SC(C2)S(=O)(=O)N)NC,,,,,,
4829,444831,"(2R)-3-(1H-indol-3-yl)-2-[[4-(4-phenyl-3,4-dihydro-2H-pyridin-1-yl)phenyl]sulfonylamino]propanoic acid",C1CN(C=CC1C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N[C@H](CC4=CNC5=CC=CC=C54)C(=O)O,,,,,,
4830,444832,[1-[1-(6-Carbamoyl-Cyclohex-2-Enylcarbamoyl)-Cyclohexylcarbamoyl]-2-(4-Phosphonooxy-Phenyl)-Ethyl]-Carbamic Acid 3-Aminobenzylester,C1CCC(CC1)(C(=O)N[C@@H]2C=CCC[C@@H]2C(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)OP(=O)(O)O)NC(=O)OCC4=CC(=CC=C4)N,,,,,,
4831,444833,CID 444833,C1=C(C2=C(N1)C(=O)N=CN2)[C@H]3[C@@H]([C@@H]([C@H](N3)COP(=O)(O)O)O)O,,,,,,
4832,444834,CID 444834,CC1=C2C=CC(=O)C=C2OC(=C1CC(=O)N)O,,,,,,
4833,444835,CID 444835,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(OP(=O)(O)OP(=O)(O)O)S)O)O)N,,,,,,
4834,444836,"2',3'-Dideoxyadenosine-5'-triphosphate",C1C[C@H](O[C@H]1COP(=O)(O)OP(=O)(O)OP(=O)(O)O)N2C=NC3=C(N=CN=C32)N,,,,,,
4835,444837,CoA-s-acetyl tryptamine,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)[C@H](C(=O)NCCC(=O)NCCSCC(=O)NCCC4=CNC5=CC=CC=C54)O,,,,,,
4836,444838,[(5S)-6-[[(2R)-6-azaniumylhexan-2-yl]amino]-5-[[(2S)-1-[(2S)-1-[(2S)-4-methyl-2-[[(2S)-2-[[(2S)-1-[(2S)-1-[(2S)-pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-6-oxohexyl]azanium,C[C@H](CCCC[NH3+])NC(=O)[C@H](CCCC[NH3+])NC(=O)[C@@H]1CCCN1C(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H]3CCCN3C(=O)[C@@H]4CCCN4C(=O)[C@@H]5CCCN5,,,,,,
4837,444839,(2S)-N-[(2S)-1-[[(2S)-1-[(2S)-2-[(2S)-2-[[(2S)-6-amino-1-[[(2R)-6-aminohexan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]-1-[(2S)-1-[(2S)-pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide,C[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H]3CCCN3C(=O)[C@@H]4CCCN4C(=O)[C@@H]5CCCN5,,,,,,
4838,444840,H-Pro-Pro-Pro-Val-Pro-Pro-Arg-NHiPr,CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC(C)C)NC(=O)[C@@H]3CCCN3C(=O)[C@@H]4CCCN4C(=O)[C@@H]5CCCN5,,,,,,
4839,444841,CID 444841,C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C5NC(=NC6=O)N)O)O)O)O)NC(=NC2=O)N,,,,,,
4840,444842,N-(3-chlorophenyl)-9-methylpurin-6-amine,CN1C=NC2=C(N=CN=C21)NC3=CC(=CC=C3)Cl,,,,,,
4841,444843,"(E)-4-(2-aminoethoxy)-2-[[2-methyl-3-oxo-5-(phosphonooxymethyl)-2,6-dihydro-1H-pyridin-4-yl]methylamino]but-3-enoic acid",CC1C(=O)C(=C(CN1)COP(=O)(O)O)CNC(/C=C/OCCN)C(=O)O,,,,,,
4842,444844,"1-[(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,8,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-yl]-3-heptadecyldioxiran-1-ium",CCCCCCCCCCCCCCCCCC1O[O+]1[C@H]2CC[C@@]3([C@H]4CC[C@]5([C@H]([C@@H]4C=CC3=C2)CC[C@@H]5[C@H](C)CCCC(C)C)C)C,,,,,,
4843,444845,CID 444845,CNP(=O)(NP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C2NC(=NC3=O)N)O)O)O,,,,,,
4844,444846,"3-[2-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-amino-7,8-dihydropurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethylsulfanyl]-3-oxopropanoic acid",CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2CNC3=C(N=CN=C32)N)O)OP(=O)(O)O)[C@H](C(=O)NCCC(=O)NCCSC(=O)CC(=O)O)O,,,,,,
4845,444847,CID 444847,CC1=CC2=C(C=C1C)N(C3C(=N2)C(=O)NC(=O)N3)C[C@@H]([C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,,,,,,
4846,444848,6-O-Phosphono-Alpha-D-Fructofuranose,C([C@@H]1[C@H]([C@@H]([C@@](O1)(CO)O)O)O)OP(=O)(O)O,,,,,,
4847,444849,Phenylalanylaminodi(ethyloxy)ethyl benzenesulfonamideaminocarbonylbenzenesulfonamide,C1=CC=C(C=C1)C[C@@H](C(=O)NCCOCCOCCNC(=O)C2=CC=C(C=C2)S(=O)(=O)N)N,,,,,,
4848,444850,"Carbon monoxide;3-[18-(2-carboxyethyl)-8,13-diethyl-3,7,12,17-tetramethylporphyrin-21,23-diid-2-yl]propanoic acid;iron(3+)",CCC1=C(C2=CC3=NC(=CC4=C(C(=C([N-]4)C=C5C(=C(C(=N5)C=C1[N-]2)C)CCC(=O)O)CCC(=O)O)C)C(=C3CC)C)C.[C-]#[O+].[Fe+3],,,,,,
4849,444851,CID 444851,CCC1=C(C2=CC3=NC(=CC4=C(C(=C([N-]4)C=C5C(=C(C(=N5)C=C1[N-]2)C)CC)C)CCC(=O)O)C(=C3C)CCC(=O)O)C.[Co+2],,,,,,
4850,444852,"[[[[(2R,3S,4R,5R)-5-(6-amino-7,8-dihydropurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]amino]phosphonic acid",C1NC2=C(N=CN=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(NP(=O)(O)O)O)O)O)N,,,,,,
4851,444853,"[(1S,3S,4S,5S,7R,8S)-7-ethyl-4-hydroxy-3-[(1E,3E,5E)-6-(4-methoxy-3-methyl-6-oxopyran-2-yl)hexa-1,3,5-trienyl]-1,5-dimethyl-2,6-dioxabicyclo[3.2.1]octan-8-yl] acetate",CC[C@@H]1[C@]2([C@H]([C@@](O1)([C@H]([C@@H](O2)/C=C/C=C/C=C/C3=C(C(=CC(=O)O3)OC)C)O)C)OC(=O)C)C,,,,,,
4852,444854,CID 444854,C[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)CS)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)C,,,,,,
4853,444855,"4-O-Methyl-2,6-dideoxy-beta-D-glucose",C[C@@H]1[C@H]([C@@H](C[C@@H](O1)O)O)OC,,,,,,
4854,444856,CID 444856,CC[C@@H](C)C1=C(C2=C(C3=C(C[C@H]([C@@H](C3O)O)[C@@H](C(=O)[C@H]([C@@H](C)O)O)OC)C=C2C=C1O)O)O,,,,,,
4855,444857,"3-[2-[[3-(2-carboxyethyl)-5-[(4-ethyl-3-methyl-5-oxo-1,2-dihydropyrrol-2-yl)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-4-methyl-5-[[(3R,4R)-4-methyl-5-oxo-3-[(1R)-1-sulfanylethyl]pyrrolidin-2-yl]methyl]-1H-pyrrol-3-yl]propanoic acid",CCC1=C(C(NC1=O)CC2=C(C(=C(N2)CC3=C(C(=C(N3)CC4[C@@H]([C@H](C(=O)N4)C)[C@@H](C)S)C)CCC(=O)O)CCC(=O)O)C)C,,,,,,
4856,444858,CID 444858,CC1=C(C2=CC3=C(C(=C([N-]3)C=C4C(=C(C(=CC5=C(C(=C([N-]5)CC1[N-]2)C)CCC(=O)O)[N-]4)CCC(=O)O)C)C=C)C)C=C.[Fe],,,,,,
4857,444859,CID 444859,CC1=C(C2=CC3=C(C(=C(N3)C=C4C(=C(/C(=C/C5=C(C(=C(N5)CC1N2)C)CCC(=O)O)/N4)CCC(=O)O)C)C=C)C)C=C,,,,,,
4858,444860,2-[O-Phosphonopyridoxyl]-amino-butyric acid,CC[C@H](C(=O)O)NCC1=C(C(=NC=C1COP(=O)(O)O)C)O,,,,,,
4859,444861,2-[O-Phosphonopyridoxyl]-amino-pentanoic acid,CCC[C@@H](C(=O)O)NCC1=C(C(=NC=C1COP(=O)(O)O)C)O,,,,,,
4860,444862,2-[O-Phosphonopyridoxyl]-amino-hexanoic acid,CCCC[C@@H](C(=O)O)NCC1=C(C(=NC=C1COP(=O)(O)O)C)O,,,,,,
4861,444863,beta-L-Fucose,C[C@H]1[C@H]([C@H]([C@@H]([C@H](O1)O)O)O)O,,,,,,
4862,444864,CID 444864,CCOC(=O)C[C@@H]([C@H](CC1CCNC1=O)NC(=O)[C@@H](CC2=CC=C(C=C2)F)CC(=O)[C@H](C(C)C)NC(=O)C3=NOC(=C3)C)S,,,,,,
4863,444865,Equilenin,C[C@]12CCC3=C([C@@H]1CCC2=O)C=CC4=C3C=CC(=C4)O,,,,,,
4864,444866,"[(2R)-2-[8-[(1S,2R)-2-hexylcyclopropyl]octanoyloxy]-3-phosphonooxypropyl] hexadecanoate",CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)O)OC(=O)CCCCCCC[C@H]1C[C@H]1CCCCCC,,,,,,
4865,444867,CID 444867,CCCC1=CC=CC=C1CC/C=C\C.C([C@@H]([C@@H](CO)O)O)N,,,,,,
4866,444868,CID 444868,CCCC1=CC=CC=C1CC/C=C\C,,,,,,
4867,444869,"(2R,3S)-4-aminobutane-1,2,3-triol",C([C@@H]([C@@H](CO)O)O)N,,,,,,
4868,444870,"(3S)-1-ethyl-3-sulfanylpyrrolidine-2,5-dione",CCN1C(=O)C[C@@H](C1=O)S,,,,,,
4869,444871,"(2E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,6,8-trien-1-ol",CC1=C(C(CCC1)(C)C)/C=C/C(=C/CC/C(=C/CO)/C)/C,,,,,,
4870,444872,CID 444872,CC1=C(/C/2=C/C3=C(C(=C(N3)/C=C\4/C(=C(C)S)C(=C(N4)C=C5C(=C(C)S)C(=C(N5)C=C1N2)C)C)C)CCC(=O)O)CCC(=O)O,,,,,,
4871,444873,"2,4-Dioxopentanedioic acid",C(C(=O)C(=O)O)C(=O)C(=O)O,,,,,,
4872,444874,CID 444874,CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC[NH+]=C(N)N)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC[NH+]=C(N)N)C(=O)N[C@H](C)C(=O)O)NC(=O)CNC(=O)CNC(=O)[C@H](CS)[NH3+],,,,,,
4873,444875,CID 444875,CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](C)C(=O)O)NC(=O)CNC(=O)CNC(=O)[C@H](CS)N,,,,,,
4874,444876,Isoleucyl-Proline,CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)O)N,,,,,,
4875,444877,"(2S,3S)-4-amino-2-hydroxy-4-oxo-3-sulfanylbutanoic acid",[C@@H]([C@@H](C(=O)N)S)(C(=O)O)O,,,,,,
4876,444878,Carboxymethyl-coenzyme A,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)[C@H](C(=O)NCCC(=O)NCCSCC(=O)O)O,,,,,,
4877,444879,Amidocarboxymethyldethia coenzyme *a,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)[C@H](C(=O)NCCC(=O)NCCCC(=O)N)O,,,,,,
4878,444880,Carboxymethyldethia coenzyme *a,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)[C@H](C(=O)NCCC(=O)NCCCC(=O)O)O,,,,,,
4879,444881,L-tryptophanium,C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)[NH3+],,,,,,
4880,444882,alpha-Fluoro-amidocarboxymethyldethia coenzyme a complex,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)[C@H](C(=O)NCCC(=O)NCC[C@H](C(=O)N)F)O,,,,,,
4881,444883,alpha-Fluoro-carboxymethyldethia coenzyme a complex,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)[C@H](C(=O)NCCC(=O)NCC[C@@H](C(=O)O)F)O,,,,,,
4882,444884,CID 444884,C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)OP(=O)(O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NC(CC(C)C)C(=O)N)NC(=O)C)O,,,,,,
4883,444885,O-sialic acid,CC(=O)N[C@@H]1[C@H](C[C@@](O[C@H]1[C@@H]([C@@H](CO)O)O)(C(=O)O)O)O,"['Treatment of distal myopathy, Nonaka type (hereditary inclusion-body myopathy)']",,,,,
4884,444886,"[(4S)-4-[[(2S,3S)-2-[[2-[[2-[[(2R)-2-azaniumyl-3-sulfanylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-methylpentanoyl]amino]-5-[[2-[[(2S)-4-carboxy-1-[[(2S)-1-(carboxymethylamino)-5-(diaminomethylideneazaniumyl)-1-oxopentan-2-yl]amino]-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-5-oxopentyl]-(diaminomethylidene)azanium",CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC[NH+]=C(N)N)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC[NH+]=C(N)N)C(=O)NCC(=O)O)NC(=O)CNC(=O)CNC(=O)[C@H](CS)[NH3+],,,,,,
4885,444887,"(4S)-4-[[2-[[(2S)-2-[[(2S,3S)-2-[[2-[[2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-5-[[(2S)-1-(carboxymethylamino)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-oxopentanoic acid",CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)O)NC(=O)CNC(=O)CNC(=O)[C@H](CS)N,,,,,,
4886,444888,O-(4-trifluoroacetamidobenzylphosphonyl)chloramphenicol,C1=CC(=CC=C1CP(=O)(O)O[C@H](C2=CC=C(C=C2)[N+](=O)[O-])[C@@H](CO)NC(=O)C(Cl)Cl)NC(=O)C(F)(F)F,,,,,,
4887,444889,Uranium;hydrate,O.[U],,,,,,
4888,444890,Iodwasserstoff Iodwasserstoff,I.I,,,,,,
4889,444891,10-[3-(4-Methylpyrazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine,CN1C=CN(C=C1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F,,,,,,
4890,444892,"4-Hydroxy-3,4-dihydro-zebularine",C1=CN(C(=O)N[C@@H]1O)C2[C@@H]([C@@H]([C@H](O2)CO)O)O,,,,,,
4891,444893,CID 444893,CCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CCSC)C(=O)N[C@H](C)C(=O)O,,,,,,
4892,444894,"2',5'-Dideoxy-adenosine 3'-monophosphate",C[C@@H]1[C@H](C[C@@H](O1)N2C=NC3=C(N=CN=C32)N)OP(=O)(O)O,,,,,,
4893,444895,"[(4R)-5-[[(2R,3R)-1-[[2-[[2-[[(2R)-1-amino-1-oxo-3-sulfanylpropan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-[[2-[[(2R)-4-carboxy-2-[[(2R)-2-[(2-carboxyacetyl)amino]-5-(diaminomethylideneazaniumyl)pentanoyl]amino]butanoyl]amino]acetyl]amino]-5-oxopentyl]-(diaminomethylidene)azanium",CC[C@@H](C)[C@H](C(=O)NCC(=O)NCC(=O)N[C@@H](CS)C(=O)N)NC(=O)[C@@H](CCC[NH+]=C(N)N)NC(=O)CNC(=O)[C@@H](CCC(=O)O)NC(=O)[C@@H](CCC[NH+]=C(N)N)NC(=O)CC(=O)O,,,,,,
4894,444896,"(4R)-5-[[2-[[(2R)-1-[[(2R,3R)-1-[[2-[[2-[[(2R)-1-amino-1-oxo-3-sulfanylpropan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-4-[[(2R)-2-[(2-carboxyacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-oxopentanoic acid",CC[C@@H](C)[C@H](C(=O)NCC(=O)NCC(=O)N[C@@H](CS)C(=O)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@@H](CCC(=O)O)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)CC(=O)O,,,,,,
4895,444897,H-D-Phe-Phe-Arg-MeSH,C1=CC=C(C=C1)C[C@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)CS)N,,,,,,
4896,444898,CID 444898,CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@H](C)C(=O)N[C@]1(C(=O)O1)CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)N,,,,,,
4897,444899,Arachidonic acid,CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O,,,,,"['Arachidonic acid has known human metabolites that include 10-HETE, 11,12-EET, 11-HETE, 12-HETE, 13-HETE, 14,15-EET, 15-HETE, 16-HETE, 17-HETE, 18-HETE, 19-HETE, 20-HETE, 5,6-EET, 5-HETE, 7-HETE, 8,9-EET, 8-HETE, and 9-HETE.']",
4898,444900,Hydroxypyrrole-imidazole-pyrrole polyamide,CN1C=CN=C1C(=O)NC2=CN(C(=C2)C(=O)NC3=CN(C(=C3O)C(=O)NC4=CN(C(=C4)C(=O)NCCC(=O)NCCCN(C)C)C)C)C,,,,,,
4899,444901,"(2R,3R)-N-[(2S)-1-(dimethylamino)-1-oxo-3-phenylpropan-2-yl]-2-hydroxy-N'-(2-pyridin-2-ylethyl)-3-sulfanylbutanediamide",CN(C)C(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H]([C@H](C(=O)NCCC2=CC=CC=N2)S)O,,,,,,
4900,444902,CID 444902,C1[C@@H]([C@H](O[C@H]1N2C=CC(=NC2=O)N)COP(=O)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=O)(O)O[C@H]4C[C@@H](O[C@@H]4CO)N5C=NC6=C(N=CN=C65)N)N7C=NC8=C7NC(=NC8=O)N)O,,,,,,
4901,444903,"[(4R)-4-amino-5-[[(2R)-1-[[2-[[(2R)-1-[[(2R,3R)-1-[[2-[[2-[[(2R)-1-amino-1-oxo-3-sulfanylpropan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneazaniumyl)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-5-oxopentyl]-(diaminomethylidene)azanium",CC[C@@H](C)[C@H](C(=O)NCC(=O)NCC(=O)N[C@@H](CS)C(=O)N)NC(=O)[C@@H](CCC[NH+]=C(N)N)NC(=O)CNC(=O)[C@@H](CCC(=O)O)NC(=O)[C@@H](CCC[NH+]=C(N)N)N,,,,,,
4902,444904,"(4R)-4-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-[[2-[[(2R)-1-[[(2R,3R)-1-[[2-[[2-[[(2R)-1-amino-1-oxo-3-sulfanylpropan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-5-oxopentanoic acid",CC[C@@H](C)[C@H](C(=O)NCC(=O)NCC(=O)N[C@@H](CS)C(=O)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@@H](CCC(=O)O)NC(=O)[C@@H](CCCN=C(N)N)N,,,,,,
4903,444905,(2R)-3-amino-2-methyl-3-oxopropanoic acid,C[C@H](C(=O)N)C(=O)O,,,,,,
4904,444906,H-Glu-Gly-Asp-Phe-Glu-Glu-Val-Leu-OH,CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)N,,,,,,
4905,444907,H-Gln-Phe-Glu-Glu-Ile-Pro-OH,CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCC(=O)N)N,,,,,,
4906,444908,"6-[(1E,3E,5E,7E)-3,7-dimethylnona-1,3,5,7-tetraenyl]-1,5,5-trimethylcyclohexene",C/C=C(\C)/C=C/C=C(\C)/C=C/C1C(=CCCC1(C)C)C,,,,,,
4907,444909,"2,2-Dihydroxy-8-methyl-3-propylsulfonyl-7-thia-3,4-diaza-2-boranuidabicyclo[4.3.0]nona-1(6),4-diene",[B-]1(C2=C(C=NN1S(=O)(=O)CCC)SC(C2)C)(O)O,,,,,,
4908,444910,(2S)-3-amino-2-methyl-3-oxopropanoic acid,C[C@@H](C(=O)N)C(=O)O,,,,,,
4909,444911,"N,N'-(3,7-Diazanonylene)-bis-naphthalimide",C1=CC2=C3C(=C1)C(=O)N(C(=O)C3=CC=C2)CC[NH2+]CCC[NH2+]CCN4C(=O)C5=CC=CC6=C5C(=CC=C6)C4=O,,,,,,
4910,444912,Elinafide,C1=CC2=C3C(=C1)C(=O)N(C(=O)C3=CC=C2)CCNCCCNCCN4C(=O)C5=CC=CC6=C5C(=CC=C6)C4=O,,,,,,
4911,444913,alpha-CYCLODEXTRIN,C([C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5O)O)O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6O)O)O[C@@H]7[C@H](O[C@H](O2)[C@@H]([C@H]7O)O)CO)CO)CO)CO)CO)O)O)O,,,,,,
4912,444914,4-Deoxy-alpha-D-glucose,C1[C@H](O[C@@H]([C@@H]([C@H]1O)O)O)CO,,,,,,
4913,444915,alpha-D-Glucopyranosyl fluoride,C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)F)O)O)O)O,,,,,,
4914,444916,CID 444916,CCC1=C(C2=CC3=C(C(=C([N-]3)C=C4C(=C(C(=N4)C=C5C(=C(C(=CC1=N2)[N-]5)CO)CCC(=O)O)CCC(=O)O)C)CO)C=CS)C.[Fe+2],,,,,,
4915,444917,CID 444917,CCC1=C(C2=CC3=C(C(=C(N3)C=C4C(=C(C(=N4)C=C5C(=C(C(=N5)C=C1N2)CO)CCC(=O)O)CCC(=O)O)C)CO)C=CS)C,,,,,,
4916,444918,N-hydroxy-2-[4-[4-(4-methylphenoxy)phenyl]sulfonyloxan-4-yl]acetamide,CC1=CC=C(C=C1)OC2=CC=C(C=C2)S(=O)(=O)C3(CCOCC3)CC(=O)NO,,,,,,
4917,444919,"[(2R,3S)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate",CC1=CN(C(=O)NC1=O)C2C[C@@H]([C@H](O2)COP(=O)(O)O)O,,,,,,
4918,444920,3'-Thymidylic acid,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)OP(=O)(O)O,,,,,,
4919,444921,CID 444921,CC1=C2CC3C(=C(C(=CC4=C(C(=C([N-]4)C=C5C(=C(C(=CC(=C1CCC(=O)O)[N-]2)[N-]5)CCC(=O)O)C)C)[C@H](C)S)[N-]3)C)[C@H](C)S.[Fe],,,,,,
4920,444922,CID 444922,CC1=C2CC3C(=C(/C(=C/C4=C(C(=C(N4)C=C5C(=C(/C(=C/C(=C1CCC(=O)O)N2)/N5)CCC(=O)O)C)C)[C@H](C)S)/N3)C)[C@H](C)S,,,,,,
4921,444923,"3-[18-(2-Carboxyethyl)-12-ethenyl-7-ethyl-3,8,13,17-tetramethylporphyrin-21,23-diid-2-yl]propanoic acid;iron(2+)",CCC1=C(C2=CC3=C(C(=C([N-]3)C=C4C(=C(C(=N4)C=C5C(=C(C(=CC1=N2)[N-]5)C)CCC(=O)O)CCC(=O)O)C)C)C=C)C.[Fe+2],,,,,,
4922,444924,Dinuclear Copper Ion,[Cu].[Cu],,,,,,
4923,444925,CID 444925,CCCCC[C@H](/C=C/C1=C(C(CC1)O)C/C=C\CCCC(=O)O)O,,,,,,
4924,444926,H-Pro-Phe(4-I)-Cys(Me)-Unk,CC(C)OC(=O)[C@@H]([C@H](CC1CCCCC1)NC(=O)[C@H](CSC)NC(=O)[C@H](CC2=CC=C(C=C2)I)NC(=O)[C@@H]3CCCN3)O,,,,,,
4925,444927,CID 444927,C1=CC2C([Hg]2)C=C1,,,,,,
4926,444928,CID 444928,C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]1CCCN1C(=O)C)O,,,,,,
4927,444929,CID 444929,C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]1CCCN1)O,,,,,,
4928,444930,Ac-Pro-Val-Gln-Glu-Thr-Leu-His-al,C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=CN1)C=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)C)O,,,,,,
4929,444931,Ac-Pro-Val-Gln-Glu-Thr-Leu-His-Gly-Cys-al,C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)NCC(=O)N[C@@H](CS)C=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)C)O,,,,,,
4930,444932,Ac-Pro-Val-Gln-Glu-Thr-NH2,C[C@H]([C@@H](C(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1C(=O)C)O,,,,,,
4931,444933,Ac-Met-Leu-Ser-Val-Glu-Glu-Glu-NHEt,CCNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)C,,,,,,
4932,444934,Ac-Pro-Ile-Gln-Glu-Glu-OH,CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)C,,,,,,
4933,444935,CID 444935,C[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C)C(=O)O)N,,,,,,
4934,444936,CID 444936,C[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C)C(=O)O)NC(=O)CNC(=O)C,,,,,,
4935,444937,CID 444937,C[C@@H](C(=O)N[C@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)O)NC(=O)CN,,,,,,
4936,444938,CID 444938,C[C@@H](C(=O)N)O[C@@H]1[C@H]([C@@H](O[C@@H]([C@H]1O)CO)O)NC(=O)C,,,,,,
4937,444939,L-alaninamide,C[C@@H](C(=O)N)N,,,,,,
4938,444940,Bulgecin a,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O[C@H]2C[C@H](N[C@@H]2CO)C(=O)NCCS(=O)(=O)O)CO)OS(=O)(=O)O)O,,,,,,
4939,444941,alpha-Ribazole-5'-phosphate,CC1=CC2=C(C=C1C)N(C=N2)[C@@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O,,,,,,
4940,444942,CID 444942,[BeH2].C1=CC(=CC(=C1)[N+](=O)[O-])NCCOP(=O)(O)OP(=O)(O)O.[F-].[F-].[F-],,,,,,
4941,444943,CID 444943,[BeH2].C1=CC=C(C(=C1)NCCOP(=O)(O)OP(=O)(O)O)[N+](=O)[O-].[F-].[F-].[F-],,,,,,
4942,444944,CID 444944,[BeH2].C1=CC(=CC=C1NCCOP(=O)(O)OP(=O)(O)O)[N+](=O)[O-].[F-].[F-].[F-],,,,,,
4943,444945,"(2S,4S)-4-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2-(1-hydroxyethyl)-7-methoxy-3,4-dihydro-1H-tetracene-2,5,6,11-tetrol",C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=CC4=C(C5=C(C(=CC=C5)OC)C(=C4C(=C23)O)O)O)(C(C)O)O)N)O,,,,,,
4944,444946,"(2S,4S)-4-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2-(1,2-dihydroxyethyl)-7-methoxy-3,4-dihydro-1H-tetracene-2,5,6,11,12-pentol",C[C@H]1[C@@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C(C4=C(C5=C(C(=CC=C5)OC)C(=C4C(=C23)O)O)O)O)(C(CO)O)O)N)O,,,,,,
4945,444947,CID 444947,[BeH2].C1=CC(=C(C=C1[N+](=O)[O-])[N+](=O)[O-])NCCOP(=O)(O)OP(=O)(O)O.[F-].[F-].[F-],,,,,,
4946,444948,CID 444948,[BeH2].C1=CC(=C(C=C1[N+](=O)[O-])[N+](=O)[O-])NCCCOP(=O)(O)OP(=O)(O)O.[F-].[F-].[F-],,,,,,
4947,444949,CID 444949,[BeH2].CN(CCOP(=O)(O)OP(=O)(O)O)C1=CC=CC=C1[N+](=O)[O-].[F-].[F-].[F-],,,,,,
4948,444950,2-(N-methyl-2-nitroanilino)ethyl phosphono hydrogen phosphate,CN(CCOP(=O)(O)OP(=O)(O)O)C1=CC=CC=C1[N+](=O)[O-],,,,,,
4949,444951,"(6R)-2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-2,3,4a,5,6,7-hexahydro-1H-pteridin-4-one",C[C@@H]([C@@H]([C@H]1CN=C2C(N1)C(=O)NC(N2)N)O)O,,,,,,
4950,444952,2-Thiazolidinamine,C1CSC(N1)N,,,,,,
4951,444953,"methyl (1R,10S,12S,13R,21R,22S,23R,24R)-23-[formyl(methyl)amino]-4,6,8,12,17,22,24-heptahydroxy-1,12-dimethyl-10-[(2R,3R,4R,5S,6S)-3,4,5-trimethoxy-4,6-dimethyloxan-2-yl]oxy-20,25-dioxahexacyclo[19.3.1.02,19.05,18.07,16.09,14]pentacosa-2(19),3,5,7,9(14),15,17-heptaene-13-carboxylate",C[C@H]1[C@@H]([C@@]([C@H]([C@@H](O1)O[C@H]2C[C@]([C@@H](C3=C2C(=C4C(=C3)C(=C5C(=C4O)C(=CC6=C5O[C@H]7[C@H]([C@@H]([C@H]([C@@]6(O7)C)O)N(C)C=O)O)O)O)O)C(=O)OC)(C)O)OC)(C)OC)OC,,,,,,
4952,444954,Magnesium;tetrahydroxide,[OH-].[OH-].[OH-].[OH-].[Mg+2],,,,,,
4953,444955,"1-[(2S,4S)-4-[(2R,4S,5S,6S)-4-amino-5-[(2S,4S,5R,6S)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-2,5,6,11,12-pentahydroxy-7-methoxy-3,4-dihydro-1H-tetracen-2-yl]ethanone",C[C@H]1[C@@H]([C@H](C[C@@H](O1)O[C@@H]2[C@@H](O[C@H](C[C@@H]2N)O[C@H]3C[C@@](CC4=C(C5=C(C6=C(C(=CC=C6)OC)C(=C5C(=C34)O)O)O)O)(C(=O)C)O)C)O)O,,,,,,
4954,444956,"(8S,10S)-10-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-8-[(1R)-1,2-dihydroxyethyl]-9,10-dihydro-7H-tetracene-1,5,8,11,12-pentol",C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=CC4=C(C5=C(C(=CC=C5)O)C(=C4C(=C23)O)O)O)([C@@H](CO)O)O)N)O,,,,,,
4955,444957,"1-[(2S,4S)-4-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,6,11,12-pentahydroxy-3,4-dihydro-1H-tetracen-2-yl]ethanone",C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C(C4=C(C5=CC=CC=C5C(=C4C(=C23)O)O)O)O)(C(=O)C)O)N)O,,,,,,
4956,444958,Methane;sulfane;2-sulfanylethanol;hydrate,C.C.C(CS)O.O.S,,,,,,
4957,444959,Decyl-hydroxy-dimethylazanium,CCCCCCCCCC[N+](C)(C)O,,,,,,
4958,444960,CID 444960,CC(=O)/C(=C(\NC1=CC=C(C=C1)C(F)(F)F)/O)/C#N,,,,,,
4959,444961,1-[2-[4-[[2-[4-(2-Pyrrolidin-1-ylethoxy)phenyl]-1-benzothiophen-3-yl]methyl]phenoxy]ethyl]pyrrole,C1CCN(C1)CCOC2=CC=C(C=C2)C3=C(C4=CC=CC=C4S3)CC5=CC=C(C=C5)OCCN6C=CC=C6,,,,,,
4960,444962,"3-[18-(2-Carboxyethyl)-7,12,13-tris(ethenyl)-3,8,17-trimethylporphyrin-21,23-diid-2-yl]propanoic acid;iron(2+)",CC1=C(C2=CC3=NC(=CC4=C(C(=C([N-]4)C=C5C(=C(C(=N5)C=C1[N-]2)C=C)C)C=C)C=C)C(=C3CCC(=O)O)C)CCC(=O)O.[Fe+2],,,,,,
4961,444963,"3-[18-(2-Carboxyethyl)-7,8,13-tris(ethenyl)-3,12,17-trimethyl-22,23-dihydroporphyrin-2-yl]propanoic acid",CC1=C(C2=CC3=NC(=CC4=NC(=CC5=C(C(=C(N5)C=C1N2)C=C)C=C)C(=C4CCC(=O)O)C)C(=C3C)CCC(=O)O)C=C,,,,,,
4962,444964,[6-(2-Pyrrolidin-1-ylethoxy)pyridin-3-yl]-[2-[4-(2-pyrrol-1-ylethoxy)phenyl]-1-benzothiophen-3-yl]methanone,C1CCN(C1)CCOC2=NC=C(C=C2)C(=O)C3=C(SC4=CC=CC=C43)C5=CC=C(C=C5)OCCN6C=CC=C6,,,,,,
4963,444965,[(S)-5-Amino-5-carboxypentyl]trihydroxyboronanion,[B-](CCCC[C@@H](C(=O)O)N)(O)(O)O,,,,,,
4964,444966,Chlorocopper;chloride,[Cl-].Cl[Cu],,,,,,
4965,444967,"4-[6-[6-(4-methyl-2,3-dihydropyrazin-1-yl)-1H-benzimidazol-2-yl]-1H-benzimidazol-2-yl]phenol",CN1CCN(C=C1)C2=CC3=C(C=C2)N=C(N3)C4=CC5=C(C=C4)N=C(N5)C6=CC=C(C=C6)O,,,,,,
4966,444968,CID 444968,CC1=C(/C/2=C/C3=C(C(=C(N3)C=C4C(=C(C)S)C(=C(N4)C=C5C(=C(C)S)C(=C(N5)C=C1N2)C)C)C)CCC(=O)O)CCC(=O)O,,,,,,
4967,444969,"[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2S,3R,4S)-5-(7,8-dimethyl-2,4-dioxo-1H-benzo[g]pteridin-10-ium-10-yl)-2,3,4-trihydroxypentyl] hydrogen phosphate",CC1=CC2=C(C=C1C)[N+](=C3C(=N2)C(=O)NC(=O)N3)C[C@@H]([C@H]([C@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,,,,,,
4968,444970,CID 444970,CC1=C(C2=CC3=C(C(=C(N3)/C=C\4/C(=C(C)S)C(=C(N4)C=C5C(=C(C)S)C(=C(N5)C=C1N2)C)C)C)CCC(=O)O)CCC(=O)O,,,,,,
4969,444971,CID 444971,CC1=C(C2=CC3=C(C(=C(N3)C=C4C(=C(C)S)C(=C(N4)/C=C\5/C(=C(C)S)C(=C(N5)C=C1N2)C)C)C)CCC(=O)O)CCC(=O)O,,,,,,
4970,444972,Fumaric acid,C(=C/C(=O)O)\C(=O)O,,,,"['The total activity of labeled carbon dioxide in the blood entering and leaving the brain was determined following a single injection of fumarate-2-(14)C in four normal human subjects. Blood samples were drawn simultaneously from the femoral artery and the superior bulb of the internal jugular vein. Also, cerebrospinal fluid specimens were collected. Evidence from the experiments indicates that there was an immmediate formation of (14)CO2 by the brain after injection of the isotope. It suggests that fumarate penetrates the blood-brain barrier with little difficulty.']",,
4971,444973,"2,5-Dibenzyloxy-3,4-dihydroxy-hexanedioic acid benzylamide (2-hydroxy-indan-1-YL)-amide",C1[C@H]([C@H](C2=CC=CC=C21)NC(=O)[C@@H]([C@@H]([C@H]([C@H](C(=O)NCC3=CC=CC=C3)OCC4=CC=CC=C4)O)O)OCC5=CC=CC=C5)O,,,,,,
4972,444974,"2,5-Dibenzyloxy-3-hydroxy-hexanedioic acid bis-[(2-hydroxy-indan-1-YL)-amide]",C1[C@H]([C@H](C2=CC=CC=C21)NC(=O)[C@@H](C[C@H]([C@H](C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)OCC5=CC=CC=C5)O)OCC6=CC=CC=C6)O,,,,,,
4973,444975,"2,5-Dibenzyloxy-3,4-dihydroxy-hexanedioic acid 2-chloro-6-fluoro-benzylamide (2-hydroxy-indan-1-YL)-amide",C1[C@H]([C@H](C2=CC=CC=C21)NC(=O)[C@@H]([C@@H]([C@H]([C@H](C(=O)NCC3=C(C=CC=C3Cl)F)OCC4=CC=CC=C4)O)O)OCC5=CC=CC=C5)O,,,,,,
4974,444976,"N-13-[(10S,13S)-9,12-Dioxo-10-(2-butyl)-2-oxa-8,11-diazabicyclo [13.2.2] nonadeca-15,17,18-triene] (2R)-benzyl-(4S)-hydroxy-5-aminopentanoic (1R)-hydroxy-(2S)-indaneamide",CC[C@H](C)[C@H]1C(=O)NCCCCCOC2=CC=C(C[C@@H](C(=O)N1)NC[C@H](C[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)O)C=C2,,,,,,
4975,444977,"(10s,13s,1'r)-13-[1'-Hydroxy-2'-(n-p-aminobenzenesulfonyl-1''-amino-3''-methylbutyl)ethyl]-8,11-dioxo-10-isopropyl-2-oxa-9,12-diazabicyclo [13.2.2]nonadeca-15,17,18-triene",CC(C)CCN(C[C@H]([C@@H]1CC2=CC=C(C=C2)OCCCCCC(=O)N[C@H](C(=O)N1)C(C)C)O)S(=O)(=O)C3=CC=C(C=C3)N,,,,,,
4976,444978,"3-Methyl-5-[7-[4-(1,3-oxazolidin-2-yl)phenoxy]heptyl]-1,2-oxazolidine",CC1CC(ON1)CCCCCCCOC2=CC=C(C=C2)C3NCCO3,,,,,,
4977,444979,"[[(1R,3R,4R,5S)-3-(6-aminopurin-9-yl)-4-phosphonooxy-2,6-dioxabicyclo[3.1.0]hexan-1-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate",C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@]34[C@@H](O3)[C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)OP(=O)(O)O)O)O)C(=O)N,,,,,,
4978,444980,2-(4-benzylpiperidine-1-carbonyl)-1H-indole-5-carboximidamide,C1CN(CCC1CC2=CC=CC=C2)C(=O)C3=CC4=C(N3)C=CC(=C4)C(=N)N,,,,,,
4979,444981,CID 444981,CC[C@H](C1C(=C[C@](OC1=O)(CCC2=CC=CC=C2)C=CC)O)C3=CC=CC=C3.C1=CC(=NC=C1C(F)(F)F)S(=O)(=O)N,,,,,,
4980,444982,CID 444982,CC[C@H](C1C(=C[C@](OC1=O)(CCC2=CC=CC=C2)C=CC)O)C3=CC=CC=C3,,,,,,
4981,444983,5-(Trifluoromethyl)pyridine-2-sulfonamide,C1=CC(=NC=C1C(F)(F)F)S(=O)(=O)N,,,,,,
4982,444984,"N-[3-[(1S)-1-[(3R,6R)-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-3H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide",CCC[C@]1(C=C([C@H](C(=O)O1)[C@H](CC)C2=CC(=CC=C2)NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)O)CCC4=CC=CC=C4,,,,,,
4983,444985,CID 444985,C1[C@@H]([C@H](O[C@H]1N2C=NC3=C2NC(=NC3=O)N)COP(=O)(O)O[C@H]4C[C@@H](O[C@@H]4CO)N5C=CC(=NC5=O)N)O,,,,,,
4984,444986,CID 444986,C1[C@@H]([C@H](O[C@H]1N2CNC3=C2NC(=NC3=O)N)COP(=O)(O)O[C@H]4C[C@@H](O[C@@H]4COP(=O)(O)O[C@H]5C[C@@H](O[C@@H]5COP(=O)(O)O[C@H]6C[C@@H](O[C@@H]6CO)N7C=CC(=NC7=O)N)N8CNC9=C8NC(=NC9=O)N)N1C=CC(=NC1=O)N)O,,,,,,
4985,444987,"1-[(2S,4S)-4-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,6,11,12-pentahydroxy-7-methoxy-3,4-dihydro-1H-tetracen-2-yl]-2-hydroxyethanone",C[C@H]1[C@@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C(C4=C(C5=C(C(=CC=C5)OC)C(=C4C(=C23)O)O)O)O)(C(=O)CO)O)N)O,,,,,,
4986,444988,Cadmium monohydroxide,O.[Cd],,,,,,
4987,444989,CID 444989,CC1([C@H](N(CCCS1)S(=O)(=O)C2=CC=C(C=C2)OC)C(NO)O)C,,,,,,
4988,444990,Ac-Cha-Arg-Ala-Met-Cys(Acm)-Ser-Leu-NH2,C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CSCNC(=O)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1CCCCC1)NC(=O)C,,,,,,
4989,444991,Manganese;dihydrate,O.O.[Mn],,,,,,
4990,444992,CID 444992,C[C@H](C(=O)N[C@H]1CCC2=C3C(=CC=C2)C[C@H](N3C1=O)C(=O)NC(CO)CO)N(C)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC4CCCCC4)NC(=O)C,,,,,,
4991,444993,CID 444993,C[C@H](C(=O)N[C@H]1CCC(=O)N2CCC[C@H](N2C1=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC3CCCCC3)NC(=O)C,,,,,,
4992,444994,Arsane;dihydrate,O.O.[AsH3],,,,,,
4993,444995,4-[2-(4-Carbamimidoylanilino)hydrazinyl]benzenecarboximidamide,C1=CC(=CC=C1C(=N)N)NNNC2=CC=C(C=C2)C(=N)N,,,,,,
4994,444996,Ac-Cha-Arg-MePhg-Met-Ala-Ser-tLeu-NH2,C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N)C(C)(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](C1=CC=CC=C1)N(C)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC2CCCCC2)NC(=O)C,,,,,,
4995,444997,[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]azanium,CSCC[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CC(=O)O)[NH3+],,,,,,
4996,444998,Asp-Tyr-Met-Gly-Trp-Met-Asp-Phe-NH2,CSCC[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CC(=O)O)N,,,,,,
4997,444999,CID 444999,O.O.[MgH2],,,,,,
4998,445000,H-Asp-Phe-Glu-Gly-Ile-Pro-Glu-Glu-Tyr(SO3H)-Leu-al,CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)OS(=O)(=O)O)C(=O)N[C@@H](CC(C)C)C=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)N,,,,,,
